<SEC-DOCUMENT>0001213900-24-037717.txt : 20240430
<SEC-HEADER>0001213900-24-037717.hdr.sgml : 20240430
<ACCEPTANCE-DATETIME>20240430143847
ACCESSION NUMBER:		0001213900-24-037717
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240430
DATE AS OF CHANGE:		20240430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		24896396

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		5 HACHAROSHET ST.
		CITY:			RAANANA
		STATE:			L3
		ZIP:			4365603
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0204561-20f_xtlbiopharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 18:16:37 UTC 2024 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xtlb="http://xtlb.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-19434">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-19435">&#9744;</ix:nonNumeric> <b>REGISTRATION STATEMENT PURSUANT TO SECTION
12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-19436">&#9746;</ix:nonNumeric> <b>ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-19437"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-19438">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-19439">2023</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-19440">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-19441">&#9744;</ix:nonNumeric> <b>SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from ____________to
___________.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-77"><b>001-36000</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-83"><b>XTL BIOPHARMACEUTICALS LTD.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of Registrant&#8217;s Name into English)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-19442">Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Jurisdiction of incorporation or organization)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-19443">26 Ben-Gurion St</ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-19444">Ramat Gan</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-19445">5112001</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-19446">Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-19447">Shlomo Shalev</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Executive Officer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-19448">26 Ben-Gurion St</ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-19449">Ramat Gan</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-19450">5112001</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-19451">Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-19452">+972</ix:nonNumeric>-<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-19453">3-6116600</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fax: <ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelFaxNumber" id="ixv-19454">+972-3-611-6605</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, Telephone, E-mail and/or Facsimile number
and Address of Company Contact Person)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities registered or to be registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-19455">American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1</ix:nonNumeric></p></td> <td style="width: 2%">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-138"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTLB</span></ix:nonNumeric></td> <td style="width: 2%">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-19456">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> <tr> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Title of Class)</b></span></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol </b></span></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Name of each exchange on which registered)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities registered or to be registered pursuant to Section 12(g)
of the Act: None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities for which there is a reporting obligation pursuant to Section
15(d) of the Act: None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2023, 2,923,276 American Depositary Shares and&#160;<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-19457">544,906,149</ix:nonFraction>
Ordinary Shares were issued and outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-19458">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-19459">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the
preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject
to such filing requirements for the past 90&#160;days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-19460">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-19461">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer&#8221;, &#8220;accelerated filer&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Large accelerated filer&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated
filer&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-19462">Non-accelerated filer</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerging growth
company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-19463">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#8224;</td><td style="text-align: justify">The term &#8220;new or revised financial accounting standard&#8221;
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-19464">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-19465">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">&#160;</td> <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US GAAP</span></td> <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&#160;</span></td> <td style="width: 65%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-19466">International Financial Reporting Standards</ix:nonNumeric> as issued&#160;by the International Accounting Standards Board</span></td> <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#160; &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been check in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Item&#160;17&#160;&#9744;&#160;&#160;&#160; Item&#160;18&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-19467">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>XTL BIOPHARMACEUTICALS LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANNUAL REPORT ON FORM 20-F</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 10%">&#160;</td>
    <td style="width: 81%">&#160;</td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPLANATORY NOTE</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td colspan="2"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING
    STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1</span></a></td>
    <td><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identity of Directors, Senior Management and Advisers</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2</span></a></td>
    <td><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Statistics and Expected Timetable</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3</span></a></td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Information</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4</span></a></td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information on the Company</span></a></td>
    <td style="text-align: center">21</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A</span></a></td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center">34</td></tr>
  <tr>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5</span></a></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and Financial Review and Prospects</span></a></td>
    <td style="text-align: center">34</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6</span></a></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Senior Management and Employees</span></a></td>
    <td style="text-align: center">40</td></tr>
  <tr>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7</span></a></td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders and Related Party Transactions</span></a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8</span></a></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Information</span></a></td>
    <td style="text-align: center">52</td></tr>
  <tr>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9</span></a></td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offer and Listing</span></a></td>
    <td style="text-align: center">52</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10</span></a></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information</span></a></td>
    <td style="text-align: center">52</td></tr>
  <tr>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11</span></a></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market
    Risk</span></a></td>
    <td style="text-align: center">77</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12</span></a></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities other than Equity Securities</span></a></td>
    <td style="text-align: center">78</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13</span></a></td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults, Dividend Arrearages and Delinquencies</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14</span></a></td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Modifications to the Rights of Security Holders
    and Use of Proceeds</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15</span></a></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16</span></a></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A</span></a></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Financial Expert</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B</span></a></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C</span></a></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees And Services</span></a></td>
    <td style="text-align: center">79</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D</span></a></td>
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemptions From The Listing Standards For Audit Committees</span></a></td>
    <td style="text-align: center">80</td></tr>
  <tr>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E</span></a></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases Of Equity Securities By The Issuer And Affiliated
    Purchasers</span></a></td>
    <td style="text-align: center">80</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F</span></a></td>
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change In Registrant&#8217;s Registered Accountant</span></a></td>
    <td style="text-align: center">80</td></tr>
  <tr>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G</span></a></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</span></a></td>
    <td style="text-align: center">80</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H</span></a></td>
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosure </span></a></td>
    <td style="text-align: center">81</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I</span></a></td>
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent
    Inspections</span></a></td>
    <td style="text-align: center">81</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J</span></a></td>
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy </span></a></td>
    <td style="text-align: center">81</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K</span></a></td>
    <td><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity </span></a></td>
    <td style="text-align: center">81</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19</span></a></td>
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="text-align: center">82</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="text-align: center">84</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain matters discussed
in this report, including matters discussed under the caption &#8220;Item 5. Operating and Financial Review and Prospects,&#8221; may
constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities
Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause
our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed
or implied by such forward-looking statements. In some instances, you can identify these forward-looking statements by words such as &#8220;anticipates,&#8221;
&#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; or similar expressions, including their negatives.
These forward-looking statements include, without limitation, statements relating to our expectations and beliefs regarding:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in the market price of our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that our securities could be delisted from Nasdaq or the Tel-Aviv Stock Exchange (&#8220;TASE&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential dilution to the holders of our securities as a result of future issuances of our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations in our results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy of our financial forecasts in our drug development activity and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and cost of the in-licensing, partnering and acquisition of new product opportunities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the timing of expenses associated with product
development and manufacturing of the proprietary drug candidates that we have acquired - hCDR1 for the treatment of SLE and SS, and those
that may be in-licensed, partnered or acquired;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&#8217;s offices are located in Israel and, therefore, the business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel and in the Middle East;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks and uncertainties described in this report.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual results may differ
materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation,
those discussed under &#8220;Item 3. Key Information-Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; &#8220;Item
5. Operating and Financial Review and Prospects,&#8221; and elsewhere in this report, as well as factors which may be identified from
time to time in our other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking
statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these
cautionary statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
contained in this report reflect our views and assumptions only as of the date this report is filed. Therefore, you should not place undue
reliance on any forward-looking statement as a prediction of future results. Forward-looking statements made in this report and the documents
incorporated by reference are made as of the date of the respective documents, and we undertake no obligation to update them in light
of new information or future results. Except as required by law, we assume no responsibility for updating any forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Unless the context requires
otherwise, references in this report to &#8220;XTL,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;
refer to XTL Biopharmaceuticals Ltd, an Israeli company and our consolidated subsidiary. We have prepared our consolidated financial statements
in United States, or US, dollars and in accordance with International Financial Reporting Standards, or IFRS. All references herein to
&#8220;dollars&#8221; or &#8220;$&#8221; are to US dollars, and all references to &#8220;Shekels&#8221; or &#8220;NIS&#8221; are to New
Israeli Shekels.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. KEY INFORMATION </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Selected Financial Data </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Reserved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Capitalization And Indebtedness</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Reasons For Offer And Use Of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Before you invest in our
ordinary shares or American Depositary Shares, you should understand the high degree of risk involved. You should carefully consider the
risks described below and other information in this report, including our consolidated financial statements and related notes included
elsewhere in this report, before you decide to purchase our ordinary shares or American Depositary Shares (&#8220;ADSs&#8221;). If any
of the following risks actually occur, our business, financial condition and operating results could be adversely affected. As a result,
the trading price of our ordinary shares or ADSs could decline and you could lose part or all of your investment.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Risk factor Summary</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred substantial operating losses since our inception. We expect to continue to incur losses in the future in our drug development activity and may never become profitable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not yet commercialized any products or technologies, and we may never become profitable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to successfully complete our clinical trial programs for our drug candidates, or if such clinical trials take longer to complete than we project, our ability to execute our current business strategy will be adversely affected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have limited experience in conducting and managing clinical trials necessary to obtain regulatory approvals. If our drug candidates and technologies do not receive the necessary regulatory approvals, we will be unable to commercialize our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third parties on which we will have to rely for clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our international clinical trials may be delayed or otherwise adversely impacted by social, political and economic factors affecting the particular foreign country.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the clinical data related to our drug candidates and technologies do not confirm positive early clinical data or preclinical data, our corporate strategy and financial results will be adversely impacted.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not establish or maintain drug development and marketing arrangements with third parties, we may be unable to commercialize our drug candidates and technologies into products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.6pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we or our collaborative/strategic partners or potential collaborative/strategic partners receive approval to market our drug candidates, if our products fail to achieve market acceptance, we will never record meaningful revenues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the third parties upon whom we rely to manufacture our products do not successfully manufacture our products, our business will be harmed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors develop and market products that are less expensive, more effective or safer than our products, our revenues and results may be harmed and our commercial opportunities may be reduced or eliminated.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we lose our key personnel or are unable to attract and retain additional personnel, our business could be harmed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Chief Financial Officer is not required to work exclusively for us, which could materially and adversely affect us and our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face product liability risks and may not be able to obtain adequate insurance.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because all of our proprietary drug candidates and technologies are licensed to us by third parties, termination of these license agreements could prevent us from developing our drug candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time, money and other resources defending such claims and adversely affect our ability to develop and commercialize our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25pt">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ADSs are traded in small volumes, limiting ability to sell ADSs that represent ordinary shares at a desirable price, if at all.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our stock price can be volatile, which increases the risk of litigation and may result in a significant decline in the value of your investment.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of ownership of our ordinary shares among our principal stockholders may prevent new investors from influencing significant corporate decisions.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ordinary shares and ADSs trade on two different markets, and this may result in price variations and regulatory compliance issues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of our ordinary shares or ADSs who are U.S. citizens or residents may be required to pay additional income taxes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 5.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic issuers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADS holders are not shareholders and do not have shareholder rights.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are circumstances where it may be unlawful or impractical to make distributions to the holders of the ADSs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may fail to remain in compliance with the continued listing standards of the Nasdaq Capital Market and a delisting of our ADSs could make it more difficult for investors to sell their shares</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s offices are located in Israel and, therefore, the business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel and in the Middle East.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of failure to complete the Transaction with the Social Proxy, we may incur in significant legal and other expenses and we may fail to comply with certain with the continued listing standards of the Nasdaq Capital Market.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our results of operations may be adversely affected by inflation and foreign currency fluctuations.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It may be difficult to enforce a U.S. judgment against us, our officers or our directors or to assert U.S. securities law claims in Israel.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your rights and responsibilities as a shareholder will be governed by Israeli law which may differ in some respects from the rights and responsibilities of shareholders of U.S. companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Risks Related to Our Financial Position
and Capital Requirements</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred substantial operating losses
since our inception. We expect to continue to incur losses in the future in our drug development activity and may never become profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should consider our prospects
in light of the risks and difficulties frequently encountered by development stage companies. We have incurred operating losses since
our inception and expect to continue to incur operating losses for the foreseeable future. We have not yet commercialized any of our drug
candidates or technologies and cannot be sure we will ever be able to do so. Even if we commercialize one or more of our drug candidates
or technologies, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability
to complete our development efforts, consummate out-licensing agreements, obtain regulatory approval for our drug candidates and technologies
and successfully commercialize them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
losses for the foreseeable future, and these losses will likely increase as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate and manage pre-clinical development and clinical trials for our current and new product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory approvals for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement internal systems and infrastructures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to license additional technologies to develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire management and other personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">progress product candidates towards commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
fail in clinical trials or do not gain regulatory clearance or approval, or if our product candidates do not achieve market acceptance,
we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results
of operations, and cash flows. Moreover, our prospects must be considered in light of the risks and uncertainties encountered by an early-stage
company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory approval and market acceptance
of our products are uncertain. There can be no assurance that our efforts will ultimately be successful or result in revenues or profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will require substantial
additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit,
reduce or terminate our product development or commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
had approximately $1,401 thousand in cash and cash equivalents, working capital of approximately $1,840 thousand and an accumulated deficit
of approximately $158,246 thousand. We have incurred continuing losses and depend on outside financing resources to continue future activities.
Based on existing business plans, we estimate that our outstanding cash and cash equivalent balances will allow us to finance our activities
for an additional period of at least 12 months from the date of this Report. In order to perform clinical trials aimed at developing our
product until obtaining its marketing approval, we will need to raise additional financing by issuing securities. Should we fail to raise
additional capital under terms acceptable to us, we will be required to reduce our development activities or sell or grant a sublicense
to third parties to use all or part of our technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have expended and believe
that, subject to receiving adequate financing and/or entering into a collaboration agreement, we will continue to expend significant operating
and capital expenditures for the foreseeable future developing our product candidates. These expenditures will include, but are not limited
to, costs associated with research and development, manufacturing, conducting preclinical experiments and clinical trials, contracting
with contract manufacturing organizations and contract research organizations, hiring additional management and other personnel and obtaining
regulatory approvals, as well as commercializing any products approved for sale. Because the outcome of our planned and anticipated clinical
trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization
of our product candidates and any other future product. In addition, other unanticipated costs may arise. As a result of these and other
factors currently unknown to us, we will require additional funds, through public or private equity or debt financings or other sources,
such as strategic partnerships and alliances and licensing arrangements. In addition, we may seek additional capital due to favorable
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. A
failure to fund these activities may harm our growth strategy, competitive position, quality compliance, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and characteristics of products we develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of researching and developing our product candidates and conducting preclinical and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of, and the costs involved in, obtaining regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of commercialization activities if any are approved for sale, including marketing, sales and distribution costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing any product candidate we successfully commercialize;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain strategic partnerships, licensing, supply or other arrangements and the financial terms of such agreements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of in-licensing further patents and technologies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of development of in-licensed technologies</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, receipt and amount of sales of, or royalties on, any future products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract and retain skilled personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to existing and/or any future products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional funds may not be
available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis,
we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities
for our product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities
that may be necessary to commercialize our product candidates or any future products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may cause dilution
to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing
shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect shareholder rights. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such
as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships and
alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates,
or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when
needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to our Drug Development Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not yet commercialized any products
or technologies, and we may never become profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any products or technologies, and we may never be able to do so. We do not know when or if we will complete any of our product development
efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved
products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products
gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance of these products
will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of regulatory approvals in the countries, and for the uses, we seek;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the competitive environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment and demonstration in the medical community of the safety and clinical efficacy of our products and their potential advantages over existing therapeutic products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to enter into strategic agreements with pharmaceutical and biotechnology companies with strong marketing and sales capabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the adequacy and success of distribution, sales and marketing efforts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement policies of government and third-party payors, such as insurance companies, health maintenance organizations and other plan administrators.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians, patients, third-party
payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of third-party payors, cover
any of our products or products incorporating our technologies. As a result, we are unable to predict the extent of future losses or the
time required to achieve profitability, if at all. Even if we successfully develop one or more products that incorporate our technologies,
we may not become profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to successfully complete
our clinical trial programs for our drug candidates, or if such clinical trials take longer to complete than we project, our ability to
execute our current business strategy will be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not and how quickly
we complete clinical trials depends in part upon the rate at which we are able to engage clinical trial sites and, thereafter, the rate
of enrollment of patients, and the rate at which we are able to collect, clean, lock and analyze the clinical trial database. Patient
enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the
eligibility criteria for the study, the existence of competitive clinical trials, and whether existing or new drugs are approved for the
indication we are studying. We are aware that other companies are planning clinical trials that will seek to enroll patients with the
same diseases and stages as we are studying. If we experience delays in identifying and contracting with sites and/or in patient enrollment
in our clinical trial programs, we may incur additional costs and delays in our development programs, and may not be able to complete
our clinical trials on a cost-effective or timely basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited experience in conducting
and managing clinical trials necessary to obtain regulatory approvals. If our drug candidates and technologies do not receive the necessary
regulatory approvals, we will be unable to commercialize our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not received, and
may never receive, regulatory approval for commercial sale for hCDR1. We currently do not have any drug candidates pending approval with
the Food and Drug Administration, or FDA or with regulatory authorities of other countries. We will need to conduct significant additional
research and human testing before we can apply for product approval with the FDA or with regulatory authorities of other countries. In
order to obtain FDA approval to market a new drug product, we or our potential partners must demonstrate proof of safety and efficacy
in humans. To meet these requirements, we and/or our potential partners will have to conduct &#8220;adequate and well-controlled&#8221;
clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical development is a
long, expensive and uncertain process. Clinical trials are very difficult to design and implement, in part because they are subject to
rigorous regulatory requirements. Satisfaction of regulatory requirements typically depends on the nature, complexity and novelty of the
product and requires the expenditure of substantial resources. The commencement and rate of completion of clinical trials may be delayed
by many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory approvals to commence a clinical trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching agreement on acceptable terms with prospective CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower than expected rates of patient recruitment due to narrow screening requirements and competing clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability of patients to meet protocol requirements imposed by the FDA or other regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need or desire to modify our manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays, suspension, or termination of the clinical trials due to the institutional review board responsible for overseeing the study at a particular study site; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governmental or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of the trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the completion of
a clinical trial, regulators may not interpret data obtained from pre-clinical and clinical tests of our drug candidates and technologies
the same way that we do, which could delay, limit or prevent our receipt of regulatory approval. In addition, the designs of any clinical
trials may not be reviewed or approved by the FDA prior to their commencement, and consequently the FDA could determine that the parameters
of any studies are insufficient to demonstrate proof of safety and efficacy in humans. Failure to approve a completed study could also
result from several other factors, including unforeseen safety issues, the determination of dosing, low rates of patient recruitment,
the inability to monitor patients adequately during or after treatment, the inability or unwillingness of medical investigators to follow
our clinical protocols, and the lack of effectiveness of the trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the regulators
could determine that the studies indicate the drugs may have serious side effects. In the U.S., this is called a black box warning, which
is a type of warning that appears on the package insert for prescription drugs indicating that they may cause serious adverse effects.
A black box warning means that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse
effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the clinical trials fail
to satisfy the criteria required, the FDA and/or other regulatory agencies/authorities may request additional information, including additional
clinical data, before approval of marketing a product. Negative or inconclusive results or medical events during a clinical trial could
also cause us to delay or terminate our development efforts. If we experience delays in the testing or approval process, or if we need
to perform more or larger clinical trials than originally planned, our financial results and the commercial prospects for our drug candidates
and technologies may be materially impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials have a high
risk of failure. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks
in clinical trials, even after achieving promising results in earlier trials. It may take us many years to complete the testing of our
drug candidates and technologies, and failure can occur at any stage of this process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory approval
is obtained, our products and their manufacture will be subject to continual review, and there can be no assurance that such approval
will not be subsequently withdrawn or restricted. Changes in applicable legislation or regulatory policies, or discovery of problems with
the products or their manufacture, may result in the imposition of regulatory restrictions, including withdrawal of the product from the
market, or result in increased costs to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If third parties on which we will have to
rely for clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for
or commercialize our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will have to depend on
independent clinical investigators, and other third-party service providers to conduct the clinical trials of our drug candidates and
technologies. We also may, from time to time, engage a clinical research organization for the execution of our clinical trials. We will
rely heavily on these parties for successful execution of our clinical trials, but we will not control many aspects of their activities.
Nonetheless, we are responsible for confirming that each of our clinical trials is conducted in accordance with the general investigational
plan and protocol. Our reliance on these third parties that we do not control does not relieve us of our responsibility to comply with
the regulations and standards of the FDA and/or other foreign regulatory agencies/authorities relating to good clinical practices. Third
parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or the
applicable trial&#8217;s plans and protocols. The failure of these third parties to carry out their obligations could delay or prevent
the development, approval and commercialization of our products, or could result in enforcement action against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our international clinical trials may be
delayed or otherwise adversely impacted by social, political and economic factors affecting the particular foreign country.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may conduct clinical trials
in different geographical locations. Our ability to successfully initiate, enroll and complete a clinical trial in any of these countries,
or in any future foreign country in which we may initiate a clinical trial, are subject to numerous risks unique to conducting business
in foreign countries, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty in establishing or managing relationships with clinical research organizations and physicians;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different standards for the conduct of clinical trials and/or health care reimbursement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to locate qualified local consultants, physicians, and partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical products and treatment; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general geopolitical risks, such as political and economic instability, and changes in diplomatic and trade relations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any disruption to our international
clinical trial program could significantly delay our product development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the clinical data related to our drug
candidates and technologies do not confirm positive early clinical data or preclinical data, our corporate strategy and financial results
will be adversely impacted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates and technologies
are in clinical stages. Specifically, our product candidate, hCDR1 is planned for and/or ready for advanced clinical studies. In order
for our candidates to proceed to later stage clinical testing or marketing approval, they must show positive clinical results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preliminary results of pre-clinical,
clinical observations or clinical tests do not necessarily predict the final results, and promising results in pre-clinical, clinical
observations or early clinical testing might not be obtained in later clinical trials. Drug candidates in the later stages of clinical
development may fail to show the desired safety and efficacy traits despite having progressed through initial clinical testing. Any negative
results from future tests may prevent us from proceeding to later stage clinical testing or marketing approval, which would materially
impact our corporate strategy, and our financial results may be adversely impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not establish or maintain drug
development and marketing arrangements with third parties, we may be unable to commercialize our drug candidates and technologies into
products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not possess all of the
capabilities to fully commercialize our drug candidates and technologies on our own. From time to time, we may need to contract with third
parties to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assist us in developing, testing and obtaining regulatory approval for some of our compounds and technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture our drug candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market and distribute our products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can provide no assurance
that we will be able to successfully enter into agreements with such third-parties on terms that are acceptable to us. If we are unable
to successfully contract with third parties for these services when needed, or if existing arrangements for these services are terminated,
whether or not through our actions, or if such third parties do not fully perform under these arrangements, we may have to delay, scale
back or end one or more of our drug development programs or seek to develop or commercialize our drug candidates and technologies independently,
which could result in delays. Further, such failure could result in the termination of license rights to one or more of our drug candidates
and technologies. Moreover, if these development or marketing agreements take the form of a partnership or strategic alliance, such arrangements
may provide our collaborators with significant discretion in determining the efforts and resources that they will apply to the development
and commercialization of our products. Accordingly, to the extent that we rely on third parties to research, develop or commercialize
our products, we may be unable to control whether such products will be scientifically or commercially successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we or our collaborative/strategic
partners or potential collaborative/strategic partners receive approval to market our drug candidates, if our products fail to achieve
market acceptance, we will never record meaningful revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our products are approved
for sale, they may not be commercially successful in the marketplace. Market acceptance of our product candidates will depend on a number
of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceptions by members of the health care community, including physicians, of the safety and efficacy of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rates of adoption of our products by medical practitioners and the target populations for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential advantages that our products offer over existing treatment methods or other products that may be developed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost-effectiveness of our products relative to competing products including potential generic competition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of government or third-party pay or reimbursement for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the side effects of our products which may lead to unfavorable publicity concerning our products or similar products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our and/or our partners&#8217; sales, marketing and distribution efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, hCDR1, if successfully
developed and commercially launched for the treatment of systemic lupus erythematosus, or SLE, and Sjogren&#8217;s syndrome, or SS, on
the one hand, will compete with both currently marketed and new products marketed by other companies. Health care providers may not accept
or utilize any of our product candidates. Physicians and other prescribers may not be inclined to prescribe our products unless our products
bring clear and demonstrable advantages over other products currently marketed for the same indications. Because we expect sales of our
products to generate substantially all of our revenues in the long-term, the failure of our products to find market acceptance would harm
our business and could require us to seek additional financing or other sources of revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the third parties upon whom we rely to
manufacture our products do not successfully manufacture our products, our business will be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have the
ability to manufacture the compounds that we need to conduct our clinical trials and, therefore, rely upon, and intend to continue to
rely upon, certain manufacturers to produce and supply our drug candidates for use in clinical trials and for future sales. In order to
commercialize our products, such products will need to be manufactured in commercial quantities while adhering to all regulatory and other
local requirements, all at an acceptable cost. We may not be able to enter into future third-party contract manufacturing agreements on
acceptable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our contract manufacturers
or other third parties fail to deliver our product candidates for clinical use on a timely basis, with sufficient quality, and at commercially
reasonable prices, and we fail to find replacement manufacturers or sources, we may be required to delay or suspend clinical trials or
otherwise discontinue development and production of our drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract manufacturers
will be required to produce our clinical drug candidates under strict compliance with current Good Manufacturing Practices, or cGMP, in
order to meet acceptable regulatory standards for our clinical trials. If such standards change, the ability of contract manufacturers
to produce our drug candidates on the schedule we require for our clinical trials may be affected. In addition, contract manufacturers
may not perform their obligations under their agreements with us or may discontinue their business before the time required by us to successfully
produce and market our drug candidates. Any difficulties or delays in our contractors&#8217; manufacturing and supply of drug candidates
could increase our costs, cause us to lose revenue or make us postpone or cancel clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our contract
manufacturers will be subject to ongoing periodic, unannounced inspections by the FDA and corresponding foreign or local governmental
agencies to ensure strict compliance with, among other things, cGMP, in addition to other governmental regulations and corresponding foreign
standards. We will not have control over, other than by contract, third-party manufacturers&#8217; compliance with these regulations and
standards. No assurance can be given that our third-party manufacturers will comply with these regulations or other regulatory requirements
now or in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that we are unable
to obtain or retain third-party manufacturers, we will not be able to commercialize our products as planned. If third-party manufacturers
fail to deliver the required quantities of our products on a timely basis and at commercially reasonable prices, our ability to develop
and deliver products on a timely and competitive basis may be adversely impacted and our business, financial condition or results of operations
will be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our competitors develop and market products
that are less expensive, more effective or safer than our products, our revenues and results may be harmed and our commercial opportunities
may be reduced or eliminated.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry
is highly competitive. Our commercial opportunities may be reduced or eliminated if our competitors develop and market products that are
less expensive, more effective or safer than our products. Other companies have drug candidates in various stages of pre-clinical or clinical
development to treat diseases for which we are also seeking to discover and develop drug candidates. Some of these potential competing
drugs are already commercialized or are further advanced in development than our drug candidates and may be commercialized earlier. Even
if we are successful in developing safe, effective drugs, our products may not compete successfully with products produced by our competitors,
who may be able to market their drugs more effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors include pharmaceutical
companies and biotechnology companies, as well as universities and public and private research institutions. In addition, companies that
are active in different but related fields present substantial competition for us. Many of our competitors have significantly greater
capital resources, larger research and development staffs and facilities and greater experience in drug development, regulation, manufacturing
and marketing than we do. These organizations also compete with us to recruit qualified personnel, attract partners for joint ventures
or other collaborations, and license technologies that are competitive with ours. As a result, our competitors may be able to more easily
develop products that could render our technologies or our drug candidates obsolete or noncompetitive. Development of new drugs, medical
technologies and competitive medical devices may damage the demand for our products without any certainty that we will successfully and
effectively contend with those competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we lose our key personnel or are unable
to attract and retain additional personnel, our business could be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 30, 2024, we have
no employees, we have only four part-time service providers. To successfully develop our drug candidates and technologies, we must cooperate
with third parties or to be able to attract and retain highly skilled personnel, including consultants and employees. The retention of
their services cannot be guaranteed. Our failure to retain and/or recruit such professionals might impair our performance and materially
affect our technological and product development capabilities and our product marketing ability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Chief Financial Officer is not required
to work exclusively for us, which could materially and adversely affect us and our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Itay Weinstein, our Chief
Financial Officer, is not required to work exclusively for us and does not devote all of his time to our operations. Since serving as
our Chief Financial Officer, he has devoted approximately 6 hours a week of his time to the operation of our business. He&#160;also serves&#160;as
a Partner of the accounting firm Shimony C.P.A. It is possible that his pursuit of other activities may slow our operations and impact
our ability to timely complete our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any acquisitions or in-licensing transactions
we make may dilute your equity or require a significant amount of our available cash and may not be scientifically or commercially successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our business strategy,
we may effect acquisitions or in-licensing transactions to obtain additional businesses, products, technologies, capabilities and personnel.
If we complete one or more such transactions in which the consideration includes our ordinary shares or other securities, your equity
may be significantly diluted. If we complete one or more such transactions in which the consideration includes cash, we may be required
to use a substantial portion of our available cash.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acquisitions and in-licensing
transactions also involve a number of operational risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty and expense of assimilating the operations, technology or personnel of the business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to attract and retain management and key personnel necessary to conduct the business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to maintain relationships with key third parties, such as alliance partners, associated with the business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to legal claims for activities of the business prior to the acquisition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&#8217;s attention from our other drug development businesses; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential impairment of goodwill and write-off of in-process research and development costs, adversely affecting our reported results of operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the basis for
completing the acquisition or in-licensing could prove to be unsuccessful as the drugs or processes involved could fail to be scientifically
or commercially viable. We may also be required to pay third parties substantial transaction fees, in the form of cash or ordinary shares,
in connection with such transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these risks occur,
it could have an adverse effect on both the business we acquire or in-license and our existing operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A material breach in security relating to
the Company&#8217;s information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect
the Company, expose us to liability and affect our business and reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information security risks
have generally increased in recent years, in part because of the proliferation of new technologies and the use of the Internet, and the
increased sophistication and activity of organized crime, hackers, terrorists, activists, cybercriminals and other external parties, some
of which may be linked to terrorist organizations or hostile foreign governments. Cybersecurity attacks are becoming more sophisticated
and include malicious software, ransomware, attempts to gain unauthorized access to data and other electronic security breaches that could
lead to disruptions in critical systems, unauthorized release of confidential or otherwise protected information and corruption of data,
substantially damaging the Company&#8217;s reputation. Any person who circumvents the security measures could steal proprietary or confidential
customer information or cause interruptions in the Company&#8217;s operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are increasingly dependent
on our information technology systems and infrastructure for our business. We, our collaborators and our service providers collect, store,
and transmit sensitive information including intellectual property, proprietary business information, and personal information in connection
with our business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of
this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including
organized criminal groups, &#8220;hacktivists,&#8221; disgruntled former employees, nation-state and nation-state supported actors, and
others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and
infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have implemented information
security measures to protect our systems, proprietary information, and sensitive data against the risk of inappropriate and unauthorized
external use and disclosure and other types of compromise. However, despite these measures, and due to the ever-changing information cyber-threat
landscape, we cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents
and we may be subject to data breaches through cyber-attacks, malicious code (such as viruses and worms), phishing attacks, social engineering
schemes, and insider theft or misuse. Any such breach could compromise our networks and the information stored there could be accessed,
modified, destroyed, publicly disclosed, lost or stolen. If our systems become compromised, we may not promptly discover the intrusion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any security breach or other
incident, whether real or perceived, could cause us to suffer reputational damage. Such incidents could result in costs to respond to,
investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies
and other third parties, legal claims or proceedings, and liability under our contracts with other parties and federal and state laws
that protect the privacy and security of personal information. The Company&#8217;s failure to prevent security breaches, or well-publicized
security breaches affecting the Internet in general, could significantly harm the Company&#8217;s reputation and business and financial
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face product liability risks and may
not be able to obtain adequate insurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of our drug candidates
and technologies in clinical trials, and the sale of any approved products, exposes us to liability claims. If we cannot successfully
defend ourselves against product liability claims, we may incur substantial liabilities or be required to cease clinical trials of our
drug candidates and technologies or limit commercialization of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we will be
able to obtain sufficient product liability insurance coverage for our planned clinical trials. We intend to expand our insurance coverage
to include the commercial sale of any approved products if marketing approval is obtained; however, insurance coverage is becoming increasingly
expensive. We may not be able to maintain insurance coverage at a reasonable cost. We may not be able to obtain additional insurance coverage
that will be adequate to cover product liability risks that may arise. Regardless of merit or eventual outcome, product liability claims
may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for a product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to continue to develop a drug candidate or technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial volunteers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consequently, a product liability
claim or product recall may result in material losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are currently operating in a period of
economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing
military conflict between Russia and&#160;Ukraine. Our business, financial condition and results of operations may be materially adversely
affected by any negative impact on the global economy and capital markets resulting from the conflict in&#160;Ukraine&#160;or any other
geopolitical tensions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. and global markets are
experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between
Russia and&#160;Ukraine. On February 24, 2022, a full-scale military invasion of&#160;Ukraine&#160;by Russian troops was reported. Although
the length and impact of the ongoing military conflict is highly unpredictable, the conflict in&#160;Ukraine&#160;could lead to market
disruptions, including significant volatility in credit and capital markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, Russia&#8217;s
prior annexation of Crimea, recent recognition of two separatist republics in the Donetsk and Luhansk regions of&#160;Ukraine&#160;and
subsequent military interventions in&#160;Ukraine&#160;have led to sanctions and other penalties being levied by the United States, European
Union and other countries against Russia, Belarus, the Crimea Region of&#160;Ukraine, the so-called Donetsk People&#8217;s Republic, and
the so-called Luhansk People&#8217;s Republic, including agreement to remove certain Russian financial institutions from the Society for
Worldwide Interbank Financial Telecommunication, or SWIFT, payment system. Additional potential sanctions and penalties have also been
proposed and/or threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial
markets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the abovementioned
factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action,
sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify
the impact of other risks described in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because all of our proprietary drug candidates
and technologies are licensed to us by third parties, termination of these license agreements could prevent us from developing our drug
candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own any of our drug
candidates and technologies. We have licensed the rights, patent or otherwise, to our drug candidates from third parties. We have licensed
hCDR1 from Yeda Research and Development Company Ltd., or Yeda. We licensed a use patent for the use of rHuEPO from Yeda and Mor Research
Applications Ltd., or Mor which we acquired from Bio-Gal Limited, or Bio-Gal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These license agreements require
us to meet development or financing milestones and impose development and commercialization due diligence requirements on us. In addition,
under these agreements, we must pay royalties on sales of products resulting from licensed drugs and technologies and pay the patent filing,
prosecution and maintenance costs related to the licenses. While we have the right to defend patent rights related to our licensed drug
candidates and technologies, we are not obligated to do so. In the event that we decide to defend our licensed patent rights, we will
be obligated to cover all of the expenses associated with that effort. If we do not meet our obligations in a timely manner, or if we
otherwise breach the terms of our agreements, our licensors could terminate the agreements, and we would lose the rights to our drug candidates
and technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, our license
agreement with Yeda imposes certain obligations on us, including obligations to use diligent efforts to meet development thresholds, funding
requirements, payment obligations and commercialization. If we are unable to meet our obligations, some or all of our rights under the
agreement may be restricted or terminated. The license agreement may be terminated by Yeda upon 45 days prior written notice if either
we fail to meet certain development milestones or commercial sales shall have commenced and there shall be a period of 6 months of no
sales, subject to certain exceptions. Yeda shall also be entitled to terminate the license agreement if we were to commence legal action
against Yeda challenging the validity of any of the licensed patents, and we were unsuccessful in such challenge, in which event we would
be required to pay to Yeda liquidated damages of $8 million. Either party may also terminate the license agreement in the case of a material
breach that remains uncured or certain bankruptcy events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has decided not
to conduct Phase 2 under the license agreement by itself, and instead is seeking a strategic partner for the conduct of Phase 2. As a
result, the second milestone under the license agreement (commencement of Phase 2) has not been met yet. Accordingly, the license agreement
may be terminated by Yeda upon 45 days prior written notice. To date, while the Company and Yeda have held discussions regarding further
amendment to the payment scheme under the license agreement, they have not reached an agreement regarding such amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the license agreement were
to be terminated by Yeda, we would lose our rights to HCDR1 and thus would not be able to develop hCDR1, which would have a material adverse
effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, in the
ordinary course of business, we may have disagreements with our licensors or collaborators regarding the terms of our agreements or ownership
of proprietary rights, which could lead to delays in the research, development, collaboration and commercialization of our drug candidates,
or could require or result in litigation or arbitration, which could be time-consuming and expensive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to adequately protect our
intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success will
depend in part on our ability and the ability of our licensors to obtain and maintain patent protection on our drug products and technologies
and successfully defend these patents and technologies against third-party challenges. As part of our business strategy, our policy is
to actively file patent applications in the U.S. and internationally to cover methods of use, new chemical compounds, pharmaceutical compositions
and dosing of the compounds and composition and improvements in each of these. Because of the extensive time required for development,
testing and regulatory review of a potential product, it is possible that before we commercialize any of our products, any related patent
may expire or remain in force for only a short period following commercialization, thus reducing any advantage of the patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of pharmaceutical
and biotechnology companies can be highly uncertain and involve complex legal and factual questions. No consistent policy regarding the
breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, the patents we use may not be sufficiently broad
to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop
similar or alternative technologies or design around our patented technologies. The patents we use may be challenged or invalidated or
may fail to provide us with any competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, patent applications
in the U.S. are maintained in secrecy for a period of at least 18 months. Since publication of discoveries in the scientific or patent
literature often lag behind actual discoveries, we are not certain that we were the first to make the inventions covered by each of our
pending patent applications or that we were the first to file those patent applications. We cannot predict the breadth of claims allowed
in biotechnology and pharmaceutical patents, or their enforceability. Third parties or competitors may challenge or circumvent our patents
or patent applications, if issued. If our competitors prepare and file patent applications in the U.S. that claim compounds or technology
also claimed by us, we may be required to challenge competing patent rights, which could result in substantial cost, even if the eventual
outcome is favorable to us. While we have the right to defend patent rights related to the licensed drug candidates and technologies,
we are not obligated to do so. In the event that we decide to defend our licensed patent rights, we will be obligated to cover all of
the expenses associated with that effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets
to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets are difficult to protect. While
we require our collaborators and consultants to enter into confidentiality agreements, this may not be sufficient to protect our trade
secrets or other proprietary information adequately. In addition, we share ownership and publication rights to data relating to some of
our drug candidates and technologies with our research collaborators and scientific advisors. If we cannot maintain the confidentiality
of this information, our ability to protect our proprietary information will be at risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Litigation or third-party claims of intellectual
property infringement could require us to spend substantial time, money and other resources defending such claims and adversely affect
our ability to develop and commercialize our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are using their proprietary technology without authorization. In addition, third parties may have or obtain patents in the future and
claim that our products infringe their patents. If we are required to defend against patent suits brought by third parties, or if we sue
third parties to protect our patent rights, we may be required to pay substantial litigation costs, and our management&#8217;s attention
may be diverted from operating our business. In addition, any legal action against our licensors or us that seeks damages or an injunction
of our commercial activities relating to the affected products could subject us to monetary liability and require our licensors or us
to obtain a license to continue to use the affected technologies. We cannot predict whether our licensors or we would prevail in any of
these types of actions or that any required license would be made available on commercially acceptable terms, if at all. In addition,
any legal action against us that seeks damages or an injunction relating to the affected activities could subject us to monetary liability
and/or require us to discontinue the affected technologies or obtain a license to continue use thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, there can be
no assurance that our patents or patent applications or those licensed to us will not become involved in opposition or revocation proceedings
instituted by third parties. If such proceedings were initiated against one or more of our patents, or those licensed to us, the defense
of such rights could involve substantial costs and the outcome could not be predicted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors or potential competitors
may have filed applications for, may have been granted patents for, or may obtain additional patents and proprietary rights that may relate
to compounds or technologies competitive with ours. If patents are granted to other parties that contain claims having a scope that is
interpreted to cover any of our products (including the manufacture thereof), there can be no assurance that we will be able to obtain
licenses to such patents at reasonable cost, if at all, or be able to develop or obtain alternative technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Risks Related to our ADSs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need additional capital in the future.
If additional capital is not available, we may not be able to continue to operate our business pursuant to our business plan or we may
have to discontinue our operations entirely.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net cash used in operating
activities for the year ended December 31, 2023 was $707 thousand. If we continue to use cash at this rate we will need significant additional
financing, which we may seek to raise through, among other things, public and private equity offerings and debt financing. Any equity
financings will likely be dilutive to existing stockholders, and any debt financings will likely involve covenants restricting our business
activities. Additional financing may not be available on acceptable terms, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The ADSs are traded in small volumes, limiting
ability to sell ADSs that represent ordinary shares at a desirable price, if at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of the
ADSs has historically been low. Even if the trading volume of the ADSs increases, we can give no assurance that it will be maintained
or will result in a desirable stock price. As a result of this low trading volume, it may be difficult to identify buyers to whom shareholders
can sell ADSs in desirable volume and shareholders may be unable to sell your ADSs at an established market price, at a price that is
favorable, or at all. A low volume market also limits shareholders&#8217; ability to sell large blocks of the ADSs at a desirable or stable
price at any one time. Shareholders should be prepared to own the ADSs indefinitely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our stock price can be volatile, which increases
the risk of litigation and may result in a significant decline in the value of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of the ADSs
representing our ordinary shares is likely to be highly volatile and subject to wide fluctuations in price in response to various factors,
many of which are beyond our control. These factors include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of technological innovations by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions or announcements of new products by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments in the markets of the field of activities and changes in customer attributes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us of significant acquisitions, in/out license transactions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates by securities analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in interim operating results and near-term working capital as well as failure to raise required funds for the continued development and operations of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration or termination of licenses, patents, research contracts or other collaboration agreements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions or trends in the regulatory climate and the biotechnology and pharmaceutical industries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to obtain orphan drug designation status for the relevant drug candidates in the relevant regions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in costs and lengthy timing of the clinical trials according to regulatory requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to increase awareness of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in reimbursement policy by governments or insurers in markets we operate or may operate in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any changes in the regulatory environment relating to our drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">changes in the market valuations of similar companies;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">geopolitical instabilities, including the war between Russia and Ukraine; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, equity markets
in general, and the market for biotechnology and life sciences companies in particular, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of companies traded in those markets. These broad market
and industry factors may materially affect the market price of the ADSs, regardless of our development and operating performance. In the
past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often
been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such
claims and divert management&#8217;s attention and resources even if we prevail in the litigation, all of which could seriously harm our
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future issuances or sales of the ADSs could
depress the market for the ADSs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future issuances of a substantial
number of the ADSs, or the perception by the market that those issuances could occur, could cause the market price of our ordinary shares
or ADSs to decline or could make it more difficult for us to raise funds through the sale of equity in the future. Also, if we make one
or more significant acquisitions in which the consideration includes ordinary shares or other securities, your portion of shareholders&#8217;
equity in us may be significantly diluted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of ownership of our ordinary
shares among our principal stockholders may prevent new investors from influencing significant corporate decisions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is one shareholder (Mr.
Alexander Rabinovitch, a director), who in the aggregate beneficially holds approximately 23.54% of our ordinary shares, as of April 30,
2024). As a result, this person, may have the ability to significantly influence the outcome of all matters submitted to our shareholders
for approval, including the election and removal of directors and any merger, consolidation or sale of all or substantially all of our
assets. In addition, such persons, acting alone or together, may have the ability to effectively control our management and affairs. Accordingly,
this concentration of ownership may depress the market price of our ordinary shares or ADSs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ordinary shares and ADSs trade on two
different markets, and this may result in price variations and regulatory compliance issues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADSs representing our ordinary
shares are listed for trading on the Nasdaq Capital Market, or Nasdaq, and our ordinary shares are traded on the TASE. Trading in our
securities on these markets is made in different currencies and at different times, including as a result of different time zones, different
trading days and different public holidays in the U.S. and Israel. Consequently, the effective trading prices of our securities on these
two markets may differ. Any decrease in the trading price of our securities on one of these markets could cause a decrease in the trading
price of our securities on the other market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holders of our ordinary shares or ADSs who
are U.S. citizens or residents may be required to pay additional income taxes.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a risk that we will
be classified as a passive foreign investment company, or PFIC, for certain tax years. If we are classified as a PFIC, a U.S. holder of
our ordinary shares or ADSs representing our ordinary shares will be subject to special federal income tax rules that determine the amount
of federal income tax imposed on income derived with respect to the PFIC shares. We will be a PFIC if either 75% or more of our gross
income in a tax year is passive income or the average percentage of our assets (by value) that produce or are held for the production
of passive income in a tax year is at least 50%. The risk that we will be classified as a PFIC arises because cash balances, even if held
as working capital, are considered to be assets that produce passive income. Therefore, any determination of PFIC status will depend upon
the sources of our income and the relative values of passive and non-passive assets, including goodwill. A determination as to a corporation&#8217;s
status as a PFIC must be made annually. We believe we may be a PFIC during 2023 and although we have not determined whether we will be
a PFIC in 2024, or in any subsequent year, our operating results for any such years may cause us to be a PFIC. Although we may not be
a PFIC in any one year, the PFIC taint remains with respect to those years in which we were or are a PFIC and the special PFIC taxation
regime will continue to apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In view of the complexity
of the issues regarding our treatment as a PFIC, U.S. shareholders are urged to consult their own tax advisors for guidance as to our
status as a PFIC.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a foreign private issuer, we are permitted
to follow certain home country corporate governance practices instead of applicable SEC and Nasdaq requirements, which may result in less
protection than is accorded to investors under rules applicable to domestic issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are permitted to follow certain home country corporate governance practices instead of those otherwise required under Nasdaq for domestic
issuers. For instance, we may follow home country practice in Israel with regard to, among other things, composition and function of the
audit committee and other committees of our Board of Directors and certain general corporate governance matters. In addition, in certain
instances we will follow our home country law, instead of the Nasdaq, which requires that we obtain shareholder approval for certain dilutive
events, such as an issuance that will result in a change of control of the company, certain transactions other than a public offering
involving issuances of a 20% or more interest in the company and certain acquisitions of the stock or assets of another company. We comply
with the director independence requirements of the Nasdaq, including the requirement that a majority of the Board of Directors be independent.
Following our home country governance practices as opposed to the requirements that would otherwise apply to a United States company listed
on Nasdaq may provide less protection than is accorded to investors under Nasdaq applicable to domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a foreign
private issuer, we are exempt from the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange
Act, related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from
the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required
under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as domestic companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>ADS holders are not shareholders and do
not have shareholder rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as depositary, executes and delivers the ADSs on our behalf. Each ADS is a certificate evidencing a specific number of ADSs. The ADS holders
will not be treated as shareholders and do not have the rights of shareholders. The depositary will be the holder of the shares underlying
the ADSs. Holders of the ADSs will have ADS holder rights. A deposit agreement among us, the depositary and the ADS holders, and the beneficial
owners of ADSs, sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement
and the ADSs. Our shareholders have shareholder rights prescribed by Israeli law. Israeli law and our Articles of Association, or Articles,
govern such shareholder rights. The ADS holders do not have the same voting rights as our shareholders. Shareholders are entitled to our
notices of general meetings and to attend and vote at our general meetings of shareholders. At a general meeting, every shareholder present
(in person or by proxy, attorney or representative) and entitled to vote has one vote on a show of hands. Every shareholder present (in
person or by proxy, attorney or representative) and entitled to vote has one vote per fully paid ordinary share on a poll. This is subject
to any other rights or restrictions which may be attached to any shares. The ADS holders may instruct the depositary to vote the ordinary
shares underlying their ADSs, but only if we ask the depositary to ask for their instructions. If we do not ask the depositary to ask
for their instructions, the ADS holders are not entitled to receive our notices of general meeting or instruct the depositary how to vote.
The ADS holders will not be entitled to attend and vote at a general meeting unless they withdraw the ordinary shares from the depository.
However, the ADS holders may not know about the meeting far enough in advance to withdraw the ordinary shares. If we ask for the ADS holders&#8217;
instructions, the depositary will notify the ADS holders of the upcoming vote and arrange to deliver our voting materials and form of
notice to them. The depositary will try, as far as is practical, subject to the provisions of the deposit agreement, to vote the shares
as the ADS holders instruct. The depositary will not vote or attempt to exercise the right to vote other than in accordance with the instructions
of the ADS holders. We cannot assure the ADS holders that they will receive the voting materials in time to ensure that they can instruct
the depositary to vote their shares. In addition, there may be other circumstances in which the ADS holders may not be able to exercise
voting rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADS holders do not have
the same rights to receive dividends or other distributions as our shareholders. Subject to any special rights or restrictions attached
to a share, the directors may determine that a dividend will be payable on a share and fix the amount, the time for payment and the method
for payment (although we have never declared or paid any cash dividends on our ordinary stock and we do not anticipate paying any cash
dividends in the foreseeable future). Dividends and other distributions payable to our shareholders with respect to our ordinary shares
generally will be payable directly to them. Any dividends or distributions payable with respect to ordinary shares will be paid to the
depositary, which has agreed to pay to the ADS holders the cash dividends or other distributions it or the custodian receives on shares
or other deposited securities, after deducting its fees and expenses. The ADS holders will receive these distributions in proportion to
the number of shares their ADSs represent. In addition, there may be certain circumstances in which the depositary may not pay to the
ADS holders amounts distributed by us as a dividend or distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There are circumstances where it may be
unlawful or impractical to make distributions to the holders of the ADSs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The deposit agreement with
the depositary allows the depositary to distribute foreign currency only to those ADS holders to whom it is possible to do so. If a distribution
is payable by us in New Israeli Shekels, the depositary will hold the foreign currency it cannot convert for the account of the ADS holders
who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. If the exchange rates fluctuate
during a time when the depositary cannot convert the foreign currency, the ADS holders may lose some of the value of the distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The depositary is not responsible
if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. This means that the ADS holders
may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for the depository to make
such distributions available to them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholders&#8217; percentage ownership
in us may be diluted by future issuances of share capital, which could reduce their influence over matters on which shareholders vote.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Issuances of additional shares
would reduce shareholders&#8217; influence over matters on which our shareholders vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may fail to remain in compliance with
the continued listing standards of the Nasdaq Capital Market and a delisting of our ADSs could make it more difficult for investors to
sell their shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs were approved for
listing on the Nasdaq Capital Market in July 2013 where they continue to be listed. We are required to meet certain qualitative and financial
tests (including having stockholders&#8217; equity of at least $2.5 million, a market value of listed securities of $35 million or $500,000
of net income from continuing operations for the most recently completed fiscal year or two of the most recently completed fiscal years,
to maintain the listing of our ADSs on the Nasdaq Capital Market as set forth in Nasdaq listing rule 5550(b)(1) the (&#8220;Stockholders&#8217;
Equity Requirement&#8221; or &#8220;Rule 5550(b)(1)&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2023, the Company
received a written notification (the &#8220;Notice&#8221;) from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), notifying the Company
that it was not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on the Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq Listing Rule 5550(a)(2)
(the &#8220;Listing Rule&#8221;) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule
5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30
consecutive business days. Based on the closing bid price of the Company&#8217;s ADSs for the 30 consecutive business days from September
6, 2023, to October 17, 2023, the Company failed to meet the minimum bid price requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
the Company had 180 calendar days, or until April 15, 2024, to regain compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2024, the Company
received formal notice from Nasdaq stating that the Company regained compliance with the minimum bid price requirement set forth in the
Listing Rule. To regain compliance with the Listing Rule, the Company&#8217;s ADSs were required to maintain a minimum closing bid price
of $1.00 or more for at least 10 consecutive business days, which was achieved from March 18, 2024 through April 1, 2024. Nasdaq has stated
that this matter is now closed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not maintain compliance
with the continued listing requirements for Nasdaq within specified periods and subject to permitted extensions, our ADSs may be recommended
for delisting (subject to any appeal we would file). If our ADSs were delisted, it could be more difficult to buy or sell our ADSs and
to obtain accurate quotations, and the price of our stock could suffer a material decline. Delisting would also impair our ability to
raise capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to maintain compliance
with Nasdaq&#8217;s continued listing standards, we may be delisted and our ADSs will trade, if at all, only on the over-the-counter market,
such as the OTC Bulletin Board or OTCQX market, and then only if one or more registered broker-dealer market makers comply with quotation
requirements. In addition, delisting of our ADSs could depress the price of our ADSs, substantially limit liquidity of our ADSs and materially
adversely affect our ability to raise capital on terms acceptable to us, or at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, delisting of our
ADSs would likely result in our ADSs becoming a &#8220;penny stock&#8221; under the Securities Exchange Act. The principal result or effect
of being designated a &#8220;penny stock&#8221; is that securities broker-dealers cannot recommend the shares but must trade it on an
unsolicited basis. Penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those
rules, to deliver a standardized risk disclosure document prepared by the SEC, which specifies information about penny stocks and the
nature and significance of risks of the penny stock market. A broker-dealer must also provide the customer with bid and offer quotations
for the penny stock, the compensation of the broker-dealer and sales person in the transaction, and monthly account statements indicating
the market value of each penny stock held in the customer&#8217;s account. In addition, the penny stock rules require that, prior to a
transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the
penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written agreement to the transaction. These disclosure
requirements may have the effect of reducing the trading activity in the secondary market for shares that become subject to those penny
stock rules. Under such circumstances, shareholders may find it more difficult to sell, or to obtain accurate quotations, for our ADSs,
and our ADSs would become substantially less attractive to certain purchasers such as financial institutions, hedge funds and other similar
investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Relating to Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We conduct our
operations in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and
its region.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
headquarters, are located in Israel and we conduct operations in Israel. Accordingly, political, economic and military conditions in the
Middle East may affect our business directly. Since the establishment of the State of Israel in 1948, a number of armed conflicts have
taken place between Israel and its neighboring countries, as well as terrorist acts committed within Israel by hostile elements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
particular, in October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of
attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers
located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands
of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers. Following the attack, Israel&#8217;s security
cabinet declared war against Hamas and commenced a military campaign against Hamas and these terrorist organizations in parallel continued
rocket and terror attacks. As a result of the events of October 7, 2023 whereby Hamas terrorists invaded southern Israel and launched
thousands of rockets in a widespread terrorist attack on Israel, the Israeli government declared that the country was at war and the Israeli
military began to call-up reservists for active duty. Military service call ups that result in absences of personnel from us for an extended
period of time may materially and adversely affect our business, prospects, financial condition and results of operations. As of the date
hereof, we have no employees, and our management which provide services through a consultant agreement weren&#8217;t called for duty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, since the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon
(with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). It is possible that hostilities with
Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank
as well as other hostile countries, such as Iran, will join the hostilities. Such clashes may escalate in the future into a greater regional
conflict. Further, in April 2024, Iran launched a direct attack on Israel involving hundreds of drones, ballistic missiles and cruise
missiles and may attack again. In addition, Iran is widely believed to be developing nuclear weapons. Iran is also believed to have a
strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various
rebel militia groups in Syria and Iraq. These situations may potentially escalate in the future to more violent events which may affect
Israel and us. Any hostilities, armed conflicts, terrorist activities involving Israel or the interruption or curtailment of trade between
Israel and its trading partners, or any political instability in the region could adversely affect business conditions and our results
of operations and could make it more difficult for us to raise capital and could adversely affect the market price of our ordinary share.
An escalation of tensions or violence might result in a significant downturn in the economic or financial condition of Israel, which could
have a material adverse effect on our operations in Israel and our business. Parties with whom we do business have sometimes declined
to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order
to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom
we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements
pursuant to force majeure provisions in such agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Since
the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced disruptions
to our operations. the intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict at this stage, as are
such war&#8217;s economic implications on the Company&#8217;s business and operations and on Israel&#8217;s economy in general. if the
war extends for a long period of time or expands to other fronts, such as Lebanon, Syria and the West Bank, our operations may be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
commercial insurance does not cover losses that may occur as a result of events associated with the security situation in the Middle East.
Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts
of war, we cannot assure you that this government coverage will be maintained. Any losses or damages incurred by us could have a material
adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions
and could harm our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the State of Israel
and Israeli companies have been subjected to an economic boycott. Several countries still restrict business with the State of Israel and
with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or
the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Finally,
political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior
to October 2023, the Israeli government pursued extensive changes to Israel&#8217;s judicial system, which sparked extensive political
debate and unrest. To date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel
or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in
turn, our business, financial condition, results of operations and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our results of operations may be adversely
affected by inflation and foreign currency fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hold most of our cash,
cash equivalents and bank deposits in U.S. dollars. As we are located in Israel, a significant portion of our expenses are in New Israeli
Shekels, or NIS, mainly due to payment to Israeli service providers and suppliers. Our investment in the shares of InterCure Ltd. is also
in NIS. As a result, we could be exposed to the risk that the U.S. dollar will be devalued against the NIS or other currencies, and consequentially
our financial results could be harmed. To protect against currency fluctuations, we may decide to hold a significant portion of our cash,
cash equivalents, bank deposits and marketable securities in NIS, as well as to enter into currency hedging transactions. These measures,
however, may not adequately protect us from the adverse effects of inflation in Israel. In addition, we are exposed to the risk that the
rate of inflation in Israel will exceed the rate of devaluation of the New Israeli Shekel in relation to the U.S. dollar or that the timing
of any devaluation may lag behind inflation in Israel.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law may delay, prevent
or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of
such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated
under the laws of the State of Israel, we are subject to Israeli corporate law regulates mergers, requires tender offers for acquisitions
of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders
and regulates other matters that may be relevant to these types of transactions. For example, a merger may not be consummated unless at
least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of Companies
and at least 30 days from the date that the shareholders of both merging companies approved the merger. In addition, the holder of a majority
of each class of securities of the target company must approve a merger. Moreover, a full tender offer can only be completed if the acquirer
receives at least 95% of the issued share capital (provided that a majority of the offerees that do not have a personal interest in such
tender offer shall have approved the tender offer, except that if the total votes to reject the tender offer represent less than 2% of
the company&#8217;s issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that do not have a
personal interest in such tender offer is not required to complete the tender offer), and the shareholders, including those who indicated
their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition the court
to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder that accepts the
offer may not seek appraisal rights).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to those of our shareholders whose country of residence does not have a tax treaty
with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to
the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the
deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction
during which sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap
transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of
the shares has occurred.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other similar provisions
could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be
beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a U.S. judgment
against us, our officers or our directors or to assert U.S. securities law claims in Israel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Service of process upon us,
since we are incorporated in Israel, and upon our directors and officers, who reside outside the U.S., may be difficult to obtain within
the U.S. In addition, because substantially all of our assets and most of our directors and officers are located outside the U.S., any
judgment obtained in the U.S. against us or any of our directors and officers may not be collectible within the U.S. There is a doubt
as to the enforceability of civil liabilities under the Securities Act or the Exchange Act pursuant to original actions instituted in
Israel. Subject to particular time limitations and provided certain conditions are met, executory judgments of a U.S. court for monetary
damages in civil matters may be enforced by an Israeli court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Under applicable U.S. and Israeli law, we
may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise
of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions irrespective of their
agreements with us, which in turn could impact our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter into non-competition
agreements with our key consultants. These agreements prohibit our key consultants, if they cease working for us, from competing directly
with us or working for our competitors or clients for a limited period of time. We may be unable to enforce these agreements under the
laws of the jurisdictions in which our key consultants work and it may be difficult for us to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us. For example, Israeli courts have required employers
seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee
will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy
of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that
such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees
or consultants and our ability to remain competitive may be diminished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Chapter 8 to
the Israeli Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during
his or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law, sets
forth that if there is no agreement which explicitly determines whether the employee is entitled to compensation for the service inventions
and the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory
committee of the Israeli Patents Office. As a result, it is unclear if, and to what extent, our research and development employees may
be able to claim compensation with respect to our future revenue. As a result, we may receive less revenue from future products if such
claims are successful, which in turn could impact our future profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a shareholder
will be governed by Israeli law which may differ in some respects from the rights and responsibilities of shareholders of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of the holders of our ordinary shares and ADSs are governed by our Articles of Association
and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical
U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith toward the company and other
shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share
capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who knows
that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive
officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the
implications of these provisions that govern shareholders&#8217; actions. These provisions may be interpreted to impose additional obligations
and liabilities on holders of our ordinary shares and ADSs that are not typically imposed on shareholders of U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Relating to Weaknesses in Internal Accounting
Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management previously
identified a deficiency that was concluded to represent a material weakness in our internal control over financial reporting related to
our improper classification of the Company&#8217;s warrants as equity (and not as a non-current liability). The SEC defines the term &#8220;material
weakness&#8221; as &#8220;a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected
on a timely basis.&#8221;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To remediate the material
weakness, we developed a new quarterly control to review the proper classification of warrant instruments. This control includes the participation
of the CFO, Controller and outside legal counsel to ensure that the accounting and financial reporting impacts are appropriately analyzed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have remediated the
previously identified material weakness, we may discover future deficiencies in our internal controls over financial reporting, including
those identified through testing conducted by us or subsequent testing by our independent registered public accounting firm. Any failure
to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in
additional material weaknesses or significant deficiencies and cause us to fail to meet our reporting obligations or result in material
misstatements in our financial statements. Furthermore, any failure in the effectiveness of our system of internal control over financial
reporting could have a material adverse impact on our ability to report our financial results in an accurate and timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>A.
ITEM 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>A. History and Development of XTL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Our current IP portfolio
is surrounding hCDR1 for the treatment of Lupus disease (SLE) and Sj&#246;gren&#8217;s Syndrom (SS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Company Information and History</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial name
is XTL Biopharmaceuticals Ltd. We were established as a private company limited by shares under the laws of the State of Israel on March
9, 1993, under the name Xenograft Technologies Ltd. We re-registered as a public company on June 7, 1993, in Israel, and changed our name
to XTL Biopharmaceuticals Ltd. on July 3, 1995.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We commenced operations to
use and commercialize technology developed at the Weizmann Institute, in Rehovot, Israel. Since 1993, we have pursued therapeutic and
pharmaceutical development programs for the treatment of a variety of indications including hepatitis B, hepatitis C, diabetic neuropathic
pain, schizophrenia, SLE, and multiple myeloma, most of which have terminated. We are looking at additional assets both in the field of
drug development as well as other fields.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have one subsidiary,
Xtepo Ltd., a private company limited by shares under the laws of the State of Israel which holds a license for the exclusive use of rHuEPO
for the treatment of multiple myeloma. As of December 31, 2023, we hold approximately 1.04% of the issued and outstanding share capital
of InterCure Ltd., a related party and former subsidiary of ours (subsidiary between mid-2012 and the beginning of 2015).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs are listed for trading
on the Nasdaq Capital Market under the symbol &#8220;XTLB.&#8221; Our ordinary shares are traded on the TASE under the symbol &#8220;XTLB.&#8221;
We operate under the laws of the State of Israel under the Israeli Companies Law, and in the U.S., the Securities Act and the Exchange
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal offices are
located at 26 Ben-Gurion St., Ramat Gan 5112001, Israel, and our telephone number is (972) 3-6116600. Our primary internet address is
www.xtlbio.com. None of the information on our website is incorporated by reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Introduction</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
company, the current core business of which is the acquisition and development of pharmaceutical drugs for the treatment of autoimmune
diseases. Our current drug, hCDR1, is a potential treatment for (1) systemic lupus erythematosus, or SLE and (2) Sjogren&#8217;s syndrome,
or SS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sole drug candidate is
hCDR1, a Phase II-ready asset for the treatment of SLE, the most prominent type of lupus. There is currently no known cure for SLE. Lupus
is a chronic autoimmune disease involving many systems in the human body, including joints, kidneys, the central nervous system, heart,
the hematological system and others. The biologic basis of the disease is a dysfunction of the immune (defense) system, leading to production
of self (auto) antibodies, attacking healthy organs and causing damage that can be irreversible. According to research estimates of the
Lupus Foundation of America, at least 1.5 million Americans have the disease (more than 5 million worldwide) with more than 16,000 new
cases diagnosed each year in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">hCDR1 is a peptide (short
protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. It
postulated to do so by specific upstream immunomodulation through the generation of regulatory T cells, reducing inflammation and resuming
immune balance. More than 40 peer-reviewed papers have been published on hCDR1. Two placebo-controlled Phase I trials and a placebo controlled
Phase 2 trial, or the PRELUDE trial, were conducted on patients with SLE by Teva Pharmaceutical Industries, Ltd., or Teva, which had previously
in-licensed hCDR1 from Yeda Research and Development, or Yeda. The studies consisted of over 400 patients and demonstrated that hCDR1
is well tolerated by patients and has a favorable safety profile. The PRELUDE trial did not achieve its primary efficacy endpoint based
on the SLE Disease Activity Index, or SLEDAI scale, resulting in Teva returning the asset to Yeda. However, the PRELUDE trial showed encouraging
results in its secondary clinical endpoint, the British Isles Lupus Activity Group index, or BILAG index, and, in fact, the 0.5 mg weekly
dose showed a substantial effect. Multiple post-hoc analyses also showed impressive results for this dose using the BILAG index. Such
dose will be the focus of the clinical development plan moving forward. Subsequent to Teva&#8217;s return of the program to Yeda, the
FDA directed that the primary endpoint in future trials for Lupus therapies, including those for hCDR1, should be based on either the
BILAG index or the SLE Responder Index (&#8220;SRI&#8221;). The FDA has provided the Company with written guidance confirming the acceptability
of BILAG as the primary endpoint in our planned study. The Company has decided to reduce its research and development expenditures in
connection with the execution of clinical trials relating to hCDR1 until full funding for the trials or cooperation with a strategic partner
is secured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">hCDR1is also Phase II-ready
for the treatment of SS. SS is also a chronic autoimmune disorder affecting lacrimal and salivary gland function (glandular) but may also
affect other organs and systems (extraglandular) such as the kidneys, gastrointestinal system, blood vessels, lungs, liver, pancreas,
and the nervous system. There is currently no known cure for SS. The only specific treatments available, such as Salagen and Evoxac, are
symptomatic, aiming to alleviate dry eyes and dry mouth. A number of immunomodulatory agents including corticosteroids, hydroxychloroquine,
cyclosporine, and other immunosuppressive agents are used to treat SS. The biologic basis of the disease is a dysfunction of the immune
system, leading to production of antibodies that attack healthy organs causing damage that may be irreversible. Disease prevalence estimations
vary from 2.5 million patients (Global Data Research 2016) to 4 million patients (Sjogren&#8217;s Syndrome Foundation) in the US alone,
with a worldwide estimate of up to an aggregate of 7.7 million in in the United States, France, Germany, Italy, Spain, United Kingdom,
and Japan by the year 2024 (Global Data Research).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, blood
mononuclear cells (PBMCs) obtained from blood samples of patients with primary SS (pSS) were incubated in vitro in the presence of hCDR1
and a control peptide. Following 48 hours of incubation, cells were collected and mRNA was prepared from all samples. The expression of
various genes was determined using real-time -PCR. The results obtained to date indicate that in vitro incubation of PBMCs of pSS patients
with hCDR1 resulted in a significant reduction of gene expression of four pathogenic cytokines known to be involved in SS and lupus (including
B-lymphocyte stimulator or BLyS), as well as upregulation of two immunosuppressive genes, one of which is a marker for activity of regulatory
T cells. The majority of such effects were previously seen in similar studies involving lupus patients. Because amelioration of SLE manifestations
in murine models as well as in SLE patients was associated with down-regulation of pathogenic cytokines, we believe it is likely that
hCDR1 is capable of beneficially affecting SS patients. In addition, based on hCDR1&#8217;s favorable safety profile in over 400 SLE patients
(as noted above), as well as the same route of administration as in SLE and similar doses, we believe we believe in hCDR1 potential to
be of benefit for SLE patients as well .</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">The Company is exploring
the expansion of its IP portfolio surrounding hCDR1 and at the same time has decided to reduce its research and development expenditures
in connection with execution of its clinical trials. In parallel, the Company searches to identify additional assets to add to XTL&#8217;s
portfolio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our objective is to be a leading
biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
We are currently looking for new opportunities in order to expand our business by acquiring new activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is expanding its
IP portfolio surrounding hCDR1 and has decided a few years ago to reduce its research and development expenditures in connection with
execution of its clinical trials until full funding for the trials or cooperation with a strategic partner is secured. In parallel, the
Company will look to identify additional assets to add to XTL&#8217;s portfolio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
March 17, 2024 the Company&#8217;s board of directors approved the grant of 148,500 options exercisable into 148,500 ADSs of the Company,
out of which 138,500 are subject to shareholders meeting to be held on April 30, 2024 (which was approved on April 30, 2024 by Company&#8217;s
shareholders meeting) to certain officers and directors of the Company. 100,000 options will be fully vested on date of grant and 48,500
options will vest according to Company&#8217;s 2011 share option plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
March 20, 2024, the Company announced that it entered into a binding term sheet with THE SOCIAL PROXY Ltd. (the &#8220;Social Proxy&#8221;)
an artificial intelligence web data company, developing and powering a unique ethical, intellectual property based, proxy and data extraction
platform for artificial intelligence and BI applications at scale (the &#8220;Term Sheet&#8221;).</span> The proposed Transaction is part
of the Company&#8217;s strategy to expand its assets portfolio with high potential assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Term Sheet,
the Company will acquire all of the issued and outstanding share capital of The Social Proxy on a fully diluted basis (the &#8220;Transaction&#8221;)
in exchange for the issuance by the Company to the shareholders of the Social Proxy, such number of ordinary shares of the Company, representing
immediately after such issuance, 44.6% of the issued and outstanding share capital of the Company and the payment of $430,000 to the
shareholders of the Social Proxy. In addition, as part of the Transaction, the shareholders of Social Proxy will be issued additional
warrants or ordinary shares, which may only be exercised or granted upon reaching certain financial measured milestones within a period
of up to three years from the closing of the Transaction. The securities to be issued to the owners of the Social Proxy will be issued
pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 (the &#8220;Securities Act&#8221;),
as amended, for transactions not involving a public offering. The Transaction is conditioned upon certain closing conditions which are
fully described in the Term Sheet. Social Proxy will operate as fully owned subsidiary of the Company and its shareholders will be entitled
to appoint two representatives to the Company&#8217;s board of directors out of a total of up to seven directors. Consequently, the Company
approved to extend the resigning directors options exercise period for an additional 9 months period and up to an aggregate 12 months
period following such termination date, which is subject to shareholders approval (which was approved on April 30, 2024 by Company&#8217;s
shareholders meeting).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to support the
Company&#8217;s financial needs and in order to complete the Transaction, the Company has secured a commitment of an investment of
an amount of $1,500,000 through a private placement to be consummated upon and subject to the closing of the Transaction (the
&#8220;Private Placement&#8221;). In exchange for the investment in the Private Placement, the investors will be issued 1,500,000
units (reflecting a price per each unit of US$1.00) consisting of one ADS and one warrant, such warrant may be exercised during a
period of five years from its issuance into one ADS at an exercise price of $1.20 per warrant. Consummation of the Private Placement
is conditioned upon customary closing conditions and obtaining shareholders&#8217; approval as Alexander Rabinovich, a 23.5%
shareholder and a director of the Company, is one of the investors in this Private Placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The completion of the Transaction
is subject to negotiation of definitive agreements, containing representations, warranties and covenants as well as the satisfaction of
various conditions required prior to closing, all as are customary for transactions of this nature, including, without limitation, the
satisfaction of the Company, in its sole discretion, of a due diligence into Social Proxy, the approval of the&#160;Transaction&#160;by
the Company&#8217;s shareholders and receipt of necessary government or third-party approvals, if required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2024 we entered into a loan agreement with the Social
Proxy. According to the loan agreement, On March 27, 2024, we provided a $150 thousands loan. The loan bears an annual interest of 8%.
The loan and accrued interest will be repaid at the earlier of (1) 120 days following March 27, 2024 or (2) the date upon which the parties
decide to abandon attempts for Transaction. Upon repayment date, Social Proxy may repay the outstanding loan and accrued interest in 18
equal monthly installments. Social Proxy provided a first priority floating charge over all of it assets as a security to ensure repayment
of the loan and accrued interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Products Under Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>hCDR1 for the Treatment of Systemic Lupus Erythematosus</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Market Opportunity</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">hCDR1 (edratide) is a Phase
2-ready asset for the treatment of SLE, the most prominent type of lupus. SLE is a heterogenous, chronic, debilitating inflammatory autoimmune
disease characterized by the production of an array of autoantibodies, including antibodies to double-stranded DNA, to other nuclear antigens,
and to ribonucleoproteins. Although SLE can affect any part of the body, most patients experience systemic symptoms including fever, fatigue
and malaise along with symptoms in one or only a few organs. The most common signs and symptoms are arthralgia, arthritis, fatigue, fever,
skin rashes, including a characteristic butterfly-shaped rash across the cheeks and nose, anemia and pleurisy. The clinical course of
SLE may also include periods in which few, if any, symptoms are evident and other times when the disease becomes more active.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to research estimates
of the Lupus Foundation of America, at least 1.5 million Americans have the disease (more than 5 million worldwide) with more than 16,000
new cases diagnosed each year in the United States. The Lupus Foundation of America reports that lupus affects mostly women of childbearing
age (15-44). SLE is one of the most common forms of lupus, affecting over 70% of lupus patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SLE treatment is highly individualized
and is based on a patient&#8217;s disease severity, organ involvement and previous response. Mild forms of SLE may be treated with antimalarial
medications, non-steroidal anti-inflammatory drugs, and topical and/or low-dose glucocorticoids, although treatment with methotrexate
may be needed. In addition, low-dose oral steroids or intramuscular injections of depot steroid preparations can be used for mild disease.
More severe cases of SLE may be treated with high-dose glucocorticoids and immunosuppressive or cytotoxic drugs to suppress the immune
system. GlaxoSmithKline&#8217;s Benlysta (belimumab), a monoclonal antibody, is a newer medication that is FDA-approved for patients with
mild to moderate SLE currently taking standard therapy who have not yet experienced an adequate response. Benlysta is the first product
to gain marketing approval for patients with SLE in more than 50 years, paving the way for the introduction of new disease-modifying therapies
and reigniting the interest of pharmaceutical developers in this therapy area. GlaxoSmithKline reported that its 2020 sales of Benlysta
were up 17% AER (annual equivalent rate), 19% CER (coupon equivalent rate) to &#163;719 million (approximately USD 982 million), including
sales of the sub-cutaneous formulation of &#163;354 (approximately USD 483 million) million up 32% AER, 33% CER.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>hCDR1: General &amp; Mechanism
of Action</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">hCDR1 is a synthetic peptide
composed of 19 amino-acid residues. It was developed by Teva in collaboration with Prof. Edna Mozes of the Weizmann Institute of Science,
Rehovot, Israel. The sequence of the peptide is based on the complementarity determining region 1 (CDR1) of a pathogenic human anti-dsDNA
mAb that bears the 16/6 idiotype. The idiotype was found to have clinical relevance in SLE patients.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accumulating data from&#160;<i>in
vivo</i>&#160;and&#160;<i>in vitro</i>&#160;studies demonstrate that hCDR1 functions by inducing regulatory T cell function through multiple
pathways. Administration of hCDR1 to mice has been shown to induce CD4&#160;+&#160;CD25&#160;+&#160;cells using regulatory and suppressor
characteristics such as CD45RB&#160;LOW, TGF-, CTLA-4 and Foxp3. This induction suppresses autoreactive CD4&#160;+&#160;cell activation,
indicated by the reduced expression of CD69 and Fas ligand; ultimately, resulting in reduced rates of activation-induced apoptosis. Inhibition
by hCDR1-induced CD4&#160;+&#160;CD25&#160;+&#160;cells is mediated through the immunosuppressive cytokine TGF-. TGF- secretion is up
regulated and activated autoreactive cells are decreased; both are associated with a decrease of pathogenic cytokines such as interferon
gamma (IFN-), interleukin-10 (IL-10), interleukin-1 beta (IL-1), and tumor necrosis factor-alpha (TNF-). Effects on TGF- and Foxp3 have
been shown to correlate with a significant decrease in SLEDAI-2K and BILAG scores in patients treated with hCDR1 in comparison with patients
treated with placebo. Another subset of T cells (CD8&#160;+&#160;CD28&#160;-) expresses Foxp3 and has been shown to be essential for the
induction and the optimal suppressive function of CD4&#160;+&#160;CD25&#160;+&#160;cells. The function of hCDR1-induced subsets of regulatory
T cells result in the effective suppression, ultimately leading to the modulation of the underlying aberrancy of the immune system, which
we believe culminates in the diminished activity of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">hCDR1 was extensively investigated
for its ability to down-regulate the autoimmune response elicited by the pathogenic antibodies and autoreactive T cells in SLE and up-regulate
the expression of gene markers, such as TGF-&#946; and FoxP3. Therefore hCDR1 may attenuate the general SLE-associated autoimmune process
and provide effective treatment for many clinical manifestations of SLE. The clinical development plan is thus designed to demonstrate
the efficacy of hCDR1 in the systemic disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Clinical Trial History</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to being licensed to
us by Yeda, hCDR1 was licensed to Teva which performed two placebo controlled Phase I trials and a placebo controlled Phase 2 trial, or
the PRELUDE trial. The Phase I and Phase 2 studies consisted of over 400 patients, demonstrating that hCDR1 is well tolerated by patients
and has a favorable safety profile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRELUDE trial was a 26-week
study conducted at 48 centers in 12 countries: Canada, France, Germany, Holland, Hungary, Israel, Italy, Mexico, Russia, Spain, UK and
U.S. enrolling 340 patients with mild to moderate SLE. The PRELUDE trial did not achieve its primary efficacy endpoint based on the SLEDAI
scale, resulting in Teva returning the asset to Yeda in 2009. However, the PRELUDE trial showed encouraging results in its secondary clinical
endpoint, the BILAG index, and, in fact, the 0.5 mg weekly dose showed a substantial effect. Multiple post-hoc analyses also showed impressive
results for this dose using the BILAG index. Such dose will be the focus of clinical development moving forward. Subsequent to Teva&#8217;s
return of the program to Yeda, in 2010 the FDA directed that the primary endpoint in future trials for lupus therapies, including those
for hCDR1, should be based on either the BILAG index or the Systemic Lupus Erythematosus Responder Index. The FDA has provided the Company
with written guidance confirming the acceptability of BILAG as the primary endpoint in our planned study, subject to receipt of adequate
financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Planned Clinical Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company submitted a pre-Investigational
New Drug (&#8220;IND&#8221;) meeting package, including a draft protocol for our planned clinical trial, to the FDA in December 2015.
In January 2016, the Company received a written response to its pre-IND meeting package in which the FDA provided guidance on several
key aspects of its proposed clinical trial including: acceptance of the primary efficacy endpoint to be based on the BILAG index, a measure
of lupus disease activity which was the secondary efficacy endpoint in the PRELUDE trial and confirmation of the appropriate patient population
and total number of patients required to prove safety for a new drug application (NDA) for marketing approval. The FDA recommended that
the trial be a Phase 2 study and also provided additional guidance on other aspects of the trial design including doses and study duration.
The Company has decided to reduce its research and development expenditures in connection with the execution of clinical trials relating
to hCDR1 until full funding for the trials or cooperation with a strategic partner is secured. Subject to receipt of such funding or cooperation
with a strategic partner, based on the FDA&#8217;s response, XTL could file its IND, and initiate a global clinical trial for hCDR1 in
the treatment of SLE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>hCDR1 for the Treatment of Sjogren&#8217;s Syndrome</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Market Opportunity</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">hCDR1 (Edratide) is a Phase
2-ready asset for the treatment of SS. SS is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of exocrine
glands. Sjogren&#8217;s syndrome may be an isolated disease, termed primary Sjogren syndrome (pSS) or may accompany another autoimmune
disease, thus termed secondary Sjogren&#8217;s syndrome. Clinical presentation varies from mild symptoms such as classic sicca symptoms
of dry eyes (xerophthalmia), dry mouth (xerostomia) and parotid gland enlargements to severe systemic symptoms involving multiple organ
systems such as arthritis, arthralgia, myalgia, pulmonary disease, gastrointestinal disease, neuropathy and lymphoma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to SLE, SS&#160;is
a heterogenous, chronic, inflammatory autoimmune disease. Some of the autoantibodies characteristic of pSS occur in SLE as well, including
antinuclear antibody (ANA), anti-Ro (also termed anti SSA), anti-La (also termed anti SSB) as well as rheumatoid factor (RF). Hypergammaglobulinemia
is common as well. pSS affects the salivary and lacrimal glands with chronic inflammation leading to the most common symptoms seen in
SS including dry eyes and dry mouth. In addition, SS may affect multiple systems with clinical manifestations similar to those seen in
SLE including fever, fatigue and malaise along with symptoms in one or only a few organs including arthralgia, arthritis, fatigue, vasculitic
rashes, interstitial lung disease, kidney disease as well as neurologic manifestations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disease prevalence estimations
vary from 2.5 million (Global Data Research 2016) to 4 million patients (Sjogren&#8217;s Syndrome Fopundation) in the US alone, with a
worldwide estimate of up to 7.7 million in the 7 Major Markets (US, France, Germany, Italy, Spain, the UK and Japan) by the year 2024
(Global Data Research). pSS affects mostly middle aged women (40-50 years of age) with a female to male prevalence ratio of 9:1 (some
estimates even go as far as 20:1). pSS patients have an increased risk of developing non-Hodgkin&#8217;s B cell lymphoma (relative risk
of 13.76.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">pSS treatment is highly individualized
and is based on a patient&#8217;s disease severity, organ involvement and previous response. Mild forms of pSS may be treated symptomatically
with artificial tears and salivary flow stimulation. Fatigue and arthralgia may respond to antimalarial medications. More severe, systemic
manifestations may be treated with high-dose glucocorticoids and immunosuppressive or cytotoxic drugs to suppress the immune system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Global Data estimates the
drug sales for SS in 2014 were approximately $990 million in the US and $1.1 billion across the markets covered in its forecast. By the
end of the forecast period of 2024, sales are estimated to grow to $1.9 billion in the US and $2.2 billion across the markets covered
in its forecast with a Compound Annual Growth Rate of 7.2%. The market size estimate in 2014 includes Salagen (pilocarpine) and Evoxac
(cevimeline), the two FDA approved agents for SS, and the common use of off-label agents, such as biologics approved for other autoimmune
diseases, and systemic and topical immunosuppressants and corticosteroids.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>hCDR1: General &amp; Mechanism
of Action</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See above discussion regarding the Mechanism of
Action of hCDR1 for SLE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since SS is an autoimmune
disease similar to SLE with some autoantibodies and clinical manifestations identical with those detected in SLE, and since there is no
specific treatment for Sjogren&#8217;s syndrome, the experiments were undertaken on the Company&#8217;s behalf by Professor Edna Mozes
of the Weizmann Institute in Israel to determine the ability of hCDR1 to beneficially affect autoimmune responses related to this disease.
To this end, PBMCs obtained from blood samples of pSS patients were incubated in vitro in the presence of hCDR1 and a control peptide.
Following 48 hours of incubation, cells were collected and mRNA was prepared from all samples. The expression of various genes was determined
using real-time PCR. The results obtained to date indicate that in vitro incubation of PBMCs of pSS patients with hCDR1 resulted in a
significant reduction of gene expression of four pathogenic cytokines known to be involved in SS and lupus (including B-lymphocyte stimulator
or BLyS), as well as upregulation of two immunosuppressive genes, one of which is a marker for activity of regulatory T cells. The vast
majority of such effects were previously seen in similar studies involving lupus patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Clinical Trial History</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No clinical trials with hCDR1
in SS have been performed to date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Planned Clinical Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, hCDR1 has
been tested in greater than 400 SLE patients to date. Given its clean safety profile, shown in three different clinical studies, subject
to receipt of adequate financing and/or entry into a collaboration agreement, we will consider whether to test hCDR1 in a small Phase
2 clinical trial in pSS. The objectives of the study will be to test the safety &amp; efficacy of different doses of hCDR1 in pSS patients
in addition to a control arm. Such study is not being actively considered due to financial constraints and, therefore, we do not have
accurate forecasts regarding the size and duration of such study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>rHuEPO for the Treatment
of Multiple Myeloma</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our focus has changed,
we do not anticipate conducting material research and development activities for rHuEPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt; text-align: justify; text-indent: 28.35pt"><b>Patents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt; text-align: justify; text-indent: 28.35pt"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents and other proprietary
rights are very important to the development of our business. We will be able to protect our proprietary technologies from unauthorized
use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained
as trade secrets. We intend to seek and maintain patent and trade secret protection for our drug candidates and our proprietary technologies.
As part of our business strategy, our policy is to file patent applications in the U.S. and internationally to cover methods of use, new
chemical compounds, pharmaceutical compositions and dosing of the compounds and compositions and improvements in each of these. We also
rely on trade secret information, technical know-how, innovation and agreements with third parties to continuously expand and protect
our competitive position. Because of the extensive time required for development, testing and regulatory review of a potential product,
it is possible that before we commercialize any of our products, any related patent may expire or remain in existence for only a short
period following commercialization, thus reducing any commercial advantage or financial value attributable to the patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, patent applications
in the U.S. are maintained in secrecy for a period of at least 18 months. Since publication of discoveries in the scientific or patent
literature often lag behind actual discoveries, we are not certain that we were the first to make the inventions covered by each of our
pending patent applications or that we were the first to file those patent applications. The patent positions of biotechnology and pharmaceutical
companies are highly uncertain and involve complex legal and factual questions. Therefore, we cannot predict the breadth of claims allowed
in biotechnology and pharmaceutical patents, or their enforceability. To date, there has been no consistent policy regarding the breadth
of claims allowed in biotechnology patents. Third parties or competitors may challenge or circumvent our patents or patent applications,
if issued. Granted patents can be challenged and ruled invalid at any time, therefore the grant of a patent is not of itself sufficient
to demonstrate our entitlement to a proprietary right. The disallowance of a claim or invalidation of a patent in any one territory can
have adverse commercial consequences in other territories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our competitors prepare
and file patent applications in the U.S. that claim technology also claimed by us, we may choose to challenge competing patent rights,
which could result in substantial cost, even if the eventual outcome is favorable to us. While we have the right to defend patent rights
related to our licensed drug candidates and technologies, we are not obligated to do so. In the event that we decide to defend our licensed
patent rights, we will be obligated to cover all of the expenses associated with that effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a patent is issued to a
third party containing one or more preclusive or conflicting claims, and those claims are ultimately determined to be valid and enforceable,
we may be required to obtain a license under such patent or to develop or obtain alternative technology. In the event of a litigation
involving a third party claim, an adverse outcome in the litigation could subject us to significant liabilities to such third party, require
us to seek a license for the disputed rights from such third party, and/or require us to cease use of the technology. Further, our breach
of an existing license or failure to obtain a license to technology required to commercialize our products may seriously harm our business.
We also may need to commence litigation to enforce any patents issued to us or to determine the scope, validity and/or enforceability
of third-party proprietary rights. Litigation would involve substantial costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt; text-align: justify; text-indent: 28.35pt"><b><i>hCDR1 for
the Treatment of SLE and SS</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have exclusively licensed
from Yeda, three families of patents relating to hCDR1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A basic patent family entitled &#8220;Synthetic Human Peptides and Pharmaceutical Compositions Comprising Them&#8221; for the Treatment of Systemic Lupus Erythematosus&#8221; that covers the active pharmaceutical agent, the Edratide peptide. The patent has been granted in a large number of jurisdictions: U.S., Europe (Austria, Denmark, Finland, France, Germany, Ireland, Italy, Liechtenstein, Spain, Sweden, Switzerland, The Netherlands and the UK), Australia, Canada, Hong Kong, India, Israel, Japan, Korea, Mexico, Norway, Hungary and Russia. The patent expired on February 26, 2022 except in the case of the U.S., which expired on September 22, 2022. Even once the patent expired the company is still protected by data exclusivity for 7-10 years in Europe and in the U.S.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A patent family for the formulation entitled &#8220;Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus&#8221; that covers a very specific pharmaceutical composition comprising Edratide. It has been granted in the U.S., Europe (Switzerland, Germany, Denmark, Spain, Finland, France, Great Britain, Ireland, Italy, Netherlands and Sweden), China, India, Israel, Japan, Mexico, and Canada. The patent expired on January 14, 2024. Even once the patent expired the company is still protected by data exclusivity for 7-10 years in Europe and in the U.S.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A patent family for treatment of Sj&#246;gren&#8217;s syndrome with Edratide and similar peptides was filed on January 4, 2018. A patent was Issued in UAS and the application was allowed in Japan and a patent is expected to be granted shortly. A patent application is pending in Europe, Australia, Canada, China, Hong Kong, and Israel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt; text-align: justify; text-indent: 28.35pt"><b>Other Intellectual
Property Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend upon trademarks,
trade secrets, know-how and continuing technological advances to develop and maintain our competitive position. To maintain the confidentiality
of trade secrets and proprietary information, we require our scientific advisors, consultants and collaborators, upon commencement of
a relationship with us, to execute confidentiality agreements and, in the case of parties other than our research and development collaborators,
to agree to assign their inventions to us. These agreements are designed to protect our proprietary information and to grant us ownership
of technologies that are developed in connection with their relationship with us. These agreements may not, however, provide protection
for our trade secrets in the event of unauthorized disclosure of such information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>Licensing
Agreements and Collaborations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.65pt; text-align: justify; text-indent: 28.35pt"><b>hCDR1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 7, 2014, we entered
into a license agreement with Yeda, as amended on September 6, 2015, which grants us the exclusive worldwide right to research, develop,
and commercialize hCDR1 for all indications. Yeda is the commercial arm of the Weizmann Institute of Science.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration, we are responsible
for a patent expense reimbursement to Yeda in six installments totaling $382,989. On May 14, 2014, we issued 222,605 of our ordinary shares
to Yeda, as the first of six installments, representing a value of approximately $38,000. On January 21, 2015, we issued a further 802,912
of our ordinary shares to Yeda as the second of six installments, representing a value of approximately $84,000. The remaining installments
of approximately $64,000 each, payable in cash, are due every six months commencing on July 1, 2015, with the final payment due on January
1, 2017. In July 2016, the Company and Yeda signed a second amendment to the license agreement whereby, the final two payments due under
the Agreement were to made on April 7, 2017, provided that if we receive funding of at least $5,000,000 then we shall be required to promptly
pay Yeda any unpaid patent expense reimbursement in one lump-sum cash payment. To this date the patent expenses were incurred but not
yet paid and the Company and Yeda have held discussions regarding further amendment to the payment scheme under the license agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the license agreement,
we are required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical trial, $1 million upon FDA
approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European Union&#8217;s Group of
Five. In addition, we are required to pay 2-3% royalties of annual net sales and sublicense fees of 15-20% of whatever we receive from
any sub-licensee. Under the license agreement, we are also required to meet certain development milestones including the delivery of a
trial protocol to Yeda by January 1, 2016 (which we delivered), receipt of investment of at least $5 million by August 1, 2016 (of which
$4 million was received in April 2015) and commencement of a Phase II clinical trial by January 1, 2017. In subsequent amendments signed
between the Company and Yeda, the parties agreed to postpone the last two installments of the patent expense reimbursement until April
7, 2017, receipt of the remainder of the required $5 million investment by May 1, 2017 and commencement of a Phase 2 clinical trial in
respect of hCDR1 by October 1, 2017. The Company decided not to conduct the phase 2 by itself and to look for a strategic partner. As
a result, the second milestone (commencement of Phase 2) was not met yet. To this date the Company and Yeda have held discussions regarding
further amendment to the payment scheme under the license agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of the license agreement
is the later of the date of expiry of the last of the licensed patents or the expiry of a continuous period of 11 years after first commercial
sale in any country during which there shall not have been a first commercial sale in the U.S., EU, Japan, China or any OECD member. The
license agreement may be terminated by us without cause upon 60 days prior written notice. The license agreement may also be terminated
by Yeda upon 45 days prior written notice if either we fail to meet certain development milestones or commercial sale shall have commenced
and there shall be a period of 6 months of no sales, subject to certain exceptions. Yeda shall also be entitled to terminate the license
agreement if we were to commence legal action against Yeda challenging the validity of any of the licensed patents, and we were unsuccessful
in such challenge, in which event we would be required to pay to Yeda liquidated damages of $8 million. Either party may also terminate
the license agreement in the case of a material breach that remains uncured or certain bankruptcy events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition in the pharmaceutical
and biotechnology industries is intense. Our competitors include pharmaceutical companies and biotechnology companies, as well as universities
and public and private research institutions. In addition, companies that are active in different but related fields represent substantial
competition for us. Many of our competitors have significantly greater capital resources, larger research and development staffs and facilities
and greater experience in drug development, regulation, manufacturing and marketing than we do. These organizations also compete with
us to recruit qualified personnel, attract partners for joint ventures or other collaborations, and license technologies that are competitive
with ours. To compete successfully in this industry we must identify novel and unique drugs or methods of treatment and then complete
the development of those drugs as treatments in advance of our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The drugs that we are attempting
to develop will have to compete with existing therapies. In addition, a large number of companies are pursuing the development of pharmaceuticals
that target the same diseases and conditions that we are targeting. Other companies have products or drug candidates in various stages
of pre-clinical or clinical development to treat diseases for which we are also seeking to discover and develop drug candidates. Some
of these potential competing drugs are further advanced in development than our drug candidates and may be commercialized earlier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>Competing
Products for Treatment of SLE</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Very few drugs have been approved
for Lupus in the last 50 years, including GlaxoSmithKline&#8217;s Benlysta (belimumab) and Aurinia Pharmaceuticals Voclosporin for lupus
nephritis. Other commonly used therapies include non-steroidal anti-inflammatory drugs, corticosteroids, anti-malarials and immunosuppressants.
Corticosteroids and immunosuppressants lead to broad, non-selective immunosuppression often associated with significant adverse events.
In addition these therapies are not effective in all SLE patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite initial enthusiasm
following approval of Benlysta as the first drug approved for SLE with a selective target, it has been approved to date only in patients
with mild to moderate disease, without active renal or CNS disease, its onset of action is slow and sales have been lower than expected.
Additional drugs are in advanced clinical development to treat SLE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>Competing Products for
Treatment of pSS</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No specific drug has been
approved for the cure of pSS. A variety of drugs are used for the symptomatic relief of signs and symptoms including the use of cholinergic
agonists e.g. Salagen (pilocarpine) and Evoxac (cevilemine). Immunomodulatory treatments, usually for extra-glandular disease, which may
be used include cyclosporine (ocular inflammation), hydroxychloroquine (mild inflammatory symptoms of joints, muscles&amp; skin), corticosteroids
(rare but serious symptoms: vasculitic rash, interstitial lung disease, interstitial nephritis, glomerulonephritis), immunosuppressive
agents e.g. methotrexate, azathioprine, cyclophosphamide (used to treat serious internal organ manifestations) and biologic agents e.g.
rituximab. Corticosteroids lead to broad, non-selective immunosuppression often associated with significant adverse events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and operations
are generally not affected by seasonal fluctuations or factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Raw Materials and Suppliers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the raw materials
that we require to manufacture hCDR1 and rHuEPO are widely available from numerous suppliers and are generally considered to be generic
industrial chemical supplies. We do not rely on a single or unique supplier for the current production of any therapeutic small molecule
in our pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no manufacturing
capabilities and do not intend to establish any such capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our drug candidate,
hCDR1, we believe that we will be able to outsource production to a contract manufacturer in order to obtain sufficient inventory to satisfy
the clinical supply needs for our future development for the treatment of SLE and SS. With respect to our drug candidate rHuEPO, we believe
that we will either be able to purchase rHuEPO from existing pharmaceutical companies or to enter into collaborative agreements with contract
manufacturers or other third-parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the time of commercial
sale, to the extent that it is possible and commercially practicable, we plan to engage a back-up supplier for each of our product candidates.
Until such time, we expect that we will rely on a single contract manufacturer to produce each of our product candidates under cGMP regulations.
Our third-party manufacturers have a limited number of facilities in which our product candidates can be produced and will have limited
experience in manufacturing our product candidates in quantities sufficient for conducting clinical trials or for commercialization. Our
third-party manufacturers will have other clients and may have other priorities that could affect our contractor&#8217;s ability to perform
the work satisfactorily and/or on a timely basis. Both of these occurrences would be beyond our control. We anticipate that we will similarly
rely on contract manufacturers for our future proprietary product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to similarly rely
on contract manufacturing relationships for any products that we may in-license or acquire in the future. However, there can be no assurance
that we will be able to successfully contract with such manufacturers on terms acceptable to us, or at all.</p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Contract manufacturers are
subject to ongoing periodic inspections by the FDA, the U.S. Drug Enforcement Agency and corresponding state and local agencies to ensure
strict compliance with cGMP and other state and federal regulations. We do not have control over third-party manufacturers&#8217; compliance
with these regulations and standards, other than through contractual obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we need to change manufacturers,
the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will involve testing and
additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. Furthermore,
switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for
us to find a replacement manufacturer quickly or on terms acceptable to us, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Environmental Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to time be
subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater
discharges, noise emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup
of contaminated sites. We believe that our business, operations and facilities are being operated in compliance in all material respects
with applicable environmental and health and safety laws and regulations. Based on information currently available to us, we do not expect
environmental costs and contingencies to have a material adverse effect on us. The operation of our testing facilities, however, entails
risks in these areas. Significant expenditures could be required in the future if these facilities are required to comply with new or
more stringent environmental or health and safety laws, regulations or requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government and Industry Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Numerous governmental authorities,
principally the FDA and corresponding state and foreign regulatory agencies, impose substantial regulations upon the clinical development,
manufacture and marketing of our drug candidates and technologies, as well as our ongoing research and development activities. None of
our drug candidates have been approved for sale in any market in which we have marketing rights. Before marketing in the U.S., any drug
that we develop must undergo rigorous pre-clinical testing and clinical trials and an extensive regulatory approval process implemented
by the FDA, under the Federal Food, Drug and Cosmetic Act of 1938, as amended. The FDA regulates, among other things, the pre-clinical
and clinical testing, safety, efficacy, approval, manufacturing, record keeping, adverse event reporting, packaging, labeling, storage,
advertising, promotion, export, sale and distribution of biopharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulatory review and
approval process is lengthy, expensive and uncertain. We are required to submit extensive pre-clinical and clinical data and supporting
information to the FDA for each indication or use to establish a drug candidate&#8217;s safety and efficacy before we can secure FDA approval.
The approval process takes many years, requires the expenditure of substantial resources and may involve ongoing requirements for post-marketing
studies or surveillance. According to the FDA, before commencing clinical trials in humans, we must submit an IND to the FDA containing,
among other things, pre-clinical data, chemistry, manufacturing and control information, and an investigative plan. Our submission of
an IND may not result in FDA authorization to commence a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were granted an Orphan-drug
designation from the FDA in May 2011, for rHuEPO. In the U.S., Orphan-drug designation is granted by the FDA Office of Orphan Drug Products
to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides
the drug developer with a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified
indication or if it demonstrates superior safety, efficacy, or a major contribution to patient care versus another drug of its type previously
granted the designation for the same indication, as well as with tax credits for clinical research costs, the ability to apply for annual
grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act filing fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may apply to the European
Medicines Agency in order to obtain Orphan-drug designation for its Recombinant Erythropoietin in Europe. Orphan designation is granted
by the European Medicines Agency, following a positive opinion from the Committee for Orphan Medicinal Products, to a medicinal product
that is intended for the diagnosis, prevention or treatment of a life-threatening or a chronically debilitating condition affecting not
more than five in 10,000 persons in the European Community when the application for designation is submitted. Orphan drug designation
provides the sponsor with access to the Centralized Procedure for the application for marketing authorization, protocol assistance, up
to a 100% reduction in fees related to a marketing authorization application, pre-authorization inspection and post-authorization activities,
and could provide ten years of market exclusivity in the EU, once approved for the treatment of Multiple Myeloma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may permit expedited
development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening conditions for which
there is an unmet medical need under its fast track drug development programs. A sponsor can apply for fast track designation at the time
of submission of an IND, or at any time prior to receiving marketing approval of the NDA. To receive fast track designation, an applicant
must demonstrate that the drug:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is intended to treat a serious or life-threatening condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is intended to treat a serious aspect of the condition; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has the potential to address unmet medical needs, and this potential is being evaluated in the planned drug development program.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing must meet
requirements for institutional review board oversight, informed consent and good clinical practices, and must be conducted pursuant to
an IND, unless exempted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of NDA approval,
clinical trials are typically conducted in the following sequential phases:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1: The drug is administered to a small group of humans, either healthy volunteers or patients, to test for safety, dosage tolerance, absorption, metabolism, excretion, and clinical pharmacology.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2: Studies are conducted on a larger number of patients to assess the efficacy of the product, to ascertain dose tolerance and the optimal dose range, and to gather additional data relating to safety and potential adverse events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3: Studies establish safety and efficacy in an expanded patient population.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 4: The FDA may require Phase 4 post-marketing studies to find out more about the drug&#8217;s long-term risks, benefits, and optimal use, or to test the drug in different populations, such as children.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The length of time necessary
to complete clinical trials varies significantly and may be difficult to predict. Clinical results are frequently susceptible to varying
interpretations that may delay, limit or prevent regulatory approvals. Additional factors that can cause delay or termination of our clinical
trials, or that may increase the costs of these trials, include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slow patient enrollment due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors, and the number of sites participating in the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequately trained or insufficient personnel at the study site to assist in overseeing and monitoring clinical trials or delays in approvals from a study site&#8217;s review board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer treatment time required to demonstrate efficacy or determine the appropriate product dose;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient supply of the drug candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse medical events or side effects in treated patients; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness of the drug candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA may place
a clinical trial on hold or terminate it if it concludes that subjects are being exposed to an unacceptable health risk. Any drug is likely
to produce some toxicity or undesirable side effects when administered at sufficiently high doses and/or for a sufficiently long period
of time. Unacceptable toxicity or side effects may occur at any dose level at any time in the course of studies designed to identify unacceptable
effects of a drug candidate, known as toxicological studies, or clinical trials of drug candidates. The appearance of any unacceptable
toxicity or side effect could bring us or regulatory authorities to interrupt, limit, delay, or abort the development of any of our drug
candidates and could ultimately prevent approval by the FDA or foreign regulatory authorities for any or all targeted indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before receiving FDA approval
to market a product, we must demonstrate that the product is safe and effective for its intended use by submitting to the FDA an NDA containing
the pre-clinical and clinical data that have been accumulated, together with chemistry and manufacturing and controls specifications and
information, and proposed labeling, among other things. The FDA may refuse to accept an NDA for filing if certain content criteria are
not met and, even after accepting an NDA, the FDA may often require additional information, including clinical data, before approval of
marketing a product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the approval process,
the FDA must inspect and approve each manufacturing facility. Among the conditions of approval is the requirement that a manufacturer&#8217;s
quality control and manufacturing procedures conform to cGMP. Manufacturers must expend time, money and effort to ensure compliance with
cGMP, and the FDA conducts periodic inspections to certify compliance. It may be difficult for our manufacturers or us to comply with
the applicable cGMP and other FDA regulatory requirements. If we or our contract manufacturers fail to comply, then the FDA will not allow
us to market products that have been affected by the failure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA grants approval,
the approval will be limited to those disease states, conditions and patient populations for which the product is safe and effective,
as demonstrated through clinical studies. Further, a product may be marketed only in those dosage forms and for those indications approved
in the NDA. Certain changes to an approved NDA, including, with certain exceptions, any changes to labeling, require approval of a supplemental
application before the drug may be marketed as changed. Any products that we manufacture or distribute pursuant to FDA approvals are subject
to continuing regulation by the FDA, including compliance with cGMP and the reporting of adverse experiences with the drugs. The nature
of marketing claims that the FDA will permit us to make in the labeling and advertising of our products will be limited to those specified
in an FDA approval, and the advertising of our products will be subject to comprehensive regulation by the FDA. Claims exceeding those
that are approved will constitute a violation of the Federal Food, Drug, and Cosmetic Act. Violations of the Federal Food, Drug, and Cosmetic
Act or regulatory requirements at any time during the product development process, approval process, or after approval may result in agency
enforcement actions, including withdrawal of approval, recall, seizure of products, injunctions, fines and/or civil or criminal penalties.
Any agency enforcement action could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should we wish to market our
products in countries other than the U.S., we must receive marketing authorization from the appropriate regulatory authorities. The requirements
governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. At present,
companies are typically required to apply for foreign marketing authorizations at a national level. However, within the EU, registration
procedures are available to companies wishing to market a product in more than one EU member state. Typically, if the regulatory authority
is satisfied that a company has presented adequate evidence of safety, quality and efficacy, then the regulatory authority will grant
a marketing authorization. This regulatory approval process, however, involves risks similar or identical to the risks associated with
FDA approval discussed above, and therefore we cannot guarantee that we will be able to obtain the appropriate marketing authorization
for any product in any particular country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to comply with applicable
laws and regulations would likely have a material adverse effect on our business. In addition, laws and regulations regarding the manufacture
and sale of new drugs are subject to future changes. We cannot predict the likelihood, nature, effect or extent of adverse governmental
regulation that might arise from future legislative or administrative action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 30, 2024, we have
no employees, only four part-time service providers. We and Israeli employees who might be employed by us, are subject, by an extension
order of the Israeli Ministry of Welfare, to certain provisions of collective bargaining agreements between the Histadrut, the General
Federation of Labor Unions in Israel and the Coordination Bureau of Economic Organizations, including the Industrialists Associations.
Our part-time service providers are not subject to these collective bargaining agreements. These provisions principally address cost of
living increases, recreation pay, travel expenses, vacation pay and other conditions of employment. We provide our employees with benefits
and working conditions equal to or above the required minimum. Other than those provisions, our employees are not represented by a labor
union.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organizational structure</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial name
is XTL Biopharmaceuticals Ltd. We were established as a private company limited by shares under the laws of the State of Israel on March
9, 1993, under the name Xenograft Technologies Ltd. We re-registered as a public company on June 7, 1993, in Israel, and changed our name
to XTL Biopharmaceuticals Ltd. on July 3, 1995.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We commenced operations to
use and commercialize technology developed at the Weizmann Institute, in Rehovot, Israel. Since 1993 we pursued therapeutic and pharmaceutical
development programs for the treatment of a variety of indications including hepatitis B, hepatitis C, diabetic neuropathic pain, schizophrenia,
SLE and multiple myeloma, most of which have terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have one subsidiary,
Xtepo Ltd., a private company limited by shares under the laws of the State of Israel which holds a license for the exclusive use of rHuEPO
for the treatment of multiple myeloma. As of April 30, 2024, we hold approximately 1.04% of the issued and outstanding share capital of
InterCure Ltd., a now former subsidiary of ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs are listed for trading
on the Nasdaq Capital Market under the symbol &#8220;XTLB.&#8221; Our ordinary shares are traded on the TASE under the symbol &#8220;XTLB.&#8221;
We operate under the laws of the State of Israel under the Israeli Companies Law, and in the U.S., the Securities Act and the Exchange
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal offices are
located at 26 Ben-Gurion St., Ramat Gan 5112001, Israel, and our telephone number is (972) 3-6116600. Our primary internet address is
www.xtlbio.com. None of the information on our website is incorporated by reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read the following
discussion and analysis in conjunction with our audited consolidated financial statements, including the related notes, prepared in accordance
with International Financial Reporting Standards (&#8220;IFRS&#8221;) for the years ended December 31, 2023, 2022 and 2021, and as of
December 31, 2023 and 2022, contained in &#8220;Item 18. Consolidated Financial Statements&#8221; and with any other selected financial
data included elsewhere in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tables below present selected
financial data for the fiscal years ended as of December 31, 2023, 2022 and 2021. We have derived this selected financial data from our
audited consolidated financial statements, included elsewhere in this report and prepared in accordance with IFRS issued by the IASB.
You should read the selected financial data in conjunction with &#8220;Item 3. Key Information&#8221; and &#8220;Item 8. Financial Information&#8221;
and &#8220;Item 18. Consolidated Financial Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Consolidated Statements of Comprehensive Income (Loss):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands<br/> (except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Continuing operations:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(31</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(30</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(30</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(734</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(850</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,001</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(765</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,031</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Revaluation of warrants to purchase ADS&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">719</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,022</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,531</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">747</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other finance income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other finance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(468</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,466</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total income (loss) for the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,782</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">435</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total income (loss) attributable to:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Equity holders of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,782</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">435</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total comprehensive income (loss) attributable to:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Equity holders of the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,782)</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1,348</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">435</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Basic earnings (loss) per share (in&#160;U.S.&#160;dollars)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.003</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.001</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Diluted earnings (loss) per share (in&#160;U.S.&#160;dollars)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.003</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.002</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Consolidated Statements of Financial Position Data:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S Dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,094</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,619</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,426</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,186</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Long term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Our current lead
drug compound, hCDR1, is for the treatment of SLE and SS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were established as a corporation
under the laws of Israel in 1993, and commenced operations to use and commercialize technology developed at the Weizmann Institute, in
Rehovot, Israel. Since commencing operations, our activities have been primarily devoted to developing our technologies and drug candidates,
acquiring pre-clinical and clinical-stage compounds, raising capital, purchasing assets for our facilities, and recruiting personnel.
We have had no drug product sales to date. Our major sources of working capital have been proceeds from various private and public offerings
of our securities and option and warrant exercises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred negative
cash flow from operations each year since our inception and we anticipate incurring negative cash flows from operating activities for
the foreseeable future. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business
strategy, including our planned product development efforts, our clinical trials, and potential in-licensing and acquisition opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses primarily consisted of expenses related to the hCDR1 development plan. As part of the preparations for future clinical trials
of hCDR1, we engaged regulatory and clinical consultants and commenced work on Chemistry, Manufacturing and Control, or CMC, including
production and testing of the drug substance. The Company is expanding its IP portfolio surrounding hCDR1 and has decided to reduce its
research and development expenditures in connection with execution of its clinical trials until full funding for the trials or cooperation
with a strategic partner is secured. In parallel, the Company will look to identify additional assets to add to XTL&#8217;s portfolio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to receiving adequate
financing and/or entering into a collaboration agreement, we plan to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate an international, prospective advanced clinical study intended to assess the safety and efficacy of hCDR1 when given to patients with SLE;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate a prospective Phase 2 study intended to assess the safety and efficacy of hCDR1 when given to patients with pSS; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continually build our pipeline of therapeutic candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and administrative
expenses consist primarily of management fees, consultant fees, and related expenses for executive, finance and other administrative personnel,
professional fees, director fees and other corporate expenses, including investor relations, business development costs and facilities
related expenses. We expense our general and administrative costs as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our results of operations
include non-cash compensation expense as a result of the grants of XTL stock options. Compensation expense for awards of options granted
to key service providers and directors represents the fair value of the award (measured using the Black-Scholes valuation model) recorded
over the respective vesting periods of the individual stock options (see details below.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For awards of options to consultants
and other third-parties, according to IFRS 2, the treatment of such options is the same as employee options compensation expense (see
note 12 to the consolidated financial statements for the year ended December 31, 2023). We record compensation expense based on the fair
value of the award at the grant date according to the Black-Scholes valuation model. According to IFRS 2, in non-performance-based options,
we recognize options expenses using the graded vesting method (accelerated amortization). Graded vesting means that portions of a single
option grant will vest on several dates, equal to the number of tranches. We treat each tranche as a separate share option grant; because
each tranche has a different vesting period, and hence the fair value of each tranche is different. Therefore, under this method the compensation
cost amortization is accelerated to earlier periods in the overall vesting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our planned clinical trials
will be lengthy and expensive. Even if these trials show that our drug candidates are effective in treating certain indications, there
is no guarantee that we will be able to record commercial sales of any of our product candidates in the near future or generate licensing
revenues from upfront payments associated with out-licensing transactions. In addition, we expect losses in our drug development activity
to continue as we continue to fund development of our drug candidates. As we continue our development efforts, we may enter into additional
third-party collaborative agreements and may incur additional expenses, such as licensing fees and milestone payments. As a result, our
periodical results may fluctuate and a period-by-period comparison of our operating results may not be a meaningful indication of our
future performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Year ended December 31, 2023 compared to the year ended December
31, 2022</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Research and Development
Expenses</i>. Research and development expenses in the years ended December 31, 2023 and 2022 totaled approximately $31 thousand and $30
thousand, respectively. Research and development expenses are comprised mainly of expenses related to maintenance of our intangible assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><i>General and Administrative
Expenses</i>. General and administrative expenses for the years ended December 31, 2023 and 2022 totaled approximately $734 thousand and
$850 thousand, respectively. The decrease in 2023 compared to 2022 is mainly from lower patent fee and from lower insurance fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Impairment of intangible
assets. </i>The Company is required to determine, at least on an annual basis and as of year-end, whether the fair value of its unamortized
intangible assets exceeds their book value. As of December 31, 2023 and 2022, the Company recognized no impairments. For further information,
see also Note 8 of the consolidated financial statements for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Finance income (expenses),
net</i>. Finance income, net for the years ended December 31, 2023 and 2022 totaled approximately $1,017 thousand and $468 thousand, respectively.
The difference is primarily from revaluation of marketable securities and warrants to purchase ADS&#8217;s which wasn&#8217;t recognized
during 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Year ended December 31, 2022 compared to the year ended December
31, 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Refer to Form 20-F of December
31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Material Accounting Policies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our material accounting
policies in Note 3 to our consolidated financial statements for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impact of Inflation and Currency Fluctuations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While a substantial amount
of our operating expenses are in US dollars, we incur a portion of our expenses in New Israeli Shekels. In addition, we also pay for some
of our services and supplies in the local currencies of our suppliers. As a result, we are exposed to the risk that the US dollar will
be devalued against the New Israeli Shekel or other currencies, and as result our financial results could be harmed if we are unable to
protect against currency fluctuations in Israel or other countries in which services and supplies are obtained in the future. Accordingly,
we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of
currencies. The Company&#8217;s treasury&#8217;s risk management policy is to hold NIS-denominated cash and cash equivalents and short-term
deposits in the amount of the anticipated NIS-denominated liabilities for six consecutive months from time to time in line with the directives
of the Company&#8217;s Board. These measures, however, may not adequately protect us from the adverse effects of inflation in Israel.
In addition, we are exposed to the risk that the rate of inflation in Israel will exceed the rate of devaluation of the New Israeli Shekel
in relation to the US Dollar or that the timing of any devaluation may lag behind inflation in Israel. Future activities may lead us to
perform a clinical trial in Israel, which may lead us to reassess our use of the US dollar as our functional currency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, had
the Group&#8217;s functional currency strengthened by 10% against the NIS with all other variables remaining constant, loss for the year
would have been $144 thousand lower (2022 loss would have been approximately $152 thousand higher; 2021 - profit approximately $328 thousand
lower), mainly as a result of exchange rate changes on translation of other accounts receivable, net and exchange rate changes on NIS-denominated
cash and cash equivalents and marketable securities &#8211; investment in InterCure Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Governmental Economic, Fiscal, Monetary or Political Policies
that Materially Affected or Could Materially Affect Our Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Tax rates applicable to the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxable income of the Company is subject to a corporate tax rate as follow: 2023 and 2022 - 23%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, XTL
Biopharmaceuticals Ltd. did not have any taxable income. As of December 31, 2023, our net operating loss carry forwards for Israeli tax
purposes registered on behalf of XTL Biopharmaceuticals Ltd. amounted to approximately $38.9 million and approximately $22.9 million capital
loss carryforward which may be offset against future capital gain. Under Israeli law, these net-operating losses may be carried forward
indefinitely and offset within XTL Biopharmaceuticals Ltd only, against future taxable income, including capital gains from the sale of
assets used in the business, with no expiration date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
from inception primarily through various proceeds from various private and public offerings of our securities and option and warrant exercises.
As of December 31, 2023, we received net proceeds of approximately $85.9 million <span>from </span>various
private placement transactions, public offerings and exercises of warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
had approximately $1,401 thousands in cash and cash equivalents, compared to approximately $2,094 thousands on December 31, 2022. The
decrease is mainly from the general and administrative expenses of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December 31, 2023 was $707 thousand, compared to net cash used in operating activities of $901 thousand
for year ended December 31, 2022. The decrease in net cash used in operating activities is mainly from the general and administrative
expenses of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities for the year ended December 31, 2023 was $41 thousand compared to $36 thousand for the year ended December 31, 2022. The increase
in net cash provided by investing activities is due to an increase in interest income from deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Net cash provided by financing
activities for the year ended December 31, 2023 and for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred continuing
losses and depend on outside financing resources to continue our activities. We have decided to reduce our research and development expenditures
in connection with execution of our clinical trials until full funding for the trials or cooperation with a strategic partner is secured.
In parallel, we will look to identify additional assets to add to our portfolio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to receiving adequate
financing and/or entering into a collaboration agreement, we plan to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate an international, prospective advanced clinical study intended to assess the safety and efficacy of hCDR1 when given to patients with SLE;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate a prospective Phase 2 study intended to assess the safety and efficacy of hCDR1 when given to patients with pSS; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continually build our pipeline of therapeutic candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on existing business
plans, our management estimates that our outstanding cash and cash equivalent balances will allow us to finance our activities for an
additional period of at least 12 months from the date of this report. However, the amount of cash which we will need in practice to finance
our activities depends on numerous factors which include, but are not limited to, the timing, planning and execution of clinical trials
of existing drugs and future projects which we might acquire or other business development activities such as acquiring new technologies
and/or changes in circumstances which are liable to cause significant expenses to us in excess of management&#8217;s current and known
expectations as of the date of these financial statements and which will require us to reallocate funds against plans, also due to circumstances
beyond our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to incur additional
losses through the end of 2024 and beyond arising from research and development activities, testing additional technologies and operating
activities, which will be reflected in negative cash flows from operating activities. In order to perform the clinical trials aimed at
developing a product until obtaining its marketing approval, we may be required to raise additional funds in the future by issuing securities.
Should we fail to raise additional capital in the future under standard terms, we will be required to minimize our activities or sell
or grant a sublicense to third parties to use all or part of its technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. Research and Development, Patents and Licenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
in 2023, 2022, 2021 substantially derived from costs related to the hCDR1 and, to a lesser degree, development plans. As part of the preparations
for a planned clinical study of hCDR1, the Company engaged regulatory and clinical consultants and completed work on CMC, including production
and testing of the drug substance and drug product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>hCDR1 for the Treatment of SLE</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is expanding its
IP portfolio surrounding hCDR1 and has decided to reduce its R&amp;D expenditure in connection with execution of its clinical trials until
full funding for the trials or cooperation with a strategic partner is secured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>rHuEPO for the Treatment of Multiple Myeloma</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have decided to concentrate
our efforts and resources on the development of hCDR1 and therefore do not expect to initiate any activities related to rHuEPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the research and development costs for the years 2023, 2022 and 2021 including all costs related to the clinical-stage projects, our pre-clinical
activities, and all other research and development. We in-licensed hCDR1 in January 2014 and started preparations for clinical development
of this asset during the year. We started preparations for rHuEPO clinical development in the last quarter of 2010 (after the completion
of the Bio-Gal transaction on August 2010). We in-licensed SAM-101 in November 2011 and in June 2015, the Company terminated the license
agreement and all rights in and to the licensed technology reverted to MinoGuard. Whether or not and how quickly we commence and complete
development of our clinical stage projects is dependent on a variety of factors, including the rate at which we are able to engage clinical
trial sites and the rate of enrollment of patients. As such, the costs associated with the development of our drug candidates will probably
increase significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Research and development<br/> Expenses in thousand US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; padding-bottom: 1.5pt">hCDR1</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">30</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">30</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Research and Development</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">30</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">30</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Trend Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development stage
company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization
efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments
or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability,
liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results
or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are identified
in the preceding subsections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Estimates and judgments are
continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed
to be reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical accounting estimates and assumptions </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Accounting estimates will, by definition,
seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to
the carrying amounts of assets and liabilities within the next financial year are addressed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
asset is not yet available for use and therefore not amortized, an impairment in its respect is tested at least every year. In addition,
discretion is exercised as to whether there is an indication to examine impairment more frequently.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not entered into any
transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments
or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a
variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;&#160;&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. DIRECTORS AND SENIOR MANAGEMENT </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Senior Management</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth information
with respect to our directors and executive officers as of the date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 54%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Shalev </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director </span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itay Weinstein</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Osnat Hillel Fain</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive and External Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iris Shapira Yalon</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive and External Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Rabinovich</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron Turgeman </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director and Chairman of the Board</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jonathan Schapiro</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Dobroslav Melamed</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Shlomo Shalev</i></b>
joined our Board of Directors in December 2014. On May 19, 2020, Mr. Shalev was appointed to serve as Chief Executive Officer of the Company.
In August 2015, Mr. Shalev was appointed to serve as Chairman, and served in such capacity through June 2018. He most recently served
as Chairman of the Board of Intercure, a TASE and Nasdaq listed company. In addition to serving as a board member on a number of NASDAQ
and TASE listed companies, such as OphirOptronics, Arel Communications and PowerDsine, Mr. Shalev was the Senior Vice President of Investments
for Ampal. He has also worked on a number of transactions in mergers and acquisitions and initial public offerings. With an educational
background in economics, Mr. Shalev was Israel&#8217;s Consul for Economic Affairs and the Economic Advisor to the Director General, Ministry
of Industry and Trade. Mr. Shalev holds an MBA from the University of San Francisco and a B.A. degree in Economics from the University
of Ben Gurion, Beer Sheva, Israel. We believe Mr. Shalev&#8217;s extensive company strategy and oversight experience, along with his board
experience makes him well-qualified to serve as a Director of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Itay Weinstein </i></b>was
appointed our Chief Financial Officer in July, 2017. Mr. Itay Weinstein is a Partner at Shimony C.P.A. and has been employed there since
1999. Mr. Weinstein served as the Controller of Can-Fite BioPharma Ltd. since 2003 and as the Chief Financial Officer of Ophthalix Inc.
from November 2011 through November 2017. Prior to joining Shimony C.P.A, Mr. Weinstein served as an auditor at Oren Horowitz. Mr. Weinstein
holds a B.A. in economics and accounting from the Tel Aviv University, Israel, and has been a licensed CPA since 1999. Mr. Weinstein is
also a board member of Uno Management and Consulting Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Osnat Hillel Fain</i></b>
joined our Board of Directors in March 2015. Ms. Fain served as Founder, Director and Managing Partner of Newton Propulsion Technologies
LTD from 2003 to 2016. Since 2017, Ms. Fain has served as Consultant, Strategy and Business Development at Adi Shefaram Management LTD
where she locates, examines and screens economic feasibility for ventures in various fields and provides business development assistance
among other duties. In addition, Ms. Fain serves as a board member on a number of TASE listed companies, including Tigi, Alrov Real Estate
and Mehadrin and a former director of TASE listed companies such as DIC Discount Investment Corporation, Elron, PBC Group, ICB, Priortech
LTD, E.T.VIEW, Aran R&amp;D, Leumi Start LTD. Ms. Fain was the Business Development Manager at Giora Eiland Ltd., a representative of
the Cheyne Capital Group in Israel, General Director of InterVision, Managing Partner at Aran Medical Ventures Hedge Fund, Marketing Manager
at Datasphere Ltd. and a marketing consultant for TCB, Elgan Office Supplies, the Haifa Theatre, Adar (software house). Ms. Fain earned
a BA in Humanities and Executive MBA from Tel Aviv University and completed a one year course in Management at the Tel Aviv campus of
the College of Management. We believe Ms. Fain&#8217;s extensive management and board experience makes her well-qualified to serve as
a member of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Iris Shapira Yalon </i></b>was
appointed a director on January 29, 2020. Ms. Yalon serves as External Director of Shufersal Ltd (The leading Israeli retail chain).,
as well as Director of Rotem Industries Ltd. (Israeli government-owned&#160;company), Mei Avivim, (a water corporation of Tel Aviv) and
in several associations for the benefit of the public and as a Lecturer of Director&#8217;s course. Prior to that, Ms. Yalon served as
Board member on a number of TASE listed companies, including Electra real estate Ltd., Computer Direct Group Ltd. and on a dual listed
company such as TAT Technologies Ltd., Ms. Yalon served as the Chief Financial Officer of multiple companies such as Kryon Systems Ltd.,
Haldor Advanced Technologies Ltd., Mofet Technology Fund Ltd., and Cloverleaf Media Ltd.,which was acquired in 2010 by Dot Hill. Moreover,
Ms. Yalon has served as Audit Team Manager at Ernest &amp; Young. She earned a BA in Economics and Accounting (cum laude) at Tel Aviv
University and she is licensed accountant. We believe Ms. Yalon&#8217;s extensive board experience makes her well-qualified to serve as
a member of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Alexander Rabinovich
</i></b>joined our Board of Directors in April 2017. He has significant public company experience with both NASDAQ and TASE listed companies.
Mr. Rabinovich is currently the Chief Executive Officer and director of Green Forest Holdings Ltd., a fully owned company engaged in capital
investments. He served as director in Pilat Media Global PLC, public company listed on TASE and on the Alternative Investment Market of
the London Stock Exchange and several other private companies such as Visualety Systems Ltd. Mr. Rabinovich holds a B.A. degree in Economics
and Accounting from the University of Haifa. We believe Mr. Rabinovich&#8217;s extensive company strategy and oversight experience, along
with his board experience makes him well-qualified to serve as a Director of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Doron Turgeman</i></b>
joined our Board of Directors in December 2014 and was appointed Chief Executive Officer on January 29, 2020. On May 19, 2020, Mr. Turgeman
resigned as Chief Executive Officer. Mr. Turgeman remains on the board following his resignation as Chief Executive Officer. He has served
as Chairman of our Board of Directors since July 2018 through present. Mr. Turgeman has significant public company experience with both
NASDAQ and TASE listed companies. He has gained considerable experience in mergers and acquisitions involving both debt and equity. Mr.
Turgeman holds a B.A. degree in Economics and Accounting from the Hebrew University of Jerusalem and is a certified public accountant
in Israel. We believe Mr. Turgeman&#8217;s extensive company strategy experience and technical background makes him well-qualified to
serve as a Director of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr. Jonathan Schapiro
</i></b>joined our Board of Directors in December 2014. He is Director of HIV/AIDS at the National Hemophilia Center at Sheba Medical
Center in Tel-Aviv, Israel, and the Head of the Advisory Committee for the Stanford University HIVDB Drug Resistance Interpretation System,
as well as Co-Chair, Research and Innovation Working Group Subcommittee, World Health Organization HIV Drug Resistance Network, Geneva,
Switzerland. He served as a committee member on the United States Food and Drug Administration Antiviral Drugs Advisory Committee and
is a member of the Liverpool University HIV Drug Interactions Editorial Board. Dr. Schapiro is on the organizing and scientific committee
of international conferences on antiviral drug development, clinical pharmacology, and resistance, as well as contributing to guidelines
publications. His research has appeared in major journals such as Lancet and Annals of Internal Medicine. He has served on the scientific
advisory boards of major pharmaceutical and molecular diagnostic companies and has been involved in the development of multiple antiviral
drugs over the last 20 years. Dr. Schapiro has devoted his career to HIV clinical care, research, and education since completing his Fellowship
in Infectious Diseases and Geographic Medicine at Stanford University School of Medicine, Stanford CA. He graduated from the Ben Gurion
University School of Medicine and completed his Medical Residency at the Rabin Medical Center in Israel. We believe Dr. Schapiro&#8217;s
extensive company strategy experience and technical background makes him well-qualified to serve as a Director of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr. Dobroslav Melamed
</i></b>joined our Board of Directors in December 2014. He is a biotech entrepreneur with over 10 years of experience in the life science
industry. He has demonstrated success in taking drugs from the lab to the shelf by identifying target markets, planning regulatory strategy,
raising capital, executing successful clinical trials and scaling up to commercial production. He is currently establishing two companies
involved in the development of a treatment for Ebola and novel drug delivery. Until September 2014, he was the President of SciVac (formerly
SciGen IL), a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology
derived products, including vaccines. Dr. Melamed was responsible for SciVac&#8217;s operations, clinical trials and new business. Dr.
Melamed is the co-founder of Periness LTD, a developer of new drugs for male infertility and Oshadi LTD, a developer of oral carriers
for proteins like insulin. He has also been a researcher at Bar-Ilan University&#8217;s Male Fertility clinic, where he assisted in the
development of new drugs for male infertility; and QBI, where he worked in the Pre-clinical and Research Pharmacology Department establishing
In-Vivo models for drug discovery and delivery. Dr. Melamed earned a PhD in Biotechnology and a Bachelor of Arts degree in Biotechnology
from the Bar-Ilan University, Israel. We believe Dr. Melamed&#8217;s extensive company strategy experience and technical background makes
him well-qualified to serve as a Director of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate compensation
paid by us to all persons who served as directors or officers for the year 2023 (8 persons) was approximately $243 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All members of our Board of
Directors who are not our employees are reimbursed for their expenses for each meeting attended, save for Alexander Rabinovich, who is
a significant shareholder of our Company. Our directors are eligible to receive stock options under our stock option plans. Non-executive
directors do not receive any remuneration from us other than fees for their services as members of the board or committees of the board
and expense reimbursement, save for one director who is eligible for fees for consulting services provided to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2017, we fixed the monetary
compensation for non-executive directors as follows: annual consideration of NIS 29 thousand (to be paid in 4 equal quarterly payments),
payments of NIS 1,460 for attendance at each board or committee meeting in person, NIS 876 for meetings held by teleconference, NIS 730
for unanimous written board resolutions and reimbursement of reasonable out-of-pocket expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For further details regarding
share options granted to our directors and service providers, see Note 12 and 19 to the consolidated financial statements for the year
ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shlomo Shalev </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer,
Shlomo Shalev, was appointed on May 19, 2020. Mr. Shalev will receive compensation as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monthly Salary &#8211; Mr. Shalev shall be entitled to a fixed gross monthly fee of NIS 30,000 (approximately USD 9,331), excluding value added tax. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working Hours &#8211; Mr. Shalev shall be employed at a 50% capacity. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social Benefits &#8211; Mr. Shalev shall be entitled to receive monthly car expense payments of NIS 3,000 (approximately USD 933).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options &#8211; Mr. Shalev was issued 10,000,000 options (the &#8220;Options&#8221;) to purchase, under the approved ESOP plan of the Company, 10,000,000 ordinary shares of the Company consisting of about two per cent (2%) of the total issued and outstanding capital share of the Company, at an exercise price of NIS 0.09 (approximately USD 0.03) per Option. The Options shall vest on a quarterly basis over 36 months, so that 1/12 of the Options shall vest on the last day of each three-month period, provided that on such date Mr. Shalev is still employed by the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Itay Weinstein </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2017, we entered into
a service agreement with Mr. Itay Weinstein pursuant to which he serves as our Chief Financial Officer on a part time basis. Mr. Weinstein
is entitled to a monthly gross payment of NIS 15,000 (NIS 180,000 annually).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we pay Shimony
C.P.A, the accounting firm of which Mr. Weinstein is a Partner, monthly fees of NIS 15,000 for controller and bookkeeping services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Jonathan Schapiro</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a consulting
agreement dated January 1, 2015 with Dr. Jonathan Schapiro, a director. Commencing on such date, Dr. Schapiro shall serve as a consultant
to us for a monthly fee of $2,000 increasing to $3,000 upon the successful completion of a cash fund raising of at least $3 million in
a public offering or private placement of equity securities, including securities convertible or exercisable into equity by us or any
entity in our control. In addition, under the consulting agreement, on December 30, 2014, Dr. Schapiro was granted options to purchase
150,000 ordinary shares at an exercise price of NIS 0.4915 per share (in addition to the options granted to him as a director on the same
day as described below). One third of the options vest on the twelve month anniversary of the grant date, and the remaining two thirds
vest on a quarterly basis over the following two years provided Dr. Schapiro provides services to us. The options have a term of ten years.
The consulting agreement continues in force unless terminated without cause upon 30 days&#8217; advance written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Schapiro receives a fixed
fee of $2,000 per month (in addition to his board membership fee).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the requirements
of Israeli Law, we determine our directors&#8217; compensation in the following manner:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">first, our compensation committee reviews the proposal for compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">second, provided that the compensation committee approves the proposed compensation, the proposal is then submitted to our Board of Directors for review, except that a director who is the beneficiary of the proposed compensation does not participate in any discussion or voting with respect to such proposal; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">finally, if our Board of Directors approves the proposal, it must then submit its recommendation to our shareholders, which is usually done in connection with our shareholders&#8217; general meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval of a majority
of the shareholders voting at a duly convened shareholders meeting is required to implement any such compensation proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Board Practices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Election of Directors and Terms of Office</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors currently
consists of seven members. Other than our two external directors, our directors are elected by an ordinary resolution at the annual general
meeting of our shareholders. The nomination of our directors is proposed by our Board of Directors or a designated nomination committee
composed of three members of our Board of Directors, whose proposal is then approved by the board. Our board, following receipt of a proposal
of the nomination committee, has the authority to add additional directors up to the maximum number of 12 directors allowed under our
Articles. Such directors appointed by the board serve until the next annual general meeting of the shareholders. Unless they resign before
the end of their term or are removed in accordance with our Articles, all of our directors, other than our external directors, will serve
as directors until our next annual general meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our directors or officers
has any family relationship with any other director or officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles permit us to
maintain directors&#8217; and officers&#8217; liability insurance and to indemnify our directors and officers for actions performed on
behalf of us, subject to specified limitations. We maintain a directors and officers insurance policy which covers the liability of our
directors and officers as allowed under Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no service contracts
or similar arrangements with any director that provide for benefits upon termination of a directorship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>External and Independent Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires Israeli companies with shares that have been offered to the public either in or outside of Israel to appoint two external directors.
No person may be appointed as an external director if that person or that person&#8217;s relative, partner, employer or any entity under
the person&#8217;s control, has or had, on or within the two years preceding the date of that person&#8217;s appointment to serve as an
external director, any affiliation with the company or any entity controlling, controlled by or under common control with the company.
The term affiliation includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an employment relationship;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business or professional relationship maintained on a regular basis;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service as an office holder, other than service as an officer for a period of not more than three months, during which the company first offered shares to the public.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person may serve as an
external director if that person&#8217;s position or business activities create, or may create, a conflict of interest with that person&#8217;s
responsibilities as an external director or may otherwise interfere with his/her ability to serve as an external director. If, at the
time external directors are to be appointed, all current members of the Board of Directors are of the same gender, then at least one external
director must be of the other gender. A director in one company shall not be appointed as an external director in another company if at
that time a director of the other company serves as an external director in the first company. In addition, no person may be appointed
as an external director if he/she is a member or employee of the Israeli Security Authority, and also not if he/she is a member of the
Board of Directors or an employee of a stock exchange in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors are to
be elected by a majority vote at a shareholders&#8217; meeting, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the majority of shares voted at the meeting, including at least one-half of the shares held by non-controlling shareholders or other shareholders who have a personal interest in such election voted at the meeting, vote in favor of election of the director, with abstaining votes not being counted in this vote; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares held by non-controlling shareholders voted against the election of the director does not exceed two percent of the aggregate voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The initial term of an external
director is three years and may be extended for two additional three-year terms. Notwithstanding, pursuant applicable articles of the Companies Regulations
(Reliefs for Israeli companies whose securities are listed for trading on a stock exchange outside of Israel), promulgated under the Companies
Law and as amended from time to time, following the Audit Committee and the Board of Directors recommendation, the Company shareholders
may re-elect an external director for additional terms. An external director may be removed only by the same
percentage of shareholders as is required for their election, or by a court, and then only if such external director ceases to meet the
statutory qualifications for their appointment or violates his or her duty of loyalty to the company. Both external directors must serve
on every committee that is empowered to exercise one of the functions of the Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An external director is entitled
to compensation as provided in regulations adopted under the Israeli Companies Law and is otherwise prohibited from receiving any other
compensation, directly or indirectly, in connection with service provided as an external director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Osnat Hillel Fain and Iris
Shapira Yalon serve as external directors pursuant to the provisions of the Israeli Companies Law. They both serve on our audit committee,
our committee for the approval of financial statements, our nomination committee and our compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires public companies to appoint an audit committee. The responsibilities of the audit committee include identifying irregularities
in the management of the company&#8217;s business and approving related party transactions as required by law. An audit committee must
consist of at least three directors, including all of its external directors. The chairman of the Board of Directors, any director employed
by or otherwise providing services to the company, and a controlling shareholder or any relative of a controlling shareholder, may not
serve as members of the audit committee. An audit committee may not approve an action or a transaction with a controlling shareholder,
or with an office holder, unless at the time of approval two external directors are serving as members of the audit committee and at least
one of the external directors was present at the meeting in which an approval was granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is currently
comprised of three independent non-executive directors. The audit committee is chaired by Osnat Hillel Fain, who serves as the audit committee
financial expert, Iris Shapira Yalon and Dobroslav Melamed as members. The audit committee meets at least four times a year and monitors
the adequacy of our internal controls, accounting policies and financial reporting. It regularly reviews the results of the ongoing risk
self-assessment process, which we undertake, and our interim and annual reports prior to their submission for approval by the full Board
of Directors. The audit committee oversees the activities of the internal auditor, sets its annual tasks and goals and reviews its reports.
The audit committee reviews the objectivity and independence of the external auditors and also considers the scope of their work and fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
charter for our audit committee, setting forth its responsibilities as outlined by the regulations of the SEC. In addition, our audit
committee has adopted procedures for the receipt, retention and treatment of complaints we may receive regarding accounting, internal
accounting controls, or auditing matters and the submission by our key consultants of concerns regarding questionable accounting or auditing
matters. In addition, SEC rules mandate that the audit committee of a listed issuer consist of at least three members, all of whom must
be independent, as such term is defined by rules and regulations promulgated by the SEC. We are in compliance with the independence requirements
of the SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Statement Examination Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to regulations promulgated
under the Companies law and since we are considered as a &#8220;Small Corporation&#8221; under the Israeli Securities law Regulation,
we are not required to appoint a financial statement examination committee, therefore our financial statements are examined and approved
by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee and to adopt a compensation policy with respect to its
officers, or the Compensation Policy. In addition, the Companies Law sets forth the approval process required for a public company&#8217;s
engagement with its officers (with specific reference to a director, a non-director officer, a chief executive officer and controlling
shareholders and their relatives who are employed by the company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
shall be nominated by the board of directors and be comprised of its members. The compensation committee must consist of at least three
members. All of the external directors must serve on the compensation committee and constitute a majority of its members. The remaining
members of the compensation committee must be directors who qualify to serve as members of the audit committee (including the fact that
they are independent) and their compensation should be identical to the compensation paid to the external directors of the company. The
approval of the compensation committee is required in order to approve terms of office and/or employment of office holders. The Company&#8217;s
Compensation Policy was duly approved on January 7, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to the rules that
apply to the audit committee, the compensation committee may not include the chairman of the board, or any director employed by the company,
by a controlling shareholder or by any entity controlled by a controlling shareholder, or any director providing services to the company,
to a controlling shareholder or to any entity controlled by a controlling shareholder on a regular basis, or any director whose primary
income is dependent on a controlling shareholder, and may not include a controlling shareholder or any of its relatives. Individuals who
are not permitted to be compensation committee members may not participate in the committee&#8217;s meetings other than to present a particular
issue; provided, however, that an employee that is not a controlling shareholder or relative may participate in the committee&#8217;s
discussions, but not in any vote, and the company&#8217;s legal counsel and corporate secretary may participate in the committee&#8217;s
discussions and votes if requested by the committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The roles of the compensation
committee are, among other things, to: (i) recommend to the board of directors the Compensation Policy for office holders and recommend
to the board once every three years the extension of a Compensation Policy that had been approved for a period of more than three years;
(ii) recommend to the directors any update of the Compensation Policy, from time to time, and examine its implementation; (iii) decide
whether to approve the terms of office and of employment of office holders that require approval of the compensation committee; and (iv)
decide, in certain circumstances, whether to exempt the approval of terms of office of a chief executive officer from the requirement
of shareholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or the shareholders
holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However, under special
circumstances, the board of directors may approve the Compensation Policy without shareholder approval, if the compensation committee
and thereafter the board of directors decided, based on substantiated reasons after they have reviewed the compensation policy again,
that the Compensation Policy is in the best interest of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy must
serve as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including
exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The Compensation
Policy must relate to certain factors, including advancement of the company&#8217;s objectives, the company&#8217;s business and its long-term
strategy, and creation of appropriate incentives for executives. It must also consider, among other things, the company&#8217;s risk management,
size and the nature of its operations. The Compensation Policy must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the knowledge, skills, expertise and accomplishments of the relevant director or executive; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the terms offered and the average and median compensation of the key consultants of the company; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of disparities in salary upon work relationships in the company; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">The compensation
policy must also include the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable compensation and long-term performance and measurable criteria; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which a director or executive would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy must
also consider appropriate incentives from a long-term perspective and maximum limits for severance compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Osnat Hillel Fain is the chairman
of our compensation committee. Dobroslav Melamed and Iris Shapira Yalon serve as the other members of our compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Approval of Compensation to Our Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
prescribes that compensation to officers must be approved by a company&#8217;s board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As detailed above, our compensation
committee consists of three independent directors: Dobroslav Melamed, Osnat Hillel Fain and Iris Shapira Yalon. The responsibilities of
the compensation committee are to set our overall policy on executive remuneration and to decide the specific remuneration, benefits and
terms of employment for directors, officers and the Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The objectives of the compensation
committee&#8217;s policies are that such individuals should receive compensation which is appropriate given their performance, level of
responsibility and experience. Compensation packages should also allow us to attract and retain executives of the necessary caliber while,
at the same time, motivating them to achieve the highest level of corporate performance in line with the best interests of shareholders.
In order to determine the elements and level of remuneration appropriate to each executive director, the compensation committee reviews
surveys on executive pay, obtains external professional advice and considers individual performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Internal Auditor</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the board of directors must appoint an internal auditor, nominated by the audit committee. Our internal auditor is Daniel Spira.
The role of the internal auditor is to examine, among other matters, whether the company&#8217;s actions comply with the law and orderly
business procedure. Under the Israeli Companies Law, an internal auditor may not be:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative of a person) who holds more than 5% of the company&#8217;s shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an executive officer or director of the company; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a member of the company&#8217;s independent accounting firm.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We comply with the requirement
of the Israeli Companies Law relating to internal auditors. Our internal auditors examine whether our various activities comply with the
law and orderly business procedure. Our internal auditor is not our employee, but the managing partner of a firm which specializes in
internal auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of April 30, 2024, we have
no employees, only four part-time service providers. We and Israeli employees who might be employed by us, are subject, by an extension
order of the Israeli Ministry of Welfare, to certain provisions of collective bargaining agreements between the Histadrut, the General
Federation of Labor Unions in Israel and the Coordination Bureau of Economic Organizations, including the Industrialists Associations.
Our part-time service providers are not subject to these collective bargaining agreements. These provisions principally address cost of
living increases, recreation pay, travel expenses, vacation pay and other conditions of employment. We provide our employees with benefits
and working conditions equal to or above the required minimum. Other than those provisions, our employees are not represented by a labor
union.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Share Ownership</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify; text-indent: -13.2pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of our outstanding ordinary shares as of April 30, 2024 by the members of our senior management,
board of directors, individually and as a group, and each person who we know beneficially owns 5% or more of our outstanding ordinary
shares. The beneficial ownership of ordinary shares is based on 544,906,149 ordinary shares outstanding as of April 30, 2024 and is determined
in accordance with the rules of the SEC and generally includes any ordinary shares over which a person exercises sole or shared voting
or investment power. For purposes of the table below, we deem shares subject to options or warrants that are currently exercisable or
exercisable within 60 days of April 30, 2024, to be outstanding and to be beneficially owned by the person holding the options or warrants
for the purposes of computing the percentage ownership of that person but we do not treat them as outstanding for the purpose of computing
the percentage ownership of any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name&#160;of&#160;Beneficial&#160;Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> Ordinary <br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage&#160;of <br/> Class*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Senior Management and Directors</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Shalev&#160; <br/> <i>Chief Executive Officer and Director </i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,669,309</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.63</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Osnat Hillel Fain<br/> <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iris Shapira Yalon&#160; <br/> <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Rabinovich <br/> <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,288,887</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan Schapiro&#160; <br/> <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dobroslav Melamed&#160; <br/> <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron Turgeman<br/> <i>Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490,000</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itay Weinstein<br/> <i>Chief Finance Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Directors and Senior Management as a group (8 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,198,196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Beneficial owners of 5% or more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Alexander Rabinovitch</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,288,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.54</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes less than 1%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 3,019,309 ordinary shares, (ii) 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.4325 per share exercisable until December 29, 2024, (iii) 1,500,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.6 per share exercisable until March 30, 2026, and (iv) 10,000,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.09 per share exercisable until July 6, 2030. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.4 per share exercisable until March 24, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.0495 per share exercisable until March 1, 2033.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 62,149,487 ordinary shares, and (ii) 661,394 ADSs representing 66,139,400 ordinary shares. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.4325 per share exercisable until December 29, 2024, and (ii) 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.4915 per share exercisable until December 29, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.4325 per share exercisable until December 29, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 340,000 ordinary shares represented by 3,400 ADSs, and (ii) 150,000 ordinary shares issuable upon the exercise of options at an exercise price of NIS 0.4325 per share exercisable until December 29, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Share Option Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain the following
share option plans for our and our subsidiary&#8217;s directors and consultants. In addition to the discussion below, see note 12 of our
consolidated financial statements for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors administers
our share option plans and has the authority to designate all terms of the options granted under our plans including the grantees, exercise
prices, grant dates, vesting schedules and expiration dates, which may be no more than ten years after the grant date. Options may not
be granted with an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless otherwise determined
by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
have granted to directors and consultants options that are outstanding to purchase up to 12,550,000 ordinary shares under two share option
plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>2011 Share Option Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 29, 2011, our Board
of Directors approved the adoption of an employee stock option scheme for the grant of options exercisable into shares of the Company
according to section 102 to the Israeli Tax Ordinance, or the 2011 Plan, and to reserve up to 10 million ordinary shares in the framework
of the 2011 Plan, for options allocation to employees, directors and consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2020 it was decided
to enlarge the reserve to 30 million options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2011 Plan shall be subject
to section 102 of the Israeli Tax Ordinance. According to the Capital Gain Track, which was adopted by us and the abovementioned section
102, we are not entitled to receive a tax deduction that relates to remuneration paid to employees, including amounts recorded as salary
benefit for options granted to employees in the framework of the 2011 Plan, except the yield benefit component, if available, that was
determined on the grant date. The terms of the options which will be granted according to the 2011 Plan, including option period, exercise
price, vesting period and exercise period, shall be determined by our Board of Directors on the date of the actual allocation. On March
14, 2023, Company&#8217;s Board of directors approved to extend retroactively the expire date of the 2011 plan by additional 5 years to
August 29, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
have granted options to purchase 12,550,000 ordinary shares under the 2011 Plan at exercise prices between $0.03 and $0.17 per ordinary
share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For further details regarding
share options granted to our directors and service providers, see note 12 and 19 to the consolidated financial statements for the year
ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Major shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, there
were 2,879,572&#160;ADSs outstanding, held by approximately 50 DTC participants and a registered shareholder, whose holdings represented
approximately 52.8% of the total outstanding ordinary shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the number of our ordinary shares owned by any person known to us to be the beneficial owner of 5% or more of our ordinary shares as of
the date hereof. The information in this table is based on 544,906,149 outstanding ordinary shares as of such date. The number of Ordinary
Shares beneficially owned by a person includes Ordinary Shares subject to options held by that person that were currently exercisable.
None of the holders of the Ordinary Shares listed in this table have voting rights different from other holders of the Ordinary Shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> shares<br/> owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of<br/> ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Alexander Rabinovitch</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">128,288,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23.54</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.8pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of some of the transactions with related parties to which we, or our subsidiaries, are party, and which were in effect within the past
three fiscal years. The descriptions provided below are summaries of the terms of such agreements, do not purport to be complete and are
qualified in their entirety by the complete agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have executed
all of our transactions with related parties on terms no less favorable to us than those we could have obtained from unaffiliated third
parties. We are required by Israeli law to ensure that all future transactions between us and our officers, directors and principal shareholders
and their affiliates are approved by a majority of our board of directors, including a majority of the independent and disinterested members
of our board of directors, and that they are on terms no less favorable to us than those that we could obtain from unaffiliated third
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Consulting Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have or have had employment,
consulting or related agreements with our senior management. See Item 6 - Compensation-Employment Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law permits a company
to insure an office holder in respect of liabilities incurred by him or her as a result of an act or omission in the capacity of an office
holder for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the office holder&#8217;s duty of care towards the company or towards another person;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the office holder&#8217;s fiduciary duty to the company, provided that he or she acted in good faith and had reasonable cause to believe that the act would not prejudice the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon the office holder in favor of another person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A financial liability imposed on the office holder&#8217;s for all victims of the violation in an Administrative Proceeding.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses incurred by the office holder&#8217;s in connection with an Administrative Proceeding conducted in his or her case, including litigation expenses and reasonable legal fees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, a company can indemnify
an office holder for any of the following obligations or expenses incurred in connection with the acts or omissions of such person in
his or her capacity as an office holder:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monetary liability imposed upon him or her in favor of a third party by a judgment, including a settlement or an arbitral award confirmed by the court; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including legal fees, actually incurred by the office holder or imposed upon him or her by a court, in a proceeding brought against him or her by or on behalf of the company or by a third party, or in a criminal action in which he or she was acquitted, or in a criminal action which does not require criminal intent in which he or she was convicted; furthermore, a company can, with a limited exception, exculpate an office holder in advance, in whole or in part, from liability for damages sustained by a breach of duty of care to the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial liability imposed on the office holder for all victims of the violation in an Administrative Proceeding.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by the office holder in connection with an Administrative Proceeding conducted in his or her case, including litigation expenses and reasonable legal fees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles of Association
allow for insurance, exculpation and indemnification of office holders to the fullest extent permitted by law. We have entered into indemnification,
insurance and exculpation agreements with our directors and executive officers, following shareholder approval of these agreements. We
have directors&#8217; and officers&#8217; liability insurance covering our officers and directors for a claim imposed upon them as a result
of an action carried out while serving as an officer or director, for (a) the breach of duty of care towards us or towards another person,
(b) the breach of fiduciary duty towards us, provided that the officer or director acted in good faith and had reasonable grounds to assume
that the action would not harm our interests, and (c) a monetary liability imposed upon him in favor of a third party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Consolidated Statements and Other Financial
Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audited consolidated financial
statements appear in this annual report on Form 20-F. See &#8220;Item 18. Financial Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Markets and Share Price History</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have been
trading on the Tel Aviv Stock Exchange, or TASE, since July 2005. Our ordinary shares currently trade on the TASE under the symbol &#8220;XTLB&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&#160;1, 2012, the
Company filed an application for relisting its ADSs on the Nasdaq Capital Market, or Nasdaq. On July 10, 2013, the Company received a
notice from Nasdaq stating that the admission committee had approved the Company&#8217;s application to relist its ADSs for trading on
the Nasdaq Capital Market. Accordingly, on July 15, 2013, the Company&#8217;s ADSs began trading on Nasdaq under the ticker symbol &#8220;XTLB&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Memorandum and Articles of Association</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Objects and Purposes of the Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Part B, Section
3 of our Articles of Association, we may undertake any lawful activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Powers and Obligations of the Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law and our Articles of Association, a director is not permitted to vote on a proposal, arrangement or contract in which he or she has
a personal interest. Also, the directors may not vote on compensation to themselves or any members of their body, as that term is defined
under Israeli law, without the approval of our audit committee and our shareholders at a general meeting. The power of our directors to
enter into borrowing arrangements on our behalf is limited to the same extent as any other transaction by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
codifies the fiduciary duties that office holders, including directors and executive officers, owe to a company. An office holder&#8217;s
fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care generally requires an office holder to act with the
same level of care as a reasonable office holder in the same position would employ under the same circumstances. The duty of loyalty includes
avoiding any conflict of interest between the office holder&#8217;s position in the company and such person&#8217;s personal affairs,
avoiding any competition with the company, avoiding exploiting any corporate opportunity of the company in order to receive personal advantage
for such person or others, and revealing to the company any information or documents relating to the company&#8217;s affairs which the
office holder has received due to his or her position as an office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification of Directors and Officers;
Limitations on Liability</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law permits a company
to insure an office holder in respect of liabilities incurred by him or her as a result of an act or omission in the capacity of an office
holder for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the office holder&#8217;s duty of care towards the company or towards another person;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the office holder&#8217;s fiduciary duty to the company, provided that he or she acted in good faith and had reasonable cause to believe that the act would not prejudice the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon the office holder in favor of another person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A financial liability imposed on the office holder&#8217;s for all victims of the violation in an Administrative Proceeding.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses incurred by the office holder&#8217;s in connection with an Administrative Proceeding conducted in his or her case, including litigation expenses and reasonable legal fees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, a company can indemnify
an office holder for any of the following obligations or expenses incurred in connection with the acts or omissions of such person in
his or her capacity as an office holder:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monetary liability imposed upon him or her in favor of a third party by a judgment, including a settlement or an arbitral award confirmed by the court; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including legal fees, actually incurred by the office holder or imposed upon him or her by a court, in a proceeding brought against him or her by or on behalf of the company or by a third party, or in a criminal action in which he or she was acquitted, or in a criminal action which does not require criminal intent in which he or she was convicted; furthermore, a company can, with a limited exception, exculpate an office holder in advance, in whole or in part, from liability for damages sustained by a breach of duty of care to the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial liability imposed on the office holder for all victims of the violation in an Administrative Proceeding.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by the office holder in connection with an Administrative Proceeding conducted in his or her case, including litigation expenses and reasonable legal fees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles of Association
allow for insurance, exculpation and indemnification of office holders to the fullest extent permitted by law. We have entered into indemnification,
insurance and exculpation agreements with our directors and executive officers, following shareholder approval of these agreements. We
have directors&#8217; and officers&#8217; liability insurance covering our officers and directors for a claim imposed upon them as a result
of an action carried out while serving as an officer or director, for (a) the breach of duty of care towards us or towards another person,
(b) the breach of fiduciary duty towards us, provided that the officer or director acted in good faith and had reasonable grounds to assume
that the action would not harm our interests, and (c) a monetary liability imposed upon him in favor of a third party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Approval of Related Party Transactions under
the Israeli Companies Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fiduciary duties of the office holders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
imposes a duty of care and a duty of loyalty on all office holders of a company. The duty of care of an office holder is based on the
duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty
of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would
have acted under the same circumstances. The duty of care includes a duty to use reasonable means, in light of the circumstances, to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty requires
an office holder to act in good faith and for the benefit of the company, and includes the duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any act involving a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-indent: -0.1in"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any activity that is competitive with the business of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may approve an act performed
in breach of the duty of loyalty of an office holder provided that the office holder acted in good faith, the act or its approval does
not harm the company, and the office holder discloses his or her personal interest, as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of personal interests of an office
holder and approval of acts and transactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires that an office holder promptly disclose to the company any personal interest that he or she may have and all related material
information or documents relating to any existing or proposed transaction by the company. An interested office holder&#8217;s disclosure
must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered.
An office holder is not obligated to disclose such information if the personal interest of the office holder derives solely from the personal
interest of his or her relative in a transaction that is not considered as an extraordinary transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term personal interest
is defined under the Israeli Companies Law to include the personal interest of a person in an action or in the business of a company,
including the personal interest of such person&#8217;s relative or the interest of any corporation in which the person is an interested
party, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest furthermore
includes the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with respect
to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal interest
in the approval of the matter. An office holder is not, however, obligated to disclose a personal interest if it derives solely from the
personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, an extraordinary transaction which requires approval is defined any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction other than in the ordinary course of business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that is not on market terms; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transaction that may have a material impact on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, once an office holder has complied with the disclosure requirement described above, a company may approve a transaction between the
company and the office holder or a third party in which the office holder has a personal interest, or approve an action by the office
holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is
adverse to the company&#8217;s interest or that is not performed by the office holder in good faith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, unless
the articles of association of a company provide otherwise, a transaction with an office holder, a transaction with a third party in which
the office holder has a personal interest, and an action of an office holder that would otherwise be deemed a breach of duty of loyalty
requires approval by the board of directors. Our Articles of Association do not provide otherwise. If the transaction or action considered
is (i) an extraordinary transaction, (ii) an action of an office holder that would otherwise be deemed a breach of duty of loyalty and
may have a material impact on a company&#8217;s profitability, assets or liabilities, (iii) an undertaking to indemnify or insure an office
holder who is not a director, or (iv) for matters considered an undertaking concerning the terms of compensation of an office holder who
is not a director, including, an undertaking to indemnify or insure such office holder, then approval by the audit committee is required
prior to approval by the board of directors. Arrangements regarding the compensation, indemnification or insurance of a director require
the approval of the audit committee, board of directors and shareholders, in that order.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director who has a personal
interest in a matter that is considered at a meeting of the board of directors or the audit committee may generally not be present at
the meeting or vote on the matter, unless a majority of the directors or members of the audit committee have a personal interest in the
matter or the chairman of the audit committee or board of directors, as applicable, determines that he or she should be present to present
the transaction that is subject to approval. If a majority of the directors have a personal interest in the matter, such matter would
also require approval of the shareholders of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of personal interests of a controlling
shareholder and approval of transactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. Extraordinary
transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement
in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly or
indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning
the terms of engagement of a controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office holder or an
employee, require the approval of the audit committee, the board of directors and a majority of the shares voted by the shareholders of
the company participating and voting on the matter in a shareholders&#8217; meeting. In addition, such shareholder approval must fulfill
one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any such
transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years,
unless the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Duties of shareholders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in
exercising its rights and performing its obligations to the company and other shareholders, including, among other things, voting at general
meetings of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an amendment to the articles of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the company&#8217;s authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the company&#8217;s authorized share capital; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of discrimination against other
shareholders, additional remedies are available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Israeli Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ORDINARY SHARES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rights Attached to Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through March 18, 2009, our
authorized share capital was NIS 10,000,000 consisting of 500,000,000 ordinary shares, par value NIS 0.02 per share. On March 18, 2009,
pursuant to a shareholder&#8217;s meeting, the share capital of our company was consolidated and re-divided so that each five (5) shares
of NIS 0.02 nominal value was consolidated into one (1) share of NIS 0.1 nominal value so that following such consolidation and re-division,
our authorized share capital consisted of 100,000,000 ordinary shares, par value NIS 0.10 per share. In addition, the authorized share
capital of our company was increased from NIS 10,000,000 to NIS 70,000,000 divided into 700,000,000 ordinary shares, NIS 0.10 nominal
value. The share consolidation was effected in June 22, 2009. Effective August 3, 2017, the authorized share capital of the company increased
from NIS 70,000,000 divided into 700,000,000 ordinary shares to NIS 145,000,000 divided into 1,450,000,000 ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of ordinary shares
have one vote per share, and are entitled to participate equally in the payment of dividends and share distributions and, in the event
of our liquidation, in the distribution of assets after satisfaction of liabilities to creditors. No preferred shares are currently authorized.
All outstanding ordinary shares are validly issued and fully paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Transfer of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fully paid ordinary shares
are issued in registered form and may be freely transferred under our Articles of Association unless the transfer is restricted or prohibited
by another instrument or applicable securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividend and Liquidation Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of ordinary shares according to their rights and interests in our profits. In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of ordinary shares in proportion to the
nominal value of their holdings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This right may be affected
by the grant of preferential dividend or distribution rights, to the holders of a class of shares with preferential rights that may be
authorized in the future. Under the Israeli Companies Law, the declaration of a dividend does not require the approval of the shareholders
of the company, unless the company&#8217;s articles of association require otherwise. Our Articles provide that the Board of Directors
may declare and distribute dividends without the approval of the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Annual and Extraordinary General Meetings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must hold our annual general
meeting of shareholders each year and no later than 15 months from the last annual meeting, at a time and place determined by the Board
of Directors, upon at least 21 days&#8217; prior notice to our shareholders, to which we need to add an additional three days for notices
sent outside of Israel. A special meeting may be convened by request of two directors, 25% of the directors then in office, one or more
shareholders holding at least 5% of our issued share capital and at least 1% of our issued voting rights, or one or more shareholders
holding at least 5% of our issued voting rights. Notice of a general meeting must set forth the date, time and place of the meeting. Such
notice must be given at least 21 days but not more than 45 days prior to the general meeting. The quorum required for a meeting of shareholders
consists of at least two shareholders present in person or by proxy who hold or represent between them at least one-third of the voting
rights in the company. A meeting adjourned for lack of a quorum generally is adjourned to the same day in the following week at the same
time and place (with no need for any notice to the shareholders) or until such other later time if such time is specified in the original
notice convening the general meeting, or if we serve notice to the shareholders no less than seven days before the date fixed for the
adjourned meeting. If at an adjourned meeting there is no quorum present half an hour after the time set for the meeting, any number participating
in the meeting shall represent a quorum and shall be entitled to discuss the matters set down on the agenda for the original meeting.
All shareholders who are registered in our registrar on the record date, or who will provide us with proof of ownership on that date as
applicable to the relevant registered shareholder, are entitled to participate in a general meeting and may vote as described in &#8220;Voting
Rights&#8221; and &#8220;Voting by Proxy and in Other Manners,&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares do not
have cumulative voting rights in the election of directors. As a result, the holders of ordinary shares that represent more than 50% of
the voting power represented at a shareholders meeting in which a quorum is present have the power to elect all of our directors, except
the external directors whose election requires a special majority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of ordinary shares
have one vote for each ordinary share held on all matters submitted to a vote of shareholders. Shareholders may vote in person or by proxy.
These voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights
that may be authorized in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless otherwise provided in the Articles of Association or by applicable law, all resolutions of the shareholders require a simple
majority. Our Articles of Association provide that all decisions may be made by a simple majority. See &#8220;Approval of Related Party
Transactions&#8221; above for certain duties of shareholders towards the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Voting by Proxy and in Other Manners</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles of Association
enable a shareholder to appoint a proxy, who need not be a shareholder, to vote at any shareholders meeting. We require that the appointment
of a proxy be in writing signed by the person making the appointment or by an attorney authorized for this purpose, and if the person
making the appointment is a corporation, by a person or persons authorized to bind the corporation. In the document appointing a proxy,
each shareholder may specify how the proxy should vote on any matter presented at a shareholders meeting. The document appointing the
proxy shall be deposited in our offices or at such other address as shall be specified in the notice of the meeting not less than 48 hours
before the time of the meeting at which the person specified in the appointment is due to vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
and our Articles of Association do not permit resolutions of the shareholders to be adopted by way of written consent, for as long as
our ordinary shares are publicly traded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations on the Rights to Own Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership or voting of
ordinary shares by non-residents of Israel is not restricted in any way by our Articles of Association or the laws of the State of Israel,
except that nationals of countries which are, or have been, in a state of war with Israel may not be recognized as owners of ordinary
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-Takeover Provisions under Israeli Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
permits merger transactions with the approval of each party&#8217;s board of directors and shareholders. In accordance with the Israeli
Companies Law, a merger may be approved at a shareholders meeting by a majority of the voting power represented at the meeting, in person
or by proxy, and voting on that resolution. In determining whether the required majority has approved the merger, shares held by the other
party to the merger, any person holding at least 25% of the outstanding voting shares or means of appointing the board of directors of
the other party to the merger, or the relatives or companies controlled by these persons, are excluded from the vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a merging company must inform its creditors of the proposed merger. Any creditor of a party to the merger may seek a court order
blocking the merger, if there is a reasonable concern that the surviving company will not be able to satisfy all of the obligations of
the parties to the merger. Moreover, a merger may not be completed until at least 30 days have passed from the time the merger was approved
in a general meeting of each of the merging companies, and at least 50 days have passed from the time that a merger proposal was filed
with the Israeli Registrar of Companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law provides
that an acquisition of shares in a public company must be made by means of a tender offer if, as a result of such acquisition, the purchaser
would become a 25% or greater shareholder of the company. This rule does not apply if there is already another shareholder with 25% or
greater shares in the company. Similarly, Israeli corporate law provides that an acquisition of shares in a public company must be made
by means of a tender offer if, as a result of the acquisition, the purchaser&#8217;s shareholdings would entitle the purchaser to over
45% of the shares in the company, unless there is a shareholder with 45% or more of the shares in the company. These requirements do not
apply if, in general, the acquisition (1) was made in a private placement that received the approval of the company&#8217;s shareholders;
(2) was from a 25% or greater shareholder of the company which resulted in the purchaser becoming a 25% or greater shareholder of the
company, or (3) was from a 45% or greater shareholder of the company which resulted in the acquirer becoming a 45% or greater shareholder
of the company. These rules do not apply if the acquisition is made by way of a merger. Regulations promulgated under the Israeli Companies
Law provide that these tender offer requirements do not apply to companies whose shares are listed for trading external of Israel if,
according to the law in the country in which the shares are traded, including the rules and regulations of the stock exchange or which
the shares are traded, either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there is a limitation on acquisition of any level of control of the company; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the acquisition of any level of control requires the purchaser to do so by means of a tender offer to the public.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.8pt; text-indent: -13.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Israeli Companies Law
provides specific rules and procedures for the acquisition of shares held by minority shareholders, if the majority shareholder holds
more than 90% of the outstanding shares. If, as a result of an acquisition of shares, the purchaser will hold more than 90% of a company&#8217;s
outstanding shares, the acquisition must be made by means of a tender offer for all of the outstanding shares. If less than 5% of the
outstanding shares are not tendered in the tender offer, all the shares that the purchaser offered to purchase will be transferred to
it. The Israeli Companies Law provides for appraisal rights if any shareholder files a request in court within three months following
the consummation of a full tender offer. If more than 5% of the outstanding shares are not tendered in the tender offer, then the purchaser
may not acquire shares in the tender offer that will cause his shareholding to exceed 90% of the outstanding shares of the company. Israeli
tax law treats specified acquisitions, including a stock-for-stock swap between an Israeli company and a foreign company, less favorably
than does U.S. tax law. These laws may have the effect of delaying or deterring a change in control of us, thereby limiting the opportunity
for shareholders to receive a premium for their shares and possibly affecting the price that some investors are willing to pay for our
securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rights of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our shareholders have the right to inspect certain documents and registers including the minutes of general meetings, the register
of shareholders and the register of substantial shareholders, any document held by us that relates to an act or transaction requiring
the consent of the general meeting as stated above under &#8220;Approval of Related Party Transactions&#8221; our Articles of Association
and our financial statements, and any other document which we are required to file under the Israeli Companies Law or under any law with
the Registrar of Companies or the Israeli Securities Authority, and is available for public inspection at the Registrar of Companies or
the Securities Authority, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the document required for
inspection by one of our shareholders relates to an act or transaction requiring the consent of the general meeting as stated above, we
may refuse the request of the shareholder if in our opinion the request was not made in good faith, the documents requested contain a
commercial secret or a patent, or disclosure of the documents could prejudice our good in some other way.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that with the approval of the court any of our shareholders or directors may file a derivative action on our behalf if the court
finds the action is a priori, to our benefit, and the person demanding the action is acting in good faith. The demand to take action can
be filed with the court only after it is serviced to us, and we decline or omit to act in accordance to this demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enforceability of Civil Liabilities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Israel
and most of our directors and officers named in this report reside outside the U.S. Service of process upon them may be difficult to effect
within the U.S. Furthermore, because substantially all of our assets, and those of our non-U.S. directors and officers and the Israeli
experts named herein, are located outside the U.S., any judgment obtained in the U.S. against us or any of these persons may not be collectible
within the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been informed by our
legal counsel in Israel, Doron Tikotsky Kantor Gutman &amp; Amit Gross, that there is doubt as to the enforceability of civil liabilities
under the Securities Act or the Exchange Act, pursuant to original actions instituted in Israel. However, subject to particular time limitations,
executory judgments of a U.S. court for monetary damages in civil matters may be enforced by an Israeli court, provided that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was obtained after due process before a court of competent jurisdiction, that recognizes and enforces similar judgments of Israeli courts, and the court had authority according to the rules of private international law currently prevailing in Israel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate service of process was effected and the defendant had a reasonable opportunity to be heard;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is not contrary to the law, public policy, security or sovereignty of the State of Israel and its enforcement is not contrary to the laws governing enforcement of judgments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment was not obtained by fraud and does not conflict with any other valid judgment in the same matter between the same parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is no longer appealable; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign judgments enforced
by Israeli courts generally will be payable in Israeli currency. The usual practice in an action before an Israeli court to recover an
amount in a non-Israeli currency is for the Israeli court to render judgment for the equivalent amount in Israeli currency at the rate
of exchange in force on the date of the judgment. Under existing Israeli law, a foreign judgment payable in foreign currency may be paid
in Israeli currency at the rate of exchange for the foreign currency published on the day before date of payment. Current Israeli exchange
control regulations also permit a judgment debtor to make payment in foreign currency. Pending collection, the amount of the judgment
of an Israeli court stated in Israeli currency ordinarily may be linked to Israel&#8217;s consumer price index plus interest at the annual
statutory rate set by Israeli regulations prevailing at that time. Judgment creditors must bear the risk of unfavorable exchange rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>AMERICAN DEPOSITORY SHARES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have issued and deposited
ordinary shares with Bank Hapoalim B.M., The Bank of New York&#8217;s custodian in Tel Aviv, Israel. The Bank of New York in turn issued
American Depositary Shares, or ADSs, representing American Depositary Shares, or ADSs. One ADS represents an ownership interest in one
hundred of our ordinary shares. Each ADS also represents securities, cash or other property deposited with The Bank of New York but not
distributed to ADS holders. The Bank of New York&#8217;s Corporate Trust Office is located at 101 Barclay Street, New York, NY 10286,
U.S.A. Their principal executive office is located at One Wall Street, New York, NY 10286, U.S.A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may hold ADSs either directly
or indirectly through your broker or other financial institution. If you hold ADSs directly, you are an ADS holder. This description assumes
you hold your ADSs directly. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution
to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out
what those procedures are.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because The Bank of New York
will actually hold the ordinary shares, you must rely on it to exercise the rights of a shareholder. The obligations of The Bank of New
York are set out in a deposit agreement among us, The Bank of New York and you, as an ADS holder. The agreement and the ADSs are generally
governed by New York law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the agreement. Because it is a summary, it does not contain all the information that may be important to you. For more complete information,
you should read the entire agreement and the ADS. Directions on how to obtain copies of these are provided in the section entitled &#8220;Where
You Can Find More Information.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Share Dividends and Other Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York has agreed
to pay to you the cash dividends or other distributions it or the custodian receives on shares or other deposited securities after deducting
its fees and expenses. You will receive these distributions in proportion to the number of shares your ADSs represent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cash.</i>&#160;The Bank
of New York will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable
basis and can transfer the U.S. dollars to the U.S. If that is not possible or if any approval from any government or agency thereof is
needed and cannot be obtained, the agreement allows The Bank of New York to distribute the foreign currency only to those ADS holders
to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been
paid. It will not invest the foreign currency and it will not be liable for the interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before making a distribution,
any withholding taxes that must be paid under U.S. law will be deducted. The Bank of New York will distribute only whole U.S. dollars
and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when The Bank of New
York cannot convert the foreign currency, you may lose some or all of the value of the distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Shares.</i>&#160;The Bank
of New York may distribute new ADSs representing any shares we may distribute as a dividend or free distribution, if we furnish it promptly
with satisfactory evidence that it is legal to do so. The Bank of New York will only distribute whole ADSs. It will sell shares which
would require it to use a fractional ADS and distribute the net proceeds in the same way as it does with cash. If The Bank of New York
does not distribute additional ADSs, each ADS will also represent the new shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Rights to receive additional
shares</i>. If we offer holders of our ordinary shares any rights to subscribe for additional shares or any other rights, The Bank of
New York may make these rights available to you. We must first instruct The Bank of New York to do so and furnish it with satisfactory
evidence that it is legal to do so. If we do not furnish this evidence and/or give these instructions, and The Bank of New York decides
it is practical to sell the rights, The Bank of New York will sell the rights and distribute the proceeds, in the same way as it does
with cash. The Bank of New York may allow rights that are not distributed or sold to lapse. In that case, you will receive no value for
them. If The Bank of New York makes rights available to you, upon instruction from you, it will exercise the rights and purchase the shares
on your behalf. The Bank of New York will then deposit the shares and issue ADSs to you. It will only exercise rights if you pay it the
exercise price and any other charges the rights require you to pay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. securities laws may restrict
the sale, deposit, cancellation and transfer of the ADSs issued after exercise of rights. For example, you may not be able to trade the
ADSs freely in the U.S. In this case, The Bank of New York may issue the ADSs under a separate restricted deposit agreement, which will
contain the same provisions as the agreement, except for the changes needed to put the restrictions in place.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Other Distributions</i>.
The Bank of New York will send to you anything else we distribute on deposited securities by any means it thinks is legal, fair and practical.
If it cannot make the distribution in that way, The Bank of New York has a choice. It may decide to sell what we distributed and distribute
the net proceeds in the same way as it does with cash or it may decide to hold what we distributed, in which case the ADSs will also represent
the newly distributed property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York is not
responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation
to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to
permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distribution
we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deposit, Withdrawal and Cancellation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York will
issue ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian upon payment of its fees and
expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees. The Bank of New York will register the appropriate
number of ADSs in the names you request and will deliver the ADSs at its office to the persons you request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may turn in your ADSs
at The Bank of New York&#8217;s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock
transfer taxes or fees, The Bank of New York will deliver (1) the underlying shares to an account designated by you and (2) any other
deposited securities underlying the ADS at the office of the custodian; or, at your request, risk and expense, The Bank of New York will
deliver the deposited securities at its office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may instruct The Bank
of New York to vote the shares underlying your ADSs but only if we ask The Bank of New York to ask for your instructions. Otherwise, you
will not be able to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in
advance to withdraw the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we ask for your instructions,
The Bank of New York will notify you of the upcoming vote and arrange to deliver our voting materials to you. The materials will (1) describe
the matters to be voted on and (2) explain how you, on a certain date, may instruct The Bank of New York to vote the shares or other deposited
securities underlying your ADSs as you direct. For instructions to be valid, The Bank of New York must receive them on or before the date
specified. The Bank of New York will try, as far as practical, subject to Israeli law and the provisions of our Articles of Association,
to vote or to have its agents vote the shares or other deposited securities as you instruct. The Bank of New York will only vote or attempt
to vote as you instruct. However, if The Bank of New York does not receive your voting instructions, it will deem you to have instructed
it to give a discretionary proxy to vote the shares underlying your ADSs to a person designated by us provided that no such instruction
shall be deemed given and no such discretionary proxy shall be given with respect to any matter as to which we inform The Bank of New
York that (x) we do not wish such proxy given, (y) substantial opposition exists, (z) such matter materially affects the rights of the
holders of the shares underlying the ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
you will receive the voting materials in time to ensure that you can instruct The Bank of New York to vote your shares. In addition, The
Bank of New York and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting
instructions. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your shares are
not voted as you requested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rights of Non-Israeli Shareholders to Vote</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs may be freely held
and traded pursuant to the General Permit and the Currency Control Law. The ownership or voting of ADSs by non-residents of Israel is
not restricted in any way by our Articles of Association or by the laws of the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fees and Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 44%; text-indent: 0pt"><b><i>ADS
    holders must pay:</i></b></td>
    <td style="padding: 0pt 0pt 1.5pt; width: 2%; text-indent: 0pt"><b><i>&#160;</i></b></td>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 54%; text-indent: 0pt"><b><i>For:</i></b></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt">$5.00 (or less) per 100 ADSs (or portion thereof)</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><p style="text-align: justify; margin-top: 0; margin-bottom: 0">Each issuance of an ADS, including as a result of a distribution of shares or rights or other property.</p>
                                               <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                               <p style="text-align: justify; margin-top: 0; margin-bottom: 0">Each cancellation of an ADS, including if the agreement terminates.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">$0.05 (or less) per ADS&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Any cash payment.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Registration or Transfer Fees</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Transfer and registration of shares on the share register of the Foreign Registrar from your name to the name of The Bank of New York or its agent when you deposit or withdraw shares.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Expenses of The Bank of New York</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt"><p style="text-align: justify; margin-top: 0; margin-bottom: 0">Conversion of foreign currency to U.S. dollars.</p>
                                               <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                               <p style="text-align: justify; margin-top: 0; margin-bottom: 0">Cable, telex and facsimile transmission expenses.</p>
                                               <p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                               <p style="text-align: justify; margin-top: 0; margin-bottom: 0">Servicing of shares or deposited securities.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify; text-indent: -0.125in">$0.02 (or less) per ADS per calendar year (if the depositary has not collected any cash distribution fee during that year)</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Depositary services.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Taxes and other governmental charges</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">As necessary The Bank of New York or the Custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify; text-indent: -0.125in">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the ordinary shares had been deposited for issuance of ADSs</td>
    <td style="text-align: justify; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Payment of Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be responsible for
any taxes or other governmental charges payable on your ADSs or on the deposited securities underlying your ADSs. The Bank of New York
may refuse to transfer your ADSs or allow you to withdraw the deposited securities underlying your ADSs until such taxes or other charges
are paid. It may apply payments owed to you or sell deposited securities underlying your ADSs to pay any taxes owed and you will remain
liable for any deficiency. If it sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and
pay to you any proceeds, or send to you any property, remaining after it has paid the taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Reclassifications, Recapitalizations and Mergers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; border-bottom: black 1.5pt solid; width: 44%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
    we:</i></b></span></td>
    <td style="padding: 0pt; width: 2%; text-indent: 0pt"><b>&#160;</b></td>
    <td style="padding: 0pt; border-bottom: black 1.5pt solid; width: 54%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Then:</i></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt">
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Change the nominal or par value of our shares;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cash, shares or other securities received by The Bank of New York will become deposited securities. Each ADS will automatically represent its equal share of the new deposited securities. The Bank of New York may, and will if we ask it to, distribute some or all of the cash, shares or other securities it received. It may also issue new ADSs or ask you to surrender your outstanding ADSs in exchange for new ADSs, identifying the new deposited securities.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassify, split up or consolidate any of the deposited securities;&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribute securities on the shares that are not distributed to you; or&#160;</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or takes any similar action.</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amendment and Termination</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may agree with The Bank
of New York to amend the agreement and the ADSs without your consent for any reason. If the amendment adds or increases fees or charges,
except for taxes and other governmental charges or registration fees, cable, telex or facsimile transmission costs, delivery costs or
other such expenses, or prejudices an important right of ADS holders, it will only become effective thirty days after The Bank of New
York notifies you of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADS, to
agree to the amendment and to be bound by the ADSs and the agreement is amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York will
terminate the agreement if we ask it to do so. The Bank of New York may also terminate the agreement if The Bank of New York has told
us that it would like to resign and we have not appointed a new depositary bank within ninety days. In both cases, The Bank of New York
must notify you at least ninety days before termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After termination, The Bank
of New York and its agents will be required to do only the following under the agreement: (1) advise you that the agreement is terminated,
and (2) collect distributions on the deposited securities and deliver shares and other deposited securities upon cancellation of ADSs.
After termination, The Bank of New York will, if practical, sell any remaining deposited securities by public or private sale. After that,
The Bank of New York will hold the proceeds of the sale, as well as any other cash it is holding under the agreement for the pro rata
benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and will have no liability for interest.
The Bank of New York&#8217;s only obligations will be to account for the proceeds of the sale and other cash. After termination our only
obligations will be with respect to indemnification and to pay certain amounts to The Bank of New York.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations on Obligations and Liability
to ADS Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement expressly limits
our obligations and the obligations of The Bank of New York, and it limits our liability and the liability of The Bank of New York. We
and The Bank of New York:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are only obligated to take the actions specifically set forth in the agreement without negligence or bad faith;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not liable if either is prevented or delayed by law or circumstances beyond their control from performing their obligations under the agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not liable if either exercises discretion permitted under the agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the agreement on your behalf or on behalf of any other party; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may rely upon any documents they believe in good faith to be genuine and to have been signed or presented by the proper party.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the agreement, we and The
Bank of New York agree to indemnify each other under certain circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Requirements for Depositary Actions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before The Bank of New York
will issue or register transfer of an ADS, make a distribution on an ADS, or make a withdrawal of shares, The Bank of New York may require
payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for
the:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer of any shares or other deposited securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production of satisfactory proof of the identity and genuineness of any signature or other information it deems necessary, and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with regulations it may establish, from time to time, consistent with the agreement, including presentation of transfer documents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York may refuse
to deliver, transfer, or register transfers of ADSs generally when the books of The Bank of New York or our books are closed, or at any
time if The Bank of New York or we think it advisable to do so. You have the right to cancel your ADSs and withdraw the underlying shares
at any time except:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when temporary delays arise because: (1) The Bank of New York or we have closed its transfer books; (2) the transfer of shares is blocked to permit voting at a shareholders&#8217; meeting; or (3) we are paying a dividend on the shares; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: -0.1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This right of withdrawal may
not be limited by any other provision of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Release of ADSs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain circumstances,
subject to the provisions of the agreement, The Bank of New York may issue ADSs before deposit of the underlying shares. This is called
a pre-release of the ADS. The Bank of New York may also deliver shares upon cancellation of pre-released ADSs (even if the ADSs are cancelled
before the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying shares are delivered to
The Bank of New York. The Bank of New York may receive ADSs instead of shares to close out a pre-release. The Bank of New York may pre-release
ADSs only under the following conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being made
must represent to The Bank of New York in writing that it or its customer owns the shares or ADSs to be deposited; (2) the pre-release
must be fully collateralized with cash or other collateral that The Bank of New York considers appropriate; and (3) The Bank of New York
must be able to close out the pre-release on not more than five business days&#8217; notice. In addition, The Bank of New York will limit
the number of ADSs that may be outstanding at any time as a result of prerelease, although The Bank of New York may disregard the limit
from time to time, if it thinks it is appropriate to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inspection of Books of the Depositary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the agreement,
holders of ADSs may inspect the transfer books of the depositary at any reasonable time, provided that such inspection shall not be for
the purpose of communicating with holders of ADSs in the interest of a business or object other than either our business or a matter related
to the deposit agreement or ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Book-Entry Only Issuance - The Depository
Trust Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Depository Trust Company,
or DTC, New York, New York, will act as securities depository for the ADSs. The ADSs will be represented by one global security that will
be deposited with and registered in the name of Cede &amp; Co. (DTC&#8217;s partnership nominee), or such other name as may be requested
by an authorized representative of DTC. This means that we will not issue certificates to you for the ADSs. One global security will be
issued to DTC, which will keep a computerized record of its participants (for example, your broker) whose clients have purchased the ADSs.
Each participant will then keep a record of its clients. Unless it is exchanged in whole or in part for a certificated security, a global
security may not be transferred. However, DTC, its nominees, and their successors may transfer a global security as a whole to one another.
Beneficial interests in the global security will be shown on, and transfers of the global security will be made only through, records
maintained by DTC and its participants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DTC is a limited-purpose trust
company organized under the New York Banking Law, a &#8220;banking organization&#8221; within the meaning of the New York Banking Law,
a member of the United States Federal Reserve System, a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform
Commercial Code and a &#8220;clearing agency&#8221; registered under the provisions of Section 17A of the Exchange Act. DTC holds securities
that its participants (direct participants) deposit with DTC. DTC also records the settlement among direct participants of securities
transactions, such as transfers and pledges, in deposited securities through computerized records for direct participant&#8217;s accounts.
This eliminates the need to exchange certificates. Direct participants include securities brokers and dealers, banks, trust companies,
clearing corporations and certain other organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DTC&#8217;s book-entry system
is also used by other organizations such as securities brokers and dealers, banks and trust companies that work through a direct participant.
The rules that apply to DTC and its participants are on file with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DTC is a wholly-owned subsidiary
of The Depository Trust &amp; Clearing Corporation, or DTCC. DTCC is, in turn, owned by a number of DTC&#8217;s direct participants and
by the New York Stock Exchange, Inc., the American Stock Exchange, Inc. and the National Association of Securities Dealers, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When you purchase ADSs through
the DTC system, the purchases must be made by or through a direct participant, who will receive credit for the ADSs on DTC&#8217;s records.
Since you actually own the ADSs, you are the beneficial owner and your ownership interest will only be recorded on the direct (or indirect)
participants&#8217; records. DTC has no knowledge of your individual ownership of the ADSs. DTC&#8217;s records only show the identity
of the direct participants and the amount of ADSs held by or through them. You will not receive a written confirmation of your purchase
or sale or any periodic account statement directly from DTC. You will receive these from your direct (or indirect) participant. Thus the
direct (or indirect) participants are responsible for keeping accurate account of the holdings of their customers like you.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will wire dividend payments
to DTC&#8217;s nominee, and we will treat DTC&#8217;s nominee as the owner of the global security for all purposes. Accordingly, we will
have no direct responsibility or liability to pay amounts due on the global security to you or any other beneficial owners in the global
security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any redemption notices will
be sent by us directly to DTC, who will in turn inform the direct participants, who will then contact you as a beneficial holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is DTC&#8217;s current
practice, upon receipt of any payment of dividends or liquidation amount, to credit direct participants&#8217; accounts on the payment
date based on their holdings of beneficial interests in the global securities as shown on DTC&#8217;s records. In addition, it is DTC&#8217;s
current practice to assign any consenting or voting rights to direct participants whose accounts are credited with preferred securities
on a record date, by using an omnibus proxy. Payments by participants to owners of beneficial interests in the global securities, and
voting by participants, will be based on the customary practices between the participants and owners of beneficial interests, as is the
case with the ADSs held for the account of customers registered in &#8220;street name.&#8221; However, payments will be the responsibility
of the participants and not of DTC or us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADSs represented by a global
security will be exchangeable for certificated securities with the same terms in authorized denominations only if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC is unwilling or unable to continue as depositary or if DTC ceases to be a clearing agency registered under applicable law and a successor depositary is not appointed by us within 90 days; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we determine not to require all of the ADSs to be represented by a global security.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the book-entry only system
is discontinued, the transfer agent will keep the registration books for the ADSs at its corporate office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this section
concerning DTC and DTC&#8217;s book-entry system has been obtained from sources we believe to be reliable, but we take no responsibility
for the accuracy thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exchange Controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no Israeli government
laws, decrees or regulations that restrict or that affect our export or import of capital or the remittance of dividends, interest or
other payments to non-resident holders of our securities, including the availability of cash and cash equivalents for use by us and our
wholly-owned subsidiaries, except or otherwise as set forth under Taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion summarizes
certain Israeli and U.S. federal income tax consequences that may be material to our shareholders, but is not intended, and should not
be construed, as legal or professional tax advice and does not exhaust all possible tax considerations that may be relevant to holders
of our ordinary shares. This discussion is based on existing law, judicial authorities and administrative interpretations, all of which
are subject to change or differing interpretations, possibly with retroactive effect. This summary does not purport to be a complete analysis
of all potential tax consequences of owning our ordinary shares. In particular, this discussion does not take into account the specific
circumstances of any particular holder or holders who may be subject to special rules, such as tax-exempt entities, broker-dealers, shareholders
subject to Alternative Minimum Tax, shareholders that actually or constructively own 10% or more of our voting securities, shareholders
that hold ordinary shares or ADSs as part of straddle or hedging or conversion transaction, traders in securities that elect mark to market,
banks and other financial institutions or partnerships or other pass-through entities. The following tax considerations are not relevant
to employees of the company or any controlling shareholders. The tax aspects do not include reference to the Encouragement of Capital
Investments Law and the Encouragement of Industry Taxes Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>We urge shareholders to
consult their own tax advisors as to the potential U.S., Israeli, or other tax consequences of the purchase, ownership and disposition
of ordinary shares and ADSs, including, in particular, the effect of any foreign, state or local taxes. For purposes of the entire Taxation
discussion, we refer to ordinary shares and ADSs collectively as ordinary shares.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli Tax Considerations and Government Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a brief summary of the material
Israeli tax laws applicable to us and certain Israeli Government programs that benefit us. This section also contains a discussion of
material Israeli tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the
aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to
some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders
in securities who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new
tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate
tax authorities or the courts will accept the views expressed in this discussion. The discussion below is subject to change, including
due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change
could affect the tax consequences described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General Corporate Tax Structure in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident (as defined below) companies,
such as us, are generally subject to corporate tax at the rate of 23% since 2018. However, the effective tax rate imposed on a company
that derives income from a Preferred Enterprise or a Preferred Technology Enterprise (as discussed below) may be considerably lower. Capital
gains derived by an Israeli company are generally subject to tax at the prevailing corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Law for the Encouragement of Industry (Taxes),
5729-1969</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement of Industry (Taxes),
5729-1969 (the &#8220;Industry Encouragement Law&#8221;), grants several tax benefits for &#8220;Industrial Companies.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Industry Encouragement Law defines an &#8220;Industrial
Company&#8221; as a company resident in Israel, of which 90% or more of its income in any tax year, other than income deriving from defense
loans, and is derived from an &#8220;Industrial Enterprise&#8221; owned by it. An &#8220;Industrial Enterprise&#8221; is defined as an
enterprise whose principal activity in a given tax year is industrial production (and several other activities listed in the said law,
and are associated with industrial production).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following corporate tax benefits, among others,
are available to Industrial Companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">amortization over an eight-year period of the cost of patents
and/or rights to use a patent and know-how which were purchased in good faith and/or are used for the development or advancement of the
Industrial Enterprise over an eight-year period;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">deduction of expenses incurred in connection with the issuance
and listing of shares on a stock market over a three-year period; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">under certain conditions, an election to file its tax returns
along with related Israeli Industrial Companies.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance that we currently qualify,
or will continue to qualify, as an Industrial Company or that the benefits described above will be available in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Law for the Encouragement of Capital Investments,
5719-1959</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Benefits for Income from Preferred Enterprise</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement of Capital Investments,
5719-1959 (the &#8220;Investment Law&#8221;), currently provides certain tax benefits for income generated by &#8220;Preferred Companies&#8221;
from their &#8220;Preferred Enterprises.&#8221; The definition of a Preferred Company includes, inter alia, a company incorporated in
Israel and that is not wholly owned by a governmental entity, which:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">owns a Preferred Enterprise, which is defined as an &#8220;Industrial
Enterprise&#8221; (as defined under the Investment Law) that is classified as either a &#8220;Competitive Enterprise&#8221; (as defined
under the Investment Law) or a &#8220;Competitive Enterprise in the Field of Renewable Energy&#8221; (as defined under the Investment
Law);</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">is controlled and managed from Israel;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">is not a &#8220;Family Company,&#8221; a &#8220;Home Company,&#8221;
or a &#8220;Kibbutz&#8221; (collective community) as defined under the Income Tax Ordinance;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">keeps acceptable ledgers and files reports in accordance with
the provisions of the Investment Law and the Income Tax Ordinance; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">was not, and certain officers of which were not, convicted
of certain crimes in the 10 years prior to the tax year with respect to which benefits are being claimed.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 1, 2017, a Preferred Company is
currently entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise, unless the Preferred
Enterprise is located in development area A, in which case the rate is currently 7.5% (our operations are currently not located in development
area A).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid out of income attributed to a Preferred
Enterprise are generally subject to tax at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. However,
if such dividends are paid to an Israeli company, such dividends should be exempt from tax (although, if such dividends are subsequently
distributed to non-Israeli individuals or a non-Israeli company, tax at a rate of 20% or such lower rate as may be provided in an applicable
tax treaty will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If in the future we generate taxable income, to
the extent that we qualify as a &#8220;Preferred Company,&#8221; the benefits provided under the Investment Law could potentially reduce
our corporate tax liabilities. Therefore, the termination or substantial reduction of the benefits available under the Investment Law
could materially increase our tax liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Benefits for Income from Preferred Technology
Enterprise</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An amendment to the Investment Law was enacted
as part of the Economic Efficiency Law that was published on December 29, 2016, and entered into effect as of January 1, 2017 (the &#8220;2017
Amendment&#8221;). The 2017 Amendment provides additional tax benefits to Preferred Companies for &#8220;Technology Enterprises,&#8221;
as described below, and is in addition to the Preferred Enterprise regime provided under the Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Amendment provides that a technology
company satisfying certain conditions will qualify as a &#8220;Preferred Technology Enterprise&#8221; and may thereby enjoy a reduced
corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technology Income,&#8221; as defined in the Investment Law. The
tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development area A. In addition, a Preferred Technology
Enterprise may enjoy a reduced capital gains tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefited Intangible
Assets&#8221; (as defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets were acquired from a
foreign company on or after January 1, 2017 for at least NIS 200 million, pending that the sale receives is pre-approved by the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends distributed by a Preferred Technology
Enterprise that are paid out of Preferred Technology Income are subject to tax at the rate of 20%, but if they are distributed to a foreign
company and at least 90% of the shares of the distributing company are held by foreign resident companies then the tax rate may be as
low as 4%, subject to the fulfillment of certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we have not yet generated taxable income, there
is no assurance that we qualify as a Preferred Technology Enterprise or that the benefits described above will be available to us in the
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If in the future we generate taxable income, to
the extent that we qualify as a &#8220;Preferred Company,&#8221; the benefits provided under the Investment Law could potentially reduce
our corporate tax liabilities. Therefore, the termination or substantial reduction of the benefits available under the Investment Law
could materially increase our tax liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Encouragement of Research, Development
and Technological Innovation in the Industry Law 5744</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Encouragement of Research, Development
and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Law for the Encouragement of Research and Development
in Industry 5744-1984) (&#8220;Innovation Law&#8221;), and the regulations and guidelines promulgated thereunder, research and development
programs which meet specified criteria and are approved by a committee of the IIA, are eligible for grants. The grants awarded are typically
up to 50% of the project&#8217;s expenditures, as determined by the research committee. The grantee is required to pay royalties to the
State of Israel from the sale of products developed under the program. Regulations under the Innovation Law generally provide for the
payment of royalties of 3% to 6% on income generated from products and services based on technology developed using grants, until 100%
of the grant, linked to the dollar and bearing interest at the LIBOR rate, is repaid. In July 2017, new regulations came into force. According
to the new regulations, the royalties range between 1.3-5% depending on the company&#8217;s size and sector. The terms of the IIA participation
also require that products developed with IIA grants be manufactured in Israel and that the know-how developed thereunder may not be transferred
outside of Israel, unless approval is received from the IIA and additional payments are made to the IIA. However, this does not restrict
the export of products that incorporate the funded know-how. The royalty repayment ceiling can reach up to three times the amount of the
grant received (plus interest) if manufacturing is transferred outside of Israel, and repayment of up to six times the amount of the grant
(plus interest) may be required if the technology itself is transferred outside of Israel or license to use it was granted to a foreign
entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Taxation of our Shareholders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Capital Gains Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law generally imposes a capital gains
tax (i) on the sale of any capital assets by residents of Israel, as defined for Israeli tax purposes, and (ii) on the sale of capital
assets located in Israel, including shares of Israeli companies, by non-residents of Israel, unless a specific exemption is available
or unless a tax treaty between Israel and the shareholder&#8217;s country of residence provides otherwise. The law distinguishes between
real gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain that is equivalent to the increase
of the relevant asset&#8217;s purchase price which is attributable to the increase in the Israeli consumer price index or a foreign currency
exchange rate between the date of purchase and the date of sale. The real gain is the excess of the total capital gain over the inflationary
surplus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Israeli Residents</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, as of January 1, 2012 and thereafter,
the tax rate applicable to real capital gains derived from the sale of shares, whether listed on a stock market or not, is 25% for Israeli
individuals, unless such shareholder claims a deduction for financing expenses in connection with such shares, in which case the gain
will generally be taxed at a rate of 30%. Additionally, if such shareholder is considered a &#8220;substantial shareholder&#8221; (SSH)
at the time of the sale or at any time during the 12-month period preceding such sale, the tax rate will be 30%. A &#8220;substantial
shareholder&#8221; is defined as one who holds, directly or indirectly, alone or &#8220;together with another&#8221; (i.e., together with
a relative, or together with someone who is not a relative but with whom, according to an agreement, there is regular cooperation in material
matters of the company, directly or indirectly), directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; in
the company. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive
officer, receive assets upon liquidation, or instruct someone who holds any of the aforementioned rights regarding the manner in which
such rights are to be exercised. However, different tax rates will apply to dealers in securities. Israeli companies are subject to capital
gains tax at the regular corporate tax rate (i.e., 23% for the tax year 2018 and thereafter) on real capital gains derived from the sale
of listed shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 1, 2024, Israeli resident shareholders
who are individuals with taxable income that exceeds NIS 721,560 in a tax year (linked to the Israeli consumer price index each year)
will be subject to an additional tax at the rate of 3% on the portion of their taxable income for such tax year that is in excess of NIS
721,560 (linked to the Israeli consumer price index each year). For this purpose, taxable income includes taxable capital gains from the
sale of our shares and taxable income from dividend distributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our shareholders are liable
for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax
at source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Israeli Residents</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-Israeli resident who derives capital gains
from the sale of shares in an Israeli resident company that were purchased after the company was listed for trading on a stock exchange
outside of Israel will be exempt from Israeli tax so long as the shares were not held through a permanent establishment that the non-resident
maintains in Israel. However, non-Israeli resident corporations will not be entitled to the foregoing exemption if (i) an Israeli resident
has a controlling interest, directly or indirectly, alone, &#8220;together with another&#8221; (as defined above), or together with another
Israeli resident, of more than 25% in one or more of the &#8220;means of control&#8221; (as defined above) in such non-Israeli resident
corporation, or (ii) Israeli residents are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli
resident corporation, whether directly or indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a sale of securities by a non-Israeli
resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, pursuant to the provisions
of the Convention between the Government of the United States of America and the Government of the State of Israel with respect to Taxes
on Income, as amended (the &#8220;U.S.-Israel Tax Treaty&#8221;), capital gains arising from the sale, exchange or disposition of our
ordinary shares by (i) a person who qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty, (ii)
who holds the shares as a capital asset, and (iii) who is entitled to claim the benefits afforded to such person by the U.S.-Israel Tax
Treaty generally is generally exempt from Israeli capital gains tax. Such exemption will not apply if: (i) such person holds, directly
or indirectly, shares representing 10% or more of our voting power during any part of the 12-month period preceding such sale, exchange,
or disposition, subject to particular conditions; (ii) the capital gains from such sale, exchange, or disposition are attributable to
a permanent establishment in Israel; or (iii) such person is an individual and was present in Israel for 183 days or more during the relevant
tax year. In such case, the capital gain arising from the sale, exchange, or disposition of our ordinary shares would be subject to Israeli
tax, to the extent applicable; however, under the U.S.-Israel Tax Treaty, the taxpayer may be permitted to claim a credit for such taxes
against the U.S. federal income tax imposed with respect to such sale, exchange, or disposition, subject to the limitations under U.S.
law applicable to foreign tax credits. The U.S.-Israel Tax Treaty does not relate to U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders may be required to demonstrate that
they are exempt from tax on their capital gains in order to refrain from withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It should be noted that in the event that the
real capital gain realized by an individual shareholder is not exempt from tax in Israel, the tax rates applicable to Israeli resident
individual shareholders should generally apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our shareholders may be
liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli
tax at source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Taxation of Dividend Distributions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Israeli Residents</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident individuals are generally subject
to Israeli income tax on the receipt of dividends paid on our ordinary shares, other than bonus shares (share dividends). As of January
1, 2012 and thereafter, the tax rate applicable to such dividends is generally 25%. With respect to a person who is a &#8220;substantial
shareholder&#8221; (as defined above) at the time the dividend is received or at any time during the preceding 12-month period, the applicable
tax rate is 30%. Dividends paid from income derived from Preferred Enterprises and Preferred Technology Enterprises will generally be
subject to income tax at a rate of 20%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 1, 2024, Israeli resident shareholders
who are individuals with taxable income that exceeds NIS 721,560 in a tax year (linked to the Israeli consumer price index each year)
will be subject to an additional tax at the rate of 3% on the portion of their taxable income for such tax year that is in excess of NIS
721,560 (linked to the Israeli consumer price index each year). For this purpose, taxable income includes taxable capital gains from the
sale of our shares and taxable income from dividend distributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid to an Israeli resident individual
shareholder on our ordinary shares will generally be subject to withholding tax at the rates corresponding with the income tax rates detailed
above unless we are provided in advance with a withholding tax certificate issued by the Israel Tax Authority stipulating a different
rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above, dividends paid to an
Israeli resident &#8220;substantial shareholder&#8221; (as defined above) on publicly traded shares, like our ordinary shares, which are
held via a &#8220;nominee company&#8221; (as defined under the Israeli Securities Law), are generally subject to Israeli withholding tax
at a rate of 25%, unless a different rate is provided under an applicable tax treaty, provided that a certificate from the Israel Tax
Authority allowing for a reduced withholding tax rate is obtained in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the dividend is attributable partly to income
derived from a Preferred Enterprise or a Preferred Technology Enterprise and partly to other sources of income, the tax rate will be a
blended rate reflecting the relative portions of the various types of income. We cannot assure you that we will designate the profits
that are being distributed in a way that will reduce shareholders&#8217; tax liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident companies are generally exempt
from tax on the receipt of dividends paid on our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Israeli Residents</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless a tax relief is provided by a treaty between
Israel and the shareholder&#8217;s country of residence, non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our ordinary shares at the rate of 25%. With respect to a person (including a corporation) who is a &#8220;substantial
shareholder&#8221; (as defined above) at the time of receiving the dividend or at any time during the preceding 12-month period, absent
treaty relief as mentioned above, the applicable Israeli income tax rate is 30%. Notwithstanding the above, dividends paid from income
derived from Preferred Enterprises will be subject to Israeli income tax at a rate of 20%. In addition, dividends distributed by a Preferred
Technology Enterprise that are paid out of Preferred Technology Income are subject to tax at the rate of 20%, but if they are distributed
to a foreign company and at least 90% of the shares of the distributing company are held by foreign resident companies then the tax rate
may be as low as 4%, subject to the fulfillment of certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this regard, dividends paid to a non-Israeli
resident shareholder on our ordinary shares will generally be subject to withholding tax at the rates corresponding with the income tax
rates detailed above unless we are provided in advance with a withholding tax certificate issued by the Israel Tax Authority stipulating
a different rate (e.g., in accordance with the provisions of an applicable tax treaty).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above, dividends paid to a
non-Israeli resident &#8220;substantial shareholder&#8221; (as defined above) on publicly traded shares, like our ordinary shares, which
are held via a &#8220;nominee company&#8221; (as defined under the Israeli Securities Law), are generally subject to Israeli withholding
tax at a rate of 25%, unless a different rate is provided under an applicable tax treaty, provided that a certificate from the Israel
Tax Authority allowing for a reduced withholding tax rate is obtained in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, it should be noted that an additional
3% tax might be applicable to individual shareholders if certain conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the U.S.-Israel Tax Treaty, the maximum
Israeli tax on dividends paid to a holder of ordinary shares who qualifies as a resident of the United States within the meaning of the
U.S.-Israel Tax Treaty is 25%. Such tax rate is generally reduced to 12.5% if: (i) the shareholder is a U.S. corporation and holds at
least 10% of the outstanding shares of our voting stock during the part of our tax year that precedes the date of payment of the dividends
and during the whole of our prior tax year; (ii) not more than 25% of our gross income in the tax year preceding the payment of the dividends
consists of interest or dividends, other than dividends or interest received from subsidiary corporations 50% or more of the outstanding
shares of voting stock of which is owned by us at the time such dividends or interest are received by us; and (iii) the dividends are
not sourced from income derived during a period for which we were entitled to the reduced tax rate applicable to a Preferred Enterprise
under the Investment Law. If the dividends are sourced from income derived during a period for which we are entitled to the reduced tax
rate applicable to a Preferred Enterprise or a Preferred Technology Enterprise under the Investment Law, to the extent that the first
two conditions detailed above are met, the Israeli tax rate applicable to such dividends should be 15%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the dividend is attributable partly to income
derived from a Preferred Enterprise or a Preferred Technology Enterprise and partly to other sources of income, the tax rate will be a
blended rate reflecting the relative portions of the various types of income. We cannot assure you that we will designate the profits
that are being distributed in a way that will reduce shareholders&#8217; tax liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Estate and gift tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law presently does not impose estate tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law also does not presently impose gift
taxes upon the transfer of assets to Israeli resident individuals so long as it is demonstrated to the satisfaction of the Israel Tax
Authority that the transfer was executed in good faith</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. Federal Income Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>TO ENSURE COMPLIANCE WITH
U.S. TREASURY DEPARTMENT CIRCULAR 230, PROSPECTIVE HOLDERS OF ORDINARY SHARES ARE HEREBY NOTIFIED THAT: (A) ANY DISCUSSION OF U.S. FEDERAL
TAX ISSUES IN THIS MEMORANDUM IS NOT INTENDED OR WRITTEN TO BE RELIED UPON, AND CANNOT BE RELIED UPON, BY HOLDERS OF ORDINARY SHARES FOR
THE PURPOSE OF AVOIDING PENALTIES THAT MAY BE IMPOSED ON SUCH HOLDERS UNDER THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE &#8220;CODE&#8221;);
(B) SUCH DISCUSSION IS WRITTEN IN CONNECTION WITH THE PROMOTION OR MARKETING OF THE TRANSACTIONS OR MATTERS ADDRESSED HEREIN; AND (C)
PROSPECTIVE HOLDERS OF ORDINARY SHARES SHOULD SEEK ADVICE BASED ON THEIR PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion applies
only to a holder of our ordinary shares who qualifies as a &#8220;U.S. holder&#8221;. For purposes of this discussion a &#8220;U.S. holder&#8221;
is a beneficial owner of our ordinary shares that is for U.S. federal income tax purposes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a U.S. citizen or U.S. resident alien;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) that was created or organized under the laws of the U.S., any state thereof or the District of Columbia;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust (i) if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more &#8220;United States persons&#8221; (as defined in the Code) have the authority to control all substantial decisions of the trust, or (ii) if the trust has a valid election in effect under applicable Treasury Regulations to be treated as a &#8220;United States person.&#8221;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion is based on
current provisions of the Internal Revenue Code of 1986, as amended, which we refer to as the Code, current and proposed Treasury regulations
promulgated under the Code, and administrative and judicial decisions as of the date of this report, all of which are subject to change
or differing interpretation, possibly on a retroactive basis. This discussion does not address any aspect of state, local or non-U.S.
tax laws. Except where noted, this discussion addresses only those holders who hold our shares as capital assets. This discussion does
not purport to be a comprehensive description of all of the tax considerations that may be relevant to U.S. holders entitled to special
treatment under U.S. federal income tax laws, for example, financial institutions, insurance companies, tax-exempt organizations and broker/dealers,
and it does not address all aspects of U.S. federal income taxation that may be relevant to any particular shareholder based on the shareholder&#8217;s
individual circumstances. In particular, this discussion does not address the potential application of the alternative minimum tax, or
the special U.S. federal income tax rules applicable in special circumstances, including to U.S. holders who:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have elected mark-to-market accounting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hold our ordinary shares as part of a straddle, hedge or conversion transaction with other investments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">own directly, indirectly or by attribution at least 10% of our voting power;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are tax exempt entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are persons who acquire shares in connection with employment or other performance of services; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have a functional currency that is not the U.S. dollar.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, this discussion
does not consider the tax treatment of partnerships or persons who hold ordinary shares through a partnership or other pass-through entity
or the possible application of U.S. federal gift or estate taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EACH PROSPECTIVE SHAREHOLDER
IS URGED TO CONSULT ITS TAX ADVISOR REGARDING THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF OWNERSHIP AND DISPOSITION OF OUR SHARES,
AS WELL AS ANY TAX CONSEQUENCES THAT MAY ARISE UNDER THE LAWS OF ANY OTHER RELEVANT FOREIGN, STATE, LOCAL, OR OTHER TAXING JURISDICTION.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Distributions Paid on Ordinary
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the description
of the passive foreign investment company rules below, a U.S. holder will be required to include in gross income as ordinary income from
sources outside of the U.S. the amount of any distribution paid on ordinary shares, including any Israeli taxes withheld from the amount
paid, to the extent the distribution is paid out of our current or accumulated earnings and profits as determined for U.S. federal income
tax purposes. Distributions in excess of these earnings and profits will be applied against and will reduce the U.S. holder&#8217;s basis
in the ordinary shares and, to the extent in excess of this basis, will be treated as gain from the sale or exchange of ordinary shares.
We do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles and, therefore, U.S. holder
should expect that the entire amount of any distribution generally will be reported as dividend income.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 22, 2017, President
Trump signed into law the Tax Cuts and Jobs Act, or the TCJA. The TCJA provides a 100% deduction for the foreign-source portion of dividends
received from &#8220;specified 10-percent owned foreign corporations&#8221; by U.S. corporate holders, subject to a one-year holding period.
No foreign tax credit, including Israeli withholding tax (or deduction for foreign taxes paid with respect to qualifying dividends) would
be permitted for foreign taxes paid or accrued with respect to a qualifying dividend. Deduction would be unavailable for &#8220;hybrid
dividends.&#8221; The dividend received deduction enacted under the TCJA may not apply to dividends from a passive foreign investment
company, as discussed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain dividend income may
be eligible for a reduced rate of taxation. Dividend income will be taxed to a non-corporate holder at the applicable long-term capital
gains rate if the dividend is received from a &#8220;qualified foreign corporation,&#8221; and the shareholder of such foreign corporation
holds such stock for more than 60 days during the 121 day period that begins on the date that is 60 days before the ex-dividend date for
the stock. The holding period is tolled for any days on which the shareholder has reduced his risk of loss with respect to the stock.
A &#8220;qualified foreign corporation&#8221; is either a corporation that is eligible for the benefits of a comprehensive income tax
treaty with the U.S. or a corporation whose stock, the shares of which are with respect to any dividend paid by such corporation, is readily
tradable on an established securities market in the United States (including, for this purpose, ADSs traded on a securities market in
the United States with respect to the foreign corporation&#8217;s shares). However, a foreign corporation will not be treated as a &#8220;qualified
foreign corporation&#8221; if it is a passive foreign investment company (as discussed below) for the year in which the dividend was paid
or the preceding year. Distributions of current or accumulated earnings and profits paid in foreign currency to a U.S. holder will be
includible in the income of a U.S. holder in a U.S. dollar amount calculated by reference to the exchange rate in effect on the day the
distribution is received by the U.S. holder (or, in the case of ADSs, on the day the distribution is received by the depository). A U.S.
holder that receives a foreign currency distribution and converts the foreign currency into U.S. dollars subsequent to receipt will have
foreign exchange gain or loss based on any appreciation or depreciation in the value of the foreign currency against the U.S. dollar,
which will generally be U.S. source ordinary income or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described above, we will
generally be required to withhold Israeli income tax from any dividends paid to holders who are not residents of Israel. See &#8220;-
Israeli Tax Considerations&#8212;Taxation of Dividends&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to certain non-corporate
U.S. Holders, including individual U.S. Holders, dividends may be taxed at the lower capital gain rates applicable to &#8220;qualified
dividend income,&#8221; provided (1) our ordinary shares are readily tradable on an established securities market in the United States
(such as Nasdaq), (2) we are neither a PFIC nor treated as such with respect to you (as discussed above) for either the taxable year in
which the dividend was paid or the preceding taxable year, (3) certain holding period requirements are met and (4) you are not under an
obligation to make related payments with respect to positions in substantially similar or related property. As discussed above under &#8220;Passive
foreign investment company,&#8221; there is a significant risk that we will be a PFIC for U.S. federal income tax purposes, and, as a
result, the qualified dividend rate may be unavailable with respect to dividends we pay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any distribution
paid in a currency other than U.S. dollars will be equal to the U.S. dollar value of such currency on the date such distribution is includible
in your income, regardless of whether the payment is in fact converted into U.S. dollars at that time. The amount of any distribution
of property other than cash will be the fair market value of such property on the date of distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any dividends will constitute
foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed
above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will in general be
limited to the gross amount of the dividend, multiplied by the reduced tax rate applicable to qualified dividend income and divided by
the highest tax rate normally applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with
respect to specific classes of income. For this purpose, dividends distributed by us with respect to our ordinary shares will generally
constitute &#8220;passive category income&#8221; but could, in the case of certain U.S. Holders, constitute &#8220;general category income.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Israeli withholding taxes
apply to any dividends paid to you with respect to our ordinary shares, subject to certain conditions and limitations, such withholding
taxes may be treated as foreign taxes eligible for credit against your U.S. federal income tax liability. Instead of claiming a credit,
you may elect to deduct such taxes in computing taxable income, subject to applicable limitations. If a refund of the tax withheld is
available under the applicable laws of Israel or under the Israel-U.S. income tax treaty (the &#8220;Treaty&#8221;), the amount of tax
withheld that is refundable will not be eligible for such credit against your U.S. federal income tax liability (and will not be eligible
for the deduction against your U.S. federal taxable income). The rules relating to the determination of the foreign tax credit are complex,
and you should consult your tax advisor regarding the availability of a foreign tax credit in your particular circumstances, including
the effects of the Treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special rules, described below,
apply if we are a passive foreign investment company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of the Disposition of Ordinary
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the description
of the passive foreign investment company rules below, upon the sale, exchange or other disposition of our ordinary shares, a U.S. holder
will recognize capital gain or loss in an amount equal to the difference between the U.S. holder&#8217;s basis in the ordinary shares,
which is usually the cost of those shares, and the amount realized on the disposition. Capital gain from the sale, exchange or other disposition
of ordinary shares held more than one year is long-term capital gain and is eligible for a reduced rate of taxation for non-corporate
holders. In general, gain realized by a U.S. holder on a sale, exchange or other disposition of ordinary shares generally will be treated
as U.S. source income for U.S. foreign tax credit purposes. A loss realized by a U.S. holder on the sale, exchange or other disposition
of ordinary shares is generally allocated to U.S. source income. However, regulations require the loss to be allocated to foreign source
income to the extent certain dividends were received by the taxpayer within the 24-month period preceding the date on which the taxpayer
recognized the loss. The deductibility of a loss realized on the sale, exchange or other disposition of ordinary shares is subject to
limitations for both corporate and individual shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. holder that uses the
cash method of accounting calculates the U.S. dollar value of the proceeds received from a sale of ordinary shares as of the date that
the sale settles, and will generally have no additional foreign currency gain or loss on the sale, while a U.S. holder that uses the accrual
method of accounting is required to calculate the value of the proceeds of the sale as of the trade date and may therefore realize foreign
currency gain or loss, unless the U.S. holder has elected to use the settlement date to determine its proceeds of sale for purposes of
calculating this foreign currency gain or loss. In addition, a U.S. holder that receives foreign currency upon disposition of our ordinary
shares and converts the foreign currency into U.S. dollars subsequent to receipt will have foreign exchange gain or loss based on any
appreciation or depreciation in the value of the foreign currency against the U.S. dollar, which will generally be U.S. source ordinary
income or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Consequences if we are a Passive Foreign
Investment Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special federal income tax
rules apply to the timing and character of income received by a U.S. holder of a PFIC. We will be a PFIC if either 75% or more of our
gross income in a tax year is passive income or the average percentage of our assets (by value) that produce or are held for the production
of passive income in a tax year is at least 50%. The IRS has indicated that cash balances, even if held as working capital, are considered
to be assets that produce passive income. Therefore, any determination of PFIC status will depend upon the sources of our income, and
the relative values of passive and non- passive assets, including goodwill. Furthermore, because the goodwill of a publicly-traded corporation
is largely a function of the trading price of its shares, the valuation of that goodwill is subject to significant change throughout each
year. A determination as to a corporation&#8217;s status as a PFIC must be made annually. We believe we may be a PFIC during 2022 and
although we have not determined whether we will be a PFIC in 2023, or in any subsequent year, our operating results for any such years
may cause us to be a PFIC. Although we may not be a PFIC in any one year, the PFIC taint remains with respect to those years in which
we were or are a PFIC and the special PFIC taxation regime will continue to apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are classified as a
PFIC, a special tax regime would apply to both (a) any &#8220;excess distribution&#8221; by us (generally, the U.S. holder&#8217;s ratable
share of distributions in any year that are greater than 125% of the average annual distributions received by such U.S. holder in the
three preceding years or its holding period, if shorter) and (b) any gain recognized on the sale or other disposition of your ordinary
shares. Under this special regime, any excess distribution and recognized gain would be treated as ordinary income and the federal income
tax on such ordinary income would be determined as follows: (i) the amount of the excess distribution or gain would be allocated ratably
over the U.S. holder&#8217;s holding period for our ordinary shares; (ii) U.S. federal income tax would be determined for the amounts
allocated to the first year in the holding period in which we were classified as a PFIC and for all subsequent years (except the year
in which the excess distribution was received or the sale occurred) by applying the highest applicable tax rate in effect in the year
to which the income was allocated; (iii) an interest charge would be added to this tax, calculated by applying the underpayment interest
rate to the tax for each year determined under the preceding sentence from the due date of the income tax return for such year to the
due date of the return for the year in which the excess distribution or sale occurs; and (iv) amounts allocated to a year prior to the
first year in the U.S. holder&#8217;s holding period in which we were classified as a PFIC or to the year in which the excess distribution
or the disposition occurred would be taxed as ordinary income but without the imposition of an interest charge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. holder may generally
avoid the PFIC &#8220;excess distribution&#8221; regime by electing to treat his PFIC shares as a &#8220;qualified electing fund.&#8221;
If a U.S. holder elects to treat PFIC shares as a qualified electing fund, also known as a &#8220;QEF Election,&#8221; the U.S. holder
must include annually in gross income (for each year in which PFIC status is met) his <i>pro rata</i> share of the PFIC&#8217;s ordinary
earnings and net capital gains, whether or not such amounts are actually distributed to the U.S. holder. A U.S. holder may make a QEF
Election with respect to a PFIC for any taxable year in which he was a shareholder. A QEF Election is effective for the year in which
the election is made and all subsequent taxable years of the U.S. holder. Procedures exist for both retroactive elections and the filing
of protective statements. A U.S. holder making the QEF Election must make the election on or before the due date, as extended, for the
filing of the U.S. holder&#8217;s income tax return for the first taxable year to which the election will apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A QEF Election is made on
a shareholder-by-shareholder basis. A U.S. holder must make a QEF Election by completing Form 8621, Return by a Shareholder of a Passive
Foreign Investment Company or Qualified Electing Fund, and attaching it to the holder&#8217;s timely filed U.S. federal income tax return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alternatively, a U.S. holder
may also generally avoid the PFIC regime by making a so-called &#8220;mark-to-market&#8221; election. Such an election may be made by
a U.S. holder with respect to ordinary shares owned at the close of such holder&#8217;s taxable year, provided that we are a PFIC and
the ordinary shares are considered &#8220;marketable stock.&#8221; The ordinary shares will be marketable stock if they are regularly
traded on a national securities exchange that is registered with the Securities and Exchange Commission, or the national market system
established pursuant to section 11A of the Securities Exchange Act of 1934, or an equivalent regulated and supervised foreign securities
exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S. holder were to make
a mark-to-market election with respect to ordinary shares, such holder generally will be required to include in its annual gross income
the excess of the fair market value of the PFIC shares at year-end over such shareholder&#8217;s adjusted tax basis in the ordinary shares.
Such amounts will be taxable to the U.S. holder as ordinary income, and will increase the holder&#8217;s tax basis in the ordinary shares.
Alternatively, if in any year, a United States holder&#8217;s tax basis exceeds the fair market value of the ordinary shares at year-end,
then the U.S. holder generally may take an ordinary loss deduction to the extent of the aggregate amount of ordinary income inclusions
for prior years not previously recovered through loss deductions and any loss deductions taken will reduce the shareholder&#8217;s tax
basis in the ordinary shares. Gains from an actual sale or other disposition of the ordinary shares with a &#8220;mark-to-market&#8221;
election will be treated as ordinary income, and any losses incurred on an actual sale or other disposition of the ordinary shares will
be treated as an ordinary loss to the extent of any prior &#8220;unreversed inclusions&#8221; as defined in Section 1296(d) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The mark-to-market election
is made on a shareholder-by-shareholder basis. The mark-to-market election is made by completing Form 8621, Return by a Shareholder of
a Passive Foreign Investment Company or Qualified Electing Fund, and attaching it to the holder&#8217;s timely filed U.S. federal income
tax return for the year of election. Such election is effective for the taxable year for which made and all subsequent years until either
(a) the ordinary shares cease to be marketable stock or (b) the election is revoked with the consent of the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>In view of the complexity
of the issues regarding our treatment as a PFIC, U.S. shareholders are urged to consult their own tax advisors for guidance as to our
status as a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Back-Up Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. holders generally are
subject to information reporting requirements with respect to dividends paid in the U.S. on ordinary shares. Existing regulations impose
information reporting and back-up withholding on dividends paid in the U.S. on ordinary shares and on proceeds from the disposition of
ordinary shares unless the U.S. holder provides IRS Form W-9 or otherwise establishes an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prospective investors should
consult their tax advisors concerning the effect, if any, of these Treasury regulations on an investment in ordinary shares. Back-up withholding
is not an additional tax. The amount of any back-up withholding will be allowed as a credit against a holder&#8217;s U.S. federal income
tax liability and may entitle the holder to a refund, provided that specified required information is furnished to the IRS on a timely
basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Documents on Display</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file reports and other
information with the SEC under the Exchange Act and the regulations thereunder applicable to foreign private issuers. You may inspect
and copy reports and other information filed by us with the SEC at the SEC&#8217;s public reference facilities described below. Although
as a foreign private issuer we are not required to file periodic information as frequently or as promptly as U.S. companies, we generally
announce publicly our interim and year-end results promptly on a voluntary basis and will file that periodic information with the SEC
under cover of Form 6-K. As a foreign private issuer, we are also exempt from the rules under the Exchange Act prescribing the furnishing
and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and other provisions
in Section 16 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can review our SEC filings
by accessing the SEC&#8217;s internet site at&#160;http://www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain a website
at http://www.xtlbio.com, but information contained on our website does not constitute a part of this report and is not incorporated by
reference into this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Interest Rate Risk</i>.
The primary objective of our investment activities is to preserve principal while maximizing our income from investments and minimizing
our market risk. We invest in bank deposits and marketable securities in accordance with our investment policy. As of December 31, 2023,
our portfolio of financial instruments consists of cash and cash equivalents and marketable securities. Due to the short-term nature of
these investments, we believe we have no material exposure to interest rate risk arising from our investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Foreign Currency and Inflation
Risk.</i> We hold most of our cash, cash equivalents and bank deposits in U.S. dollars. While a substantial amount of our operating expenses
are in U.S. dollars, we incur a portion of our expenses in New Israeli Shekels. In addition, we also pay for some of our services and
supplies in the local currencies of our suppliers, as our head office is located in Israel. As a result, we are exposed to the risk that
the U.S. dollar will be devalued against the New Israeli Shekel or other currencies, and as a result our financial results could be harmed
if we are unable to guard against currency fluctuations in Israel or other countries in which services and supplies are obtained in the
future. Accordingly, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the
exchange rates of currencies. The Company&#8217;s treasury risk management policy is to hold NIS-denominated cash and cash equivalents
and short-term deposits in the amount of the anticipated NIS-denominated liabilities for six consecutive months from time to time and
this in line with the directives of the Company&#8217;s Board. These measures, however, may not adequately protect us from the adverse
effects of inflation in Israel. In addition, we are exposed to the risk that the rate of inflation in Israel will exceed the rate of devaluation
of the New Israeli Shekel in relation to the dollar or that the timing of any devaluation may lag behind inflation in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As of December 31, 2023,
had the Group&#8217;s functional currency strengthened by 10% against the NIS with all other variables remaining constant, loss for the
year would have been $144 thousand lower (2022 - loss would have been $152 thousand higher; 2021 - profit approximately $328 thousand
lower), mainly as a result of exchange rate changes on translation of other accounts receivable and exchange rate changes on NIS-denominated
cash and cash equivalents.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Credit Risk</i>. Credit
risks are managed at the Group level. The Group has no significant concentrations of credit risk. The Group has a policy to ensure collection
through sales of its products to wholesalers with an appropriate credit history and through retail sales in cash or by credit card.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Liquidity Risk.</i> Cash
flow forecasting is performed by the Group&#8217;s management both in the entities of the Group and aggregated by the Group. The Group&#8217;s
management monitors rolling forecasts of the Group&#8217;s liquidity requirements to ensure it has sufficient cash to meet operations.
The Group currently does not use credit facilities. Forecasting takes into consideration several factors such as raising capital to finance
operations and certain liquidity ratios that the Group strives to achieve.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Surplus cash held to finance
operating activities is invested in interest bearing current accounts, time deposits and other similar channels. These channels were chosen
by reference to their appropriate maturities or liquidity to provide sufficient cash balances to the Group as determined by the abovementioned
forecasts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#160;<i>Disclosure controls
and procedures</i>.&#160;Our management is responsible for establishing and maintaining effective disclosure controls and procedures,
as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. As of December 31, 2023, an evaluation was performed
under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure
controls and procedures. Based on that evaluation, management, including the Chief Executive Officer and Chief Financial Officer, concluded
that our disclosure controls and procedures as of December 31, 2023 were effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#160;<i>Management&#8217;s
annual report on internal controls over financial reporting</i>. Our management is responsible for establishing and maintaining adequate
control over financial reporting, as such term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Under the supervision and
with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation
of the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, our management
used the criteria established in <i>Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO) (2013).</i> Based on that evaluation, our management concludes our internal control over financial reporting
was effective as of December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All internal control systems,
no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect
misstatements and can provide only reasonable assurances with respect to the preparation and presentation of financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#160;Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#160;<i>Internal controls</i>.
There has been no significant change in our internal control over financial reporting that occurred during the year ended December 31,
2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. RESERVED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
determined that Osnat Hillel Fain, chairperson of our audit committee, is an audit committee financial expert, as defined by applicable
SEC regulations, and is independent in accordance with applicable SEC regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Code of
Conduct applicable to all directors and officers of our company, including our principal executive officer, principal financial officer,
principal accounting officer or controller and other individuals performing similar functions. A copy of our Code of Conduct can be found
on our website (http://www.xtlbio.com) and may also be obtained, without charge, upon a written request addressed to our investor relations
department, XTL Biopharmaceuticals Ltd., 26 Ben-Gurion St., Ramat Gan 5112001, Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Policy on Pre-Approval of Audit and Non-Audit Services of Independent
Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is responsible
for the oversight of the independent registered public accounting firm&#8217;s work. The audit committee&#8217;s policy is to pre-approve
all audit and non-audit services provided by our independent registered public accounting firm, Somekh Chaikin, a member firm of KPMG
International (&#8220;KPMG&#8221;), located in Tel Aviv, Israel, PCAOB ID No. <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-19468">1057</ix:nonNumeric>). These services may include audit services, audit-related
services and tax services, as further described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Principal Accountant Fees and Services</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following <span>table
presents the aggregate amount of </span>fees for professional services rendered <span>to the Company </span>by
<span>our principal accountant, </span>for the years ended December 31, 2023 and December 31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">85</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit fees for the year
ended December 31, 2023 and 2022 were for professional services rendered for the audit of our annual consolidated financial statements
and for review of interim consolidated financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the fiscal years ended
December 31, 2023 and December 31, 2022 all of the services performed by our independent registered public accounting firm were pre-approved
by the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b>&#160;</b></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><b>&#160;</b></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S REGISTERED
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the NASDAQ corporate
governance rules, foreign private issuers are exempt from many of the requirements if they instead elect to comply with home country practices
and disclose where they have elected to do so. As noted above, we are currently in compliance with NASDAQ rules relating to the independence
of our board of directors and our audit committee. Our board of directors and our audit committee has adopted a written charter for the
audit committee setting forth the responsibilities of the audit committee as required by the SEC and NASDAQ. Also as noted above, we currently
have a nomination committee to identify, review and recommend to the Board of Directors individuals believed to be qualified to become
directors. We have adopted a written charter for the nomination committee, as required by NASDAQ. We currently have in place a compensation
committee, as discussed in more detail above. We have adopted a written charter for the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company does not follow NASDAQ Rule 5635(d), which requires shareholder approval in order to enter into any transaction, other than a
public offering, involving the sale, issuance or potential issuance by the Company of ordinary shares (or securities convertible into
or exercisable for ordinary shares) equal to 20% or more of the outstanding share capital of the Company or 20% or more of the voting
power outstanding before the issuance for less than the greater of book or market value of the ordinary shares. We will follow Israeli
law with respect to any requirement to obtain shareholder approval in connection with any private placements of equity securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company does not follow NASDAQ Rule 5635(c), which requires shareholder approval prior to an issuance of securities when a stock option
or purchase plan is to be established or materially amended or other equity compensation arrangement made or materially amended, pursuant
to which stock may be acquired by officers, directors, employees or consultants. We will follow Israeli law with respect to any requirement
to obtain shareholder approval in connection with such issuances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2005, our board
of directors adopted a Code of Conduct that applies to all employees, directors and officers of our company, including our principal executive
officer, principal financial officer, principal accounting officer or controller and other individuals performing similar functions. A
copy of our Code of Conduct may be obtained, without charge, upon a written request addressed to our investor relations department, XTL
Biopharmaceuticals Ltd., 26 Ben-Gurion St., Ramat Gan 5112001, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established policies and processes for
assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk
management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized
occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability
of our information systems or any information residing therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conduct periodic risk assessments to identify
cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information
systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal
and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures,
systems, and safeguards in place to manage such risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following these risk assessments, we re-design,
implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards;
and regularly monitor the effectiveness of our safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity
risks rests with our chief financial officer, to manage the risk assessment and mitigation process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is responsible for cybersecurity
oversight and monitoring risk. Management informs the audit committee of such risk by committee meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our overall risk management system,
we monitor and test our safeguards and train our key consultants on these safeguards, in collaboration with IT and management. Personnel
at all levels and departments are made aware of our cybersecurity policies through trainings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engage consultants, or other third parties
in connection with our risk assessment processes. These service providers assist us to design and implement our cybersecurity policies
and procedures, as well as to monitor and test our safeguards. We are in the process of requiring each third-party service provider to
certify that it has the ability to implement and maintain appropriate security measures, consistent with all applicable laws, to implement
and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of its security
measures that may affect our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report, we have not encountered
cybersecurity challenges that have materially impaired our operations or financial standing. For additional information regarding risks
from cybersecurity threats, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to furnish
financial statements and related information specified in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>XTL
BIOPHARMACEUTICALS LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>AS
OF DECEMBER 31, 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Page</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#fin_001">Report of Independent Registered Public Accounting Firm</a> </b></span></td>
    <td style="text-align: center"><b>F-<span style="font-family: Times New Roman, Times, Serif">2 </span></b></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated Financial Statements - in
    U.S. dollars:</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#fin_002">Statements of Financial Position</a></b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> F-3</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#fin_003">Statements of Comprehensive Income (Loss)</a></b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>F-4</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#fin_004">Statements of Changes in Equity</a></b></span></td>
    <td style="text-align: center"><b>F <span style="font-family: Times New Roman, Times, Serif">5 - F 6 </span></b></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#fin_005">Statements of Cash Flows</a></b></span></td>
    <td style="text-align: center"><b>F 7 <span style="font-family: Times New Roman, Times, Serif">- F 8</span></b></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><a href="#fin_006">Notes to Consolidated Financial Statements</a></b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>F 9 - F 29</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">-
- - - - - - - - - - -</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 88; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Report
of Independent Registered Public Accounting Firm</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">To
the Shareholders and Board of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XTL
Biopharmaceuticals Ltd.:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Opinion
on the Consolidated Financial Statements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have audited the accompanying consolidated statements of financial position of XTL Biopharmaceuticals Ltd. and its subsidiary (hereinafter
&#8211; &#8220;the Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of comprehensive income (loss),
changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes (collectively,
&#8220;the consolidated financial statements&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended
December 31, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards
Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Basis
for Opinion</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Critical
Audit Matters</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial
statements and (ii) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit
matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 40%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-19469">Somekh Chaikin</ix:nonNumeric></span></td> <td style="width: 60%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Somekh Chaikin</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member&#160;Firm&#160;of&#160;KPMG&#160;International</span></td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have served as the Company&#8217;s auditor since 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-8827"><span style="font-family: Times New Roman, Times, Serif">Tel
Aviv, Israel</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">April
30, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="fin_002"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
                                            STATEMENTS OF FINANCIAL POSITION</b></span></p></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.125in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19470">1,401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19471">2,094</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Marketable securities &#8211; InterCure Ltd.</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:CurrentMarketableSecurities" scale="3" unitRef="usd" id="ixv-19472">605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:CurrentMarketableSecurities" scale="3" unitRef="usd" id="ixv-19473">1,627</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-19474">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-19475">85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-19476">2,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-19477">3,806</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-19478">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-19479">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-19480">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-19481">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-19482">2,426</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-19483">4,186</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">9</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19484">206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19485">187</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td>&#160;</td>
    <td style="text-align: center">11, 12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Share capital - ordinary shares of NIS <ix:nonFraction contextRef="c2" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-19486"><ix:nonFraction contextRef="c3" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-19487">0.1</ix:nonFraction></ix:nonFraction> par value: Authorized - December 31, 2023 and 2022 <b>-</b> <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-19488"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-19489">1,450,000,000</ix:nonFraction></ix:nonFraction>; Issued and outstanding <b>-</b> December 31, 2023 and 2022 - <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-19490"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-19491"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-19492"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-19493">544,906,149</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>.</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="3" unitRef="usd" id="ixv-19494">14,120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="3" unitRef="usd" id="ixv-19495">14,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalPaidinCapital" scale="3" unitRef="usd" id="ixv-19496">146,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalPaidinCapital" scale="3" unitRef="usd" id="ixv-19497">146,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Reserve from transactions with non-controlling interests</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" unitRef="usd" id="ixv-19498">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="3" unitRef="usd" id="ixv-19499">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-19500">158,246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-19501">156,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19502">2,220</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19503">3,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities and equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-19504">2,426</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-19505">4,186</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shlomo Shalev</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Doron Turgeman</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Itay Weinstein</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chairman of the Board</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Date
of approval of the financial statements by the Company&#8217;s Board of Directors: April 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><div><a id="fin_003"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED STATEMENTS OF
  COMPREHENSIVE INCOME (LOSS)</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands <br/> (except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">13</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19506">31</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19507">30</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19508">30</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">14</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19509">734</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19510">850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19511">1,001</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19512">765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19513">880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19514">1,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Revaluation of warrants to purchase ADS's</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfWarrantsToPurchaseAds" scale="3" unitRef="usd" id="ixv-19515">1,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfWarrantsToPurchaseAds" scale="3" unitRef="usd" id="ixv-19516">719</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of marketable securities</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19517">1,022</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19518">1,531</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfMarketableSecurities" scale="3" unitRef="usd" id="ixv-19519">747</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other finance income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="3" unitRef="usd" id="ixv-19520">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="3" unitRef="usd" id="ixv-19521">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="3" unitRef="usd" id="ixv-19522">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other finance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceCost" scale="3" unitRef="usd" id="ixv-19523">36</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceCost" scale="3" unitRef="usd" id="ixv-19524">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceCost" scale="3" unitRef="usd" id="ixv-19525">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">15</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-19526">1,017</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-19527">468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="3" unitRef="usd" id="ixv-19528">1,466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total comprehensive income (loss) for the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-19529">1,782</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-19530">1,348</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="3" unitRef="usd" id="ixv-19531">435</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Basic earnings (loss) per share (in U.S. dollars):</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">18</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-19532">0.003</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-19533">0.002</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-19534">0.001</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Diluted loss per share (in U.S. dollars):</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">18</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-19535">0.003</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-19536">0.002</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-19537">0.000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Weighted average number of issued ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-19538">544,906,149</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-19539">544,906,149</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-19540">531,995,467</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Diluted weighted average number of ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-19541">544,906,149</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-19542">544,909,149</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-19543">615,548,446</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="fin_004"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED STATEMENTS OF
  CHANGES IN EQUITY</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to equity holders of the Company</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>capital</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid in capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reserve
    from transactions with non-controlling interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>equity</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January 1, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19544">14,120</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19545">146,326</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-19546">156,467</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19547">20</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19548">3,999</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">loss
    for the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19549">1,782</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19550">1,782</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-5; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-19551">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-19552">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19553">14,120</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19554">146,326</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-19555">158,246</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19556">20</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19557">2,220</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to equity holders of the Company</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>capital</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid in capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reserve
    from transactions with non-controlling interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>equity</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January 1, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19558">14,120</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19559">146,326</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-19560">155,133</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19561">20</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19562">5,333</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">loss
    for the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-7; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19563">1,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19564">1,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-19565">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-19566">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19567">14,120</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19568">146,326</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-19569">156,467</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19570">20</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19571">3,999</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED STATEMENTS OF
  CHANGES IN EQUITY</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Attributable
    to equity holders of the Company</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>capital</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid in capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reserve
    from transactions with non-controlling interests</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>equity</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January 1, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19572">13,182</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19573">146,015</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-19574">155,605</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19575">20</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19576">3,612</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Income
    for the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" unitRef="usd" id="ixv-19577">435</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" unitRef="usd" id="ixv-19578">435</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of warrants to ordinary shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-19579">938</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-19580">311</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-19581">1,249</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-19582">37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" unitRef="usd" id="ixv-19583">37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -7.1pt; padding-left: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19584">14,120</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19585">146,326</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-19586">155,133</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19587">20</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-19588">5,333</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="fin_005"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED STATEMENTS OF
  CASH FLOWS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Cash flows from operating activities:</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income (loss) for the year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19589">1,782</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19590">1,348</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" unitRef="usd" id="ixv-19591">435</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net income (loss) to net cash used&#160;in operating activities (a)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" scale="3" unitRef="usd" id="ixv-19592">1,075</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" scale="3" unitRef="usd" id="ixv-19593">447</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19594">1,484</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19595">707</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19596">901</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-19597">1,049</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from
    investing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest from bank deposit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-19598">41</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-19599">36</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-19600">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-19601">41</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-19602">36</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-19603">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from
    financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-19604">385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-19605">385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Decrease in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-19606">666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-19607">865</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-19608">656</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Losses from exchange rate differences on cash
    and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-19609">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-19610">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-19611">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents at beginning of year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19612">2,094</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19613">2,969</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19614">3,631</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents at end of year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19615">1,401</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19616">2,094</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19617">2,969</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED STATEMENT OF
  CASH FLOWS</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="padding-bottom: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S. dollars in thousands</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to reconcile net income (loss) to net cash used&#160;in operating activities:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income and expenses not involving operating cash flows:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 4%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-19618">1</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-19619">1</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revaluation of marketable securities</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19620">1,022</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19621">1,531</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfMarketableSecurities" scale="3" unitRef="usd" id="ixv-19622">747</ix:nonFraction>)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revaluation of warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfWarrantsToPurchase" scale="3" unitRef="usd" id="ixv-19623">1,054</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfWarrantsToPurchase" scale="3" unitRef="usd" id="ixv-19624">719</ix:nonFraction>)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment expense</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-19625">3</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-19626">14</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-19627">37</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses&#160;&#160;from exchange rate differences on cash and cash equivalents</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" unitRef="usd" id="ixv-19628">27</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" unitRef="usd" id="ixv-19629">10</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" unitRef="usd" id="ixv-19630">6</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="3" unitRef="usd" id="ixv-19631">41</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="3" unitRef="usd" id="ixv-19632">36</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="3" unitRef="usd" id="ixv-19633">8</ix:nonFraction>)</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows" scale="3" unitRef="usd" id="ixv-19634">1,011</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows" scale="3" unitRef="usd" id="ixv-19635">466</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows" scale="3" sign="-" unitRef="usd" id="ixv-19636">1,430</ix:nonFraction>)</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in operating asset and liability items:</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease (increase) in prepaid expenses and other current assets</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" unitRef="usd" id="ixv-19637">45</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" unitRef="usd" id="ixv-19638">25</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" sign="-" unitRef="usd" id="ixv-19639">31</ix:nonFraction>)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease) in accounts payable</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-19640">19</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-19641">44</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-19642">23</ix:nonFraction>)</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-19643">64</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19644">19</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-19645">54</ix:nonFraction>)</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" scale="3" unitRef="usd" id="ixv-19646">1,075</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" scale="3" unitRef="usd" id="ixv-19647">447</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperations" scale="3" sign="-" unitRef="usd" id="ixv-19648">1,484</ix:nonFraction>)</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="vertical-align: bottom"/>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Non-cash activities:</span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of warrants</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" unitRef="usd" id="ixv-19649">864</ix:nonFraction></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><div><a id="fin_006"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory" id="ixv-12379"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 1:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">GENERAL</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            general description of the Company and its activity:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XTL
Biopharmaceuticals Ltd. (the &#8220;Company&#8221;) is engaged in the development of therapeutics for the treatment of unmet medical
needs. The Company was incorporated under the Israeli Companies Law on March&#160;9, 1993. The registered office of the Company is located
at 26 Ben-Gurion Street, Ramat Gan, Israel. The Company has decided, at this time, to explore collaboration with a strategic partner
in order to execute the clinical trials. In parallel, the Company is looking to expand and identify additional assets to add to XTL&#8217;s
portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s American Depository Shares (&#8220;ADSs&#8221;) are listed for trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
and its ordinary shares are traded on the Tel-Aviv Stock Exchange (&#8220;TASE&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, the Company has a wholly-owned subsidiary, Xtepo Ltd. ("Xtepo"), which was incorporated in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company and Xtepo are heretofore referred to as &#8220;the Group&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            Group has incurred continuing losses and depends on outside financing resources to continue
                                            its activities. Based on existing business plans, the Company&#8217;s management estimates
                                            that its outstanding cash and cash equivalent balances will allow the Company to finance
                                            its activities which include, but are not limited to maintenance and ongoing expenses related
                                            to <span style="font-size: 10pt">hCDR1</span>, for an additional period of at least 12 months
                                            from the date of this report. However, the amount of cash which the Company will need to
                                            finance its future activities depends on numerous factors which include, but are not limited
                                            to future projects which the Company might acquire or other business development activities
                                            such as acquiring new technologies and/or changes in circumstances which are liable to cause
                                            significant expenses to the Company in excess of management&#8217;s current and known expectations
                                            as of the date of these Financial Statements and which will require the Company to reallocate
                                            funds against plans, also due to circumstances beyond its control.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to incur additional losses in 2024 arising from research and development activities, testing additional technologies
and operating activities, which will be reflected in negative cash flows from operating activities. In order to perform the clinical
trials aimed at developing a product until obtaining its marketing approval, the Company will need to raise additional funds by issuing
securities. The Company decided to seek collaboration with third parties to finance the clinical trials and continues to seek additional
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
                                            October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip
                                            and conducted a series of attacks on civilian and military targets, launched extensive rocket
                                            attacks and kidnapped many Israeli civilians and soldiers.&#160; Following the attack, Israel
                                            declared war against Hamas. In parallel, border clashes between Israel and the Hezbollah
                                            terrorist group on Israel&#8217;s northern border with Lebanon intensified and may escalate
                                            into a greater regional conflict. The Israel Defence Force (the &#8220;IDF&#8221;), the national
                                            military of Israel, is a conscripted military service, subject to certain exceptions. Since
                                            October 7, 2023, the IDF has called up several hundred thousand of its reserve forces to
                                            serve.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 1:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">GENERAL
                                            (Cont.)</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_2" id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
a result, its operations in Israel may be disrupted by such absences, which disruption may materially and adversely affect its business,
prospects, financial condition and results of operations. In addition, since the commencement of these events, there have been continued
hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the
Houthi movement in Yemen). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations,
including Palestinian military organizations in the West Bank as well as other hostile countries, such as Iran, will join the hostilities.
Such clashes may escalate in the future into a greater regional conflict. Further, in April 2024, Iran launched a direct attack on Israel
involving hundreds of drones, ballistic missiles and cruise missiles and may attack again. Although until approval of these financial
statements, the impact of the war on the Company was negligible, it is currently not possible to predict the duration or severity of
the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly
evolving and developing, and could disrupt its business and operations, and hamper its ability to raise additional funds or sell its
securities, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
                                            March 19, 2024, the Company has entered into a binding term sheet, subject to due diligence,
                                            with THE SOCIAL PROXY Ltd. (the &#8220;Social Proxy&#8221;) an AI web data company, developing
                                            and powering a unique ethical, IP based, proxy and data extraction platform for AI &amp;
                                            BI Applications at scale (the &#8220;Term Sheet&#8221;).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Term Sheet, the Company will acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis
(the &#8220;Transaction&#8221;) in exchange for the issuance by the Company to the shareholders of the Social Proxy, by way of a private
placement, such number of ordinary shares of the Company, representing immediately after such issuance, <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="xtlb:IssuedAndOutstandingRate" scale="-2" unitRef="pure" id="ixv-19650">44.6</ix:nonFraction>% of the issued and outstanding
share capital of the Company and the payment of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:PaymentOfShareholders" scale="3" unitRef="usd" id="ixv-19651">430</ix:nonFraction> thousands to the shareholders of the Social Proxy. In addition, as part of the Transaction,
the shareholders of Social Proxy will be issued additional warrants or ordinary shares, which may only be exercised or granted upon reaching
certain financial measured milestones within a period of up to <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="xtlb:PeriodOfClosingTransaction" id="ixv-19652">3</ix:nonNumeric> years from the closing of the Transaction. The Transaction is conditioned
upon certain closing conditions which are fully described in the Term Sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Social
Proxy will operate as fully owned subsidiary of the Company and its shareholders will be entitled to appoint 2 representatives to the
Company&#8217;s board of directors out of a total of up to 7 directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
proposed Transaction is part of the Company&#8217;s strategy to expand its assets portfolio with high potential assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, the Company secured
an investment commitment from several shareholders (including one shareholder, who is also a related party), in the amount of
US$<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-19653">1,500</ix:nonFraction> thousand through a private placement to be consummated upon and subject to the closing of the Transaction (the
&#8220;Private Placement&#8221;). In exchange for the investment in the Private Placement, the investors will be issued <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="xtlb:InvestorIssued" scale="0" unitRef="shares" id="ixv-19654">1,500,000</ix:nonFraction>
units (reflecting a price per each unit of US$<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="xtlb:PricePerUnit" scale="0" unitRef="usdPershares" id="ixv-19655">1.00</ix:nonFraction>) consisting of <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="xtlb:ADSIssued" scale="0" unitRef="shares" id="ixv-19656">one</ix:nonFraction> ADS and <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="xtlb:PrivatePlacementWarrantsIssued" scale="0" unitRef="shares" id="ixv-19657">one</ix:nonFraction> warrant, with each such warrant being exercised
during a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="xtlb:WarrantExercisedPeriod" id="ixv-19658">five years</ix:nonNumeric> from its issuance into one ADS at an exercise price of US$<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19659">1.20</ix:nonFraction> per warrant. The Investment is
conditioned upon customary closing conditions and obtaining shareholders&#8217; approval (which was approved on April 30, 2024 by Company&#8217;s shareholders meeting).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 1:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">GENERAL
                                            (Cont.)</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfGeneralHedgeAccountingExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Definitions:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#8220;Related
party&#8221; - as the term is defined in IAS 24, <i>&#8220;Related Party Disclosures&#8221;</i> (&#8220;IAS 24&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">f.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Approval
                                            of financial statements:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
financial statements were approved by the Company&#8217;s Board of Directors (&#8220;BoD&#8221;) on April 30, 2024.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="ixv-12585"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 2:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BASIS
                                            OF PREPARATION</span></td>
</tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Statement
                                            of Compliance:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of the Company (the &#8220;Financial Statements&#8221;) have been prepared in accordance with International
Financial Reporting Standards (IFRSs), as issued by the International Accounting Standards Board (IASB).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Basis
                                            of measurement:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Financial Statements have been prepared under the historical cost convention, except for financial assets and liabilities measured at
fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Use
                                            of judgments and estimates:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of Financial Statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires
the Group&#8217;s management to exercise its judgment in the process of applying the Group&#8217;s accounting policies. Actual results
could significantly differ from the estimates and assumptions used by the Group&#8217;s management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Estimates
and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events
that are believed to be reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Critical
accounting estimates and assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounting
estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of
causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets &#8211; the intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested
at least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 2:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BASIS OF PREPARATION
                                            (Cont.)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Translation
                                            of balances and transactions in foreign currency:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Functional
                                            currency and presentation currency:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Items
included in the Financial Statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment
in which the entity operates (the &#8220;Functional Currency&#8221;). The consolidated financial statements are presented in U.S. dollars,
which is the Functional Currency of each of the Group&#8217;s entities and the Company&#8217;s presentation currency and have been rounded
to the nearest thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" id="ixv-12718"><span style="font-family: Times New Roman, Times, Serif">Below
are the exchange rate of the U.S. dollar in relation to the NIS:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exchange&#160;rate&#160;of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"/><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    $ 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>As of</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" unitRef="pure" id="ixv-19660">3.627</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" unitRef="pure" id="ixv-19661">3.519</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Transactions
                                            and balances:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Transactions
in a currency other than the Functional Currency (&#8220;Foreign Currency&#8221;) are translated into the Functional Currency using the
exchange rates at the dates of the transactions. After initial recognition, monetary assets and liabilities denominated in Foreign Currency
are translated at the end of each reporting period into the Functional Currency at the exchange rate at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Exchange
differences are recognized in the statement of comprehensive income (loss) in the line-item finance income (expenses), net. Non-monetary
assets and liabilities denominated in foreign currency and measured at cost are translated at the exchange rate at the date of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Initial
                                            application of new standards, amendments to standards and interpretations</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Amendment
to IAS 1, Presentation of Financial Statements: "Disclosure of Accounting Policies" (&#8220;the Amendment&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">According
to the Amendment, companies must provide disclosure of their material accounting policies rather than their material accounting policies.
Pursuant to the Amendment, accounting policy information is material if, when considered with other information disclosed in the financial
statements, it can be reasonably be expected to influence decisions that the users of the financial statements make on the basis of those
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Amendment also clarifies that accounting policy information is expected to be material if, without it, the users of the financial statements
would be unable to understand other material information in the financial statements. The Amendment also clarifies that immaterial accounting
policy information need not be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
a result of applying the Amendment, the extent of the accounting policy disclosure provided in the financial statements for 2023 was
reduced and adjusted according to the Company&#8217;s specific circumstances.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="ixv-12860"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 3:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">MATERIAL
                                            ACCOUNTING POLICIES</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
accounting policies have been consistently applied to all the years presented, unless otherwise stated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="ixv-12873"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; padding-right: 74.75pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets:</span></td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Unamortized
                                            intangible assets (licenses and patent rights):</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
assets are reviewed for impairment once a year and whenever there are indicators of a possible impairment, in accordance with the provisions
of IAS 36, <i>Impairment of Assets</i> (see also Note 8). The amortization of an asset on a straight-line basis over its useful life
begins when the development procedure is completed and the asset is available for use.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Research
                                            and development:</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Research
expenditures are recognized as expenses when incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="ixv-12914"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Impairment of non-financial assets:</span></td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets which are not yet available for use are not amortized and impairment in their respect is tested at least every year. Depreciable
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable
amount is the higher of an asset&#8217;s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets
are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Non-financial
assets that sustained impairment are reviewed for possible reversal of the impairment at each date of the statement of financial position.
Company&#8217;s intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested at
least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="ixv-12934"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Investments and other financial assets:</span></td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Group classifies its equity investments as financial assets at fair value through profit or loss (FVPL).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 3:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">MATERIAL
                                            ACCOUNTING POLICIES (Cont.)</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfMaterialAccountingPolicyInformationExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-12993"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Share-based payment:</span></td></tr></table></ix:nonNumeric>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group operates share-based payment plan to employees, directors, officers and to other service providers who render services that are
settled with the Group&#8217;s equity instruments. In this framework, the Company grants employees, directors, officers and other service
providers, from time to time, and, at its discretion, options to purchase shares of the Company. The fair value of options granted is
measured according to the Black-Scholes model as of the date of grant (the date of the Company's Board of Directors' decision unless
shareholders&#8217; approval is required) and recognized as an expense in the statement of comprehensive income (loss) and correspondingly
carried to equity. The total amount recognized as an expense over the vesting term of the options (the term over which all pre-established
vesting conditions are expected to be satisfied) is determined by reference to the fair value of the options granted at grant date.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
each reporting date, the Company revises its estimates of the number of options that are expected to vest based on the non-market vesting
conditions and recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive income (loss) with
a corresponding adjustment in equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
options are exercised, the Company issues new shares. The proceeds net of any directly attributable transaction costs are credited to
share capital (nominal value) and share premium.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-13018"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="padding-bottom: 0pt; text-align: left; padding-right: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Earning (loss) per share:</span></td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
earning (loss) per share is calculated by dividing the earnings attributable to equity holders of the Company by the weighted average
number of ordinary shares outstanding during the period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average
number of shares and ordinary shares that are potentially issuable in connection with service-provider share-based payment and warrants,
using the treasury stock method. If the inclusion of potentially issuable shares would decrease loss per share, the potentially issuable
shares are excluded from the weighted average number of shares outstanding used to calculate diluted earnings per share.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-13039"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">f.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Leases:</span></td></tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
16 requiring lessees to recognize a liability for a lease, reflecting the discounted value of future lease payments, and a &#8220;right
to use&#8221; asset, with respect to all leases (except as stated below), with no distinction between financing lease and operating lease.
However, IFRS 16 allows lessees not to apply these provisions for short-term leases, by groups of underlying assets, and for leases in
which the underlying asset of the lease is of low value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company elected to apply the practical expedient for short-term leases (leases with a lease term of 12 months or less).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company leases an office. The Company has a termination option with a notice period of 60 days. Therefore, the enforceable period of
the lease is 60 days, and the lease qualifies for the short-term lease exemption.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="ixv-13095"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 4:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>FINANCIAL
                                            INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left; padding-right: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            risk management:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: left; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            risk factors:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s activities expose it to a variety of financial risks: market risks and liquidity risk. The Group&#8217;s overall risk management
program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group&#8217;s financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk
management is carried out by the Group&#8217;s management under policies approved by the Board. The Group&#8217;s treasury identifies,
evaluates and defines financial risks. The Board provides written principles for overall risk management, as well as written policies
covering specific areas, such as foreign exchange risk, interest rate risk and investment of excess liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left; padding-right: 141.75pt"><span style="font-family: Times New Roman, Times, Serif">Market
                                            risks:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Foreign
currency exchange rate risk:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures with respect to the NIS.
Foreign exchange risk arises from assets and liabilities denominated in currency that is other than the functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group treasury&#8217;s risk management policy is to hold NIS-denominated cash and cash equivalents in the amount of the anticipated NIS-denominated
liabilities for six to twelve consecutive months from time to time and this in line with the directives of the Company&#8217;s Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, had the Group&#8217;s functional currency strengthened by <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="xtlb:PercentageOfFunctionalCurrency" scale="-2" unitRef="pure" id="ixv-19662">10</ix:nonFraction>% against the NIS with all other variables remaining
constant, loss for the year would have been $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-19663">144</ix:nonFraction> thousand lower (2022 - loss would have been $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-19664">152</ix:nonFraction> thousand higher; 2021 - profit approximately
$<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-19665">328</ix:nonFraction> thousand lower), mainly as a result of exchange rate changes on translation of other accounts receivable and exchange rate changes
on NIS-denominated cash and cash equivalents and investment in marketable securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 4:</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>FINANCIAL
                                            INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_2" id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Equity
securities price risk:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
group&#8217;s exposure to equity securities price risk arises from investments held by the group and classified in the balance sheet
at fair value through profit or loss (currently only the investment in the shares of InterCure Ltd).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left; padding-right: 141.75pt"><span style="font-family: Times New Roman, Times, Serif">Liquidity
                                            risk:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
flow forecasting is performed by the Group&#8217;s management both in the entities of the Group and aggregated by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s management monitors rolling forecasts of the Group&#8217;s liquidity requirements to ensure it has sufficient cash to meet
operations. The Group does not use borrowing credit facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Surplus
cash held to finance operating activities is invested in interest bearing current accounts and time deposits. The Company holds cash
and deposits with banks and financial institutions and in the estimation of management, the credit risk for these financial instruments
is low.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
channels were chosen by reference to their appropriate maturities or liquidity to provide sufficient cash balances to the Group as determined
by the abovementioned forecasts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December&#160;31, 2023 and 2022, the maturity of the Group&#8217;s financial liabilities are less than one year from each of the reporting
dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: left; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Capital
                                            management:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s objectives when managing capital are to ensure the Group&#8217;s ability to continue as a going concern in order to provide
returns on investments for shareholders and benefits for other interested parties and to maintain an optimal capital structure to reduce
the cost of capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
order to maintain or adjust the capital structure, the Group may take a variety of measures such as issue new shares or sell assets to
reduce liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left; padding-right: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            instruments by category:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
asset of the group is classified in one category: measured subsequently at fair value or through profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, all financial liabilities were classified in one category: Trade and other account payables, measured
at amortized cost.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 4:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>FINANCIAL
                                            INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfFinancialRiskManagementExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: left; padding-right: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="ixv-13330"><span style="font-family: Times New Roman, Times, Serif">Changes in financial liabilities classified as cash flow from finance activities:</span></ix:nonNumeric></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as
    of December 31, 2020</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-19666">2,637</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation during the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SettlementsFairValueMeasurementLiabilities" scale="3" unitRef="usd" id="ixv-19667">719</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercises during
    the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ExercisesDuringTheYear" scale="3" unitRef="usd" id="ixv-19668">864</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December
    31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-19669">1,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Revaluation during
    the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SettlementsFairValueMeasurementLiabilities" scale="3" unitRef="usd" id="ixv-19670">1,054</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December
    31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation during the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-13455"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 5:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>CASH
                                            AND CASH EQUIVALENTS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" id="ixv-13467"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash in banks and on hand</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="3" unitRef="usd" id="ixv-19671">133</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="3" unitRef="usd" id="ixv-19672">1,413</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Bank deposits with original
    maturities of three months or less*</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd">1,268</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd">681</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19675">1,401</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19676">2,094</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Deposits with maturity of less than <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="xtlb:DepositsWithMaturity" id="ixv-19677">three months</ix:nonNumeric>, which in 2023 bear an interest of <ix:nonFraction contextRef="c44" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-19678">4.41</ix:nonFraction>%-<ix:nonFraction contextRef="c45" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-19679">5.1</ix:nonFraction>% per annum (in 2022: <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-19680">4.5</ix:nonFraction> %).</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock-c0_cont_1" escape="true" name="xtlb:DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" id="ixv-13607"><span style="font-family: Times New Roman, Times, Serif">The
currencies in which the cash and cash equivalents are denominated or linked to are:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. dollars</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19681">382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19682">2,009</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NIS (not linked to the
    Israeli CPI)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19683">1,019</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19684">85</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19685">1,401</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-19686">2,094</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="xtlb:MarketableSecuritiesInterCureLtdTextBlock" id="ixv-13775"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>MARKETABLE
                                            SECURITIES &#8211; InterCure Ltd</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">All
                                            marketable securities held by the Company constitute Level 1 financial instruments, as defined
                                            in IFRS 13 - &#8220;<i>Fair Value Measurement</i>&#8221;. Level 1 inputs are quoted prices
                                            (unadjusted) in active markets for identical assets or liabilities that the entity can access
                                            at the measurement date.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left; padding-right: 0.5in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-13803"><span style="font-family: Times New Roman, Times, Serif">The Company holds the following financial instruments:</span></ix:nonNumeric></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities - InterCure Ltd</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:CurrentMarketableSecurities" scale="3" unitRef="usd" id="ixv-19687">605</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:CurrentMarketableSecurities" scale="3" unitRef="usd" id="ixv-19688">1,627</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of December 31,
2023 and 2022 the Company holds approximately <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="xtlb:PercentageOfHoldingShare" scale="-2" unitRef="pure" id="ixv-19689">1.04</ix:nonFraction>% of InterCure Ltd&#8217;s shares (the shares are traded at the Tel-Aviv Stock Exchange
- &#8220;TASE&#8221; and at the Nasdaq Capital Market - &#8220;Nasdaq&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock-c0_cont_1" escape="true" name="xtlb:DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" id="ixv-13888"><span style="font-family: Times New Roman, Times, Serif">Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:</span></ix:nonNumeric></td></tr></table>

<p style="text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair
    value opening balance</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAvailableforsale" scale="3" unitRef="usd" id="ixv-19690">1,627</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAvailableforsale" scale="3" unitRef="usd" id="ixv-19691">3,158</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAvailableforsale" scale="3" unitRef="usd" id="ixv-19692">2,411</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in fair value during the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:GainsLossesOnFairValueOnMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19693">1,022</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:GainsLossesOnFairValueOnMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19694">1,531</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:GainsLossesOnFairValueOnMarketableSecurities" scale="3" unitRef="usd" id="ixv-19695">747</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value closing balance</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAvailableforsale" scale="3" unitRef="usd" id="ixv-19696">605</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAvailableforsale" scale="3" unitRef="usd" id="ixv-19697">1,627</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAvailableforsale" scale="3" unitRef="usd" id="ixv-19698">3,158</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory" id="ixv-14067"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 7:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>PREPAID
                                            EXPENSES AND OTHE CURRENT ASSETS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOtherCurrentAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="ixv-14080"><span style="font-family: Times New Roman, Times, Serif">Composition:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_DisclosureOfOtherCurrentAssetsExplanatory-c0_cont_2" id="_DisclosureOfOtherCurrentAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other receivables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-19699">29</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-19700">71</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Government
    authorities (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="xtlb:GovernmentAuthorities" scale="3" unitRef="usd">11</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="xtlb:GovernmentAuthorities" scale="3" unitRef="usd">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-19703">40</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-19704">85</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfOtherCurrentAssetsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The government authorities are monetary items, which are denominated or linked is NIS.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amount of government authorities is a reasonable approximation of the fair value because the effect of discounting is immaterial.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-14261"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 8:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>INTANGIBLE
                                            ASSETS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
                                            January 7, 2014, the Company signed a licensing agreement with Yeda, as amended on September
                                            6, 2015, to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus
                                            (&#8220;SLE&#8221;). The license from Yeda also included all clinical data of the phase 1
                                            and phase 2A conducted in the hCDR1. The terms of the licensing agreement include, among
                                            other things, expense reimbursement for patent expenses payable in six installments, certain
                                            milestone payments to Yeda, low single-digit royalties based on net sales, and additional
                                            customary royalties to the Office of the Israel innovation authority.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><ix:nonNumeric contextRef="c0" name="xtlb:LicenseAgreement" id="ixv-14282"><span style="font-family: Times New Roman, Times, Serif">Under
the license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical
trial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European
Union&#8217;s Group of Five. In addition, the Company is required to pay <ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="xtlb:PercentageOfRoyalties" scale="-2" unitRef="pure" id="ixv-19705">2</ix:nonFraction>%-<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="xtlb:PercentageOfRoyalties" scale="-2" unitRef="pure" id="ixv-19706">3</ix:nonFraction>% royalties of annual net sales and sublicense fees of <ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="xtlb:PercentageOfSublicenseFees" scale="-2" unitRef="pure" id="ixv-19707">15</ix:nonFraction>%-<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="xtlb:PercentageOfSublicenseFees" scale="-2" unitRef="pure" id="ixv-19708">20</ix:nonFraction>%
of whatever it receives from any sub-licensee.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
the license agreement, the Company is also required to meet certain development milestones including the delivery of a trial protocol
to Yeda by January 1, 2016 (which it delivered), receipt of investment of at least $<ix:nonFraction contextRef="c52" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="6" unitRef="usd" id="ixv-19709">5</ix:nonFraction> million by August 1, 2016 (of which $<ix:nonFraction contextRef="c53" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="6" unitRef="usd" id="ixv-19710">4</ix:nonFraction> million
was received in April 2015) and commencement of a Phase II clinical trial by January 1, 2017. In subsequent amendments signed between
the Company and Yeda, the parties agreed to postpone the last two installments of the patent expense reimbursement until April 7, 2017,
receipt of the remainder of the required $<ix:nonFraction contextRef="c54" decimals="-6" format="ixt:num-dot-decimal" name="xtlb:ReceiptOfRequiredInvestment" scale="6" unitRef="usd" id="ixv-19711">5</ix:nonFraction> million investment by May 1, 2017 and commencement of a Phase 2 clinical trial in respect
of hCDR1 by October 1, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
term of the license agreement is the later of the date of expiry of the last of the licensed patents or the expiry of a continuous period
of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="xtlb:ExpirTerm" id="ixv-19712">11</ix:nonNumeric> years after first commercial sale in any country during which there shall not have been a first commercial sale in the U.S., EU,
Japan, China or any OECD member. The license agreement may be terminated by the Company without cause upon 60 days prior written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
license agreement may also be terminated by Yeda upon 45 days prior written notice if either the Company fails to meet certain development
milestones or commercial sale shall have commenced and there shall be a period of 6 months of no sales, subject to certain exceptions.
Yeda shall also be entitled to terminate the license agreement if the Company were to commence legal action against Yeda challenging
the validity of any of the licensed patents, and the Company was unsuccessful in such challenge, in which event the Company would be
required to pay to Yeda liquidated damages of $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:ReceivablesFromContractsWithCustomers" scale="6" unitRef="usd" id="ixv-19713">8</ix:nonFraction> million. Either party may also terminate the license agreement in the case of a material
breach that remains uncured or certain bankruptcy events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, all expense reimbursement for patent expenses to Yeda in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RemainingLiability" scale="3" unitRef="usd" id="ixv-19714">380</ix:nonFraction> thousands were paid, except for a remaining
liability of $<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RemainingLiability" scale="3" unitRef="usd" id="ixv-19715">127</ix:nonFraction> thousand, disclosed under accounts payable. The reason for the remaining liability is that the Company decided not
to conduct the phase 2 by itself and to look for a strategic partner. As a result, the second milestone (commencement of Phase 2) was
not met yet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
                            8:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>INTANGIBLE
                                            ASSETS (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accordingly,
the license agreement may be terminated by Yeda upon 45 days prior written notice. To this date the Company and Yeda have held discussions
regarding further amendment to the payment scheme under the license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="xtlb_IntangibleAssetOtherInformationMaturityDate-c0_cont_1" name="xtlb:IntangibleAssetOtherInformationMaturityDate" id="ixv-14353"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company exclusively licensed two families of patents relating to hCDR1:</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_IntangibleAssetOtherInformationMaturityDate-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">One
expired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January
14, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company reviews the hCDR1 asset for impairment once a year on December 31 or more frequently if events or changes in circumstances indicate
that there is an impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
the carrying amount exceeds their recoverable amount, the assets are reduced to their recoverable amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
asset is not ready for usage (the development was paused before finishing) and therefore has not been amortized yet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
order to measure the recoverable amount of the hCDR1 asset,&#160;Company management deducted the fair value of its other assets and liabilities
from the amount representing its market value as of December 31, 2023. The resulting fair value attributable to the hCDR1 asset was higher
than the book value of the hCDR1 asset and therefore no impairment was recorded in the Company's financial statements as of December
31, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Composition
                                            and movement:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no </span><span style="font-family: Times New Roman, Times, Serif">changes or movements in 2023, 2022 and 2021 and the balance remained
$<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AssetsRemainedAmount" scale="3" unitRef="usd" id="ixv-19716"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AssetsRemainedAmount" scale="3" unitRef="usd" id="ixv-19717"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AssetsRemainedAmount" scale="3" unitRef="usd" id="ixv-19718">380</ix:nonFraction></ix:nonFraction></ix:nonFraction> thousands.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-14395"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
                            9:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ACCOUNTS
                                            PAYABLE</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock-c0_cont_1" escape="true" name="xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock" id="ixv-14414"><span style="font-family: Times New Roman, Times, Serif">Composition:</span></ix:nonNumeric></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19719">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19720">2</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="3" unitRef="usd" id="ixv-19721">205</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="3" unitRef="usd" id="ixv-19722">185</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19723">206</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19724">187</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amount of accounts payable is a reasonable approximation of their fair value because the effect of discounting is immaterial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
                            9:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ACCOUNTS
                                            PAYABLE (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock-c0_cont_1" escape="true" name="xtlb:ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" id="ixv-14602"><span style="font-family: Times New Roman, Times, Serif">The carrying amount of accounts payable is denominated in the following currencies:</span></ix:nonNumeric></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19725">157</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19726">137</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NIS
    (not linked to the Israeli CPI)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19727">49</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19728">50</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19729">206</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-19730">187</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="xtlb_DisclosureOfWarrantsTextBlock-c0_cont_1" escape="true" name="xtlb:DisclosureOfWarrantsTextBlock" id="ixv-14737"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 10:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>WARRANTS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2017, the Company raised gross funds amounted to $<ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:GrossFundRaised" scale="3" unitRef="usd" id="ixv-19731">5,300</ix:nonFraction> thousand by issuance of <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-19732">2,400,000</ix:nonFraction> ADS's and <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="xtlb:WarrantsIssued" scale="0" unitRef="shares" id="ixv-19733">2,400,000</ix:nonFraction>
warrants to purchase the same amount of ADS's. <ix:nonNumeric contextRef="c0" name="xtlb:DescriptionOfWarrantsExercisable" id="ixv-19734">The warrants shall be exercisable six months following the issuance date and will expire
five and one-half years from the issuance date.</ix:nonNumeric> The number of warrants and their exercise price could be adjusted upon standard anti-dilution
protection clauses and subject to a cashless exercise mechanism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
13 "Fair Value Measurement", ("IFRS 13"), defines fair value as the price that would be received from selling an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
determining <ix:nonNumeric contextRef="c0" name="ifrs-full:InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" id="ixv-19735">the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal
or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the
asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
13 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level
of input that is significant to the fair value measurement. IFRS 13 establishes three levels of inputs that may be used to measure fair
value.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
    1 -&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">quoted prices in active markets for identical
    assets or liabilities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
    2 -&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">inputs other than Level 1 that are observable,
    either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical
    or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
    3 -&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">unobservable inputs that are supported by
    little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounted for the warrants issued to investors with a cashless exercise mechanism as a non-current liability according to provisions
of IAS 32. The Company measured the warrants at fair value by using a Black-Scholes model.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 10:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>WARRANTS
                                            (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="xtlb_DisclosureOfWarrantsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
warrants were measured in each reporting period. Changes in the fair value were recognized in the Company`s statement of comprehensive
income (loss) as financial income or expense, as appropriate. The warrants were classified as level&#160;3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" id="ixv-14849"><span style="font-family: Times New Roman, Times, Serif">The
Company used the following assumptions to estimate the Investors' warrants:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_2" id="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">0.19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">60.83</ix:nonFraction>-<ix:nonFraction contextRef="c64" decimals="4" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">62.46</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual
    term life (in years) (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c63" format="ixt-sec:duryear" id="ix_7_fact" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">0.63</ix:nonNumeric>-<ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" id="ix_8_fact" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">0.68</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend
    yield (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; -sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_3" id="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_4" id="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_5" id="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Expected
life - the expected life was based on the expiration date of the warrants.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">For
more information about the warrants exercised during 2021, see Note 18.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
2022, all warrants have expired and as such, as of December 31, 2023 and 2022 there are no outstanding warrants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="xtlb:ShareCapitalReservesAndRetainedEarnings" id="ixv-15070"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
                            11:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>SHARE
                                            CAPITAL, RESERVES AND ACCUMULATED DEFICIT</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s Ordinary shares of NIS&#160;<ix:nonFraction contextRef="c65" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="ilsPershares" id="ixv-19742">0.1</ix:nonFraction> par value are traded on the TASE. The Company&#8217;s ADSs are listed for trading on the Nasdaq Capital Market in the U.S. Each ADS consist of 100 Company&#8217;s Ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Ordinary
shares confer upon their holders voting rights and right to participate in the shareholders&#8217; meeting, right to receive dividends
and the right to participate in the excess of assets upon liquidation of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Company&#8217;s authorized share capital is <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-19743">1,450,000,000</ix:nonFraction> Ordinary Shares.</span></td></tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-15137"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE
                            12:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">SHARE-BASED
                                            <b>PAYMENT</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2011, the Company&#8217;s Board of Directors approved the adoption of an employee share option plan for the grant of options
exercisable into shares of the Company, in accordance with section 102 to the Israeli Tax Ordinance (the &#8220;2011 Plan&#8221;) which
ended after <ix:nonNumeric contextRef="c66" format="ixt-sec:duryear" name="xtlb:SharebasedPaymentAwardRemainingContractualTerm" id="ixv-19744">10</ix:nonNumeric> years, and the holding of up to <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="xtlb:NumberOfShareExercisableInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-19745">10,000,000</ix:nonFraction> shares in the framework of the 2011 Plan, for option allocation to Company
employees, directors and consultants. The terms of the options, which will be granted according to the 2011 Plan, including the option
period, exercise price, vesting period and exercise period shall be determined by the Company&#8217;s Board of Directors on the date
of the actual allocation. On January 29, 2020, it was decided to increase the reserve by <ix:nonFraction contextRef="c68" decimals="-6" format="ixt:num-dot-decimal" name="xtlb:IncreaseOfReserve" scale="6" unitRef="shares" id="ixv-19746">10</ix:nonFraction> million and on May 19, 2020 it was decided
to increase the reserve by another <ix:nonFraction contextRef="c69" decimals="-6" format="ixt:num-dot-decimal" name="xtlb:IncreaseOfReserve" scale="6" unitRef="shares" id="ixv-19747">10</ix:nonFraction> million options. The total reserve after these increases is <ix:nonFraction contextRef="c70" decimals="-6" format="ixt:num-dot-decimal" name="xtlb:OptionsReserve" scale="6" unitRef="shares" id="ixv-19748">30</ix:nonFraction> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
of December&#160;31, 2023, the remaining number of options available for grant under the 2011 Plan is <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="xtlb:RemainingNumberOfOptionsAvailableForGrant" scale="0" unitRef="shares" id="ixv-19749">17,450,000</ix:nonFraction> options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 2, 2023, the Company&#8217;s shareholders approved the grant of options exercisable into <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="xtlb:OptionsExercisableIntoOrdinaryShares" scale="0" unitRef="shares" id="ixv-19750">150,000</ix:nonFraction> of the Company&#8217;s ordinary
shares to one of Company&#8217;s directors for an exercise price of NIS <ix:nonFraction contextRef="c71" decimals="4" format="ixt:num-dot-decimal" name="xtlb:OrdinarySharesExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19751">0.0495</ix:nonFraction> per share (USD <ix:nonFraction contextRef="c71" decimals="3" format="ixt:num-dot-decimal" name="xtlb:OrdinarySharesExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19752">0.014</ix:nonFraction> per share, respectively, based on
the exchange rate reported by the Bank of Israel on the same day). The options were fully vested on the day of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 14, 2023, Company&#8217;s Board of directors approved retroactively to extend the expire date of the 2011 plan by additional <ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="xtlb:ExtendedExpiryTerm" id="ixv-19753">5</ix:nonNumeric>
years to August 29, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Regarding
options granted subsequent to balance sheet date and the extension of exercise period for certain directors, refer to Note 19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock-c0_cont_1" escape="true" name="xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" id="ixv-15169"><span style="font-family: Times New Roman, Times, Serif">Movements
in the number of share options and their related weighted average exercise prices (in dollars) during the years ended December 31, 2023,
2022 and 2021 are as follows:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19754">12,400,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19755">0.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19756">12,400,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19757">0.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19758">16,200,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19759">0.07</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-19760">150,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19761">0.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-19762">3,433,331</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19763">0.16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-19764">366,669</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19765">0.08</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at end of
    year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19766">12,550,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19767">0.05</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19768">12,400,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19769">0.05</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19770">12,400,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19771">0.05</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable at end of
    year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-19772">12,550,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19773">0.05</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-19774">10,733,330</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19775">0.05</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-19776">7,399,998</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-19777">0.07</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE
                            12:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">SHARE-BASED
                                            PAYMENT (Cont.)</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock-c0_cont_1" escape="true" name="xtlb:DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" id="ixv-15802"><span style="font-family: Times New Roman, Times, Serif">Below
is information about the exercise price (in dollars) and the remaining contractual life (in years) for options outstanding at end of
year:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock-c0_cont_2" id="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options<br/>
    outstanding at<br/>
 end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of<br/> exercise prices<br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average<br/> remaining<br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options<br/>
    outstanding at <br/> end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of<br/> exercise prices<br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> remaining<br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19778">10,900,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19779">0.03</ix:nonFraction> - <ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19780">0.14</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><ix:nonNumeric contextRef="c83" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-15928"><span style="font-family: Times New Roman, Times, Serif">6.07</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19781">10,900,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19782">0.03</ix:nonFraction> - <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19783">0.14</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 13%; text-align: right"><ix:nonNumeric contextRef="c87" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-15953"><span style="font-family: Times New Roman, Times, Serif">6.94</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19784">1,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19785">0.17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c89" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-15977"><span style="font-family: Times New Roman, Times, Serif">1.66</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19786">1,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19787">0.17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c91" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-16002"><span style="font-family: Times New Roman, Times, Serif">2.66</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19788">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19789">0.01</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c93" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-16026"><span style="font-family: Times New Roman, Times, Serif">9.17</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19790">12,550,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19791">12,400,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    <br/> outstanding at<br/>
    end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range
    of<br/> exercise prices <br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    <br/> average <br/> remaining <br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 31%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19792">10,900,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 31%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19793">0.03</ix:nonFraction> - <ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19794">0.14</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 30%; text-align: right"><ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-16218"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.94</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19795">1,500,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-19796">0.17</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-16242"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19797">12,400,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Share
based expenses recognized in the Company&#8217;s statements of comprehensive income (loss) for the years ended December 31, 2023, 2022
and 2021 for grant of options to employees and service providers were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" scale="3" unitRef="usd" id="ixv-19798">3</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" scale="3" unitRef="usd" id="ixv-19799">14</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" scale="3" unitRef="usd" id="ixv-19800">37</ix:nonFraction> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock-c0_cont_1" escape="true" name="xtlb:DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" id="ixv-19801">The
table below summarizes the outstanding options as of December 31, 2023 that have been granted to the Company&#8217;s executives, directors
and consultants </ix:nonNumeric>&#8211;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock-c0_cont_2" id="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    <br/> &#160;outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Position</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>date
                                            (*)</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/>
    price in<br/>
    NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
                                            value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>USD
                                            in<br/>
                                            thousands</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Vesting
    schedule</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19802">750,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 13%; text-align: center"><ix:nonNumeric contextRef="c103" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" id="ixv-16386"><span style="font-family: Times New Roman, Times, Serif">Four Directors</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 14%; text-align: center"><ix:nonNumeric contextRef="c103" id="ix_10_fact" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement"><span style="font-family: Times New Roman, Times, Serif">December 30, 2014</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19803">0.4325</ix:nonFraction>-<ix:nonFraction contextRef="c105" decimals="4" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19804">0.4915</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" scale="3" unitRef="usd" id="ixv-19805">46</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 35%; text-align: left"><ix:nonNumeric contextRef="c103" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" id="ixv-16412"><span style="font-family: Times New Roman, Times, Serif">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19806">150,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c107" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" id="ixv-16424"><span style="font-family: Times New Roman, Times, Serif">One Director</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c107" id="ix_11_fact" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement"><span style="font-family: Times New Roman, Times, Serif">March 25, 2015</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19807">0.40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" scale="3" unitRef="usd" id="ixv-19808">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c107" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" id="ixv-16450"><span style="font-family: Times New Roman, Times, Serif">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19809">1,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c109" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" id="ixv-16462"><span style="font-family: Times New Roman, Times, Serif">Chairman of Board</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c109" id="ix_12_fact" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement"><span style="font-family: Times New Roman, Times, Serif">March 31, 2016</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c108" decimals="1" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19810">0.6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" scale="3" unitRef="usd" id="ixv-19811">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c109" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" id="ixv-16488"><span style="font-family: Times New Roman, Times, Serif">12 equal portions each quarter over a period of 3 years from the date of grant</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19812">10,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c111" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" id="ixv-16500"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c111" id="ix_13_fact" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement"><span style="font-family: Times New Roman, Times, Serif">July 7, 2020</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19813">0.09</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" scale="3" unitRef="usd" id="ixv-19814">103</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c111" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" id="ixv-16526"><span style="font-family: Times New Roman, Times, Serif">12 equal portions each quarter over a period of 3 years from the grant date</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19815">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c113" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" id="ixv-16538"><span style="font-family: Times New Roman, Times, Serif">Director</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c113" id="ix_14_fact" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement"><span style="font-family: Times New Roman, Times, Serif">March 2, 2023</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-19816">0.0495</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" scale="3" unitRef="usd" id="ixv-19817">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c113" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" id="ixv-16564"><span style="font-family: Times New Roman, Times, Serif">Fully vested on date of grant</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-19818">12,550,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Date of the Company's Board of Directors&#8217; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 12:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">SHARE-BASED
                                            PAYMENT (Cont.)</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock-c0_cont_1" escape="true" name="xtlb:ScheduleOfFairValueForOptionsGrantedTableTextBlock" id="ixv-16694"><span style="font-family: Times New Roman, Times, Serif">The
fair value for options granted in 2023 is estimated at the date of grant using a Black-Scholes model with the following weighted average
assumptions:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    2, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-19819">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-19820">67.5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-19821">4.08</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected life (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-16759"><span style="font-family: Times New Roman, Times, Serif">10</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">We
have calculated the volatility based on the Company's historical volatility. The share price was set according to the Company's share
market value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">No
options were granted in 2022 and 2021.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" id="ixv-16775"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"/>
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 13:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RESEARCH
                                            AND DEVELOPMENT EXPENSES</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" id="ixv-16787"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 67%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Fees
    related to service providers</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FeesRelatedToServiceProviders" scale="3" unitRef="usd" id="ixv-19822">31</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FeesRelatedToServiceProviders" scale="3" unitRef="usd" id="ixv-19823">30</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FeesRelatedToServiceProviders" scale="3" unitRef="usd" id="ixv-19824">30</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory" id="ixv-16887"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE</b> 14:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> GENERAL AND ADMINISTRATIVE EXPENSES</b></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="ixv-16900"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Management fees and expenses relating
    to service providers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-19825">107</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-19826">117</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WagesAndSalaries" scale="3" unitRef="usd" id="ixv-19827">123</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share based payment expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-19828">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-19829">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" unitRef="usd" id="ixv-19830">37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents and fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:PatentsAndFees" scale="3" unitRef="usd" id="ixv-19831">94</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:PatentsAndFees" scale="3" unitRef="usd" id="ixv-19832">141</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:PatentsAndFees" scale="3" unitRef="usd" id="ixv-19833">137</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors&#8217; fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-19834">60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-19835">68</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DirectorsRemunerationExpense" scale="3" unitRef="usd" id="ixv-19836">64</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investor relations and travel</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TravelExpense" scale="3" unitRef="usd" id="ixv-19837">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Rent and office maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RentAndOfficeMaintenance" scale="3" unitRef="usd" id="ixv-19838">12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RentAndOfficeMaintenance" scale="3" unitRef="usd" id="ixv-19839">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RentAndOfficeMaintenance" scale="3" unitRef="usd" id="ixv-19840">15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="3" unitRef="usd" id="ixv-19841">119</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="3" unitRef="usd" id="ixv-19842">202</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="3" unitRef="usd" id="ixv-19843">229</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-19844">330</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-19845">291</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" unitRef="usd" id="ixv-19846">381</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-19847">9</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-19848">11</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="3" unitRef="usd" id="ixv-19849">12</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19850">734</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19851">850</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19852">1,001</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 7.1pt"></p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 7.1pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 7.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-17294"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 15:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>FINANCE
                                            INCOME (EXPENSES), NET</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" id="ixv-17306"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of marketable securities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FinanceExpensesRevaluationOfMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19853">1,022</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FinanceExpensesRevaluationOfMarketableSecurities" scale="3" sign="-" unitRef="usd" id="ixv-19854">1,531</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Bank account management fees and commissions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-19855">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-19856">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-19857">21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exchange rate differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ExchangeDifferences" scale="3" unitRef="usd" id="ixv-19858">32</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:ExchangeDifferences" scale="3" unitRef="usd" id="ixv-19859">16</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total finance expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-19860">1,058</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-19861">1,558</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-19862">21</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of warrants to purchase ADS's</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfWarrantsToPurchaseADSs" scale="3" unitRef="usd" id="ixv-19863">1,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationOfWarrantsToPurchaseADSs" scale="3" unitRef="usd" id="ixv-19864">719</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RevaluationMarketableSecurities" scale="3" unitRef="usd" id="ixv-19865">747</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income on bank deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd" id="ixv-19866">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd" id="ixv-19867">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="3" unitRef="usd" id="ixv-19868">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exchange rate differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax" scale="3" unitRef="usd" id="ixv-19869">13</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total finance income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-19870">41</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-19871">1,090</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-19872">1,487</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income (expenses), net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FinanceIncomeexpensesNet" scale="3" sign="-" unitRef="usd" id="ixv-19873">1,017</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FinanceIncomeexpensesNet" scale="3" sign="-" unitRef="usd" id="ixv-19874">468</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:FinanceIncomeexpensesNet" scale="3" unitRef="usd" id="ixv-19875">1,466</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-17778"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 16:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>TAXES
                                            ON INCOME</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left; padding-right: 128.7pt"><span style="font-family: Times New Roman, Times, Serif">Tax
                                            rates applicable to the Company:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since
the tax year 2018, the taxable income of the Company and its subsidiary is subject to a corporate tax rate of <ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ApplicableTaxRate" scale="-2" unitRef="pure" id="ixv-19876">23</ix:nonFraction>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">The Group&#8217;s carryforward tax losses as of December&#160;31, 2023, totaled approximately $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfImpairmentOfGoodwill" scale="6" unitRef="usd" id="ixv-19877">39</ix:nonFraction> million which may be carried forward and offset against taxable income in the future for an indefinite period and approximately $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="xtlb:DeferredTaxAssetsCapitalLossCarryforward" scale="6" unitRef="usd" id="ixv-19878">23</ix:nonFraction> million capital loss carryforward which may be offset against future capital gain. The Company did not recognize deferred taxes for carryforward losses and temporary differences, as well as capital losses and real losses, because their utilization in the foreseeable future is not probable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">The main reconciling items between the &#8220;theoretical&#8221; tax expense, assuming that all the income were taxed at the regular tax rate applicable to companies in Israel (<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" sign="-" unitRef="pure" id="ixv-19879">23</ix:nonFraction>%) and the taxes recorded in the statements of comprehensive income (loss) in the reporting year are revaluation expenses (income) not recognized for tax purposes, changes in taxes resulting from exchange rate differences, changes in deferred tax for tax losses carryforwards, and taxable losses for which no deferred taxes were recognized.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: left; padding-right: 85.05pt"><span style="font-family: Times New Roman, Times, Serif">Tax
                                            assessments:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company and Xtepo filed self-assessments that are deemed final through the 2018 tax year.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 16:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>TAXES
                                            ON INCOME (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfIncomeTaxExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="text-align: left; padding-right: 85.05pt"><span style="font-family: Times New Roman, Times, Serif">Unrecognized
                                            deferred taxes:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, the Company&#8217;s had a deferred tax liability of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" scale="3" unitRef="usd" id="ixv-19880">141</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" scale="3" unitRef="usd" id="ixv-19881">86</ix:nonFraction> thousand, respectively
due to an investment in marketable securities &#8211; InterCure Ltd. The deferred tax liability was fully offset by a deferred tax asset
due to utilization of tax losses from prior years.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="ixv-17894"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>TRANSACTIONS
                                            AND BALANCES WITH RELATED PARTIES</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s key management personnel who are included, along with other factors, in the definition of related party, as above in
IAS 24, includes directors, members of the executive committee and InterCure Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Compensation
to key management personnel:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" id="ixv-17914"><span style="font-family: Times New Roman, Times, Serif">The
compensation to key management personnel for employee services provided to the Company is shown below:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Management fees, directors, and
    consulting fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" unitRef="usd" id="ixv-19882">240</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" unitRef="usd" id="ixv-19883">262</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" unitRef="usd" id="ixv-19884">263</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-19885">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-19886">14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-19887">37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-19888">243</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-19889">276</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-19890">300</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Number of persons</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfEmployees" scale="0" unitRef="pure" id="ixv-19891">8</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfEmployees" scale="0" unitRef="pure" id="ixv-19892">8</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfEmployees" scale="0" unitRef="pure" id="ixv-19893">8</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company pays to an accounting firm of which the company's CFO is a Partner (&#8220;accounting firm&#8221;), a monthly fees of NIS <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFeeAndCommissionExpense" scale="3" unitRef="ils" id="ixv-19894">15</ix:nonFraction>
thousand (approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-19895">4</ix:nonFraction> thousand) for controller and bookkeeping services. Total fees for controller and bookkeeping services for
the years ended 2023, 2022 and 2021 were approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AdministrativeFeeExpense" scale="3" unitRef="usd" id="ixv-19896">49</ix:nonFraction> thousand, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AdministrativeFeeExpense" scale="3" unitRef="usd" id="ixv-19897">53</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:AdministrativeFeeExpense" scale="3" unitRef="usd" id="ixv-19898">66</ix:nonFraction> thousands respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, as of December 31, 2023 and 2022, the Company&#8217;s balances with key management personnel and the accounting firm, totaled
approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-19899">32</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-19900">34</ix:nonFraction> thousands (all of which were linked to the NIS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
further information regarding share-based payment to related parties, see also Note 12 above and Note 19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">InterCure
Ltd:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, the Company's share in the shares of InterCure Ltd was <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="xtlb:PercentageOfShare" scale="-2" unitRef="pure" id="ixv-19901"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="xtlb:PercentageOfShare" scale="-2" unitRef="pure" id="ixv-19902">1.04</ix:nonFraction></ix:nonFraction>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company's investment in the shares of InterCure Ltd is presented as Marketable securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>TRANSACTIONS
                                            AND BALANCES WITH RELATED PARTIES (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfRelatedPartyExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, the Company&#8217;s balances of InterCure Ltd's shares total approximately $<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:CurrentMarketableSecuritie" scale="3" unitRef="usd" id="ixv-19903">605</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:CurrentMarketableSecuritie" scale="3" unitRef="usd" id="ixv-19904">1,627</ix:nonFraction> thousand,
respectively. See also Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company subleases an office from Canndoc Ltd., which is a subsidiary of InterCure Ltd. During 2023, 2022 and 2021, the Company recorded
rent expenses of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RentExpense" scale="3" unitRef="usd" id="ixv-19905">11</ix:nonFraction> thousands, $<ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RentExpense" scale="3" unitRef="usd" id="ixv-19906">5</ix:nonFraction> thousands and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:RentExpense" scale="3" unitRef="usd" id="ixv-19907">14</ix:nonFraction> thousands to Canndoc Ltd. As of December 31, 2023, the balance due
from Canndoc Ltd was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-19908">3</ix:nonFraction> thousands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Regarding
investment agreement signed subsequent to balance sheet date with one of the Company&#8217;s shareholders see Note 1d.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:EarningsPerShareExplanatory" id="ixv-18228"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 18:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>EARNINGS
                                            (LOSS) PER SHARE</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Basic
earnings (loss) per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
calculation of basic earnings per share (EPS) is based on the following profit (loss) attributable to shareholders and weighted-average
number of ordinary shares outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-18250"><span style="font-family: Times New Roman, Times, Serif">Profit
(loss) attributed to ordinary shareholders (basic)</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfEarningsPerShareExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive
    income (loss) for the year</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-19909">1,782</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-19910">1,348</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-19911">435</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="ixv-18316"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
number of ordinary shares (basic)</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued ordinary shares at January
    1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:IssuedOrdinarySharesAtJanuary1" scale="0" unitRef="shares" id="ixv-19912">544,906,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:IssuedOrdinarySharesAtJanuary1" scale="0" unitRef="shares" id="ixv-19913">544,906,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:IssuedOrdinarySharesAtJanuary1" scale="0" unitRef="shares" id="ixv-19914">514,205,799</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued March 7,2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c121" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:Issued" scale="0" unitRef="shares" id="ixv-19915">10,634,406</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued May 4, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c124" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:Issued" scale="0" unitRef="shares" id="ixv-19916">639,508</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued July 6, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c127" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:Issued" scale="0" unitRef="shares" id="ixv-19917">4,145,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued August 30, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c130" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:Issued" scale="0" unitRef="shares" id="ixv-19918">1,179,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued September 1, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:Issued" scale="0" unitRef="shares" id="ixv-19919">414,384</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issued October 11, 2021
    due to warrant exercise</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:Issued" scale="0" unitRef="shares" id="ixv-19920">776,713</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of ordinary shares (basic)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedAverageNumberOfOrdinarySharesbasic" scale="0" unitRef="shares" id="ixv-19921">544,906,149</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedAverageNumberOfOrdinarySharesbasic" scale="0" unitRef="shares" id="ixv-19922">544,906,149</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedAverageNumberOfOrdinarySharesbasic" scale="0" unitRef="shares" id="ixv-19923">531,995,467</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Diluted
earnings (loss) per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
calculation of diluted EPS is based on the following profit (loss) attributable to shareholders and weighted-average number of ordinary
shares outstanding after adjustment for the effects of all dilutive potential ordinary shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right; width: 100%"><span style="font-family: Times New Roman, Times, Serif"><b>XTL BIOPHARMACEUTICALS LTD.&#160;</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONSOLIDATED FINANCIAL
  STATEMENTS</b></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 18:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>EARNINGS
                                            (LOSS) PER SHARE (Cont.)</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_EarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock-c0_cont_1" escape="true" name="xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" id="ixv-18653"><span style="font-family: Times New Roman, Times, Serif">Profit
(loss) attributed to ordinary shareholders (diluted)</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S. dollars
    in thousands</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive income (loss)
    for the year (basic)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-19924">1,782</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-19925">1,348</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeBeforeTax" scale="3" unitRef="usd" id="ixv-19926">435</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrant revaluation
    income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:WarrantRevaluationIncome" scale="3" sign="-" unitRef="usd" id="ixv-19927">660</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:comprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-19928">1,782</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:comprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-19929">1,348</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="xtlb:comprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-19930">225</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock-c0_cont_1" escape="true" name="xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" id="ixv-18773"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
number of ordinary shares (diluted)</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number of ordinary
    shares (basic)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedaverageNumberOfOrdinarySharesbasic" scale="0" unitRef="shares" id="ixv-19931">544,906,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedaverageNumberOfOrdinarySharesbasic" scale="0" unitRef="shares" id="ixv-19932">544,906,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedaverageNumberOfOrdinarySharesbasic" scale="0" unitRef="shares" id="ixv-19933">531,995,467</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effect of warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:EffectOfWarrants" scale="0" unitRef="shares" id="ixv-19934">83,552,979</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of ordinary shares (diluted)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedAverageNumberOfOrdinarySharesdiluted" scale="0" unitRef="shares" id="ixv-19935">544,906,149</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedAverageNumberOfOrdinarySharesdiluted" scale="0" unitRef="shares" id="ixv-19936">544,906,149</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="xtlb:WeightedAverageNumberOfOrdinarySharesdiluted" scale="0" unitRef="shares" id="ixv-19937">615,548,446</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
2023 and 2022 all options and warrants were excluded from the diluted weighted average number of shares calculation because their effect
would have been anti-dilutive. In 2021,&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-19938">12,400,000</ix:nonFraction>&#160;options and&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="xtlb:warrants" scale="0" unitRef="shares" id="ixv-19939">650,000</ix:nonFraction>&#160;warrants (each warrant is exercisable to&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="xtlb:EachWarrantIsExercisableToShares" scale="0" unitRef="shares" id="ixv-19940">100</ix:nonFraction>&#160;shares)
were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
average market value of the Company&#8217;s shares for calculating the dilutive effect of share options and warrants was based on quoted
market prices for the year during which the options were outstanding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-18929"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 19:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>SUBSEQUENT
                                            EVENTS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 17, 2024 the Company&#8217;s board of directors approved the grant of <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="xtlb:NumberOfShareOptionsExercisableSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-19941">148,500</ix:nonFraction> options exercisable into <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="xtlb:ADSIssued" scale="0" unitRef="shares" id="ixv-19942">148,500</ix:nonFraction> ADSs of the Company,
out of which <ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-19943">138,500</ix:nonFraction> are subject to shareholders meeting to be held on April 30, 2024 (which was approved on April 30, 2024 by Company&#8217;s shareholders
meeting) to certain officers and directors of the Company.
<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="xtlb:NumberOfOptionsFullyVested" scale="0" unitRef="shares" id="ixv-19944">100,000</ix:nonFraction> options will be fully vested on date of grant and <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="xtlb:NumberOfOptionsVest" scale="0" unitRef="shares" id="ixv-19945">48,500</ix:nonFraction> options will vest according to Company&#8217;s 2011 share option plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 19, 2024, the Company signed a binding term sheet, subject to due diligence, with THE SOCIAL PROXY Ltd. (the &#8220;Social Proxy&#8221;)
to acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis. The acquisition included, among
other things, the grant to the Social Proxy current shareholders of the right to appoint of 2 new directors to the Company&#8217;s board
of directors, against the resignation of 2 Company&#8217;s current directors. Consequently, the Company approved to extend the resigning
directors options exercise period for an additional <ix:nonNumeric contextRef="c142" format="ixt-sec:durmonth" name="xtlb:ExercisedPeriod" id="ixv-19946">9</ix:nonNumeric> months period and up to an aggregate <ix:nonNumeric contextRef="c142" format="ixt-sec:durmonth" name="xtlb:TerminationPeriod" id="ixv-19947">12</ix:nonNumeric> months period following such termination
date, which is subject to shareholders approval</span> (which was approved on April 30, 2024 by Company&#8217;s shareholders meeting).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Company has secured a commitment of an investment of an amount of US$<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-19948">1,500</ix:nonFraction> thousands through a private placement to be
consummated upon the closing of the Transaction, see also Note 1d.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On March 27, 2024 the Company entered into a loan agreement with the
Social Proxy. According to the loan agreement, on March 27, 2024, the Company provided the Social Proxy with a loan of US$<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossLoanCommitments" scale="3" unitRef="usd" id="ixv-19949">150</ix:nonFraction> thousand.
The loan bears an annual interest of <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="xtlb:LoanInterestRate" scale="-2" unitRef="pure" id="ixv-19950">8</ix:nonFraction>%. The loan and accrued interest will be repaid at the earlier of (1) 120 days following March 27,
2024 or (2) the date upon which the parties decide to abandon attempts for Transaction. Upon repayment date, Social Proxy may repay the
outstanding loan and accrued interest in 18 equal monthly installments. Social Proxy provided a first priority floating charge over all
of it assets as a security to ensure repayment of the loan and accrued interest.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>








</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="a_032"></a></div><p style="margin: 0pt"><b>ITEM 19. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following exhibits are filed as part of this
annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420405024363/v022798_ex1.htm">Articles of Association (9)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420407014214/v068912_ex4-1.htm">Form of Share Certificate (including both Hebrew and English translations) (2)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm">Form of American Depositary Receipt (included in Exhibit 4.1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000121390021015290/f20f2020ex2d_xtlbiopharma.htm">Description of Securities (11)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000101915507000345/xtlexdepagmt83105.htm">Deposit Agreement, dated as of August 31, 2005, by and between XTL Biopharmaceuticals Ltd., The Bank of New York, as Depositary, and each holder and beneficial owner of American Depositary Shares issued thereunder (1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-3.htm">2011 Share Option Plan dated August 29, 2011 (6)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420409019131/v145414_ex10-44.htm">Research and License Agreement Between Yeda Research and Development Company Ltd., Mor Research Applications Ltd., Biogal Ltd. (under its previous name Haverfield Ltd.) and Biogal Advanced Biotechnology Ltd. dated January 7, 2002 (3) &#8224;</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420409019131/v145414_ex10-45.htm">Amendment to Research and License Agreement Between Yeda Research and Development Company Ltd., Mor Research Applications Ltd., Haverfield Ltd. and Biogal Advanced Biotechnology Ltd. effective April 1, 2008 (3) &#8224;</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420411033048/v224319_ex10-52.htm">Option to License Agreement, dated as of September 1, 2010, between XTL Biopharmaceuticals Ltd. and Yeda Research and Development Company Limited&#160;(4)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420414020261/v373623_ex10-13.htm">License Agreement dated January 7, 2014, by and between Yeda Research and Development Company Limited and XTL Biopharmaceuticals Ltd (5)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-8.htm">Form of First Amendment to License Agreement between Yeda Research and Development Company Limited and XTL Biopharmaceuticals Ltd (6)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex10-11.htm">Form of Consulting Agreement dated January 1, 2015 between XTL Biopharmaceuticals Ltd. and Schapiro Education Ltd. (6)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1023549/000114420415073635/v427869_ex21-1.htm">List of Subsidiaries (6)</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Options: NewSection; Value: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>


</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1 </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="ea020456101ex12-1_xtlbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002,*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2 </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020456101ex12-2_xtlbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1 </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020456101ex13-1_xtlbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 USC. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea020456101ex99-7_xtlbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback Policy*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain confidential information contained in this exhibit was omitted.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the registration statement on F-6 filed with the Securities and Exchange Commission on November 28, 2007, as it may be amended or restated.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23, 2007.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on April 6, 2009.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on May 31, 2011.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on April 2, 2014.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the registration statement on Form F-1 filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on December 31, 2015.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the current report on Form 6-K filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on February 22, 2017.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the current report on Form 6-K filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 9, 2017.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the registration statement on Form 20-F filed with the Securities and Exchange Commission on August 10, 2005.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the registration statement on Form F-1/A filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on February 1, 2018.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the annual report on Form 20-F filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 15, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this registration
statement on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XTL BIOPHARMACEUTICALS LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Registrant</i>) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 30, 2024</span></td>
    <td style="white-space: nowrap; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:&#160;&#160; </span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shlomo Shalev </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Shalev </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 119; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></span></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c0" id="hidden-fact-0" name="xtlb:RevaluationOfWarrantsToPurchaseAds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-1" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-2" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-3" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-4" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-6" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-7" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-8" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-9" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-10" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-11" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-12" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-13" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-14" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-15" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-16" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-17" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-18" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-19" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c35" id="hidden-fact-20" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-21" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-22" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-23" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-24" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-25" name="ifrs-full:DepreciationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-26" name="xtlb:RevaluationOfWarrantsToPurchase" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-27" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-28" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-29" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-30" name="ifrs-full:SettlementsFairValueMeasurementLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-31" name="ifrs-full:FinancialLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-32" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-33" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c63" id="hidden-fact-34" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-35" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-37" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-38" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-39" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xsi:nil="true"/>
<ix:nonNumeric contextRef="c4" id="hidden-fact-40" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-42" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c63" id="hidden-fact-43" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-44" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-45" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-46" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-47" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-48" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-49" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-50" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-51" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-52" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-53" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-54" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-55" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-56" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-57" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-58" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-59" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c76" id="hidden-fact-60" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-61" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-62" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c94" id="hidden-fact-63" name="ifrs-full:NumberOfOutstandingShareOptions" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c94" id="hidden-fact-64" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c95" id="hidden-fact-65" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-66" name="ifrs-full:TravelExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-67" name="ifrs-full:TravelExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-68" name="xtlb:FinanceExpensesRevaluationOfMarketableSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-69" name="xtlb:ExchangeDifferences" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-70" name="xtlb:RevaluationOfWarrantsToPurchaseADSs" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="xtlb:RevaluationMarketableSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-72" name="xtlb:RevaluationMarketableSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-73" name="xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-74" name="xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-75" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c120" id="hidden-fact-76" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c122" id="hidden-fact-77" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c123" id="hidden-fact-78" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c125" id="hidden-fact-79" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c126" id="hidden-fact-80" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c128" id="hidden-fact-81" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-82" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c131" id="hidden-fact-83" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c132" id="hidden-fact-84" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c134" id="hidden-fact-85" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c135" id="hidden-fact-86" name="xtlb:Issued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-87" name="xtlb:WarrantRevaluationIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-88" name="xtlb:WarrantRevaluationIncome" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c137" id="hidden-fact-89" name="xtlb:EffectOfWarrants" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-90" name="xtlb:EffectOfWarrants" unitRef="shares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-20044">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-20045">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-20046">0001023549</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="xtlb-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"/>
<ix:relationship fromRefs="ix_2_fact ix_3_fact" toRefs="ix_1_footnote"/>
<ix:relationship fromRefs="hidden-fact-32 hidden-fact-33 hidden-fact-34 ix_4_fact hidden-fact-35" toRefs="ix_2_footnote"/>
<ix:relationship fromRefs="hidden-fact-36 hidden-fact-37 ix_5_fact hidden-fact-38 ix_6_fact" toRefs="ix_3_footnote"/>
<ix:relationship fromRefs="hidden-fact-39 hidden-fact-40 ix_7_fact ix_8_fact" toRefs="ix_4_footnote"/>
<ix:relationship fromRefs="hidden-fact-41 hidden-fact-42 hidden-fact-43 ix_9_fact hidden-fact-44" toRefs="ix_5_footnote"/>
<ix:relationship fromRefs="ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact" toRefs="ix_6_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">xtlb:PrivatePlacementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:ForeignCurrenciesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:ForeignCurrenciesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:IsraeliCpiForwardContractsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:IsraeliCpiForwardContractsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:AgreementAxis">xtlb:LicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-08-01</xbrli:startDate>
    <xbrli:endDate>2016-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2015-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-05-01</xbrli:startDate>
    <xbrli:endDate>2017-05-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:YedaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:UnitedStatesDollarMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:UnitedStatesDollarMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:IsraeliNewShekelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:IsraeliNewShekelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DepositaryShareAxis">xtlb:AmericanDepositorySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:NamePlanAxis">xtlb:TwoThousandElevenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2011-08-01</xbrli:startDate>
    <xbrli:endDate>2011-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:NamePlanAxis">xtlb:TwoThousandElevenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2011-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2011-08-29</xbrli:startDate>
    <xbrli:endDate>2011-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra6k700T0sfKUwmSs7S9L++IDK0p1gPKHpO5dJ65hhGy9fwjj4/n7KN1SulI4ach77W9Wwz3+E1J9+r5NDv+DmNmsAUzk5MtuyzUCloU3JxeD1/AQx6LR+1dL0GkSZzfKNlWQ16gCepUKiGvC6mXEyCUNC1IRhKJbbVo8P15/+mdT+aHSxd4w05eDD5LmDCTYdsnFU3ts+vIR2atVwPY64Uoit+pW7pKkw=] CSR-->
  <xbrli:period>
    <xbrli:instant>2023-03-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-14</xbrli:startDate>
    <xbrli:endDate>2023-03-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:OneDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:OneDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:ChairmanOfBoardMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:ChairmanOfBoardMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedElevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedElevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThirteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThirteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">xtlb:BlackScholesMertonOptionsPricingModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:InterCureLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:InterCureLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:CanndocLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMarch72021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMarch72021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMarch72021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMay42021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMay42021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMay42021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedJuly62021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedJuly62021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedJuly62021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedAugust302021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedAugust302021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedAugust302021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedSeptember12021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedSeptember12021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedSeptember12021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedOctober112021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedOctober112021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedOctober112021DueToWarrantExerciseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">xtlb:NumberOfSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">xtlb:NumberOfSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">xtlb:NumberOfSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-17</xbrli:startDate>
    <xbrli:endDate>2024-03-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-19</xbrli:startDate>
    <xbrli:endDate>2024-03-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023549</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-27</xbrli:startDate>
    <xbrli:endDate>2024-03-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>ea020456101ex12-1_xtlbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Shlomo Shalev, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 20-F of XTL Biopharmaceuticals Ltd. (the &ldquo;Company&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other key consultants who have a significant role in the Company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 11pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; width: 60%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 30, 2024</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; width: 40%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shlomo Shalev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Shalev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>ea020456101ex12-2_xtlbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Itay Weinstein, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 20-F of XTL Biopharmaceuticals Ltd. (the &ldquo;Company&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by this annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other key consultants who have a significant role in the Company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 11pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; width: 60%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 30, 2024</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; width: 40%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Itay Weinstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itay Weinstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>ea020456101ex13-1_xtlbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 USC. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of XTL Biopharmaceuticals
Ltd. (the &ldquo;Company&rdquo;) on Form 20-F for the year ending December 31, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), the undersigned, Shlomo Shalev, Chief Executive Officer of the Company, and Itay Weinstein,
Chief Financial Officer of the Company, certify, pursuant to 18 USC. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; width: 60%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 30, 2024</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; width: 40%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shlomo Shalev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shlomo Shalev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Itay Weinstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itay Weinstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Financial Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>5
<FILENAME>ea020456101ex99-7_xtlbio.htm
<DESCRIPTION>CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
99.7</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif">XTL
Biopharmaceuticals Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Executive
Officer Clawback Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Approved
by the Compensation Committee of the Board of Directors on November 23, 2023 (the &ldquo;Adoption Date&rdquo;)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I.
<U>Purpose</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Executive Officer Clawback Policy describes the circumstances under which Covered Persons of XTL Biopharmaceuticals Ltd. and any of its
direct or indirect subsidiaries (the &ldquo;Company&rdquo;) will be required to repay or return Erroneously-Awarded Compensation to the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Policy and any terms used in this Policy shall be construed in accordance with any SEC regulations promulgated to comply with Section
954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, including without limitation Rule 10D-1 promulgated under
the Securities Exchange Act of 1934, as amended, and the rules adopted by Nasdaq, as well as the provisions of the Israeli Companies
Law of 1999 (the &ldquo;Companies Law&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
Covered Person of the Company shall sign an Acknowledgement and Agreement to the Clawback Policy in the form attached hereto as <U>Exhibit
A</U> as a condition to his or her participation in any of the Company&rsquo;s incentive-based compensation programs; provided that this
Policy shall apply to each Covered Person irrespective of whether such Covered Person shall have failed, for any reason, to have executed
such Acknowledgement and Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">II.
<U>Definitions</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of this Policy, the following capitalized terms shall have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Accounting
                                            Restatement</U></B>&rdquo; shall mean an accounting restatement (i) due to the material noncompliance
                                            of the Company with any financial reporting requirement under the securities laws, including
                                            any required accounting restatement to correct an error in previously issued financial restatements
                                            that is material to the previously issued financial statements (a &ldquo;Big R&rdquo; restatement),
                                            or (ii) that corrects an error that is not material to previously issued financial statements,
                                            but would result in a material misstatement if the error were corrected in the current period
                                            or left uncorrected in the current period (a &ldquo;little r&rdquo; restatement). Notwithstanding
                                            the foregoing, none of the following changes to the Company&rsquo;s financial statements
                                            represent error corrections and shall not be deemed an Accounting Restatement: (a) retrospective
                                            application of a change in accounting principle; (b) retrospective revision to reportable
                                            segment information due to a change in the structure of the Company&rsquo;s internal organization;
                                            (c) retrospective reclassification due to a discontinued operation; (d) retrospective application
                                            of a change in reporting entity, such as from a reorganization of entities under common control;
                                            and (e) retrospective revision for share splits, reverse share splits, share dividends or
                                            other changes in capital structure.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Board</U></B>&rdquo;
                                            shall mean the Board of Directors of the Company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Clawback-Eligible
                                            Incentive Compensation</U></B>&rdquo; shall mean, in connection with an Accounting Restatement,
                                            any Incentive-Based Compensation Received by a Covered Person (regardless of whether such
                                            Covered Person was serving at the time that Erroneously-Awarded Compensation is required
                                            to be repaid) (i) on or after the Nasdaq Effective Date, (ii) after beginning service as
                                            a Covered Person, (iii) while the Company has a class of securities listed on a national
                                            securities exchange or national securities association and (iv) during the Clawback Period.</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Clawback
                                            Period</U></B>&rdquo; shall mean, with respect to any Accounting Restatement, the three completed
                                            fiscal years immediately preceding the Restatement Date and any transition period (that results
                                            from a change in the Company&rsquo;s fiscal year) of less than nine months within or immediately
                                            following those three completed fiscal years.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Committee</U></B>&rdquo;
                                            shall mean the Compensation Committee of the Board.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Covered
                                            Person</U></B>&rdquo; shall mean any person who is, or was at any time, during the Clawback
                                            Period, an Executive Officer of the Company. For the avoidance of doubt, Covered Person may
                                            include a former Executive Officer that left the Company, retired or transitioned to an employee
                                            non-Executive Officer role (including after serving as an Executive Officer in an interim
                                            capacity) during the Clawback Period, and this Policy applies regardless of whether the Covered
                                            Person was at fault for an accounting error or other action that resulted in, or contributed
                                            to, the Accounting Restatement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Erroneously-Awarded
                                            Compensation</U></B>&rdquo; shall mean the amount of Clawback-Eligible Incentive Compensation
                                            that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received
                                            had it been determined based on the restated amounts. This amount must be computed without
                                            regard to any taxes paid.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Executive
                                            Officer</U></B>&rdquo; shall mean (i) the Company&rsquo;s president, principal financial
                                            officer, principal accounting officer (or if there is no such accounting officer, the controller),
                                            any vice-president in charge of a principal business unit, division, or function (such as
                                            sales, administration, or finance), any other officer who performs a policy-making function,
                                            (ii) any other person (including an officer of the Company&rsquo;s parent(s) or subsidiaries)
                                            who performs similar policy-making functions for the Company, or (iii) an &ldquo;Officer&rdquo;
                                            within the meaning set forth in the Companies Law.. For the sake of clarity, at a minimum,
                                            all persons who would be executive officers pursuant to Rule 401(b) under Regulation S-K
                                            shall be deemed &ldquo;Executive Officers&rdquo;.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Financial
                                            Reporting Measures</U></B>&rdquo; shall mean measures that are determined and presented in
                                            accordance with the accounting principles used in preparing the Company&rsquo;s financial
                                            statements, and all other measures that are derived wholly or in part from such measures,
                                            including, without limitation, measures that are &ldquo;non-GAAP financial measures&rdquo;
                                            for purposes of Exchange Act Regulation G and Item 10(e) of Regulation S-K, as well other
                                            measures, metrics and ratios that are not non- GAAP measures. For purposes of this Policy,
                                            Financial Reporting Measures shall include stock price and total shareholder return (and
                                            any measures that are derived wholly or in part from stock price or total shareholder return).
                                            A Financial Reporting Measure need not be presented within the Company&rsquo;s financial
                                            statements or included in a Company filing with the SEC.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Incentive-Based
                                            Compensation</U></B>&rdquo; shall have the meaning set forth in Section III below.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Nasdaq</U></B>&rdquo;
                                            shall mean The Nasdaq Stock Market.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Nasdaq
                                            Effective Date</U></B>&rdquo; shall mean October 2, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Policy</U></B>&rdquo;
                                            shall mean this Executive Officer Clawback Policy, as the same may be amended and/or restated
                                            from time to time.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Received</U></B>&rdquo;
                                            shall mean Incentive-Based Compensation received, or deemed to be received, in the Company&rsquo;s
                                            fiscal period during which the Financial Reporting Measure specified in the Incentive- Based
                                            Compensation is attained, even if the payment or grant occurs after the fiscal period.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Repayment
                                            Agreement</U></B>&rdquo; shall have the meaning set forth in Section V below.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>Restatement
                                            Date</U></B>&rdquo; shall mean the earlier of (i) the date the Board, a committee of the
                                            Board or the officers of the Company authorized to take such action if Board action is not
                                            required, concludes, or reasonably should have concluded, that the Company is required to
                                            prepare an Accounting Restatement, or (ii) the date that a court, regulator or other legally
                                            authorized body directs the Company to prepare an Accounting Restatement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>SARs</U></B>&rdquo;
                                            shall mean stock appreciation rights.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(r)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><U>SEC</U></B>&rdquo;
                                            shall mean the U.S. Securities and Exchange Commission.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">III.
<U>Incentive-Based Compensation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Incentive-Based
Compensation&rdquo; shall mean any compensation that is granted, earned or vested wholly or in part upon the attainment of a Financial
Reporting Measure.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of this Policy, specific examples of Incentive-Based Compensation include, but are not limited to:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-equity
                                            incentive plan awards that are earned based, wholly or in part, based on satisfaction of
                                            a Financial Reporting Measure performance goal;</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonuses
                                            paid from a &ldquo;bonus pool,&rdquo; the size of which is determined, wholly or in part,
                                            based on satisfaction of a Financial Reporting Measure performance goal;</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
                                            cash awards based on satisfaction of a Financial Reporting Measure performance goal;</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted
                                            stock, restricted stock units, performance share units, stock options and SARs that are granted
                                            or become vested, wholly or in part, on satisfaction of a Financial Reporting Measure performance
                                            goal; and</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
                                            received upon the sale of shares acquired through an incentive plan that were granted or
                                            vested based, wholly or in part, on satisfaction of a Financial Reporting Measure performance
                                            goal.</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of this Policy, Incentive-Based Compensation excludes:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                            base salaries (except with respect to any salary increases earned, wholly or in part, based
                                            on satisfaction of a Financial Reporting Measure performance goal);</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonuses
                                            paid solely at the discretion of the Committee or Board that are not paid from a &ldquo;bonus
                                            pool&rdquo; that is determined by satisfying a Financial Reporting Measure performance goal;</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonuses
                                            paid solely upon satisfying one or more subjective standards and/or completion of a specified
                                            employment period;</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-equity
                                            incentive plan awards earned solely upon satisfying one or more strategic measures or operational
                                            measures; and</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 23pt"></TD><TD STYLE="text-align: justify; width: 17.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
                                            awards that vest solely based on the passage of time and/or satisfaction of one or more non-
                                            Financial Reporting Measures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IV.
<U>Determination and Calculation of Erroneously-Awarded Compensation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event of an Accounting Restatement, the Committee shall promptly determine the amount of any Erroneously-Awarded Compensation for
each Executive Officer in connection with such Accounting Restatement and shall promptly thereafter provide each Executive Officer with
a written notice containing the amount of Erroneously-Awarded Compensation and a demand for repayment, forfeiture or return thereof,
as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Cash
Awards</U></B>. With respect to cash awards, the Erroneously-Awarded Compensation is the difference between the amount of the cash award
(whether payable as a lump sum or over time) that was Received and the amount that should have been Received applying the restated Financial
Reporting Measure.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Cash
Awards Paid From Bonus Pools</U></B>. With respect to cash awards paid from bonus pools, the Erroneously-Awarded Compensation is the
pro rata portion of any deficiency that results from the aggregate bonus pool that is reduced based on applying the restated Financial
Reporting Measure.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Equity
Awards</U></B>. With respect to equity awards, if the shares, options, SARs or other equity awards are still held at the time of recovery,
the Erroneously-Awarded Compensation is the number of such securities Received in excess of the number that should have been received
applying the restated Financial Reporting Measure (or the value in excess of that number). If the options, SARs or other equity awards
have been exercised, vested, settled or otherwise converted into underlying shares, but the underlying shares have not been sold, the
Erroneously-Awarded Compensation is the number of shares underlying the excess options or SARs (or the value thereof). If the underlying
shares have already been sold, the Erroneously-Awarded Compensation is the higher of the value of the stock upon vesting, exercise or
sale.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Compensation
Based on Stock Price or Total Shareholder Return</U></B>. For Incentive-Based Compensation based on (or derived from) stock price or
total shareholder return, where the amount of Erroneously-Awarded Compensation is not subject to mathematical recalculation directly
from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable
estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation
was Received (in which case, the Committee shall maintain documentation of such determination of that reasonable estimate and provide
such documentation to Nasdaq in accordance with applicable listing standards).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">V.
<U>Recovery of Erroneously-Awarded Compensation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Once
the Committee has determined the amount of Erroneously-Awarded Compensation recoverable from the applicable Covered Person, the Committee
shall take all necessary actions to recover the Erroneously- Awarded Compensation. Unless otherwise determined by the Committee, the
Committee shall pursue the recovery of Erroneously-Awarded Compensation in accordance with the below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Cash
Awards</U></B>. With respect to cash awards, the Committee shall either (i) require the Covered Person to repay the Erroneously-Awarded
Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously-Awarded
Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer to enter into a Repayment
Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time as determined by the Committee,
the Company shall countersign such Repayment Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Unvested
Equity Awards</U></B>. With respect to those equity awards that have not yet vested, the Committee shall take all necessary action to
cancel, or otherwise cause to be forfeited, the awards in the amount of the Erroneously-Awarded Compensation.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Vested
Equity Awards</U></B>. With respect to those equity awards that have vested and the underlying shares have not been sold, the Committee
shall take all necessary action to cause the Covered Person to deliver and surrender the underlying shares in the amount of the Erroneously-Awarded
Compensation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event that the Covered Person has sold the underlying shares, the Committee shall either (i) require the Covered Person to repay
the Erroneously-Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to
such Erroneously-Awarded Compensation) reasonably promptly following the Restatement Date or (ii) if approved by the Committee, offer
to enter into a Repayment Agreement. If the Covered Person accepts such offer and signs the Repayment Agreement within a reasonable time
as determined by the Committee, the Company shall countersign such Repayment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Repayment
Agreement</U></B>. &ldquo;Repayment Agreement&rdquo; shall mean an agreement (in a form reasonably acceptable to the Committee) with
the Covered Person for the repayment of the Erroneously-Awarded Compensation as promptly as possible without unreasonable economic hardship
to the Covered Person.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Effect
of Non-Repayment</U></B>. To the extent that a Covered Person fails to repay all Erroneously-Awarded Compensation to the Company when
due (as determined in accordance with this Policy), the Company shall, or shall cause one or more other members of the Company to, take
all actions reasonable and appropriate to recover such Erroneously-Awarded Compensation from the applicable Covered Person. Unless otherwise
determined by the Committee in its discretion, the applicable Covered Person shall be required to reimburse the Company for any and all
expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously-Awarded Compensation in accordance
with the immediately preceding sentence.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously-Awarded Compensation based on all
applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery.
However, in no event may the Company accept an amount that is less than the amount of Erroneously-Awarded Compensation in satisfaction
of a Covered Person&rsquo;s obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">VI.
<U>Discretionary Recovery</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
anything herein to the contrary, the Company shall not be required to take action to recover Erroneously-Awarded Compensation if any
one of the following conditions are met and the Committee determines that recovery would be impracticable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
direct expenses paid to a third party to assist in enforcing this Policy against a Covered Person would exceed the amount to be recovered,
after the Company has made a reasonable attempt to recover the applicable Erroneously-Awarded Compensation, documented such attempts
and provided such documentation to Nasdaq;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recovery
would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would
be impracticable to recover any amount of Erroneously-Awarded Compensation based on violation of home country law, the Company has obtained
an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is
provided to Nasdaq; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recovery
would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company,
to fail to meet the requirements of 26</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.C.
401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">VII.
<U>Reporting and Disclosure Requirements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including
the disclosure required by the applicable filings required to be made with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">VIII.
<U>Effective Date</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Policy shall apply to any Incentive-Based Compensation Received on or after the Nasdaq Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IX.
<U>No Indemnification</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company shall not indemnify any Covered Person against the loss of Erroneously-Awarded Compensation and shall not pay, or reimburse any
Covered Persons for premiums, for any insurance policy to fund such Covered Person&rsquo;s potential recovery obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">X.
<U>Administration</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Committee has the sole discretion to administer this Policy and ensure compliance with <FONT STYLE="font-size: 10pt">Nasdaq</FONT> Rules
and any other applicable law, regulation, rule or interpretation of the SEC or <FONT STYLE="font-size: 10pt">Nasdaq</FONT> promulgated
or issued in connection therewith. Actions of the Committee pursuant to this Policy shall be taken by the vote of a majority of its members.
The Committee shall, subject to the provisions of this Policy, make such determinations and interpretations and take such actions as
it deems necessary, appropriate or advisable. All determinations and interpretations made by the Committee shall be final, binding and
conclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XI.
<U>Amendment; Termination</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and
when it determines that it is legally required by any federal securities laws, SEC rule, the Companies Law or the rules of any national
securities exchange or national securities association on which the Company&rsquo;s securities are then listed. The Committee may terminate
this Policy at any time. Notwithstanding anything in this Section XI to the contrary, no amendment or termination of this Policy shall
be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with
such amendment or termination) cause the Company to violate any federal securities laws, SEC rule, the Companies Law or the rules of
any national securities exchange or national securities association on which the Company&rsquo;s securities are then listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XII.
<U>Other Recoupment Rights; No Additional Payments</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment
agreement, equity award agreement or any other agreement entered into on or after the Adoption Date shall, as a condition to the
grant of any benefit thereunder, require a Covered Person to agree to abide by the terms of this Policy. Any right of recoupment
under this Policy is in addition to, and not in lieu of, any other rights under applicable law, regulation or rule or pursuant to
any similar policy in any employment agreement, equity plan, compensation policy, equity award agreement or similar arrangement and
any other legal remedies available to the Company. However, this Policy shall not provide for recovery of Incentive-Based
Compensation that the Company has already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery
obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">XIII.
<U>Successors</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Policy shall be binding and enforceable against all Covered Persons and their beneficiaries, heirs, executors, administrators or other
legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0cm"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit
A</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ACKNOWLEDGEMENT
AND AGREEMENT TO THE</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXECUTIVE
OFFICER CLAWBACK POLICY OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>XTL
BIOPHARMACEUTICALS LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By
signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of XTL Biopharmaceuticals
Ltd. Executive Officer Clawback Policy (the &ldquo;Policy&rdquo;). Capitalized terms used but not otherwise defined in this Acknowledgement
Form (this &ldquo;Acknowledgement Form&rdquo;) shall have the meanings ascribed to such terms in the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By
signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to
the Policy and that the Policy will apply both during and after the undersigned&rsquo;s employment with the Company. Further, by signing
below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously-Awarded
Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner permitted by, the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; width: 40%">Signature</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">Name</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">Date</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">7</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $, G # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **,T9H :Q
M4D] *YP^,],$\4.)2TDIB'R]"*WYFVPN<@<'D]*\1N+R<>,;:$WD"GSR^X*-
MM<]6IRM6-(0YCW%2" 1T/-/J&%@T2'<#D#D5-FMHNZ,[6"BBBJ ***,T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMXN9']P/3WH$W8Z.BLW2M7LM;T^.]L)EEA?N#R#W!]#6B#F@8M%%% !1110
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MO01I]W9K%(JW%S]IWAOF1_\ 9/8>U;1F?2M%MC)'N>-$C(SWP!6FIRH/J,T
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M?Q#'>2/!86L<@^ZTTBYZ>@K*CM;B48>9]O\ =4X4?A5VULXXHM\A58T&6)X
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MV374FRM78LUO$6/4E!DU3T33AIMB(WP97.YS[FM2O0@K(^6K3YYME?[#:?\
M/K#_ -^Q1]AM/^?6'_OV*LT59D8>K^&-*URWCM[RV0P)()"BJ%W$=,X[58O[
M*&/0Y[>WB6.-8R%1!@8':M3%(0#P>E%P/-](D!"@\=L5B>,[<P:S;WH#;)X]
MC'L&'^-=+K5BVDZNTRK_ *-<-E3_ '6[BG75M;ZSI;V=P<*WW6[HW8UUQELR
M6<OIMR !S6VT-K>B(3* %D\PX_C.,<UR%S;WFA77D7BD*#\DH^ZP[<U>@U0
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MP3BNMM9Q<VL4X&!(@< ]LC-2I)[$J2>Q9HHHJB@HHHH **** "BBB@ HHHH
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M-#T>YF6U^W-;CY[6#!*CU8=A5;4?%D^G_P!GR_V4[V=T(@)!(-VY^RKU..]
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MO 8S^5=#10 @I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 -9-P(/0C!%85SX7M);9X5>3!5D02,65
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>xtlb-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 18:16:36 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:xtlb="http://xtlb.com/20231231" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://xtlb.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="xtlb-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="xtlb-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="xtlb-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="xtlb-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet" id="xtlb_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals" id="xtlb_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Statements of Financial Position (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ConsolidatedIncomeStatement" id="xtlb_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ShareholdersEquityType2or3" id="xtlb_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ConsolidatedCashFlow" id="xtlb_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/General" id="xtlb_r_General">
        <link:definition>006 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/BasisofPreparation" id="xtlb_r_BasisofPreparation">
        <link:definition>007 - Disclosure - Basis of Preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/MaterialAccountingPolicies" id="xtlb_r_MaterialAccountingPolicies">
        <link:definition>008 - Disclosure - Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement" id="xtlb_r_FinancialInstrumentsandFinancialRiskManagement">
        <link:definition>009 - Disclosure - Financial Instruments and Financial Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/CashandCashEquivalents" id="xtlb_r_CashandCashEquivalents">
        <link:definition>010 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtd" id="xtlb_r_MarketableSecuritiesInterCureLtd">
        <link:definition>011 - Disclosure - Marketable Securities &#8211; InterCure Ltd</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets" id="xtlb_r_PrepaidExpensesandOtheCurrentAssets">
        <link:definition>012 - Disclosure - Prepaid Expenses and Othe Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/IntangibleAssets" id="xtlb_r_IntangibleAssets">
        <link:definition>013 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/AccountsPayable" id="xtlb_r_AccountsPayable">
        <link:definition>014 - Disclosure - Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/Warrants" id="xtlb_r_Warrants">
        <link:definition>015 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit" id="xtlb_r_ShareCapitalReservesandAccumulatedDeficit">
        <link:definition>016 - Disclosure - Share Capital, Reserves and Accumulated Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ShareBasedPayment" id="xtlb_r_ShareBasedPayment">
        <link:definition>017 - Disclosure - Share-Based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ResearchandDevelopmentExpenses" id="xtlb_r_ResearchandDevelopmentExpenses">
        <link:definition>018 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/GeneralandAdministrativeExpenses" id="xtlb_r_GeneralandAdministrativeExpenses">
        <link:definition>019 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/FinanceIncomeExpensesNet" id="xtlb_r_FinanceIncomeExpensesNet">
        <link:definition>020 - Disclosure - Finance Income (Expenses), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/TaxesonIncome" id="xtlb_r_TaxesonIncome">
        <link:definition>021 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedParties" id="xtlb_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>022 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/EarningsLossPerShare" id="xtlb_r_EarningsLossPerShare">
        <link:definition>023 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/SubsequentEvents" id="xtlb_r_SubsequentEvents">
        <link:definition>024 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/AccountingPoliciesByPolicy" id="xtlb_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/BasisofPreparationTables" id="xtlb_r_BasisofPreparationTables">
        <link:definition>996001 - Disclosure - Basis of Preparation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables" id="xtlb_r_FinancialInstrumentsandFinancialRiskManagementTables">
        <link:definition>996002 - Disclosure - Financial Instruments and Financial Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/CashandCashEquivalentsTables" id="xtlb_r_CashandCashEquivalentsTables">
        <link:definition>996003 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables" id="xtlb_r_MarketableSecuritiesInterCureLtdTables">
        <link:definition>996004 - Disclosure - Marketable Securities &#8211; InterCure Ltd (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables" id="xtlb_r_PrepaidExpensesandOtheCurrentAssetsTables">
        <link:definition>996005 - Disclosure - Prepaid Expenses and Othe Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/AccountsPayableTables" id="xtlb_r_AccountsPayableTables">
        <link:definition>996006 - Disclosure - Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/WarrantsTables" id="xtlb_r_WarrantsTables">
        <link:definition>996007 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ShareBasedPaymentTables" id="xtlb_r_ShareBasedPaymentTables">
        <link:definition>996008 - Disclosure - Share-Based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ResearchandDevelopmentExpensesTables" id="xtlb_r_ResearchandDevelopmentExpensesTables">
        <link:definition>996009 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/GeneralandAdministrativeExpensesTables" id="xtlb_r_GeneralandAdministrativeExpensesTables">
        <link:definition>996010 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/FinanceIncomeExpensesNetTables" id="xtlb_r_FinanceIncomeExpensesNetTables">
        <link:definition>996011 - Disclosure - Finance Income (Expenses), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="xtlb_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>996012 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/EarningsLossPerShareTables" id="xtlb_r_EarningsLossPerShareTables">
        <link:definition>996013 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/GeneralDetails" id="xtlb_r_GeneralDetails">
        <link:definition>996014 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofExchangeRateTable" id="xtlb_r_ScheduleofExchangeRateTable">
        <link:definition>996015 - Disclosure - Basis of Preparation (Details) - Schedule of Exchange Rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails" id="xtlb_r_FinancialInstrumentsandFinancialRiskManagementDetails">
        <link:definition>996016 - Disclosure - Financial Instruments and Financial Risk Management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" id="xtlb_r_ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable">
        <link:definition>996017 - Disclosure - Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/CashandCashEquivalentsDetails" id="xtlb_r_CashandCashEquivalentsDetails">
        <link:definition>996018 - Disclosure - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable" id="xtlb_r_ScheduleofCashandCashEquivalentsTable">
        <link:definition>996019 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" id="xtlb_r_ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable">
        <link:definition>996020 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails" id="xtlb_r_MarketableSecuritiesInterCureLtdDetails">
        <link:definition>996021 - Disclosure - Marketable Securities &#8211; InterCure Ltd (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofFinancialInstrumentsTable" id="xtlb_r_ScheduleofFinancialInstrumentsTable">
        <link:definition>996022 - Disclosure - Marketable Securities &#8211; InterCure Ltd (Details) - Schedule of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable" id="xtlb_r_ScheduleofChangesinMarketableSecuritiesTable">
        <link:definition>996023 - Disclosure - Marketable Securities &#8211; InterCure Ltd (Details) - Schedule of Changes in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable" id="xtlb_r_ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996024 - Disclosure - Prepaid Expenses and Othe Current Assets (Details) - Schedule of Composition of Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/IntangibleAssetsDetails" id="xtlb_r_IntangibleAssetsDetails">
        <link:definition>996025 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable" id="xtlb_r_ScheduleofCompositionofAccountsPayableTable">
        <link:definition>996026 - Disclosure - Accounts Payable (Details) - Schedule of Composition of Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable" id="xtlb_r_ScheduleofCarryingAmountofAccountsPayableTable">
        <link:definition>996027 - Disclosure - Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/WarrantsDetails" id="xtlb_r_WarrantsDetails">
        <link:definition>996028 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable" id="xtlb_r_ScheduleofAssumptionsofInvestorsWarrantsTable">
        <link:definition>996029 - Disclosure - Warrants (Details) - Schedule of Assumptions of Investors' Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails" id="xtlb_r_ShareCapitalReservesandAccumulatedDeficitDetails">
        <link:definition>996030 - Disclosure - Share Capital, Reserves and Accumulated Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ShareBasedPaymentDetails" id="xtlb_r_ShareBasedPaymentDetails">
        <link:definition>996031 - Disclosure - Share-Based Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" id="xtlb_r_ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable">
        <link:definition>996032 - Disclosure - Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" id="xtlb_r_ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable">
        <link:definition>996033 - Disclosure - Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra6k700T0sfKUwmSs7S9L++IDK0p1gPKHpO5dJ65hhGy9fwjj4/n7KN1SulI4ach77W9Wwz3+E1J9+r5NDv+DmNmsAUzk5MtuyzUCloU3JxeD1/AQx6LR+1dL0GkSZzfKNlWQ16gCepUKiGvC6mXEyCUNC1IRhKJbbVo8P15/+mdT+aHSxd4w05eDD5LmDCTYdsnFU3ts+vIfY4WXxqZ3MGIwNGAaTVE/6XjxxVEL2BoA==] CSR-->
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofOutstandingOptionsTable" id="xtlb_r_ScheduleofOutstandingOptionsTable">
        <link:definition>996034 - Disclosure - Share-Based Payment (Details) - Schedule of Outstanding Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable" id="xtlb_r_ScheduleofFairValueforOptionsGrantedTable">
        <link:definition>996035 - Disclosure - Share-Based Payment (Details) - Schedule of Fair Value for Options Granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable" id="xtlb_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996036 - Disclosure - Research and Development Expenses (Details) - Schedule of Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable" id="xtlb_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996037 - Disclosure - General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable" id="xtlb_r_ScheduleofFinanceIncomeExpensesNetTable">
        <link:definition>996038 - Disclosure - Finance Income (Expenses), Net (Details) - Schedule of Finance Income (Expenses), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/TaxesonIncomeDetails" id="xtlb_r_TaxesonIncomeDetails">
        <link:definition>996039 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="xtlb_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>996040 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable" id="xtlb_r_ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable">
        <link:definition>996041 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employee Services</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/EarningsLossPerShareDetails" id="xtlb_r_EarningsLossPerShareDetails">
        <link:definition>996042 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable" id="xtlb_r_ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable">
        <link:definition>996043 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" id="xtlb_r_ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable">
        <link:definition>996044 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable" id="xtlb_r_ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable">
        <link:definition>996045 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" id="xtlb_r_ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable">
        <link:definition>996046 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/SubsequentEventsDetails" id="xtlb_r_SubsequentEventsDetails">
        <link:definition>996047 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://xtlb.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ConsolidatedStatementsOfChangesInEquityAbstract"/>
  <xs:element name="ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract"/>
  <xs:element name="ScheduleOfCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCashAndCashEquivalentsAbstract"/>
  <xs:element name="ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract"/>
  <xs:element name="MarketableSecuritiesInterCureLtdAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
  <xs:element name="ScheduleOfFinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfFinancialInstrumentsAbstract"/>
  <xs:element name="ScheduleOfChangesInMarketableSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract"/>
  <xs:element name="ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfCompositionOfAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfCarryingAmountOfAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract"/>
  <xs:element name="DisclosureOfWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfWarrantsAbstract"/>
  <xs:element name="ScheduleOfAssumptionsOfInvestorsWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract"/>
  <xs:element name="ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract"/>
  <xs:element name="ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract"/>
  <xs:element name="ScheduleOfOutstandingOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfOutstandingOptionsAbstract"/>
  <xs:element name="ScheduleOfFairValueForOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfFairValueForOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="ScheduleOfFinanceIncomeExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract"/>
  <xs:element name="ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract"/>
  <xs:element name="ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract"/>
  <xs:element name="ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract34"/>
  <xs:element name="AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract53"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract54"/>
  <xs:element name="FinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FinanceExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract55"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract56"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FinanceIncomeAbstract"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract57"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract60"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfSharesAbstract"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract61"/>
  <xs:element name="NumberOfSharesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfSharesAbstract0"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnlabeledAbstract62"/>
  <xs:element name="CurrentMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_CurrentMarketableSecurities"/>
  <xs:element name="RevaluationOfWarrantsToPurchaseAds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RevaluationOfWarrantsToPurchaseAds"/>
  <xs:element name="RevaluationOfMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RevaluationOfMarketableSecurities"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities"/>
  <xs:element name="RevaluationOfWarrantsToPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RevaluationOfWarrantsToPurchase"/>
  <xs:element name="TotalIncomeAndExpensesNotInvolvingCashFlows" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows"/>
  <xs:element name="MarketableSecuritiesInterCureLtdTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_MarketableSecuritiesInterCureLtdTextBlock"/>
  <xs:element name="DisclosureOfWarrantsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfWarrantsTextBlock"/>
  <xs:element name="ShareCapitalReservesAndRetainedEarnings" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareCapitalReservesAndRetainedEarnings"/>
  <xs:element name="DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock"/>
  <xs:element name="ScheduleOfCompositionOfAccountsPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock"/>
  <xs:element name="ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock"/>
  <xs:element name="ScheduleOfFairValueForOptionsGrantedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock"/>
  <xs:element name="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
  <xs:element name="ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock"/>
  <xs:element name="ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock"/>
  <xs:element name="FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"/>
  <xs:element name="ExercisesDuringTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ExercisesDuringTheYear"/>
  <xs:element name="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"/>
  <xs:element name="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems"/>
  <xs:element name="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable"/>
  <xs:element name="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems"/>
  <xs:element name="GainsLossesOnFairValueOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GainsLossesOnFairValueOnMarketableSecurities"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GovernmentAuthorities"/>
  <xs:element name="TypeOfCurrencyDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_TypeOfCurrencyDomainDomain"/>
  <xs:element name="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable"/>
  <xs:element name="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems"/>
  <xs:element name="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable"/>
  <xs:element name="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems"/>
  <xs:element name="FeesRelatedToServiceProviders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FeesRelatedToServiceProviders"/>
  <xs:element name="PatentsAndFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PatentsAndFees"/>
  <xs:element name="RentAndOfficeMaintenance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RentAndOfficeMaintenance"/>
  <xs:element name="FinanceExpensesRevaluationOfMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FinanceExpensesRevaluationOfMarketableSecurities"/>
  <xs:element name="ExchangeDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ExchangeDifferences"/>
  <xs:element name="RevaluationOfWarrantsToPurchaseADSs" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RevaluationOfWarrantsToPurchaseADSs"/>
  <xs:element name="RevaluationMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RevaluationMarketableSecurities"/>
  <xs:element name="GainOnExchangeDifferencesOnTranslationNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax"/>
  <xs:element name="FinanceIncomeexpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FinanceIncomeexpensesNet"/>
  <xs:element name="DateDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DateDomainDomain"/>
  <xs:element name="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"/>
  <xs:element name="IssuedOrdinarySharesAtJanuary1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedOrdinarySharesAtJanuary1"/>
  <xs:element name="Issued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_Issued"/>
  <xs:element name="WeightedAverageNumberOfOrdinarySharesbasic" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WeightedAverageNumberOfOrdinarySharesbasic"/>
  <xs:element name="WarrantRevaluationIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WarrantRevaluationIncome"/>
  <xs:element name="comprehensiveIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_comprehensiveIncome"/>
  <xs:element name="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"/>
  <xs:element name="WeightedaverageNumberOfOrdinarySharesbasic" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WeightedaverageNumberOfOrdinarySharesbasic"/>
  <xs:element name="EffectOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_EffectOfWarrants"/>
  <xs:element name="WeightedAverageNumberOfOrdinarySharesdiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_GeneralDetailsTable"/>
  <xs:element name="GeneralDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GeneralDetailsLineItems"/>
  <xs:element name="IssuedAndOutstandingRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedAndOutstandingRate"/>
  <xs:element name="PaymentOfShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PaymentOfShareholders"/>
  <xs:element name="PeriodOfClosingTransaction" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PeriodOfClosingTransaction"/>
  <xs:element name="InvestorIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_InvestorIssued"/>
  <xs:element name="PricePerUnit" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PricePerUnit"/>
  <xs:element name="ADSIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ADSIssued"/>
  <xs:element name="PrivatePlacementWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PrivatePlacementWarrantsIssued"/>
  <xs:element name="WarrantExercisedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WarrantExercisedPeriod"/>
  <xs:element name="PercentageOfFunctionalCurrency" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PercentageOfFunctionalCurrency"/>
  <xs:element name="CashandCashEquivalentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_CashandCashEquivalentsDetailsTable"/>
  <xs:element name="CashandCashEquivalentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_CashandCashEquivalentsDetailsLineItems"/>
  <xs:element name="DepositsWithMaturity" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DepositsWithMaturity"/>
  <xs:element name="MarketableSecuritiesInterCureLtdDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_MarketableSecuritiesInterCureLtdDetailsTable"/>
  <xs:element name="MarketableSecuritiesInterCureLtdDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems"/>
  <xs:element name="PercentageOfHoldingShare" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PercentageOfHoldingShare"/>
  <xs:element name="AgreementDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AgreementDomainDomain"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_IntangibleAssetsDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IntangibleAssetsDetailsLineItems"/>
  <xs:element name="PercentageOfRoyalties" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PercentageOfRoyalties"/>
  <xs:element name="PercentageOfSublicenseFees" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PercentageOfSublicenseFees"/>
  <xs:element name="ReceiptOfRequiredInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ReceiptOfRequiredInvestment"/>
  <xs:element name="ExpirTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ExpirTerm"/>
  <xs:element name="RemainingLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RemainingLiability"/>
  <xs:element name="IntangibleAssetOtherInformationMaturityDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IntangibleAssetOtherInformationMaturityDate"/>
  <xs:element name="AssetsRemainedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AssetsRemainedAmount"/>
  <xs:element name="LicenseAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_LicenseAgreement"/>
  <xs:element name="DepositaryShareDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DepositaryShareDomainDomain"/>
  <xs:element name="WarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_WarrantsDetailsTable"/>
  <xs:element name="WarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WarrantsDetailsLineItems"/>
  <xs:element name="GrossFundRaised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GrossFundRaised"/>
  <xs:element name="WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_WarrantsIssued"/>
  <xs:element name="DescriptionOfWarrantsExercisable" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DescriptionOfWarrantsExercisable"/>
  <xs:element name="ShareCapitalReservesandAccumulatedDeficitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable"/>
  <xs:element name="ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems"/>
  <xs:element name="NamePlanDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NamePlanDomainDomain"/>
  <xs:element name="ShareBasedPaymentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_ShareBasedPaymentDetailsTable"/>
  <xs:element name="ShareBasedPaymentDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedPaymentDetailsLineItems"/>
  <xs:element name="SharebasedPaymentAwardRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_SharebasedPaymentAwardRemainingContractualTerm"/>
  <xs:element name="NumberOfShareExercisableInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement"/>
  <xs:element name="IncreaseOfReserve" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IncreaseOfReserve"/>
  <xs:element name="OptionsReserve" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_OptionsReserve"/>
  <xs:element name="RemainingNumberOfOptionsAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RemainingNumberOfOptionsAvailableForGrant"/>
  <xs:element name="OptionsExercisableIntoOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_OptionsExercisableIntoOrdinaryShares"/>
  <xs:element name="OrdinarySharesExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="xtlb_OrdinarySharesExercisePrice"/>
  <xs:element name="ExtendedExpiryTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ExtendedExpiryTerm"/>
  <xs:element name="ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees"/>
  <xs:element name="DeferredTaxAssetsCapitalLossCarryforward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DeferredTaxAssetsCapitalLossCarryforward"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="AdministrativeFeeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AdministrativeFeeExpense"/>
  <xs:element name="PercentageOfShare" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PercentageOfShare"/>
  <xs:element name="CurrentMarketableSecuritie" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_CurrentMarketableSecuritie"/>
  <xs:element name="RentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RentExpense"/>
  <xs:element name="warrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_warrants"/>
  <xs:element name="EachWarrantIsExercisableToShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_EachWarrantIsExercisableToShares"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="xtlb_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NumberOfShareOptionsExercisableSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfOptionsFullyVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfOptionsFullyVested"/>
  <xs:element name="NumberOfOptionsVest" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfOptionsVest"/>
  <xs:element name="ExercisedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ExercisedPeriod"/>
  <xs:element name="TerminationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_TerminationPeriod"/>
  <xs:element name="LoanInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_LoanInterestRate"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="xtlb_AgreementAxis"/>
  <xs:element name="DateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="xtlb_DateAxis"/>
  <xs:element name="DepositaryShareAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="xtlb_DepositaryShareAxis"/>
  <xs:element name="NamePlanAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="xtlb_NamePlanAxis"/>
  <xs:element name="TypeOfCurrencyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="xtlb_TypeOfCurrencyAxis"/>
  <xs:element name="AmericanDepositorySharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_AmericanDepositorySharesMember"/>
  <xs:element name="BlackScholesMertonOptionsPricingModelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_BlackScholesMertonOptionsPricingModelMember"/>
  <xs:element name="CanndocLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_CanndocLtdMember"/>
  <xs:element name="ChairmanOfBoardMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ChairmanOfBoardMember"/>
  <xs:element name="ForeignCurrenciesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ForeignCurrenciesMember"/>
  <xs:element name="FourDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FourDirectorsMember"/>
  <xs:element name="GrandDateIssuedEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GrandDateIssuedEightMember"/>
  <xs:element name="GrandDateIssuedFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GrandDateIssuedFiveMember"/>
  <xs:element name="GrandsDateIssuedElevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GrandsDateIssuedElevenMember"/>
  <xs:element name="GrandsDateIssuedThirteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GrandsDateIssuedThirteenMember"/>
  <xs:element name="GrandsDateIssuedThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GrandsDateIssuedThreeMember"/>
  <xs:element name="InterCureLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_InterCureLtdMember"/>
  <xs:element name="IsraeliCpiForwardContractsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IsraeliCpiForwardContractsMember"/>
  <xs:element name="IsraeliNewShekelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IsraeliNewShekelMember"/>
  <xs:element name="IssuedAugust302021DueToWarrantExerciseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedAugust302021DueToWarrantExerciseMember"/>
  <xs:element name="IssuedJuly62021DueToWarrantExerciseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedJuly62021DueToWarrantExerciseMember"/>
  <xs:element name="IssuedMarch72021DueToWarrantExerciseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedMarch72021DueToWarrantExerciseMember"/>
  <xs:element name="IssuedMay42021DueToWarrantExerciseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedMay42021DueToWarrantExerciseMember"/>
  <xs:element name="IssuedOctober112021DueToWarrantExerciseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedOctober112021DueToWarrantExerciseMember"/>
  <xs:element name="IssuedSeptember12021DueToWarrantExerciseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IssuedSeptember12021DueToWarrantExerciseMember"/>
  <xs:element name="LicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_LicenseAgreementMember"/>
  <xs:element name="NonAdjustingEventsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NonAdjustingEventsMember"/>
  <xs:element name="NumberOfSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NumberOfSharesMember"/>
  <xs:element name="OneDirectorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_OneDirectorMember"/>
  <xs:element name="PrivatePlacementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_PrivatePlacementsMember"/>
  <xs:element name="RangeOfExercisePricesOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RangeOfExercisePricesOneMember"/>
  <xs:element name="RangeOfExercisePricesThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RangeOfExercisePricesThreeMember"/>
  <xs:element name="RangeOfExercisePricesTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_RangeOfExercisePricesTwoMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_StockOptionsMember"/>
  <xs:element name="TwoThousandElevenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_TwoThousandElevenPlanMember"/>
  <xs:element name="UnitedStatesDollarMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_UnitedStatesDollarMember"/>
  <xs:element name="YedaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_YedaMember"/>
  <xs:element name="ChangesInOperatingAssetAndLiabilityItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract"/>
  <xs:element name="FinanceIncomeExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_FinanceIncomeExpensesNetAbstract"/>
  <xs:element name="GeneralAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_GeneralAbstract"/>
  <xs:element name="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract"/>
  <xs:element name="MaterialAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_MaterialAccountingPoliciesAbstract"/>
  <xs:element name="NoncashActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_NoncashActivitiesAbstract"/>
  <xs:element name="ResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems"/>
  <xs:element name="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems"/>
  <xs:element name="ShareBasedPaymentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_ShareBasedPaymentAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="xtlb_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>xtlb-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 18:16:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedBalanceSheet" roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedIncomeStatement" roleURI="http://xtlb.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedCashFlow" roleURI="http://xtlb.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompositionofAccountsPayableTable" roleURI="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFinanceIncomeExpensesNetTable" roleURI="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable" roleURI="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_CurrentMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="xtlb_CurrentMarketableSecurities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_AdditionalPaidinCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseAds" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseAds"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseAds" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="xtlb_RevaluationOfMarketableSecurities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceCost" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_FinanceIncomeCost" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:href="xtlb-20231231.xsd#xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:href="xtlb-20231231.xsd#xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="ifrs-full_DepreciationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra6k700T0sfKUwmSs7S9L++IDK0p1gPKHpO5dJ65hhGy9fwjj4/n7KN1SulI4ach77W9Wwz3+E1J9+r5NDv+DmNmsAUzk5MtuyzUCloU3JxeD1/AQx6LR+1dL0GkSZzfKNlWQ16gCepUKiGvC6mXEyCUNC1IRhKJbbVo8P15/+mdT+aHSxd4w05eDD5LmDCTYdsnFU3ts+vIbeAghsCtqIumDjTFem78DyA5uWmRLnuSA==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="xtlb_RevaluationOfMarketableSecurities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchase" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchase"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="xtlb_RevaluationOfWarrantsToPurchase" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="ifrs-full_RevenueFromInterest" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashOnHand" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_GovernmentAuthorities" xlink:href="xtlb-20231231.xsd#xtlb_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="xtlb_GovernmentAuthorities" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_WagesAndSalaries" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_PatentsAndFees" xlink:href="xtlb-20231231.xsd#xtlb_PatentsAndFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="xtlb_PatentsAndFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TravelExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_TravelExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_RentAndOfficeMaintenance" xlink:href="xtlb-20231231.xsd#xtlb_RentAndOfficeMaintenance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="xtlb_RentAndOfficeMaintenance" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_InsuranceExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_ProfessionalFeesExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_OtherExpenseByNature" order="9" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FeeAndCommissionExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExchangeDifferences" xlink:href="xtlb-20231231.xsd#xtlb_ExchangeDifferences"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="xtlb_ExchangeDifferences" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesRevaluationOfMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseADSs" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseADSs"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseADSs" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="xtlb_RevaluationMarketableSecurities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="xtlb-20231231.xsd#xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeexpensesNet" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeexpensesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_FinanceIncomeexpensesNet" xlink:to="ifrs-full_FinanceIncome" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xtlb_FinanceIncomeexpensesNet" xlink:to="ifrs-full_FinanceCosts" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>xtlb-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 18:16:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedBalanceSheet" roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedIncomeStatement" roleURI="http://xtlb.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareholdersEquityType2or3" roleURI="http://xtlb.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedCashFlow" roleURI="http://xtlb.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_General" roleURI="http://xtlb.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_BasisofPreparation" roleURI="http://xtlb.com/role/BasisofPreparation"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MaterialAccountingPolicies" roleURI="http://xtlb.com/role/MaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinancialInstrumentsandFinancialRiskManagement" roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_CashandCashEquivalents" roleURI="http://xtlb.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MarketableSecuritiesInterCureLtd" roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtd"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_PrepaidExpensesandOtheCurrentAssets" roleURI="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_IntangibleAssets" roleURI="http://xtlb.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_AccountsPayable" roleURI="http://xtlb.com/role/AccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_Warrants" roleURI="http://xtlb.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareCapitalReservesandAccumulatedDeficit" roleURI="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareBasedPayment" roleURI="http://xtlb.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ResearchandDevelopmentExpenses" roleURI="http://xtlb.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_GeneralandAdministrativeExpenses" roleURI="http://xtlb.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinanceIncomeExpensesNet" roleURI="http://xtlb.com/role/FinanceIncomeExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TaxesonIncome" roleURI="http://xtlb.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TransactionsandBalanceswithRelatedParties" roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_EarningsLossPerShare" roleURI="http://xtlb.com/role/EarningsLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_SubsequentEvents" roleURI="http://xtlb.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_AccountingPoliciesByPolicy" roleURI="http://xtlb.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_BasisofPreparationTables" roleURI="http://xtlb.com/role/BasisofPreparationTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinancialInstrumentsandFinancialRiskManagementTables" roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_CashandCashEquivalentsTables" roleURI="http://xtlb.com/role/CashandCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MarketableSecuritiesInterCureLtdTables" roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_PrepaidExpensesandOtheCurrentAssetsTables" roleURI="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_AccountsPayableTables" roleURI="http://xtlb.com/role/AccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_WarrantsTables" roleURI="http://xtlb.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareBasedPaymentTables" roleURI="http://xtlb.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ResearchandDevelopmentExpensesTables" roleURI="http://xtlb.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_GeneralandAdministrativeExpensesTables" roleURI="http://xtlb.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinanceIncomeExpensesNetTables" roleURI="http://xtlb.com/role/FinanceIncomeExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_EarningsLossPerShareTables" roleURI="http://xtlb.com/role/EarningsLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofExchangeRateTable" roleURI="http://xtlb.com/role/ScheduleofExchangeRateTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" roleURI="http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFinancialInstrumentsTable" roleURI="http://xtlb.com/role/ScheduleofFinancialInstrumentsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofChangesinMarketableSecuritiesTable" roleURI="http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompositionofAccountsPayableTable" roleURI="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCarryingAmountofAccountsPayableTable" roleURI="http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofAssumptionsofInvestorsWarrantsTable" roleURI="http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" roleURI="http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" roleURI="http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofOutstandingOptionsTable" roleURI="http://xtlb.com/role/ScheduleofOutstandingOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFairValueforOptionsGrantedTable" roleURI="http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFinanceIncomeExpensesNetTable" roleURI="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable" roleURI="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable" roleURI="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" roleURI="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable" roleURI="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" roleURI="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_GeneralDetails" roleURI="http://xtlb.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinancialInstrumentsandFinancialRiskManagementDetails" roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_CashandCashEquivalentsDetails" roleURI="http://xtlb.com/role/CashandCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MarketableSecuritiesInterCureLtdDetails" roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_IntangibleAssetsDetails" roleURI="http://xtlb.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_WarrantsDetails" roleURI="http://xtlb.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareCapitalReservesandAccumulatedDeficitDetails" roleURI="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareBasedPaymentDetails" roleURI="http://xtlb.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TaxesonIncomeDetails" roleURI="http://xtlb.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_EarningsLossPerShareDetails" roleURI="http://xtlb.com/role/EarningsLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_SubsequentEventsDetails" roleURI="http://xtlb.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#DocumentAndEntityInformation" roleURI="http://xtlb.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_CurrentMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="xtlb_CurrentMarketableSecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_AdditionalPaidinCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ParValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseAds" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseAds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseAds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="xtlb_RevaluationOfMarketableSecurities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherFinanceCost" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:href="xtlb-20231231.xsd#xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="xtlb_RevaluationOfMarketableSecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchase" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="xtlb_RevaluationOfWarrantsToPurchase" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:href="xtlb-20231231.xsd#xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NoncashActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_NoncashActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="xtlb_NoncashActivitiesAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NoncashActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/General">
    <loc xlink:type="locator" xlink:label="xtlb_GeneralAbstract" xlink:href="xtlb-20231231.xsd#xtlb_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralAbstract" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/BasisofPreparation">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/MaterialAccountingPolicies">
    <loc xlink:type="locator" xlink:label="xtlb_MaterialAccountingPoliciesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MaterialAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MaterialAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/CashandCashEquivalents">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/MarketableSecuritiesInterCureLtd">
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:to="xtlb_MarketableSecuritiesInterCureLtdTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentPrepaymentsAbstract" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/AccountsPayable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/Warrants">
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfWarrantsTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DisclosureOfWarrantsAbstract" xlink:to="xtlb_DisclosureOfWarrantsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareCapitalReservesAndRetainedEarnings" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesAndRetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="xtlb_ShareCapitalReservesAndRetainedEarnings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareBasedPayment">
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ResearchandDevelopmentExpenses">
    <loc xlink:type="locator" xlink:label="xtlb_ResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/GeneralandAdministrativeExpenses">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinanceIncomeExpensesNet">
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeExpensesNetAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/TransactionsandBalanceswithRelatedParties">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/EarningsLossPerShare">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/BasisofPreparationTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/CashandCashEquivalentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables">
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:to="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentPrepaymentsAbstract" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/AccountsPayableTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DisclosureOfWarrantsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareBasedPaymentTables">
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentAbstract" xlink:to="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentAbstract" xlink:to="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentAbstract" xlink:to="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentAbstract" xlink:to="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ResearchandDevelopmentExpensesTables">
    <loc xlink:type="locator" xlink:label="xtlb_ResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ResearchAndDevelopmentExpensesAbstract" xlink:to="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/GeneralandAdministrativeExpensesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinanceIncomeExpensesNetTables">
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeExpensesNetAbstract" xlink:to="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/EarningsLossPerShareTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofExchangeRateTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_AverageForeignExchangeRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:href="xtlb-20231231.xsd#xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_SettlementsFairValueMeasurementLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExercisesDuringTheYear" xlink:href="xtlb-20231231.xsd#xtlb_ExercisesDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="xtlb_ExercisesDuringTheYear" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashOnHand" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable">
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:to="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ForeignCurrenciesMember" xlink:href="xtlb-20231231.xsd#xtlb_ForeignCurrenciesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="xtlb_ForeignCurrenciesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IsraeliCpiForwardContractsMember" xlink:href="xtlb-20231231.xsd#xtlb_IsraeliCpiForwardContractsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="xtlb_IsraeliCpiForwardContractsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFinancialInstrumentsTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFinancialInstrumentsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_CurrentMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfFinancialInstrumentsAbstract" xlink:to="xtlb_CurrentMarketableSecurities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable">
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GainsLossesOnFairValueOnMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_GainsLossesOnFairValueOnMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="xtlb_GainsLossesOnFairValueOnMarketableSecurities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GovernmentAuthorities" xlink:href="xtlb-20231231.xsd#xtlb_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="xtlb_GovernmentAuthorities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:href="xtlb-20231231.xsd#xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:href="xtlb-20231231.xsd#xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:to="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_TypeOfCurrencyAxis" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:to="xtlb_TypeOfCurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_TypeOfCurrencyDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="xtlb_TypeOfCurrencyAxis" xlink:to="xtlb_TypeOfCurrencyDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_TypeOfCurrencyDomainDomain_0" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="xtlb_TypeOfCurrencyAxis" xlink:to="xtlb_TypeOfCurrencyDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnitedStatesDollarMember" xlink:href="xtlb-20231231.xsd#xtlb_UnitedStatesDollarMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TypeOfCurrencyDomainDomain" xlink:to="xtlb_UnitedStatesDollarMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IsraeliNewShekelMember" xlink:href="xtlb-20231231.xsd#xtlb_IsraeliNewShekelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TypeOfCurrencyDomainDomain" xlink:to="xtlb_IsraeliNewShekelMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable">
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:to="ifrs-full_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInstrumentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_TypesOfInstrumentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInstrumentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_TypesOfInstrumentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_StockOptionsMember" xlink:href="xtlb-20231231.xsd#xtlb_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInstrumentMember" xlink:to="xtlb_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInstrumentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_TypesOfInstrumentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInstrumentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra6k700T0sfKUwmSs7S9L++IDK0p1gPKHpO5dJ65hhGy9fwjj4/n7KN1SulI4ach77W9Wwz3+E1J9+r5NDv+DmNmsAUzk5MtuyzUCloU3JxeD1/AQx6LR+1dL0GkSZzfKNlWQ16gCepUKiGvC6mXEyCUNC1IRhKJbbVo8P15/+mdT+aHSxd4w05eDD5LmDCTYdsnFU3ts+vIdr01BzpeWSYYf0rGdhqUHY=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_TypesOfInstrumentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RangeOfExercisePricesOneMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="xtlb_RangeOfExercisePricesOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RangeOfExercisePricesTwoMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="xtlb_RangeOfExercisePricesTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RangeOfExercisePricesThreeMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="xtlb_RangeOfExercisePricesThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_StockOptionsMember" xlink:href="xtlb-20231231.xsd#xtlb_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInstrumentMember" xlink:to="xtlb_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofOutstandingOptionsTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_CreationDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_FourDirectorsMember" xlink:href="xtlb-20231231.xsd#xtlb_FourDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="xtlb_FourDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_OneDirectorMember" xlink:href="xtlb-20231231.xsd#xtlb_OneDirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="xtlb_OneDirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ChairmanOfBoardMember" xlink:href="xtlb-20231231.xsd#xtlb_ChairmanOfBoardMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="xtlb_ChairmanOfBoardMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="srt_ChiefExecutiveOfficerMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="srt_DirectorMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandsDateIssuedThreeMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="xtlb_GrandsDateIssuedThreeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandDateIssuedFiveMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandDateIssuedFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="xtlb_GrandDateIssuedFiveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandDateIssuedEightMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandDateIssuedEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="xtlb_GrandDateIssuedEightMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandsDateIssuedElevenMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedElevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="xtlb_GrandsDateIssuedElevenMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandsDateIssuedThirteenMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedThirteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="xtlb_GrandsDateIssuedThirteenMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_BlackScholesMertonOptionsPricingModelMember" xlink:href="xtlb-20231231.xsd#xtlb_BlackScholesMertonOptionsPricingModelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="xtlb_BlackScholesMertonOptionsPricingModelMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_FeesRelatedToServiceProviders" xlink:href="xtlb-20231231.xsd#xtlb_FeesRelatedToServiceProviders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="xtlb_FeesRelatedToServiceProviders" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PatentsAndFees" xlink:href="xtlb-20231231.xsd#xtlb_PatentsAndFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="xtlb_PatentsAndFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TravelExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_TravelExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RentAndOfficeMaintenance" xlink:href="xtlb-20231231.xsd#xtlb_RentAndOfficeMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="xtlb_RentAndOfficeMaintenance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_InsuranceExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ProfessionalFeesExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="xtlb_FinanceExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesRevaluationOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceExpensesAbstract" xlink:to="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceExpensesAbstract" xlink:to="ifrs-full_FeeAndCommissionExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExchangeDifferences" xlink:href="xtlb-20231231.xsd#xtlb_ExchangeDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceExpensesAbstract" xlink:to="xtlb_ExchangeDifferences" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="xtlb_FinanceIncomeAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseADSs" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseADSs"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseADSs" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="xtlb_RevaluationMarketableSecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="xtlb-20231231.xsd#xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeexpensesNet" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeexpensesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="xtlb_FinanceIncomeexpensesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_NumberOfEmployees" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:href="xtlb-20231231.xsd#xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:to="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DateAxis" xlink:href="xtlb-20231231.xsd#xtlb_DateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:to="xtlb_DateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DateDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_DateDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="xtlb_DateAxis" xlink:to="xtlb_DateDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DateDomainDomain_0" xlink:href="xtlb-20231231.xsd#xtlb_DateDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="xtlb_DateAxis" xlink:to="xtlb_DateDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedMarch72021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedMarch72021DueToWarrantExerciseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_IssuedMarch72021DueToWarrantExerciseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedMay42021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedMay42021DueToWarrantExerciseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_IssuedMay42021DueToWarrantExerciseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedJuly62021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedJuly62021DueToWarrantExerciseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_IssuedJuly62021DueToWarrantExerciseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedAugust302021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedAugust302021DueToWarrantExerciseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_IssuedAugust302021DueToWarrantExerciseMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedSeptember12021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedSeptember12021DueToWarrantExerciseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_IssuedSeptember12021DueToWarrantExerciseMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedOctober112021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedOctober112021DueToWarrantExerciseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_IssuedOctober112021DueToWarrantExerciseMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfSharesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:to="xtlb_NumberOfSharesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedOrdinarySharesAtJanuary1" xlink:href="xtlb-20231231.xsd#xtlb_IssuedOrdinarySharesAtJanuary1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NumberOfSharesAbstract" xlink:to="xtlb_IssuedOrdinarySharesAtJanuary1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_Issued" xlink:href="xtlb-20231231.xsd#xtlb_Issued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NumberOfSharesAbstract" xlink:to="xtlb_Issued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesbasic" xlink:href="xtlb-20231231.xsd#xtlb_WeightedAverageNumberOfOrdinarySharesbasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NumberOfSharesAbstract" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesbasic" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantRevaluationIncome" xlink:href="xtlb-20231231.xsd#xtlb_WarrantRevaluationIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="xtlb_WarrantRevaluationIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_comprehensiveIncome" xlink:href="xtlb-20231231.xsd#xtlb_comprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="xtlb_comprehensiveIncome" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable">
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:href="xtlb-20231231.xsd#xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:to="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfSharesMember" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="xtlb_NumberOfSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfSharesAbstract0" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:to="xtlb_NumberOfSharesAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_WeightedaverageNumberOfOrdinarySharesbasic" xlink:href="xtlb-20231231.xsd#xtlb_WeightedaverageNumberOfOrdinarySharesbasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NumberOfSharesAbstract0" xlink:to="xtlb_WeightedaverageNumberOfOrdinarySharesbasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_EffectOfWarrants" xlink:href="xtlb-20231231.xsd#xtlb_EffectOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NumberOfSharesAbstract0" xlink:to="xtlb_EffectOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted" xlink:href="xtlb-20231231.xsd#xtlb_WeightedAverageNumberOfOrdinarySharesdiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NumberOfSharesAbstract0" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="xtlb_GeneralDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_GeneralDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_GeneralDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_GeneralDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PrivatePlacementsMember" xlink:href="xtlb-20231231.xsd#xtlb_PrivatePlacementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="xtlb_PrivatePlacementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedAndOutstandingRate" xlink:href="xtlb-20231231.xsd#xtlb_IssuedAndOutstandingRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_IssuedAndOutstandingRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PaymentOfShareholders" xlink:href="xtlb-20231231.xsd#xtlb_PaymentOfShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_PaymentOfShareholders" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PeriodOfClosingTransaction" xlink:href="xtlb-20231231.xsd#xtlb_PeriodOfClosingTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_PeriodOfClosingTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_InvestorIssued" xlink:href="xtlb-20231231.xsd#xtlb_InvestorIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_InvestorIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PricePerUnit" xlink:href="xtlb-20231231.xsd#xtlb_PricePerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_PricePerUnit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ADSIssued" xlink:href="xtlb-20231231.xsd#xtlb_ADSIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_ADSIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PrivatePlacementWarrantsIssued" xlink:href="xtlb-20231231.xsd#xtlb_PrivatePlacementWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_PrivatePlacementWarrantsIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantExercisedPeriod" xlink:href="xtlb-20231231.xsd#xtlb_WarrantExercisedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_WarrantExercisedPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfFunctionalCurrency" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfFunctionalCurrency"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="xtlb_PercentageOfFunctionalCurrency" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/CashandCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_CashandCashEquivalentsDetailsLineItems" xlink:to="xtlb_CashandCashEquivalentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_CashandCashEquivalentsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositsWithMaturity" xlink:href="xtlb-20231231.xsd#xtlb_DepositsWithMaturity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_CashandCashEquivalentsDetailsLineItems" xlink:to="xtlb_DepositsWithMaturity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_CashandCashEquivalentsDetailsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails">
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:to="xtlb_MarketableSecuritiesInterCureLtdDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfHoldingShare" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfHoldingShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:to="xtlb_PercentageOfHoldingShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="xtlb_IntangibleAssetsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_IntangibleAssetsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AgreementAxis" xlink:href="xtlb-20231231.xsd#xtlb_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_IntangibleAssetsDetailsTable" xlink:to="xtlb_AgreementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AgreementDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="xtlb_AgreementAxis" xlink:to="xtlb_AgreementDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AgreementDomainDomain_0" xlink:href="xtlb-20231231.xsd#xtlb_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="xtlb_AgreementAxis" xlink:to="xtlb_AgreementDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_IntangibleAssetsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_IntangibleAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_YedaMember" xlink:href="xtlb-20231231.xsd#xtlb_YedaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="xtlb_YedaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_LicenseAgreementMember" xlink:href="xtlb-20231231.xsd#xtlb_LicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_AgreementDomainDomain" xlink:to="xtlb_LicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfRoyalties" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_PercentageOfRoyalties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfSublicenseFees" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfSublicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_PercentageOfSublicenseFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_LoansReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ReceiptOfRequiredInvestment" xlink:href="xtlb-20231231.xsd#xtlb_ReceiptOfRequiredInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_ReceiptOfRequiredInvestment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExpirTerm" xlink:href="xtlb-20231231.xsd#xtlb_ExpirTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_ExpirTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromContractsWithCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RemainingLiability" xlink:href="xtlb-20231231.xsd#xtlb_RemainingLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_RemainingLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IntangibleAssetOtherInformationMaturityDate" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetOtherInformationMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_IntangibleAssetOtherInformationMaturityDate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AssetsRemainedAmount" xlink:href="xtlb-20231231.xsd#xtlb_AssetsRemainedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_AssetsRemainedAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_LicenseAgreement" xlink:href="xtlb-20231231.xsd#xtlb_LicenseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_LicenseAgreement" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="xtlb_WarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositaryShareAxis" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_WarrantsDetailsTable" xlink:to="xtlb_DepositaryShareAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositaryShareDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="xtlb_DepositaryShareAxis" xlink:to="xtlb_DepositaryShareDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositaryShareDomainDomain_0" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="xtlb_DepositaryShareAxis" xlink:to="xtlb_DepositaryShareDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_WarrantsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AmericanDepositorySharesMember" xlink:href="xtlb-20231231.xsd#xtlb_AmericanDepositorySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_DepositaryShareDomainDomain" xlink:to="xtlb_AmericanDepositorySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AntidilutiveInstrumentsMember" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrossFundRaised" xlink:href="xtlb-20231231.xsd#xtlb_GrossFundRaised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="xtlb_GrossFundRaised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsIssued" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="xtlb_WarrantsIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DescriptionOfWarrantsExercisable" xlink:href="xtlb-20231231.xsd#xtlb_DescriptionOfWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="xtlb_DescriptionOfWarrantsExercisable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails">
    <loc xlink:type="locator" xlink:label="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:to="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareBasedPaymentDetails">
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NamePlanAxis" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_ShareBasedPaymentDetailsTable" xlink:to="xtlb_NamePlanAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NamePlanDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="xtlb_NamePlanAxis" xlink:to="xtlb_NamePlanDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NamePlanDomainDomain_0" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="xtlb_NamePlanAxis" xlink:to="xtlb_NamePlanDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_TwoThousandElevenPlanMember" xlink:href="xtlb-20231231.xsd#xtlb_TwoThousandElevenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_NamePlanDomainDomain" xlink:to="xtlb_TwoThousandElevenPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_SharebasedPaymentAwardRemainingContractualTerm" xlink:href="xtlb-20231231.xsd#xtlb_SharebasedPaymentAwardRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_SharebasedPaymentAwardRemainingContractualTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_IncreaseOfReserve" xlink:href="xtlb-20231231.xsd#xtlb_IncreaseOfReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_IncreaseOfReserve" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_OptionsReserve" xlink:href="xtlb-20231231.xsd#xtlb_OptionsReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_OptionsReserve" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RemainingNumberOfOptionsAvailableForGrant" xlink:href="xtlb-20231231.xsd#xtlb_RemainingNumberOfOptionsAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_RemainingNumberOfOptionsAvailableForGrant" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_OptionsExercisableIntoOrdinaryShares" xlink:href="xtlb-20231231.xsd#xtlb_OptionsExercisableIntoOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_OptionsExercisableIntoOrdinaryShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_OrdinarySharesExercisePrice" xlink:href="xtlb-20231231.xsd#xtlb_OrdinarySharesExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_OrdinarySharesExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExtendedExpiryTerm" xlink:href="xtlb-20231231.xsd#xtlb_ExtendedExpiryTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_ExtendedExpiryTerm" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfImpairmentOfGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfImpairmentOfGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_TaxEffectOfImpairmentOfGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_DeferredTaxAssetsCapitalLossCarryforward" xlink:href="xtlb-20231231.xsd#xtlb_DeferredTaxAssetsCapitalLossCarryforward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="xtlb_DeferredTaxAssetsCapitalLossCarryforward" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_InterCureLtdMember" xlink:href="xtlb-20231231.xsd#xtlb_InterCureLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="xtlb_InterCureLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_CanndocLtdMember" xlink:href="xtlb-20231231.xsd#xtlb_CanndocLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="xtlb_CanndocLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_OtherFeeAndCommissionExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_AdministrativeFeeExpense" xlink:href="xtlb-20231231.xsd#xtlb_AdministrativeFeeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="xtlb_AdministrativeFeeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfShare" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="xtlb_PercentageOfShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_CurrentMarketableSecuritie" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecuritie"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="xtlb_CurrentMarketableSecuritie" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_RentExpense" xlink:href="xtlb-20231231.xsd#xtlb_RentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="xtlb_RentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/EarningsLossPerShareDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_warrants" xlink:href="xtlb-20231231.xsd#xtlb_warrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="xtlb_warrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_EachWarrantIsExercisableToShares" xlink:href="xtlb-20231231.xsd#xtlb_EachWarrantIsExercisableToShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="xtlb_EachWarrantIsExercisableToShares" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="xtlb_SubsequentEventsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="xtlb_SubsequentEventsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="xtlb_SubsequentEventsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NonAdjustingEventsMember" xlink:href="xtlb-20231231.xsd#xtlb_NonAdjustingEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="xtlb_NonAdjustingEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ADSIssued" xlink:href="xtlb-20231231.xsd#xtlb_ADSIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_ADSIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfOptionsFullyVested" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfOptionsFullyVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_NumberOfOptionsFullyVested" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfOptionsVest" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfOptionsVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_NumberOfOptionsVest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExercisedPeriod" xlink:href="xtlb-20231231.xsd#xtlb_ExercisedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_ExercisedPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_TerminationPeriod" xlink:href="xtlb-20231231.xsd#xtlb_TerminationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_TerminationPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLoanCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLoanCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="ifrs-full_GrossLoanCommitments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="xtlb_LoanInterestRate" xlink:href="xtlb-20231231.xsd#xtlb_LoanInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_LoanInterestRate" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://xtlb.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>xtlb-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 18:16:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total, Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US">Finance income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive income (loss) for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of CashFlows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <loc xlink:type="locator" xlink:label="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:href="xtlb-20231231.xsd#xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows_lbl" xml:lang="en-US">Net income and expenses not involving operating cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Net operating asset and liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GeneralAbstract" xlink:href="xtlb-20231231.xsd#xtlb_GeneralAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GeneralAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GeneralAbstract" xlink:to="xtlb_GeneralAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Basis of Preparation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeRatesAbstract_lbl" xml:lang="en-US">Schedule of Exchange Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_ForeignExchangeRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MaterialAccountingPoliciesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MaterialAccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MaterialAccountingPoliciesAbstract_lbl" xml:lang="en-US">Material Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MaterialAccountingPoliciesAbstract" xlink:to="xtlb_MaterialAccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments and Financial Risk Management [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="xtlb_ScheduleOfCashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MarketableSecuritiesInterCureLtdAbstract_lbl" xml:lang="en-US">Marketable Securities &#8211; InterCure Ltd [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdAbstract" xlink:to="xtlb_MarketableSecuritiesInterCureLtdAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFinancialInstrumentsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Schedule of Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfFinancialInstrumentsAbstract" xlink:to="xtlb_ScheduleOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_FinancialAssetsAvailableforsale_lbl" xml:lang="en-US">Fair value opening balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAvailableforsale" xlink:to="ifrs-full_FinancialAssetsAvailableforsale_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_FinancialAssetsAvailableforsale_lbl0" xml:lang="en-US">Fair value closing balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAvailableforsale" xlink:to="ifrs-full_FinancialAssetsAvailableforsale_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaymentsAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Othe Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAbstract" xlink:to="ifrs-full_CurrentPrepaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Composition of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of Composition of Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="xtlb_ScheduleOfCompositionOfAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Total accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_TypeOfCurrencyAxis" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_TypeOfCurrencyAxis_lbl" xml:lang="en-US">Type Of Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TypeOfCurrencyAxis" xlink:to="xtlb_TypeOfCurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfWarrantsAbstract_lbl" xml:lang="en-US">Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfWarrantsAbstract" xlink:to="xtlb_DisclosureOfWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US">Share Capital, Reserves and Accumulated Deficit [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentAbstract_lbl" xml:lang="en-US">Share-Based Payment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentAbstract" xlink:to="xtlb_ShareBasedPaymentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Number of options, outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Number of options, outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Options outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl2" xml:lang="en-US">Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price, outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_lbl" xml:lang="en-US">Continuing involvement in derecognised financial assets by type of instrument [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ResearchAndDevelopmentExpensesAbstract" xlink:to="xtlb_ResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Schedule of Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNatureAbstract_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseByNatureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FinanceIncomeExpensesNetAbstract_lbl" xml:lang="en-US">Finance Income (Expenses), Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceIncomeExpensesNetAbstract" xlink:to="xtlb_FinanceIncomeExpensesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract_lbl" xml:lang="en-US">Schedule of Finance Income (Expenses), Net [Abstarct]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Total finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Total finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeexpensesNet" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeexpensesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xtlb_FinanceIncomeexpensesNet_lbl" xml:lang="en-US">Finance income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceIncomeexpensesNet" xlink:to="xtlb_FinanceIncomeexpensesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract_lbl" xml:lang="en-US">Schedule of Compensation to Key Management Personnel For Employee Services [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract_lbl" xml:lang="en-US">Schedule of Profit Loss Attributed to Ordinary Shareholders Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" xlink:to="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DateAxis" xlink:href="xtlb-20231231.xsd#xtlb_DateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DateAxis_lbl" xml:lang="en-US">Date Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DateAxis" xlink:to="xtlb_DateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract_lbl" xml:lang="en-US">Schedule of Profit Loss Attributed to Ordinary Shareholders Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelFaxNumber_lbl" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract" xlink:to="xtlb_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CurrentMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_CurrentMarketableSecurities_lbl" xml:lang="en-US">Marketable securities &#8211; InterCure Ltd.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecurities" xlink:to="xtlb_CurrentMarketableSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xtlb_CurrentMarketableSecurities_lbl0" xml:lang="en-US">Marketable securities - InterCure Ltd</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecurities" xlink:to="xtlb_CurrentMarketableSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract0" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract0" xlink:to="xtlb_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract1" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract1" xlink:to="xtlb_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract2" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract2" xlink:to="xtlb_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract3" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract3" xlink:to="xtlb_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract4" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract4" xlink:to="xtlb_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract5" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract5" xlink:to="xtlb_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract6" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract6" xlink:to="xtlb_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Share capital - ordinary shares of NIS 0.1 par value: Authorized - December 31, 2023 and 2022 - 1,450,000,000; Issued and outstanding - December 31, 2023 and 2022 - 544,906,149.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Ordinary shares, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Ordinary shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">ADS&apos;s issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalPaidinCapital_lbl" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapital" xlink:to="ifrs-full_AdditionalPaidinCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Reserve from transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract7" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract7" xlink:to="xtlb_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract8" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract8" xlink:to="xtlb_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract9" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract9" xlink:to="xtlb_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract10" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract10" xlink:to="xtlb_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseAds" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseAds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseAds_lbl" xml:lang="en-US">Revaluation of warrants to purchase ADS&apos;s</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchaseAds" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseAds_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RevaluationOfMarketableSecurities_lbl" xml:lang="en-US">Revaluation of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfMarketableSecurities" xlink:to="xtlb_RevaluationOfMarketableSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xtlb_RevaluationOfMarketableSecurities_lbl0" xml:lang="en-US">Revaluation of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfMarketableSecurities" xlink:to="xtlb_RevaluationOfMarketableSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinanceIncome_lbl" xml:lang="en-US">Other finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract11" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract11" xlink:to="xtlb_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract12" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract12" xlink:to="xtlb_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract13" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract13" xlink:to="xtlb_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic earnings (loss) per share (in U.S. dollars): (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per share (in U.S. dollars): (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract14" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract14" xlink:to="xtlb_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of issued ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Diluted weighted average number of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract15" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract15" xlink:to="xtlb_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Income (loss) for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract16" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract16" xlink:to="xtlb_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract17" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract17" xlink:to="xtlb_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract18" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract18" xlink:to="xtlb_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract19" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract19" xlink:to="xtlb_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract20" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract20" xlink:to="xtlb_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract21" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract21" xlink:to="xtlb_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract22" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract22" xlink:to="xtlb_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Exercise of warrants to ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract23" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract23" xlink:to="xtlb_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract24" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract24" xlink:to="xtlb_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract25" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract25" xlink:to="xtlb_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:href="xtlb-20231231.xsd#xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities (a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:to="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract26" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract26" xlink:to="xtlb_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract27" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract27" xlink:to="xtlb_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract28" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract28" xlink:to="xtlb_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Interest from bank deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract29" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract29" xlink:to="xtlb_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract30" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract30" xlink:to="xtlb_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract31" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract31" xlink:to="xtlb_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract32" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract32" xlink:to="xtlb_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract33" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract33" xlink:to="xtlb_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Losses from exchange rate differences on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract34" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract34" xlink:to="xtlb_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">(a) Adjustments to reconcile net income (loss) to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract35" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract35" xlink:to="xtlb_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract_lbl" xml:lang="en-US">Income and expenses not involving operating cash flows:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract36" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract36" xlink:to="xtlb_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US">Losses from exchange rate differences on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract37" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract37" xlink:to="xtlb_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract_lbl" xml:lang="en-US">Changes in operating asset and liability items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract38" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract38" xlink:to="xtlb_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xml:lang="en-US">Decrease (increase) in prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract39" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract39" xlink:to="xtlb_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract40" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract40" xlink:to="xtlb_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract41" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract41" xlink:to="xtlb_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NoncashActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_NoncashActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NoncashActivitiesAbstract_lbl" xml:lang="en-US">(b) Non-cash activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NoncashActivitiesAbstract" xlink:to="xtlb_NoncashActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract42" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract42" xlink:to="xtlb_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherFinanceCost_lbl" xml:lang="en-US">Other finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceCost" xlink:to="ifrs-full_OtherFinanceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchase" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xtlb_RevaluationOfWarrantsToPurchase_lbl" xml:lang="en-US">Revaluation of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchase" xlink:to="xtlb_RevaluationOfWarrantsToPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalPaidinCapitalMember_lbl" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapitalMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US">Reserve from transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">BASIS OF PREPARATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xml:lang="en-US">Schedule of Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US">Exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US">MATERIAL ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash in banks and on hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Bank deposits with original maturities of three months or less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract43" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract43" xlink:to="xtlb_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents are Denominated or Linked</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract44" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract44" xlink:to="xtlb_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_MarketableSecuritiesInterCureLtdTextBlock_lbl" xml:lang="en-US">MARKETABLE SECURITIES &#8211; InterCure Ltd</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdTextBlock" xlink:to="xtlb_MarketableSecuritiesInterCureLtdTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GainsLossesOnFairValueOnMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_GainsLossesOnFairValueOnMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GainsLossesOnFairValueOnMarketableSecurities_lbl" xml:lang="en-US">Changes in fair value during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GainsLossesOnFairValueOnMarketableSecurities" xlink:to="xtlb_GainsLossesOnFairValueOnMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract45" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract45" xlink:to="xtlb_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHE CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Composition of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US">Prepaid expenses and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GovernmentAuthorities" xlink:href="xtlb-20231231.xsd#xtlb_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GovernmentAuthorities" xlink:to="xtlb_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract46" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract46" xlink:to="xtlb_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock_lbl" xml:lang="en-US">Schedule of Composition of Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock" xlink:to="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract47" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract47" xlink:to="xtlb_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock_lbl" xml:lang="en-US">Schedule of Carrying Amount of Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" xlink:to="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract48" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract48" xlink:to="xtlb_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfWarrantsTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfWarrantsTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfWarrantsTextBlock" xlink:to="xtlb_DisclosureOfWarrantsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xml:lang="en-US">Schedule of Assumptions of Investors&apos; Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk-free interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Contractual term life (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareCapitalReservesAndRetainedEarnings" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesAndRetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ShareCapitalReservesAndRetainedEarnings_lbl" xml:lang="en-US">SHARE CAPITAL, RESERVES AND ACCUMULATED DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareCapitalReservesAndRetainedEarnings" xlink:to="xtlb_ShareCapitalReservesAndRetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE-BASED PAYMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract49" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract49" xlink:to="xtlb_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract50" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract50" xlink:to="xtlb_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Range of exercise prices (USD)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract51" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract51" xlink:to="xtlb_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract52" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract52" xlink:to="xtlb_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition_lbl" xml:lang="en-US">Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl" xml:lang="en-US">Grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice_lbl" xml:lang="en-US">Exercise price in NIS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl" xml:lang="en-US">Fair value USD in thousands</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xml:lang="en-US">Vesting schedule</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract53" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract53" xlink:to="xtlb_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value for Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock" xlink:to="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FeesRelatedToServiceProviders" xlink:href="xtlb-20231231.xsd#xtlb_FeesRelatedToServiceProviders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_FeesRelatedToServiceProviders_lbl" xml:lang="en-US">Fees related to service providers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FeesRelatedToServiceProviders" xlink:to="xtlb_FeesRelatedToServiceProviders_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US">Management fees and expenses relating to service providers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US">Share based payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PatentsAndFees" xlink:href="xtlb-20231231.xsd#xtlb_PatentsAndFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PatentsAndFees_lbl" xml:lang="en-US">Patents and fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PatentsAndFees" xlink:to="xtlb_PatentsAndFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl" xml:lang="en-US">Directors&#8217; fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TravelExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US">Investor relations and travel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RentAndOfficeMaintenance" xlink:href="xtlb-20231231.xsd#xtlb_RentAndOfficeMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RentAndOfficeMaintenance_lbl" xml:lang="en-US">Rent and office maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RentAndOfficeMaintenance" xlink:to="xtlb_RentAndOfficeMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US">Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US">Professional services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract54" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract54" xlink:to="xtlb_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">FINANCE INCOME (EXPENSES), NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Finance Income (Expenses), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" xlink:to="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_FinanceExpensesAbstract_lbl" xml:lang="en-US">Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceExpensesAbstract" xlink:to="xtlb_FinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesRevaluationOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_FinanceExpensesRevaluationOfMarketableSecurities_lbl" xml:lang="en-US">Revaluation of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" xlink:to="xtlb_FinanceExpensesRevaluationOfMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract55" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract55" xlink:to="xtlb_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract56" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract56" xlink:to="xtlb_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinanceIncomeAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_FinanceIncomeAbstract_lbl" xml:lang="en-US">Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="xtlb_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseADSs" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseADSs"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseADSs_lbl" xml:lang="en-US">Revaluation of warrants to purchase ADS&apos;s</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchaseADSs" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseADSs_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RevaluationMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RevaluationMarketableSecurities_lbl" xml:lang="en-US">Revaluation of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationMarketableSecurities" xlink:to="xtlb_RevaluationMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl" xml:lang="en-US">Interest income on bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="xtlb-20231231.xsd#xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax_lbl" xml:lang="en-US">Exchange rate differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract57" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract57" xlink:to="xtlb_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract58" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract58" xlink:to="xtlb_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl" xml:lang="en-US">Schedule of Compensation to Key Management Personnel for Employee Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US">Management fees, directors, and consulting fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract59" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract59" xlink:to="xtlb_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract60" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract60" xlink:to="xtlb_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US">Number of persons</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Total comprehensive income (loss) for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Weighted-Average Number of Ordinary Shares (Basic)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfSharesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfSharesAbstract" xlink:to="xtlb_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedOrdinarySharesAtJanuary1" xlink:href="xtlb-20231231.xsd#xtlb_IssuedOrdinarySharesAtJanuary1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedOrdinarySharesAtJanuary1_lbl" xml:lang="en-US">Issued ordinary shares at January 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedOrdinarySharesAtJanuary1" xlink:to="xtlb_IssuedOrdinarySharesAtJanuary1_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_Issued" xlink:href="xtlb-20231231.xsd#xtlb_Issued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_Issued_lbl" xml:lang="en-US">Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_Issued" xlink:to="xtlb_Issued_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract61" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract61" xlink:to="xtlb_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesbasic" xlink:href="xtlb-20231231.xsd#xtlb_WeightedAverageNumberOfOrdinarySharesbasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesbasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares (basic)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedAverageNumberOfOrdinarySharesbasic" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesbasic_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock_lbl" xml:lang="en-US">Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" xlink:to="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax_lbl" xml:lang="en-US">Total comprehensive income (loss) for the year (basic)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantRevaluationIncome" xlink:href="xtlb-20231231.xsd#xtlb_WarrantRevaluationIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_WarrantRevaluationIncome_lbl" xml:lang="en-US">Warrant revaluation income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantRevaluationIncome" xlink:to="xtlb_WarrantRevaluationIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_comprehensiveIncome" xlink:href="xtlb-20231231.xsd#xtlb_comprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_comprehensiveIncome_lbl" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_comprehensiveIncome" xlink:to="xtlb_comprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock_lbl" xml:lang="en-US">Schedule of Weighted-Average Number of Ordinary Shares (Diluted)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" xlink:to="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfSharesAbstract0" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfSharesAbstract0_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfSharesAbstract0" xlink:to="xtlb_NumberOfSharesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WeightedaverageNumberOfOrdinarySharesbasic" xlink:href="xtlb-20231231.xsd#xtlb_WeightedaverageNumberOfOrdinarySharesbasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_WeightedaverageNumberOfOrdinarySharesbasic_lbl" xml:lang="en-US">Weighted-average number of ordinary shares (basic)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedaverageNumberOfOrdinarySharesbasic" xlink:to="xtlb_WeightedaverageNumberOfOrdinarySharesbasic_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_EffectOfWarrants" xlink:href="xtlb-20231231.xsd#xtlb_EffectOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_EffectOfWarrants_lbl" xml:lang="en-US">Effect of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EffectOfWarrants" xlink:to="xtlb_EffectOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnlabeledAbstract62" xlink:href="xtlb-20231231.xsd#xtlb_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract62" xlink:to="xtlb_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted" xlink:href="xtlb-20231231.xsd#xtlb_WeightedAverageNumberOfOrdinarySharesdiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted_lbl" xml:lang="en-US">Weighted average number of ordinary shares (diluted)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SettlementsFairValueMeasurementLiabilities_lbl" xml:lang="en-US">Revaluation during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:to="ifrs-full_SettlementsFairValueMeasurementLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExercisesDuringTheYear" xlink:href="xtlb-20231231.xsd#xtlb_ExercisesDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xtlb_ExercisesDuringTheYear_lbl" xml:lang="en-US">Exercises during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExercisesDuringTheYear" xlink:to="xtlb_ExercisesDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Bank account management fees and commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExchangeDifferences" xlink:href="xtlb-20231231.xsd#xtlb_ExchangeDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xtlb_ExchangeDifferences_lbl" xml:lang="en-US">Exchange rate differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExchangeDifferences" xlink:to="xtlb_ExchangeDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ForeignCurrenciesMember" xlink:href="xtlb-20231231.xsd#xtlb_ForeignCurrenciesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ForeignCurrenciesMember_lbl" xml:lang="en-US">U.S. dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ForeignCurrenciesMember" xlink:to="xtlb_ForeignCurrenciesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IsraeliCpiForwardContractsMember" xlink:href="xtlb-20231231.xsd#xtlb_IsraeliCpiForwardContractsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IsraeliCpiForwardContractsMember_lbl" xml:lang="en-US">NIS (not linked to the Israeli CPI) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IsraeliCpiForwardContractsMember" xlink:to="xtlb_IsraeliCpiForwardContractsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_UnitedStatesDollarMember" xlink:href="xtlb-20231231.xsd#xtlb_UnitedStatesDollarMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_UnitedStatesDollarMember_lbl" xml:lang="en-US">U.S. dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnitedStatesDollarMember" xlink:to="xtlb_UnitedStatesDollarMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IsraeliNewShekelMember" xlink:href="xtlb-20231231.xsd#xtlb_IsraeliNewShekelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IsraeliNewShekelMember_lbl" xml:lang="en-US">NIS (not linked to the Israeli CPI) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IsraeliNewShekelMember" xlink:to="xtlb_IsraeliNewShekelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_StockOptionsMember" xlink:href="xtlb-20231231.xsd#xtlb_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_StockOptionsMember" xlink:to="xtlb_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RangeOfExercisePricesOneMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RangeOfExercisePricesOneMember_lbl" xml:lang="en-US">Range of Exercise Prices One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RangeOfExercisePricesOneMember" xlink:to="xtlb_RangeOfExercisePricesOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RangeOfExercisePricesTwoMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RangeOfExercisePricesTwoMember_lbl" xml:lang="en-US">Range of Exercise Prices Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RangeOfExercisePricesTwoMember" xlink:to="xtlb_RangeOfExercisePricesTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RangeOfExercisePricesThreeMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RangeOfExercisePricesThreeMember_lbl" xml:lang="en-US">Range of Exercise Prices Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RangeOfExercisePricesThreeMember" xlink:to="xtlb_RangeOfExercisePricesThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FourDirectorsMember" xlink:href="xtlb-20231231.xsd#xtlb_FourDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_FourDirectorsMember_lbl" xml:lang="en-US">Four Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FourDirectorsMember" xlink:to="xtlb_FourDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandsDateIssuedThreeMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GrandsDateIssuedThreeMember_lbl" xml:lang="en-US">December 30, 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedThreeMember" xlink:to="xtlb_GrandsDateIssuedThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_OneDirectorMember" xlink:href="xtlb-20231231.xsd#xtlb_OneDirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_OneDirectorMember_lbl" xml:lang="en-US">One Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OneDirectorMember" xlink:to="xtlb_OneDirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandDateIssuedFiveMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandDateIssuedFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GrandDateIssuedFiveMember_lbl" xml:lang="en-US">March 25, 2015 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandDateIssuedFiveMember" xlink:to="xtlb_GrandDateIssuedFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ChairmanOfBoardMember" xlink:href="xtlb-20231231.xsd#xtlb_ChairmanOfBoardMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ChairmanOfBoardMember_lbl" xml:lang="en-US">Chairman of Board [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ChairmanOfBoardMember" xlink:to="xtlb_ChairmanOfBoardMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandDateIssuedEightMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandDateIssuedEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GrandDateIssuedEightMember_lbl" xml:lang="en-US">March 31, 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandDateIssuedEightMember" xlink:to="xtlb_GrandDateIssuedEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandsDateIssuedElevenMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedElevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GrandsDateIssuedElevenMember_lbl" xml:lang="en-US">July 7, 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedElevenMember" xlink:to="xtlb_GrandsDateIssuedElevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrandsDateIssuedThirteenMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GrandsDateIssuedThirteenMember_lbl" xml:lang="en-US">March 2, 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedThirteenMember" xlink:to="xtlb_GrandsDateIssuedThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_BlackScholesMertonOptionsPricingModelMember" xlink:href="xtlb-20231231.xsd#xtlb_BlackScholesMertonOptionsPricingModelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_BlackScholesMertonOptionsPricingModelMember_lbl" xml:lang="en-US">Black-Scholes-Merton Options pricing model [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_BlackScholesMertonOptionsPricingModelMember" xlink:to="xtlb_BlackScholesMertonOptionsPricingModelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedMarch72021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedMarch72021DueToWarrantExerciseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedMarch72021DueToWarrantExerciseMember_lbl" xml:lang="en-US">Issued March 7,2021 due to warrant exercise [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedMarch72021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedMarch72021DueToWarrantExerciseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedMay42021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedMay42021DueToWarrantExerciseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedMay42021DueToWarrantExerciseMember_lbl" xml:lang="en-US">Issued May 4, 2021 due to warrant exercise [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedMay42021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedMay42021DueToWarrantExerciseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedJuly62021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedJuly62021DueToWarrantExerciseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedJuly62021DueToWarrantExerciseMember_lbl" xml:lang="en-US">Issued July 6, 2021 due to warrant exercise [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedJuly62021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedJuly62021DueToWarrantExerciseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedAugust302021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedAugust302021DueToWarrantExerciseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedAugust302021DueToWarrantExerciseMember_lbl" xml:lang="en-US">Issued August 30, 2021 due to warrant exercise [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedAugust302021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedAugust302021DueToWarrantExerciseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedSeptember12021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedSeptember12021DueToWarrantExerciseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedSeptember12021DueToWarrantExerciseMember_lbl" xml:lang="en-US">Issued September 1, 2021 due to warrant exercise [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedSeptember12021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedSeptember12021DueToWarrantExerciseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedOctober112021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedOctober112021DueToWarrantExerciseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedOctober112021DueToWarrantExerciseMember_lbl" xml:lang="en-US">Issued October 11, 2021 due to warrant exercise [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedOctober112021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedOctober112021DueToWarrantExerciseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfSharesMember" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfSharesMember_lbl" xml:lang="en-US">Number of shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfSharesMember" xlink:to="xtlb_NumberOfSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AgreementAxis" xlink:href="xtlb-20231231.xsd#xtlb_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AgreementAxis" xlink:to="xtlb_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositaryShareAxis" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DepositaryShareAxis_lbl" xml:lang="en-US">Depositary Share [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DepositaryShareAxis" xlink:to="xtlb_DepositaryShareAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NamePlanAxis" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NamePlanAxis_lbl" xml:lang="en-US">Name Plan [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NamePlanAxis" xlink:to="xtlb_NamePlanAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IssuedAndOutstandingRate" xlink:href="xtlb-20231231.xsd#xtlb_IssuedAndOutstandingRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IssuedAndOutstandingRate_lbl" xml:lang="en-US">Issued and outstanding, rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedAndOutstandingRate" xlink:to="xtlb_IssuedAndOutstandingRate_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PaymentOfShareholders" xlink:href="xtlb-20231231.xsd#xtlb_PaymentOfShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PaymentOfShareholders_lbl" xml:lang="en-US">Payment to shareholders (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PaymentOfShareholders" xlink:to="xtlb_PaymentOfShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PeriodOfClosingTransaction" xlink:href="xtlb-20231231.xsd#xtlb_PeriodOfClosingTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PeriodOfClosingTransaction_lbl" xml:lang="en-US">Closing period of transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PeriodOfClosingTransaction" xlink:to="xtlb_PeriodOfClosingTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentIncome_lbl" xml:lang="en-US">Investment commitment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InvestmentIncome_lbl0" xml:lang="en-US">Receipt of investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_InvestmentIncome_lbl1" xml:lang="en-US">Investment amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl1"/>
    <loc xlink:type="locator" xlink:label="xtlb_InvestorIssued" xlink:href="xtlb-20231231.xsd#xtlb_InvestorIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_InvestorIssued_lbl" xml:lang="en-US">Investor issued (units)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_InvestorIssued" xlink:to="xtlb_InvestorIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PricePerUnit" xlink:href="xtlb-20231231.xsd#xtlb_PricePerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PricePerUnit_lbl" xml:lang="en-US">Price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PricePerUnit" xlink:to="xtlb_PricePerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ADSIssued" xlink:href="xtlb-20231231.xsd#xtlb_ADSIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ADSIssued_lbl" xml:lang="en-US">ADS issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ADSIssued" xlink:to="xtlb_ADSIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xtlb_ADSIssued_lbl0" xml:lang="en-US">ADS share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ADSIssued" xlink:to="xtlb_ADSIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_PrivatePlacementWarrantsIssued" xlink:href="xtlb-20231231.xsd#xtlb_PrivatePlacementWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PrivatePlacementWarrantsIssued_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PrivatePlacementWarrantsIssued" xlink:to="xtlb_PrivatePlacementWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantExercisedPeriod" xlink:href="xtlb-20231231.xsd#xtlb_WarrantExercisedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_WarrantExercisedPeriod_lbl" xml:lang="en-US">Warrant exercised period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantExercisedPeriod" xlink:to="xtlb_WarrantExercisedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfFunctionalCurrency" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfFunctionalCurrency"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PercentageOfFunctionalCurrency_lbl" xml:lang="en-US">Percentage of functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfFunctionalCurrency" xlink:to="xtlb_PercentageOfFunctionalCurrency_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Profit (loss) on exchange rate changes in translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositsWithMaturity" xlink:href="xtlb-20231231.xsd#xtlb_DepositsWithMaturity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DepositsWithMaturity_lbl" xml:lang="en-US">Maturity period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DepositsWithMaturity" xlink:to="xtlb_DepositsWithMaturity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfHoldingShare" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfHoldingShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PercentageOfHoldingShare_lbl" xml:lang="en-US">Percentage of shares hold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfHoldingShare" xlink:to="xtlb_PercentageOfHoldingShare_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfRoyalties" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PercentageOfRoyalties_lbl" xml:lang="en-US">Percentage of royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfRoyalties" xlink:to="xtlb_PercentageOfRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfSublicenseFees" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfSublicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PercentageOfSublicenseFees_lbl" xml:lang="en-US">Percentage of sublicense fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfSublicenseFees" xlink:to="xtlb_PercentageOfSublicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US">Received amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ReceiptOfRequiredInvestment" xlink:href="xtlb-20231231.xsd#xtlb_ReceiptOfRequiredInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ReceiptOfRequiredInvestment_lbl" xml:lang="en-US">Receipt of required investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ReceiptOfRequiredInvestment" xlink:to="xtlb_ReceiptOfRequiredInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExpirTerm" xlink:href="xtlb-20231231.xsd#xtlb_ExpirTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ExpirTerm_lbl" xml:lang="en-US">Expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExpirTerm" xlink:to="xtlb_ExpirTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromContractsWithCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xml:lang="en-US">Required payment of liquidated damages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromContractsWithCustomers" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RemainingLiability" xlink:href="xtlb-20231231.xsd#xtlb_RemainingLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RemainingLiability_lbl" xml:lang="en-US">Remaining liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RemainingLiability" xlink:to="xtlb_RemainingLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IntangibleAssetOtherInformationMaturityDate" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetOtherInformationMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IntangibleAssetOtherInformationMaturityDate_lbl" xml:lang="en-US">Expires term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IntangibleAssetOtherInformationMaturityDate" xlink:to="xtlb_IntangibleAssetOtherInformationMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AssetsRemainedAmount" xlink:href="xtlb-20231231.xsd#xtlb_AssetsRemainedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_AssetsRemainedAmount_lbl" xml:lang="en-US">Assets remained amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AssetsRemainedAmount" xlink:to="xtlb_AssetsRemainedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_LicenseAgreement" xlink:href="xtlb-20231231.xsd#xtlb_LicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_LicenseAgreement_lbl" xml:lang="en-US">License agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LicenseAgreement" xlink:to="xtlb_LicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GrossFundRaised" xlink:href="xtlb-20231231.xsd#xtlb_GrossFundRaised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_GrossFundRaised_lbl" xml:lang="en-US">Gross funds raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrossFundRaised" xlink:to="xtlb_GrossFundRaised_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsIssued" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_WarrantsIssued_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantsIssued" xlink:to="xtlb_WarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DescriptionOfWarrantsExercisable" xlink:href="xtlb-20231231.xsd#xtlb_DescriptionOfWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DescriptionOfWarrantsExercisable_lbl" xml:lang="en-US">Description of warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DescriptionOfWarrantsExercisable" xlink:to="xtlb_DescriptionOfWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" xlink:to="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_SharebasedPaymentAwardRemainingContractualTerm" xlink:href="xtlb-20231231.xsd#xtlb_SharebasedPaymentAwardRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_SharebasedPaymentAwardRemainingContractualTerm_lbl" xml:lang="en-US">Share based payment award remaining contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_SharebasedPaymentAwardRemainingContractualTerm" xlink:to="xtlb_SharebasedPaymentAwardRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of share holding of up</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement" xlink:to="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IncreaseOfReserve" xlink:href="xtlb-20231231.xsd#xtlb_IncreaseOfReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_IncreaseOfReserve_lbl" xml:lang="en-US">Increase of reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IncreaseOfReserve" xlink:to="xtlb_IncreaseOfReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_OptionsReserve" xlink:href="xtlb-20231231.xsd#xtlb_OptionsReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_OptionsReserve_lbl" xml:lang="en-US">Total options reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OptionsReserve" xlink:to="xtlb_OptionsReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RemainingNumberOfOptionsAvailableForGrant" xlink:href="xtlb-20231231.xsd#xtlb_RemainingNumberOfOptionsAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RemainingNumberOfOptionsAvailableForGrant_lbl" xml:lang="en-US">Remaining number of options available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RemainingNumberOfOptionsAvailableForGrant" xlink:to="xtlb_RemainingNumberOfOptionsAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_OptionsExercisableIntoOrdinaryShares" xlink:href="xtlb-20231231.xsd#xtlb_OptionsExercisableIntoOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_OptionsExercisableIntoOrdinaryShares_lbl" xml:lang="en-US">Options exercisable into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OptionsExercisableIntoOrdinaryShares" xlink:to="xtlb_OptionsExercisableIntoOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_OrdinarySharesExercisePrice" xlink:href="xtlb-20231231.xsd#xtlb_OrdinarySharesExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_OrdinarySharesExercisePrice_lbl" xml:lang="en-US">Ordinary shares exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OrdinarySharesExercisePrice" xlink:to="xtlb_OrdinarySharesExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExtendedExpiryTerm" xlink:href="xtlb-20231231.xsd#xtlb_ExtendedExpiryTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ExtendedExpiryTerm_lbl" xml:lang="en-US">Extended expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExtendedExpiryTerm" xlink:to="xtlb_ExtendedExpiryTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees_lbl" xml:lang="en-US">Share based expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" xlink:to="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfImpairmentOfGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfImpairmentOfGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxEffectOfImpairmentOfGoodwill_lbl" xml:lang="en-US">Carryforward tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfImpairmentOfGoodwill" xlink:to="ifrs-full_TaxEffectOfImpairmentOfGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DeferredTaxAssetsCapitalLossCarryforward" xlink:href="xtlb-20231231.xsd#xtlb_DeferredTaxAssetsCapitalLossCarryforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_DeferredTaxAssetsCapitalLossCarryforward_lbl" xml:lang="en-US">Capital loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DeferredTaxAssetsCapitalLossCarryforward" xlink:to="xtlb_DeferredTaxAssetsCapitalLossCarryforward_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xml:lang="en-US">Tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xml:lang="en-US">Deferred tax liability</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra6k700T0sfKUwmSs7S9L++IDK0p1gPKHpO5dJ65hhGy9fwjj4/n7KN1SulI4ach77W9Wwz3+E1J9+r5NDv+DmNmsAUzk5MtuyzUCloU3JxeD1/AQx6LR+1dL0GkSZzfKNlWQ16gCepUKiGvC6mXEyCUNC1IRhKJbbVo8P15/+mdT+aHSxd4w05eDD5LmDCTYdsnFU3ts+vIRjaJw0VaJ2B1VchWvEnUqPQw5EXNXZJMA==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl" xml:lang="en-US">Monthly fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AdministrativeFeeExpense" xlink:href="xtlb-20231231.xsd#xtlb_AdministrativeFeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_AdministrativeFeeExpense_lbl" xml:lang="en-US">Total fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AdministrativeFeeExpense" xlink:to="xtlb_AdministrativeFeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl" xml:lang="en-US">Balance of key management personnel &amp; accounting firm, total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PercentageOfShare" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PercentageOfShare_lbl" xml:lang="en-US">Percentage of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfShare" xlink:to="xtlb_PercentageOfShare_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CurrentMarketableSecuritie" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecuritie"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_CurrentMarketableSecuritie_lbl" xml:lang="en-US">Balances of shares total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecuritie" xlink:to="xtlb_CurrentMarketableSecuritie_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_RentExpense" xlink:href="xtlb-20231231.xsd#xtlb_RentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_RentExpense_lbl" xml:lang="en-US">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RentExpense" xlink:to="xtlb_RentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Balance due from Canndoc Ltd</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US">Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_warrants" xlink:href="xtlb-20231231.xsd#xtlb_warrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_warrants_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_warrants" xlink:to="xtlb_warrants_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_EachWarrantIsExercisableToShares" xlink:href="xtlb-20231231.xsd#xtlb_EachWarrantIsExercisableToShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_EachWarrantIsExercisableToShares_lbl" xml:lang="en-US">Each warrant is exercisable to shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EachWarrantIsExercisableToShares" xlink:to="xtlb_EachWarrantIsExercisableToShares_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options exercisable shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement" xlink:to="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Shareholders meeting shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfOptionsFullyVested" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfOptionsFullyVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfOptionsFullyVested_lbl" xml:lang="en-US">Options fully vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfOptionsFullyVested" xlink:to="xtlb_NumberOfOptionsFullyVested_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NumberOfOptionsVest" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfOptionsVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NumberOfOptionsVest_lbl" xml:lang="en-US">Options vest for share option plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfOptionsVest" xlink:to="xtlb_NumberOfOptionsVest_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ExercisedPeriod" xlink:href="xtlb-20231231.xsd#xtlb_ExercisedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_ExercisedPeriod_lbl" xml:lang="en-US">Option exercise period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExercisedPeriod" xlink:to="xtlb_ExercisedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_TerminationPeriod" xlink:href="xtlb-20231231.xsd#xtlb_TerminationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_TerminationPeriod_lbl" xml:lang="en-US">Updated options exercise period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TerminationPeriod" xlink:to="xtlb_TerminationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLoanCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLoanCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossLoanCommitments_lbl" xml:lang="en-US">Loan value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLoanCommitments" xlink:to="ifrs-full_GrossLoanCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_LoanInterestRate" xlink:href="xtlb-20231231.xsd#xtlb_LoanInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_LoanInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LoanInterestRate" xlink:to="xtlb_LoanInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_lbl" xml:lang="en-US">Investments and other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earning (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_PrivatePlacementsMember" xlink:href="xtlb-20231231.xsd#xtlb_PrivatePlacementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_PrivatePlacementsMember_lbl" xml:lang="en-US">Private Placement [Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PrivatePlacementsMember" xlink:to="xtlb_PrivatePlacementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_LicenseAgreementMember" xlink:href="xtlb-20231231.xsd#xtlb_LicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LicenseAgreementMember" xlink:to="xtlb_LicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_YedaMember" xlink:href="xtlb-20231231.xsd#xtlb_YedaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_YedaMember_lbl" xml:lang="en-US">Yeda [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_YedaMember" xlink:to="xtlb_YedaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AmericanDepositorySharesMember" xlink:href="xtlb-20231231.xsd#xtlb_AmericanDepositorySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_AmericanDepositorySharesMember_lbl" xml:lang="en-US">American Depository Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AmericanDepositorySharesMember" xlink:to="xtlb_AmericanDepositorySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_TwoThousandElevenPlanMember" xlink:href="xtlb-20231231.xsd#xtlb_TwoThousandElevenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_TwoThousandElevenPlanMember_lbl" xml:lang="en-US">2011 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TwoThousandElevenPlanMember" xlink:to="xtlb_TwoThousandElevenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_InterCureLtdMember" xlink:href="xtlb-20231231.xsd#xtlb_InterCureLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_InterCureLtdMember_lbl" xml:lang="en-US">InterCure Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_InterCureLtdMember" xlink:to="xtlb_InterCureLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CanndocLtdMember" xlink:href="xtlb-20231231.xsd#xtlb_CanndocLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_CanndocLtdMember_lbl" xml:lang="en-US">Canndoc Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CanndocLtdMember" xlink:to="xtlb_CanndocLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NonAdjustingEventsMember" xlink:href="xtlb-20231231.xsd#xtlb_NonAdjustingEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_NonAdjustingEventsMember_lbl" xml:lang="en-US">Non adjusting Events [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NonAdjustingEventsMember" xlink:to="xtlb_NonAdjustingEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:href="xtlb-20231231.xsd#xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable_lbl" xml:lang="en-US">Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:to="xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US">Financial instruments, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable_lbl" xml:lang="en-US">Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:to="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents are Denominated or Linked [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:to="xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities &#8211; InterCure Ltd (Details) - Schedule of Changes in Marketable Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:to="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems_lbl" xml:lang="en-US">Schedule of Changes in Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_TypeOfCurrencyDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TypeOfCurrencyDomainDomain_lbl" xml:lang="en-US">TypeOfCurrencyDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TypeOfCurrencyDomainDomain" xlink:to="xtlb_TypeOfCurrencyDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:href="xtlb-20231231.xsd#xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable_lbl" xml:lang="en-US">Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:to="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:href="xtlb-20231231.xsd#xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems_lbl" xml:lang="en-US">Schedule of Carrying Amount of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:to="xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable_lbl" xml:lang="en-US">Warrants (Details) - Schedule of Assumptions of Investors&apos; Warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:to="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems_lbl" xml:lang="en-US">Schedule of Assumptions of Investors&apos; Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInstrumentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfInstrumentMember_lbl" xml:lang="en-US">Types of instrument [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInstrumentMember" xlink:to="ifrs-full_TypesOfInstrumentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US">Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl" xml:lang="en-US">Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of Outstanding Options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" xml:lang="en-US">Schedule of Outstanding Options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of Fair Value for Options Granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems_lbl" xml:lang="en-US">Schedule of Fair Value for Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DateDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_DateDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DateDomainDomain_lbl" xml:lang="en-US">DateDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DateDomainDomain" xlink:to="xtlb_DateDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:href="xtlb-20231231.xsd#xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable_lbl" xml:lang="en-US">Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:to="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems_lbl" xml:lang="en-US">Schedule of Weighted-Average Number of Ordinary Shares Basic [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:to="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:href="xtlb-20231231.xsd#xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable_lbl" xml:lang="en-US">Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:to="xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems_lbl" xml:lang="en-US">Schedule of Weighted-Average Number of Ordinary Shares Diluted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:to="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GeneralDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GeneralDetailsTable" xlink:to="xtlb_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_GeneralDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_GeneralDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GeneralDetailsLineItems_lbl" xml:lang="en-US">General [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GeneralDetailsLineItems" xlink:to="xtlb_GeneralDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CashandCashEquivalentsDetailsTable_lbl" xml:lang="en-US">Cash and Cash Equivalents (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CashandCashEquivalentsDetailsTable" xlink:to="xtlb_CashandCashEquivalentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_CashandCashEquivalentsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CashandCashEquivalentsDetailsLineItems_lbl" xml:lang="en-US">Cash and Cash Equivalents (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CashandCashEquivalentsDetailsLineItems" xlink:to="xtlb_CashandCashEquivalentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsTable_lbl" xml:lang="en-US">Marketable Securities &#8211; InterCure Ltd (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsTable" xlink:to="xtlb_MarketableSecuritiesInterCureLtdDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems_lbl" xml:lang="en-US">Disclosure of Marketable Securities Explanatory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:to="xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_AgreementDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_AgreementDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AgreementDomainDomain_lbl" xml:lang="en-US">AgreementDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AgreementDomainDomain" xlink:to="xtlb_AgreementDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IntangibleAssetsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IntangibleAssetsDetailsTable" xlink:to="xtlb_IntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_IntangibleAssetsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IntangibleAssetsDetailsLineItems_lbl" xml:lang="en-US">Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IntangibleAssetsDetailsLineItems" xlink:to="xtlb_IntangibleAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AntidilutiveInstrumentsMember_lbl" xml:lang="en-US">Antidilutive instruments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AntidilutiveInstrumentsMember" xlink:to="ifrs-full_AntidilutiveInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_DepositaryShareDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DepositaryShareDomainDomain_lbl" xml:lang="en-US">DepositaryShareDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DepositaryShareDomainDomain" xlink:to="xtlb_DepositaryShareDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantsDetailsTable_lbl" xml:lang="en-US">Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantsDetailsTable" xlink:to="xtlb_WarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_WarrantsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantsDetailsLineItems_lbl" xml:lang="en-US">Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantsDetailsLineItems" xlink:to="xtlb_WarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable_lbl" xml:lang="en-US">Share Capital, Reserves and Accumulated Deficit (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:to="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems_lbl" xml:lang="en-US">Share Capital, Reserves and Accumulated Deficit [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:to="xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_NamePlanDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NamePlanDomainDomain_lbl" xml:lang="en-US">NamePlanDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NamePlanDomainDomain" xlink:to="xtlb_NamePlanDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsTable_lbl" xml:lang="en-US">Share-Based Payment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsTable" xlink:to="xtlb_ShareBasedPaymentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_ShareBasedPaymentDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentDetailsLineItems" xlink:to="xtlb_ShareBasedPaymentDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US">Non-adjusting events after reporting period [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_SubsequentEventsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_SubsequentEventsDetailsTable" xlink:to="xtlb_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="xtlb_SubsequentEventsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_SubsequentEventsDetailsLineItems" xlink:to="xtlb_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl0" xml:lang="en-US">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:to="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_AdministrativeFeeExpense_lbl0" xml:lang="en-US">Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AdministrativeFeeExpense" xlink:to="xtlb_AdministrativeFeeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_AssetsRemainedAmount_lbl0" xml:lang="en-US">Assets remained amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AssetsRemainedAmount" xlink:to="xtlb_AssetsRemainedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_CurrentMarketableSecuritie_lbl0" xml:lang="en-US">Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecuritie" xlink:to="xtlb_CurrentMarketableSecuritie_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_CurrentMarketableSecurities_lbl1" xml:lang="en-US">Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecurities" xlink:to="xtlb_CurrentMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DeferredTaxAssetsCapitalLossCarryforward_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DeferredTaxAssetsCapitalLossCarryforward" xlink:to="xtlb_DeferredTaxAssetsCapitalLossCarryforward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DepositsWithMaturity_lbl0" xml:lang="en-US">Deposits with maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DepositsWithMaturity" xlink:to="xtlb_DepositsWithMaturity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DescriptionOfWarrantsExercisable_lbl0" xml:lang="en-US">Description of warrants shall be exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DescriptionOfWarrantsExercisable" xlink:to="xtlb_DescriptionOfWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about currencies in which the cash and cash equivalents are denominated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about the exercise price and the remaining contractual life for options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about changes in marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about the number and weighted average exercise prices of share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about the outstanding options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_DisclosureOfWarrantsTextBlock_lbl0" xml:lang="en-US">The entire disclosure of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfWarrantsTextBlock" xlink:to="xtlb_DisclosureOfWarrantsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_EachWarrantIsExercisableToShares_lbl0" xml:lang="en-US">Each warrant is exercisable to shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EachWarrantIsExercisableToShares" xlink:to="xtlb_EachWarrantIsExercisableToShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_EffectOfWarrants_lbl0" xml:lang="en-US">Effect of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EffectOfWarrants" xlink:to="xtlb_EffectOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ExchangeDifferences_lbl0" xml:lang="en-US">Exchange differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExchangeDifferences" xlink:to="xtlb_ExchangeDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ExercisedPeriod_lbl0" xml:lang="en-US">Exercised period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExercisedPeriod" xlink:to="xtlb_ExercisedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ExercisesDuringTheYear_lbl0" xml:lang="en-US">Exercises during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExercisesDuringTheYear" xlink:to="xtlb_ExercisesDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ExpirTerm_lbl0" xml:lang="en-US">Expir term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExpirTerm" xlink:to="xtlb_ExpirTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ExtendedExpiryTerm_lbl0" xml:lang="en-US">Extended expiry term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExtendedExpiryTerm" xlink:to="xtlb_ExtendedExpiryTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_FeesRelatedToServiceProviders_lbl0" xml:lang="en-US">The amount of fees related to service providers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FeesRelatedToServiceProviders" xlink:to="xtlb_FeesRelatedToServiceProviders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_FinanceExpensesRevaluationOfMarketableSecurities_lbl0" xml:lang="en-US">Finance expenses revaluation of marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" xlink:to="xtlb_FinanceExpensesRevaluationOfMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_FinanceIncomeexpensesNet_lbl0" xml:lang="en-US">The amount of income or cost associated with interest and other financing activities of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceIncomeexpensesNet" xlink:to="xtlb_FinanceIncomeexpensesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax_lbl0" xml:lang="en-US">The gain recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_GainsLossesOnFairValueOnMarketableSecurities_lbl0" xml:lang="en-US">The gains (losses) arising from changes in fair value marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GainsLossesOnFairValueOnMarketableSecurities" xlink:to="xtlb_GainsLossesOnFairValueOnMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_GrossFundRaised_lbl0" xml:lang="en-US">The amount of gross fund raised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrossFundRaised" xlink:to="xtlb_GrossFundRaised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_IncreaseOfReserve_lbl0" xml:lang="en-US">Represents increase in reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IncreaseOfReserve" xlink:to="xtlb_IncreaseOfReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_InvestorIssued_lbl0" xml:lang="en-US">Investor issued shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_InvestorIssued" xlink:to="xtlb_InvestorIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_Issued_lbl0" xml:lang="en-US">Issued March 7,2021 due to warrant exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_Issued" xlink:to="xtlb_Issued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_IssuedAndOutstandingRate_lbl0" xml:lang="en-US">Percentage of issued and outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedAndOutstandingRate" xlink:to="xtlb_IssuedAndOutstandingRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_IssuedOrdinarySharesAtJanuary1_lbl0" xml:lang="en-US">Issued ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedOrdinarySharesAtJanuary1" xlink:to="xtlb_IssuedOrdinarySharesAtJanuary1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_LicenseAgreement_lbl0" xml:lang="en-US">License agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LicenseAgreement" xlink:to="xtlb_LicenseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_LoanInterestRate_lbl0" xml:lang="en-US">Loan interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LoanInterestRate" xlink:to="xtlb_LoanInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_MarketableSecuritiesInterCureLtdTextBlock_lbl0" xml:lang="en-US">The entire disclosure of marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdTextBlock" xlink:to="xtlb_MarketableSecuritiesInterCureLtdTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_NumberOfOptionsFullyVested_lbl0" xml:lang="en-US">The number of shares options fully vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfOptionsFullyVested" xlink:to="xtlb_NumberOfOptionsFullyVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_NumberOfOptionsVest_lbl0" xml:lang="en-US">Number of options vest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfOptionsVest" xlink:to="xtlb_NumberOfOptionsVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The number of share options exercisable in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement" xlink:to="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement" xlink:to="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_OptionsExercisableIntoOrdinaryShares_lbl0" xml:lang="en-US">Number of options exercisable into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OptionsExercisableIntoOrdinaryShares" xlink:to="xtlb_OptionsExercisableIntoOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_OptionsReserve_lbl0" xml:lang="en-US">Represents options reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OptionsReserve" xlink:to="xtlb_OptionsReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_OrdinarySharesExercisePrice_lbl0" xml:lang="en-US">Ordinary shares exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OrdinarySharesExercisePrice" xlink:to="xtlb_OrdinarySharesExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PatentsAndFees_lbl0" xml:lang="en-US">The amount of expenses for patents and fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PatentsAndFees" xlink:to="xtlb_PatentsAndFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PaymentOfShareholders_lbl0" xml:lang="en-US">Payment of shareholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PaymentOfShareholders" xlink:to="xtlb_PaymentOfShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PercentageOfFunctionalCurrency_lbl0" xml:lang="en-US">Percentage of functional currency.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfFunctionalCurrency" xlink:to="xtlb_PercentageOfFunctionalCurrency_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PercentageOfHoldingShare_lbl0" xml:lang="en-US">Percentage of holding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfHoldingShare" xlink:to="xtlb_PercentageOfHoldingShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PercentageOfRoyalties_lbl0" xml:lang="en-US">Percentage of royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfRoyalties" xlink:to="xtlb_PercentageOfRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PercentageOfShare_lbl0" xml:lang="en-US">Percentage of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfShare" xlink:to="xtlb_PercentageOfShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PercentageOfSublicenseFees_lbl0" xml:lang="en-US">Percentage of sublicense fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfSublicenseFees" xlink:to="xtlb_PercentageOfSublicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PeriodOfClosingTransaction_lbl0" xml:lang="en-US">Transaction of closing period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PeriodOfClosingTransaction" xlink:to="xtlb_PeriodOfClosingTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PricePerUnit_lbl0" xml:lang="en-US">Price per unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PricePerUnit" xlink:to="xtlb_PricePerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_PrivatePlacementWarrantsIssued_lbl0" xml:lang="en-US">Represents private placement warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PrivatePlacementWarrantsIssued" xlink:to="xtlb_PrivatePlacementWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ReceiptOfRequiredInvestment_lbl0" xml:lang="en-US">Receipt of required investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ReceiptOfRequiredInvestment" xlink:to="xtlb_ReceiptOfRequiredInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RemainingLiability_lbl0" xml:lang="en-US">Remaining liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RemainingLiability" xlink:to="xtlb_RemainingLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RemainingNumberOfOptionsAvailableForGrant_lbl0" xml:lang="en-US">Remaining number of options available for grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RemainingNumberOfOptionsAvailableForGrant" xlink:to="xtlb_RemainingNumberOfOptionsAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RentAndOfficeMaintenance_lbl0" xml:lang="en-US">The amount of expense rent and office maintenance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RentAndOfficeMaintenance" xlink:to="xtlb_RentAndOfficeMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RentExpense_lbl0" xml:lang="en-US">The amount of rent expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RentExpense" xlink:to="xtlb_RentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RevaluationMarketableSecurities_lbl0" xml:lang="en-US">Revaluation of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationMarketableSecurities" xlink:to="xtlb_RevaluationMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RevaluationOfMarketableSecurities_lbl1" xml:lang="en-US">Revaluable of marketable securites.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfMarketableSecurities" xlink:to="xtlb_RevaluationOfMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RevaluationOfWarrantsToPurchase_lbl0" xml:lang="en-US">Revaluation of warrants to purchase .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchase" xlink:to="xtlb_RevaluationOfWarrantsToPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseAds_lbl0" xml:lang="en-US">Revaluation of warrants to purchase ads.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchaseAds" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseAds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock_lbl0" xml:lang="en-US">Schedule of carrying amount of other accounts payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" xlink:to="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock_lbl0" xml:lang="en-US">Schedule of composition of accounts payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock" xlink:to="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock_lbl0" xml:lang="en-US">The table disclose the finance income (cost) for during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" xlink:to="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of fair value for options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock" xlink:to="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock_lbl0" xml:lang="en-US">Schedule of profit (loss) attributed to ordinary shareholders (diluted).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" xlink:to="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock_lbl0" xml:lang="en-US">Schedule of weighted-average number of ordinary shares (diluted).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" xlink:to="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl0" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award options position.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees_lbl0" xml:lang="en-US">Share-based payment transactions to employees and non-employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" xlink:to="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_SharebasedPaymentAwardRemainingContractualTerm_lbl0" xml:lang="en-US">Sharebased payment award remaining contractual term for the during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_SharebasedPaymentAwardRemainingContractualTerm" xlink:to="xtlb_SharebasedPaymentAwardRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_TerminationPeriod_lbl0" xml:lang="en-US">Directors termination period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TerminationPeriod" xlink:to="xtlb_TerminationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows_lbl0" xml:lang="en-US">Total amount of income and expenses not involving cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_WarrantExercisedPeriod_lbl0" xml:lang="en-US">Exercise period of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantExercisedPeriod" xlink:to="xtlb_WarrantExercisedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_WarrantRevaluationIncome_lbl0" xml:lang="en-US">Warrant revaluation income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantRevaluationIncome" xlink:to="xtlb_WarrantRevaluationIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesbasic_lbl0" xml:lang="en-US">Weighted average number of ordinary shares (basic).&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedAverageNumberOfOrdinarySharesbasic" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesbasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted_lbl0" xml:lang="en-US">Weighted average number of ordinary shares (diluted).&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_WeightedaverageNumberOfOrdinarySharesbasic_lbl0" xml:lang="en-US">Weighted-average number of ordinary shares (basic).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedaverageNumberOfOrdinarySharesbasic" xlink:to="xtlb_WeightedaverageNumberOfOrdinarySharesbasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_comprehensiveIncome_lbl0" xml:lang="en-US">comprehensive income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_comprehensiveIncome" xlink:to="xtlb_comprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_warrants_lbl0" xml:lang="en-US">warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_warrants" xlink:to="xtlb_warrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xtlb_GrandsDateIssuedThreeMember_lbl0" xml:lang="en-US">Grands Date Issued Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedThreeMember" xlink:to="xtlb_GrandsDateIssuedThreeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RangeOfExercisePricesOneMember_lbl0" xml:lang="en-US">Range Of Exercise Prices One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RangeOfExercisePricesOneMember" xlink:to="xtlb_RangeOfExercisePricesOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RentExpense_lbl1" xml:lang="en-US">Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RentExpense" xlink:to="xtlb_RentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PercentageOfSublicenseFees_lbl1" xml:lang="en-US">Percentage Of Sublicense Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfSublicenseFees" xlink:to="xtlb_PercentageOfSublicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract61" xlink:to="xtlb_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract62" xlink:to="xtlb_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract60" xlink:to="xtlb_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RevaluationMarketableSecurities_lbl1" xml:lang="en-US">Revaluation Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationMarketableSecurities" xlink:to="xtlb_RevaluationMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Outstanding Options Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PercentageOfHoldingShare_lbl1" xml:lang="en-US">Percentage Of Holding Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfHoldingShare" xlink:to="xtlb_PercentageOfHoldingShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of financial liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of general and administrative expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_OptionsExercisableIntoOrdinaryShares_lbl1" xml:lang="en-US">Options Exercisable Into Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OptionsExercisableIntoOrdinaryShares" xlink:to="xtlb_OptionsExercisableIntoOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl0" xml:lang="en-US">Amounts payable, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_YedaMember_lbl0" xml:lang="en-US">Yeda Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_YedaMember" xlink:to="xtlb_YedaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_SharebasedPaymentAwardRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Payment Award Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_SharebasedPaymentAwardRemainingContractualTerm" xlink:to="xtlb_SharebasedPaymentAwardRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl0" xml:lang="en-US">Finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IncreaseOfReserve_lbl1" xml:lang="en-US">Increase Of Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IncreaseOfReserve" xlink:to="xtlb_IncreaseOfReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Number Of Ordinary Shares Diluted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract" xlink:to="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FinanceIncomeexpensesNet_lbl1" xml:lang="en-US">Finance Incomeexpenses Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceIncomeexpensesNet" xlink:to="xtlb_FinanceIncomeexpensesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl0" xml:lang="en-US">Other fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TypeOfCurrencyAxis_lbl0" xml:lang="en-US">Type Of Currency Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TypeOfCurrencyAxis" xlink:to="xtlb_TypeOfCurrencyAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Exercisable In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement" xlink:to="xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ForeignCurrenciesMember_lbl0" xml:lang="en-US">Foreign Currencies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ForeignCurrenciesMember" xlink:to="xtlb_ForeignCurrenciesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract38" xlink:to="xtlb_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract39" xlink:to="xtlb_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information about understanding financial position and liquidity of entity [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CurrentMarketableSecuritie_lbl1" xml:lang="en-US">Current Marketable Securitie</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecuritie" xlink:to="xtlb_CurrentMarketableSecuritie_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract40" xlink:to="xtlb_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CanndocLtdMember_lbl0" xml:lang="en-US">Canndoc Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CanndocLtdMember" xlink:to="xtlb_CanndocLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract43" xlink:to="xtlb_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract44" xlink:to="xtlb_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract41" xlink:to="xtlb_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract42" xlink:to="xtlb_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract47" xlink:to="xtlb_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract48" xlink:to="xtlb_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract45" xlink:to="xtlb_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted_lbl0" xml:lang="en-US">Information about how expected volatility was determined, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" xlink:to="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract46" xlink:to="xtlb_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract49" xlink:to="xtlb_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AmericanDepositorySharesMember_lbl0" xml:lang="en-US">American Depository Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AmericanDepositorySharesMember" xlink:to="xtlb_AmericanDepositorySharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Assumptions Of Investors Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract" xlink:to="xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract_lbl0" xml:lang="en-US">Income And Expenses Not Involving Operating Cash Flows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_CurrentMarketableSecurities_lbl2" xml:lang="en-US">Current Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_CurrentMarketableSecurities" xlink:to="xtlb_CurrentMarketableSecurities_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract50" xlink:to="xtlb_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_InterCureLtdMember_lbl0" xml:lang="en-US">Inter Cure Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_InterCureLtdMember" xlink:to="xtlb_InterCureLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract51" xlink:to="xtlb_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DepositaryShareAxis_lbl0" xml:lang="en-US">Depositary Share Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DepositaryShareAxis" xlink:to="xtlb_DepositaryShareAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract54" xlink:to="xtlb_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract55" xlink:to="xtlb_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract52" xlink:to="xtlb_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract53" xlink:to="xtlb_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract58" xlink:to="xtlb_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl0" xml:lang="en-US">Other expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract59" xlink:to="xtlb_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract56" xlink:to="xtlb_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees_lbl1" xml:lang="en-US">Share Based Payment Transactions To Employees And Non Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" xlink:to="xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract57" xlink:to="xtlb_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract18" xlink:to="xtlb_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract19" xlink:to="xtlb_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantRevaluationIncome_lbl1" xml:lang="en-US">Warrant Revaluation Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantRevaluationIncome" xlink:to="xtlb_WarrantRevaluationIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract16" xlink:to="xtlb_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Description of vesting requirements for share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract17" xlink:to="xtlb_UnlabeledAbstract17_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFairValueForOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value For Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfFairValueForOptionsGrantedAbstract" xlink:to="xtlb_ScheduleOfFairValueForOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfOptionsVest_lbl1" xml:lang="en-US">Number Of Options Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfOptionsVest" xlink:to="xtlb_NumberOfOptionsVest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DepositsWithMaturity_lbl1" xml:lang="en-US">Deposits With Maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DepositsWithMaturity" xlink:to="xtlb_DepositsWithMaturity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FeesRelatedToServiceProviders_lbl1" xml:lang="en-US">Fees Related To Service Providers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FeesRelatedToServiceProviders" xlink:to="xtlb_FeesRelatedToServiceProviders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract21" xlink:to="xtlb_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract22" xlink:to="xtlb_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PercentageOfShare_lbl1" xml:lang="en-US">Percentage Of Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfShare" xlink:to="xtlb_PercentageOfShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl0" xml:lang="en-US">Insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract20" xlink:to="xtlb_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract25" xlink:to="xtlb_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract26" xlink:to="xtlb_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract23" xlink:to="xtlb_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract24" xlink:to="xtlb_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract29" xlink:to="xtlb_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract27" xlink:to="xtlb_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract28" xlink:to="xtlb_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_comprehensiveIncome_lbl1" xml:lang="en-US">comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_comprehensiveIncome" xlink:to="xtlb_comprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AssetsRemainedAmount_lbl1" xml:lang="en-US">Assets Remained Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AssetsRemainedAmount" xlink:to="xtlb_AssetsRemainedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnitedStatesDollarMember_lbl0" xml:lang="en-US">United States Dollar Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnitedStatesDollarMember" xlink:to="xtlb_UnitedStatesDollarMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract32" xlink:to="xtlb_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract33" xlink:to="xtlb_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract30" xlink:to="xtlb_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract31" xlink:to="xtlb_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract36" xlink:to="xtlb_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract37" xlink:to="xtlb_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FinanceExpensesAbstract_lbl0" xml:lang="en-US">Finance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceExpensesAbstract" xlink:to="xtlb_FinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract34" xlink:to="xtlb_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract35" xlink:to="xtlb_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedMay42021DueToWarrantExerciseMember_lbl0" xml:lang="en-US">Issued May42021 Due To Warrant Exercise Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedMay42021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedMay42021DueToWarrantExerciseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PeriodOfClosingTransaction_lbl1" xml:lang="en-US">Period Of Closing Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PeriodOfClosingTransaction" xlink:to="xtlb_PeriodOfClosingTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted_lbl1" xml:lang="en-US">Weighted Average Number Of Ordinary Sharesdiluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesdiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ExercisesDuringTheYear_lbl1" xml:lang="en-US">Exercises During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExercisesDuringTheYear" xlink:to="xtlb_ExercisesDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WeightedaverageNumberOfOrdinarySharesbasic_lbl1" xml:lang="en-US">Weightedaverage Number Of Ordinary Sharesbasic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedaverageNumberOfOrdinarySharesbasic" xlink:to="xtlb_WeightedaverageNumberOfOrdinarySharesbasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WeightedAverageNumberOfOrdinarySharesbasic_lbl1" xml:lang="en-US">Weighted Average Number Of Ordinary Sharesbasic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WeightedAverageNumberOfOrdinarySharesbasic" xlink:to="xtlb_WeightedAverageNumberOfOrdinarySharesbasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLoanCommitments_lbl0" xml:lang="en-US">Gross loan commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLoanCommitments" xlink:to="ifrs-full_GrossLoanCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl3" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl0" xml:lang="en-US">Transactionsand Balanceswith Related Parties Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PrivatePlacementWarrantsIssued_lbl1" xml:lang="en-US">Private Placement Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PrivatePlacementWarrantsIssued" xlink:to="xtlb_PrivatePlacementWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RangeOfExercisePricesThreeMember_lbl0" xml:lang="en-US">Range Of Exercise Prices Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RangeOfExercisePricesThreeMember" xlink:to="xtlb_RangeOfExercisePricesThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_warrants_lbl1" xml:lang="en-US">warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_warrants" xlink:to="xtlb_warrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl1" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract10" xlink:to="xtlb_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock_lbl1" xml:lang="en-US">Schedule Of Profitloss Attributed To Ordinary Shareholdersdiluted Table Tex Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" xlink:to="xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract11" xlink:to="xtlb_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract14" xlink:to="xtlb_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract15" xlink:to="xtlb_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract12" xlink:to="xtlb_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract13" xlink:to="xtlb_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ChairmanOfBoardMember_lbl0" xml:lang="en-US">Chairman Of Board Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ChairmanOfBoardMember" xlink:to="xtlb_ChairmanOfBoardMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalPaidinCapital_lbl0" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapital" xlink:to="ifrs-full_AdditionalPaidinCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelFaxNumber_lbl0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract2" xlink:to="xtlb_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract1" xlink:to="xtlb_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract4" xlink:to="xtlb_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract3" xlink:to="xtlb_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract0" xlink:to="xtlb_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract9" xlink:to="xtlb_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_OneDirectorMember_lbl0" xml:lang="en-US">One Director Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OneDirectorMember" xlink:to="xtlb_OneDirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract6" xlink:to="xtlb_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl0" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl0" xml:lang="en-US">Professional fees expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract5" xlink:to="xtlb_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract8" xlink:to="xtlb_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract7" xlink:to="xtlb_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GrandDateIssuedFiveMember_lbl0" xml:lang="en-US">Grand Date Issued Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandDateIssuedFiveMember" xlink:to="xtlb_GrandDateIssuedFiveMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract_lbl" xml:lang="en-US">Schedule Of Number Of Share Options And Their Related Weighted Average Exercise Prices Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract" xlink:to="xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantsIssued_lbl0" xml:lang="en-US">Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantsIssued" xlink:to="xtlb_WarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SettlementsFairValueMeasurementLiabilities_lbl0" xml:lang="en-US">Settlements, fair value measurement, liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:to="ifrs-full_SettlementsFairValueMeasurementLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract_lbl0" xml:lang="en-US">Changes In Operating Asset And Liability Items Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_BlackScholesMertonOptionsPricingModelMember_lbl0" xml:lang="en-US">Black Scholes Merton Options Pricing Model Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_BlackScholesMertonOptionsPricingModelMember" xlink:to="xtlb_BlackScholesMertonOptionsPricingModelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Currencies Cash And Cash Equivalents Denominated Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_MarketableSecuritiesInterCureLtdTextBlock_lbl1" xml:lang="en-US">Marketable Securities Inter Cure Ltd Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_MarketableSecuritiesInterCureLtdTextBlock" xlink:to="xtlb_MarketableSecuritiesInterCureLtdTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock_lbl1" xml:lang="en-US">Schedule Of Carrying Amount Of Other Accounts Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" xlink:to="xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_UnlabeledAbstract" xlink:to="xtlb_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows_lbl1" xml:lang="en-US">Total Income And Expenses Not Involving Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:to="xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfWarrantsTextBlock_lbl1" xml:lang="en-US">Disclosure Of Warrants Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfWarrantsTextBlock" xlink:to="xtlb_DisclosureOfWarrantsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_OrdinarySharesExercisePrice_lbl1" xml:lang="en-US">Ordinary Shares Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OrdinarySharesExercisePrice" xlink:to="xtlb_OrdinarySharesExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl0" xml:lang="en-US">Receivables from contracts with customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromContractsWithCustomers" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">AAdjustments To Reconcile Net Income Loss To Net Cash Used In Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Marketable Securities Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalents Are Denominated Or Linked Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract" xlink:to="xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FourDirectorsMember_lbl0" xml:lang="en-US">Four Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FourDirectorsMember" xlink:to="xtlb_FourDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentIncome_lbl2" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ADSIssued_lbl1" xml:lang="en-US">ADSIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ADSIssued" xlink:to="xtlb_ADSIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RentAndOfficeMaintenance_lbl1" xml:lang="en-US">Rent And Office Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RentAndOfficeMaintenance" xlink:to="xtlb_RentAndOfficeMaintenance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FinanceExpensesRevaluationOfMarketableSecurities_lbl1" xml:lang="en-US">Finance Expenses Revaluation Of Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceExpensesRevaluationOfMarketableSecurities" xlink:to="xtlb_FinanceExpensesRevaluationOfMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl0" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl0" xml:lang="en-US">Disclosure of financial risk management [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other current assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax_lbl1" xml:lang="en-US">Gain On Exchange Differences On Translation Net Of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAvailableforsale_lbl1" xml:lang="en-US">Financial assets available-for-sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAvailableforsale" xlink:to="ifrs-full_FinancialAssetsAvailableforsale_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AgreementAxis_lbl0" xml:lang="en-US">Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AgreementAxis" xlink:to="xtlb_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl0" xml:lang="en-US">Applicable tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfSharesAbstract0_lbl0" xml:lang="en-US">Number Of Shares Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfSharesAbstract0" xlink:to="xtlb_NumberOfSharesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl0" xml:lang="en-US">Wages and salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedOctober112021DueToWarrantExerciseMember_lbl0" xml:lang="en-US">Issued October112021 Due To Warrant Exercise Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedOctober112021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedOctober112021DueToWarrantExerciseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Changes In Financial Liabilities Classified As Cash Flow From Finance Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract" xlink:to="xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PatentsAndFees_lbl1" xml:lang="en-US">Patents And Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PatentsAndFees" xlink:to="xtlb_PatentsAndFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_Issued_lbl1" xml:lang="en-US">Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_Issued" xlink:to="xtlb_Issued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of prepayments and other assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncome_lbl0" xml:lang="en-US">Other finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DateAxis_lbl0" xml:lang="en-US">Date Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DateAxis" xlink:to="xtlb_DateAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl0" xml:lang="en-US">Disclosure of general hedge accounting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AdministrativeFeeExpense_lbl1" xml:lang="en-US">Administrative Fee Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AdministrativeFeeExpense" xlink:to="xtlb_AdministrativeFeeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IntangibleAssetOtherInformationMaturityDate_lbl0" xml:lang="en-US">Intangible Asset Other Information Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IntangibleAssetOtherInformationMaturityDate" xlink:to="xtlb_IntangibleAssetOtherInformationMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedAndOutstandingRate_lbl1" xml:lang="en-US">Issued And Outstanding Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedAndOutstandingRate" xlink:to="xtlb_IssuedAndOutstandingRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl0" xml:lang="en-US">Accruals classified as current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalPaidinCapitalMember_lbl0" xml:lang="en-US">Additional paid-in capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapitalMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfImpairmentOfGoodwill_lbl0" xml:lang="en-US">Tax effect of impairment of goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfImpairmentOfGoodwill" xlink:to="ifrs-full_TaxEffectOfImpairmentOfGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ExercisedPeriod_lbl1" xml:lang="en-US">Exercised Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExercisedPeriod" xlink:to="xtlb_ExercisedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl0" xml:lang="en-US">Other reserves [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_WarrantExercisedPeriod_lbl1" xml:lang="en-US">Warrant Exercised Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_WarrantExercisedPeriod" xlink:to="xtlb_WarrantExercisedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PercentageOfFunctionalCurrency_lbl1" xml:lang="en-US">Percentage Of Functional Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfFunctionalCurrency" xlink:to="xtlb_PercentageOfFunctionalCurrency_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock_lbl1" xml:lang="en-US">Schedule Of Composition Of Accounts Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock" xlink:to="xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GrandDateIssuedEightMember_lbl0" xml:lang="en-US">Grand Date Issued Eight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandDateIssuedEightMember" xlink:to="xtlb_GrandDateIssuedEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedMarch72021DueToWarrantExerciseMember_lbl0" xml:lang="en-US">Issued March72021 Due To Warrant Exercise Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedMarch72021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedMarch72021DueToWarrantExerciseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Number And Weighted Average Exercise Prices Of Share Options Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_EffectOfWarrants_lbl1" xml:lang="en-US">Effect Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EffectOfWarrants" xlink:to="xtlb_EffectOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PrivatePlacementsMember_lbl0" xml:lang="en-US">Private Placements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PrivatePlacementsMember" xlink:to="xtlb_PrivatePlacementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DescriptionOfWarrantsExercisable_lbl1" xml:lang="en-US">Description Of Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DescriptionOfWarrantsExercisable" xlink:to="xtlb_DescriptionOfWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GovernmentAuthorities_lbl0" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GovernmentAuthorities" xlink:to="xtlb_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax_lbl0" xml:lang="en-US">Other comprehensive income, before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TwoThousandElevenPlanMember_lbl0" xml:lang="en-US">Two Thousand Eleven Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TwoThousandElevenPlanMember" xlink:to="xtlb_TwoThousandElevenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NamePlanAxis_lbl0" xml:lang="en-US">Name Plan Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NamePlanAxis" xlink:to="xtlb_NamePlanAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl0" xml:lang="en-US">Current prepayments and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PricePerUnit_lbl1" xml:lang="en-US">Price Per Unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PricePerUnit" xlink:to="xtlb_PricePerUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedOrdinarySharesAtJanuary1_lbl1" xml:lang="en-US">Issued Ordinary Shares At January1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedOrdinarySharesAtJanuary1" xlink:to="xtlb_IssuedOrdinarySharesAtJanuary1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ConsolidatedStatementsOfChangesInEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="xtlb_ConsolidatedStatementsOfChangesInEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl0" xml:lang="en-US">Earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RemainingNumberOfOptionsAvailableForGrant_lbl1" xml:lang="en-US">Remaining Number Of Options Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RemainingNumberOfOptionsAvailableForGrant" xlink:to="xtlb_RemainingNumberOfOptionsAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_LoanInterestRate_lbl1" xml:lang="en-US">Loan Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LoanInterestRate" xlink:to="xtlb_LoanInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DeferredTaxAssetsCapitalLossCarryforward_lbl1" xml:lang="en-US">Deferred Tax Assets Capital Loss Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DeferredTaxAssetsCapitalLossCarryforward" xlink:to="xtlb_DeferredTaxAssetsCapitalLossCarryforward_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_TerminationPeriod_lbl1" xml:lang="en-US">Termination Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_TerminationPeriod" xlink:to="xtlb_TerminationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule Of Carrying Amount Of Accounts Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract" xlink:to="xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl1" xml:lang="en-US">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:to="xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ExchangeDifferences_lbl1" xml:lang="en-US">Exchange Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExchangeDifferences" xlink:to="xtlb_ExchangeDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Number Of Ordinary Shares Basic Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract" xlink:to="xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IsraeliCpiForwardContractsMember_lbl0" xml:lang="en-US">Israeli Cpi Forward Contracts Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IsraeliCpiForwardContractsMember" xlink:to="xtlb_IsraeliCpiForwardContractsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Exercise Price And Remaining Contractual Life For Options Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract" xlink:to="xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl0" xml:lang="en-US">Increase (decrease) in deferred tax liability (asset)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Options Exercisable Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement" xlink:to="xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfEmployees_lbl0" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RangeOfExercisePricesTwoMember_lbl0" xml:lang="en-US">Range Of Exercise Prices Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RangeOfExercisePricesTwoMember" xlink:to="xtlb_RangeOfExercisePricesTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Date of grant of share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl0" xml:lang="en-US">Interest income on deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedSeptember12021DueToWarrantExerciseMember_lbl0" xml:lang="en-US">Issued September12021 Due To Warrant Exercise Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedSeptember12021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedSeptember12021DueToWarrantExerciseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl0" xml:lang="en-US">Travel expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedJuly62021DueToWarrantExerciseMember_lbl0" xml:lang="en-US">Issued July62021 Due To Warrant Exercise Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedJuly62021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedJuly62021DueToWarrantExerciseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NoncashActivitiesAbstract_lbl0" xml:lang="en-US">Noncash Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NoncashActivitiesAbstract" xlink:to="xtlb_NoncashActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RemainingLiability_lbl1" xml:lang="en-US">Remaining Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RemainingLiability" xlink:to="xtlb_RemainingLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GrossFundRaised_lbl1" xml:lang="en-US">Gross Fund Raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrossFundRaised" xlink:to="xtlb_GrossFundRaised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GrandsDateIssuedThreeMember_lbl1" xml:lang="en-US">Grands Date Issued Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedThreeMember" xlink:to="xtlb_GrandsDateIssuedThreeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfSharesMember_lbl0" xml:lang="en-US">Number Of Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfSharesMember" xlink:to="xtlb_NumberOfSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl0" xml:lang="en-US">Average foreign exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GainsLossesOnFairValueOnMarketableSecurities_lbl1" xml:lang="en-US">Gains Losses On Fair Value On Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GainsLossesOnFairValueOnMarketableSecurities" xlink:to="xtlb_GainsLossesOnFairValueOnMarketableSecurities_lbl1"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfOutstandingOptionsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfOutstandingOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfOutstandingOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfOutstandingOptionsAbstract" xlink:to="xtlb_ScheduleOfOutstandingOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl0" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_FinanceIncomeAbstract_lbl0" xml:lang="en-US">Finance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_FinanceIncomeAbstract" xlink:to="xtlb_FinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RevaluationOfMarketableSecurities_lbl2" xml:lang="en-US">Revaluation Of Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfMarketableSecurities" xlink:to="xtlb_RevaluationOfMarketableSecurities_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IssuedAugust302021DueToWarrantExerciseMember_lbl0" xml:lang="en-US">Issued August302021 Due To Warrant Exercise Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IssuedAugust302021DueToWarrantExerciseMember" xlink:to="xtlb_IssuedAugust302021DueToWarrantExerciseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl1" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ExtendedExpiryTerm_lbl1" xml:lang="en-US">Extended Expiry Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExtendedExpiryTerm" xlink:to="xtlb_ExtendedExpiryTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl1" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Other comprehensive income, attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl0" xml:lang="en-US">Cash flows from (used in) operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_InvestorIssued_lbl1" xml:lang="en-US">Investor Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_InvestorIssued" xlink:to="xtlb_InvestorIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GrandsDateIssuedThirteenMember_lbl0" xml:lang="en-US">Grands Date Issued Thirteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedThirteenMember" xlink:to="xtlb_GrandsDateIssuedThirteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl0" xml:lang="en-US">Average effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_StockOptionsMember" xlink:to="xtlb_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl0" xml:lang="en-US">Cash on hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_LicenseAgreement_lbl1" xml:lang="en-US">License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LicenseAgreement" xlink:to="xtlb_LicenseAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RevaluationOfWarrantsToPurchase_lbl1" xml:lang="en-US">Revaluation Of Warrants To Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchase" xlink:to="xtlb_RevaluationOfWarrantsToPurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceCost_lbl0" xml:lang="en-US">Other finance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceCost" xlink:to="ifrs-full_OtherFinanceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_OptionsReserve_lbl1" xml:lang="en-US">Options Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_OptionsReserve" xlink:to="xtlb_OptionsReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Interest received, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl1" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NonAdjustingEventsMember_lbl0" xml:lang="en-US">Non Adjusting Events Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NonAdjustingEventsMember" xlink:to="xtlb_NonAdjustingEventsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl0" xml:lang="en-US">Loans received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_EachWarrantIsExercisableToShares_lbl1" xml:lang="en-US">Each Warrant Is Exercisable To Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_EachWarrantIsExercisableToShares" xlink:to="xtlb_EachWarrantIsExercisableToShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseAds_lbl1" xml:lang="en-US">Revaluation Of Warrants To Purchase Ads</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchaseAds" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseAds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfSharesAbstract" xlink:to="xtlb_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl0" xml:lang="en-US">Directors&apos; remuneration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock_lbl1" xml:lang="en-US">Schedule Of Weightedaverage Number Of Ordinary Sharesdiluted Table Tex Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" xlink:to="xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_IsraeliNewShekelMember_lbl0" xml:lang="en-US">Israeli New Shekel Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_IsraeliNewShekelMember" xlink:to="xtlb_IsraeliNewShekelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ReceiptOfRequiredInvestment_lbl1" xml:lang="en-US">Receipt Of Required Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ReceiptOfRequiredInvestment" xlink:to="xtlb_ReceiptOfRequiredInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_GrandsDateIssuedElevenMember_lbl0" xml:lang="en-US">Grands Date Issued Eleven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_GrandsDateIssuedElevenMember" xlink:to="xtlb_GrandsDateIssuedElevenMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PercentageOfRoyalties_lbl1" xml:lang="en-US">Percentage Of Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PercentageOfRoyalties" xlink:to="xtlb_PercentageOfRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_NumberOfOptionsFullyVested_lbl1" xml:lang="en-US">Number Of Options Fully Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_NumberOfOptionsFullyVested" xlink:to="xtlb_NumberOfOptionsFullyVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Details Information About Finance Income Expense Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" xlink:to="xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ShareCapitalReservesAndRetainedEarnings_lbl0" xml:lang="en-US">Share Capital Reserves And Retained Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ShareCapitalReservesAndRetainedEarnings" xlink:to="xtlb_ShareCapitalReservesAndRetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Fair Value For Options Granted Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock" xlink:to="xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Schedule Of Changes In Marketable Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract" xlink:to="xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl0" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Exercise Price And Contractual Life For Options Outstanding Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" xlink:to="xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of material accounting policy information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_ExpirTerm_lbl1" xml:lang="en-US">Expir Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_ExpirTerm" xlink:to="xtlb_ExpirTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_PaymentOfShareholders_lbl1" xml:lang="en-US">Payment Of Shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_PaymentOfShareholders" xlink:to="xtlb_PaymentOfShareholders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_LicenseAgreementMember_lbl0" xml:lang="en-US">License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_LicenseAgreementMember" xlink:to="xtlb_LicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl2" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xtlb_RevaluationOfWarrantsToPurchaseADSs_lbl0" xml:lang="en-US">Revaluation Of Warrants To Purchase ADSs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xtlb_RevaluationOfWarrantsToPurchaseADSs" xlink:to="xtlb_RevaluationOfWarrantsToPurchaseADSs_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>xtlb-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 30 18:16:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedBalanceSheet" roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedIncomeStatement" roleURI="http://xtlb.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareholdersEquityType2or3" roleURI="http://xtlb.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ConsolidatedCashFlow" roleURI="http://xtlb.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_General" roleURI="http://xtlb.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_BasisofPreparation" roleURI="http://xtlb.com/role/BasisofPreparation"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MaterialAccountingPolicies" roleURI="http://xtlb.com/role/MaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinancialInstrumentsandFinancialRiskManagement" roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_CashandCashEquivalents" roleURI="http://xtlb.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MarketableSecuritiesInterCureLtd" roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtd"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_PrepaidExpensesandOtheCurrentAssets" roleURI="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_IntangibleAssets" roleURI="http://xtlb.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_AccountsPayable" roleURI="http://xtlb.com/role/AccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_Warrants" roleURI="http://xtlb.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareCapitalReservesandAccumulatedDeficit" roleURI="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareBasedPayment" roleURI="http://xtlb.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ResearchandDevelopmentExpenses" roleURI="http://xtlb.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_GeneralandAdministrativeExpenses" roleURI="http://xtlb.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinanceIncomeExpensesNet" roleURI="http://xtlb.com/role/FinanceIncomeExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TaxesonIncome" roleURI="http://xtlb.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TransactionsandBalanceswithRelatedParties" roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_EarningsLossPerShare" roleURI="http://xtlb.com/role/EarningsLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_SubsequentEvents" roleURI="http://xtlb.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_AccountingPoliciesByPolicy" roleURI="http://xtlb.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_BasisofPreparationTables" roleURI="http://xtlb.com/role/BasisofPreparationTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinancialInstrumentsandFinancialRiskManagementTables" roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_CashandCashEquivalentsTables" roleURI="http://xtlb.com/role/CashandCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MarketableSecuritiesInterCureLtdTables" roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_PrepaidExpensesandOtheCurrentAssetsTables" roleURI="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_AccountsPayableTables" roleURI="http://xtlb.com/role/AccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_WarrantsTables" roleURI="http://xtlb.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareBasedPaymentTables" roleURI="http://xtlb.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ResearchandDevelopmentExpensesTables" roleURI="http://xtlb.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_GeneralandAdministrativeExpensesTables" roleURI="http://xtlb.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinanceIncomeExpensesNetTables" roleURI="http://xtlb.com/role/FinanceIncomeExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_EarningsLossPerShareTables" roleURI="http://xtlb.com/role/EarningsLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofExchangeRateTable" roleURI="http://xtlb.com/role/ScheduleofExchangeRateTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" roleURI="http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" roleURI="http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFinancialInstrumentsTable" roleURI="http://xtlb.com/role/ScheduleofFinancialInstrumentsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofChangesinMarketableSecuritiesTable" roleURI="http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompositionofAccountsPayableTable" roleURI="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCarryingAmountofAccountsPayableTable" roleURI="http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofAssumptionsofInvestorsWarrantsTable" roleURI="http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" roleURI="http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" roleURI="http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofOutstandingOptionsTable" roleURI="http://xtlb.com/role/ScheduleofOutstandingOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFairValueforOptionsGrantedTable" roleURI="http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofFinanceIncomeExpensesNetTable" roleURI="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable" roleURI="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable" roleURI="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" roleURI="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable" roleURI="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" roleURI="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_GeneralDetails" roleURI="http://xtlb.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_FinancialInstrumentsandFinancialRiskManagementDetails" roleURI="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_CashandCashEquivalentsDetails" roleURI="http://xtlb.com/role/CashandCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_MarketableSecuritiesInterCureLtdDetails" roleURI="http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_IntangibleAssetsDetails" roleURI="http://xtlb.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_WarrantsDetails" roleURI="http://xtlb.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareCapitalReservesandAccumulatedDeficitDetails" roleURI="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_ShareBasedPaymentDetails" roleURI="http://xtlb.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TaxesonIncomeDetails" roleURI="http://xtlb.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_EarningsLossPerShareDetails" roleURI="http://xtlb.com/role/EarningsLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#xtlb_r_SubsequentEventsDetails" roleURI="http://xtlb.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="xtlb-20231231.xsd#DocumentAndEntityInformation" roleURI="http://xtlb.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="CurrentMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_AdditionalPaidinCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ParValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfWarrantsToPurchaseAds" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseAds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="RevaluationOfWarrantsToPurchaseAds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="RevaluationOfMarketableSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherFinanceCost" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherReservesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" xlink:href="xtlb-20231231.xsd#xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="RevaluationOfMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfWarrantsToPurchase" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="RevaluationOfWarrantsToPurchase" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="TotalIncomeAndExpensesNotInvolvingCashFlows" xlink:href="xtlb-20231231.xsd#xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract" xlink:to="TotalIncomeAndExpensesNotInvolvingCashFlows" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="ChangesInOperatingAssetAndLiabilityItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetAndLiabilityItemsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_NoncashActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="NoncashActivitiesAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/General">
    <loc xlink:type="locator" xlink:label="GeneralAbstract" xlink:href="xtlb-20231231.xsd#xtlb_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/BasisofPreparation">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/MaterialAccountingPolicies">
    <loc xlink:type="locator" xlink:label="MaterialAccountingPoliciesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MaterialAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/CashandCashEquivalents">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/MarketableSecuritiesInterCureLtd">
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdAbstract" xlink:to="MarketableSecuritiesInterCureLtdTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentPrepaymentsAbstract" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/AccountsPayable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/Warrants">
    <loc xlink:type="locator" xlink:label="DisclosureOfWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfWarrantsTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfWarrantsAbstract" xlink:to="DisclosureOfWarrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalReservesAndRetainedEarnings" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesAndRetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ShareCapitalReservesAndRetainedEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareBasedPayment">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ResearchandDevelopmentExpenses">
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/GeneralandAdministrativeExpenses">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinanceIncomeExpensesNet">
    <loc xlink:type="locator" xlink:label="FinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeExpensesNetAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/TransactionsandBalanceswithRelatedParties">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/EarningsLossPerShare">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/BasisofPreparationTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/CashandCashEquivalentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables">
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdAbstract" xlink:to="DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentPrepaymentsAbstract" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/AccountsPayableTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCompositionOfAccountsPayableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ScheduleOfCompositionOfAccountsPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfWarrantsAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareBasedPaymentTables">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentAbstract" xlink:to="DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentAbstract" xlink:to="DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentAbstract" xlink:to="DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForOptionsGrantedTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentAbstract" xlink:to="ScheduleOfFairValueForOptionsGrantedTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ResearchandDevelopmentExpensesTables">
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpensesAbstract" xlink:to="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/GeneralandAdministrativeExpensesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinanceIncomeExpensesNetTables">
    <loc xlink:type="locator" xlink:label="FinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeExpensesNetAbstract" xlink:to="ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesTable" xlink:to="TransactionsandBalanceswithRelatedPartiesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesTablesLineItems" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/EarningsLossPerShareTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofExchangeRateTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_AverageForeignExchangeRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:href="xtlb-20231231.xsd#xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract" xlink:to="FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SettlementsFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettlementsFairValueMeasurementLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_SettlementsFairValueMeasurementLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisesDuringTheYear" xlink:href="xtlb-20231231.xsd#xtlb_ExercisesDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ExercisesDuringTheYear" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExercisesDuringTheYear" xlink:to="ifrs-full_FinancialLiabilities_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashOnHand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract" xlink:to="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrenciesMember" xlink:href="xtlb-20231231.xsd#xtlb_ForeignCurrenciesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ForeignCurrenciesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IsraeliCpiForwardContractsMember" xlink:href="xtlb-20231231.xsd#xtlb_IsraeliCpiForwardContractsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="IsraeliCpiForwardContractsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable" xlink:to="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFinancialInstrumentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInstrumentsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInstrumentsAbstract" xlink:to="CurrentMarketableSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInMarketableSecuritiesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInMarketableSecuritiesAbstract" xlink:to="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable" xlink:to="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="GainsLossesOnFairValueOnMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_GainsLossesOnFairValueOnMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="GainsLossesOnFairValueOnMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAvailableforsale_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems" xlink:to="ifrs-full_FinancialAssetsAvailableforsale_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="xtlb-20231231.xsd#xtlb_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="GovernmentAuthorities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompositionOfAccountsPayableAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompositionOfAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompositionOfAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCarryingAmountOfAccountsPayableAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:href="xtlb-20231231.xsd#xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:href="xtlb-20231231.xsd#xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCarryingAmountOfAccountsPayableAbstract" xlink:to="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyAxis" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:to="TypeOfCurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_TypeOfCurrencyDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="TypeOfCurrencyDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UnitedStatesDollarMember" xlink:href="xtlb-20231231.xsd#xtlb_UnitedStatesDollarMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="UnitedStatesDollarMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IsraeliNewShekelMember" xlink:href="xtlb-20231231.xsd#xtlb_IsraeliNewShekelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="IsraeliNewShekelMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable" xlink:to="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssumptionsOfInvestorsWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssumptionsOfInvestorsWarrantsAbstract" xlink:to="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable" xlink:to="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract" xlink:to="ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="xtlb-20231231.xsd#xtlb_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="StockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra6k700T0sfKUwmSs7S9L++IDK0p1gPKHpO5dJ65hhGy9fwjj4/n7KN1SulI4ach77W9Wwz3+E1J9+r5NDv+DmNmsAUzk5MtuyzUCloU3JxeD1/AQx6LR+1dL0GkSZzfKNlWQ16gCepUKiGvC6mXEyCUNC1IRhKJbbVo8P15/+mdT+aHSxd4w05eDD5LmDCTYdsnFU3ts+vIcGXlxXF2Ct/V71qBGSvQ/g=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract" xlink:to="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInstrumentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInstrumentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="ifrs-full_TypesOfInstrumentMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="xtlb-20231231.xsd#xtlb_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePricesOneMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="RangeOfExercisePricesOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePricesTwoMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="RangeOfExercisePricesTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangeOfExercisePricesThreeMember" xlink:href="xtlb-20231231.xsd#xtlb_RangeOfExercisePricesThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="RangeOfExercisePricesThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofOutstandingOptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingOptionsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfOutstandingOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_CreationDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GrandsDateIssuedThreeMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrandsDateIssuedThreeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrandDateIssuedFiveMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandDateIssuedFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrandDateIssuedFiveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrandDateIssuedEightMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandDateIssuedEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrandDateIssuedEightMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrandsDateIssuedElevenMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedElevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrandsDateIssuedElevenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrandsDateIssuedThirteenMember" xlink:href="xtlb-20231231.xsd#xtlb_GrandsDateIssuedThirteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="GrandsDateIssuedThirteenMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FourDirectorsMember" xlink:href="xtlb-20231231.xsd#xtlb_FourDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="FourDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneDirectorMember" xlink:href="xtlb-20231231.xsd#xtlb_OneDirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OneDirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChairmanOfBoardMember" xlink:href="xtlb-20231231.xsd#xtlb_ChairmanOfBoardMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ChairmanOfBoardMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="srt_DirectorMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForOptionsGrantedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFairValueForOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForOptionsGrantedAbstract" xlink:to="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BlackScholesMertonOptionsPricingModelMember" xlink:href="xtlb-20231231.xsd#xtlb_BlackScholesMertonOptionsPricingModelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="BlackScholesMertonOptionsPricingModelMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable" xlink:to="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="FeesRelatedToServiceProviders" xlink:href="xtlb-20231231.xsd#xtlb_FeesRelatedToServiceProviders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="FeesRelatedToServiceProviders" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentsAndFees" xlink:href="xtlb-20231231.xsd#xtlb_PatentsAndFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="PatentsAndFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DirectorsRemunerationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_DirectorsRemunerationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TravelExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_TravelExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentAndOfficeMaintenance" xlink:href="xtlb-20231231.xsd#xtlb_RentAndOfficeMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="RentAndOfficeMaintenance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_InsuranceExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ProfessionalFeesExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="FinanceExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesRevaluationOfMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_FinanceExpensesRevaluationOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="FinanceExpensesRevaluationOfMarketableSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="ifrs-full_FeeAndCommissionExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeDifferences" xlink:href="xtlb-20231231.xsd#xtlb_ExchangeDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="ExchangeDifferences" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAbstract" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="FinanceIncomeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfWarrantsToPurchaseADSs" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationOfWarrantsToPurchaseADSs"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="RevaluationOfWarrantsToPurchaseADSs" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationMarketableSecurities" xlink:href="xtlb-20231231.xsd#xtlb_RevaluationMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="RevaluationMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="xtlb-20231231.xsd#xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="GainOnExchangeDifferencesOnTranslationNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeexpensesNet" xlink:href="xtlb-20231231.xsd#xtlb_FinanceIncomeexpensesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinanceIncomeExpensesNetAbstract" xlink:to="FinanceIncomeexpensesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract" xlink:to="ifrs-full_NumberOfEmployees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:href="xtlb-20231231.xsd#xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract" xlink:to="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DateAxis" xlink:href="xtlb-20231231.xsd#xtlb_DateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:to="DateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DateDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_DateDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="DateDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IssuedMarch72021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedMarch72021DueToWarrantExerciseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="IssuedMarch72021DueToWarrantExerciseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedMay42021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedMay42021DueToWarrantExerciseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="IssuedMay42021DueToWarrantExerciseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedJuly62021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedJuly62021DueToWarrantExerciseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="IssuedJuly62021DueToWarrantExerciseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAugust302021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedAugust302021DueToWarrantExerciseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="IssuedAugust302021DueToWarrantExerciseMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedSeptember12021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedSeptember12021DueToWarrantExerciseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="IssuedSeptember12021DueToWarrantExerciseMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedOctober112021DueToWarrantExerciseMember" xlink:href="xtlb-20231231.xsd#xtlb_IssuedOctober112021DueToWarrantExerciseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DateAxis" xlink:to="IssuedOctober112021DueToWarrantExerciseMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable" xlink:to="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems" xlink:to="NumberOfSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedOrdinarySharesAtJanuary1" xlink:href="xtlb-20231231.xsd#xtlb_IssuedOrdinarySharesAtJanuary1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="IssuedOrdinarySharesAtJanuary1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Issued" xlink:href="xtlb-20231231.xsd#xtlb_Issued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="Issued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfOrdinarySharesbasic" xlink:href="xtlb-20231231.xsd#xtlb_WeightedAverageNumberOfOrdinarySharesbasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="WeightedAverageNumberOfOrdinarySharesbasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantRevaluationIncome" xlink:href="xtlb-20231231.xsd#xtlb_WarrantRevaluationIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="WarrantRevaluationIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="comprehensiveIncome" xlink:href="xtlb-20231231.xsd#xtlb_comprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract" xlink:to="comprehensiveIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:href="xtlb-20231231.xsd#xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract" xlink:to="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesMember" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="NumberOfSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable" xlink:to="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract0" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfSharesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems" xlink:to="NumberOfSharesAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaverageNumberOfOrdinarySharesbasic" xlink:href="xtlb-20231231.xsd#xtlb_WeightedaverageNumberOfOrdinarySharesbasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="WeightedaverageNumberOfOrdinarySharesbasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfWarrants" xlink:href="xtlb-20231231.xsd#xtlb_EffectOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="EffectOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfOrdinarySharesdiluted" xlink:href="xtlb-20231231.xsd#xtlb_WeightedAverageNumberOfOrdinarySharesdiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract0" xlink:to="WeightedAverageNumberOfOrdinarySharesdiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="GeneralAbstract" xlink:href="xtlb-20231231.xsd#xtlb_GeneralAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_GeneralDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAbstract" xlink:to="GeneralDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementsMember" xlink:href="xtlb-20231231.xsd#xtlb_PrivatePlacementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="PrivatePlacementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingRate" xlink:href="xtlb-20231231.xsd#xtlb_IssuedAndOutstandingRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="IssuedAndOutstandingRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfShareholders" xlink:href="xtlb-20231231.xsd#xtlb_PaymentOfShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="PaymentOfShareholders" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PeriodOfClosingTransaction" xlink:href="xtlb-20231231.xsd#xtlb_PeriodOfClosingTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="PeriodOfClosingTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorIssued" xlink:href="xtlb-20231231.xsd#xtlb_InvestorIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="InvestorIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerUnit" xlink:href="xtlb-20231231.xsd#xtlb_PricePerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="PricePerUnit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ADSIssued" xlink:href="xtlb-20231231.xsd#xtlb_ADSIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ADSIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementWarrantsIssued" xlink:href="xtlb-20231231.xsd#xtlb_PrivatePlacementWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="PrivatePlacementWarrantsIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExercisedPeriod" xlink:href="xtlb-20231231.xsd#xtlb_WarrantExercisedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="WarrantExercisedPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFunctionalCurrency" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfFunctionalCurrency"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="PercentageOfFunctionalCurrency" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/CashandCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_CashandCashEquivalentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="CashandCashEquivalentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsTable" xlink:to="CashandCashEquivalentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DepositsWithMaturity" xlink:href="xtlb-20231231.xsd#xtlb_DepositsWithMaturity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsLineItems" xlink:to="DepositsWithMaturity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails">
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdAbstract" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdAbstract"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsTable"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdAbstract" xlink:to="MarketableSecuritiesInterCureLtdDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsTable" xlink:to="MarketableSecuritiesInterCureLtdDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfHoldingShare" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfHoldingShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesInterCureLtdDetailsLineItems" xlink:to="PercentageOfHoldingShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="IntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="xtlb-20231231.xsd#xtlb_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="AgreementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_AgreementDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreementMember" xlink:href="xtlb-20231231.xsd#xtlb_LicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="LicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YedaMember" xlink:href="xtlb-20231231.xsd#xtlb_YedaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="YedaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="IntangibleAssetsDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRoyalties" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="PercentageOfRoyalties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSublicenseFees" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfSublicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="PercentageOfSublicenseFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_LoansReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptOfRequiredInvestment" xlink:href="xtlb-20231231.xsd#xtlb_ReceiptOfRequiredInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ReceiptOfRequiredInvestment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirTerm" xlink:href="xtlb-20231231.xsd#xtlb_ExpirTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ExpirTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromContractsWithCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingLiability" xlink:href="xtlb-20231231.xsd#xtlb_RemainingLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="RemainingLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetOtherInformationMaturityDate" xlink:href="xtlb-20231231.xsd#xtlb_IntangibleAssetOtherInformationMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="IntangibleAssetOtherInformationMaturityDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetsRemainedAmount" xlink:href="xtlb-20231231.xsd#xtlb_AssetsRemainedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="AssetsRemainedAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreement" xlink:href="xtlb-20231231.xsd#xtlb_LicenseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="LicenseAgreement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfWarrantsAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DisclosureOfWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfWarrantsAbstract" xlink:to="WarrantsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DepositaryShareAxis" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="DepositaryShareAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositaryShareDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_DepositaryShareDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositaryShareAxis" xlink:to="DepositaryShareDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AmericanDepositorySharesMember" xlink:href="xtlb-20231231.xsd#xtlb_AmericanDepositorySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositaryShareAxis" xlink:to="AmericanDepositorySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AntidilutiveInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_AntidilutiveInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="WarrantsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GrossFundRaised" xlink:href="xtlb-20231231.xsd#xtlb_GrossFundRaised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="GrossFundRaised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssued" xlink:href="xtlb-20231231.xsd#xtlb_WarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="WarrantsIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfWarrantsExercisable" xlink:href="xtlb-20231231.xsd#xtlb_DescriptionOfWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="DescriptionOfWarrantsExercisable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ShareCapitalReservesandAccumulatedDeficitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalReservesandAccumulatedDeficitDetailsTable" xlink:to="ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalReservesandAccumulatedDeficitDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/ShareBasedPaymentDetails">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAbstract" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentAbstract" xlink:to="ShareBasedPaymentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NamePlanAxis" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="NamePlanAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NamePlanDomainDomain" xlink:href="xtlb-20231231.xsd#xtlb_NamePlanDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NamePlanAxis" xlink:to="NamePlanDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandElevenPlanMember" xlink:href="xtlb-20231231.xsd#xtlb_TwoThousandElevenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NamePlanAxis" xlink:to="TwoThousandElevenPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="ShareBasedPaymentDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentAwardRemainingContractualTerm" xlink:href="xtlb-20231231.xsd#xtlb_SharebasedPaymentAwardRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="SharebasedPaymentAwardRemainingContractualTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareExercisableInSharebasedPaymentArrangement" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="NumberOfShareExercisableInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseOfReserve" xlink:href="xtlb-20231231.xsd#xtlb_IncreaseOfReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="IncreaseOfReserve" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsReserve" xlink:href="xtlb-20231231.xsd#xtlb_OptionsReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="OptionsReserve" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingNumberOfOptionsAvailableForGrant" xlink:href="xtlb-20231231.xsd#xtlb_RemainingNumberOfOptionsAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="RemainingNumberOfOptionsAvailableForGrant" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsExercisableIntoOrdinaryShares" xlink:href="xtlb-20231231.xsd#xtlb_OptionsExercisableIntoOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="OptionsExercisableIntoOrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesExercisePrice" xlink:href="xtlb-20231231.xsd#xtlb_OrdinarySharesExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="OrdinarySharesExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtendedExpiryTerm" xlink:href="xtlb-20231231.xsd#xtlb_ExtendedExpiryTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="ExtendedExpiryTerm" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" xlink:href="xtlb-20231231.xsd#xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsLineItems" xlink:to="ShareBasedPaymentTransactionsToEmployeesAndNonEmployees" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_ApplicableTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfImpairmentOfGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfImpairmentOfGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_TaxEffectOfImpairmentOfGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsCapitalLossCarryforward" xlink:href="xtlb-20231231.xsd#xtlb_DeferredTaxAssetsCapitalLossCarryforward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="DeferredTaxAssetsCapitalLossCarryforward" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InterCureLtdMember" xlink:href="xtlb-20231231.xsd#xtlb_InterCureLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InterCureLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CanndocLtdMember" xlink:href="xtlb-20231231.xsd#xtlb_CanndocLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="CanndocLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_OtherFeeAndCommissionExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdministrativeFeeExpense" xlink:href="xtlb-20231231.xsd#xtlb_AdministrativeFeeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="AdministrativeFeeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfShare" xlink:href="xtlb-20231231.xsd#xtlb_PercentageOfShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="PercentageOfShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentMarketableSecuritie" xlink:href="xtlb-20231231.xsd#xtlb_CurrentMarketableSecuritie"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="CurrentMarketableSecuritie" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentExpense" xlink:href="xtlb-20231231.xsd#xtlb_RentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="RentExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/EarningsLossPerShareDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="warrants" xlink:href="xtlb-20231231.xsd#xtlb_warrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="warrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EachWarrantIsExercisableToShares" xlink:href="xtlb-20231231.xsd#xtlb_EachWarrantIsExercisableToShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="EachWarrantIsExercisableToShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="xtlb-20231231.xsd#xtlb_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="xtlb-20231231.xsd#xtlb_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonAdjustingEventsMember" xlink:href="xtlb-20231231.xsd#xtlb_NonAdjustingEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonAdjustingEventsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsExercisableSharebasedPaymentArrangement" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfShareOptionsExercisableSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ADSIssued" xlink:href="xtlb-20231231.xsd#xtlb_ADSIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ADSIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsFullyVested" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfOptionsFullyVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfOptionsFullyVested" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsVest" xlink:href="xtlb-20231231.xsd#xtlb_NumberOfOptionsVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfOptionsVest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisedPeriod" xlink:href="xtlb-20231231.xsd#xtlb_ExercisedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExercisedPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TerminationPeriod" xlink:href="xtlb-20231231.xsd#xtlb_TerminationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="TerminationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ifrs-full_InvestmentIncome" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLoanCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLoanCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ifrs-full_GrossLoanCommitments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanInterestRate" xlink:href="xtlb-20231231.xsd#xtlb_LoanInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="LoanInterestRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xtlb.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="xtlb-20231231.xsd#xtlb_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504070176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XTL BIOPHARMACEUTICALS LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XTLB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">544,906,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001023549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Ben-Gurion St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramat Gan<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5112001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Somekh Chaikin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel
Aviv, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Ben-Gurion St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramat Gan<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5112001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Shlomo Shalev<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-6116600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">+972-3-611-6605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548447312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 2,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CurrentMarketableSecurities', window );">Marketable securities &#8211; InterCure Ltd.</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">3,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total, Non-current assets</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="nump">4,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital - ordinary shares of NIS 0.1 par value: Authorized - December 31, 2023 and 2022 - 1,450,000,000; Issued and outstanding - December 31, 2023 and 2022 - 544,906,149.</a></td>
<td class="nump">14,120<span></span>
</td>
<td class="nump">14,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Additional paid in capital</a></td>
<td class="nump">146,326<span></span>
</td>
<td class="nump">146,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserve from transactions with non-controlling interests</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(158,246)<span></span>
</td>
<td class="num">(156,467)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 4,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_CurrentMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_CurrentMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504065520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares, par value (in New Shekels per share)</a></td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="nump">1,450,000,000<span></span>
</td>
<td class="nump">1,450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504271312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">$ (31)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(734)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(765)<span></span>
</td>
<td class="num">(880)<span></span>
</td>
<td class="num">(1,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RevaluationOfWarrantsToPurchaseAds', window );">Revaluation of warrants to purchase ADS's</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RevaluationOfMarketableSecurities', window );">Revaluation of marketable securities</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other finance income</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Other finance expenses</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income (expenses), net</a></td>
<td class="num">(1,017)<span></span>
</td>
<td class="num">(468)<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss) for the year</a></td>
<td class="num">$ (1,782)<span></span>
</td>
<td class="num">$ (1,348)<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings (loss) per share (in U.S. dollars): (in Dollars per share)</a></td>
<td class="num">$ (0.003)<span></span>
</td>
<td class="num">$ (0.002)<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in U.S. dollars): (in Dollars per share)</a></td>
<td class="num">$ (0.003)<span></span>
</td>
<td class="num">$ (0.002)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of issued ordinary shares (in Shares)</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">531,995,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted weighted average number of ordinary shares (in Shares)</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,909,149<span></span>
</td>
<td class="nump">615,548,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RevaluationOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluable of marketable securites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RevaluationOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RevaluationOfWarrantsToPurchaseAds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of warrants to purchase ads.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RevaluationOfWarrantsToPurchaseAds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503753520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Reserve from transactions with non-controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 13,182<span></span>
</td>
<td class="nump">$ 146,015<span></span>
</td>
<td class="num">$ (155,605)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss) for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants to ordinary shares</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">14,120<span></span>
</td>
<td class="nump">146,326<span></span>
</td>
<td class="num">(155,133)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss) for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,348)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">14,120<span></span>
</td>
<td class="nump">146,326<span></span>
</td>
<td class="num">(156,467)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss) for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,782)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14,120<span></span>
</td>
<td class="nump">$ 146,326<span></span>
</td>
<td class="num">$ (158,246)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 2,220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504023872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss) for the year</a></td>
<td class="num">$ (1,782)<span></span>
</td>
<td class="num">$ (1,348)<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities', window );">Adjustments to reconcile net income (loss) to net cash used in operating activities (a)</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(901)<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest from bank deposit</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(666)<span></span>
</td>
<td class="num">(865)<span></span>
</td>
<td class="num">(656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Losses from exchange rate differences on cash and cash equivalents</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract', window );"><strong>Income and expenses not involving operating cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RevaluationOfMarketableSecurities', window );">Revaluation of marketable securities</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
<td class="num">(747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RevaluationOfWarrantsToPurchase', window );">Revaluation of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Losses from exchange rate differences on cash and cash equivalents</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows', window );">Net income and expenses not involving operating cash flows</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="num">(1,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract', window );"><strong>Changes in operating asset and liability items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Decrease (increase) in prepaid expenses and other current assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in accounts payable</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Net operating asset and liability</a></td>
<td class="nump">64<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NoncashActivitiesAbstract', window );"><strong>(b) Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NoncashActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NoncashActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RevaluationOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluable of marketable securites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RevaluationOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RevaluationOfWarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of warrants to purchase .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RevaluationOfWarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of income and expenses not involving cash flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548454048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GeneralAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory', window );">GENERAL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 1:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">GENERAL</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            general description of the Company and its activity:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">XTL
Biopharmaceuticals Ltd. (the &#8220;Company&#8221;) is engaged in the development of therapeutics for the treatment of unmet medical
needs. The Company was incorporated under the Israeli Companies Law on March&#160;9, 1993. The registered office of the Company is located
at 26 Ben-Gurion Street, Ramat Gan, Israel. The Company has decided, at this time, to explore collaboration with a strategic partner
in order to execute the clinical trials. In parallel, the Company is looking to expand and identify additional assets to add to XTL&#8217;s
portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s American Depository Shares (&#8220;ADSs&#8221;) are listed for trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
and its ordinary shares are traded on the Tel-Aviv Stock Exchange (&#8220;TASE&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, the Company has a wholly-owned subsidiary, Xtepo Ltd. ("Xtepo"), which was incorporated in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company and Xtepo are heretofore referred to as &#8220;the Group&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            Group has incurred continuing losses and depends on outside financing resources to continue
                                            its activities. Based on existing business plans, the Company&#8217;s management estimates
                                            that its outstanding cash and cash equivalent balances will allow the Company to finance
                                            its activities which include, but are not limited to maintenance and ongoing expenses related
                                            to <span style="font-size: 10pt">hCDR1</span>, for an additional period of at least 12 months
                                            from the date of this report. However, the amount of cash which the Company will need to
                                            finance its future activities depends on numerous factors which include, but are not limited
                                            to future projects which the Company might acquire or other business development activities
                                            such as acquiring new technologies and/or changes in circumstances which are liable to cause
                                            significant expenses to the Company in excess of management&#8217;s current and known expectations
                                            as of the date of these Financial Statements and which will require the Company to reallocate
                                            funds against plans, also due to circumstances beyond its control.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to incur additional losses in 2024 arising from research and development activities, testing additional technologies
and operating activities, which will be reflected in negative cash flows from operating activities. In order to perform the clinical
trials aimed at developing a product until obtaining its marketing approval, the Company will need to raise additional funds by issuing
securities. The Company decided to seek collaboration with third parties to finance the clinical trials and continues to seek additional
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
                                            October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip
                                            and conducted a series of attacks on civilian and military targets, launched extensive rocket
                                            attacks and kidnapped many Israeli civilians and soldiers.&#160; Following the attack, Israel
                                            declared war against Hamas. In parallel, border clashes between Israel and the Hezbollah
                                            terrorist group on Israel&#8217;s northern border with Lebanon intensified and may escalate
                                            into a greater regional conflict. The Israel Defence Force (the &#8220;IDF&#8221;), the national
                                            military of Israel, is a conscripted military service, subject to certain exceptions. Since
                                            October 7, 2023, the IDF has called up several hundred thousand of its reserve forces to
                                            serve.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
a result, its operations in Israel may be disrupted by such absences, which disruption may materially and adversely affect its business,
prospects, financial condition and results of operations. In addition, since the commencement of these events, there have been continued
hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the
Houthi movement in Yemen). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations,
including Palestinian military organizations in the West Bank as well as other hostile countries, such as Iran, will join the hostilities.
Such clashes may escalate in the future into a greater regional conflict. Further, in April 2024, Iran launched a direct attack on Israel
involving hundreds of drones, ballistic missiles and cruise missiles and may attack again. Although until approval of these financial
statements, the impact of the war on the Company was negligible, it is currently not possible to predict the duration or severity of
the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly
evolving and developing, and could disrupt its business and operations, and hamper its ability to raise additional funds or sell its
securities, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
                                            March 19, 2024, the Company has entered into a binding term sheet, subject to due diligence,
                                            with THE SOCIAL PROXY Ltd. (the &#8220;Social Proxy&#8221;) an AI web data company, developing
                                            and powering a unique ethical, IP based, proxy and data extraction platform for AI &amp;
                                            BI Applications at scale (the &#8220;Term Sheet&#8221;).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Term Sheet, the Company will acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis
(the &#8220;Transaction&#8221;) in exchange for the issuance by the Company to the shareholders of the Social Proxy, by way of a private
placement, such number of ordinary shares of the Company, representing immediately after such issuance, 44.6% of the issued and outstanding
share capital of the Company and the payment of $430 thousands to the shareholders of the Social Proxy. In addition, as part of the Transaction,
the shareholders of Social Proxy will be issued additional warrants or ordinary shares, which may only be exercised or granted upon reaching
certain financial measured milestones within a period of up to 3 years from the closing of the Transaction. The Transaction is conditioned
upon certain closing conditions which are fully described in the Term Sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Social
Proxy will operate as fully owned subsidiary of the Company and its shareholders will be entitled to appoint 2 representatives to the
Company&#8217;s board of directors out of a total of up to 7 directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
proposed Transaction is part of the Company&#8217;s strategy to expand its assets portfolio with high potential assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition, the Company secured
an investment commitment from several shareholders (including one shareholder, who is also a related party), in the amount of
US$1,500 thousand through a private placement to be consummated upon and subject to the closing of the Transaction (the
&#8220;Private Placement&#8221;). In exchange for the investment in the Private Placement, the investors will be issued 1,500,000
units (reflecting a price per each unit of US$1.00) consisting of one ADS and one warrant, with each such warrant being exercised
during a period of five years from its issuance into one ADS at an exercise price of US$1.20 per warrant. The Investment is
conditioned upon customary closing conditions and obtaining shareholders&#8217; approval (which was approved on April 30, 2024 by Company&#8217;s shareholders meeting).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Definitions:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#8220;Related
party&#8221; - as the term is defined in IAS 24, <i>&#8220;Related Party Disclosures&#8221;</i> (&#8220;IAS 24&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">f.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Approval
                                            of financial statements:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
financial statements were approved by the Company&#8217;s Board of Directors (&#8220;BoD&#8221;) on April 30, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general hedge accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Hedge accounting<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g21A-24G_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_GeneralAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_GeneralAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548459456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Basis of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">BASIS OF PREPARATION</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 2:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BASIS
                                            OF PREPARATION</span></td>
</tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Statement
                                            of Compliance:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of the Company (the &#8220;Financial Statements&#8221;) have been prepared in accordance with International
Financial Reporting Standards (IFRSs), as issued by the International Accounting Standards Board (IASB).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Basis
                                            of measurement:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Financial Statements have been prepared under the historical cost convention, except for financial assets and liabilities measured at
fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Use
                                            of judgments and estimates:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of Financial Statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires
the Group&#8217;s management to exercise its judgment in the process of applying the Group&#8217;s accounting policies. Actual results
could significantly differ from the estimates and assumptions used by the Group&#8217;s management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Estimates
and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events
that are believed to be reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Critical
accounting estimates and assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounting
estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of
causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets &#8211; the intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested
at least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Translation
                                            of balances and transactions in foreign currency:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Functional
                                            currency and presentation currency:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Items
included in the Financial Statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment
in which the entity operates (the &#8220;Functional Currency&#8221;). The consolidated financial statements are presented in U.S. dollars,
which is the Functional Currency of each of the Group&#8217;s entities and the Company&#8217;s presentation currency and have been rounded
to the nearest thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Below
are the exchange rate of the U.S. dollar in relation to the NIS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exchange&#160;rate&#160;of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    $ 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>As of</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.627</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Transactions
                                            and balances:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Transactions
in a currency other than the Functional Currency (&#8220;Foreign Currency&#8221;) are translated into the Functional Currency using the
exchange rates at the dates of the transactions. After initial recognition, monetary assets and liabilities denominated in Foreign Currency
are translated at the end of each reporting period into the Functional Currency at the exchange rate at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Exchange
differences are recognized in the statement of comprehensive income (loss) in the line-item finance income (expenses), net. Non-monetary
assets and liabilities denominated in foreign currency and measured at cost are translated at the exchange rate at the date of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Initial
                                            application of new standards, amendments to standards and interpretations</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Amendment
to IAS 1, Presentation of Financial Statements: "Disclosure of Accounting Policies" (&#8220;the Amendment&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">According
to the Amendment, companies must provide disclosure of their material accounting policies rather than their material accounting policies.
Pursuant to the Amendment, accounting policy information is material if, when considered with other information disclosed in the financial
statements, it can be reasonably be expected to influence decisions that the users of the financial statements make on the basis of those
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Amendment also clarifies that accounting policy information is expected to be material if, without it, the users of the financial statements
would be unable to understand other material information in the financial statements. The Amendment also clarifies that immaterial accounting
policy information need not be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
a result of applying the Amendment, the extent of the accounting policy disclosure provided in the financial statements for 2023 was
reduced and adjusted according to the Company&#8217;s specific circumstances.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548613008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_MaterialAccountingPoliciesAbstract', window );"><strong>Material Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">MATERIAL ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE 3:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">MATERIAL
                                            ACCOUNTING POLICIES</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
accounting policies have been consistently applied to all the years presented, unless otherwise stated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; padding-right: 74.75pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Unamortized
                                            intangible assets (licenses and patent rights):</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
assets are reviewed for impairment once a year and whenever there are indicators of a possible impairment, in accordance with the provisions
of IAS 36, <i>Impairment of Assets</i> (see also Note 8). The amortization of an asset on a straight-line basis over its useful life
begins when the development procedure is completed and the asset is available for use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Research
                                            and development:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Research
expenditures are recognized as expenses when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Impairment of non-financial assets:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets which are not yet available for use are not amortized and impairment in their respect is tested at least every year. Depreciable
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable
amount is the higher of an asset&#8217;s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets
are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Non-financial
assets that sustained impairment are reviewed for possible reversal of the impairment at each date of the statement of financial position.
Company&#8217;s intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested at
least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Investments and other financial assets:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Group classifies its equity investments as financial assets at fair value through profit or loss (FVPL).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Share-based payment:</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group operates share-based payment plan to employees, directors, officers and to other service providers who render services that are
settled with the Group&#8217;s equity instruments. In this framework, the Company grants employees, directors, officers and other service
providers, from time to time, and, at its discretion, options to purchase shares of the Company. The fair value of options granted is
measured according to the Black-Scholes model as of the date of grant (the date of the Company's Board of Directors' decision unless
shareholders&#8217; approval is required) and recognized as an expense in the statement of comprehensive income (loss) and correspondingly
carried to equity. The total amount recognized as an expense over the vesting term of the options (the term over which all pre-established
vesting conditions are expected to be satisfied) is determined by reference to the fair value of the options granted at grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
each reporting date, the Company revises its estimates of the number of options that are expected to vest based on the non-market vesting
conditions and recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive income (loss) with
a corresponding adjustment in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
options are exercised, the Company issues new shares. The proceeds net of any directly attributable transaction costs are credited to
share capital (nominal value) and share premium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="padding-bottom: 0pt; text-align: left; padding-right: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Earning (loss) per share:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
earning (loss) per share is calculated by dividing the earnings attributable to equity holders of the Company by the weighted average
number of ordinary shares outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average
number of shares and ordinary shares that are potentially issuable in connection with service-provider share-based payment and warrants,
using the treasury stock method. If the inclusion of potentially issuable shares would decrease loss per share, the potentially issuable
shares are excluded from the weighted average number of shares outstanding used to calculate diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">f.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Leases:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
16 requiring lessees to recognize a liability for a lease, reflecting the discounted value of future lease payments, and a &#8220;right
to use&#8221; asset, with respect to all leases (except as stated below), with no distinction between financing lease and operating lease.
However, IFRS 16 allows lessees not to apply these provisions for short-term leases, by groups of underlying assets, and for leases in
which the underlying asset of the lease is of low value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company elected to apply the practical expedient for short-term leases (leases with a lease term of 12 months or less).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company leases an office. The Company has a termination option with a notice period of 60 days. Therefore, the enforceable period of
the lease is 60 days, and the lease qualifies for the short-term lease exemption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_MaterialAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_MaterialAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548608832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Financial Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments and Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 4:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>FINANCIAL
                                            INSTRUMENTS AND FINANCIAL RISK MANAGEMENT</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left; padding-right: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            risk management:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: left; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            risk factors:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s activities expose it to a variety of financial risks: market risks and liquidity risk. The Group&#8217;s overall risk management
program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group&#8217;s financial
performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk
management is carried out by the Group&#8217;s management under policies approved by the Board. The Group&#8217;s treasury identifies,
evaluates and defines financial risks. The Board provides written principles for overall risk management, as well as written policies
covering specific areas, such as foreign exchange risk, interest rate risk and investment of excess liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left; padding-right: 141.75pt"><span style="font-family: Times New Roman, Times, Serif">Market
                                            risks:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Foreign
currency exchange rate risk:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures with respect to the NIS.
Foreign exchange risk arises from assets and liabilities denominated in currency that is other than the functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group treasury&#8217;s risk management policy is to hold NIS-denominated cash and cash equivalents in the amount of the anticipated NIS-denominated
liabilities for six to twelve consecutive months from time to time and this in line with the directives of the Company&#8217;s Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, had the Group&#8217;s functional currency strengthened by 10% against the NIS with all other variables remaining
constant, loss for the year would have been $144 thousand lower (2022 - loss would have been $152 thousand higher; 2021 - profit approximately
$328 thousand lower), mainly as a result of exchange rate changes on translation of other accounts receivable and exchange rate changes
on NIS-denominated cash and cash equivalents and investment in marketable securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Equity
securities price risk:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
group&#8217;s exposure to equity securities price risk arises from investments held by the group and classified in the balance sheet
at fair value through profit or loss (currently only the investment in the shares of InterCure Ltd).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left; padding-right: 141.75pt"><span style="font-family: Times New Roman, Times, Serif">Liquidity
                                            risk:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
flow forecasting is performed by the Group&#8217;s management both in the entities of the Group and aggregated by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s management monitors rolling forecasts of the Group&#8217;s liquidity requirements to ensure it has sufficient cash to meet
operations. The Group does not use borrowing credit facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Surplus
cash held to finance operating activities is invested in interest bearing current accounts and time deposits. The Company holds cash
and deposits with banks and financial institutions and in the estimation of management, the credit risk for these financial instruments
is low.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
channels were chosen by reference to their appropriate maturities or liquidity to provide sufficient cash balances to the Group as determined
by the abovementioned forecasts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December&#160;31, 2023 and 2022, the maturity of the Group&#8217;s financial liabilities are less than one year from each of the reporting
dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: left; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Capital
                                            management:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group&#8217;s objectives when managing capital are to ensure the Group&#8217;s ability to continue as a going concern in order to provide
returns on investments for shareholders and benefits for other interested parties and to maintain an optimal capital structure to reduce
the cost of capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
order to maintain or adjust the capital structure, the Group may take a variety of measures such as issue new shares or sell assets to
reduce liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left; padding-right: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            instruments by category:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
asset of the group is classified in one category: measured subsequently at fair value or through profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, all financial liabilities were classified in one category: Trade and other account payables, measured
at amortized cost.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: left; padding-right: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Changes in financial liabilities classified as cash flow from finance activities:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as
    of December 31, 2020</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,637</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation during the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(719</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercises during
    the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(864</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December
    31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Revaluation during
    the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,054</span></td><td style="padding-bottom: 1.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December
    31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation during the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548579712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 5:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>CASH
                                            AND CASH EQUIVALENTS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash in banks and on hand</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">133</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,413</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Bank deposits with original
    maturities of three months or less*</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,268</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">681</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,401</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deposits with maturity of less than three months, which in 2023 bear an interest of 4.41%-5.1% per annum (in 2022: 4.5 %).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
currencies in which the cash and cash equivalents are denominated or linked to are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. dollars</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,009</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NIS (not linked to the
    Israeli CPI)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,019</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">85</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,401</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548544128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities &#8211; InterCure Ltd<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_MarketableSecuritiesInterCureLtdAbstract', window );"><strong>Marketable Securities &#8211; InterCure Ltd [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_MarketableSecuritiesInterCureLtdTextBlock', window );">MARKETABLE SECURITIES &#8211; InterCure Ltd</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>MARKETABLE
                                            SECURITIES &#8211; InterCure Ltd</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">All
                                            marketable securities held by the Company constitute Level 1 financial instruments, as defined
                                            in IFRS 13 - &#8220;<i>Fair Value Measurement</i>&#8221;. Level 1 inputs are quoted prices
                                            (unadjusted) in active markets for identical assets or liabilities that the entity can access
                                            at the measurement date.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left; padding-right: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Company holds the following financial instruments:</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities - InterCure Ltd</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">605</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,627</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of December 31,
2023 and 2022 the Company holds approximately 1.04% of InterCure Ltd&#8217;s shares (the shares are traded at the Tel-Aviv Stock Exchange
- &#8220;TASE&#8221; and at the Nasdaq Capital Market - &#8220;Nasdaq&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:</span></td></tr></table>

<p style="text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair
    value opening balance</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,627</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,158</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,411</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in fair value during the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,022</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,531</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">747</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value closing balance</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">605</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,627</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,158</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_MarketableSecuritiesInterCureLtdAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_MarketableSecuritiesInterCureLtdAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_MarketableSecuritiesInterCureLtdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_MarketableSecuritiesInterCureLtdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503827664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Othe Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAbstract', window );"><strong>Prepaid Expenses and Othe Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory', window );">PREPAID EXPENSES AND OTHE CURRENT ASSETS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 7:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>PREPAID
                                            EXPENSES AND OTHE CURRENT ASSETS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Composition:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other receivables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Government
    authorities (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">85</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The government authorities are monetary items, which are denominated or linked is NIS.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amount of government authorities is a reasonable approximation of the fair value because the effect of discounting is immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504518816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 8:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>INTANGIBLE
                                            ASSETS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
                                            January 7, 2014, the Company signed a licensing agreement with Yeda, as amended on September
                                            6, 2015, to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus
                                            (&#8220;SLE&#8221;). The license from Yeda also included all clinical data of the phase 1
                                            and phase 2A conducted in the hCDR1. The terms of the licensing agreement include, among
                                            other things, expense reimbursement for patent expenses payable in six installments, certain
                                            milestone payments to Yeda, low single-digit royalties based on net sales, and additional
                                            customary royalties to the Office of the Israel innovation authority.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
the license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical
trial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European
Union&#8217;s Group of Five. In addition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20%
of whatever it receives from any sub-licensee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
the license agreement, the Company is also required to meet certain development milestones including the delivery of a trial protocol
to Yeda by January 1, 2016 (which it delivered), receipt of investment of at least $5 million by August 1, 2016 (of which $4 million
was received in April 2015) and commencement of a Phase II clinical trial by January 1, 2017. In subsequent amendments signed between
the Company and Yeda, the parties agreed to postpone the last two installments of the patent expense reimbursement until April 7, 2017,
receipt of the remainder of the required $5 million investment by May 1, 2017 and commencement of a Phase 2 clinical trial in respect
of hCDR1 by October 1, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
term of the license agreement is the later of the date of expiry of the last of the licensed patents or the expiry of a continuous period
of 11 years after first commercial sale in any country during which there shall not have been a first commercial sale in the U.S., EU,
Japan, China or any OECD member. The license agreement may be terminated by the Company without cause upon 60 days prior written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
license agreement may also be terminated by Yeda upon 45 days prior written notice if either the Company fails to meet certain development
milestones or commercial sale shall have commenced and there shall be a period of 6 months of no sales, subject to certain exceptions.
Yeda shall also be entitled to terminate the license agreement if the Company were to commence legal action against Yeda challenging
the validity of any of the licensed patents, and the Company was unsuccessful in such challenge, in which event the Company would be
required to pay to Yeda liquidated damages of $8 million. Either party may also terminate the license agreement in the case of a material
breach that remains uncured or certain bankruptcy events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, all expense reimbursement for patent expenses to Yeda in the amount of $380 thousands were paid, except for a remaining
liability of $127 thousand, disclosed under accounts payable. The reason for the remaining liability is that the Company decided not
to conduct the phase 2 by itself and to look for a strategic partner. As a result, the second milestone (commencement of Phase 2) was
not met yet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accordingly,
the license agreement may be terminated by Yeda upon 45 days prior written notice. To this date the Company and Yeda have held discussions
regarding further amendment to the payment scheme under the license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company exclusively licensed two families of patents relating to hCDR1:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">One
expired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January
14, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company reviews the hCDR1 asset for impairment once a year on December 31 or more frequently if events or changes in circumstances indicate
that there is an impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
the carrying amount exceeds their recoverable amount, the assets are reduced to their recoverable amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
asset is not ready for usage (the development was paused before finishing) and therefore has not been amortized yet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
order to measure the recoverable amount of the hCDR1 asset,&#160;Company management deducted the fair value of its other assets and liabilities
from the amount representing its market value as of December 31, 2023. The resulting fair value attributable to the hCDR1 asset was higher
than the book value of the hCDR1 asset and therefore no impairment was recorded in the Company's financial statements as of December
31, 2023, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Composition
                                            and movement:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no </span><span style="font-family: Times New Roman, Times, Serif">changes or movements in 2023, 2022 and 2021 and the balance remained
$380 thousands.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503157008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">ACCOUNTS PAYABLE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
                            9:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ACCOUNTS
                                            PAYABLE</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Composition:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
carrying amount of accounts payable is a reasonable approximation of their fair value because the effect of discounting is immaterial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">The carrying amount of accounts payable is denominated in the following currencies:</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">157</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NIS
    (not linked to the Israeli CPI)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548579712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfWarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 10:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>WARRANTS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2017, the Company raised gross funds amounted to $5,300 thousand by issuance of 2,400,000 ADS's and 2,400,000
warrants to purchase the same amount of ADS's. The warrants shall be exercisable six months following the issuance date and will expire
five and one-half years from the issuance date. The number of warrants and their exercise price could be adjusted upon standard anti-dilution
protection clauses and subject to a cashless exercise mechanism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
13 "Fair Value Measurement", ("IFRS 13"), defines fair value as the price that would be received from selling an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal
or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the
asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
13 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level
of input that is significant to the fair value measurement. IFRS 13 establishes three levels of inputs that may be used to measure fair
value.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
    1 -&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">quoted prices in active markets for identical
    assets or liabilities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
    2 -&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">inputs other than Level 1 that are observable,
    either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical
    or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
    3 -&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">unobservable inputs that are supported by
    little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounted for the warrants issued to investors with a cashless exercise mechanism as a non-current liability according to provisions
of IAS 32. The Company measured the warrants at fair value by using a Black-Scholes model.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
warrants were measured in each reporting period. Changes in the fair value were recognized in the Company`s statement of comprehensive
income (loss) as financial income or expense, as appropriate. The warrants were classified as level&#160;3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company used the following assumptions to estimate the Investors' warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">0.19</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 10pt">60.83-62.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual
    term life (in years) (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.63-0.68</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend
    yield (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; -sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected
life - the expected life was based on the expiration date of the warrants.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">For
more information about the warrants exercised during 2021, see Note 18.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
2022, all warrants have expired and as such, as of December 31, 2023 and 2022 there are no outstanding warrants.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503458336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital, Reserves and Accumulated Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Share Capital, Reserves and Accumulated Deficit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareCapitalReservesAndRetainedEarnings', window );">SHARE CAPITAL, RESERVES AND ACCUMULATED DEFICIT</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
                            11:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>SHARE
                                            CAPITAL, RESERVES AND ACCUMULATED DEFICIT</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s Ordinary shares of NIS&#160;0.1 par value are traded on the TASE. The Company&#8217;s ADSs are listed for trading on the Nasdaq Capital Market in the U.S. Each ADS consist of 100 Company&#8217;s Ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Ordinary
shares confer upon their holders voting rights and right to participate in the shareholders&#8217; meeting, right to receive dividends
and the right to participate in the excess of assets upon liquidation of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Company&#8217;s authorized share capital is 1,450,000,000 Ordinary Shares.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareCapitalReservesAndRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareCapitalReservesAndRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503749392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedPaymentAbstract', window );"><strong>Share-Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENT</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">NOTE
                            12:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">SHARE-BASED
                                            <b>PAYMENT</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2011, the Company&#8217;s Board of Directors approved the adoption of an employee share option plan for the grant of options
exercisable into shares of the Company, in accordance with section 102 to the Israeli Tax Ordinance (the &#8220;2011 Plan&#8221;) which
ended after 10 years, and the holding of up to 10,000,000 shares in the framework of the 2011 Plan, for option allocation to Company
employees, directors and consultants. The terms of the options, which will be granted according to the 2011 Plan, including the option
period, exercise price, vesting period and exercise period shall be determined by the Company&#8217;s Board of Directors on the date
of the actual allocation. On January 29, 2020, it was decided to increase the reserve by 10 million and on May 19, 2020 it was decided
to increase the reserve by another 10 million options. The total reserve after these increases is 30 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
of December&#160;31, 2023, the remaining number of options available for grant under the 2011 Plan is 17,450,000 options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 2, 2023, the Company&#8217;s shareholders approved the grant of options exercisable into 150,000 of the Company&#8217;s ordinary
shares to one of Company&#8217;s directors for an exercise price of NIS 0.0495 per share (USD 0.014 per share, respectively, based on
the exchange rate reported by the Bank of Israel on the same day). The options were fully vested on the day of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 14, 2023, Company&#8217;s Board of directors approved retroactively to extend the expire date of the 2011 plan by additional 5
years to August 29, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Regarding
options granted subsequent to balance sheet date and the extension of exercise period for certain directors, refer to Note 19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Movements
in the number of share options and their related weighted average exercise prices (in dollars) during the years ended December 31, 2023,
2022 and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,200,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.07</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,433,331</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(366,669</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at end of
    year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable at end of
    year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,733,330</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,399,998</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Below
is information about the exercise price (in dollars) and the remaining contractual life (in years) for options outstanding at end of
year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options<br/>
    outstanding at<br/>
 end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of<br/> exercise prices<br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average<br/> remaining<br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options<br/>
    outstanding at <br/> end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of<br/> exercise prices<br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> remaining<br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,900,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.14</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.07</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,900,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.14</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.94</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    <br/> outstanding at<br/>
    end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range
    of<br/> exercise prices <br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    <br/> average <br/> remaining <br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 31%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,900,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 31%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.14</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.94</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Share
based expenses recognized in the Company&#8217;s statements of comprehensive income (loss) for the years ended December 31, 2023, 2022
and 2021 for grant of options to employees and service providers were $3, $14 and $37 thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes the outstanding options as of December 31, 2023 that have been granted to the Company&#8217;s executives, directors
and consultants &#8211;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    <br/> &#160;outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Position</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>date
                                            (*)</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/>
    price in<br/>
    NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
                                            value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>USD
                                            in<br/>
                                            thousands</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Vesting
    schedule</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">750,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Four Directors</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 30, 2014</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4325-0.4915</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">One Director</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 25, 2015</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chairman of Board</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 31, 2016</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">12 equal portions each quarter over a period of 3 years from the date of grant</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 7, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">12 equal portions each quarter over a period of 3 years from the grant date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Director</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">March 2, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0495</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Fully vested on date of grant</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Date of the Company's Board of Directors&#8217; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
fair value for options granted in 2023 is estimated at the date of grant using a Black-Scholes model with the following weighted average
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    2, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected life (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">We
have calculated the volatility based on the Company's historical volatility. The share price was set according to the Company's share
market value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">No
options were granted in 2022 and 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645500597504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 13:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RESEARCH
                                            AND DEVELOPMENT EXPENSES</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 67%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Fees
    related to service providers</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548599488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE</b> 14:</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> GENERAL AND ADMINISTRATIVE EXPENSES</b></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Management fees and expenses relating
    to service providers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share based payment expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents and fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">137</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors&#8217; fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investor relations and travel</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Rent and office maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">229</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">330</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">291</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">381</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">734</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">850</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,001</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548506800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expenses), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FinanceIncomeExpensesNetAbstract', window );"><strong>Finance Income (Expenses), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">FINANCE INCOME (EXPENSES), NET</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 15:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>FINANCE
                                            INCOME (EXPENSES), NET</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of marketable securities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,531</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Bank account management fees and commissions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exchange rate differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total finance expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,058</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,558</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of warrants to purchase ADS's</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">719</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income on bank deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exchange rate differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total finance income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,090</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,487</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income (expenses), net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,017</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(468</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,466</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FinanceIncomeExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FinanceIncomeExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504559568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 16:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>TAXES
                                            ON INCOME</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: left; padding-right: 128.7pt"><span style="font-family: Times New Roman, Times, Serif">Tax
                                            rates applicable to the Company:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Since
the tax year 2018, the taxable income of the Company and its subsidiary is subject to a corporate tax rate of 23%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">The Group&#8217;s carryforward tax losses as of December&#160;31, 2023, totaled approximately $39 million which may be carried forward and offset against taxable income in the future for an indefinite period and approximately $23 million capital loss carryforward which may be offset against future capital gain. The Company did not recognize deferred taxes for carryforward losses and temporary differences, as well as capital losses and real losses, because their utilization in the foreseeable future is not probable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">The main reconciling items between the &#8220;theoretical&#8221; tax expense, assuming that all the income were taxed at the regular tax rate applicable to companies in Israel (23%) and the taxes recorded in the statements of comprehensive income (loss) in the reporting year are revaluation expenses (income) not recognized for tax purposes, changes in taxes resulting from exchange rate differences, changes in deferred tax for tax losses carryforwards, and taxable losses for which no deferred taxes were recognized.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: left; padding-right: 85.05pt"><span style="font-family: Times New Roman, Times, Serif">Tax
                                            assessments:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company and Xtepo filed self-assessments that are deemed final through the 2018 tax year.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="text-align: left; padding-right: 85.05pt"><span style="font-family: Times New Roman, Times, Serif">Unrecognized
                                            deferred taxes:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, the Company&#8217;s had a deferred tax liability of approximately $141 thousand and $86 thousand, respectively
due to an investment in marketable securities &#8211; InterCure Ltd. The deferred tax liability was fully offset by a deferred tax asset
due to utilization of tax losses from prior years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645502971840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>TRANSACTIONS
                                            AND BALANCES WITH RELATED PARTIES</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s key management personnel who are included, along with other factors, in the definition of related party, as above in
IAS 24, includes directors, members of the executive committee and InterCure Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Compensation
to key management personnel:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
compensation to key management personnel for employee services provided to the Company is shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Management fees, directors, and
    consulting fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">262</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">263</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">243</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">276</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Number of persons</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company pays to an accounting firm of which the company's CFO is a Partner (&#8220;accounting firm&#8221;), a monthly fees of NIS 15
thousand (approximately $4 thousand) for controller and bookkeeping services. Total fees for controller and bookkeeping services for
the years ended 2023, 2022 and 2021 were approximately $49 thousand, $53 thousand and $66 thousands respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, as of December 31, 2023 and 2022, the Company&#8217;s balances with key management personnel and the accounting firm, totaled
approximately $32 thousand and $34 thousands (all of which were linked to the NIS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
further information regarding share-based payment to related parties, see also Note 12 above and Note 19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">InterCure
Ltd:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, the Company's share in the shares of InterCure Ltd was 1.04%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company's investment in the shares of InterCure Ltd is presented as Marketable securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023 and 2022, the Company&#8217;s balances of InterCure Ltd's shares total approximately $605 thousand and $1,627 thousand,
respectively. See also Note 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company subleases an office from Canndoc Ltd., which is a subsidiary of InterCure Ltd. During 2023, 2022 and 2021, the Company recorded
rent expenses of approximately $11 thousands, $5 thousands and $14 thousands to Canndoc Ltd. As of December 31, 2023, the balance due
from Canndoc Ltd was $3 thousands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Regarding
investment agreement signed subsequent to balance sheet date with one of the Company&#8217;s shareholders see Note 1d.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503010384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 18:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>EARNINGS
                                            (LOSS) PER SHARE</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Basic
earnings (loss) per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
calculation of basic earnings per share (EPS) is based on the following profit (loss) attributable to shareholders and weighted-average
number of ordinary shares outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Profit
(loss) attributed to ordinary shareholders (basic)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive
    income (loss) for the year</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,782</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
number of ordinary shares (basic)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued ordinary shares at January
    1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">514,205,799</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued March 7,2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,634,406</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued May 4, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">639,508</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued July 6, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,145,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued August 30, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,179,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued September 1, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">414,384</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issued October 11, 2021
    due to warrant exercise</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,713</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of ordinary shares (basic)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">531,995,467</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Diluted
earnings (loss) per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
calculation of diluted EPS is based on the following profit (loss) attributable to shareholders and weighted-average number of ordinary
shares outstanding after adjustment for the effects of all dilutive potential ordinary shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Profit
(loss) attributed to ordinary shareholders (diluted)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S. dollars
    in thousands</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive income (loss)
    for the year (basic)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,782</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrant revaluation
    income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(660</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,782</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(225</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
number of ordinary shares (diluted)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number of ordinary
    shares (basic)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">531,995,467</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effect of warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83,552,979</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of ordinary shares (diluted)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">615,548,446</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
2023 and 2022 all options and warrants were excluded from the diluted weighted average number of shares calculation because their effect
would have been anti-dilutive. In 2021,&#160;12,400,000&#160;options and&#160;650,000&#160;warrants (each warrant is exercisable to&#160;100&#160;shares)
were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
average market value of the Company&#8217;s shares for calculating the dilutive effect of share options and warrants was based on quoted
market prices for the year during which the options were outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548510912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 19:</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>SUBSEQUENT
                                            EVENTS</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 17, 2024 the Company&#8217;s board of directors approved the grant of 148,500 options exercisable into 148,500 ADSs of the Company,
out of which 138,500 are subject to shareholders meeting to be held on April 30, 2024 (which was approved on April 30, 2024 by Company&#8217;s shareholders
meeting) to certain officers and directors of the Company.
100,000 options will be fully vested on date of grant and 48,500 options will vest according to Company&#8217;s 2011 share option plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
March 19, 2024, the Company signed a binding term sheet, subject to due diligence, with THE SOCIAL PROXY Ltd. (the &#8220;Social Proxy&#8221;)
to acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis. The acquisition included, among
other things, the grant to the Social Proxy current shareholders of the right to appoint of 2 new directors to the Company&#8217;s board
of directors, against the resignation of 2 Company&#8217;s current directors. Consequently, the Company approved to extend the resigning
directors options exercise period for an additional 9 months period and up to an aggregate 12 months period following such termination
date, which is subject to shareholders approval</span> (which was approved on April 30, 2024 by Company&#8217;s shareholders meeting).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Company has secured a commitment of an investment of an amount of US$1,500 thousands through a private placement to be
consummated upon the closing of the Transaction, see also Note 1d.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On March 27, 2024 the Company entered into a loan agreement with the
Social Proxy. According to the loan agreement, on March 27, 2024, the Company provided the Social Proxy with a loan of US$150 thousand.
The loan bears an annual interest of 8%. The loan and accrued interest will be repaid at the earlier of (1) 120 days following March 27,
2024 or (2) the date upon which the parties decide to abandon attempts for Transaction. Upon repayment date, Social Proxy may repay the
outstanding loan and accrued interest in 18 equal monthly installments. Social Proxy provided a first priority floating charge over all
of it assets as a security to ensure repayment of the loan and accrued interest.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548680096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; padding-right: 74.75pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets:</span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Unamortized
                                            intangible assets (licenses and patent rights):</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
assets are reviewed for impairment once a year and whenever there are indicators of a possible impairment, in accordance with the provisions
of IAS 36, <i>Impairment of Assets</i> (see also Note 8). The amortization of an asset on a straight-line basis over its useful life
begins when the development procedure is completed and the asset is available for use.</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1.25in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify; padding-right: 1.25in"><span style="font-family: Times New Roman, Times, Serif">Research
                                            and development:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Research
expenditures are recognized as expenses when incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Impairment of non-financial assets:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets which are not yet available for use are not amortized and impairment in their respect is tested at least every year. Depreciable
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognized for the amount by which the asset&#8217;s carrying amount exceeds its recoverable amount. The recoverable
amount is the higher of an asset&#8217;s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets
are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Non-financial
assets that sustained impairment are reviewed for possible reversal of the impairment at each date of the statement of financial position.
Company&#8217;s intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested at
least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Investments and other financial assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Investments and other financial assets:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Group classifies its equity investments as financial assets at fair value through profit or loss (FVPL).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">d.</span></td><td style="text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif">Share-based payment:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Group operates share-based payment plan to employees, directors, officers and to other service providers who render services that are
settled with the Group&#8217;s equity instruments. In this framework, the Company grants employees, directors, officers and other service
providers, from time to time, and, at its discretion, options to purchase shares of the Company. The fair value of options granted is
measured according to the Black-Scholes model as of the date of grant (the date of the Company's Board of Directors' decision unless
shareholders&#8217; approval is required) and recognized as an expense in the statement of comprehensive income (loss) and correspondingly
carried to equity. The total amount recognized as an expense over the vesting term of the options (the term over which all pre-established
vesting conditions are expected to be satisfied) is determined by reference to the fair value of the options granted at grant date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">At
each reporting date, the Company revises its estimates of the number of options that are expected to vest based on the non-market vesting
conditions and recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive income (loss) with
a corresponding adjustment in equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">When
options are exercised, the Company issues new shares. The proceeds net of any directly attributable transaction costs are credited to
share capital (nominal value) and share premium.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earning (loss) per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">e.</span></td><td style="padding-bottom: 0pt; text-align: left; padding-right: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">Earning (loss) per share:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
earning (loss) per share is calculated by dividing the earnings attributable to equity holders of the Company by the weighted average
number of ordinary shares outstanding during the period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average
number of shares and ordinary shares that are potentially issuable in connection with service-provider share-based payment and warrants,
using the treasury stock method. If the inclusion of potentially issuable shares would decrease loss per share, the potentially issuable
shares are excluded from the weighted average number of shares outstanding used to calculate diluted earnings per share.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">f.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Leases:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">IFRS
16 requiring lessees to recognize a liability for a lease, reflecting the discounted value of future lease payments, and a &#8220;right
to use&#8221; asset, with respect to all leases (except as stated below), with no distinction between financing lease and operating lease.
However, IFRS 16 allows lessees not to apply these provisions for short-term leases, by groups of underlying assets, and for leases in
which the underlying asset of the lease is of low value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company elected to apply the practical expedient for short-term leases (leases with a lease term of 12 months or less).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company leases an office. The Company has a termination option with a notice period of 60 days. Therefore, the enforceable period of
the lease is 60 days, and the lease qualifies for the short-term lease exemption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548546224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Basis of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Schedule of Exchange Rate</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Below
are the exchange rate of the U.S. dollar in relation to the NIS:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exchange&#160;rate&#160;of</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    $ 1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>As of</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">December 31, 2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.627</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503067136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Financial Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments and Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Changes in financial liabilities classified as cash flow from finance activities:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as
    of December 31, 2020</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,637</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation during the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(719</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercises during
    the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(864</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December
    31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Revaluation during
    the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,054</span></td><td style="padding-bottom: 1.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance as of December
    31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revaluation during the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503048368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash in banks and on hand</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">133</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,413</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Bank deposits with original
    maturities of three months or less*</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,268</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">681</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,401</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deposits with maturity of less than three months, which in 2023 bear an interest of 4.41%-5.1% per annum (in 2022: 4.5 %).</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock', window );">Schedule of Cash and Cash Equivalents are Denominated or Linked</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
currencies in which the cash and cash equivalents are denominated or linked to are:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. dollars</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">382</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,009</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NIS (not linked to the
    Israeli CPI)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,019</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">85</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,401</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that may be relevant to users of financial statements in understanding the financial position and liquidity of an entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about currencies in which the cash and cash equivalents are denominated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548654160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities &#8211; InterCure Ltd (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_MarketableSecuritiesInterCureLtdAbstract', window );"><strong>Marketable Securities &#8211; InterCure Ltd [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Schedule of Financial Instruments</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The Company holds the following financial instruments:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities - InterCure Ltd</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">605</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,627</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock', window );">Schedule of Changes in Marketable Securities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fair
    value opening balance</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,627</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,158</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,411</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    in fair value during the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,022</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,531</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">747</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Fair
    value closing balance</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">605</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,627</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,158</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about changes in marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_MarketableSecuritiesInterCureLtdAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_MarketableSecuritiesInterCureLtdAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548669184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Othe Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAbstract', window );"><strong>Prepaid Expenses and Othe Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Schedule of Composition of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Composition:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other receivables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Government
    authorities (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">85</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The government authorities are monetary items, which are denominated or linked is NIS.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504304736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock', window );">Schedule of Composition of Accounts Payable</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Composition:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock', window );">Schedule of Carrying Amount of Accounts Payable</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The carrying amount of accounts payable is denominated in the following currencies:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">157</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NIS
    (not linked to the Israeli CPI)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of carrying amount of other accounts payable Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of composition of accounts payable Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548576128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Schedule of Assumptions of Investors' Warrants</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
Company used the following assumptions to estimate the Investors' warrants:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free
    interest rate (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">0.19</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected
    volatility (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 10pt">60.83-62.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Contractual
    term life (in years) (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.63-0.68</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend
    yield (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; -sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected
life - the expected life was based on the expiration date of the warrants.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503552880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedPaymentAbstract', window );"><strong>Share-Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock', window );">Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Movements
in the number of share options and their related weighted average exercise prices (in dollars) during the years ended December 31, 2023,
2022 and 2021 are as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> exercise<br/> price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,200,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.07</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,433,331</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(366,669</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.08</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at end of
    year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable at end of
    year</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,733,330</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.05</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,399,998</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock', window );">Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Below
is information about the exercise price (in dollars) and the remaining contractual life (in years) for options outstanding at end of
year:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options<br/>
    outstanding at<br/>
 end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of<br/> exercise prices<br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average<br/> remaining<br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options<br/>
    outstanding at <br/> end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of<br/> exercise prices<br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    average<br/> remaining<br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,900,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.14</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.07</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,900,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.14</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.94</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    <br/> outstanding at<br/>
    end of year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range
    of<br/> exercise prices <br/> (USD)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    <br/> average <br/> remaining <br/> contractual life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 31%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,900,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 31%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03 - 0.14</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.94</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,400,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock', window );">Schedule of Outstanding Options</a></td>
<td class="text">The
table below summarizes the outstanding options as of December 31, 2023 that have been granted to the Company&#8217;s executives, directors
and consultants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options
    <br/> &#160;outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Position</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>date
                                            (*)</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise<br/>
    price in<br/>
    NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
                                            value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>USD
                                            in<br/>
                                            thousands</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Vesting
    schedule</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">750,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Four Directors</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 30, 2014</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4325-0.4915</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">One Director</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 25, 2015</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chairman of Board</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March 31, 2016</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">12 equal portions each quarter over a period of 3 years from the date of grant</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 7, 2020</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">103</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">12 equal portions each quarter over a period of 3 years from the grant date</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Director</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">March 2, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.0495</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Fully vested on date of grant</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,550,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Date of the Company's Board of Directors&#8217; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock', window );">Schedule of Fair Value for Options Granted</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
fair value for options granted in 2023 is estimated at the date of grant using a Black-Scholes model with the following weighted average
assumptions:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    2, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected life (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about the exercise price and the remaining contractual life for options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about the number and weighted average exercise prices of share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about the outstanding options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value for options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548525280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 67%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"><span style="font-family: Times New Roman, Times, Serif">Fees
    related to service providers</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503067936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 67%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Management fees and expenses relating
    to service providers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share based payment expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents and fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">137</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors&#8217; fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investor relations and travel</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Rent and office maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">202</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">229</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">330</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">291</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">381</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">734</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">850</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,001</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645502864432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expenses), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FinanceIncomeExpensesNetAbstract', window );"><strong>Finance Income (Expenses), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock', window );">Schedule of Finance Income (Expenses), Net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of marketable securities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,531</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Bank account management fees and commissions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exchange rate differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total finance expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,058</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,558</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of warrants to purchase ADS's</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">719</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">747</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income on bank deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exchange rate differences</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total finance income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,090</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,487</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance income (expenses), net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,017</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(468</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,466</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FinanceIncomeExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FinanceIncomeExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The table disclose the finance income (cost) for during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548657344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory', window );">Schedule of Compensation to Key Management Personnel for Employee Services</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
compensation to key management personnel for employee services provided to the Company is shown below:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Management fees, directors, and
    consulting fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">262</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">263</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">243</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">276</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Number of persons</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504069120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Profit
(loss) attributed to ordinary shareholders (basic)</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive
    income (loss) for the year</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,782</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of Weighted-Average Number of Ordinary Shares (Basic)</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
number of ordinary shares (basic)</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued ordinary shares at January
    1</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">514,205,799</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued March 7,2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,634,406</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued May 4, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">639,508</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued July 6, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,145,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued August 30, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,179,452</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued September 1, 2021 due to warrant exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">414,384</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Issued October 11, 2021
    due to warrant exercise</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">776,713</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of ordinary shares (basic)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">531,995,467</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock', window );">Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Profit
(loss) attributed to ordinary shareholders (diluted)</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">U.S. dollars
    in thousands</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive income (loss)
    for the year (basic)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,782</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrant revaluation
    income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(660</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,782</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(225</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock', window );">Schedule of Weighted-Average Number of Ordinary Shares (Diluted)</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
number of ordinary shares (diluted)</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average number of ordinary
    shares (basic)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">531,995,467</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Effect of warrants</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83,552,979</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number
    of ordinary shares (diluted)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">544,906,149</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">615,548,446</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of profit (loss) attributed to ordinary shareholders (diluted).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted-average number of ordinary shares (diluted).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645505235024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GeneralDetailsLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IssuedAndOutstandingRate', window );">Issued and outstanding, rate</a></td>
<td class="nump">44.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PaymentOfShareholders', window );">Payment to shareholders (in Dollars) | $</a></td>
<td class="nump">$ 430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PeriodOfClosingTransaction', window );">Closing period of transaction</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_InvestorIssued', window );">Investor issued (units)</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PricePerUnit', window );">Price per unit (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ADSIssued', window );">ADS issued</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PrivatePlacementWarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantExercisedPeriod', window );">Warrant exercised period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=xtlb_PrivatePlacementsMember', window );">Private Placement [Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GeneralDetailsLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Investment commitment (in Dollars) | $</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ADSIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ADSIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_GeneralDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_GeneralDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_InvestorIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investor issued shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_InvestorIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_IssuedAndOutstandingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_IssuedAndOutstandingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PaymentOfShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PaymentOfShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PeriodOfClosingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction of closing period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PeriodOfClosingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PrivatePlacementWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents private placement warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PrivatePlacementWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WarrantExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise period of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WarrantExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=xtlb_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=xtlb_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504382336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Preparation (Details) - Schedule of Exchange Rate<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeRatesAbstract', window );"><strong>Schedule of Exchange Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Exchange rate</a></td>
<td class="nump">3.627<span></span>
</td>
<td class="nump">3.519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503117840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Financial Risk Management (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments and Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfFunctionalCurrency', window );">Percentage of functional currency</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Profit (loss) on exchange rate changes in translation</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PercentageOfFunctionalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of functional currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PercentageOfFunctionalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503803536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities - Warrants [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Balance at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">$ 2,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettlementsFairValueMeasurementLiabilities', window );">Revaluation during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ExercisesDuringTheYear', window );">Exercises during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Balance at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettlementsFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettlementsFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ExercisesDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercises during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ExercisesDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503798800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CashandCashEquivalentsDetailsLineItems', window );"><strong>Cash and Cash Equivalents (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DepositsWithMaturity', window );">Maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CashandCashEquivalentsDetailsLineItems', window );"><strong>Cash and Cash Equivalents (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate per annum</a></td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CashandCashEquivalentsDetailsLineItems', window );"><strong>Cash and Cash Equivalents (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate per annum</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_CashandCashEquivalentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_CashandCashEquivalentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DepositsWithMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits with maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DepositsWithMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645505106592">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfCashAndCashEquivalentsAbstract', window );"><strong>Schedule of Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash in banks and on hand</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Bank deposits with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 2,094<span></span>
</td>
<td class="nump">$ 2,969<span></span>
</td>
<td class="nump">$ 3,631<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Deposits with maturity of less than three months, which in 2023 bear an interest of 4.41%-5.1% per annum (in 2022: 4.5 %).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645505160832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems', window );"><strong>Schedule of Cash and Cash Equivalents are Denominated or Linked [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 2,094<span></span>
</td>
<td class="nump">$ 2,969<span></span>
</td>
<td class="nump">$ 3,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=xtlb_ForeignCurrenciesMember', window );">U.S. dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems', window );"><strong>Schedule of Cash and Cash Equivalents are Denominated or Linked [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=xtlb_IsraeliCpiForwardContractsMember', window );">NIS (not linked to the Israeli CPI) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems', window );"><strong>Schedule of Cash and Cash Equivalents are Denominated or Linked [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=xtlb_ForeignCurrenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=xtlb_ForeignCurrenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=xtlb_IsraeliCpiForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=xtlb_IsraeliCpiForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645548568528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities &#8211; InterCure Ltd (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems', window );"><strong>Disclosure of Marketable Securities Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfHoldingShare', window );">Percentage of shares hold</a></td>
<td class="nump">1.04%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PercentageOfHoldingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of holding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PercentageOfHoldingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503711328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities &#8211; InterCure Ltd (Details) - Schedule of Financial Instruments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfFinancialInstrumentsAbstract', window );"><strong>Schedule of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CurrentMarketableSecurities', window );">Marketable securities - InterCure Ltd</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_CurrentMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_CurrentMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503778560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities &#8211; InterCure Ltd (Details) - Schedule of Changes in Marketable Securities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems', window );"><strong>Schedule of Changes in Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAvailableforsale', window );">Fair value opening balance</a></td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="nump">$ 3,158<span></span>
</td>
<td class="nump">$ 2,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GainsLossesOnFairValueOnMarketableSecurities', window );">Changes in fair value during the year</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(1,531)<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAvailableforsale', window );">Fair value closing balance</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="nump">$ 3,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAvailableforsale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAvailableforsale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_GainsLossesOnFairValueOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) arising from changes in fair value marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_GainsLossesOnFairValueOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503242464">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Othe Current Assets (Details) - Schedule of Composition of Prepaid Expenses and Other Current Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of Composition of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The government authorities are monetary items, which are denominated or linked is NIS.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645536528848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2017</div></th>
<th class="th"><div>Aug. 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Received amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ReceiptOfRequiredInvestment', window );">Receipt of required investment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ExpirTerm', window );">Expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Required payment of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RemainingLiability', window );">Remaining liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IntangibleAssetOtherInformationMaturityDate', window );">Expires term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company exclusively licensed two families of patents relating to hCDR1:One
expired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January
14, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AssetsRemainedAmount', window );">Assets remained amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_LicenseAgreement', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under
the license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical
trial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European
Union&#8217;s Group of Five. In addition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20%
of whatever it receives from any sub-licensee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfRoyalties', window );">Percentage of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfSublicenseFees', window );">Percentage of sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfRoyalties', window );">Percentage of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfSublicenseFees', window );">Percentage of sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_YedaMember', window );">Yeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RemainingLiability', window );">Remaining liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AgreementAxis=xtlb_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Receipt of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_AssetsRemainedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets remained amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_AssetsRemainedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ExpirTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expir term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ExpirTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_IntangibleAssetOtherInformationMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_IntangibleAssetOtherInformationMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_IntangibleAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_IntangibleAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_LicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_LicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PercentageOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PercentageOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PercentageOfSublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sublicense fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PercentageOfSublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ReceiptOfRequiredInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of required investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ReceiptOfRequiredInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RemainingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RemainingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_YedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_YedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_AgreementAxis=xtlb_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_AgreementAxis=xtlb_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503734608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable (Details) - Schedule of Composition of Accounts Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfCompositionOfAccountsPayableAbstract', window );"><strong>Schedule of Composition of Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued expenses</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Total accounts payable</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfCompositionOfAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfCompositionOfAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645536433200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems', window );"><strong>Schedule of Carrying Amount of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TypeOfCurrencyAxis=xtlb_UnitedStatesDollarMember', window );">U.S. dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems', window );"><strong>Schedule of Carrying Amount of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TypeOfCurrencyAxis=xtlb_IsraeliNewShekelMember', window );">NIS (not linked to the Israeli CPI) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems', window );"><strong>Schedule of Carrying Amount of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_TypeOfCurrencyAxis=xtlb_UnitedStatesDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_TypeOfCurrencyAxis=xtlb_UnitedStatesDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_TypeOfCurrencyAxis=xtlb_IsraeliNewShekelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_TypeOfCurrencyAxis=xtlb_IsraeliNewShekelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504162640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsDetailsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GrossFundRaised', window );">Gross funds raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">ADS's issued</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DescriptionOfWarrantsExercisable', window );">Description of warrants exercisable</a></td>
<td class="text">The warrants shall be exercisable six months following the issuance date and will expire
five and one-half years from the issuance date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted', window );">Expected volatility, description</a></td>
<td class="text">the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal
or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the
asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsDetailsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DepositaryShareAxis=xtlb_AmericanDepositorySharesMember', window );">American Depository Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsDetailsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">ADS's issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information about how the expected volatility used for pricing share options granted was determined, including an explanation of the extent to which expected volatility was based on historical volatility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DescriptionOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of warrants shall be exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DescriptionOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_GrossFundRaised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gross fund raised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_GrossFundRaised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DepositaryShareAxis=xtlb_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DepositaryShareAxis=xtlb_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503939808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Schedule of Assumptions of Investors' Warrants<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems', window );"><strong>Schedule of Assumptions of Investors' Warrants [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Contractual term life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems', window );"><strong>Schedule of Assumptions of Investors' Warrants [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Contractual term life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems', window );"><strong>Schedule of Assumptions of Investors' Warrants [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Contractual term life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Expected
life - the expected life was based on the expiration date of the warrants.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503474656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital, Reserves and Accumulated Deficit (Details) - Ordinary Shares [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems', window );"><strong>Share Capital, Reserves and Accumulated Deficit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares, par value | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized | shares</a></td>
<td class="nump">1,450,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503576576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2023</div></th>
<th class="th">
<div>Aug. 29, 2011 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 29, 2011 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedPaymentDetailsLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IncreaseOfReserve', window );">Increase of reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_OptionsReserve', window );">Total options reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RemainingNumberOfOptionsAvailableForGrant', window );">Remaining number of options available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_OptionsExercisableIntoOrdinaryShares', window );">Options exercisable into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_OrdinarySharesExercisePrice', window );">Ordinary shares exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0495<span></span>
</td>
<td class="nump">$ 0.014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ExtendedExpiryTerm', window );">Extended expiry term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees', window );">Share based expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NamePlanAxis=xtlb_TwoThousandElevenPlanMember', window );">2011 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedPaymentDetailsLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_SharebasedPaymentAwardRemainingContractualTerm', window );">Share based payment award remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement', window );">Number of share holding of up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ExtendedExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended expiry term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ExtendedExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_IncreaseOfReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents increase in reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_IncreaseOfReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_OptionsExercisableIntoOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options exercisable into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_OptionsExercisableIntoOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_OptionsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents options reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_OptionsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_OrdinarySharesExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_OrdinarySharesExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RemainingNumberOfOptionsAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining number of options available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RemainingNumberOfOptionsAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedPaymentDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedPaymentDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payment transactions to employees and non-employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_SharebasedPaymentAwardRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased payment award remaining contractual term for the during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_SharebasedPaymentAwardRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NamePlanAxis=xtlb_TwoThousandElevenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NamePlanAxis=xtlb_TwoThousandElevenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645536978304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, outstanding at beginning of year</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">16,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, outstanding at beginning of year</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options, Granted</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of options, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,433,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(366,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, outstanding at end of year</a></td>
<td class="nump">12,550,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, outstanding at end of year</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, exercisable at end of year</a></td>
<td class="nump">12,550,000<span></span>
</td>
<td class="nump">10,733,330<span></span>
</td>
<td class="nump">7,399,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, exercisable at end of year</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=xtlb_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=xtlb_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645499263728">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Range of exercise prices (USD)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesOneMember', window );">Range of Exercise Prices One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,900,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 11 months 8 days<span></span>
</td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesOneMember', window );">Range of Exercise Prices One [Member] | Bottom of Range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Range of exercise prices (USD)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesOneMember', window );">Range of Exercise Prices One [Member] | Top of Range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Range of exercise prices (USD)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesTwoMember', window );">Range of Exercise Prices Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Range of exercise prices (USD)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">3 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesThreeMember', window );">Range of Exercise Prices Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Range of exercise prices (USD)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years 2 months 1 day<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=xtlb_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,550,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">16,200,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Expected
life - the expected life was based on the expiration date of the warrants.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=xtlb_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=xtlb_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis=xtlb_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645536648160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment (Details) - Schedule of Outstanding Options - 12 months ended Dec. 31, 2023<br> $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>&#8362; / shares</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThreeMember', window );">December 30, 2014 [Member] | Four Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition', window );">Position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Four Directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">December 30, 2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value USD in thousands | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Vesting schedule</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThreeMember', window );">December 30, 2014 [Member] | Four Directors [Member] | Bottom of range [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice', window );">Exercise price in NIS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.4325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThreeMember', window );">December 30, 2014 [Member] | Four Directors [Member] | Top of range [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice', window );">Exercise price in NIS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandDateIssuedFiveMember', window );">March 25, 2015 [Member] | One Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition', window );">Position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">One Director<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">March 25, 2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice', window );">Exercise price in NIS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value USD in thousands | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Vesting schedule</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandDateIssuedEightMember', window );">March 31, 2016 [Member] | Chairman of Board [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition', window );">Position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Chairman of Board<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">March 31, 2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice', window );">Exercise price in NIS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value USD in thousands | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Vesting schedule</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">12 equal portions each quarter over a period of 3 years from the date of grant<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedElevenMember', window );">July 7, 2020 [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition', window );">Position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Chief Executive Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">July 7, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice', window );">Exercise price in NIS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value USD in thousands | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Vesting schedule</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">12 equal portions each quarter over a period of 3 years from the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThirteenMember', window );">March 2, 2023 [Member] | Director [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Outstanding Options [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition', window );">Position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Director<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">March 2, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice', window );">Exercise price in NIS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value USD in thousands | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Vesting schedule</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Fully vested on date of grant<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Date of the Company's Board of Directors&#8217; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_FourDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_FourDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=xtlb_GrandDateIssuedFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=xtlb_GrandDateIssuedFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_OneDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_OneDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=xtlb_GrandDateIssuedEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=xtlb_GrandDateIssuedEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_ChairmanOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_ChairmanOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=xtlb_GrandsDateIssuedThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503464528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment (Details) - Schedule of Fair Value for Options Granted - Black-Scholes-Merton Options pricing model [Member]<br></strong></div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems', window );"><strong>Schedule of Fair Value for Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">67.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest</a></td>
<td class="nump">4.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=xtlb_BlackScholesMertonOptionsPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=xtlb_BlackScholesMertonOptionsPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504723632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Details) - Schedule of Research and Development Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract', window );"><strong>Schedule of Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FeesRelatedToServiceProviders', window );">Fees related to service providers</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FeesRelatedToServiceProviders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees related to service providers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FeesRelatedToServiceProviders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645503954016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Schedule of General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Management fees and expenses relating to service providers</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based payment expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PatentsAndFees', window );">Patents and fees</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors&#8217; fees</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Investor relations and travel</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RentAndOfficeMaintenance', window );">Rent and office maintenance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional services</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 734<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 1,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from travel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PatentsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses for patents and fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PatentsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RentAndOfficeMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense rent and office maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RentAndOfficeMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645537160912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expenses), Net (Details) - Schedule of Finance Income (Expenses), Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FinanceExpensesAbstract', window );"><strong>Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FinanceExpensesRevaluationOfMarketableSecurities', window );">Revaluation of marketable securities</a></td>
<td class="num">$ (1,022)<span></span>
</td>
<td class="num">$ (1,531)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Bank account management fees and commissions</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ExchangeDifferences', window );">Exchange rate differences</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total finance expenses</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FinanceIncomeAbstract', window );"><strong>Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RevaluationOfWarrantsToPurchaseADSs', window );">Revaluation of warrants to purchase ADS's</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RevaluationMarketableSecurities', window );">Revaluation of marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnDeposits', window );">Interest income on bank deposits</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange rate differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total finance income</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_FinanceIncomeexpensesNet', window );">Finance income (expenses), net</a></td>
<td class="num">$ (1,017)<span></span>
</td>
<td class="num">$ (468)<span></span>
</td>
<td class="nump">$ 1,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on deposits. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ExchangeDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ExchangeDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FinanceExpensesRevaluationOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance expenses revaluation of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FinanceExpensesRevaluationOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_FinanceIncomeexpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_FinanceIncomeexpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RevaluationMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RevaluationMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RevaluationOfWarrantsToPurchaseADSs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RevaluationOfWarrantsToPurchaseADSs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504740048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfImpairmentOfGoodwill', window );">Carryforward tax losses</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DeferredTaxAssetsCapitalLossCarryforward', window );">Capital loss carryforward</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Tax rate</a></td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Deferred tax liability</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfImpairmentOfGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount representing the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to impairment of goodwill. [Refer: Accounting profit; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfImpairmentOfGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DeferredTaxAssetsCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DeferredTaxAssetsCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645504164208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFeeAndCommissionExpense', window );">Monthly fees</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">&#8362; 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_AdministrativeFeeExpense', window );">Total fees</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Balance of key management personnel &amp; accounting firm, total</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_PercentageOfShare', window );">Percentage of shares</a></td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RentExpense', window );">Rent expenses</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Balance due from Canndoc Ltd</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_InterCureLtdMember', window );">InterCure Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_CurrentMarketableSecuritie', window );">Balances of shares total</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_CanndocLtdMember', window );">Canndoc Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_RentExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_AdministrativeFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_AdministrativeFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_CurrentMarketableSecuritie">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_CurrentMarketableSecuritie</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_PercentageOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_PercentageOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_InterCureLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_InterCureLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_CanndocLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=xtlb_CanndocLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645502923616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employee Services<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract', window );"><strong>Schedule of Compensation to Key Management Personnel For Employee Services [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Management fees, directors, and consulting fees</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of persons</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645502354208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Options</a></td>
<td class="nump">12,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_warrants', window );">Warrants</a></td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_EachWarrantIsExercisableToShares', window );">Each warrant is exercisable to shares</a></td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_EachWarrantIsExercisableToShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Each warrant is exercisable to shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_EachWarrantIsExercisableToShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_warrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_warrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645569642864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract', window );"><strong>Schedule of Profit Loss Attributed to Ordinary Shareholders Basic [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Total comprehensive income (loss) for the year</a></td>
<td class="num">$ (1,782)<span></span>
</td>
<td class="num">$ (1,348)<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income attributable to non-controlling interests. [Refer: Non-controlling interests; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645536920864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_IssuedOrdinarySharesAtJanuary1', window );">Issued ordinary shares at January 1</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">514,205,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WeightedAverageNumberOfOrdinarySharesbasic', window );">Weighted average number of ordinary shares (basic)</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">531,995,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DateAxis=xtlb_IssuedMarch72021DueToWarrantExerciseMember', window );">Issued March 7,2021 due to warrant exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_Issued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,634,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DateAxis=xtlb_IssuedMay42021DueToWarrantExerciseMember', window );">Issued May 4, 2021 due to warrant exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_Issued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">639,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DateAxis=xtlb_IssuedJuly62021DueToWarrantExerciseMember', window );">Issued July 6, 2021 due to warrant exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_Issued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,145,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DateAxis=xtlb_IssuedAugust302021DueToWarrantExerciseMember', window );">Issued August 30, 2021 due to warrant exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_Issued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,179,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DateAxis=xtlb_IssuedSeptember12021DueToWarrantExerciseMember', window );">Issued September 1, 2021 due to warrant exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_Issued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">414,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_DateAxis=xtlb_IssuedOctober112021DueToWarrantExerciseMember', window );">Issued October 11, 2021 due to warrant exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_Issued', window );">Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">776,713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_Issued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued March 7,2021 due to warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_Issued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_IssuedOrdinarySharesAtJanuary1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_IssuedOrdinarySharesAtJanuary1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WeightedAverageNumberOfOrdinarySharesbasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of ordinary shares (basic).

..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WeightedAverageNumberOfOrdinarySharesbasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DateAxis=xtlb_IssuedMarch72021DueToWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DateAxis=xtlb_IssuedMarch72021DueToWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DateAxis=xtlb_IssuedMay42021DueToWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DateAxis=xtlb_IssuedMay42021DueToWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DateAxis=xtlb_IssuedJuly62021DueToWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DateAxis=xtlb_IssuedJuly62021DueToWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DateAxis=xtlb_IssuedAugust302021DueToWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DateAxis=xtlb_IssuedAugust302021DueToWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DateAxis=xtlb_IssuedSeptember12021DueToWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DateAxis=xtlb_IssuedSeptember12021DueToWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_DateAxis=xtlb_IssuedOctober112021DueToWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_DateAxis=xtlb_IssuedOctober112021DueToWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645505672736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract', window );"><strong>Schedule of Profit Loss Attributed to Ordinary Shareholders Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTax', window );">Total comprehensive income (loss) for the year (basic)</a></td>
<td class="num">$ (1,782)<span></span>
</td>
<td class="num">$ (1,348)<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WarrantRevaluationIncome', window );">Warrant revaluation income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_comprehensiveIncome', window );">Comprehensive income</a></td>
<td class="num">$ (1,782)<span></span>
</td>
<td class="num">$ (1,348)<span></span>
</td>
<td class="num">$ (225)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WarrantRevaluationIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant revaluation income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WarrantRevaluationIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_comprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_comprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645569666368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted) - Number of shares [Member] - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfSharesAbstract0', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WeightedaverageNumberOfOrdinarySharesbasic', window );">Weighted-average number of ordinary shares (basic)</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">531,995,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_EffectOfWarrants', window );">Effect of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,552,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_WeightedAverageNumberOfOrdinarySharesdiluted', window );">Weighted average number of ordinary shares (diluted)</a></td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">544,906,149<span></span>
</td>
<td class="nump">615,548,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_EffectOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_EffectOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NumberOfSharesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NumberOfSharesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WeightedAverageNumberOfOrdinarySharesdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of ordinary shares (diluted).

..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WeightedAverageNumberOfOrdinarySharesdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_WeightedaverageNumberOfOrdinarySharesbasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average number of ordinary shares (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_WeightedaverageNumberOfOrdinarySharesbasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=xtlb_NumberOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=xtlb_NumberOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139645505135856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Non adjusting Events [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 19, 2024</div></th>
<th class="th"><div>Mar. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement', window );">Options exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ADSIssued', window );">ADS share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Shareholders meeting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfOptionsFullyVested', window );">Options fully vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_NumberOfOptionsVest', window );">Options vest for share option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_ExercisedPeriod', window );">Option exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_TerminationPeriod', window );">Updated options exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Investment amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLoanCommitments', window );">Loan value (in Dollars)</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xtlb_LoanInterestRate', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLoanCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows for gross commitments to receive a loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLoanCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ADSIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ADSIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_ExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercised period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_ExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_LoanInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_LoanInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NumberOfOptionsFullyVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares options fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NumberOfOptionsFullyVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NumberOfOptionsVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NumberOfOptionsVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options exercisable in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xtlb_TerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors termination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xtlb_TerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xtlb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=xtlb_NonAdjustingEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=xtlb_NonAdjustingEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M0V!C@M]I+6";KAIXC7L#+='E&@.RH<#'C7N9*IBEXH&XWH_W/T'*&,%04<U
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M!)WVJ#JG02UR7=*@P :6H%-@^9HTJ$6Q/0T*]HX>.NU5=4F#6I30-"BPP2/
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M@ :L =NR&QKUX>7J=E'=E!'(PV#G8;!3>XU387B9S4:3!1C,YZ/%_%;GS\Z
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M83 72+9UC<7S#5"^F3J^LYUX(*M*F0DW2QN\@@6H;\U<Z)$[N!2D!B8)9TA
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M ]O_00] OO(7L4SH7[0_:&T+1:60+#\8PPCRM*C^R?,A$&<& &HV< X&3M/
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MN?!&J+NV,E8)!&LE%W09$KW1?BVD(&QZJ%B(5EH/%V8PJ+%\4]JJBLXKUK<
M#,A6,*.&DZ;BO*$]LJI4E3^\D;G1S2H>3XYGYY<POEX""66I20M(D\XI8 (+
M\27] R;(S_NOWKH,IO=+4VG#]\U&,*"?Q7&M+%1JQ*EJC=/>V'MQ!2S!(<\B
M<HY/KUP/&_PB*O)&&3!A94E*F@"A7Z0KY3?Q0;;:0S'X\@8(28+"KTE4EK ,
M4^D&^42X<"X=07+)W4'LM:I>'-_J6SC3%#?B[*Y8RV:E>L'7QU=G22P"R67
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MFATPW,='ACK,,T!B(:>1/(N$=N;I6'&/.SB4$I5>$7@HZ E,7(4V'J%)5=8
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MBXRP)L^9F1LO-RUTHH.MA(IG5:@)U;+DJB*;&3#MZC2E$0<3#"U:)J@,88(
MQ&XPJ45B$%%I,.*Q62R,Q<I)OL2TKU#=XH;=)N*NME5>8W"24D8"S1J>VJH9
M3R0YV,&8TZB$ 1G=Y%R #=A(*'G?2TR%Q(F) E*U;SQM6(_)W'%04=@<PJ'
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MFBQ3SBT:+E>\K;H=,#3A4TAH! !6;XF;IB"V2QYVP+8'%!K?<\Z*7)8X63+
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MG(]#T&W;:R=6U;[5;)6EQN6')?TI4#L#VB^4LH>).Z#_]\Q_ 5!+ P04
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MC^D"^V51-);XN+R/<\^]U.E&J@>]$J)D3WE6Z+/>JBS7)X.!CE<BY[HOUZ+
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MHUG4;.^S"TUV@_Y$/L?JF@)]=S2560I 49GI-HT8?^1I9I*(0&:SK *DU6[
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MX(IMA)VKW1WNZ[EP>+D2IGG#KO7M7_B0;XQ5U3Z8&%1<ME_VNN_#4<!5^$9
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MQVM@UG2_;^[-'7+'U)93D4O,"=KM#'H^J*8O-Q,C:]<+-])09W5F05<9*NM
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M (\;0G YQURB% JN=W.-.GUN<+><_V!@54DT?>O/W5I)?*H%RD=^U]9PD.P
M_7L8<AAJ!+\2=8/=L)%N'6+A4>:\<0G%0$XGVU/+Y8#R>-@$&,#=<,3;UR W
M-/3$914R6LNS["!$'^YNO'>TUU!66'%^>Y*<JU4@WG"T>'+1$IG1!4*&&4'V
MC@DZH5U'M8O4CNA:BZRCTK9ZZAD4$"RN]+XY_5X\*QCTTM"R.$5:G[LI>:/7
M[3=?'>:)98)J'D_Z[.?.['K'#94!YAYS(A2G[<<6L\I]EJFUM8UNT(,!^Z*>
M*?1V&4[9N>V]U'8\$WR(^]U^V#:QG*.[=A,G!5^BK]V6W+#7)\9'8X31E?4]
M!/_>GQZW WW:M1+\349N>VGE7>E;T!-81[IIE_!Z]0V<S[R%I#+"D64](ZR/
M:^7 7%+Y_>'24&^OL%MCV6>5E-NF%RVW^U(HX:XATBUZ.AV>O>$M5F)O-#[7
M=O#2:3GL7&,*,"M_64-?Z4JY<*-I1]O[X'FX!CU/#Y?)&VY6V#69A Q#1X.3
MCQ$SX8(67IPN_:5HJ1U>L?QCCG=:,#0!OV=:N^:%%FAOR8O_ %!+ P04
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M @RKS\/>.9CK6G8.)T4H$>!K)VM%YX8I;TPIC((FR8??@7D/<-8#GD*RK47
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M"V5I[OEE01\:U,Z!SG.E[,9P =I/U^0W4$L#!!0    ( -1TGEB[9W9'*P,
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M$4*!N74(C'X/>(5".""B<;_%##N33G%_O4-_ZWTG7Y;,X)42WWAARVDX"J'
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MBKUN1WZ[L:KV8W:I+ UMORSIE43M+I!\I93=;9R![MV=_0902P,$%     @
MU'2>6 *Y >4' P  ;P<  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
MK55-;]LP#+W[5P@N4'1 %L?.Y](D0).N6($5*)IV.PP[*#8="Y6E3)*;]M^/
MDATG&UQCAUUL22;YR/=,:K:7ZEEG (:\YESHN9\9LYL&@8XSR*GNRAT(_))*
ME5.#6[4-]$X!39Q3SH.HUQL%.67"7\S<V;U:S&1A.!-PKX@N\IRJMR5PN9_[
MH7\X>&#;S-B#8#';T2VLP3SM[A7N@CI*PG(0FDE!%*1S_RJ<+H?6WAE\8[#7
M)VMB*]E(^6PWM\G<[]F$@$-L; 2*KQ=8 ><V$*;QJXKIUY#6\71]B'[C:L=:
M-E3#2O+O+#'9W)_X)(&4%MP\R/T7J.IQ"<:2:_<D^])V\,DG<:&-S"MGS"!G
MHGS3UXJ'$X=)[QV'J'*(7-XED,ORFAJZF"FY)\I:8S2[<*4Z;TR."2O*VBC\
MRM#/+.ZH>@9#-QS(&N)",<- D_.S212&E^16&%"K0@'Y:A)R\6CM](=98!#9
M^@=QA;(L4:)W4,*(W$EA,DT^BP22/P,$F'*==W3(>QFU1KR&N$OZ88=$O:C?
M$J]?\]!W\?K_@8<?5QMM%/Y//YN8*'$&S3BVQZ9Z1V.8^]A$&M0+^(OSLW#4
MNVRI8E!7,6B+OEACSR8%UB!3<L,$%3&C'+/'= OL)*.;$FX-V9SP8P9D)?,=
M%6\DDSS1Q.!)*CGV.!-;DM;8[(@]]5 TR#>@/!3.L\)9]2+OJ;ON>@DZ4Z71
M 6/)0E.1:.^HBJ>/JGS\2X]1;TC"SB@:DQ8*AS6%PW^F<)51L0674^/_T<1F
M:_1F-D]@\B/,2<$X>QW!;V 9 MM"Y,!EW03N&1'DS2[P< _(#]65+._2[ZQ;
M-+BA3'DOE!=("5X%5MX-Y2@O5*3W.^%P0J+.( R]JA0/(Z3H1TJ_! M!MT,)
MY"+L6. /=C'LA[@8#\:G0#&7^A3HJ' )UJ1S<#($<U!;-^HUB64A3#D/Z]/Z
M-KDJA^C1O+R*4.PM_KB$0XJNO>X8157E>"\W1N[<2-U(@P/:+3.\$4%9 _R>
M2FD.&PM0W[&+WU!+ P04    " #4=)Y83E1(LJL"  #C!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6RE5$UOVS ,O?M7$!XPM$,1?R3]RA(#2=IM
M/70+FG8[##LH-A,+M25/DI/NWX^2$\\;TEQVL46)?.]1%#G:2O6L<T0#+V4A
M]-C/C:F&0:#3'$NF>[)"02<KJ4IFR%3K0%<*6>:"RB*(P_ B*!D7?C)R>W.5
MC&1M"BYPKD#79<G4KRD6<COV(W^_\<#7N;$;03*JV!H7:)ZJN2(K:%$R7J+0
M7 I0N!K[DV@X'5A_Y_"5XU9WUF S64KY;(V[;.R'5A 6F!J+P.BWP1D6A04B
M&3]WF'Y+:0.[ZSWZ!Y<[Y;)D&F>R^,8SDX_]*Q\R7+&Z, ]R^PEW^9Q;O%06
MVGUAV_A>7/N0UMK(<A=,"DHNFC][V=U#)^ J?"4@W@7$3G=#Y%3>,,.2D9);
M4-:;T.S"I>JB21P7MB@+H^B44YQ)Y@HKQC.X?:$R:]3 1 9?3(XPJY5"86"B
M-1H-)X]L6: ^'06&:&UPD.XHI@U%_ I%%,.]%";7<"LRS/X&"$AO*SK>BY[&
M1Q%O,.U!/SJ#.(S[1_#Z[27T'5[_?R_A^V2IC:*7]./0-30D@\,DMKN&NF(I
MCGUJ'XUJ@W[R]DUT$;X_DL*@36%P##U94+=F=8$@5S"3924U=Z^>S%>S4_^D
M=RBGXZP=IJ%'5<%RB<JCRGBV,K8\L??46_2\3!8%4QJX )/+6I,$[>V$>=@5
M)ITP15A\XUX<Q-=P&7D?Y0:5H'%@/%83AB)6.CQY=PI1!-' &X1P=>Y9^Y$*
MMV[=H>O.%$(I!1H:0, -EOH,MCE/<W>2H9#48\P@Z5! V3[3BFOX?+?H'2I2
MT&F\$M7:C1<-J:R%:7JPW6TGV*1IW#_NS?B[9VK-A88"5Q0:]B[/?5#-2&D,
M(RO7QDMI:"BX94Y3&)5UH/.5E&9O6()VKB>_ 5!+ P04    " #4=)Y8YI6?
M(,$"  "Z!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R=5=]OVC 0
M?L]?<<JDJ94F\@,H'8-(T&X:#YU0:;>':0\F.8C5Q,YLI[3__<X.9'2B4;67
MV&?????=Y_@\V4GUH'-$ T]E(?34SXVIQD&@TQQ+IGNR0D$[&ZE*9LA4VT!7
M"EGF@LHBB,/P(B@9%WXR<6M+E4QD;0HN<*E UV7)U/,<"[F;^I%_6+CEV]S8
MA2"95&R+*S3WU5*1%;0H&2]1:"X%*-Q,_5DTG@^MOW/XSG&GC^9@*UE+^6"-
M13;U0TL("TR-16 T/.(5%H4%(AJ_]YA^F](&'L\/Z%]<[53+FFF\DL4/GIE\
MZE_ZD.&&U86YE;NON*_'$4QEH=T7=HWO@)S36AM9[H.)0<E%,[*GO0Y' 9?A
M*P'Q/B!VO)M$CN4U,RR9*+D#9;T)S4Y<J2Z:R'%A#V5E%.URBC/)+$UE+8R&
M)7MFZP+A[,X.^GP2&(*W3D&ZAYHW4/$K4%$,-U*87,-GD6'V$B @7BVY^$!N
M'G<B7F/:@W[T >(P[G?@]=MB^PZO_]9B?\[6VBCZ,WZ=*K<!&YP&L[=EK"N6
MXM2GZZ!1/:*?O'\7782?.J@.6JJ#+O1D1;<OJXFBW,"5+"NIN?N+R?RWBE/4
M.\%/4S_*,O9(>2S7J#Q2W[/JVR.(O?O>JN=ELBB8TL %F%S6FHE,>W>*90A5
MPTA#!+%'/%6-&> 3=1!-BW$XA.AR2'@7-(Z@0Z9A*]/P[3(QI9ZYV,*LM/J\
M5:K.!*>ENLL1TD,VUF9CAVQ[&8!K:A!"TK5EAH1P@B%L2#^YLZ%IK12*E*/^
M#\5?[$3#$43]D?=ML?+.A#1 =3Q02B-=RH56# L.5\O%.0P^PC#L/(3@J)^4
MJ+:N:VIPU36MI5UM&_.LZ4=_W9NN?L/4E@L-!6XH-.R-2&[5=,K&,+)RW6DM
M#?4Z-\WI<4%E'6A_(Z4Y&#9!^UPE?P!02P,$%     @ U'2>6!-G*@F3 P
MV0<  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULA57;CMLV$'W75PQ4
MM/4"M63+CK/=V@;VDJ!Y"+#839J'H@^T.+*(I4B%I.SUWV=(RHJ;[KHP(/,R
M<^;,E<N]-D^V1G3PW$AE5VGM7'N5Y[:LL6$VTRTJNJFT:9BCK=GFMC7(>%!J
M9%Y,)HN\84*EZV4XNS?KI>Z<% KO#=BN:9@YW*#4^U4Z38\'#V);.W^0KY<M
MV^(CNL_MO:%=/J!PT:"R0BLP6*W2Z^G5S=S+!X&_!.[MR1J\)QNMG_SF U^E
M$T\()9;.(S#ZV^$M2NF!B,;7'C,=3'K%T_41_7WPG7S9,(NW6GX1W-6K]#(%
MCA7KI'O0^S^Q]^>-QRNUM.$+^R@[?YM"V5FGFUZ9&#1"Q7_VW,?A1.%R\HI"
MT2L4@7<T%%C>,<?62Z/W8+PTH?E%<#5H$SFA?%(>G:%;07IN_849PY2S,/K$
M-A+MQ3)W!.LO\[*'N(D0Q2L0TP(^:N5J"^\41_YO@)SX#*2*(ZF;XBSB'989
MS*:_03$I9F?P9H.3LX W^S\G_[[>6&>H$OYYR<T(,G\9Q'?'E6U9B:N4RM^B
MV6&Z_N6GZ6+RQQF*\X'B_!SZ^I&ZC7<205=P;:E%6E^TUF\_J!U2'1C[*QP=
M>8G]>?Q/-2:WNFF9.D!GD8.K$2HMJ2F%V@([,>DTD#U!%8]!ZL3^OK=_E5"*
ML-F@22A-B4^3SU7A/]/D0=BG<640$Z$<4JP<& \VFE[ F'Z3;/H[_)R\>VZI
M-9$G.RV9$U*X XR**+*89)>S\:+(Y@N2O*7R\EGKF$P(L $I*H(3"@[(C+V
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M,^=0M@BU12@W$!J+4#F$JP8A<PAY@W!A$<(!FDQEGC.E#R&ME"AG=HM'CCW
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MBJ#Q\/T% ].U<&<XW82V66I'31BF%;UZ:+P#[:^T=@?#!^C?T?PW4$L#!!0
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MZD<,%W^\B<>C/X\(S_;"LV/LBQ7=S*(5"*J$XR8.*3_*?5CY/\AT@*Z,0$7
M>HW:%2)PA7#52-P0!Y^'JV%0*"&8-L EV$JUALG"!#N5V*L[#^[PD8F6^9M)
M-J@A/*!U9PT,YJWFEJ.!07SBR-^YR5D:T^0T6#+Y0'<Y5ZVT!)/4.:A'6"B1
M )0,:!]J;ES3((+,@QURD- 87#WE%9,;!,TL0L'+$C62,@I-NT1CG^5>62:@
M?"7;"SJ;]H*ZB:?=^>.^"C^XVS*MF;0&K(*FU23!(%Q<KMX:. 5'F<$D?O]K
M>W)*OTDV"6ZD)>G&]CF!,&NW-04VRG#*E<60CF%ZQ+*CBM-77GLZ0I.P]R,:
ML^GDE4$8X/,QDZY-4&P\<=N1C=VN$&@\AD-'/7K1JFK4&]^0#?AR=EUK_W3?
M\R^Z5O<<WGTP/C&]X51D@25!1\/)60BZ:\+=PJK&-[ZULM1&_;2B[Q9J%T#O
M2Z7L;N$2[+^$B_\!4$L#!!0    ( -1TGEAOM(JNY0(  $<&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;*U5;6O;,!#^[E]Q># VZ&+'3M.2)8:F
M[=@8':%I-\;8!\6^Q**RY$ERT_S[G>3$34>:3\-@Z^7NN>>1[L[CM=(/ID2T
M\%0):29A:6T]BB*3EU@QTU,U2MI9*ETQ2U.]BDRMD17>J1)1$L?#J&)<AMG8
MK\UT-E:-%5SB3(-IJHKIS12%6D_"?KA;N.6KTKJ%*!O7;(5SM/?U3-,LZE *
M7J$T7$G0N)R$%_W1=.#LO<%WCFNS-P:G9*'4@YM\*29A[ BAP-PZ!$:?1[Q$
M(1P0T?BSQ0R[D,YQ?[Q#_^2UDY8%,WBIQ ]>V'(2GH=0X)(UPMZJ]6?<ZCEU
M>+D2QK]AW=J>G8:0-\:J:NM,#"HNVR][VI[#GL-Y_(I#LG5(/.\VD&=YQ2S+
MQEJM03MK0G,#+]5[$SDNW:7,K:9=3GXVN]-,&N9/R "3!4R98#)'0SQL";<H
MF,4"9DQ;3HOO[MA"H'D_CBP%=Q!1O@TT;0,EKP3J)W"CI"T-7,L"BY< $;'N
MJ"<[ZM/D*.(5YCU(^R>0Q$EZ!"_MCB+U>.G_.8I?%PMC-=G_/G08;:C!X5"N
MTD:F9CE.0BHE@_H1P^SMF_XP_GA$R* 3,CB&GLVI<HM&(*@E7*J*ZM<P7P)6
MP5?<P V35&]4619FJ(V2$@50?<-U50NU080Y,>*D_)"RH[$/*[LK,<C_(?)
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M7PE1]JCE1/'<MGDK>]';8:K[>A#&0+]?<Z[V$^.@_J<0_0=02P,$%     @
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M0MO]?EO8YP:T<[#W&Z7P9#B"[@%+_P)02P,$%     @ U'2>6$W:_'U$ @
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M:/TUL\I'T5G&5IO&_LR)1\GYD-0)9AN-[R\=5+04RA()"X1%)^=GE)AND+O
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M,-=?#" ,0#^?<JY6$[-!\PT2_P502P,$%     @ U'2>6,>27+CR @  1@@
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MU8T>A0G0^TO.U=/$O*#YZQ#]!5!+ P04    " #4=)Y8U _PTEL'  !D.
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M^JF:2XS<CB5C!92*B9)(6$V<.W\\C4R^3?C!8*L.QL14LA3BV03?LHGC&4'
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M%U?HHZRO:NJ!%J6]O%@(K45A'S.@V">9%W ]%4)O!T9!>V$V^P]02P,$%
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M(0Q),G][(_^1BF7V/L/7[#19]G7!&811/P#W9T*D#S^T@?(=FM%_4$L#!!0
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MTJCL =K/I#3'B6T<;=N/_P%02P,$%     @ U'2>6"!@78:" @  Y08  !D
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M=GK.'5\NN?9/V'2Q(8&\T496'=AF4#'1ONEC5X<=0#3> X@[0/P<,-H#2#I
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M97CV_IR :DVUG1A9>YM92&--RP]+>P^A<@'V^U)*LYVX#?J;+?T#4$L#!!0
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MA1(E&1">4((8K&;&=_LZL$=*(%_Q9P([7GM&RI5G2E_4X#::&9:R"%((A8+
M\N\5%I"F"DG:\4\):E0ZE6#]^0/]C]QYZ<PSYK"@Z5])).*9,390!"N\3<4#
MW?V TJ'<P)"F//]%NW*M9:!PRP7-2F%I09:0XA^_E434!!SG$P&G%'".%1B4
M H-C!8:EP/!8@5$ID+MN%K[GQ/E88&_*Z XQM5JBJ8><_5Q:\I40M5$>!9-O
M$RDGO">&"<=YT#C")$)SG&(2 I=VB!@]0(H%1&B)F4CDY+D/ B<I_X;.OHP'
MKG.#$H*>8KKE4I9?H*^-\=04TD2ER Q+<^:%.<XGYM@.NJ=$Q!P%)(*H"6!*
MWRH'G0\'YTXOH@_A)1K8%\BQG 'Z^>BC\Z_?.@Q;G )S>_>(SDL&NL#\X\&<
M'IN"XV'L;I@&98-J3PQRW(&>/?'K3LJC6P$9_[LKXH6R8;<R=1%>\PT.86;(
MFXX#>P7#._MBN]9-5Y1T@ODZP0)-8(V(#:N(#?O0O?S,I.]H!=!YZ II-Y=6
MGXY7;S@U7^N\%BOL<6V)/6JN\7MM.)4N36 -ND857:->NIZHP.FG9!6RHSI9
MDQ9;O?"G[L+107!&@Z:^X'")ZU9+&A2X%05N+P7ED49TA5[@77Y1B$P+9 (@
MT 88IX1 BLYPMKF1G_*0;HE(R!JM$I9=(*'8ZR+./;!RX+2(ZS7J5.(Z]+6V
M=:!)7X/BJXKBJUZ*E\!"2:CD5;',8\RZ]UN!,JFY85U:MM4^H<<M\X];%O2:
M_C^)&5?$C'N)>5#;#-YDKLN[&1D?!-:V6VST:CAU(^D$"SJ,'W:?U4G%U^2H
MLQIM :T8S= "$Q+1$-V)J(N^R<$%UKI/%KWZ3F5/)UB@":S!LVWMDV&KE^E;
M(H MM@P4M>C7/63/P#J3FGZ@4[,:K6B^5K1 %UHS)+7ZQ/Z=R6BI35?<=*+Y
M6M$"76C-N#G[N#G'7%I\_^W[/'$HH1KYC=7*/A?]^D[F^E"E[3I7K:^D+IU-
M#O=UF-U;-'BU>[[_,M):8FE%\[6B!;K0F@'9EUGV\+=>1CHKJH56-%\K6J +
MK1FW?;UG]Q=\_YEQ]LN?' FM]:'=42"V[RE-"@MZS5H[,0.VSONX'.5E8-%X
MJV:K7O'WO$/:FI^K'G+>IMS#% WH>\S6B3Q#*:PDI'5Y)1U@14^W& BZR9N6
MSU0(FN6/,> (F%H@WZ\H%1\#I:#JK'O_ E!+ P04    " #4=)Y8J';<.2(#
M  !X"0  &0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6RM5EUOTS 4_2M6
M0(A)8TF3KD6CC;0V(! :JM8!#X@'-[EM+!P[V.ZZ_7NNG32TG5<FM)?$'_<>
MGW/\.=I(]4N7 (;<55SH<5 :4U^$H<Y+J*@^DS4([%E*55&#5;4*=:V %BZI
MXF$<18.PHDP$Z<BUS50ZDFO#F8"9(GI=553=3X#+S3CH!=N&:[8JC6T(TU%-
M5S '\[6>*:R%'4K!*A":24$4+,?!9>\B&]IX%_"-P4;OE(E5LI#REZU\*L9!
M9 D!A]Q8!(J_6Y@"YQ8(:?QN,8-N2)NX6]ZB?W#:4<N":IA*_IT5IAP';P-2
MP)*NN;F6FX_0ZCFW>+GDVGW)IHV- I*OM9%5FXP,*B::/[UK?=A)B.-'$N(V
M(7YJ0M(F)$]-Z+<)?>=,(\7YD%%#TY&2&Z)L-*+9@C/39:-\)NRTSXW"7H9Y
M)KU15&CJYD 3*@HRH9R*'#3R,"6Y!DX-%&1&E6'8^#H#0QG7)^0-F>,2+-8<
MB%R2J:QP(6KJYM)(\AGNR145N'!PB1@R Z6E$, )+E3ROJJYO <@<U"WS([U
MDC!!;DJYUDA!CT*#RBR_,&]53!H5\2,J>C&YDL*4FKP7!13[ "%:TOD2;WV9
MQ$<1,\C/2-([)7$4)^3K/".O7YYXB$V?#A,?@<F>#M/SP^RI3+K93QQN\@CN
M?TWA!^\4_KA<:*-P)?WT35]#H^^G88^V"UW3',8!GET:(2%(7[WH#:)W/LN?
M$RQ[)K ]^_N=_?UCZ.F.O4L ?4H*IO \E J+=B_FN"GQ_&)BY?I]QC8##-P
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MVPLYES.J:9XIV1)ELPV;7;A2'=J88\)^E*56YI09G,[G5 DF-DCN'B7B/5F
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M+W-H965T-S(N>&ULK5;?;YLP$/Y7+"9-K;26W[3I$J2F=.JD=8L:;7V8]N#
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M1D(B?C;1*?7\9CT=^A<BPTN862JV!? -6,&K%^[(>=O$JD^QL">Q XZ#FN/
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M](2X4[B6WU*U/RY_UW++BP;5!X0B(3;)5VYNA5-U(=A2I+61E0LQ^^5JU;6
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M%?56 KT5]58"O17U5@*]%?56 KT-]38"O0WU-@*]#?4V KT-]38"O6WRLIM
M;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U
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M4$L! A0#%     @ U'2>6!]%;C.: @  6@<  !@              ("!$A0
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -1TGEBQ1-UV
MK@0  %H1   8              " @>(6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #4=)Y8(6"(%B,$  "N$P  &
M@('&&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ U'2>
M6-,C=&&$!@  1B$  !@              ("!'R   'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( -1TGEA>0-]I[ P  "@?   8
M      " @=DF  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #4=)Y8*/ [/F4(  "1%0  &               @('[,P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ U'2>6+$]+4W#"0  HQ<  !@
M             ("!ECP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( -1TGE@)9(G\Q @  /T5   9              " @8]&  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ U'2>6"6Z&WDC P
MW08  !D              ("!BD\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #4=)Y8X&2( ND#  #J"   &0              @('D
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -1TGEA'
M*J'@$0,  'X&   9              " @017  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ U'2>6,O,WEW,"0  <1<  !D
M     ("!3%H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -1TGEB3&V)!=0(  &D%   9              "
M@8U\  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ U'2>
M6/B*X&0: P  A 8  !D              ("!.7\  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #4=)Y8[\QK2#T#   H!P  &0
M        @(&*@@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( -1TGEC_\RMT^P0  #$+   9              " @?Z%  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ U'2>6!%F=R>5!0  20T
M !D              ("!,(L  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #4=)Y8@RS072 %   @#@  &0              @('\D
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -1TGECN!2AX
MJP4  /4,   9              " @5.6  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ U'2>6/_1#%S&"0  WAD  !D
M ("!-9P  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #4
M=)Y8*94R1UT"  !4!0  &0              @($RI@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -1TGEAIZMQLV (  ,8&   9
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M970S,BYX;6Q02P$"% ,4    " #4=)Y8$V<J"9,#  #9!P  &0
M    @(%/N   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M -1TGEA(=!;%4@8  $D1   9              " @1F\  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ U'2>6!TB8[5; @  4P4  !D
M             ("!HL(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #4=)Y8-7+(0  #  !P!@  &0              @($TQ0  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -1TGECC>J._)0,
M !4'   9              " @6O(  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ U'2>6&^TBJ[E @  1P8  !D              ("!
MQ\L  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #4=)Y8
MFR'<>08$  !0#   &0              @('CS@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -1TGEB1#E=:= ,   X+   9
M      " @2#3  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ U'2>6/F';QU* @  JP4  !D              ("!R]8  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #4=)Y8R&;Q=+P"   '"
M&0              @(%,V0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( -1TGEC,&\4S+0,  )P*   9              " @3_<  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ U'2>6&5X. #>
M @  -0P  !D              ("!H]\  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " #4=)Y85;?2DE@#  !."P  &0
M@(&XX@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -1T
MGEBKPE^Y-0,  ' 0   9              " @4?F  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ U'2>6 ;L!W-  @  S 0  !D
M         ("!L^D  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " #4=)Y83=K\?40"  !9!0  &0              @($J[   >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -1TGE@>%*'_ZP(  (\(
M   9              " @:7N  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ U'2>6,>27+CR @  1@@  !D              ("!Q_$
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #4=)Y8U _P
MTEL'  !D.   &0              @('P]   >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( -1TGEA[0O!2:P(  '(&   9
M  " @8+\  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MU'2>6 Q-DP[/ @  LPH  !D              ("!)/\  'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " #4=)Y8^GA'BY $   \$P  &0
M            @($J @$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( -1TGEC;1\XD;P4  -4>   9              " @?$& 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ U'2>6")9'RA" @
M&P4  !D              ("!EPP! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " #4=)Y8A?//@[$%   ^+P  &0              @($0
M#P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -1TGEC^
MTR<0,00  (05   9              " @?@4 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ U'2>6*1-02&X!@  ^#H  !D
M     ("!8!D! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -1TGE@"E3UY^0,  $\0   9              "
M@;LQ 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ U'2>
M6"GRG6/X @  #PL  !D              ("!ZS4! 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    " #4=)Y8$*%F\#X$  !E%P  &0
M        @($:.0$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( -1TGEBH=MPY(@,  '@)   9              " @8\] 0!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ U'2>6,1H>-9, @  F04
M !D              ("!Z$ ! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    " #4=)Y8 F&C3+,"   =!P  &0              @(%K0P$
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( -1TGEA+)/2I
MD00  *8=   9              " @55& 0!X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ U'2>6%1X@%4$ P   PD  !D
M ("!'4L! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " #4
M=)Y81>"KQ^8"  #]"   &0              @(%83@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( -1TGEC<T)/TB0,  (,0   9
M          " @751 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#
M%     @ U'2>6,F1MMJ0 P  F1D   T              ( !-54! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #4=)Y8EXJ[',     3 @  "P
M    @ 'P6 $ 7W)E;',O+G)E;'-02P$"% ,4    " #4=)Y8?7U_8EP%  !/
M,   #P              @ '960$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ U'2>6+?' S!" @  0BL  !H              ( !8E\! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ U'2>6/C# AT& @  3RH
M !,              ( !W&$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ %$ 40 N%@  $V0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statements of Financial Position (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Statements of Financial Position (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Basis of Preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/BasisofPreparation</Role>
      <ShortName>Basis of Preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/MaterialAccountingPolicies</Role>
      <ShortName>Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Financial Instruments and Financial Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement</Role>
      <ShortName>Financial Instruments and Financial Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/CashandCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Marketable Securities ??? InterCure Ltd</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/MarketableSecuritiesInterCureLtd</Role>
      <ShortName>Marketable Securities ??? InterCure Ltd</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Prepaid Expenses and Othe Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Othe Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/AccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Share Capital, Reserves and Accumulated Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit</Role>
      <ShortName>Share Capital, Reserves and Accumulated Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Share-Based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ShareBasedPayment</Role>
      <ShortName>Share-Based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ResearchandDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/GeneralandAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Finance Income (Expenses), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/FinanceIncomeExpensesNet</Role>
      <ShortName>Finance Income (Expenses), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://xtlb.com/role/MaterialAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Basis of Preparation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/BasisofPreparationTables</Role>
      <ShortName>Basis of Preparation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/BasisofPreparation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Financial Instruments and Financial Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables</Role>
      <ShortName>Financial Instruments and Financial Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/CashandCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/CashandCashEquivalents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Marketable Securities ??? InterCure Ltd (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables</Role>
      <ShortName>Marketable Securities ??? InterCure Ltd (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/MarketableSecuritiesInterCureLtd</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Prepaid Expenses and Othe Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Othe Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/AccountsPayableTables</Role>
      <ShortName>Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/AccountsPayable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/Warrants</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Share-Based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ShareBasedPaymentTables</Role>
      <ShortName>Share-Based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareBasedPayment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ResearchandDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/ResearchandDevelopmentExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996010 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/GeneralandAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/GeneralandAdministrativeExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Finance Income (Expenses), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/FinanceIncomeExpensesNetTables</Role>
      <ShortName>Finance Income (Expenses), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/FinanceIncomeExpensesNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://xtlb.com/role/EarningsLossPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996014 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Basis of Preparation (Details) - Schedule of Exchange Rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofExchangeRateTable</Role>
      <ShortName>Basis of Preparation (Details) - Schedule of Exchange Rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/BasisofPreparationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Financial Instruments and Financial Risk Management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails</Role>
      <ShortName>Financial Instruments and Financial Risk Management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable</Role>
      <ShortName>Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/CashandCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/CashandCashEquivalentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable</Role>
      <ShortName>Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/CashandCashEquivalentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable</Role>
      <ShortName>Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/CashandCashEquivalentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Marketable Securities ??? InterCure Ltd (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails</Role>
      <ShortName>Marketable Securities ??? InterCure Ltd (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Marketable Securities ??? InterCure Ltd (Details) - Schedule of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofFinancialInstrumentsTable</Role>
      <ShortName>Marketable Securities ??? InterCure Ltd (Details) - Schedule of Financial Instruments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Marketable Securities ??? InterCure Ltd (Details) - Schedule of Changes in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable</Role>
      <ShortName>Marketable Securities ??? InterCure Ltd (Details) - Schedule of Changes in Marketable Securities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Prepaid Expenses and Othe Current Assets (Details) - Schedule of Composition of Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expenses and Othe Current Assets (Details) - Schedule of Composition of Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/IntangibleAssets</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Accounts Payable (Details) - Schedule of Composition of Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable</Role>
      <ShortName>Accounts Payable (Details) - Schedule of Composition of Accounts Payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/AccountsPayableTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable</Role>
      <ShortName>Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/AccountsPayableTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/WarrantsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Warrants (Details) - Schedule of Assumptions of Investors' Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable</Role>
      <ShortName>Warrants (Details) - Schedule of Assumptions of Investors' Warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/WarrantsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Share Capital, Reserves and Accumulated Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails</Role>
      <ShortName>Share Capital, Reserves and Accumulated Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Share-Based Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ShareBasedPaymentDetails</Role>
      <ShortName>Share-Based Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable</Role>
      <ShortName>Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable</Role>
      <ShortName>Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Share-Based Payment (Details) - Schedule of Outstanding Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofOutstandingOptionsTable</Role>
      <ShortName>Share-Based Payment (Details) - Schedule of Outstanding Options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Share-Based Payment (Details) - Schedule of Fair Value for Options Granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable</Role>
      <ShortName>Share-Based Payment (Details) - Schedule of Fair Value for Options Granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Research and Development Expenses (Details) - Schedule of Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>Research and Development Expenses (Details) - Schedule of Research and Development Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/ResearchandDevelopmentExpensesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996037 - Disclosure - General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Finance Income (Expenses), Net (Details) - Schedule of Finance Income (Expenses), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable</Role>
      <ShortName>Finance Income (Expenses), Net (Details) - Schedule of Finance Income (Expenses), Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/FinanceIncomeExpensesNetTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/TaxesonIncome</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employee Services</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable</Role>
      <ShortName>Transactions and Balances with Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employee Services</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable</Role>
      <ShortName>Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable</Role>
      <ShortName>Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable</Role>
      <ShortName>Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable</Role>
      <ShortName>Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0204561-20f_xtlbiopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xtlb.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://xtlb.com/role/SubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted, ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted -  ea0204561-20f_xtlbiopharma.htm 13734, 13743</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0204561-20f_xtlbiopharma.htm">ea0204561-20f_xtlbiopharma.htm</File>
    <File>xtlb-20231231.xsd</File>
    <File>xtlb-20231231_cal.xml</File>
    <File>xtlb-20231231_def.xml</File>
    <File>xtlb-20231231_lab.xml</File>
    <File>xtlb-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="458">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0204561-20f_xtlbiopharma.htm": {
   "nsprefix": "xtlb",
   "nsuri": "http://xtlb.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0204561-20f_xtlbiopharma.htm"
     ]
    },
    "schema": {
     "local": [
      "xtlb-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "xtlb-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xtlb-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "xtlb-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xtlb-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 179,
   "keyCustom": 88,
   "axisStandard": 12,
   "axisCustom": 5,
   "memberStandard": 11,
   "memberCustom": 32,
   "hidden": {
    "total": 94,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 66,
    "http://xtlb.com/20231231": 25,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 145,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 452,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 458,
    "http://xbrl.sec.gov/dei/2023": 43
   },
   "report": {
    "R1": {
     "role": "http://xtlb.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xtlb.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Consolidated Statements of Financial Position (Parentheticals)",
     "shortName": "Consolidated Statements of Financial Position (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "ilsPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "ilsPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xtlb.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://xtlb.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c27",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c27",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://xtlb.com/role/ConsolidatedCashFlow",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xtlb.com/role/General",
     "longName": "006 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xtlb.com/role/BasisofPreparation",
     "longName": "007 - Disclosure - Basis of Preparation",
     "shortName": "Basis of Preparation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xtlb.com/role/MaterialAccountingPolicies",
     "longName": "008 - Disclosure - Material Accounting Policies",
     "shortName": "Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement",
     "longName": "009 - Disclosure - Financial Instruments and Financial Risk Management",
     "shortName": "Financial Instruments and Financial Risk Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xtlb.com/role/CashandCashEquivalents",
     "longName": "010 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtd",
     "longName": "011 - Disclosure - Marketable Securities \u2013 InterCure Ltd",
     "shortName": "Marketable Securities \u2013 InterCure Ltd",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets",
     "longName": "012 - Disclosure - Prepaid Expenses and Othe Current Assets",
     "shortName": "Prepaid Expenses and Othe Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://xtlb.com/role/IntangibleAssets",
     "longName": "013 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://xtlb.com/role/AccountsPayable",
     "longName": "014 - Disclosure - Accounts Payable",
     "shortName": "Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://xtlb.com/role/Warrants",
     "longName": "015 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DisclosureOfWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DisclosureOfWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit",
     "longName": "016 - Disclosure - Share Capital, Reserves and Accumulated Deficit",
     "shortName": "Share Capital, Reserves and Accumulated Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:ShareCapitalReservesAndRetainedEarnings",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:ShareCapitalReservesAndRetainedEarnings",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xtlb.com/role/ShareBasedPayment",
     "longName": "017 - Disclosure - Share-Based Payment",
     "shortName": "Share-Based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xtlb.com/role/ResearchandDevelopmentExpenses",
     "longName": "018 - Disclosure - Research and Development Expenses",
     "shortName": "Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xtlb.com/role/GeneralandAdministrativeExpenses",
     "longName": "019 - Disclosure - General and Administrative Expenses",
     "shortName": "General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xtlb.com/role/FinanceIncomeExpensesNet",
     "longName": "020 - Disclosure - Finance Income (Expenses), Net",
     "shortName": "Finance Income (Expenses), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xtlb.com/role/TaxesonIncome",
     "longName": "021 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xtlb.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "022 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xtlb.com/role/EarningsLossPerShare",
     "longName": "023 - Disclosure - Earnings (Loss) Per Share",
     "shortName": "Earnings (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xtlb.com/role/SubsequentEvents",
     "longName": "024 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xtlb.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xtlb.com/role/BasisofPreparationTables",
     "longName": "996001 - Disclosure - Basis of Preparation (Tables)",
     "shortName": "Basis of Preparation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables",
     "longName": "996002 - Disclosure - Financial Instruments and Financial Risk Management (Tables)",
     "shortName": "Financial Instruments and Financial Risk Management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xtlb.com/role/CashandCashEquivalentsTables",
     "longName": "996003 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables",
     "longName": "996004 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Tables)",
     "shortName": "Marketable Securities \u2013 InterCure Ltd (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables",
     "longName": "996005 - Disclosure - Prepaid Expenses and Othe Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Othe Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xtlb.com/role/AccountsPayableTables",
     "longName": "996006 - Disclosure - Accounts Payable (Tables)",
     "shortName": "Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xtlb.com/role/WarrantsTables",
     "longName": "996007 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xtlb.com/role/ShareBasedPaymentTables",
     "longName": "996008 - Disclosure - Share-Based Payment (Tables)",
     "shortName": "Share-Based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://xtlb.com/role/ResearchandDevelopmentExpensesTables",
     "longName": "996009 - Disclosure - Research and Development Expenses (Tables)",
     "shortName": "Research and Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://xtlb.com/role/GeneralandAdministrativeExpensesTables",
     "longName": "996010 - Disclosure - General and Administrative Expenses (Tables)",
     "shortName": "General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://xtlb.com/role/FinanceIncomeExpensesNetTables",
     "longName": "996011 - Disclosure - Finance Income (Expenses), Net (Tables)",
     "shortName": "Finance Income (Expenses), Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "996012 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://xtlb.com/role/EarningsLossPerShareTables",
     "longName": "996013 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://xtlb.com/role/GeneralDetails",
     "longName": "996014 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:IssuedAndOutstandingRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:IssuedAndOutstandingRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://xtlb.com/role/ScheduleofExchangeRateTable",
     "longName": "996015 - Disclosure - Basis of Preparation (Details) - Schedule of Exchange Rate",
     "shortName": "Basis of Preparation (Details) - Schedule of Exchange Rate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails",
     "longName": "996016 - Disclosure - Financial Instruments and Financial Risk Management (Details)",
     "shortName": "Financial Instruments and Financial Risk Management (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "xtlb:PercentageOfFunctionalCurrency",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "xtlb:PercentageOfFunctionalCurrency",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable",
     "longName": "996017 - Disclosure - Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities",
     "shortName": "Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c39",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c37",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://xtlb.com/role/CashandCashEquivalentsDetails",
     "longName": "996018 - Disclosure - Cash and Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DepositsWithMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:DepositsWithMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable",
     "longName": "996019 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashOnHand",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashOnHand",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable",
     "longName": "996020 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked",
     "shortName": "Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c46",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails",
     "longName": "996021 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Details)",
     "shortName": "Marketable Securities \u2013 InterCure Ltd (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:PercentageOfHoldingShare",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:PercentageOfHoldingShare",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://xtlb.com/role/ScheduleofFinancialInstrumentsTable",
     "longName": "996022 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of Financial Instruments",
     "shortName": "Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "xtlb:CurrentMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable",
     "longName": "996023 - Disclosure - Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of Changes in Marketable Securities",
     "shortName": "Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of Changes in Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:FinancialAssetsAvailableforsale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c31",
      "name": "ifrs-full:FinancialAssetsAvailableforsale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "xtlb:MarketableSecuritiesInterCureLtdTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996024 - Disclosure - Prepaid Expenses and Othe Current Assets (Details) - Schedule of Composition of Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Othe Current Assets (Details) - Schedule of Composition of Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://xtlb.com/role/IntangibleAssetsDetails",
     "longName": "996025 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c53",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c53",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable",
     "longName": "996026 - Disclosure - Accounts Payable (Details) - Schedule of Composition of Accounts Payable",
     "shortName": "Accounts Payable (Details) - Schedule of Composition of Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable",
     "longName": "996027 - Disclosure - Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable",
     "shortName": "Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c56",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://xtlb.com/role/WarrantsDetails",
     "longName": "996028 - Disclosure - Warrants (Details)",
     "shortName": "Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c60",
      "name": "xtlb:GrossFundRaised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "xtlb:DisclosureOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c60",
      "name": "xtlb:GrossFundRaised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "xtlb:DisclosureOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
     "longName": "996029 - Disclosure - Warrants (Details) - Schedule of Assumptions of Investors' Warrants",
     "shortName": "Warrants (Details) - Schedule of Assumptions of Investors' Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails",
     "longName": "996030 - Disclosure - Share Capital, Reserves and Accumulated Deficit (Details)",
     "shortName": "Share Capital, Reserves and Accumulated Deficit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "ilsPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xtlb:ShareCapitalReservesAndRetainedEarnings",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "ilsPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xtlb:ShareCapitalReservesAndRetainedEarnings",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://xtlb.com/role/ShareBasedPaymentDetails",
     "longName": "996031 - Disclosure - Share-Based Payment (Details)",
     "shortName": "Share-Based Payment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c68",
      "name": "xtlb:IncreaseOfReserve",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c68",
      "name": "xtlb:IncreaseOfReserve",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable",
     "longName": "996032 - Disclosure - Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices",
     "shortName": "Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c73",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
     "longName": "996033 - Disclosure - Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding",
     "shortName": "Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c80",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://xtlb.com/role/ScheduleofOutstandingOptionsTable",
     "longName": "996034 - Disclosure - Share-Based Payment (Details) - Schedule of Outstanding Options",
     "shortName": "Share-Based Payment (Details) - Schedule of Outstanding Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c102",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable",
     "longName": "996035 - Disclosure - Share-Based Payment (Details) - Schedule of Fair Value for Options Granted",
     "shortName": "Share-Based Payment (Details) - Schedule of Fair Value for Options Granted",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c114",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c114",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996036 - Disclosure - Research and Development Expenses (Details) - Schedule of Research and Development Expenses",
     "shortName": "Research and Development Expenses (Details) - Schedule of Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:FeesRelatedToServiceProviders",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:FeesRelatedToServiceProviders",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock",
       "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996037 - Disclosure - General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses",
     "shortName": "General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable",
     "longName": "996038 - Disclosure - Finance Income (Expenses), Net (Details) - Schedule of Finance Income (Expenses), Net",
     "shortName": "Finance Income (Expenses), Net (Details) - Schedule of Finance Income (Expenses), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:FinanceExpensesRevaluationOfMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:FinanceExpensesRevaluationOfMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://xtlb.com/role/TaxesonIncomeDetails",
     "longName": "996039 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c115",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c115",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "996040 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherFeeAndCommissionExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherFeeAndCommissionExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable",
     "longName": "996041 - Disclosure - Transactions and Balances with Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employee Services",
     "shortName": "Transactions and Balances with Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employee Services",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://xtlb.com/role/EarningsLossPerShareDetails",
     "longName": "996042 - Disclosure - Earnings (Loss) Per Share (Details)",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable",
     "longName": "996043 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)",
     "shortName": "Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable",
     "longName": "996044 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic)",
     "shortName": "Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "xtlb:IssuedOrdinarySharesAtJanuary1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "xtlb:IssuedOrdinarySharesAtJanuary1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable",
     "longName": "996045 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)",
     "shortName": "Earnings (Loss) Per Share (Details) - Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherComprehensiveIncomeBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherComprehensiveIncomeBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable",
     "longName": "996046 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted)",
     "shortName": "Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c137",
      "name": "xtlb:WeightedaverageNumberOfOrdinarySharesbasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c137",
      "name": "xtlb:WeightedaverageNumberOfOrdinarySharesbasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://xtlb.com/role/SubsequentEventsDetails",
     "longName": "996047 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c140",
      "name": "xtlb:NumberOfShareOptionsExercisableSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c140",
      "name": "xtlb:NumberOfShareOptionsExercisableSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204561-20f_xtlbiopharma.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "xtlb_AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AAdjustmentsToReconcileNetIncomeLossToNetCashUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Adjustments to reconcile net income (loss) to net cash used in operating activities:",
        "label": "AAdjustments To Reconcile Net Income Loss To Net Cash Used In Operating Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ADSIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ADSIssued",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails",
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS issued",
        "verboseLabel": "ADS share issued",
        "label": "ADSIssued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Carrying Amount of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AccountsPayableDetailsScheduleofCarryingAmountofAccountsPayableTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable (Details) - Schedule of Carrying Amount of Accounts Payable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accruals classified as current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapital",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital",
        "label": "Additional paid-in capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapitalMember",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital",
        "label": "Additional paid-in capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average number of ordinary shares (in Shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in prepaid expenses and other current assets",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in accounts payable",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net operating asset and liability",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 2.0
      },
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow",
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment expense",
        "verboseLabel": "Share-based payments",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from exchange rate differences on cash and cash equivalents",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r150"
     ]
    },
    "xtlb_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities (a)",
        "documentation": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities.",
        "label": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_AdministrativeFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AdministrativeFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fees",
        "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.",
        "label": "Administrative Fee Expense"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement [Axis]",
        "label": "Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_AgreementDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AgreementDomainDomain",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depository Shares [Member]",
        "label": "American Depository Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance of key management personnel &amp; accounting firm, total",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r34"
     ]
    },
    "ifrs-full_AntidilutiveInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AntidilutiveInstrumentsMember",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://xtlb.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r69",
      "r97",
      "r99"
     ]
    },
    "xtlb_AssetsRemainedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "AssetsRemainedAmount",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets remained amount",
        "documentation": "Assets remained amount.",
        "label": "Assets Remained Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "presentation": [
      "http://xtlb.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExchangeRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate",
        "label": "Average foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings (loss) per share (in U.S. dollars): (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "xtlb_BlackScholesMertonOptionsPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "BlackScholesMertonOptionsPricingModelMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes-Merton Options pricing model [Member]",
        "label": "Black Scholes Merton Options Pricing Model Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate per annum",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails",
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of Range [Member]",
        "verboseLabel": "Bottom of range [member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r74",
      "r84",
      "r115",
      "r116",
      "r154"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129"
     ]
    },
    "xtlb_CanndocLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CanndocLtdMember",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canndoc Ltd [Member]",
        "label": "Canndoc Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet",
      "http://xtlb.com/role/ConsolidatedCashFlow",
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable",
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "totalLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r64"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r53"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r53"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r53"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash flows from (used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r113"
     ]
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash in banks and on hand",
        "label": "Cash on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "xtlb_CashandCashEquivalentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CashandCashEquivalentsDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents are Denominated or Linked [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsareDenominatedorLinkedTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents are Denominated or Linked [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_CashandCashEquivalentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CashandCashEquivalentsDetailsTable",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable",
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "xtlb_ChairmanOfBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ChairmanOfBoardMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chairman of Board [Member]",
        "label": "Chairman Of Board Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ChangesInOperatingAssetAndLiabilityItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ChangesInOperatingAssetAndLiabilityItemsAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating asset and liability items:",
        "label": "Changes In Operating Asset And Liability Items Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r93"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r93"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable",
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable",
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss) for the year",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r19",
      "r58",
      "r60",
      "r63",
      "r114"
     ]
    },
    "xtlb_ConsolidatedStatementsOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ConsolidatedStatementsOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Fax Number",
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing involvement in derecognised financial assets by type of instrument [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r114"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_CurrentMarketableSecuritie": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CurrentMarketableSecuritie",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balances of shares total",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.",
        "label": "Current Marketable Securitie"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_CurrentMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "CurrentMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet",
      "http://xtlb.com/role/ScheduleofFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities \u2013 InterCure Ltd.",
        "verboseLabel": "Marketable securities - InterCure Ltd",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.",
        "label": "Current Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet",
      "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_CurrentPrepaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Othe Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_CurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other receivables",
        "label": "Current prepayments and other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "xtlb_DateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DateAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date Axis",
        "label": "Date Axis"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DateDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DateDomainDomain",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DateDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DateOfGrantOfSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DateOfGrantOfSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date",
        "label": "Date of grant of share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The date on which share-based payment arrangements are granted. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "xtlb_DeferredTaxAssetsCapitalLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DeferredTaxAssetsCapitalLossCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets Capital Loss Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DepositaryShareAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DepositaryShareAxis",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depositary Share [Axis]",
        "label": "Depositary Share Axis"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DepositaryShareDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DepositaryShareDomainDomain",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DepositaryShareDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DepositsWithMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DepositsWithMaturity",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity period",
        "documentation": "Deposits with maturity",
        "label": "Deposits With Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earning (loss) per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments and other financial assets",
        "label": "Description of accounting policy for financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of non-financial assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting schedule",
        "label": "Description of vesting requirements for share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "xtlb_DescriptionOfWarrantsExercisable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DescriptionOfWarrantsExercisable",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of warrants exercisable",
        "documentation": "Description of warrants shall be exercisable.",
        "label": "Description Of Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share (in U.S. dollars): (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DirectorsRemunerationExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors\u2019 fees",
        "label": "Directors' remuneration expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of remuneration paid or payable to the entity's directors."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Disclosure of additional information about understanding financial position and liquidity of entity [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information that may be relevant to users of financial statements in understanding the financial position and liquidity of an entity."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Compensation to Key Management Personnel for Employee Services",
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://xtlb.com/role/BasisofPreparation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PREPARATION",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENTS",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital, Reserves and Accumulated Deficit [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents are Denominated or Linked",
        "documentation": "The disclosure of detailed information about currencies in which the cash and cash equivalents are denominated.",
        "label": "Disclosure Of Detailed Information About Currencies Cash And Cash Equivalents Denominated Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding",
        "documentation": "The disclosure of detailed information about the exercise price and the remaining contractual life for options outstanding.",
        "label": "Disclosure Of Detailed Information About Exercise Price And Contractual Life For Options Outstanding Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Instruments",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r91",
      "r94"
     ]
    },
    "xtlb_DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/MarketableSecuritiesInterCureLtdTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Marketable Securities",
        "documentation": "The disclosure of detailed information about changes in marketable securities.",
        "label": "Disclosure Of Detailed Information About Marketable Securities Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices",
        "documentation": "The disclosure of detailed information about the number and weighted average exercise prices of share options.",
        "label": "Disclosure Of Detailed Information About Number And Weighted Average Exercise Prices Of Share Options Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Options",
        "documentation": "The disclosure of detailed information about the outstanding options.",
        "label": "Disclosure Of Detailed Information About Outstanding Options Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/ResearchandDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "documentation": "The disclosure of detailed information about research and development expenses.",
        "label": "Disclosure Of Detailed Information About Research And Development Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Basic)",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
     "presentation": [
      "http://xtlb.com/role/BasisofPreparationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exchange Rate",
        "label": "Disclosure of effect of changes in foreign exchange rates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for the effect of changes in foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://xtlb.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://xtlb.com/role/GeneralandAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://xtlb.com/role/FinanceIncomeExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCE INCOME (EXPENSES), NET",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Financial Risk Management [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT",
        "label": "Disclosure of financial risk management [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "presentation": [
      "http://xtlb.com/role/GeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "label": "Disclosure of general and administrative expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfGeneralHedgeAccountingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralHedgeAccountingExplanatory",
     "presentation": [
      "http://xtlb.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Disclosure of general hedge accounting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general hedge accounting."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://xtlb.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://xtlb.com/role/MaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MATERIAL ACCOUNTING POLICIES",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Number of Ordinary Shares (Basic)",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "presentation": [
      "http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Composition of Prepaid Expenses and Other Current Assets",
        "label": "Disclosure of other current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
     "presentation": [
      "http://xtlb.com/role/PrepaidExpensesandOtheCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHE CURRENT ASSETS",
        "label": "Disclosure of prepayments and other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Options [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://xtlb.com/role/ResearchandDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "label": "Disclosure of research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
     "presentation": [
      "http://xtlb.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions of Investors' Warrants",
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPayment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://xtlb.com/role/AccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS PAYABLE",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "xtlb_DisclosureOfWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_DisclosureOfWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DisclosureOfWarrantsTextBlock",
     "presentation": [
      "http://xtlb.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARRANTS",
        "documentation": "The entire disclosure of warrants.",
        "label": "Disclosure Of Warrants Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "xtlb_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r131"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_EachWarrantIsExercisableToShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "EachWarrantIsExercisableToShares",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Each warrant is exercisable to shares",
        "documentation": "Each warrant is exercisable to shares.",
        "label": "Each Warrant Is Exercisable To Shares"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesBasicTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Basic) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "EarningsLossPerShareDetailsScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share (Details) - Schedule of Weighted-Average Number of Ordinary Shares (Diluted) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from exchange rate differences on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "xtlb_EffectOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "EffectOfWarrants",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of warrants",
        "documentation": "Effect of warrants.",
        "label": "Effect Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r22",
      "r103"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable",
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet",
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r11",
      "r57",
      "r59",
      "r66",
      "r67",
      "r69"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "xtlb_ExchangeDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ExchangeDifferences",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exchange rate differences",
        "documentation": "Exchange differences.",
        "label": "Exchange Differences"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails",
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of exercise prices (USD)",
        "verboseLabel": "Exercise price per warrant (in Dollars per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "xtlb_ExercisedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ExercisedPeriod",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise period",
        "documentation": "Exercised period.",
        "label": "Exercised Period"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ExercisesDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ExercisesDuringTheYear",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercises during the year",
        "documentation": "Exercises during the year.",
        "label": "Exercises During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment expense",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "xtlb_ExpirTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ExpirTerm",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry term",
        "documentation": "Expir term.",
        "label": "Expir Term"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ExtendedExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ExtendedExpiryTerm",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extended expiry term",
        "documentation": "Extended expiry term.",
        "label": "Extended Expiry Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bank account management fees and commissions",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "xtlb_FeesRelatedToServiceProviders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FeesRelatedToServiceProviders",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees related to service providers",
        "documentation": "The amount of fees related to service providers.",
        "label": "Fees Related To Service Providers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "xtlb_FinanceIncomeexpensesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "xtlb_FinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FinanceExpensesAbstract",
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses:",
        "label": "Finance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_FinanceExpensesRevaluationOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FinanceExpensesRevaluationOfMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of marketable securities",
        "documentation": "Finance expenses revaluation of marketable securities.",
        "label": "Finance Expenses Revaluation Of Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "xtlb_FinanceIncomeexpensesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "xtlb_FinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FinanceIncomeAbstract",
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income:",
        "label": "Finance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance income (expenses), net",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "xtlb_FinanceIncomeExpensesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FinanceIncomeExpensesNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income (Expenses), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_FinanceIncomeexpensesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FinanceIncomeexpensesNet",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance income (expenses), net",
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity.",
        "label": "Finance Incomeexpenses Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAvailableforsale",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value opening balance",
        "periodEndLabel": "Fair value closing balance",
        "label": "Financial assets available-for-sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "xtlb_FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FinancialInstrumentsandFinancialRiskManagementDetailsScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Financial Risk Management (Details) - Schedule of Changes in Financial Liabilities Classified As Cash Flow from Finance Activities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "xtlb_ForeignCurrenciesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ForeignCurrenciesMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dollars [Member]",
        "label": "Foreign Currencies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exchange Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_FourDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "FourDirectorsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Directors [Member]",
        "label": "Four Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GainOnExchangeDifferencesOnTranslationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GainOnExchangeDifferencesOnTranslationNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences",
        "documentation": "The gain recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax.",
        "label": "Gain On Exchange Differences On Translation Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit (loss) on exchange rate changes in translation",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28"
     ]
    },
    "xtlb_GainsLossesOnFairValueOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GainsLossesOnFairValueOnMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value during the year",
        "documentation": "The gains (losses) arising from changes in fair value marketable securities.",
        "label": "Gains Losses On Fair Value On Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GeneralAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GeneralAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "xtlb_GeneralDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GeneralDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GeneralDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GeneralDetailsTable",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_CurrentPrepaidExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompositionofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "label": "Government Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GrandDateIssuedEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GrandDateIssuedEightMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 31, 2016 [Member]",
        "label": "Grand Date Issued Eight Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GrandDateIssuedFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GrandDateIssuedFiveMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 25, 2015 [Member]",
        "label": "Grand Date Issued Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GrandsDateIssuedElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GrandsDateIssuedElevenMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 7, 2020 [Member]",
        "label": "Grands Date Issued Eleven Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GrandsDateIssuedThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GrandsDateIssuedThirteenMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2, 2023 [Member]",
        "label": "Grands Date Issued Thirteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GrandsDateIssuedThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GrandsDateIssuedThreeMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 30, 2014 [Member]",
        "documentation": "Grands Date Issued Three [Member]",
        "label": "Grands Date Issued Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_GrossFundRaised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "GrossFundRaised",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross funds raised",
        "documentation": "The amount of gross fund raised.",
        "label": "Gross Fund Raised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossLoanCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossLoanCommitments",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan value (in Dollars)",
        "label": "Gross loan commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows for gross commitments to receive a loan."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ]
    },
    "xtlb_IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IncomeAndExpensesNotInvolvingOperatingCashFlowsAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income and expenses not involving operating cash flows:",
        "label": "Income And Expenses Not Involving Operating Cash Flows Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Increase (decrease) in deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants to ordinary shares",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "xtlb_IncreaseOfReserve": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IncreaseOfReserve",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of reserve",
        "documentation": "Represents increase in reserve.",
        "label": "Increase Of Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, description",
        "label": "Information about how expected volatility was determined, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "Information about how the expected volatility used for pricing share options granted was determined, including an explanation of the extent to which expected volatility was based on historical volatility."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_InsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "Insurance expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "xtlb_IntangibleAssetOtherInformationMaturityDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IntangibleAssetOtherInformationMaturityDate",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expires term, description",
        "label": "Intangible Asset Other Information Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IntangibleAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IntangibleAssetsDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IntangibleAssetsDetailsTable",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43"
     ]
    },
    "xtlb_InterCureLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "InterCureLtdMember",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InterCure Ltd [Member]",
        "label": "Inter Cure Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestIncomeOnDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnDeposits",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income on bank deposits",
        "label": "Interest income on deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on deposits. [Refer: Interest income]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest from bank deposit",
        "label": "Interest received, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_InvestmentIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentIncome",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails",
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment commitment (in Dollars)",
        "verboseLabel": "Receipt of investment",
        "netLabel": "Investment amount (in Dollars)",
        "label": "Investment income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investment income, such as interest and dividends."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r142"
     ]
    },
    "xtlb_InvestorIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "InvestorIssued",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor issued (units)",
        "documentation": "Investor issued shares.",
        "label": "Investor Issued"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IsraeliCpiForwardContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IsraeliCpiForwardContractsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsareDenominatedorLinkedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS (not linked to the Israeli CPI) [Member]",
        "label": "Israeli Cpi Forward Contracts Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IsraeliNewShekelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IsraeliNewShekelMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS (not linked to the Israeli CPI) [Member]",
        "label": "Israeli New Shekel Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_Issued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "Issued",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued",
        "documentation": "Issued March 7,2021 due to warrant exercise.",
        "label": "Issued"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedAndOutstandingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedAndOutstandingRate",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding, rate",
        "documentation": "Percentage of issued and outstanding.",
        "label": "Issued And Outstanding Rate"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedAugust302021DueToWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedAugust302021DueToWarrantExerciseMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued August 30, 2021 due to warrant exercise [Member]",
        "label": "Issued August302021 Due To Warrant Exercise Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital - ordinary shares of NIS 0.1 par value: Authorized - December 31, 2023 and 2022 - 1,450,000,000; Issued and outstanding - December 31, 2023 and 2022 - 544,906,149.",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "xtlb_IssuedJuly62021DueToWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedJuly62021DueToWarrantExerciseMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued July 6, 2021 due to warrant exercise [Member]",
        "label": "Issued July62021 Due To Warrant Exercise Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedMarch72021DueToWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedMarch72021DueToWarrantExerciseMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued March 7,2021 due to warrant exercise [Member]",
        "label": "Issued March72021 Due To Warrant Exercise Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedMay42021DueToWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedMay42021DueToWarrantExerciseMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued May 4, 2021 due to warrant exercise [Member]",
        "label": "Issued May42021 Due To Warrant Exercise Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedOctober112021DueToWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedOctober112021DueToWarrantExerciseMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued October 11, 2021 due to warrant exercise [Member]",
        "label": "Issued October112021 Due To Warrant Exercise Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedOrdinarySharesAtJanuary1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedOrdinarySharesAtJanuary1",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued ordinary shares at January 1",
        "documentation": "Issued ordinary shares.",
        "label": "Issued Ordinary Shares At January1"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_IssuedSeptember12021DueToWarrantExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "IssuedSeptember12021DueToWarrantExerciseMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued September 1, 2021 due to warrant exercise [Member]",
        "label": "Issued September12021 Due To Warrant Exercise Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees, directors, and consulting fees",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "xtlb_LicenseAgreement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "LicenseAgreement",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, description",
        "documentation": "License agreement.",
        "label": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement [Member]",
        "label": "License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_LoanInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "LoanInterestRate",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "documentation": "Loan interest rate.",
        "label": "Loan Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received amount",
        "label": "Loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MarketableSecuritiesInterCureLtdAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MarketableSecuritiesInterCureLtdAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities \u2013 InterCure Ltd [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MarketableSecuritiesInterCureLtdDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MarketableSecuritiesInterCureLtdDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Marketable Securities Explanatory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MarketableSecuritiesInterCureLtdDetailsScheduleofChangesinMarketableSecuritiesTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities \u2013 InterCure Ltd (Details) - Schedule of Changes in Marketable Securities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MarketableSecuritiesInterCureLtdDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MarketableSecuritiesInterCureLtdDetailsTable",
     "presentation": [
      "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities \u2013 InterCure Ltd (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MarketableSecuritiesInterCureLtdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MarketableSecuritiesInterCureLtdTextBlock",
     "presentation": [
      "http://xtlb.com/role/MarketableSecuritiesInterCureLtd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MARKETABLE SECURITIES \u2013 InterCure Ltd",
        "documentation": "The entire disclosure of marketable securities.",
        "label": "Marketable Securities Inter Cure Ltd Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_MaterialAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "MaterialAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_NamePlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NamePlanAxis",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name Plan [Axis]",
        "label": "Name Plan Axis"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_NamePlanDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NamePlanDomainDomain",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NamePlanDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_NonAdjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NonAdjustingEventsMember",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non adjusting Events [Member]",
        "label": "Non Adjusting Events Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "xtlb_NoncashActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NoncashActivitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(b) Non-cash activities:",
        "label": "Noncash Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r114"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompensationtoKeyManagementPersonnelforEmployeeServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of persons",
        "label": "Number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "xtlb_NumberOfOptionsFullyVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfOptionsFullyVested",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options fully vested",
        "documentation": "The number of shares options fully vested.",
        "label": "Number Of Options Fully Vested"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_NumberOfOptionsVest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfOptionsVest",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vest for share option plan",
        "documentation": "Number of options vest.",
        "label": "Number Of Options Vest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, outstanding at beginning of year",
        "periodEndLabel": "Number of options, outstanding at end of year",
        "terseLabel": "Options outstanding at end of year",
        "verboseLabel": "Options outstanding",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r82",
      "r84"
     ]
    },
    "xtlb_NumberOfShareExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfShareExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share holding of up",
        "documentation": "The number of share options exercisable in a share-based payment arrangement.",
        "label": "Number Of Share Exercisable In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, exercisable at end of year",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "xtlb_NumberOfShareOptionsExercisableSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfShareOptionsExercisableSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable shares",
        "documentation": "Number of share options exercisable in share-based payment arrangement.",
        "label": "Number Of Share Options Exercisable Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Exercised",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Expired",
        "label": "Number of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Forfeited",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Granted",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "xtlb_NumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfSharesAbstract",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_NumberOfSharesAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfSharesAbstract0",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued",
        "verboseLabel": "ADS's issued",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders meeting shares",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "xtlb_NumberOfSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "NumberOfSharesMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares [Member]",
        "label": "Number Of Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, outstanding",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "xtlb_OneDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "OneDirectorMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Director [Member]",
        "label": "One Director Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_OptionsExercisableIntoOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "OptionsExercisableIntoOrdinaryShares",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable into ordinary shares",
        "documentation": "Number of options exercisable into ordinary shares.",
        "label": "Options Exercisable Into Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_OptionsReserve": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "OptionsReserve",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total options reserved",
        "documentation": "Represents options reserve.",
        "label": "Options Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_OrdinarySharesExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "OrdinarySharesExercisePrice",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares exercise price",
        "documentation": "Ordinary shares exercise price.",
        "label": "Ordinary Shares Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares [member]",
        "verboseLabel": "Ordinary Shares [Member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r141"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive income (loss) for the year",
        "label": "Other comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income attributable to non-controlling interests. [Refer: Non-controlling interests; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive income (loss) for the year (basic)",
        "label": "Other comprehensive income, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_OtherExpenseByNature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherExpenseByNature",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other expenses, by nature"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r103"
     ]
    },
    "ifrs-full_OtherFeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly fees",
        "label": "Other fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_OtherFinanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceCost",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other finance expenses",
        "label": "Other finance cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_OtherFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other finance income",
        "label": "Other finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from transactions with non-controlling interests",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from transactions with non-controlling interests",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in New Shekels per share)",
        "verboseLabel": "Ordinary shares, par value",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "xtlb_PatentsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PatentsAndFees",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents and fees",
        "documentation": "The amount of expenses for patents and fees.",
        "label": "Patents And Fees"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PaymentOfShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PaymentOfShareholders",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to shareholders (in Dollars)",
        "documentation": "Payment of shareholders.",
        "label": "Payment Of Shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PercentageOfFunctionalCurrency": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PercentageOfFunctionalCurrency",
     "presentation": [
      "http://xtlb.com/role/FinancialInstrumentsandFinancialRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of functional currency",
        "documentation": "Percentage of functional currency.",
        "label": "Percentage Of Functional Currency"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PercentageOfHoldingShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PercentageOfHoldingShare",
     "presentation": [
      "http://xtlb.com/role/MarketableSecuritiesInterCureLtdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares hold",
        "documentation": "Percentage of holding shares.",
        "label": "Percentage Of Holding Share"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PercentageOfRoyalties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PercentageOfRoyalties",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties",
        "documentation": "Percentage of royalties.",
        "label": "Percentage Of Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PercentageOfShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PercentageOfShare",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares",
        "documentation": "Percentage of shares.",
        "label": "Percentage Of Share"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PercentageOfSublicenseFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PercentageOfSublicenseFees",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of sublicense fees",
        "documentation": "Percentage of sublicense fees.",
        "label": "Percentage Of Sublicense Fees"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PeriodOfClosingTransaction": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PeriodOfClosingTransaction",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing period of transaction",
        "documentation": "Transaction of closing period.",
        "label": "Period Of Closing Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PricePerUnit",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per unit (in Dollars per share)",
        "documentation": "Price per unit.",
        "label": "Price Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PrivatePlacementWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PrivatePlacementWarrantsIssued",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "documentation": "Represents private placement warrants issued.",
        "label": "Private Placement Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_PrivatePlacementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "PrivatePlacementsMember",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member",
        "label": "Private Placements Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Professional fees expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow",
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) for the year",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r18",
      "r47",
      "r58",
      "r60",
      "r97",
      "r98",
      "r114",
      "r117"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r142"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails",
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r74",
      "r84",
      "r115",
      "r116",
      "r154"
     ]
    },
    "xtlb_RangeOfExercisePricesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RangeOfExercisePricesOneMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of Exercise Prices One [Member]",
        "label": "Range Of Exercise Prices One Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RangeOfExercisePricesThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RangeOfExercisePricesThreeMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of Exercise Prices Three [Member]",
        "label": "Range Of Exercise Prices Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RangeOfExercisePricesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RangeOfExercisePricesTwoMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of Exercise Prices Two [Member]",
        "label": "Range Of Exercise Prices Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails",
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r74",
      "r84",
      "r115",
      "r116",
      "r154"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "xtlb_ReceiptOfRequiredInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ReceiptOfRequiredInvestment",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of required investment",
        "documentation": "Receipt of required investment.",
        "label": "Receipt Of Required Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReceivablesFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReceivablesFromContractsWithCustomers",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required payment of liquidated damages",
        "label": "Receivables from contracts with customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73"
     ]
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RemainingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RemainingLiability",
     "crdr": "credit",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining liability",
        "documentation": "Remaining liability.",
        "label": "Remaining Liability"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RemainingNumberOfOptionsAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RemainingNumberOfOptionsAvailableForGrant",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining number of options available for grant",
        "documentation": "Remaining number of options available for grant.",
        "label": "Remaining Number Of Options Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RentAndOfficeMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RentAndOfficeMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent and office maintenance",
        "documentation": "The amount of expense rent and office maintenance.",
        "label": "Rent And Office Maintenance"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RentExpense",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expenses",
        "documentation": "The amount of rent expenses.",
        "label": "Rent Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "xtlb_ResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ResearchAndDevelopmentExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r104"
     ]
    },
    "xtlb_RevaluationMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RevaluationMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of marketable securities",
        "documentation": "Revaluation of marketable securities",
        "label": "Revaluation Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RevaluationOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RevaluationOfMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow",
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of marketable securities",
        "negatedLabel": "Revaluation of marketable securities",
        "documentation": "Revaluable of marketable securites.",
        "label": "Revaluation Of Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RevaluationOfWarrantsToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RevaluationOfWarrantsToPurchase",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of warrants",
        "documentation": "Revaluation of warrants to purchase .",
        "label": "Revaluation Of Warrants To Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RevaluationOfWarrantsToPurchaseADSs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RevaluationOfWarrantsToPurchaseADSs",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofFinanceIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of warrants to purchase ADS's",
        "label": "Revaluation Of Warrants To Purchase ADSs"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_RevaluationOfWarrantsToPurchaseAds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "RevaluationOfWarrantsToPurchaseAds",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of warrants to purchase ADS's",
        "documentation": "Revaluation of warrants to purchase ads.",
        "label": "Revaluation Of Warrants To Purchase Ads"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r96",
      "r100",
      "r137"
     ]
    },
    "xtlb_ScheduleOfAssumptionsOfInvestorsWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfAssumptionsOfInvestorsWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assumptions Of Investors Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCarryingAmountOfAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCarryingAmountOfAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Carrying Amount Of Accounts Payable Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock",
     "presentation": [
      "http://xtlb.com/role/AccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amount of Accounts Payable",
        "documentation": "Schedule of carrying amount of other accounts payable Text Block",
        "label": "Schedule Of Carrying Amount Of Other Accounts Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCashAndCashEquivalentsAreDenominatedOrLinkedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash And Cash Equivalents Are Denominated Or Linked Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfChangesInFinancialLiabilitiesClassifiedAsCashFlowFromFinanceActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In Financial Liabilities Classified As Cash Flow From Finance Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfChangesInMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfChangesInMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In Marketable Securities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCompensationToKeyManagementPersonnelForEmployeeServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Compensation to Key Management Personnel For Employee Services [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCompositionOfAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCompositionOfAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Composition of Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCompositionOfAccountsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCompositionOfAccountsPayableTextBlock",
     "presentation": [
      "http://xtlb.com/role/AccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Composition of Accounts Payable",
        "documentation": "Schedule of composition of accounts payable Text Block",
        "label": "Schedule Of Composition Of Accounts Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfCompositionOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Composition of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/FinanceIncomeExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Income (Expenses), Net",
        "documentation": "The table disclose the finance income (cost) for during the period.",
        "label": "Schedule Of Details Information About Finance Income Expense Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfExercisePriceAndRemainingContractualLifeForOptionsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Exercise Price And Remaining Contractual Life For Options Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfFairValueForOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfFairValueForOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value For Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfFairValueForOptionsGrantedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfFairValueForOptionsGrantedTableTextBlock",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value for Options Granted",
        "documentation": "Tabular disclosure of fair value for options granted.",
        "label": "Schedule Of Fair Value For Options Granted Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfFinanceIncomeExpensesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfFinanceIncomeExpensesNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finance Income (Expenses), Net [Abstarct]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfNumberOfShareOptionsAndTheirRelatedWeightedAverageExercisePricesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Number Of Share Options And Their Related Weighted Average Exercise Prices Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfOutstandingOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfOutstandingOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfProfitLossAttributedToOrdinaryShareholdersBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Profit Loss Attributed to Ordinary Shareholders Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfProfitLossAttributedToOrdinaryShareholdersDilutedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Profit Loss Attributed to Ordinary Shareholders Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Profit (Loss) Attributed to Ordinary Shareholders (Diluted)",
        "documentation": "Schedule of profit (loss) attributed to ordinary shareholders (diluted).",
        "label": "Schedule Of Profitloss Attributed To Ordinary Shareholdersdiluted Table Tex Block"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Number Of Ordinary Shares Basic Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfWeightedAverageNumberOfOrdinarySharesBasicLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Number of Ordinary Shares Basic [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Number Of Ordinary Shares Diluted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfWeightedAverageNumberOfOrdinarySharesDilutedLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Number of Ordinary Shares Diluted [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Number of Ordinary Shares (Diluted)",
        "documentation": "Schedule of weighted-average number of ordinary shares (diluted).",
        "label": "Schedule Of Weightedaverage Number Of Ordinary Sharesdiluted Table Tex Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r72",
      "r97",
      "r109",
      "r118"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinMarketableSecuritiesTable"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r72",
      "r101",
      "r109",
      "r118"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SettlementsFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SettlementsFairValueMeasurementLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation during the year",
        "label": "Settlements, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in the fair value measurement of liabilities resulting from settlements. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price in NIS",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value USD in thousands",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Value"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Position",
        "documentation": "Share based compensation arrangement by share based payment award options position.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Position"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of Exercise Price and Remaining Contractual Life for Options Outstanding [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value for Options Granted [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofFairValueforOptionsGrantedTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of Fair Value for Options Granted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of Number of Share Options and Their Related Weighted Average Exercise Prices [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofOutstandingOptionsTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of Outstanding Options [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentDetailsTable",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareBasedPaymentTransactionsToEmployeesAndNonEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareBasedPaymentTransactionsToEmployeesAndNonEmployees",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based expenses (in Dollars)",
        "documentation": "Share-based payment transactions to employees and non-employees.",
        "label": "Share Based Payment Transactions To Employees And Non Employees"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareCapitalReservesAndRetainedEarnings": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareCapitalReservesAndRetainedEarnings",
     "presentation": [
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE CAPITAL, RESERVES AND ACCUMULATED DEFICIT",
        "label": "Share Capital Reserves And Retained Earnings"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareCapitalReservesandAccumulatedDeficitDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital, Reserves and Accumulated Deficit [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_ShareCapitalReservesandAccumulatedDeficitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "ShareCapitalReservesandAccumulatedDeficitDetailsTable",
     "presentation": [
      "http://xtlb.com/role/ShareCapitalReservesandAccumulatedDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital, Reserves and Accumulated Deficit (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "xtlb_SharebasedPaymentAwardRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "SharebasedPaymentAwardRemainingContractualTerm",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment award remaining contractual term",
        "documentation": "Sharebased payment award remaining contractual term for the during the period.",
        "label": "Sharebased Payment Award Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank deposits with original maturities of three months or less",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of CashFlows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://xtlb.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfImpairmentOfGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfImpairmentOfGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses",
        "label": "Tax effect of impairment of goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount representing the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to impairment of goodwill. [Refer: Accounting profit; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "xtlb_TerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TerminationPeriod",
     "presentation": [
      "http://xtlb.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Updated options exercise period",
        "documentation": "Directors termination period.",
        "label": "Termination Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://xtlb.com/role/CashandCashEquivalentsDetails",
      "http://xtlb.com/role/IntangibleAssetsDetails",
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofOutstandingOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of Range [Member]",
        "verboseLabel": "Top of range [member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r74",
      "r84",
      "r115",
      "r116",
      "r154"
     ]
    },
    "xtlb_TotalIncomeAndExpensesNotInvolvingCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TotalIncomeAndExpensesNotInvolvingCashFlows",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income and expenses not involving operating cash flows",
        "documentation": "Total amount of income and expenses not involving cash flows",
        "label": "Total Income And Expenses Not Involving Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xtlb.com/role/ConsolidatedBalanceSheet",
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable",
      "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts payable",
        "terseLabel": "Accounts payable",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r140"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofCompositionofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance due from Canndoc Ltd",
        "label": "Receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xtlb.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_TransactionsandBalanceswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_TransactionsandBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_TransactionsandBalanceswithRelatedPartiesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesTablesLineItems",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions and Balances with Related Parties [Abstract]",
        "label": "Transactionsand Balanceswith Related Parties Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_TransactionsandBalanceswithRelatedPartiesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TransactionsandBalanceswithRelatedPartiesTablesTable",
     "presentation": [
      "http://xtlb.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TravelExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TravelExpense",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and travel",
        "label": "Travel expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "xtlb_TwoThousandElevenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TwoThousandElevenPlanMember",
     "presentation": [
      "http://xtlb.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2011 Plan [Member]",
        "label": "Two Thousand Eleven Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_TypeOfCurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TypeOfCurrencyAxis",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type Of Currency [Axis]",
        "label": "Type Of Currency Axis"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_TypeOfCurrencyDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "TypeOfCurrencyDomainDomain",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfCurrencyDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_TypesOfInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInstrumentMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of instrument [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of financial instruments. It also represents the standard value for the 'Continuing involvement in derecognised financial assets by type of instrument' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails",
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "xtlb_UnitedStatesDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "UnitedStatesDollarMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofCarryingAmountofAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dollars [Member]",
        "label": "United States Dollar Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xtlb.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees and expenses relating to service providers",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "xtlb_WarrantExercisedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantExercisedPeriod",
     "presentation": [
      "http://xtlb.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercised period",
        "documentation": "Exercise period of warrant.",
        "label": "Warrant Exercised Period"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WarrantRevaluationIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantRevaluationIncome",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant revaluation income",
        "documentation": "Warrant revaluation income.",
        "label": "Warrant Revaluation Income"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WarrantsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantsDetailsLineItems",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsLineItems",
     "presentation": [
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions of Investors' Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantsDetailsScheduleofAssumptionsofInvestorsWarrantsTable",
     "presentation": [
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) - Schedule of Assumptions of Investors' Warrants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WarrantsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantsDetailsTable",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "label": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://xtlb.com/role/ScheduleofChangesinFinancialLiabilitiesClassifiedAsCashFlowfromFinanceActivitiesTable",
      "http://xtlb.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable at end of year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Expired",
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Forfeited",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofNumberofShareOptionsandTheirRelatedWeightedAverageExercisePricesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding at beginning of year",
        "periodEndLabel": "Weighted average exercise price, outstanding at end of year",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r82"
     ]
    },
    "xtlb_WeightedAverageNumberOfOrdinarySharesbasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WeightedAverageNumberOfOrdinarySharesbasic",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesBasicTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares (basic)",
        "documentation": "Weighted average number of ordinary shares (basic).\r \n.",
        "label": "Weighted Average Number Of Ordinary Sharesbasic"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_WeightedAverageNumberOfOrdinarySharesdiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WeightedAverageNumberOfOrdinarySharesdiluted",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares (diluted)",
        "documentation": "Weighted average number of ordinary shares (diluted).\r     \n.",
        "label": "Weighted Average Number Of Ordinary Sharesdiluted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://xtlb.com/role/ScheduleofAssumptionsofInvestorsWarrantsTable",
      "http://xtlb.com/role/ScheduleofExercisePriceandRemainingContractualLifeforOptionsOutstandingTable",
      "http://xtlb.com/role/ScheduleofFairValueforOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term life (in years)",
        "verboseLabel": "Weighted average remaining contractual life",
        "netLabel": "Expected life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://xtlb.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of issued ordinary shares (in Shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "xtlb_WeightedaverageNumberOfOrdinarySharesbasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "WeightedaverageNumberOfOrdinarySharesbasic",
     "presentation": [
      "http://xtlb.com/role/ScheduleofWeightedAverageNumberofOrdinarySharesDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of ordinary shares (basic)",
        "documentation": "Weighted-average number of ordinary shares (basic).",
        "label": "Weightedaverage Number Of Ordinary Sharesbasic"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_YedaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "YedaMember",
     "presentation": [
      "http://xtlb.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yeda [Member]",
        "label": "Yeda Member"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_comprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "comprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://xtlb.com/role/ScheduleofProfitLossAttributedtoOrdinaryShareholdersDilutedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income",
        "documentation": "comprehensive income.",
        "label": "comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "xtlb_warrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xtlb.com/20231231",
     "localname": "warrants",
     "presentation": [
      "http://xtlb.com/role/EarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "documentation": "warrants.",
        "label": "warrants"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Hedge accounting",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g21A-24G_TI",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B33&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001213900-24-037717-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-037717-xbrl.zip
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M_S>ZO6!UFO-RN+*J[3O7TY-KE"6;%6"+S"FXIZL2-D<69;&.4AB.<$>4J,Y
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M#?Q!;LN-U$<CFU!L,""!IZBP.VTX4P622:+Z)>;)"#OB(4FPEK3FR-; 89O
M!I#0W#D*I5$T#(+(Q7(T@9"= )Q5/GX0F$N#)-A5A"DC>]J@U3:)KO+";^LL
M51)^^&4PB89MLQZ3R 9/G%>()*G8V0-[-W.^YY]U<LF<,9<16NY4[$/9(BX2
M*@WK1J(+Q=1@.;&R1F4)*\$W*5U+==R6@C>TQO]P( R2O<X1?*"LB9<O(2%$
M9>H=#JN8'8W\QSFH[@B3FWB!!PB7%COL1W>)D>Q!TZJ9)NS*6&5JPM!%^C?Y
M),@(6^%QA <#9J0DB(-,E>A#@)N0+Y4J=\-AAPP[9"TC^ =5V'/[ PGSN';W
M5&>$F54_L6/()3@WRC:_;VJY7"=#7\@S1F'&6ROB03("?]US<0OXN2;X-\,.
MR/+2=XX=V&X*I"<#V]'ML1T=#&Q'W]&V^N+F7V5XYKA&,4CBZN7?Y^PG!JC2
M3#SNS(."W$VG,/.6?M_#C3_\BYI<!=O4Y.HNN[K=14>\_B'XK2)-@T@I]>)S
M/4!0$VI7$Y=VA?;6K\23?5*0QJS2)9C8A+E2!9L1_OJ :%PJ[[0/._+3WQ@M
M:,@,4U9?(S.=FTRH*$]1X+)4BBQ7%B4WA&N:]>2NZT+@E6^W6O=PU5R4B<=1
MHJ :ZD<1P]#AN^"$W0T]=LM6N5U&%$J4U<U[>SX$G<9!#8>G+?"DT[QZ*D-7
M:2[A+Q*%Q8;$P!^%63T;HSA,#"MXN_>G_"KPLRPT4F_%U03F'-%R*%[86)&N
MJ7:X7IV*O&S%^NBSO/LWX*$E+=UN5./-+(C![/::*?>?>UNPT:_7LL%G]XD!
MN!/7 %],@IWJCT1\+?5-W%WAYPW/[^"<?D/.J4;VMD@B+3-LB8-:2.TX)O86
ME76[Z8'1!*;'$UZ#A43=CGYWEB@UFV_G,R?](*9;*Z:@_C[V=DJR\C?(VR!O
M:U2+:$"1SI.6+VE8+LM*"7,#TD1$9574Q!,[2-H@:7]-LX'E9RFC7!E7PYUQ
M?""#M W2]K4CF&I*HZ&99RTZ1L]9,M3G^.$@8H.(?>4(J-NL%-ZU+#*8M 6A
M*OT@  6 MPQH\VSW\-ILZP9#!:>3%>9M0-A6K'%H>61@$$O%V&4K?!.G*B*F
M38)=B0EMNO_V/\7<:G5#E> S[;']L%JR(M2U"A]0PLS@.U#]A,0TFC$RBHW]
M64<%6&GI,B X68:47N.HU"4'VG36$VJ3 $KF.C<U;[R@,&RFD!'FJL71=2V4
M?V00G4$#T3F2@&0Y#2=IOH"AO<D+A0G>43/&&\[@I7$23 B8*PM6A'WK3.#,
M%/=M!7MA1U.OM1V*] :"J#/P_RG<,;7]9X7BW: HM%UK&#DCZ)@M9ZSS.?)B
M1[&JN>R++QM)F5A?M-"CKG>"$^2MWCW,3BBOLQMR-9HP^&2$<6*:6.:<PI]*
M.)-C7QCZGC&=(<5[3<Q1BN>E)-@RW5/#.5SP<E/QQZU-._PA87'#=.=EC0+/
M'!59QRZ4;AOA,ESFU+*8RZ,\L+_$CXF'P_4[CB5G1T#-3"FLPV9P)V.!:K%U
M"4E*Y&.C@)L*<(B?Z58;''B-(%6K'2SCI$52[OU2'Q'*XR4L!F43#O='X<'>
MP2'JWV :);QE/YE]]*_[HT=[^[" >5V*TB %9C49"@QL<*G SXN/U$];%IB+
M]YNW>_9HS]V._X\JH9Z)"DK41,>Z"GI^^_C9Z.#1$_OKGFR5!-*]3!,EQBB+
M@@=%7E>H4#U!=BR-?AQ>TIJ2OL3,6/!KA!S *$B?I$3$=@N8IU'&^1[D"*"4
MBE50^$0L)>%IZ9\Y.*E2J;/%31@1:0)O AXHB[H;33 1T'2CDX'.F2X!ZV(B
M.$#V#Y"3LIIZ6*"$MLV$-^29PN8=N^$IGJZ8:$0XG71L;EL4D:8.(%6+KC@P
MVP^.'#!%>+OC=YI82FS+0VMHN-9KG-DO(MWT>-W*8)4#*'PJQK& UMWPG+.C
M"^5J/?$>OIHRXL=T#HP"EU/'@KT;_=5](A6C:%IY,S?YU$H%JS?AS\LB(B@Z
MZ$OQW@,J=O:)<H4<-^)?X*<F@^A[]_=>+YF]3#5<B=@B8Y7B&1/@=D(C9/Q/
MR9AQET"2+4,B[R0'?OD0F\^@&43"B)TP([_U(-J,)LWI),%/P_$P&M5F-HL=
M\!YF(>,+-44!K\G7M7F^NW8VV3NE:MZ0QL597C4"C5-9C@@Z%U4"\H:YW!*M
MIY*:2:,2I<(V'$)4Q%/1@5:61UZ'*Q@.I8)Q+#@TOP,O(64U<Y?WY'U&MJ<[
M3@G7U<D'S0> V%]&F9S#<BMSH1UCXYH16*8%+Z[=U->'+/@SHWZ"OCS!B'.A
MJ&";[B>+S-(S0^DGBLR1L(S0@S%$\KBXH-)C#S>,VC]3YBP#@UC/:0W,= 6B
M0D'CBKUM35P2/4$HH&N3(ZQYZ9\B= :A,Q/-T*SWK2ARCIII=5=8V<G9M>VA
MENW=SN 3RH*F6,17KJ/3PJS*2"ZIL\9[DS"B*Q>!DP)S1[1!8G];?GR[AH%I
M<2[I0YJ?CUF^R-J*VABG_FD!*K[$XNHBKR^GX9S4,!OVS$Z$/T$?$97YN'(Z
MHK252:&<_Z/ ^#C=IJ13/9=I29E*@/_E82:\GKZM*1*WEH*\/6=4PNK&EB(%
MXB599Y+/&SLDXQ+*9E+.LQ9=B7]EGI@:X4 :)8"FJ9.GS>WB.GP.F3*P9(%G
MQ..OS:JY4Q!?"KU MO^+? '[W_3G'C6<R+G@]4;HI9-G[3@91JU6WO:U[_UY
M^$5(Y*<#$OGVD,B' Q+Y_FT_C!J*=C2JVF>;"YQ/.<.SLHO(NP7,U5TF0ZQ*
M("MZ7H((F[]]?WF2-3X%C3$!;I(=!D<FB I<C&R"%(JQ9N="#?G=^REO&\K+
MH2R6,1A[6)_/*3J;JA OH60:"N.6B3?]>>?5>'5]?F2/[S@(^/T2\#4+<85=
MA2^))T*2>"*Z.KO*TRM*EXV\:&1?.& 0P?LE@AO4L2B+3$O23D)Y_C-VP,%,
M+ 8TVO$FO[##1M%'])4I]7'\FBSZ@SC?+W&^)9%M!FZ]J*@[Z]%.75W/,\CA
M_9+##:G55E\\A9R6J99TJL7O]$=N1RY0BSFD.=( VNBO'[FUQH2+1[8HI&QI
MW"#F@YC?HO70L&31F0)Y)O&=P!; /Q$KIN*:[0(C__0/UVR2JG*)7H<\,M@9
MV+:)R*!\ \-K>B9Y1-D%7IZ+I-]=.$C__9+^6Y%PZL#JU1U/ZH)SNB2HW4+B
MS0&$!Z'[3H4.9:X!%/1$4#6E;1"V0=C^:H!JQ#"EN?0-( 0'G:;DQQ/+:1$6
M^3)BR@[,D%,NJ8&X&$S-013_BBA:3G0!6B,4KF+P%5/"L>?T4:<I?#O4@ V2
MMXZG^)&C5-M2'>-UI]&BK!$C7#B2+XNK%OAFCRK<G FX%1B$HQ;0S:N/"J*K
M2*<D_E1%L5 "J9ZJV8BZHE+@@F#H%&+NP)]QAKD#>W@Z\5"T]" #,G5/889L
MJK6"PXU*;+"\RM9^M5#4C>*-L*]XP\\0EA6XHCAA/85L+#"KL*QM4/R*["3A
M_SXW(JHG,H$E8Q^ZF+N#L\?1/'(4FC:2Y$9"TRZST@!LMDBE5@ZV7_;O"R#.
MD-F=1;ILH8 -%@<GEQ&YB4XI#8+ >UK!3[:#AVMR36END"FIWO.Z+%!I&.-*
MN>("-)+.D(M^:IA3Y<:-6OR\%\$]L-A9+/\UF-? P'41DC\;X^:39N8&M8O;
M3;"\!L"+)+>(VQVU@;RC&^%U1]<!=H.+7*BA*41&NQ?46J<VQ0B?&3_A*4 _
MX- =T#C.,S(%4&O26%WU"K>!<BW;B5E$23#$"&[08.0U)2HDYBIQ"6]6\-(:
M!\L#X.U@#(E,IM%*H&:I,S95.-%IT.HGTM=/,GP)XP[L'(\H66F.@I$\E.*3
M7DB<;V\&X_B\2>-R&8#=A2W&.NH0B(W33&,>;M(@=:=!5$J%%_X,IQ2'T"@T
M:]1,D+*/TX@O!YV<((<>'7-]J\HGGEG3U<(4W 3\;5H*>05 %@).J.RFAKF*
MTIJ.UR]5-:/ 5A])^*+L.?7Q"&\UN3#3P*6VYO//3,HJ%#W9'@$[%O8UO]@2
M^)HR3E=\96<ND-_ZM<9]! 2RN[FZVS4GX8WBD:SX]X$API:YNI4RK=O3V%\(
M(G\V@,AO#T3^: "1;_=F:9HW/"]DB';8J%%?O436TY>>LOI5BH'OE_G7IIV^
MAK/7^#%=GERO6=] #WVS(MG^>0X:58PWF><V__$?RK"]8 4>AQ:8&\;5R$J5
MH<?#W'-X!Y9G^#,4PKT0([+W\F*>2U5:GTUT#:4PX>H$4Q=8_]EGH8F*!C\(
MC,]#.-L9=-$3'Z#G ?)L-;MAF+9WK+,4F0&X:LZ*/K'Q=&A0>![P$>#_H$$$
MBZYC\4\CWX(KE)Z-T10AE5/8JF$8/9KA#.!JW]V67-IAT)A= <OUS-*;X@[^
MLCTW1'ZW-?+;P&?W$[9*[P B*BJL:C*U\W4I/A.&#[:DM>J0E_B.I-.O35;9
ME2[R#/7I(&J#J&T2Y]=,-7!>8P9'?B4$):(E9RJAC B:.'7&L5")/$Z4=%9Q
ME!U8\A_%;<O,8OHT?)1CD!.QK5%R%65("P?VU)7R(N<8$XGF1.YV]RB$87?<
MN]W1!GNC*\XD/BXZZ\6=*>3:8B0D\B"=6Z=AZ9K<\/5PI]ROKJ%?<++/3^\-
M8C^(_;KM#\ZUQZRZQ6<D9*)7U#7J33R+4WVGV)Q!,+=',#=HK<P+;;C56F&(
M>9XBS1"),+<KM08-Y<%V, ^V#.?1D@(+AF5)9X;,U6KF43A545I-N:!!"?-A
MASQ,$ILI$2""HZGI5,BWK5?[]D0-WT^7)2P1D53.82*9K--;G( 7)Q0/O&MR
M@BUZJ3*P"M/0=F#&*)*E@L5HTR@$U<7 %LST4DPNDXRU<?FCTO!/=@0#,\9%
MT TK^AG0SP4&&V1CHVZ><U[@JU5^MA^#7HRT$<90GH0 44Z-1.8*VFH]L3@J
M+\#8B$Z:A*+?1*X99'1OI3KOY.BU>QO);65X[E:3#7T)[%XF/.I2V(24,?%%
M-'-L:*W^=88+G=14&XY&&(44[$9.%'N,>Q%!\.#F2% Y:F$; O4):[54@WW-
MLL<:TC0+]6@C-%0RY#],_F.J2/G#&A$\$33+-%^$L$GCC^DRX+:-O";MM3.M
M%+&>#CE8ZWG..HDV'6("J*6V2)9K3W])'3*;0E1JH3P9<6OZ:%(AB;NY&W(K
MJJP L\.@")W6-?"=:Y^*%@O)$=+UP^2E>?Q1:!FC=,E-$]MC NF-QA'R+;[G
MAP7>$#1JQ4F=Q09IM8*TB@,+I,(YR" #AT-^CG%<LDS9'$!B9HE&F+>CH5M,
MIZX$\!0H6%DMNR$N-+(?13;<B]C/Y4@T,ASE2G(6?I2NPSQ*J2R1!1NV0*$
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M5C_DV>4.YOB9'=WCK&M, ,*8M86@^X%_+A' NEY*K!N:&Y%9QEA0>;"0CQ,
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MJ*'HMFE(3#F7>:PI[VLPQ(.(#R*^<1$'6R,O)=&2JDMJ1A?I&2?*O5!FRZ9
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MEE@8)I&;P8?S2NZ8&Y89.*Q@^MAENS_:A!:U*;/68 Z,P(YLU]Y"L4%-[=]
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M>C9&AN*9QPV&[;FQX"FS5,(Z*T%H"3]B\Q(+Y6HVI/A+_MFH$1ED>)#A6\E
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MVD(2%9J)B$8LKU2P FX;<S0BD>4OX#V>IB<]M\S:#$OJ.Z'-I%M<JK6B!\]
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M$#!/S#9!CN4T;Z<CM->HVU?RVIS.EI\IDM"3YEQ%HN+A413:=RB?ACG3FZB
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M;@+75B:\8UP:P@*Y\NVM7S'9:+E(80LI?<;>!RTQ,J\QR@ITX]SGBJJ=&RK
MVYR9#<3E+(B9%SE"]RY+9D:D;^1E^93&10NR6KI9& (2_CCVYA7@[48 @ULG
M 775*T]:#<367$T+K^\GS&$\$YH^3F?PDHBZ1599"W$=D1EG1N"5]<6U)5UW
M/2>S$Q:^6T:79\J^_!RB.@SI7_/,H>CQMW-Z77G2O([$ 4)Q&-D750X09,M)
M,$<)S6TL%!074\[J%.VY@@"T)!=J$Z9 B/"^,<W$D&!-K[Q.:Y%55VI/V2B]
MA<V9MFM&[5Q8FV?Y1=/ZID-79HI8VZ\!:/9:'(5LU$WS$"Q**N\9"KMQ;F0]
M#-49A*#9QN=;3"H4JTC5^)!8X67298&29U&+-M19T1I^RFM:)I[M.S]M+HJ@
M7[V?T5_Q2L.K67^4B8 J,4@HS.EK88YU/W-Z?-Q*'IC]<-TD@;!@83 .HZ%S
MZ6-NAJ_(Y+C>*(#O*$CHM+8=6/&G7!;(02J5^3T42#TP%&H^9\="E5;R/A$V
MACL'0FK"D?\"6I_30&0E[YUZ@%Z6"=4[](YQJU EWB)WR>$; O^5M>#R:FJX
MWW [<YLSSOB1I=)X/APYQ*V#@&,E'H+S- *>80HPQO=EI)$QGW$UG >^IECJ
M]<2\QFAB+7_ Q0BE8T0BQM:#X:WN,:7Y4>[HYFD_?4$N<\.':<[:1]$29040
M;OD^+0(^,.7 X:7;%FWBJ/3=_#RX\[T-@U4LIS'E9+JCKMLTW2">RK<O+-T?
MZFKE"ACD'([7C(6)3**QTQU-2BV:Z/!+&9_0"]5PU>?J&PP1A(JJF?&;I6NB
MZSL6_E1%@6BNCO#8B76%AB4XG08QT3WWT7*_?\S$.<X:95[@EY;O)TU3LG&:
MXL=PS+2>/<7>],HS[WHFB7")Q^*X*(J##UD[5AG9B@*Z]LC7GMLH?A/SG 6\
MV(L1ZF(E[2C?2V-LIUK*AC#680:.5'S!!7VFG:+LP[<BU 6D@_ZI[A ^B$_D
M69[]0;[C!9_<:D=^GB'?A>NOC>93%W2H6B9_XL?G:R7R33-]75&\X_><EYV3
M4]ERTVGA!5BCS!VU??X^?F_"8,P8%@<)BX_ H186%NWX&CIM8%6]\[,UTBG\
MB:&DN5NW*T4AVI53U19A/*PGN0Q+,-KPS!M\&//D\ID1/,_H9 R?%.Z$NR,H
M!.BL_@.6_?W>&6U[M1[&!-Z9=@B+_G"6G<D6.7#0R^VGOXX$6IR3,KZQ,KSS
MOJ _30M:LRV;DPW:(DQG0"]"UKC[OJ!LSQGO9OB\BHYD!X&K!QI#,X0%RM"B
MY'P"EC',X+(1.LK1"6QVP+]_HT/7$D1N$,QIV9FBO*=$]FP"W,("\9[1B=WZ
M8AK";G]ZCG5O;(KD%767^2)LF%=6^GA>.R$J4;M">TAA*K/"[';)[W4!Y\]?
M0'JI/1D^QQ!TE-4-:N H@03/:L>3/B[+'TZD?+TE*C'B]JY8[1P/(%R)4="$
MD:(RG7-\.(X&U>9P:X"/',<Z]9E[<Q+NC:[B?ZNYG\1KN$9V;4T$^"WR,%DX
M_\Q%(A&<JJ@%@9>+^?MMF)Z+O*QFQP;E]0IC(?S;BY,ISP6%&FTO%PE\;!A(
MQA%V43)E&VIC"">:GQ51>$!'TV'1@)\^2Z170V/I, R/<LDH R\4?!!KQGLM
M>?B8<C"S1VUT+GA3V=HEH8P5XE8F+J46!5QD3 $K&M65$4BHHX#U8,G.(*F^
M?I!1KGQUD&!EM(6IH_-.)8_-KU9#?E]]ORB:KA@%8*)LX67?BHX.2W<UPVF?
MY$X=1_>-E<:1G$*['\N16+?)6IZEXXD360LIE](0%$NQRSG@#ZE/3PAU!S]V
M8GG80&?0]Y+*Z<<G9%#E=G&D<TD"5'O+NG\F/0ZQ"9MMH>67R>#(@-T<BC(*
MM+<D'MFE3V^)#UU6.DF<4\CK( ]$5[KQ?ONG%>1O;0OR7[ @_V!;D/^6-Z#Y
M0$+NE"\8"0Z#+X=' $XD?P49["0X()RRKGI*0+[6.6PCOJ!IH$)!6;WC_% 3
M2%&U_MXYP%KQ0-:EL<A,?%21L;9(C;'V/9KB$'>IFA37.6FITW.XCMK1V>S^
M[LVPU^_F)$I$Q1:*D&. <N"T&J.QQ/B9?"$)FD?8,Q\<PR].3;0.B<MOJ$B,
M57K,Z/PY*PU(MG4 />S 2\L&==ZZJ?=LB2 V'\\[)O:="'EH4[2K_@9?I3F?
ME:=EO^[KF29QZ8]%CD1DT[[CQ<<M:IGI9O 07%&DTN2->%GA3\9K&OU[5>G8
MA7,7L<<=$*PYLK)1;*/UXP=R_E02%J! SM!-2^<I!<H_HX?F(9N&W(KG&W3G
M&:;XJJW*%(.K>W7M!DU%,,&-0UM3T3 P0[MO//L;$EWL-6EEQV6A]19MEV!C
M:^K.)M OHT+FKL_Q%77J1H,4 DMR[3HF&4D#%@1=B$CD^3Y.G?W151)1#62P
M?%W(C>S=>U8:UQMH*7=W.7L>IV]L %:7U7-LF3(?OE-&VR[HBUSVR5=*"V@8
M0'JR%VQHT 3B&3:-_5#0$9J6$)!/7W"@@$01JF8TFTMFJ/8]$^/IDWJT?T9#
MNP@8)60N_ARGQ*;3(1DM/JM^AVR](@<5OFFW/< +W\W^W/:A:V&LHS/VT2Q?
MP%S?MURR[=+7><^VZCD<B3OWCN[M'3ZX>R^SA15]#"I/M>C!T3MGCEM?C9$W
MBZ8(?:,!1XSD#[2W#@8)73IT*^4LF'.7$O],$-B7LX)3:?05=EYFA;\S,R?P
M\+ 6,^%/EQOXT:$10_;%X:W;MFFCAT+8GXB005 LE# :J59/WL$[G)8O4_A6
M@<)]Y\89F 2^0.C)K'-BUHPXL4J<)?J%O68NV6SF3 @NI.8D9E#U+4[3PJS/
MH_#NN.:;XI(%TAXI$187[]&FQ1%U8OQ8+O<^7C"O.#<Q M69T*70%Y1G6E>$
M"&S>ZQ-EUI94L*8"+P8Y7T2/)?0&D\"?Y;1</(LKHO3>@6.S-(S'IQ;,Z&&Y
M"*C?% OEW3\P3W66M4TT)RA D0E27V=#]:\ZDS?%+ED8\[_\PKG\:9P\HI;J
MJ%FZN+*:V J61A4Y0T-$E^=Z@#_$;JA$'+H8@OK15?>U^E  Z=#4D35:;3U_
MY_FO)';914N"UR(T[!^8< ]]Z=:30\A/A<2_C9< LPTC<5C)M8ZUDY5CCC@J
M=BUR5XSFLZX=&('E@IN>L(;V3ED&RJ9+F[OJ-"31B]$$<FC&O7Y+KN3ES _%
M58L)HSW.&XI)SG(&.#4PX\[Q97$2JW$ET0#5$E.XW\)YXH?,N0WIG#W&17-9
MM/X@U]J5J]=FRBFC!$,S..8,;+EHV,%3[]M:U4 B(6( \2@8OBI)5W.$<_#G
M2\3$3#]C/S@/WGCNWSB/#?1YA=*IK?QNZ&=-RRXX#R%Q<!RMC0O%6 #44_H\
M\7\1_=&MES'J0"(9!_'1=V=HGE%F(W[!*&R\JYO+SFG>+;CG6!JW"WT!'-:H
M8R%8H*&?:#(EOAZ03%;-6BR:4HJ5YI SMD7^; 7YW)47I)5?-9 2+3.,WGVX
M].C'M-Q:[E==77%!X<%BIPF"=$8;1"K675=*U0.JQC ?#C"%*#FF/#"6KX!C
M@^=-#,):==T1LCSXI88'_&YIAK1SEV[(5!]>QU>)0IPC%I9'M /Q8PR7:V9G
MKU7, @16Y@(Z;^I-YTY@+;X6?_(U8&O^M<C?U;(14"VLF;.F8OK:@4$FR2-!
M4G^-H]B2V&MK(*=NNOYDG^!5S$>(70_RK6J92,J T<5YJ&?(:Q*P60JN8=,+
M/0X,[1A0(%WJ^TA5JJ6T-Z* =A&O#MM7N+.$^\@KI=GA#A=HQ"/U('A6+R^Z
M003QDBF*F*+"='=WL*>$X %$P<@0*?6*;<WEKO@=)T\>\>/6:DXYGE2)%T?7
M8$]F0B]T5?U*.%<"_H=Y.[68BCL\]'-NZF$YZH^<%HW2+$5%1U$I44D.)">,
MHU  :H+#H+/Z-D QY^@SK%Q=U]H$S8.@P,C?-E 783]:ZP)Z,!0L X4C!E"G
M!-$@YS8!!F9-&IV::^!T7H,AL(SAO)B6N<)F5U82!Y4^04IKE,:@[-W5TBT-
MWFH7)7VF^;KUNT)W !?0VT'5L]XB2V(7$H?,7 :/9R,7V';5TU=9J@;39&H,
MI% 5YTI*T0G56%$S;XK+GN;.YL::V<$>EP!7O'-V?!9M*4U:9(^JY1\W3-?P
M5TF)%Y;IUM4B,D?>+J>!75XQM+Y]K^R$T$=3!Z'-V62-NROLCG/?$X'%!H,P
MKMJ^Z!0-:6S;PG>#?-IPJDV+[EL:A6$.%@5/1*@3MQC(?YJ$B^BL;.?"@J/2
MO)'.N(#KA&?=%PFP@QH]/"Z$.8>?T]$DNB((<\:A8&A">.+"EL%E-5:0W(QC
MG$L"GV_E;10K'331:^!V3D832?G%J0,:;Y[?*H$[B4MZPCMG1D+C[M[P.EON
M:$X%.)W[&77\A]P&20X]']T&@&:J#FEFO/*T2ORHUS(=;:"0B;+RN,#H :RS
M%1%:H"K$P:B<.K05*63\5MW=3P+-W-Z"9KX<:.;H8 N:^?K;BO\GIW/GO_^6
M_]^#@[O8$OG?_]VA7#E+[F]5<89C&OQ,\<'M_K(F7WV\GSQ[^^1%>GL_??;R
MZ:LW+X[?/GOU,J7_>_OSD_31JQ>OCU_^[V<._[[@XWR1</6+3G_Z<]DQJ!-G
MQ..@,D1GV#_?/O^*D??U<"\E\YZGIV6S0"4^GQ2#D&M9HJZHSVFG.X1QV%XP
MKJX!NAU=))VVPWGGZI'<\^3RA4/?E//Y4+,,(F=:A8/#0O!GKYE2XHR.D@8A
M+842Y%-*0F_VZ/&;P_77?3XLALXNF>Z</'\B%/HGO_WG?QS=OOOCN5=)Z-*3
M93U%JGKGY.2K]<Y]4?X=+HEIYB-]%JJE0JU%UOZ7*SM=BS6--221J)."$6A+
M36<V%A+M\_3A>+UWPNKR:R':ZDYD"E$WTBD4AE[ M[1M8;GH4Y>?_2A& 'BV
M+U":3AYDZ>&#![>RX'<88/K/HF[.V_R,YJ>8S.JF:LX1%]CHVF(O"(ED:!(7
MV<CH#O^#777/;C#JD1"8O<!>>$K(N[YJ2OAZY$K?XNO=^7+;Y/HE:'[UXB 1
M!7+?)(/V>_GUQ4V6]LJ68=9&DA^_%N4?"$=H6VK_ K^:-\6LN6CZS!'*B-*9
MO#H+_(U($2%:ON#WPPR>8W,;&&,*;VD9S3=97Q94**3Z8C+! AFT%LI9@<Q/
M3QOF81;\XU%&QC4_+3"$NAC:ACZ8E9-D02%WEG:36?D'K2,RLF5.\__\B8H4
M(YZFH#F=+VF$<_K(&F$";)O!3 I9ZM('T[S3 F 05&L_#3,DF'P#W%(4!''D
M1!.QHBO"7_U3>46OS>)VC,H\_P I(BM3T@MNEUGRSYZ";C8"V6>T@/K"04O"
M>,@)2+[<*BW>T_ICGL]!L%[MS\.3UZ^2M:MXO*I,>NEQ,2D87GGKT.C?+Y74
MC'.*[\NYY!0/]P]NCTDGKF1;2%:(P#+.M4MA0DJZ2BHW+]I@-C5ETJ4[P=^,
M:'5>3O>.#@Z/'%'"*9GXNE:]>_KDSK:S'U48A]N 9HZJ6ZG<2:)MXB_S;IK_
MGCY2SI 7(A?B5V:WG)\VE=5EZ-Q[:#4)=CY7BJZM*&U+7147>'M\\N2CKI?0
M!I,SH_C(G>&_94 -QR0C<$)5]_/-@&O:Z6P)63]=0G^\\8L'KY;L5XUJ1J6=
MCZ*1X(06^_3H;OJPJ/=^HMFD=WW2T_R^R<E0I#_E=7KG\/#HX. PBUPIN%!D
M1XK%#*93(=UT1NX\N'>TF][:NWMX>/?NP8'$-73_N:BA(%5:\('6<AVT2RXO
M+_??]Q5%8?MD7O?3EXH7%TQJ@,B6O.AE02:D9TQ$!)HZ!?H0Y"[P(% *+.OK
M\.J_:+SS<#]]:&SGKRZ >"TNOU1T\X4K]*X['2ETE$OHE7_)8$WN9D]T#;"(
M'TY'B,FS%,$$O66.Z]XYDV7WI5(5R?I4!7Z;25(BDP[ID%;&KH1K[QSN:M6$
MW.>*4Q5%NZ0[T@9OND&J4.0U\X!WR(B<_-9$&8M.,A9%ADZ&DY/KL+W_=,O>
M->0"LM\_@<_&I"YD5/5]Y.GK&5)!SY[M00UU*='#^C?-\0I7XA&=D*<(H%S-
M*"NVQ_S& D2:=Z!K@=\QC;!XLW2M?<E&"2!C,FN;&G';2N(K(-QCS5Q9((Y
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M)YG(&"_G"UKS=,S@#ZK"#4[NBCQXY'JF.&"7QM%+_Y@W0S^C^#]@68F"+ :
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M: 9&F):S'Q-28W[KAK1BDLZ=ABPY,Q6TJ3B)D9\6P$5-7)^ MO8;11E7+Y*
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M'YSH%WE9,6"8Z97J@6P_GRGV!J0-.EK/@0J2MD+C(SJUK5*')*L1\.N%1)A
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MC]N<)4I,+#Y7MFQ/<0@$C;2;"? C@+EX=VZ%0&N[J[:[ZBONJEM^5WFDUCI
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MLTQ$RN,-!_EFC1=S "QO'+)BHU-3L?A"^.!22!/^ECGV?9NA/3!KW*Y<C^M
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M;*9%=LJY:?+KF7I^<XC ,W8X@1O5$9@'-M4A5BIS2)!KX8.7W!90(F:F6_1
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M9X0)_?PWR>I_W ?T8FMS:^O&,IXG2IVT^.=JPN#:;PQ-/9@>?\?K>QPG%9:
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MD7A#$MJ@)+NKL1;76M/_@.D\52I^ ST,YBYZB'VM,=L3WH47^YAV0V^3EM,
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M)Y@IX,*3V"0&$6);6 !IQB@P?%0$ZD&$HV!.:U'4X5=MSJ+I)X5K_I9F5VG
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MIN)A><M[#4;?58/%_$WG%0*)33ADB@,C@!9?=*,46QTDL$ZS.:YDYG<;GM1
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M,O0[H-IV+U,*! _(R(Q,HS8Y@BCTCIZZ-L?]BO@I:#\7%7!X;!Q?!,PBV;<
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M2Q1-!)1V;97#!.4R;.UOV"$:Z&E:NL.,0AC6Y*34LIC/!O'?U2!\P>DUR2R
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M!1#UA0D4F6T(IBH>HH!E^#9L=@LT6!#PW#AKB7]1$P<+E^2W3::NR>&+UV:
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MVW;39HO7X-(\Z!1.4TG:OT*XR^_2NQOL"PUVP2SPF1OM;>K3CT^;A83^BK\
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M%-E=ITDACP,M*>>$%)(_?!T)F$8:P8XLA-('=44*UU S<>MZ$H,AYEH 5=*
MW4V%Z8.FM81HZCUL_2/PB]X03UNEL_0__^-@_]7!FP?TF()>7Z#T);GM$9W+
MI,KU9:RO.+$?9, T0XPPUN3=\RMVY&]MOEITD!VY/F5R+3!);\[ERUIE*_6*
ME]XG7X'T, ]'=<KF$A8T"OHTA,TT:ZD&PUO UX,R!?2TY/FHN<15!T,WB#U-
MKG5"X3"#^6)V+GI$X(4I*O,$\3NCJHVJ()AF!#7.2)EJ]NHE@\:LB I,'C99
MH;N33_E.8NID@CT XH78/2VW$&L)XS*<8*\6[\*%L:F FV"6KU% *;W=)<X7
MD3BB8NQ13TX]N#4IW1)@$"D! *12?MEXU>A8%X($+:G JY-@CTO!/;>A3I6P
M?X*@)J1E"%>9NLTU'(F9(/J5R9^ 162UQVQZ=F%49>*S,7I"!.19$"QKG-&0
MSC,R.\AA>+0IM^H+0:R \?WX"[",)Y203\7Y=5S+YCX'$XE<R!PF6+J'=.V;
MMGQNYZZV?#J0- +:-(0Y3(V]OAE^=H4\R!'1VZ,-#K"U/Z-F3CU5(,$_.%J.
M[QK?FBM^,% E4@8B?#4P5UQJG/SKSSXCQ# 3K#AYQGTX+IQN!!]>(%;(^SH4
MS#D]]$=T^$'(0&@<8E>YQ4Z:*Q=S U/E5M&B%-J<#TD=Z#.Z$9X+_37RK'1R
MMDRE-MV,9'AFVTPC*E&FG:S*,;%8"G0-A]87XY^5%-93^8[Z'D^JB8<WW-OV
M3Q&G!).VE6+!(>H["9:&GY'OVQ?4DNSMKU!\X!75S-/T@70:YQUZY]V4"EAN
MSQZ]L9X)2&#( 6W"ZM2I\8?&N?@.<RG,FV12\M_TLN#)F65$5'G9)*+(+UZC
MHK\6>J>\=5I>4"O3Y+7B6S>LM;;.YR.6VJ?P"76PN<OLE;P&5(4/LIV533C@
MA&X!.12ON%?;S'17L9YU^_ZSW^"[I?>\ZM)[EIC>L].E]SR_"_C9$SL8,$&3
ME8K_ XR_E=AX9\Z;3RF:P@#-SY)827,JQ"C)E46M ",(OCA)808M!8XUZ "#
MM@C3(& :K- *^GJLDA$RX8K:?/;_:9Q"4SU@K(LDAEDKP3'\'=4'F;E:]#4W
MQRE<\\%,K&_"#RD$P<BLA]E_L& DU51'3&3DR$(2?E!7SY[/GQ,4#",6V!0L
M"JS#H1<!''X!AXBHCBK/$=F<<^ZM!+6RD_R1XBTEHNF;9'].19 0JTT^L,<&
M OGA>V:NQ/XT6B%#O [U5--$G#G0&9YHKK5>U$"\-X7]M8,6)6*4% PB0TH.
M(/0ERE9QX R2PZ)CTOMB<FUC3CO2K V>DBW$YLD"ZW4S^)1)M3^L=(95*UZC
MG(*30!HOH=.2[PB_9Z\,_=/"#K&>>@DVVM3DN4D:>2Y),*$DP1!7(ZNF,82D
MQ;"5!^^,U9"R7C*&B8M-[H?+P@ #DK)S".T,8P#9J'5RLDCRF]5PC-)@;KT1
MS54!.TZX38Z+61M I?IZ3+X>3"1RR7MLE>?"P]&$)4N6?CLW(B=_D%WG?YC3
MC_0RRH*[*,2SBT(HTSZ8KH%O5[[I8M,=!:Z" EWO6 8B'&D*U*JD[N8PZK;I
M><^XFSEGYJV.6#L*?784*@*ZRPCHZ&S)63I2,T0Z-]O^(?O(:T[YMN=R2:KG
MXD["3\W*<)+EFM^1$(Y4DPXK2GIG=X2OQ%)>F[4SC!7BFQM=P'^1#]^WH:XU
M)AK&DS5(IAFW.T(Y:&4B>JLNI<8 D9K!EB(XW)G])Q58C.!H*&A&33\P@5W,
MB;G/!!;&&!U/,5>9M=IX\AVBO*N8VE;#(T@:H>F)]F?" 1875MV(FA]P,SP=
M11+V#*AB;=X8)><- ]Y9(Y3C5!*N;8(FMJ7-N IN+"O \!-=(8Y%FHH0C+F8
M[UNW&R?6].W[?.MX@,WPL-:0#P>P:+I4\X)7[G;6,V:E\=AFA!B+50+.R\.M
M\4LD_+G8+]H*P45?H.QGNL_&H*R7EJ0+K?[@&JM_K/\L'3A=HQL'#&KF:MP:
M9UPA,PL/36R6:R\(41JW:\&(-$JP(':=UCZG0@;PU*99H6OSL986\@JG<++H
M>@7]>H*"34["1"3-:4AMR5\2P&TFDK('JG-(=$K0'Y\!)V8(-9I$ 4J08VPG
M^KTA0U>*Y[/U#1/*L0D5#K 4@5D]WUP]O0YY+3'9VD\Q%UD*M)A?8F:+D;*Q
MU$%JDX[5/E&Z5EBHI2Z9H6LO?8L<E=;1R,&(?E%*81J^6HAH(:02K"TV,/<Q
M[\P;F/H:X'!T=^WQW35&Q7$I4'>Y+T+KV->3TY$7DK5+SL>$?Y0;C-(SD#+;
MLH85+]FP.68;%$:5&:P:;^9QR?J[I;B\[E)<EICBLMNEN#R_"XC!.I#8)0*T
MF$)NSXAR)B9EQ:(WA@.6W,.(##!\EN"R"4'[*O,36!G!BUI>X.C4HZ!$7<%
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M#<6F*AXV;IO3T-0$8>#1V8,KTH0&6*@$8?L$([=V?SU)ZY!MFSP@G.<!^OM
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M'_]:!VW>*CUW2A%\W:4(+C%%<+=+$7Q.5U!TB-\6:P<(/QY=R\%$]+KD*,/
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M+I-NY)+P=K+?\2__3)32F2AELC)*^=C%ZLHR90FB!O9=WUA5%G)5XHW%PE@
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MJ($)7?7.0PR!?( X?AIOQ;OI):D!H^P37)<+?6>,I.0E(TJ+:DS+UWUC=N_
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M\)X39(W"'<B0DR%V.M 3TRH/KHKTFG*=3K/X1,]EMG8K7GF^DY,:[[MW!&!
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MN<N0#.Q(BU*E9J;6"95D5N 9\]P7K38,T>QVHQ&-%EK(20W7;XA+<ZCF7H%
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MU$*MZ;;R=>?TWH?B =+J]R6E=\M ;F7BZH"37%0SL?JR\V>W,E4<])-R=;'
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M:=OD%(S# C2UCK%.;9SUN_ZN*.BA&\D-T2CBJTH?2,L:8[W13G\LF+$7CK1
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M2X1/ILN]%NH.NGOU&NKT[R+"*->0C;^<LU[149LAJXG@8300NX<Z;YCS3G+
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MTN)^4"5:NV !^$=UVB3[8T8QT:>O_K'/'>KPOY1("9%'Z/3#(87#X5&[1,W
M"G);^J*9=A&>7\'%S"#*>87)[2D>P=VGVV!ICDE77,KY%TZ^0!RB8*[39<SQ
MXM$=$6->BB"Q;6) 4=HFYKW8<6^'NO)9U;B"CYT0S?'[FW$RT7_=[H)<V++D
M$AGMAL--%5W4XW#%>*P\ZW:@<6$Z-#BH13]%W[JQ+=.+-"]\QR[9@?/E:9U/
MG)^7 LAH^_VQ\YL7WCTKTW$,3B)A0?!&Z#2*3?D\PX;01:R^59W<JB,^\N2Y
M(%<+WJZ/R(@;GL(K8;[JJ$)<<!0B$-:S7/<V<)8IJYHB;$(S(?V]OX) W@QI
M8O=H*<N. :=@K?PVWM<*GG+<8H7IF_JD(K$&\#!&+?L://(C%<<!<EO?FG[@
M=X[IGKBO)[$'314M2NQ%WS[E+JN&?6EW;Q?_IMPX='>=9F?X1H(NFFAC27P;
M'8$#(7+;;_OWI>].%?>#,V"-&FLB'&A1%86<?;H5J?EK*:"\[BLCI%3WEI!\
M>4/$2 4:DUWE$![M]J^UVKK8V-0X)^\]KM+0=X^$#9_BFQU3\CV&Q!GF2Z'"
M]8R2I,2K[E,8!T\3'W5H5P-2L:<(R:"0Q2>M>;J4UKA&FE@,TTE>+!TB!$B.
MB2 L=/5%%L5 :2A@%['U8LAMX"4>R4K8OD3[KX\;I64D?.30J&Z8/ZV[BROV
MBHQ17IVMG>07;;6;#GT_-(%> 2?VDN'62<94J#'6Z7'O'3WIZ_$M+S-T,>=6
MT/W^47MDV$,?*/($9MSU.+;ZD0GW,]P,$HZ\#&OD(^S5L ?G9)L%D&?87*MI
MYQ?$^&,B\VKQJA'.S&.$#:;8JW<3Q+IGU>D1XE[O$*&KZSI;ELVLXZJ@H3+2
MV6)S:&H<#Q(YZ@S:\^"Z@TXRZH!<U4MLX,<]CN49I [D^XV5.EW1:&S< \;@
M+)I8J/7K9**:U:,2F(;BU MNR<N<^;0OF"KQDNH7D+PG:I'<!&@WHXSG*$6Y
MA$70BC/_EH6ZP.2#.MF]Z?4:3/,L1TY WSW*8.[:S#9QU[V7.3YZLV:_D<C+
M:>!#%\(M%RVF#:.H53Y$3\[&A;D- LVEA8"G#!\WM/>^F^P.O),O*MGV[)E]
M]@Y2P7L_#+5D]:X*O=*CW^4NM;_2N$:6)I-]_**>7'#&#(([_DK88L&,LQ$K
MIFJ!@*A.Q^F!#M&]ZZ]C87L3U!,*/]G=&D8@$L,D61?)G[8NW!.R7N F?)LV
MD_0_6Z/DR=Z6$C66WCY[_]/A*\P+VCN=?MFU(Y#/+KZ0A4::Z@-R8?;,?(VN
MW,]NS?V<].YG^V.8\+,MO]4=PU>.\\QWG)AE''][\GR+IJH'5&F>707K=R9V
M*,:W/@K+7S912M.^[417EX8&31T7\E+GLQQO:'@%/TQ=P>P62VI4VUDFF8<(
MRWNV?=QJV\=+#07*V&+"2 PQ4".=-1KN$;T@59/0;EZG&'K$83@TX)#8OBV$
M]#+8]\%Y1Z-"#HB- G07*YRF2V*)O9]::QU^X+L-?N &\0//-_B!AXT?.%F;
M47+J.*7!)#9\T)'=K@HM0W6D7H[UB[RES2ZZ'\\$6H2?-_9.@BN&Z9<EWL+*
M$AN7P5^>9_Y&4\9K[D>,W(WJB&A</)I\JHF+''EAKU@41$S(M6%7 URN\Q!:
M0V\BS6N][N.7#S\W+T^A\_"8^ZF*;]--B QZ6EB$L5 !8[B&Q=<R7:G[4?ZD
M@(N?"UA-'G&02ENLR6;H4I5G1 85MQG>&G52LY'IM "[I62ADP(JFJ=EL_(9
M.PE,KG\'6HO<)] P7D&?!L92SC0/SV>4S,!TR#D-*A[_%33EJQ>#Z.QS[5-&
MH:USN'>0?-V/Q3=0L>P,&O(/=.#,^U5E)R42!1]E/?+&AEB:;)[BPPH.-3IC
MXTC":9R,B[1I8@;H?FOQ( Z=7E9MW]2\NHN0"Q*K=J3&T+ IR5GEHP,^S]6B
MIFJ+22^4HU9U[ _U'Z!2T7E H EX1'S"TU59/7"V?+IJ.'* #LDU-CQ*/PZU
M*H$#$D2;OBZ.FFF'DP5O-GAT5Q\!C4[1G;BR(-SSBR>'\&7P54F8BA0FQ=WU
M.!/J\(5Q%E3[20>4$G\\89Y$SOW2N/V9^GUZ&=LTK,D8A7<GE8MYJFE;3FR-
MO(>@Y+ KWE<)648[G- \"?TRK$6W.Q&Q!]@%D S$$_R*'!'N0J)4ECWEG7YR
M?DJ:_^!9BQ,5HNK1MK!A\T?V!BX5Q:%T!G8:.P]IV-5#QUNRQ8J5\4K,CL^U
MXSP<PVZB8O:!:P<O1=SS(OO$]?XH)@+Y0-T#5PE/A+HZ32[RAKQKM,M\<RS>
M4GY1BI\//$=-.U/ROZK\G6X9#I=[K@O>T4=O,QT+<P#M^<B$61FN)CHOGVI,
MZ3HIG1M8U'L D10B.(T6X9_N"!]Y[V7JBX,F/6$_0MU&!NBF /))O#&#UVZ4
MA7,"X1M79T@,&$> -3>44UA6]'SDIFK+N7&F#7;7XP"381R@IH7@"VW3DLE+
M!ES5B!%.26Z=OZ ;9#Z@OPJB-%27,"S!3O+*ODX$%+QB]=Q =R^ZU@(L EFU
M..[;].$=_,24P1S7Q)O0QW&47[(P1+\BYNE(HO/ZVM0MUF8S.7]^30'IO&(?
M62AVE0.[RJ;HC-O(%VG_8@H.XSZ+T=HI_XE]B;J?83_"L?:@Z,_89/X-@Y1&
MV"45TBB36#18[#@[M48B\.JX SQJN+E5-T\,JS1/EY0U]_W?]IY'+9$[C<@X
MT&$! #J&\X=WXJ?/]HL8/M9^B/?A,Y5)?]F#Y>J,N4I2<0IC&,PAG83A5H6/
MWO;8C\X"V<UM0\5"F:/8V"P##4B&?^"1"3Y\LSI@R/FF:IQEDSZDC.'2_7WM
M\*#A?)R'5S?98E&H%NYD\:D@LZQ,[\H^+B"Z5R+Y \G&ZJ;5:\&XSK1P@\N1
M-U'6VZ].'ZO@%T0;5:=,LNM)"M.)O#J^XXRA'XS?UJ.C[^4&W\NW9.WB3!"0
MI@1!,,>VX=GQFM*MSRM>!6P_493:&=-L.U$P%T?!\F;]NG>:D \LN<>I],8A
M"V2-E>$"L/]+ UC\$%<#6-S- 5B2SP&PN*\!P+(N2?C])DEX@TG"%YLDX4,)
MHQI/F8!/LI=-%#(0) 0&S^GV,,T\7[&[MW&=XW!,/_3G N_C4HWOA41D\<Z!
MZP=K+>J0K(BL[X[?,148";6T["!+8.<$Z?/R1=2"%W2\Z_803D,'8:KL:RR<
M6P*1<(?5> "D=B<]\_V+I>?>$Y@@W4K"W@_W/I76H=>H/>BG'D9425B3TJKQ
M WL3\E18+YY^P\[!X=$QV2-HE(N+@X\D>_,T+21TB!R^N!#T:/CV955_9..3
MO-R11#D9Z =>HKA-TD+0OD,\0YJ#UL11&J$;5:4MP#+VMM&.HG-,GX402.A]
M:C/;( 2.$W/2U)06M$G,(J&<H)L=_D#SM2@Z[#:(3]U)?FIKE($9S?0T&Z=J
MM>E76(CF[6F1CXOEMH#8;7D%Q@?@'&"*+="56'.3H%YUSGPZQ$DOH0XU4TSP
M#9;4/SGFO;>(*3&0A$H :TRS='SN&!&^WUGMM&$X]R!@GG> L.^T)3,DZSY%
MC-0$5[*D: T=G].LR$%>4-U)3D9^(G4C>T_W]FA[T@+L=V0X@&^*S["PU:P*
M1^B#O4"N891G(^Y5S8TJ@M'(.#JR1N<$.X6',MRK\14CE&G +S8.)\G;V7I_
M7Y3!OIFA%FE%L\"A-/[#VT2?H.^/UO.,:GOZQ0D8QJ*'>RR_T_[7<L;E$;Z"
M1_2@C!Z:&.1:C83DZSGR;$OVZ%Z$\N_!#7+H[UW*7G,2GA" N);H]>C:4KI=
M5I2R,_YNH1C&DW2+MELR8%*;; $GIM(2).F)]PI&*V.A()R8;F)GJ8M?:53
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M^4&/P^F($U8N@"H!N8,A5C:;H7ENA"7T[$'W-D82H7JEZ\F ,>(;.-ROHD1
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M2]HM+DZ,P=-YO.")9OS2=)^^9=$,TNGF0=(D2'R:$">\P'\M3/27I88K7'O
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M1\<[%088%!AA4( :QV17@C\84/1Z8-DZ*^&/1%_PJHF!?I.J7+%)%\ /6(K
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MI>N5KE^_U-M.ZTOGMM/KM+M:Z^Y::__]1Z?WEZ)@/BBHI/+MT72;0N. =*J
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M)N"!&*5\LBGD;\>?TWD\DR;_Z'OT"H_8R-,<R#CF==ET;G8R5WAH8EFUZ@J
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MU& -Q9K;L&9FL/#-<S570_'F=J5O2<-KQ"A[0RR$1K-8;YZIL1J*13>JS\Q
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M]TWA^Z_8UV-:+E9:VS@W1#/@,)YL?:+-=-M%#>V.&3(599ITEPVUD6'JYL"
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M3-S0G0@<$NS8@0>2VX^^&#U-+KFHQ<<8WF*<<X=HTC*']SY%'F$1'GQ,J1K
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MECX'K #7@/_0_$:3L'<,6_HF K]XQCA"#0X^X+,B^1P:[-EZ)7Y8:)0>&L[
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M:X( 1]:08<Q)OD6F5>A1?'97,-,B%O%_'>V+I=N$3'DM3^7_>M _HLVJ0!N
M]^!I"%)@EQ8<$ *Q8)H$R *+_$C'&"YZ HX1=4];PR#BPV#3F(2Q3-SZY+6
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M% *N&MX><:R!O([.70+6)/]O;LOW\XD$!W=T%L2Y)-!6\N#_Q./V7',H[*)
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M%Y[-BN&_YAE@)D]WM\N]S&:QX(,J/L "%PW+$:SE#URV.D#DVA%$9I+]F2\
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MZAED#?3QRJD49]0(.@LZ9U&F;8^-Q"[13C)\B?U;*LN[IH'$MZ6M@QN2&:N
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MHYO[(]V?.<D'9I\3_,FC=Z#^E+)\<5T]ND'E63=@$$#= &HM1:!6 :BB Y0
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M2$BZG0^K'(^1T!8VD'GN2*P*)(9!(K_[TF! ; L@Q@C$F@!B.)$X=R_,2Y+
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MG.JRO!7@NYN_*(QR#*A*HBAG,)2S>?J18:T*+',56%H56.$JD&%273L>X'L
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MY#TD!5FML)3>%)/OD.1PDX/2'%3>0U*0PM52FG[*=TAFO_/:DI@X>B SR66
M/@=1% Q:7?KB46>1?'&2F/5AXO08#+<$21:$)&9KZIY#KB1K=>>]69O8(&&\
M3--<!R& /;\>A^1V1ZC. 11+9K9%+O XE)4RDR];@M=$H0,\6!]"#..K$[JS
M;A<;491E!,I,KL@)8O8CL2@QYR)8-2GBU*XH,=LB3!$J)+#2$3,TGM9Z(:#+
MA:D8>PL[I!O1_*5\@-5+YUIY5V"7/Y0%L,<G8P[(2'KQ7+/.32W+C'1\?N,P
MQ['/M>+.CK/TH2P<1V*^H8Z_>R\((:G('LA%[V3W04A:4*7BQ _@.G_RH"\=
M84&!(SM+6MWI+':20O3))WT=VQ$V"VH$GN>$FPLV229'1>GH"4F@XC %DHZ,
M6 _5=,YZ!U[;?? "-FZTE65$24<W2 !3]J.I='Q"X>#R;>?<CC^4^>WUTLW4
MJ1<WP#! $-ML0C>.IOR[1EM8.?[T'<'T'7D<*%N&*PLWEV[^O;+3MX:?[T(O
MCN (K+"?>ZR?<YN9BS)")=XF(3)5*LA>T9)J^RIRITI% 59F8F2V3D5SY_3D
MW,H)G-"%OK-E?I6EW"_)R77<.0-R)L9/%4*/K\%C/XB1X[M7'A@!G[R>RX$X
M7=^'XZ8?,BI9CD@YR1'AL$U5N$L@93$ CT^+'!*!Z FA; UP?,+A, -HQ7,]
M2P/8LDWEEP9!7N'-%N+FBD]_.3\O_/O[M]^+__GW/SO#>/S#+U;<G_:H]V/B
M/S7BUR]V6+%OC#^>'B?(LT>=GYKW-;J(VN#K3]M\&>N=VTC[U_6UT;ZY&(T_
MUW]H([<=.J476],>-=2]>7H=M)'=KMR>G34;-]I0[]W?_#IL%=VOI6*__V52
MZ;[^\8=UX=LW=WH[]IJ6T^G;]O?*]]>?YMF5_K5R%A;O&J.SQN!N@&I//U^*
MWZ)X\O.I[@5/YM<Q:.@7M=_&I=N',]V]U;Z\M/_ULWMSYWW_32_UZF#X= ._
MC.JEP3^O)O6GN[K>?.C??'U^_CTHW^O%B[.!^WCF_-H>N]:K5@2-1O%VT*@_
M_G"1?_UD1NALU'PPG.CWU_L?)>LI@-'9\+L]O'EY_<=_"O7VP_EY=8>A9YYK
M^)^1Y="3X![2Y14R7 -:NZZ0+7PHBZ$G\1R=;"V#?@S]7M,?!=Z(;H9H^@T0
M@D[0\R$"[GRW6@W/"B+T>9*PRV_L3:HT:4=!YZ4UI#VS%>&6;8FGZ*JAF_WQ
M3UOF>;IBZ&9_WMZ6;CZO&+HB;FBQI2,"5'8*04Z(V]+MQU#9*00A\6WI=G\H
MYA1<R?ZR[*=0R.GS,0@[&,O[$'8 N@["5AP1P[@8=[HR,X4LA23]Z/(G6_X6
M:[&RX"K=IA8>2^8G?\K,GR3>=9/%&OW)DS+S)(F)0LEQ%7$B6I:8693<';@R
MQF6).<53 2*@/TG,8IX*$*$\26+J4W)<120]RQ*3GEF[P^-KH,X\0V+>4G)<
M19QG5$Y$IP##//ML7I&=Z)075Q&S>45VGC)+=^B'8%-Y)TDRKYQ(PYQ@%3*7
MGSC#_ <YAU0N.V4H+:Q"9G+9"3]Y:1JNFXTKLM-OIX4!L?Q)=O[NM# @BB>=
M&$,A%@8$V?BJ:X0R/#E$WIQA]@-=U_03LD*PAL(,=4-BA]CJ#M_K( X;, 2=
M* BWN@EN1QU"X!!O(TBDI'X)L3\B\L<F0C%PMYG6<@LDV=.2NF:>_$9-OQ&1
M]]0UZ^1NPKE;7A2"#.&Q>/)7%?U5N8:$NE92W5/QC'[FJ%N6^]FYZING7L/1
M9D>5QFGLD],HZ#1BEGYEU7VMWG=@.'#\5O=SX(3N=H#S<+<KV.M'RNR#U;7*
MR7-4]1PA0Y4N,V^^R>%0&&%_@X"0J!UZ@W^KVX4=L#D_\BO_DPMPU=CII^LR
M<_,G[Y$T9*G,_Q.GV[Z*YTI3P# "&WU-GM)*5YG^_S.[C9A!2F;V?]KZB"Y,
M/SN(^-J$7J]%>ASUZ,5<Z9+^L^=T7MJ=?N"1OAIA%/C3U6RR9@W]WK? W=RX
MC:M+I.^=WN'2Y;</9>(2.1#L!UE.+^_34JK,83 I3_@V\=<-ZW$(;J/-4V*)
M<J[RI*L(P&5_ND/7U6<P'=]W@\XVL''*2X*<W=!U^3C'I*GF8B6:U)_?G+#3
MM\G&LT8,'H-I6\;9)KKCK8 *690:\I%]DB$MRI@VY"/F)$-:E-VPAGQLV#JD
M)]:^./-+U,*$;_D8+-F@%B9^RT<?R0:U, %<OGV7[T/]-?8FI3VQ5CUZRT=B
M286S,*%;/LY+*IR%B=OR463OXUR+>S&*3&W_-*UZ]%:))!,6;5%BN*D2428L
MVJ)$<E,ELJP-AA%]NRY6VA8ED)LJ\66B@BU,'%>),1,5;&'"N$J<6:L3!03J
M?;'FF+:%B>0J$6<"XRU,,%>)0!,8;V'BN7Q$6FH/DN<@--]$6W>&,'*\E!?<
MQ>2STY?_Y/W-=5,^*DTRI(6)X?+1:)(A+4KTMN2CT-Z0O@M\Q_TC1A'T>U<C
M0(X[=",0/H!A$)*_W5-CI*$/_-KB!_+:56J1@PNZO1O^2Q_*!'_Y2#59\4]M
M!5\",HNMX)9\A)FL0#(&<F6?@5S)="#+QZ')BO_R0#:R'<CR\6.R KDZD(U]
M,K)Q8$:.?9B CVA%NG!C^@ X* Y!=:H4?</L,;/7WAY,GK3RU!BY'^=?8NFQ
M$ 66H=N73^W&RE,+:9693X8>PH#.M5Z0X,(1]K,E@Y-/XO(;A$X4+-W>MZI3
M\[;-TFD!_J4'K@AK #\80'_ZZCL"U]J6*7+IL6FXY]][,RH<;?<.GHK8;HB?
MOF:4D)>9WWZ3,V\<)N^XY/*3+^#X$MLCB,,.0,FO?>"X='$'OQ5_S>KLO\^!
M.ZGBO_6C@5?]/U!+ P04    " #4=)Y8EW)VE]T&   I+   '    &5A,#(P
M-#4V,3 Q97@Q,BTQ7WAT;&)I;RYH=&WM6M%.XS@4?5]I_\&JM BD0EL&]@$Z
ME0J4G4HL(*8/.X]NXC1>G#AC.RW=K]]SG:04VAE@82C#=AZFQ+ZV[TW.\;G7
M2?O3X,^SSJ^_M#_UNB?X9?2O/>@/SGJ==J/X16^C[&X?79Q\89\'7\YZ'VN1
M3MT!:S4SQP8R$9:=BPF[T@E/ZT5#G7T61D8U#,30RZ>..V0)-R.9'C R;1XR
M)V[<-E=RA"8C1[&K==I'G=Y-+(?2L=;N3JO=.(+;E\]<<-OIS"\Z:QAJYW12
MMLV[$8C4"5/K;*1#FQT^?^FEL5:+(-CCWM6@?]H_[@[Z%^<KBQ:.5 &_A =+
M@_X[MTY&TUJG#^M8Z43CARLQKL,-0UW,Q=P=_-CERT:9AH(F;>[LRW3A:0^Z
M1V<]=MP[._M\V3WNG__QL=:L^>O+[LE)=?UD[R8R=#&9-G^K>6JV!U?5+&.Z
M!0%7E;MXAK62ONW!2655SK"[E]W@H9U>G _FO=B.>"+5]. A/[RME?^(PNU:
MI[73;M!DM$.<+*ZZ]"F^W.I]%O.Q8$:,I9B($"B0EO$TS;E"8Z:-8SIEI]HD
M;+>Y?<ITQ/X:G+$CJ;.8FX0'(O>WSK(S%^ZP31<+MJ'"K[D^/-9)QM/IAO%7
M6X?S8>*_J^(I-/SS[KP2Y+:;.ZV?%'/?(/3+06%WI4 \XA;P ]:2*;M.]42)
M<"3J!1Y+((8:,Z;:L0"#N4R!TRG+4V=RP:SC3B1XQH10#F!@:Y7 <,0#-!FF
M$XB:TX7=@D$J F$M-U,R2?BU8(3CV9P6;2&<P9**E)+6((- FB!/8)9B.#P)
MA6&36 8QLSG]=SM^(HPH)Z$ $FF5X*%,1\"(BQ&@S43@':1Y,[BF0X0)D."F
M#*?SMV'-HS?.HP]ODT>"13(%4@GTM\BL@T0P1[>9ZY=IA!V?.XEY9!JH/,2<
M0/\<#.M@CC1JRC* EWA'?%3JEE@EINV]I<'=4-+$=;+(%0S )@W(^^6L]R?@
M-F:1TA-;4:T4$\:II7 :+M;GZ&(K3Q9<73/FC3-F;Z6,&=S":\-8RE5L28@R
M-:9M6D>1Q.6FW?+8ZS-NA(<X("N'2A :F0"OADK:F$:060*5(J6BZU#:0&F;
M8QSIE]&JP'IF="!"-%NV"72' EPI(-R["6*>C@3K0AJN<@6+U@>^W=K?%(47
MK?VPN"HN)=43:<$QFI^1?LQ1KV #^?+HA:(["T58B.*\0TAT4PIYL";9,TN*
MRNEE%'A--F[RK572\4183 U@^ASJ8=;4*;T+>&X?/X3RK*$  \J5BLQ-YP83
M0$S&TGI]@I5(_3Q4&]\JV[PZ&J&XIU29NI6TJ)>R23T2$@='K%8RY,Y[.;0R
ME$@W85;DEEZJ4YHDMY3O^?W'^N30:YFV KXX""<%G'$"5ZXXZ2\B\NO?YHT8
M462A\\DS_AH*,H1*8KP(UZKX;@@[?$.$?;0(+?#V\?+U:/J"\F,9DE!SJU-.
M.LTM&$T%&QI'W(05=T!DR8=223>EG'/9LK2)>)IY!A7\OV,Z5_#Y=."F#"C+
M308&6Y\C!X$VH7? EWXCD2+U52 R>D1&^P.9H*PMR(I]1&90Y#5=WPU=@Y72
MM3?F*O<Z1%@6480B38Z!0GN_V)IEPX]0U.)R>?WEJ8F!$$1;E'A#G;MO+_\8
MS><S:T'U:_3PN0D;5I6QWVU$<1O@SR%-OF;7>V%7N%HQ++"[R &JE<HJR_<L
MLNP)^D?IJ Z"W!#,%Q/ .P00]X[S_>"8VUD^2]+C:2A"K\G>YU(OITS):Z'*
M<]%[]O7GA;'FW4]P-+/_$Q[-^#=:847$^NW&3SJ4:.N 07KY.J<!I"!/R%SO
M%GLSUS@*/J>-G66*O@'S)8ET3HAOZ>M0(Q&ESE#",S_#)H@(-EN22_Q2P5F1
M7'S-)1RG *(\#?RIZ=;Z^.7="-AJCU^Z"G4,)I<@%0?$Z)@PD (4*+.\V3'(
M1/!K2MN*NL8G;KXB\Z_;JO/\)Q&K/+8HCE:7*! /,="*F0 M)V%9Q,$>9$*M
M52\21XN@;9X U(C61U(*XM+7'FMQ>E><6NT)21>Y7V0@!G4@7'C] D?\B^"2
M3/4B+9/I6*NQH-PLY:/R?;8I)>]:3/TY8JX<]^^48UU(';]#6!#L^2GFSBM!
MOT)YJT7WZ=4Q?@CI-:$PVX%6BF<63ZSZZS_"/^,A'2F5GWN52_U.*]W]](G"
M?<&J S Z8-W,2,4^-.MLM[F[]UW EV%7WZ8=*1Y<L];./NZ>/Z<^9$L#V?O1
M@31LX^[W:<MQ^+RGLAC ]_:IA\:^7/#_V\#;_<YQ+$7$>C<BR.DXB%T427V[
MT>_\Z*WHQ;\WO3\A??)+G_H6W_[2)\+_ E!+ P04    " #4=)Y82-7>MN(&
M  !B*P  '    &5A,#(P-#4V,3 Q97@Q,BTR7WAT;&)I;RYH=&WM6EU/XS@4
M?5]I_X-5:1%(@;8,[ -T*A4H.Y6Z@)A*N_/H)D[KQ8FSMM/2_?5[KI.40CL#
M+-_:\@#$L:_O=<[QN==)Z\O@]W[[YY]:7[J=$_QE]-,:] ;];KM5+_[B;KV\
MW3HZ/_G&O@Z^];N?:[%.W0%K-C+'!C(1EIV)*;O4"4^#HB%@7X61<0T#,?3B
ML>,.6<+-2*8'C+HV#ID3UVZ;*SE"DY&CL:NU6T?M[O58#J5CS=V=W5;]"&Y?
M/''";:<S/^F\8:B=TTG9MNA&*%(G3*V]D0YM=OCTJ5?&6DV"8(^[EX/>:>^X
M,^B=G[U4M'YM#\B+^\)7(BX>0A7_<SBT<@W^RJV3\:S6[@6LY_B,_2%D:AU^
M!5@?0_>8&W-W\++SEXTRC009;>SLRW3IZ0\Z1_TN.^[V^U\O.L>]L]\^UQHU
M?WW1.3FIKA_MW51&;DQ=&[_4/%5;@\O*RH26(.2J<A?/M%;2N34XJ7J5%G;W
MLFL\M=/SL\&B%]LQ3Z2:'=SGA^]KY3^B<+O6;NZTZF2,=HR3Y5E7/L;GF[W'
MQGPBF!$3*:8B @JDQ56FC6,Z9:?:)&RWL7W*=,S^'/39D=39F)N$AR+W:V99
MWT4[;-.-!=M0T=^Y/CS62<;3V8;Q5UN'B_'AUV6Q_'7_H-NOA+7MQDYS#;;V
M[IN"[8A;0 RP2F;L*M53):*1"&YA+M*PF&K'0@SF,F4 $LM39W+!K.-.)'B<
M!$8.#&!?EURQF(=H,DPG$#*GBWY+'5(1"FNYF5&7A%\)1I"=V[1HB^ ,IE2T
M@],<U"&4)LP3=$LQ')Y$PK#I6(9C9G/Z=3-^*HPHC5  B;1*\$BF(\#!C1&@
MS43H'22[&5S3$<($'K HP]GB,JPI\WXH\^E]4D:P6*8 )>'[!H0!^(+NN&T6
M[LLTQC[.G80=F88JCV 30%] 7 "22*-F+ -.B6)$/:5N.%3"U]Z9&C2-)!D.
MJ$>NT '$T4"WG\YZ?T)NQRQ6>FHK5I42P3BU%$[#Q6"!&;;R9,G5-3G>#SGV
MWI0<@QLD;1A+R88ML5\FM;3YZCB6N-RT6QYF/<:-\&@&.N50"0(>$Z#04$D[
MIA'4+8'VD/[0=21MJ+3-,8Y4R6A5P#HS.A01FBW;!) C 5H4:.U>AV.>C@3K
M8,._S!5Z-#_Q[>;^IBB\:.Y'Q55Q*:E$20LZD7U&JK# L@+XY,N#)XIO311C
M(HKS%O=PFY*_@S6?GLBGRNE5%'@AXFWRK;=DWHFP, T,^B3H?H($E)^%/+</
M'T*)TE  [.5,1>JE<P,#D(B)M%YUT$NDW@X5L#=ZM:AY1BCNV5/F7B4#@E(,
MZ8Z$<,$1JY6,N/->#JV,)/)%="N20R_ *1G)+25L?JNQ/KOS"J6M@"\.<D@!
M9YQPE"M.JHJ(_/PWB1]&%&GD8O:+_X:".D+[,%Y$:ZW[B-P<OB-N/EA:EBCZ
M<%%Z,%/![HF,2'ZYU2DG]>46Y*7B"HTC;J**)N"LY$.II)M1TKAJ6MHO/*,\
M60JJW^JZ4)QYD;\N \IRDX&LUB>Y8:A-Y!WP9=I(I,A=%3B+.R*CK8"ZH 0M
M>(DM0V;0V34S/R(SPS=E9G?"5>[5A6 KXA@%E9P </9N831/9Q^@D\7EZEK)
MLQ #(7.V*,>&.G??G_XA2L[GO075FO']QQEL6%6Q?F,1Q3+ GT,ROB;2!R12
M]+825\!T&>Y4UY05D;^S3*A'J!KEDSH,<T.(7L[@[F*=IVD^-U",'G,[STA)
M43SE1.2EUCM=RN",*7DE5'DT>:=_\+0XUAQ[7T<F^Q_PR,2_(XHJT@4W^SG)
M2Z*M ]SH/>O"UD["\(C<\W9E-G>-HSISVMAYKN<;8"])I'-"?$\VAQJI)-V,
M)#SS%C;!.3#7D@KB+U6'%:'%W[F$XQ1 G*>A/[C<6A^+?$1=>MMCD8Y"T0'C
M$OSA0!.=U(52 .UEGC8_GI@*?D6)5U&$^-3+ET_^/59U>OXH#I7'"<7IY@I=
MX1$&6C&7E=5\*RLN] =O4!@%1>IG$;3-$^ 7T?I(2IE;^9+A%23G.]\WK'GR
M(8XH.DC38H.]/ !JA9<?X-Z_-2T)$A0)E$PG6DT$95$I'Y4O?TVI6%=BYL_L
M<N6X?P$[UH52\5LD!&F>G@WNO*X:%!\MW1&#9I/6[M4A?@@U-9$PVZ%6BF<6
M3['Z[S^B/^,1G?.41"ZG^I5FNOU]$(7[C$4#H'7 .IF1BGUJ!&RWL;OW0Q*4
M85??;QTI'EZQYLX^5L^?$Q^RE8'LO70@=5N_\Q77:G ^[;$L1_"C?>J^L<_X
MQ=+_-O)6KWT\EB)FI_/]Z;S(U%OU7ONE-ZAG_TSSKD%OM$[?R!8?S=*WM?\"
M4$L#!!0    ( -1TGEB<2>]U  0  "X5   <    96$P,C T-38Q,#%E>#$S
M+3%?>'1L8FEO+FAT;>U86V_B.!1^1^(_'"%MU4I< K35#F20 H0I$@N(I-KI
MHTD<\&YB9QRGA?WU>QP"I=/+J)JF,]K9/B2-?6[?\7=\C,TK]X])KUPRKVQK
MB&_0?Z8[=B=VSVSLWCC;R*?-_FQX XY[,[$_5@+!50>:1JS 91%-8$KO8"$B
MPJN[@2HX5+*@@HJH.G^M7A<B(E>,=T"+&EU0=*-J)&0K'))LM5:5GMGOV9LU
M6S(%S7:]:3;Z&/:\0(<G?)G$W8)\>)0K*C-4 WOACD?C@>6.9U.87R^<:VOJ
M@CLK$.*1^^;O<.T,ZN#8@RR 9OO"J+Z/:\L!:SB;N_;P_6'OX7XP+F$V O?*
M!L=:]*VI[=1FGR?V#5@#5\^T#*/U#B$5RK:_TD2Q8%OIC3EX@G/J*28XW#&U
M!K6F8'&>DA 6-!92@0C@LSN!/A/QFLB(>#15S"-A4BY-E%^'4ZUR$OI?4M$=
MB"@F?'LBLZ\S0*LC(2/,6FT$@9"9^2TE$BCW&5_!D'HT6E()[685I5IM( D$
M+*3^?3@.]5+)%$.TA/M@;[PUX2L*Z"QB28*AETOH2(OZ1%%84TDQZ..X=E#V
M854SV93[5":8$.ICTM:AB 2^2$AOJS!8,QJ@)_2LV"V%61 P#Z-$LUHUAUG-
MXADKLH4_*>.)PD>U7-HICQ@GW&.8Q^>4<4PO0Q7B5"8IX0J4@$/]Y8N2U9].
M"O%%K# MQ\)[(<W:W+I#Y))PFM1FFY!NRR7+RU90TU;#)JI3+*GR08;)U4:-
M^@7CC^CL6OV)#0-[,G'FUF \_?2Q8E2R[[DU'.Z_7QW='?/56HL:OW5A*22N
M;\T384CBA&)IY?]5LFYGNHN]@UN]#DCH/1(EXDK>$4UWN)?*C;?.X\TSU;0'
MZ0Y?U,;]9C3#K>T(7BT@$0NWG6\!S&03]@_=Y:/2.VV>F0UMK?>TVR?C?#OW
M+A(NWR6"- RWF.,H#G6A'HI7TB\IDS1"-B2:B/>\/B6X/TAH7ISZ9P?VWI?Z
MH<QS!C<_M,^[NN". >-CL5O.1L:IWCO1NF;46_\3NTABMWXXL1G'AA61C*W8
M)15AV"EP-"/JGO6$2:1]+&FB"5[5TR0,D5#8Q?7>CQ,Q,C[9M9S@T!/0H,\R
MT[J%H%0:[NI#Q%1F/I.O^D6]:-[_)\@<$U^?*S)(!U>7VM/#MJ07^>WH,L3E
M[H 52Q9"V\@.,N<OTC>'O11*B:@#_9!X?T.S?H'92T3(_"X\">2\:""-I/'P
M*/0TZ;YO51X#>&F#^9;NVX'_98&;X]XS!UZS,>[]_)DXTOTQ ;ZVG(LNX8<_
M27[^!7P[]+\N\D,1/_KA^7P1%WAX^%Z#V?/RD+1"[^*^-JCO/?5]Y^X"5-^3
M_@M02P,$%     @ U'2>6$;Y+*ZB(@  AQ<! !P   !E83 R,#0U-C$P,65X
M.3DM-U]X=&QB:6\N:'1M[5U9<^.VEGYWE?\#IJ<F95?)[C6=VTNZRELGKNNT
M7;:S/4(D)"'-1>%BM_+KYRP "$J4+'J7PSMS;UL2B?7L^,[!QY_/?SGZM+[V
M\>>#G7WX5^!_/IX?GA\=?/KXG/^%7Y^;GS_N'N__*<[._SPZ^/'9($V*]^+E
MBW$ASG6L<O%%78K3-)9)C[_HB3.5Z<$S>!%>/:F_UT^C<(F7/XA89D.=;!7I
M^+V Q]T7_;0HTMA\5ZAOQ9:,]#!Y+S(]'-FO=!(J[.U%$#_[]/'S\9=S?Q1;
M QGK:/+^JO%_W/UT\&VD^[I87WOW;ON'C\]W876P-?CGY)ZG%\"$5':K\_LN
MZ>?C#T]I1G^<'ZVO[>IT/))9+ -5%CJ042Z.BG#[BGG>X11O2H(J@'E<J/6U
MX\% !RH3>Y&\[,O@JSA)(QU,EJ#+6YK=S69BZ>V^1GO;>W'X:6<\SM(+%:ZO
M]2>B&"FQE\9CE>2RT&F"'V)=%$J)=$"_[J8R"_'#OLY44*19+N"Q+]!"W(=M
M?/6Z)UZ]>/5:;.##WT7AWV7Z82=,Q]3:OBS4=QE]M_GQ^>$*[/"AV^$K1WN[
M4L5\%ZD!2A"=3,L4]XTAA;_*O-"#R0WF>K@-<_KUTTF9C=-<?7S^ZPILST,S
MX,U7_7RD\_4U)Q#%''DH0I4'F>Y#4\A8@<Z",LX+F03P30E$D8G+D0Y&P+ 7
M*E.A.%%9GB8Y<BIH$#%'@0B9A/#?"3ZF"QA(2%PMTDP I?'?>=G/=:AEIJ$K
MGZU14,"[EJ'%I8XBT5<B4W^7&L=0I/#W6$ZPN4P599:(@RQ+$Y66>339VKD$
M40*/U00.O -=K*^9QN])Q=VUQ?&HB<]0F"4%T"@QT%0..Z-A/^ 12X/Y2/(.
M!T!915;R$S((TBQ$2@0**$;4QMG!'NSXL(QH4W,!*B8NHR&(?Z** #8WFO#C
M9T!C\ R8H]^_L4IF/PW#K<^93+Z*W['+LR)3JA"G:I!F,0UT#UHM8Z#ZDRPM
MN 6Q@X0[ /7S\D4/!A9$9:B3(?62EH6(-&@R)K+3,E*P)_M;+VLC(SY:7\,1
MP*C*3!=(\@??@I%,ALJV__+=ZS<](7,A8P4OA#T:$+Z40;/P-6H[: W4Z1>9
MA_)O>OA2P3PD<R\J7)UKPY[XS6&>215IP50/O:ZO'<E+[NW=NP:NPX'!$Y;W
M.C:Y2S8YD,$()9(O6>W.&3EE>".''H$<@%2^)NEEI,*A B(IB$)VAD#$](EE
MW(R()VY3@FF\**!3Z&T$?<+S0#F@FYWKMH/JF6@0>3'45G0BLX*PA9?$6&8@
MZ/68*1[YE,6\-^COLARI)T=F@7&!^MGJ2^3[P)?(0*W#3,;Y!Z9;E-C%2!8D
M&9SPX.G+,;(UC$/)&54D=):I?(R\>D'6Y.5(%3C0O)Q]EIL;27AR('6$3 ;+
M0E/(E(0G>C1;_%V1ZD3[E1I:N/)/A$U6WM(TIN:^&NB$:#?OS,U;'^WG%'39
MF*UYHVB<*N\921-%Z27JR$".03=&^A]D;M+_'@>2:JM8-U:@?I(A/ (J&;@2
M='A?03OO'_V*-#/7^<[NT8'8.S@Z.MG9WS_\\M./SUX\H\]G)SM[]O/=Z*E+
M'18C;._%_\&\SD]M-R ,R4JW/ >MS&%"G,"^?<TT!RS[#&.>^Y\:?MM^]?TT
M1R/KWV!9-^2F6]-ZG[<K-HP!!%P(LF,'K,X2=%8R-*'>)?]SJL!K*D@;L,P!
MGF8CRI \DC>J<.DZ0.*W[X@-O2G"4ED='L/WF9:12-*$K%J-AG"[(4U9$LZ(
M!N$(C6'CX$4!G_%0R+>BH;#;AZ_FE;4*-D7N6;_M1L+ZU7AO<Q: S/>,/$-8
M)07^'/J*8!NH"TU^G=!YCJZ!/WSW>MYN0&1H@-1RRVR6?5%O55]B0UJK>5</
MQ:G=:&\\F[V6>Y4!!0 )T,#,.N350MCQ)FE1&_-RXVTYECXX-9=I";8 3*B,
M"C+RJFYCZ,GMFF8:XU%>@JEE!V^]//BBA"_@T3&\GH:MEP6%")#D%<UZ6Q+I
MH@ W+&O:E6WQ)2V0$3#$T9Z.C1FMABF\VD/>=/%+3^>15Y<[:WS*)F[:H':C
M *Z%.>'<>=G-TI#?AV8IRQLD%7"I0[100_8='-]YPNH]K-PF1E&RU&KBEKP-
MMCFH%#+I82VDF;_UX$V/XPQ$AQY'ZH/8Z$_U)Y"(<^-IL$B2_:CE,'(U9(),
MT,_AX1AYZ@^)I%J1E4%19FJ^VP*DGL .I=D0;))_J+4/[<:S$<S.,HADGNN!
M72TWO%#GX&W!.B$#IT#0W*'8"*?;\!:[M2[PEZ$2_.B?%6"WD9,#CM\@2\%+
MA ?\N>/K]*!V44%02C'\@./.TJCEXB"5;JBY9( N&1 Q;% .TP7YA3^! Z>F
MON5/H4;G,0G10VVY*.0G6GZ%93'F:D4AV[X!@J>\YZ?X-UIVJQ1HZ S4NS%0
M^P]@H-)!V92)V5)45O;HO).WFEQ\(";HZ/W1T7OP /1NHYE;!]"\;FT7'-H0
M9.TX:+Z+UB,]D":)"?X;KVF.]=32LD8_R UH:Y=BHK53JE,5*/B)@OQR.GBY
M 88GL&JD\GPZSMEN&%/M7DJ,N607.#>*OX)9 OO!3L>5!VO@E5C7KJ4QG?*A
MWEAJL'/0_T5#(Q-R4!CWDX\YQ,%@8"P$/.?OL:/$3_45<!I&C7@" 5A(+8WI
MZ56FYJ']RY&.5,U_'G%8'&TX7'[?-]8Y.B8INDD)K8J,VEJOKC%ECX5@*6QC
M_N_0?0KN ZT]V5'Z B,'&2Y"/?I/CM%5PIO_;U5$^)T-TW;P/UM;XK-64?A>
MG,@A>"MG0-L*6!8Z^R"."6Z2O\?>S/GB!_&;C$K\66QM&7C@Q_W#W^Q _>Y?
MOFKH_RU^UT^!L3+WW6Z$&_AR^WN87IY&.H013DT]02\G6FH%FH!DRZV*MQIV
M'3Z(\\D8IKN3R;X./@"/QHK7ZDN**_#2?^FY?0M_P37^^!R6IF&5^IF27[?Z
M> X+K8UIY?TAOFT8(JZFOR[\LQFZ)9^I+OVQX9AYSU:'_CL3YJ8F3/B )DP[
MG<#R>Y&E0K:).4&A2 )HJ3EV"FOU4:84@R14T59=#W0.FRPF2H*#H.-8A:"$
M5#3!&&2@0JM^O$Y)75?PCTPF.1\HVY =&1@<8VRIM4V4HA[7F8VTN1%OHL8F
MPPGZ3 18#$K$L)VCG!91D^'A3:KE:%SLKQBE^<PZUY:N<Z8Z2<222#V$)+*P
MV]L,("P![.VHOJ-ZIOK!@U ]>7BMU6^^*%! 2FUL/.A1"GYP#Y4(.M.R8(T'
M(^HUN6;7L0,0#2AFX;Q3D3KQ.67765ZDFK&3\$28EGTP :;<_EBV5'-\^ MM
M$Y0,.I\=#FET.K'S1H7A^X*.?G%PS@Q@R"8><8*>3">J96 G29.MV0%D*7CM
M&Q5(D\,$+KJ1-Z\BH=CXV$?'[881R+$,=#%9Y(-;)&>%>*5S'(61DZ:(#J_=
MM6G6TN! XN$MX]O\LS@^-<3_I]XD![H\8XP.68F:Z7A']\O6UF*1LLG9;(YV
MZJ!3!ZP.A@^@#AI"FFWCI\M$DED.QTC^R-PS<>PYH>EK %G4MT"I,)_J<&&@
MF=XC_K_4X+$PW(-0>7VEJCATN\&,) B.@EL(%>+]-$IYQOZFB07\%02*YX'F
MVP*3!>RP8]AI3@2(QRAT+,B^+4 "I:KUB OY#4@#H\R=V.G$#HN=T4.(G2HY
MM0TQ&QME@9S9(-S8;/P#44*(C #3S\!O9%3!C]KB1V@4?DN>16%^%1L812&+
M-%,,5S.XDIE'V3HPZ)%(96WQ<LC8>-ZSY29)YW8CH%C%8)=JH/TR!SF4(W)%
MPUH@7@1A)F3@#,J$S9\- X!IZ0G+"+=;AB#I=%XP<(<;IG56FSW.CR!+RRX3
MN@O@.: 5C4=*8[()MV+Y%1?(CJCE@O"AF.O*.":^)9RX_N? GL82 74;^2:.
MW\_.VVPWE-KT<@V<(K,YD\S)/*WY"HR$I,E81)]A@6O%*DQXCS"U###W\.6U
MP*%)?=JNG*A<?B5B"F "!))"QT[@5L=EW)9@@5O')G<2%X@U;M_FF7#N"DT3
M-J+,\E(R)I92RMZ\>(FH.49>G;K\-W&V]=_K1&XJ6*!9X!F/*#=KW6G,3F.R
MQM0/H#$_7T]7G3IPXR]*YB4HB 7*,S:/L$5,>,+*<D6WW6!MR2=NR?)3":QD
MGC= 8JNDV#&B(:HHPCSD<$N>KW#@?!@#4V<ET33WC. G(*&B:"(,!%]F!9^X
MD(ZT;[44@$X3]1HR9WL-8S&D@'&>GW9V3CS@M'WV6@H!%8Z?O51+P_5DZT^T
M6(>P=,"Z"%:%9^NBM\J_I>5L-PRWBO!7D>F H=MD0'AK@"!N7 !!*V#?80TU
M+P6KW3@<CS6PC>$3&_?+BS3XBF0;\*E>D1)6%D&X0"ZHFDPR_@;\VMZ<:T^-
MWGA08\\9SN9VN['L+%H3D8"G;;'UE6CPK(Q;YUJ>-VT!Y\4[1-) 1S81G;H^
M.]CK%':GL%EA__4 "GLJY'3;4367-=IHR1M EC@\/.3$T8X7.EY@7OCZ +S
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M=ZW5P26B3^S-".=T,\*9=S/"*3GME93'^R06HNB<0;-!9?#X7@:TB3:GKF$
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M?;Y[O/\GI6G]?/[+T:?_!U!+ P04    " #4=)Y8^).C+#A2  #450  #0
M &EM86=E7S P,2YJ<&>TNW58'%_7+=BX! D)!'=W=X?@P=W=:0@0/ 0)VM 0
M(+B[-@1I&DUPA^"$QMW=_>;WWG>^F3OSS9T[]\[L>M8_5:?.4^OL<_9>^U35
MRY^75<!K97DE>0 " @+ XN\!>%D R +045'14%'0T=#0,##0,;'PL;%>O<(B
M?O,6%Y^<A)*"G(2,C(J.@Y&*AHV6C(Q)D)F-BYN/CX^245A<B$>,@Y>/YY].
M$- Q,+!>81%A8Q/Q4)-1\_R_MI<. !XZ A;B1R0$&@ B'@(2'L)+#X 2 $!
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M(!C4QQ:MK/?W(LB):*^&.7QN#6!ML"K<DO(,,8JI&"G\!KF=#3,*_$[]N=5
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M#OI!'&XFI3=9%7@*DA)U7O,X:W=,/17VB"SLW%I1YE?3]G*O&#J]7LR\;)^
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M$U>%"(*2T_$'OYP2HE-@G.3&C?8+H*.QPGT^&ZV7Q!8"F9GJ]D[T*Q<KOFC
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M]DPU<=EES<,_TK$Q'&:/=F#07-^(;[WOS!G-7[55"*.=0JWN7I_3D_:RZ:"
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M4X+D$+,HNVN#!98J&STR<=;BBF8"EF(S9:%/'E,:4\4PV!MB::Q"^^7.*HC
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M2;S_JT.;6#HT4 'K*: D7?Q&IG(DP]2$YZ(@$=AV?X/ U<*?XRJ(]ZQ2E6W
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M0G?9C_$IYZX:<:Y'Q&@E,&-*DQ /MKA<3!3_@:*DL<U^#2Q_TR,@<@5N\SD
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M$+9&*#F'$!$6YE];4GNH&7G*&<:Q+G?X:1\N&2<<:?UX3+N6DN_/":*93]C
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MM]ILU6UL\,=J=3)4PR1Z8H!,V,7/5U[T;7EY9B;]"J\^I[?U>]IOEHQ$;Y:
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M[K/"32VY:=8O.,KJA-ZC>BSTT4HO%6;R,ATBY*9'H" S4XA7-5?/4GFST.H
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MTU$PZ).@DBW-"QSTW#^([*:/<; 0%0PRI+A4*J04=()"B B3="T- I3O3&'
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M\2'$M#@.T-X5/@X8.1W1:.^>5C1B8Y'1% =@)GF^.(W>H_4VV8IWBTD4ABC
M<_H<$X_6",=@\4K"80_BHF7B7>'EPT_)IGB2IK%_EV%33:-9C!V/$Z_KM4DD
MK^X*CE>*NHYIV5H&JX6S(8G4"$4)ZQ@<'.6I'V3B3EV2O@8K!:$M-TAQTLK&
M5WKK*=[>^?S:R]:O+9UJ 865(ZHRR*'G,(#B]W^L#'K>D1106B@997*W:Z:
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M<DIMYP3S$J#;!R=\%T7>HT^B>T.*Y4MBUQY!T[^I4P"X^H+"K;R&G6B'L>5
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M^X9J,[VE3/ZQ/%^C>)YI4[?B%[6[ED%)L?3+9=QKB4OX3"?9 )7!'NO6ZN=
MDH[4Q\%E'\][4-8\G("B :E<A>ZMDGG,#@XJH^UXV["; ZNNG%&O->R+X18
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M70@OG7<BGI;(Q2O'U%_Y'HZC)\D57J.PX,X]JN\/R@7&F+V*RF7^D%5/V#=
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M861H18[&%67)894?K&]'T5)(363#A$?'OJX2V5&;A 20&UD2\KBC!Q%H-&1
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MCTSW1Z;[(U,A'_3!=\DSSIN=LX _8GQJ[8)";_IHXX=8 ]9S[;F>0K^.UDY
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M_0'1-FCN@>L>B9C*:!%-N0>,7) ?Y\'2?_+Z0TBA3[-G6 $5BO"@#:ANH4U
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M^V9YON_S19#F$Z_1J;D3I(B")GF"RW*D\+QK=*KI(&3=W6'J>F=I?>;K7ZR
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M>35TN^(Y'N@QK@DF2B<X*<=Z.[R--8.$QN!!0N/A!PF-%8*$QKI!0H+N-*_
MQ^!7X./A7X&/%:[ Q]VOP"^L\/'*]9_"*T++YQ#;,V^^Q8$5.=[#9!4Y>Z"T
MNNW(@DFUVXI&4?I=T@E:TU[BQ_U^V@.RLBX&4!Q(#R:5++WM^=73^^ZQYEWF
M&/PN<SS\N\RQPEWF6/<NDW477WI3QW*X].\PI=!Q\0UFMV%+G_Q H25$E)+L
MNXYA_(591X*%^6FR7JD)'*3](@]'R8N4]/*4_)G^<D45V(Y>=S@>5WNA%]9+
MN">//6$G@W8?;.^I)I7FY>T8_/)V//S+V['"Y>U8]_)6T)WFU=88_&IK//RK
MK;'"U=98]VI+:N+,O#T.AV=-R\@:BC4MH5'1FG;2'@9O32O I-&:;N)77]:T
MYIWM&/S.=CS\.]NQPIWM6/?.MN@'C#/$$0L&.WML7[A6&#IKAPP2<F!DT.?<
MCBX(GW,K"L4U6%DOL9JZM[POR,9;/RPF8X-S-&MAHU:=M36;^G,T:T8AC,&C
M$,;#CT(8*T0AC/N-0CC3C$(X X]".!M^%,*90A3"F6X4@M1>B9-%#,XTEI$U
M%--80J.B:;Q.>QB\::P DT;3N(E?/9G&9YKA-6?@X35GPP^O.5,(KSG3#:\I
M/;1886PS\-3OQ8TII@8R8![72"AJ$5P!7;-'2<"UUS=-<^_E1<Z99CS7&7@\
MU]GPX[G.%.*YSOK-BW.F&?)R!A[R<C;\D)<SA9"7L^YY<:;K-5Y%\_7T>?5(
M&('OK A?L)_"N4=MC8EGT__0D*F]Y6*3NX0.;2 VK :AHC+G?ACBQ(C%26\H
M(-TAVR&#!)B@*$2^%]],TH*/[ ><=PR>A* #HBHU336YVI>YJQD =@8> '8V
M_ "P,X4 L#/= +#X+EMXF1T_DU:[TN8?V45A%OT.:3[JHE?Z!1A\8;U$1PC$
M "KK?D2HY5$9_8NEGR"-,\W(LS/PR+.SX4>>G2E$GIUUBCR+T4,VT>GS%GO$
M[+CQ":+VOKLGP,D0E/F;6JE"W;X-FF]=Z)0GX*!F&4[Z0YY/55K28T%UK3*7
MY7=P 60=(9 ALPL;^W$M:,:+G8''BYT-/U[L3"%>[*Q[LH]+O"66@,/RM2<X
M,G;4Y(T-DRF,0XDH/UCA2^CW6Q+955)8"J;7!3@%^^C*#VH).TQGGI,08CZB
MHXDD]4POZ98&7<M33=:\S'(-7#C">E>J!JU"'*]@!T=&T+</QY/.:9>"OL7N
M/WL!MEQ:1I[\ SL/7NI>BEUO'RW'8 HI#=( [L;:4VG"NSD @+?!D@SRRBSM
MQU;6C,4_ X_%/QM^+/Z90BS^6:<T4XD+O.CD(2")R.'KVK'N'=>)#K,(;]J=
MUUMW:MPYV99"4:10W$W%C4A[8OK&3?M"#NT,\&BN*^8,=EH,Z\DQJ!E$?P8>
M1'\V_"#Z,X4@^K/N0?3E'2I-J9&FV)AYMP'>6D[F\ $RF9KI@CYR-5(H/-W'
MW].<WO%/+ZG2VL:-<_\BU5H^JZVVV@4!/:<Q;38P2TD9/S(S28V5&H'VH@&K
M"65FWC*P;#Q9K?R=%Y'C"2TG"(1\-=I PB$T"!4[U)-%8./"(K#BMB$]]M+6
M@SKUM@*-#.[JC.LKXD'S9<D9^,N2L^&_+#E3>%ERUN_+DG/-ER7GX"]+SH?_
MLN1<X67)>;_Y+<\U _#/P0/PSX<?@'^N$(!_WBF_Y0TAB4:MZ047B5N;OC,7
M4B**^+E_B4B;D]BIQXG8,2W[1D%D")!/M1=OW+EF4/PY>%#\^?"#XL\5@N+/
MNR<YY3^@F&_-UJ.04P%SFRVE2>=5S8 >U53DJ_*FICCQ+H"[PR$F,Z 1T)=X
MCUU_2P\-IH,FY%3T";CW,> \_&!%V)9#3DJ5 ')I&^9-L?-6F9L%%G]*XB[C
MKYD+7?#W$7LXL%S2^<3>.)Y#-2G9(K%I!#;1T:-IU :"#60)0)BT8ABT2NWJ
M,*Q,RQP4%25?!J,*/SJ4G9Q3]V?\"!I?^*&Y]_6U@8'P5J5# ##V6?(VGH<I
M$$")A%=&$'>&>FZO.[RWW!T+0,L?N2[]6R*91ZNJNP36>%,??5TZ-(- A1SA
MII>UXC]@-FZ_*XHFL^55YMU!KY#NL;?#U(1+,_X8M*WJ8\-95#5:FC(_Q8]X
MH.^@) *L6DO\&;:WD6SL_//#+G0\'(87OA>1 ^8G3,OU2I 3XM4W#_[^-6G+
M,$-_8$J'84+<HT''CY ( 1#2;U'R,0P2&H5!42"?FG;4X8R5"[^PMDYDN8T0
MZ#G1'&=LF/,_AQ)9Q#%:Q5^"/V*62*^2"DXPP6ZA%[9#]S3+O;4<V_%@0"2G
M JJ,NH0F8=;OM UBD1..5T<9T+6Q@IBK%\1-\^_F58HLH@;MJ15XCO<0&@:<
M8'CS 3Q\0D3P6JUVFYU+K2ADX[6S<L!KXLKE6+5\A'/M%$C##FS4"17LL6D@
M\<:&T5<<2B0>2/)1'!L?%4H,HR<G>D0>O3\CQ@D9V*41JTYBI0[B],X7,^<
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M;Q;3.-YKOOQABL@Y[&YZLT23Q6):#!,8PJUE&[B(S4UEMO43\<(&B/U+T3#
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MXAS ,HSIG'DK?X-3\=Q@8?!E>04ZK!D->J+!KS0PQE\Y;#FR" N'YGC%81S
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M4JY7Y@BLCEK ?6 P;\9W&=AP+-[=N_$=@\S(J? Z:U,U:T!97IJ)G/><2<-
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M"%<\P-Z,]F\8%3D!80 4",N2UOBW9*!'2ZRP*@LH.X5$/MHF3=%P1%2?EUQ
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MYS$'$0$67LX)++P,  LOYP 67D:XMY9S<F\M ]Q;RSDD!5E&@(67<P(++P/
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M^P[A'\*K/?-.DC+6P?M. 5K)\D4$W'HQ)[CU(@!NO9@#W'H1 9U<S DZN0B
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M03S:YR]"/*FTC;<"%^^J)O<5XGP_>*GZ$J)Z_TZR,O7]=YV$I >Z+87/U'O
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M'NFFDDY8Y97UGUHR$_F "F%D()9'$NH#HO&+G47Q;%PG)T@LK5%Y4V<[2''
M;:1:$"D;)6QT+?&L9S_IX;4[-I/\;-13\N+YJT_DU+X!3Q#66X''794O92S0
M@@ OBJQI\GU.=V>-.IYA'-*[[C[90R')[_OQE,"G'\5$")"Y3[;9FZZT;Y+^
MH^2LZ1.E$/@P45@07^@B(LKYARQ'&_[Y_6<M%9@ #@FF$SV\/G^M"M>)*1L1
MT0K1&3H8[=B@8V$EJ65!3NA%U;3.NT=MF"TTPL8SZP/V&7UUEI)*=%3TP5^X
M^??@HLQ$OH/(-BNVQT)$7W_-FGQ+:%:7[+>&'*AT5^*^A:P2<.C;;F&E?ME
M><F\!8 4''26P&W7'(J.Y / RGX2BEG5Q<?W3U5\*]HDA_8Y"A1,ND"I.Z8"
M0JA.N8,RH"ZGEFS%L=;0#M'K.QRP<2?;^$GN.K08'Z1B$+('W%:;O2)BW0IS
ML=586 VVT3C%E,P9IMS0P@$]D3:U<[I+;[N9,A7)VSX8O<O3;F$Q6<I,?WS,
MN!8+FB'%82'!R06A@\1$&E3VXN"(N-WYJ_!F7E<UNV)>\H9CT_^3OO9P3#;;
M3566M'B@]0L4S>(-=]#W@1XR<"-JV$V@EI]0!3T3XX)H,3XP\O654.$K!B_9
M00T.VOY)7W6 [$$-D#1RA*+Y3E!IY"#U+E0.<[[Y"=+/D_VLG</:P=POW"$I
MP'G*(G8B$/704^(V>0%,G34@-83YZ643+L+$SC(^%/E2[2,^;3,I,F;OY1M\
M#A&MYMCM$^'B,6'.*[;)?5 K7K<5'66E1FE<W,/A)U<GV=0]M,_M55U7]455
M@X.9';/71?88 .A49MF'EC$ADJT '=(3(G\ *<3:+--\NK30*<DD/DST$T^&
M[O\[W3W2OJY:](VARG\_ 1V]IMULM99)QJ=OBT#9)7MP#),O7%,]_X(]=&&0
M@8)U4 &OB,8/%Q/&:>?G-I%!1-_E9V5YS(I[>JAJ)URE._%$8R):(WH;;(-W
M'6,F@\G-3N=@P;Z2!FRP,3*UG5N!G36^AB9O:74U+=]81Y*3(?OQ,\%_.MM&
MV3(IYU\+RO5CKKII.<&^9"W$B;_Z#$L]"5GX4&BN>CHV10:S1D\LNZ8Y)594
MB;6!>TCI5M*=6E5N2(EHUVTF[,SLPV';]XN=.:0HW0OVXVV]J;Z5H2&ZT(,P
M+1CZX"F^#B;&UX27UU3 :&&\A,?[L6W8Q@-ON4+AN\VP(L-.WX/<8Q\X#C8<
MQEH7O\GO9QDX-95-7%J2YI,#?CAN^UEBXRV]@+?;FBEA0\2-/XY)=2';'N:4
M-2K.'-_/[&'),1%3,D@<;+/C]1BRXB[+V?:[R YYFTW4"NX[$0@B^<2!&KP?
M^>-Y'#J %$/C8<LQ+].22.^GKIX/-7UB#T/V2/1;3@=-QY93)->S.7J'G]G%
M9G*!;[+O5_L]W;:W^YMGMK9K>#G>[G^IJMVWO'##[[+OA/)^8$[*NY[<N"3[
MXA]5$\S9YR9((@EC!A3$?2><XR[-J&LF/?^8ZM!HR(869&4I+6Q?(M#!KTLG
M4N^*AVXMVUH.?*SE;>'!XZJQ,9L243Z*V)A8SN- ECDL:SL'QNKV,9KJ7<6^
MN67'5O8(R;".Y5;<\[+J]ZL35-?U AQ^WT]594=)B!G CS$%(>RG/6\&V9.<
M*LT@EQ3^ 3,8M$.3,?E*;! ;@8P'533'553DCO3745G^O/A[,**[2Q][@._9
MBMBH\VON96Q^B!SMB^8'3EDRD[H6:L.4>5GD[W;_IH+J/2'X-:B,.FHA]1#&
MC;/Y),$EN#=[F^AO5<%&DM6OUWGAJ8DJK;]=:R*:XR::&8W=;O2U,I@JO$M"
M^^#+%UE+'SV@!2EAWI:HQFA(9LO [>*U\)8.%/4+.Q0Y?%J8FJ_@I/6_;W@/
M[K,CTKS..\T@=-S-BW&J3+&=/,C_"V/RZ6]OBO#O282']^-X/D*8=?A"PN4T
MIP)G(LO-6;GSJ3+-4)=YY[)G,DD0N,(ZK52.HE\?8AQ=)J&N8+.G(EIR?&02
M<1NK+^4LIXWYI9!A@>E6SWD#P/F)&D< (X/S?]MU,&L;X80"V_FPORB\3"/B
M-85M'TS*L1!-X=#@^?3LH$QT2*:--_OLA$DDU?FNK/NJ\HG3HB[\&^SL5"WQ
MLJ^-QVR:U*U,)=1ZV%GXPM2ONR+;\B?YA%%=-B=]^[$ND]S$:&? M"WZ&$T8
M_$";;9T?Q..Y*^(C+B:X@ISZ1=]/7]I$ZXH;+C'!EWF1!PDB6>;SBJD()3=/
M'=NGJO;&5?>-B=8:;0=8QVZ^M-P<I@ZG$W4)3%_Z.:2 IC)'NMNEM[4@"#Z2
MK[PS7+SH,*=)_CSNOFFQI#NK-M^JS5-U;)B>>570%UJRP[/TWP^L"U%]B.@$
M=T6)?4MX6#%VRB3;R=+/9L]P7Y6^8#EH(R0\CIA+GFE6&ZTA4Y.5I(^K376X
MW=^#VZ&?1]LMR]KQ*O:\;,5\$ /CX=O/#SN3J0]WZ5FTQ/A&^5+MP=%;NZ<5
MT\LZQ:C7_QHFI91P#VX;N:/U/\J\=>(-N,^4-2+0"O/,T4=KT_A'K&"F'/-Z
M2P]YG=B]S;\8X]R>OW<[4(AO]VU'S19RG)%?73.BC<Q+;Q9A1[YKS\=QVGB8
M6YD<4.;0;_\C*X_LU\5$5(SJUE4-:(GJB6>Y\G/D< KY!9"\JBD4W^(PA<!H
MX;Z#$3&,%"\\9F'LN/:SFOCH&9:0\.?E^K7+J"D3:>9H5>S]#-C/'#>K:>&)
MP^HI]Q38S O:)X<,*3K35J16/2%15I\W$]V2,LF??7H"Q9)Z?U3E-N0)Q-I]
M<CQTD/;%:."./6%E;_#\#,\$?\$4K:K(=Y!7ODM6TVCYL47=^Z@$[[$TTQG:
M(D?F2,:N4^DS_#2CW.R"E)E</;F&<>(4=RK'*4)+'J<%#NTM&^!E#EGNRMU9
MTV/<]4<%X*!:<8=8$762#-E).A!:>N@H?1P][QX%-?3C.Y)[^[ERD@B3OO35
MRT-E"0D #5P9V<%GE/'/PX]CBJ8$D'0ZS(KRTI$BT271F(YAFC_R 5+N_S3?
MG%L3/$]C/8*$AI&:4<7"A87\X=OM!X/V./V&?"66K*JUV-=>A'3: ,MB_X,[
M]"4K:.E65U5_\D%5KOQ)5$1HG@1"#7Z@/1V2[5LV2WT8,E5UPGE27O$S?MFD
M4+'8IS5.J&DQ_ ]/M"C SYR54Q!^WI3(MIC%O\V1CTTA+MZ27CUW6?U;5ARI
MGB_,7@:A)B_0T)HC#:<.Q6CH]G5M9S A7NV>/F<Y*!O*!".UOZZ*.'OP<TW0
M)?J. .G+M2IX=4>$,"J$DT%#+ 0S:CR,(D64</(^5UG)RV33IO6EBX)V1#4<
M98E*/0_C,1OBMC.%4"AG2^F.5\!0SJLAK-11)8?W$O5!.J\ANY2_86)G0]ER
MG%$!HD@6;WI)]Q1RXV^R[\(L)M/U@!7R@@WI=5_53-9.0[GJ3R!UB\SH)4D0
MH$%T(ICA((%\&MLG3D!IS>OZH^B!<@_+"YB4RJQX;7*P+9]MVV-6YUG!QGY\
M[AS$<>_+IB?--&9!FQ>YR!1UL ,K\C,R%+Q9/M-OT3>(/?%:T?',RF;U6P4U
MX0JNF,8;^UZZW@$&/J05$,VU8\I/E![>>7""T6^XZ\T"@7.-&(JV!T;)*;E-
M_I(>:KK->;S@1)2=WG0F\766T;NVE(/-] +7ED-H;":WBPD/SDW9M#6'.<1?
MK;)R)]BAOOE!<@TO[\D-B%2XR/+^NS.]<]]-F-/;^)WG+>VY+9<_/ @,T!Z'
MSF0\U53S>]X^73T?BNJ5NHW,DIAX,MG0DZU&D7QC) E5-)'].J>(P>V4.U&B
MZ=SJ?&3G,#*P"++QBA#Q'J5Y_MHW41A.>&M(34-+]LR-7LYD0/SRYE2(_B6B
M?8J<2WR?;"<_1_CW.@.4GAR;?Q(U8] [B\]X^OV8^4GVM-_0^CDO^9C]21&U
MAF8ZQ.214.-1&]/BX O-APO5V*D*CY!YIN(U@1:H:*$D!TG(Y<=%O]RGV)Z^
ML\,$E["&S]EQE[,/?P;<%UM=3G"B:$94.[R:#*,!CWU.5GZ&\@R'O&D)UL#L
M!:6+>7E-(\=:%.@MGBI&*KZPH3EP;X-<?)(2$:2L^?CPH6\G3[4M&U^$[!*Z
M>C0([J;J$+B_4@Z_W53L!_"$BUK=CNKU]F)J/6YY4Y&.,&$$A3V<_15^YK7/
M@3Q@'KL/D#-+N7.$2_B-TC&6P[M(.YUB?B41'Y?Y?D\AMZ][PE53HK5%S.=B
M#MR8"R=S"(8NS:C:ETZ\JXI\"T6:/P,R)4B3TI*/0&GNOO#D@=/BSHJ"4YN7
M.A4K@ #C=+@<TU?A8'O\NJB^<<^GV.RRY*N^V:?*!O&3<P]DA(GCPU&D0?Y)
MXB!AVK..FJV\$$XX=A3S]HD^18 G!CCT%_C(H-:!-@:Q=+PBX8F*WPD?2*@H
MO&6< 0JAD6-10_V,XBY%$4M#.\13#D]?&18]\43IIHN@K3-:Y!>'_%KX^R^J
MDH]B(H)9]B.L(Y$]2=<5.^O,%%/&=(5)H9^34\Z;@<7^K-QU<#'UK6-6?,[W
M@!(S[6PG'D'O\TV$E^F[##S@F!IF?N7987N@HO8M A_CZ$2;R7A&9]>[KC++
M<?9^$Y,:J6="PS4(U.<\^\H1#QP+%0FYWRFL&&0?+10E\H$'D>('\T8P;E?/
MHB6'&0 ?5PG#&0L\C)-_6WT2M)E_@V#L*^'-DDYH]!:!"??T,8=#IVPA%=I$
MV$7?F$!KQ,+UML&/K>!N!M,7KJ_:MGH.2O4FFGJRO:'L% L#]AW@Y#1ELC#/
M-@3;\]0V]"0&,3+?:V1)3[=WHUN/N^0I$$^7AZ'JO%FVR3=?='DHX"-]32^^
MA/X9;LT?)$_[>?)#)R\I=$!MG$D@5Z];F?@L;$UI G[EX#%1N:T+T+*9!GY1
M[=QEGGF2$=:(0"L\#[X^UK'B8O*1,I 1MLGH'=MLOE43"?NXKF(8#!H"B9?1
MJPKY>3*NN! 1) ;X9RT;$(\PD(=>Y'N-E^."8MI<>5=7T&S3:P;SZW",Q8DK
MM:5E0H7Z(2_R$[2+N3W)IV43_2@/%7>:%<*A6^RC._CP=9$].H%HJA&!5HC/
M\,%H#12:R4I2A4L%/XM\,;?E)>7E03T)0V1@M\RG4X'E4G1!WQ8N7EP&21_G
M*5_B(@7E ^./WYV+-Q4P')()+6*(DZ$VE&6+JRU>8JDOL$W-WK;%1(R::&1&
MIV%MH<&@[?O&PA=:+D[E-PA QNB).8N^VVP@,%ZF''?VM!S2'V/_<2Q>__JF
M$ZRC,._#*X!1Q[D5+**$+UI82Y#D*AAI)CMHH%P+-AO#C.MBQ#32^EE.!ECH
MO-^=%W0Z_5'7%%76YLA-,X&#N93%N:NFN3Z6N_L,'(PNV?)F!-H1T1!5LJ-!
M&V*U,I76W!)N=+ZNZCW-VZ1%4O;JFS'O^9E["B+D^%8_0?24)3LM>='YIJ\Z
MOWFJZ82W6'0AW+PG=0S>"UN/\+!BV? 3;"=R'PB\P-ENQX@V%P"F]^1)%H (
MV?@CD<WQ4U$.AV^'1-A81'//3^!H1WYW=.BL;>Q^'[E1T#?=6KZ@@#DL;LH=
M_?Z?=&HQR]:$-R>L/5J9&>OH[6O9RF):;8%]]DM69N+:N*-U4Y4E+?34 7=5
MTPI?+L\>0$NZ]]@A&3WRW!&$-$R"(B\PJTA^) =&]%-/E7R59)%=-Z=*PWZM
MOTVVJ>UB4OE@&@;31DH5<*>2;UHM^5+GVXLNPYS3V&%J;G;LDS7%?L(W_R_L
M9=9 D"EM;LOK+!?9@6_++UG])VTY4(ENC[4WII?3((((N2T)D!'93^"WGA+I
M22'ZN&,X-E6P:'&]/9N AGM7B8!/"^+P$$H5)10RF(!H"SUFHLO];%J>\*(G
MIN?,$A(Q(9+DA2A?:'GD&:*4FRS0(8A\L5H&;C^&G1RFU/$'M3JF#*ZR,1&M
M9Y (PSIZ8XE[>$R:>1XR]F<B"MQU8"^M)M>N(QP^$Q=:>@/L!%L6>VR0(%"K
M3VIG82"0IR%5WV=.=2@U5AP^/#_GR<QJPJIT=GP\-NWJYS?Y[W0BH2X\)!]>
M&+\.-UZ,L-+7KI/@8O76F\ AJ.;= ]F ). DO;1S8=]*7I83'V@7PB]_5]-#
MEN_D2)R/*-F:'$1S)7M\1)6=#;OX?2RCI1]4PSA__35KCZ<D^I8$R-=74G(2
MLTWT[6;5/F%1<DJI%E]];VFYH["&\OH5,EJZ$TR)ED0T)= 6S>IM#MNX.%R<
M)3Z=!I8,2\JKVY*G 2XR491\6SV6(C97%&&^K7W5J:_'5KI']C5+36J<'?,N
MK-OWTSM*=0[9IRRIYD[//E5U2?S^.;)/>9AWW'XG"#"UY5T_\"_9NR\O8)C[
MJGX6N9N_LD>43)D%SJ+3$_?O)'$V]1UUD@%YE88L*Z8S]*.=$>\@I^D;]TT3
MD+9"\A FHKU1=<2(@H+8K^DQ6$=[K@^!.]CNG'!F'8^02&$EG4F>2QK\@C5]
M@M),+\HLU[9U_O7(+4&;"G"1D(>G*AB51V4=G:C;N]6I2EOP1Y)IA$E;D1)
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M*O*<+!_3+OM>,D]<7.Q7^NWAB?Y)B["28JPY$>TM2C-"M(&-!],MZF$UG?;
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M2:)4_W7(LU8V7TD2565XX%E<Y><K%:1YWPV3*B.)%?<;C&<767Q5X4&RGO>
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MNQ;)2+-EN0KAP0*NSUZW^G5>2TDZ'7#3P?/L?3Z;4QU<$3OP;=<CGTB*U4U
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M"-#0UJEV(G;S _5-K T]PV\=,KA@]\:7U2X%(>"\CBCK?YY!LV^VSV.=*/M
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M[*]T>Q1$])&$,3T3\R@$/6/IP?@Q<(BGD%&A @__4J6J'HRM2A2#JC^?MB8
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M+PVZ@2E.+]D\HYMJ!'1NZ)$9T:VP@^T7-[X_7:V]8$L,<EL/.^Q'."6)T&0
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M;0P[!;L9JX,>*_8DI;?W.6-ZSA@_>'+4(T)]-+&#3"%,?8363:'8D 4;TY,
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MK '6N%7N0$/5%K<22_XM6P(,*&8-OT0?NPOTAV]5&6,J+L,WO$?2*V9FC+Z
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MB]4J"4HUR@4LI7SB5@ :8E?;D'QN%O=#C9[^53 -H5'!X:*2@F5<#V1X6^H
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M;W!H87)M82YH=&U02P$"% ,4    " #4=)Y8EW)VE]T&   I+   '
M        @ 'IPP( 96$P,C T-38Q,#%E>#$R+3%?>'1L8FEO+FAT;5!+ 0(4
M Q0    ( -1TGEA(U=ZVX@8  &(K   <              "  0#+ @!E83 R
M,#0U-C$P,65X,3(M,E]X=&QB:6\N:'1M4$L! A0#%     @ U'2>6)Q)[W4
M!   +A4  !P              ( !'-(" &5A,#(P-#4V,3 Q97@Q,RTQ7WAT
M;&)I;RYH=&U02P$"% ,4    " #4=)Y81ODLKJ(B  "'%P$ '
M    @ %6U@( 96$P,C T-38Q,#%E>#DY+3=?>'1L8FEO+FAT;5!+ 0(4 Q0
M   ( -1TGECXDZ,L.%(  -15   -              "  3+Y @!I;6%G95\P
M,#$N:G!G4$L! A0#%     @ U'2>6 N=-I^D'0  L($! !$
M ( !E4L# 'AT;&(M,C R,S$R,S$N>'-D4$L! A0#%     @ U'2>6$T13H**
M"P  YH$  !4              ( !:&D# 'AT;&(M,C R,S$R,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( -1TGEA3@ZO-^ST  ++. P 5              "  25U
M P!X=&QB+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #4=)Y8J6BW9.:D
M  "I& @ %0              @ %3LP, >'1L8BTR,#(S,3(S,5]L86(N>&UL
M4$L! A0#%     @ U'2>6/L,G!&3/@  ,_P# !4              ( !;%@$
L 'AT;&(M,C R,S$R,S%?<')E+GAM;%!+!08     "P + /H"   REP0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>ea0204561-20f_xtlbiopharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xtlb="http://xtlb.com/20231231">
    <link:schemaRef xlink:href="xtlb-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">xtlb:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:ForeignCurrenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:ForeignCurrenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:IsraeliCpiForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">xtlb:IsraeliCpiForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:AgreementAxis">xtlb:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-01</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-01</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:YedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:UnitedStatesDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:UnitedStatesDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:IsraeliNewShekelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:TypeOfCurrencyAxis">xtlb:IsraeliNewShekelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DepositaryShareAxis">xtlb:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:NamePlanAxis">xtlb:TwoThousandElevenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-08-01</startDate>
            <endDate>2011-08-29</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:NamePlanAxis">xtlb:TwoThousandElevenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-08-29</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2020-12-29</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2020-05-19</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2011-08-29</startDate>
            <endDate>2011-08-29</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis">xtlb:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">xtlb:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:FourDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:OneDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:OneDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:ChairmanOfBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:ChairmanOfBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandDateIssuedEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">xtlb:GrandsDateIssuedThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">xtlb:BlackScholesMertonOptionsPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:InterCureLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:InterCureLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">xtlb:CanndocLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMarch72021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMarch72021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMarch72021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMay42021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMay42021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedMay42021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedJuly62021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedJuly62021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedJuly62021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedAugust302021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedAugust302021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedAugust302021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedSeptember12021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedSeptember12021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedSeptember12021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedOctober112021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedOctober112021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xtlb:DateAxis">xtlb:IssuedOctober112021DueToWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">xtlb:NumberOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">xtlb:NumberOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">xtlb:NumberOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-17</startDate>
            <endDate>2024-03-17</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-17</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-19</startDate>
            <endDate>2024-03-19</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023549</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">xtlb:NonAdjustingEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-19434">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-19435">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-19436">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-19437">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-19438">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-19439">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-19440">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-19441">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-77">001-36000</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-83">XTL BIOPHARMACEUTICALS LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-19442">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-19443">26 Ben-Gurion St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-19444">Ramat Gan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-19445">5112001</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-19446">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-19447">Shlomo Shalev</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-19448">26 Ben-Gurion St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-19449">Ramat Gan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-19450">5112001</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-19451">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-19452">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-19453">3-6116600</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber contextRef="c1" id="ixv-19454">+972-3-611-6605</dei:ContactPersonnelFaxNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-19455">American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-138">XTLB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-19456">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-19457"
      unitRef="shares">544906149</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-19458">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-19459">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-19460">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-19461">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-19462">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-19463">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-19464">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-19465">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-19466">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-19467">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0" id="ixv-19468">1057</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-19469">Somekh Chaikin</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-8827">Tel Aviv, Israel</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-19470" unitRef="usd">1401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-19471" unitRef="usd">2094000</ifrs-full:CashAndCashEquivalents>
    <xtlb:CurrentMarketableSecurities contextRef="c2" decimals="-3" id="ixv-19472" unitRef="usd">605000</xtlb:CurrentMarketableSecurities>
    <xtlb:CurrentMarketableSecurities contextRef="c3" decimals="-3" id="ixv-19473" unitRef="usd">1627000</xtlb:CurrentMarketableSecurities>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" id="ixv-19474" unitRef="usd">40000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" id="ixv-19475" unitRef="usd">85000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-19476" unitRef="usd">2046000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-19477" unitRef="usd">3806000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-19478" unitRef="usd">380000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-19479" unitRef="usd">380000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-19480" unitRef="usd">380000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-19481" unitRef="usd">380000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-19482" unitRef="usd">2426000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-19483" unitRef="usd">4186000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-19484" unitRef="usd">206000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-19485" unitRef="usd">187000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:ParValuePerShare
      contextRef="c2"
      decimals="1"
      id="ixv-19486"
      unitRef="ilsPershares">0.1</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c3"
      decimals="1"
      id="ixv-19487"
      unitRef="ilsPershares">0.1</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c2"
      decimals="0"
      id="ixv-19488"
      unitRef="shares">1450000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c3"
      decimals="0"
      id="ixv-19489"
      unitRef="shares">1450000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-19490"
      unitRef="shares">544906149</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-19491"
      unitRef="shares">544906149</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-19492"
      unitRef="shares">544906149</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-19493"
      unitRef="shares">544906149</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IssuedCapital contextRef="c2" decimals="-3" id="ixv-19494" unitRef="usd">14120000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c3" decimals="-3" id="ixv-19495" unitRef="usd">14120000</ifrs-full:IssuedCapital>
    <ifrs-full:AdditionalPaidinCapital contextRef="c2" decimals="-3" id="ixv-19496" unitRef="usd">146326000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital contextRef="c3" decimals="-3" id="ixv-19497" unitRef="usd">146326000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:OtherReserves contextRef="c2" decimals="-3" id="ixv-19498" unitRef="usd">20000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c3" decimals="-3" id="ixv-19499" unitRef="usd">20000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-19500" unitRef="usd">-158246000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-19501" unitRef="usd">-156467000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-19502" unitRef="usd">2220000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-19503" unitRef="usd">3999000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-19504" unitRef="usd">2426000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-19505" unitRef="usd">4186000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-19506" unitRef="usd">31000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-19507" unitRef="usd">30000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-19508" unitRef="usd">30000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-19509" unitRef="usd">734000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-19510" unitRef="usd">850000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-19511" unitRef="usd">1001000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-19512" unitRef="usd">-765000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="-3" id="ixv-19513" unitRef="usd">-880000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c5" decimals="-3" id="ixv-19514" unitRef="usd">-1031000</ifrs-full:ProfitLossFromOperatingActivities>
    <xtlb:RevaluationOfWarrantsToPurchaseAds contextRef="c4" decimals="-3" id="ixv-19515" unitRef="usd">1054000</xtlb:RevaluationOfWarrantsToPurchaseAds>
    <xtlb:RevaluationOfWarrantsToPurchaseAds contextRef="c5" decimals="-3" id="ixv-19516" unitRef="usd">719000</xtlb:RevaluationOfWarrantsToPurchaseAds>
    <xtlb:RevaluationOfMarketableSecurities contextRef="c0" decimals="-3" id="ixv-19517" unitRef="usd">-1022000</xtlb:RevaluationOfMarketableSecurities>
    <xtlb:RevaluationOfMarketableSecurities contextRef="c4" decimals="-3" id="ixv-19518" unitRef="usd">-1531000</xtlb:RevaluationOfMarketableSecurities>
    <xtlb:RevaluationOfMarketableSecurities contextRef="c5" decimals="-3" id="ixv-19519" unitRef="usd">747000</xtlb:RevaluationOfMarketableSecurities>
    <ifrs-full:OtherFinanceIncome contextRef="c0" decimals="-3" id="ixv-19520" unitRef="usd">41000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c4" decimals="-3" id="ixv-19521" unitRef="usd">36000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c5" decimals="-3" id="ixv-19522" unitRef="usd">21000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceCost contextRef="c0" decimals="-3" id="ixv-19523" unitRef="usd">36000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost contextRef="c4" decimals="-3" id="ixv-19524" unitRef="usd">27000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost contextRef="c5" decimals="-3" id="ixv-19525" unitRef="usd">21000</ifrs-full:OtherFinanceCost>
    <ifrs-full:FinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-19526" unitRef="usd">-1017000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c4" decimals="-3" id="ixv-19527" unitRef="usd">-468000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c5" decimals="-3" id="ixv-19528" unitRef="usd">1466000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-19529" unitRef="usd">-1782000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-19530" unitRef="usd">-1348000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-19531" unitRef="usd">435000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="3"
      id="ixv-19532"
      unitRef="usdPershares">-0.003</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="3"
      id="ixv-19533"
      unitRef="usdPershares">-0.002</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="3"
      id="ixv-19534"
      unitRef="usdPershares">0.001</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="3"
      id="ixv-19535"
      unitRef="usdPershares">-0.003</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="3"
      id="ixv-19536"
      unitRef="usdPershares">-0.002</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="3"
      id="ixv-19537"
      unitRef="usdPershares">0</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-19538"
      unitRef="shares">544906149</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-19539"
      unitRef="shares">544906149</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-19540"
      unitRef="shares">531995467</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-19541"
      unitRef="shares">544906149</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-19542"
      unitRef="shares">544909149</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-19543"
      unitRef="shares">615548446</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:Equity contextRef="c6" decimals="-3" id="ixv-19544" unitRef="usd">14120000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="-3" id="ixv-19545" unitRef="usd">146326000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-19546" unitRef="usd">-156467000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-19547" unitRef="usd">20000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-19548" unitRef="usd">3999000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c12" decimals="-3" id="ixv-19549" unitRef="usd">-1782000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-19550" unitRef="usd">-1782000</ifrs-full:ProfitLoss>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c12" decimals="-3" id="ixv-19551" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c0" decimals="-3" id="ixv-19552" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-19553" unitRef="usd">14120000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="-3" id="ixv-19554" unitRef="usd">146326000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="-3" id="ixv-19555" unitRef="usd">-158246000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c17" decimals="-3" id="ixv-19556" unitRef="usd">20000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-19557" unitRef="usd">2220000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c18" decimals="-3" id="ixv-19558" unitRef="usd">14120000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" id="ixv-19559" unitRef="usd">146326000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c20" decimals="-3" id="ixv-19560" unitRef="usd">-155133000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c21" decimals="-3" id="ixv-19561" unitRef="usd">20000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c22" decimals="-3" id="ixv-19562" unitRef="usd">5333000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c25" decimals="-3" id="ixv-19563" unitRef="usd">-1348000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-19564" unitRef="usd">-1348000</ifrs-full:ProfitLoss>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c25" decimals="-3" id="ixv-19565" unitRef="usd">14000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c4" decimals="-3" id="ixv-19566" unitRef="usd">14000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c6" decimals="-3" id="ixv-19567" unitRef="usd">14120000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="-3" id="ixv-19568" unitRef="usd">146326000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-19569" unitRef="usd">-156467000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-19570" unitRef="usd">20000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-19571" unitRef="usd">3999000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="-3" id="ixv-19572" unitRef="usd">13182000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" id="ixv-19573" unitRef="usd">146015000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-19574" unitRef="usd">-155605000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c30" decimals="-3" id="ixv-19575" unitRef="usd">20000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-19576" unitRef="usd">3612000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c34" decimals="-3" id="ixv-19577" unitRef="usd">435000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-19578" unitRef="usd">435000</ifrs-full:ProfitLoss>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c32" decimals="-3" id="ixv-19579" unitRef="usd">938000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c33" decimals="-3" id="ixv-19580" unitRef="usd">311000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c5" decimals="-3" id="ixv-19581" unitRef="usd">1249000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c34" decimals="-3" id="ixv-19582" unitRef="usd">37000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c5" decimals="-3" id="ixv-19583" unitRef="usd">37000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c18" decimals="-3" id="ixv-19584" unitRef="usd">14120000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c19" decimals="-3" id="ixv-19585" unitRef="usd">146326000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c20" decimals="-3" id="ixv-19586" unitRef="usd">-155133000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c21" decimals="-3" id="ixv-19587" unitRef="usd">20000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c22" decimals="-3" id="ixv-19588" unitRef="usd">5333000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-19589" unitRef="usd">-1782000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-19590" unitRef="usd">-1348000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-19591" unitRef="usd">435000</ifrs-full:ProfitLoss>
    <xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-19592" unitRef="usd">1075000</xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities>
    <xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-19593" unitRef="usd">447000</xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities>
    <xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-19594" unitRef="usd">-1484000</xtlb:AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-19595" unitRef="usd">-707000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-19596" unitRef="usd">-901000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-19597" unitRef="usd">-1049000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c0" decimals="-3" id="ixv-19598" unitRef="usd">41000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c4" decimals="-3" id="ixv-19599" unitRef="usd">36000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-19600" unitRef="usd">8000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-19601" unitRef="usd">41000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-19602" unitRef="usd">36000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-19603" unitRef="usd">8000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c5" decimals="-3" id="ixv-19604" unitRef="usd">385000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-19605" unitRef="usd">385000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-19606" unitRef="usd">-666000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-19607" unitRef="usd">-865000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-19608" unitRef="usd">-656000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-19609" unitRef="usd">-27000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-19610" unitRef="usd">-10000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-19611" unitRef="usd">-6000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-19612" unitRef="usd">2094000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c22" decimals="-3" id="ixv-19613" unitRef="usd">2969000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c31" decimals="-3" id="ixv-19614" unitRef="usd">3631000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-19615" unitRef="usd">1401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-19616" unitRef="usd">2094000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c22" decimals="-3" id="ixv-19617" unitRef="usd">2969000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DepreciationExpense contextRef="c4" decimals="-3" id="ixv-19618" unitRef="usd">1000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c5" decimals="-3" id="ixv-19619" unitRef="usd">1000</ifrs-full:DepreciationExpense>
    <xtlb:RevaluationOfMarketableSecurities contextRef="c0" decimals="-3" id="ixv-19620" unitRef="usd">-1022000</xtlb:RevaluationOfMarketableSecurities>
    <xtlb:RevaluationOfMarketableSecurities contextRef="c4" decimals="-3" id="ixv-19621" unitRef="usd">-1531000</xtlb:RevaluationOfMarketableSecurities>
    <xtlb:RevaluationOfMarketableSecurities contextRef="c5" decimals="-3" id="ixv-19622" unitRef="usd">747000</xtlb:RevaluationOfMarketableSecurities>
    <xtlb:RevaluationOfWarrantsToPurchase contextRef="c4" decimals="-3" id="ixv-19623" unitRef="usd">1054000</xtlb:RevaluationOfWarrantsToPurchase>
    <xtlb:RevaluationOfWarrantsToPurchase contextRef="c5" decimals="-3" id="ixv-19624" unitRef="usd">719000</xtlb:RevaluationOfWarrantsToPurchase>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-19625" unitRef="usd">3000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-19626" unitRef="usd">14000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-19627" unitRef="usd">37000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c0" decimals="-3" id="ixv-19628" unitRef="usd">27000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c4" decimals="-3" id="ixv-19629" unitRef="usd">10000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c5" decimals="-3" id="ixv-19630" unitRef="usd">6000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:RevenueFromInterest contextRef="c0" decimals="-3" id="ixv-19631" unitRef="usd">41000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c4" decimals="-3" id="ixv-19632" unitRef="usd">36000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c5" decimals="-3" id="ixv-19633" unitRef="usd">8000</ifrs-full:RevenueFromInterest>
    <xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows contextRef="c0" decimals="-3" id="ixv-19634" unitRef="usd">1011000</xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows>
    <xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows contextRef="c4" decimals="-3" id="ixv-19635" unitRef="usd">466000</xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows>
    <xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows contextRef="c5" decimals="-3" id="ixv-19636" unitRef="usd">-1430000</xtlb:TotalIncomeAndExpensesNotInvolvingCashFlows>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c0" decimals="-3" id="ixv-19637" unitRef="usd">45000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c4" decimals="-3" id="ixv-19638" unitRef="usd">25000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c5" decimals="-3" id="ixv-19639" unitRef="usd">-31000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-19640" unitRef="usd">19000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c4" decimals="-3" id="ixv-19641" unitRef="usd">-44000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c5" decimals="-3" id="ixv-19642" unitRef="usd">-23000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-19643" unitRef="usd">64000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c4" decimals="-3" id="ixv-19644" unitRef="usd">-19000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c5" decimals="-3" id="ixv-19645" unitRef="usd">-54000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c0" decimals="-3" id="ixv-19646" unitRef="usd">1075000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c4" decimals="-3" id="ixv-19647" unitRef="usd">447000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c5" decimals="-3" id="ixv-19648" unitRef="usd">-1484000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c5" decimals="-3" id="ixv-19649" unitRef="usd">864000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory contextRef="c0" id="ixv-12379">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOTE 1:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;GENERAL&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
                                            general description of the Company and its activity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;XTL
Biopharmaceuticals Ltd. (the &#x201c;Company&#x201d;) is engaged in the development of therapeutics for the treatment of unmet medical
needs. The Company was incorporated under the Israeli Companies Law on March&#160;9, 1993. The registered office of the Company is located
at 26 Ben-Gurion Street, Ramat Gan, Israel. The Company has decided, at this time, to explore collaboration with a strategic partner
in order to execute the clinical trials. In parallel, the Company is looking to expand and identify additional assets to add to XTL&#x2019;s
portfolio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s American Depository Shares (&#x201c;ADSs&#x201d;) are listed for trading on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;)
and its ordinary shares are traded on the Tel-Aviv Stock Exchange (&#x201c;TASE&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023, the Company has a wholly-owned subsidiary, Xtepo Ltd. ("Xtepo"), which was incorporated in Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company and Xtepo are heretofore referred to as &#x201c;the Group&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
                                            Group has incurred continuing losses and depends on outside financing resources to continue
                                            its activities. Based on existing business plans, the Company&#x2019;s management estimates
                                            that its outstanding cash and cash equivalent balances will allow the Company to finance
                                            its activities which include, but are not limited to maintenance and ongoing expenses related
                                            to &lt;span style="font-size: 10pt"&gt;hCDR1&lt;/span&gt;, for an additional period of at least 12 months
                                            from the date of this report. However, the amount of cash which the Company will need to
                                            finance its future activities depends on numerous factors which include, but are not limited
                                            to future projects which the Company might acquire or other business development activities
                                            such as acquiring new technologies and/or changes in circumstances which are liable to cause
                                            significant expenses to the Company in excess of management&#x2019;s current and known expectations
                                            as of the date of these Financial Statements and which will require the Company to reallocate
                                            funds against plans, also due to circumstances beyond its control.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company expects to incur additional losses in 2024 arising from research and development activities, testing additional technologies
and operating activities, which will be reflected in negative cash flows from operating activities. In order to perform the clinical
trials aimed at developing a product until obtaining its marketing approval, the Company will need to raise additional funds by issuing
securities. The Company decided to seek collaboration with third parties to finance the clinical trials and continues to seek additional
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
                                            October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip
                                            and conducted a series of attacks on civilian and military targets, launched extensive rocket
                                            attacks and kidnapped many Israeli civilians and soldiers.&#160; Following the attack, Israel
                                            declared war against Hamas. In parallel, border clashes between Israel and the Hezbollah
                                            terrorist group on Israel&#x2019;s northern border with Lebanon intensified and may escalate
                                            into a greater regional conflict. The Israel Defence Force (the &#x201c;IDF&#x201d;), the national
                                            military of Israel, is a conscripted military service, subject to certain exceptions. Since
                                            October 7, 2023, the IDF has called up several hundred thousand of its reserve forces to
                                            serve.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
a result, its operations in Israel may be disrupted by such absences, which disruption may materially and adversely affect its business,
prospects, financial condition and results of operations. In addition, since the commencement of these events, there have been continued
hostilities along Israel&#x2019;s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the
Houthi movement in Yemen). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations,
including Palestinian military organizations in the West Bank as well as other hostile countries, such as Iran, will join the hostilities.
Such clashes may escalate in the future into a greater regional conflict. Further, in April 2024, Iran launched a direct attack on Israel
involving hundreds of drones, ballistic missiles and cruise missiles and may attack again. Although until approval of these financial
statements, the impact of the war on the Company was negligible, it is currently not possible to predict the duration or severity of
the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly
evolving and developing, and could disrupt its business and operations, and hamper its ability to raise additional funds or sell its
securities, among others.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
                                            March 19, 2024, the Company has entered into a binding term sheet, subject to due diligence,
                                            with THE SOCIAL PROXY Ltd. (the &#x201c;Social Proxy&#x201d;) an AI web data company, developing
                                            and powering a unique ethical, IP based, proxy and data extraction platform for AI &amp;amp;
                                            BI Applications at scale (the &#x201c;Term Sheet&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the Term Sheet, the Company will acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis
(the &#x201c;Transaction&#x201d;) in exchange for the issuance by the Company to the shareholders of the Social Proxy, by way of a private
placement, such number of ordinary shares of the Company, representing immediately after such issuance, 44.6% of the issued and outstanding
share capital of the Company and the payment of $430 thousands to the shareholders of the Social Proxy. In addition, as part of the Transaction,
the shareholders of Social Proxy will be issued additional warrants or ordinary shares, which may only be exercised or granted upon reaching
certain financial measured milestones within a period of up to 3 years from the closing of the Transaction. The Transaction is conditioned
upon certain closing conditions which are fully described in the Term Sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Social
Proxy will operate as fully owned subsidiary of the Company and its shareholders will be entitled to appoint 2 representatives to the
Company&#x2019;s board of directors out of a total of up to 7 directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
proposed Transaction is part of the Company&#x2019;s strategy to expand its assets portfolio with high potential assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition, the Company secured
an investment commitment from several shareholders (including one shareholder, who is also a related party), in the amount of
US$1,500 thousand through a private placement to be consummated upon and subject to the closing of the Transaction (the
&#x201c;Private Placement&#x201d;). In exchange for the investment in the Private Placement, the investors will be issued 1,500,000
units (reflecting a price per each unit of US$1.00) consisting of one ADS and one warrant, with each such warrant being exercised
during a period of five years from its issuance into one ADS at an exercise price of US$1.20 per warrant. The Investment is
conditioned upon customary closing conditions and obtaining shareholders&#x2019; approval (which was approved on April 30, 2024 by Company&#x2019;s shareholders meeting).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Definitions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x201c;Related
party&#x201d; - as the term is defined in IAS 24, &lt;i&gt;&#x201c;Related Party Disclosures&#x201d;&lt;/i&gt; (&#x201c;IAS 24&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;f.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Approval
                                            of financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
financial statements were approved by the Company&#x2019;s Board of Directors (&#x201c;BoD&#x201d;) on April 30, 2024.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralHedgeAccountingExplanatory>
    <xtlb:IssuedAndOutstandingRate contextRef="c0" decimals="3" id="ixv-19650" unitRef="pure">0.446</xtlb:IssuedAndOutstandingRate>
    <xtlb:PaymentOfShareholders contextRef="c0" decimals="-3" id="ixv-19651" unitRef="usd">430000</xtlb:PaymentOfShareholders>
    <xtlb:PeriodOfClosingTransaction contextRef="c0" id="ixv-19652">P3Y</xtlb:PeriodOfClosingTransaction>
    <ifrs-full:InvestmentIncome contextRef="c36" decimals="-3" id="ixv-19653" unitRef="usd">1500000</ifrs-full:InvestmentIncome>
    <xtlb:InvestorIssued
      contextRef="c0"
      decimals="0"
      id="ixv-19654"
      unitRef="shares">1500000</xtlb:InvestorIssued>
    <xtlb:PricePerUnit
      contextRef="c0"
      decimals="2"
      id="ixv-19655"
      unitRef="usdPershares">1</xtlb:PricePerUnit>
    <xtlb:ADSIssued
      contextRef="c0"
      decimals="0"
      id="ixv-19656"
      unitRef="shares">1</xtlb:ADSIssued>
    <xtlb:PrivatePlacementWarrantsIssued
      contextRef="c0"
      decimals="0"
      id="ixv-19657"
      unitRef="shares">1</xtlb:PrivatePlacementWarrantsIssued>
    <xtlb:WarrantExercisedPeriod contextRef="c0" id="ixv-19658">P5Y</xtlb:WarrantExercisedPeriod>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c2"
      decimals="2"
      id="ixv-19659"
      unitRef="usdPershares">1.2</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0" id="ixv-12585">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOTE 2:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;BASIS
                                            OF PREPARATION&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Statement
                                            of Compliance:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements of the Company (the &#x201c;Financial Statements&#x201d;) have been prepared in accordance with International
Financial Reporting Standards (IFRSs), as issued by the International Accounting Standards Board (IASB).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis
                                            of measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Financial Statements have been prepared under the historical cost convention, except for financial assets and liabilities measured at
fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Use
                                            of judgments and estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of Financial Statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires
the Group&#x2019;s management to exercise its judgment in the process of applying the Group&#x2019;s accounting policies. Actual results
could significantly differ from the estimates and assumptions used by the Group&#x2019;s management.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimates
and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events
that are believed to be reasonable under the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Critical
accounting estimates and assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounting
estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of
causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets &#x2013; the intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested
at least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Translation
                                            of balances and transactions in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Functional
                                            currency and presentation currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Items
included in the Financial Statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment
in which the entity operates (the &#x201c;Functional Currency&#x201d;). The consolidated financial statements are presented in U.S. dollars,
which is the Functional Currency of each of the Group&#x2019;s entities and the Company&#x2019;s presentation currency and have been rounded
to the nearest thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Below
are the exchange rate of the U.S. dollar in relation to the NIS:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange&#160;rate&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    $ 1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.519&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transactions
                                            and balances:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transactions
in a currency other than the Functional Currency (&#x201c;Foreign Currency&#x201d;) are translated into the Functional Currency using the
exchange rates at the dates of the transactions. After initial recognition, monetary assets and liabilities denominated in Foreign Currency
are translated at the end of each reporting period into the Functional Currency at the exchange rate at that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange
differences are recognized in the statement of comprehensive income (loss) in the line-item finance income (expenses), net. Non-monetary
assets and liabilities denominated in foreign currency and measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Initial
                                            application of new standards, amendments to standards and interpretations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Amendment
to IAS 1, Presentation of Financial Statements: "Disclosure of Accounting Policies" (&#x201c;the Amendment&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;According
to the Amendment, companies must provide disclosure of their material accounting policies rather than their material accounting policies.
Pursuant to the Amendment, accounting policy information is material if, when considered with other information disclosed in the financial
statements, it can be reasonably be expected to influence decisions that the users of the financial statements make on the basis of those
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Amendment also clarifies that accounting policy information is expected to be material if, without it, the users of the financial statements
would be unable to understand other material information in the financial statements. The Amendment also clarifies that immaterial accounting
policy information need not be disclosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
a result of applying the Amendment, the extent of the accounting policy disclosure provided in the financial statements for 2023 was
reduced and adjusted according to the Company&#x2019;s specific circumstances.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="c0" id="ixv-12718">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Below
are the exchange rate of the U.S. dollar in relation to the NIS:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange&#160;rate&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    $ 1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.519&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <ifrs-full:AverageForeignExchangeRate contextRef="c0" decimals="3" id="ixv-19660" unitRef="pure">3.627</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c4" decimals="3" id="ixv-19661" unitRef="pure">3.519</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c0" id="ixv-12860">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOTE 3:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;MATERIAL
                                            ACCOUNTING POLICIES&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
accounting policies have been consistently applied to all the years presented, unless otherwise stated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 74.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unamortized
                                            intangible assets (licenses and patent rights):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
assets are reviewed for impairment once a year and whenever there are indicators of a possible impairment, in accordance with the provisions
of IAS 36, &lt;i&gt;Impairment of Assets&lt;/i&gt; (see also Note 8). The amortization of an asset on a straight-line basis over its useful life
begins when the development procedure is completed and the asset is available for use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
                                            and development:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
expenditures are recognized as expenses when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets which are not yet available for use are not amortized and impairment in their respect is tested at least every year. Depreciable
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable
amount is the higher of an asset&#x2019;s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets
are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-financial
assets that sustained impairment are reviewed for possible reversal of the impairment at each date of the statement of financial position.
Company&#x2019;s intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested at
least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investments and other financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group classifies its equity investments as financial assets at fair value through profit or loss (FVPL).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group operates share-based payment plan to employees, directors, officers and to other service providers who render services that are
settled with the Group&#x2019;s equity instruments. In this framework, the Company grants employees, directors, officers and other service
providers, from time to time, and, at its discretion, options to purchase shares of the Company. The fair value of options granted is
measured according to the Black-Scholes model as of the date of grant (the date of the Company's Board of Directors' decision unless
shareholders&#x2019; approval is required) and recognized as an expense in the statement of comprehensive income (loss) and correspondingly
carried to equity. The total amount recognized as an expense over the vesting term of the options (the term over which all pre-established
vesting conditions are expected to be satisfied) is determined by reference to the fair value of the options granted at grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
each reporting date, the Company revises its estimates of the number of options that are expected to vest based on the non-market vesting
conditions and recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive income (loss) with
a corresponding adjustment in equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;When
options are exercised, the Company issues new shares. The proceeds net of any directly attributable transaction costs are credited to
share capital (nominal value) and share premium.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left; padding-right: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Earning (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
earning (loss) per share is calculated by dividing the earnings attributable to equity holders of the Company by the weighted average
number of ordinary shares outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average
number of shares and ordinary shares that are potentially issuable in connection with service-provider share-based payment and warrants,
using the treasury stock method. If the inclusion of potentially issuable shares would decrease loss per share, the potentially issuable
shares are excluded from the weighted average number of shares outstanding used to calculate diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;f.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IFRS
16 requiring lessees to recognize a liability for a lease, reflecting the discounted value of future lease payments, and a &#x201c;right
to use&#x201d; asset, with respect to all leases (except as stated below), with no distinction between financing lease and operating lease.
However, IFRS 16 allows lessees not to apply these provisions for short-term leases, by groups of underlying assets, and for leases in
which the underlying asset of the lease is of low value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company elected to apply the practical expedient for short-term leases (leases with a lease term of 12 months or less).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company leases an office. The Company has a termination option with a notice period of 60 days. Therefore, the enforceable period of
the lease is 60 days, and the lease qualifies for the short-term lease exemption.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c0" id="ixv-12873">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 74.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unamortized
                                            intangible assets (licenses and patent rights):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
assets are reviewed for impairment once a year and whenever there are indicators of a possible impairment, in accordance with the provisions
of IAS 36, &lt;i&gt;Impairment of Assets&lt;/i&gt; (see also Note 8). The amortization of an asset on a straight-line basis over its useful life
begins when the development procedure is completed and the asset is available for use.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
                                            and development:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
expenditures are recognized as expenses when incurred.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c0" id="ixv-12914">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets which are not yet available for use are not amortized and impairment in their respect is tested at least every year. Depreciable
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable
amount is the higher of an asset&#x2019;s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets
are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-financial
assets that sustained impairment are reviewed for possible reversal of the impairment at each date of the statement of financial position.
Company&#x2019;s intangible asset is not yet available for use and therefore not amortized, an impairment in its respect is tested at
least every year. In addition, discretion is exercised as to whether there is an indication to examine impairment more frequently.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="c0" id="ixv-12934">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investments and other financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group classifies its equity investments as financial assets at fair value through profit or loss (FVPL).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-12993">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group operates share-based payment plan to employees, directors, officers and to other service providers who render services that are
settled with the Group&#x2019;s equity instruments. In this framework, the Company grants employees, directors, officers and other service
providers, from time to time, and, at its discretion, options to purchase shares of the Company. The fair value of options granted is
measured according to the Black-Scholes model as of the date of grant (the date of the Company's Board of Directors' decision unless
shareholders&#x2019; approval is required) and recognized as an expense in the statement of comprehensive income (loss) and correspondingly
carried to equity. The total amount recognized as an expense over the vesting term of the options (the term over which all pre-established
vesting conditions are expected to be satisfied) is determined by reference to the fair value of the options granted at grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
each reporting date, the Company revises its estimates of the number of options that are expected to vest based on the non-market vesting
conditions and recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive income (loss) with
a corresponding adjustment in equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;When
options are exercised, the Company issues new shares. The proceeds net of any directly attributable transaction costs are credited to
share capital (nominal value) and share premium.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0" id="ixv-13018">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left; padding-right: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Earning (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
earning (loss) per share is calculated by dividing the earnings attributable to equity holders of the Company by the weighted average
number of ordinary shares outstanding during the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average
number of shares and ordinary shares that are potentially issuable in connection with service-provider share-based payment and warrants,
using the treasury stock method. If the inclusion of potentially issuable shares would decrease loss per share, the potentially issuable
shares are excluded from the weighted average number of shares outstanding used to calculate diluted earnings per share.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-13039">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;f.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IFRS
16 requiring lessees to recognize a liability for a lease, reflecting the discounted value of future lease payments, and a &#x201c;right
to use&#x201d; asset, with respect to all leases (except as stated below), with no distinction between financing lease and operating lease.
However, IFRS 16 allows lessees not to apply these provisions for short-term leases, by groups of underlying assets, and for leases in
which the underlying asset of the lease is of low value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company elected to apply the practical expedient for short-term leases (leases with a lease term of 12 months or less).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company leases an office. The Company has a termination option with a notice period of 60 days. Therefore, the enforceable period of
the lease is 60 days, and the lease qualifies for the short-term lease exemption.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="c0" id="ixv-13095">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 4:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;FINANCIAL
                                            INSTRUMENTS AND FINANCIAL RISK MANAGEMENT&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
                                            risk management:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
                                            risk factors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group&#x2019;s activities expose it to a variety of financial risks: market risks and liquidity risk. The Group&#x2019;s overall risk management
program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group&#x2019;s financial
performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk
management is carried out by the Group&#x2019;s management under policies approved by the Board. The Group&#x2019;s treasury identifies,
evaluates and defines financial risks. The Board provides written principles for overall risk management, as well as written policies
covering specific areas, such as foreign exchange risk, interest rate risk and investment of excess liquidity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 141.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Market
                                            risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Foreign
currency exchange rate risk:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures with respect to the NIS.
Foreign exchange risk arises from assets and liabilities denominated in currency that is other than the functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group treasury&#x2019;s risk management policy is to hold NIS-denominated cash and cash equivalents in the amount of the anticipated NIS-denominated
liabilities for six to twelve consecutive months from time to time and this in line with the directives of the Company&#x2019;s Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023, had the Group&#x2019;s functional currency strengthened by 10% against the NIS with all other variables remaining
constant, loss for the year would have been $144 thousand lower (2022 - loss would have been $152 thousand higher; 2021 - profit approximately
$328 thousand lower), mainly as a result of exchange rate changes on translation of other accounts receivable and exchange rate changes
on NIS-denominated cash and cash equivalents and investment in marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Equity
securities price risk:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
group&#x2019;s exposure to equity securities price risk arises from investments held by the group and classified in the balance sheet
at fair value through profit or loss (currently only the investment in the shares of InterCure Ltd).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 141.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liquidity
                                            risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
flow forecasting is performed by the Group&#x2019;s management both in the entities of the Group and aggregated by the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group&#x2019;s management monitors rolling forecasts of the Group&#x2019;s liquidity requirements to ensure it has sufficient cash to meet
operations. The Group does not use borrowing credit facilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Surplus
cash held to finance operating activities is invested in interest bearing current accounts and time deposits. The Company holds cash
and deposits with banks and financial institutions and in the estimation of management, the credit risk for these financial instruments
is low.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
channels were chosen by reference to their appropriate maturities or liquidity to provide sufficient cash balances to the Group as determined
by the abovementioned forecasts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December&#160;31, 2023 and 2022, the maturity of the Group&#x2019;s financial liabilities are less than one year from each of the reporting
dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 1.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 1.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital
                                            management:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Group&#x2019;s objectives when managing capital are to ensure the Group&#x2019;s ability to continue as a going concern in order to provide
returns on investments for shareholders and benefits for other interested parties and to maintain an optimal capital structure to reduce
the cost of capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
order to maintain or adjust the capital structure, the Group may take a variety of measures such as issue new shares or sell assets to
reduce liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
                                            instruments by category:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
asset of the group is classified in one category: measured subsequently at fair value or through profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023 and 2022, all financial liabilities were classified in one category: Trade and other account payables, measured
at amortized cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in financial liabilities classified as cash flow from finance activities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as
    of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,637&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation during the year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(719&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercises during
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(864&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation during
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation during the year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <xtlb:PercentageOfFunctionalCurrency contextRef="c2" decimals="2" id="ixv-19662" unitRef="pure">0.10</xtlb:PercentageOfFunctionalCurrency>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-19663" unitRef="usd">144000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-19664" unitRef="usd">152000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c5" decimals="-3" id="ixv-19665" unitRef="usd">328000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c0" id="ixv-13330">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in financial liabilities classified as cash flow from finance activities:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as
    of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,637&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation during the year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(719&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercises during
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(864&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation during
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation during the year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance
    as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:FinancialLiabilities contextRef="c37" decimals="-3" id="ixv-19666" unitRef="usd">2637000</ifrs-full:FinancialLiabilities>
    <ifrs-full:SettlementsFairValueMeasurementLiabilities contextRef="c38" decimals="-3" id="ixv-19667" unitRef="usd">719000</ifrs-full:SettlementsFairValueMeasurementLiabilities>
    <xtlb:ExercisesDuringTheYear contextRef="c38" decimals="-3" id="ixv-19668" unitRef="usd">864000</xtlb:ExercisesDuringTheYear>
    <ifrs-full:FinancialLiabilities contextRef="c39" decimals="-3" id="ixv-19669" unitRef="usd">1054000</ifrs-full:FinancialLiabilities>
    <ifrs-full:SettlementsFairValueMeasurementLiabilities contextRef="c40" decimals="-3" id="ixv-19670" unitRef="usd">1054000</ifrs-full:SettlementsFairValueMeasurementLiabilities>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-13455">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 5:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;CASH
                                            AND CASH EQUIVALENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash in banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,413&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank deposits with original
    maturities of three months or less*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,268&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;681&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,401&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deposits with maturity of less than three months, which in 2023 bear an interest of 4.41%-5.1% per annum (in 2022: 4.5 %).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
currencies in which the cash and cash equivalents are denominated or linked to are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,009&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NIS (not linked to the
    Israeli CPI)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,401&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory contextRef="c0" id="ixv-13467">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash in banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,413&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank deposits with original
    maturities of three months or less*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,268&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;681&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,401&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deposits with maturity of less than three months, which in 2023 bear an interest of 4.41%-5.1% per annum (in 2022: 4.5 %).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory>
    <ifrs-full:CashOnHand contextRef="c2" decimals="-3" id="ixv-19671" unitRef="usd">133000</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand contextRef="c3" decimals="-3" id="ixv-19672" unitRef="usd">1413000</ifrs-full:CashOnHand>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="-3" id="ix_0_fact" unitRef="usd">1268000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ix_1_fact" unitRef="usd">681000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-19675" unitRef="usd">1401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-19676" unitRef="usd">2094000</ifrs-full:CashAndCashEquivalents>
    <xtlb:DepositsWithMaturity contextRef="c0" id="ixv-19677">P3M</xtlb:DepositsWithMaturity>
    <ifrs-full:BorrowingsInterestRate contextRef="c44" decimals="4" id="ixv-19678" unitRef="pure">0.0441</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate contextRef="c45" decimals="3" id="ixv-19679" unitRef="pure">0.051</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate contextRef="c3" decimals="3" id="ixv-19680" unitRef="pure">0.045</ifrs-full:BorrowingsInterestRate>
    <xtlb:DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock contextRef="c0" id="ixv-13607">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
currencies in which the cash and cash equivalents are denominated or linked to are:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;382&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,009&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NIS (not linked to the
    Israeli CPI)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,401&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:DisclosureOfDetailedInformationAboutCurrenciesCashAndCashEquivalentsDenominatedExplanatoryTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c46" decimals="-3" id="ixv-19681" unitRef="usd">382000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c47" decimals="-3" id="ixv-19682" unitRef="usd">2009000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c48" decimals="-3" id="ixv-19683" unitRef="usd">1019000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c49" decimals="-3" id="ixv-19684" unitRef="usd">85000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-19685" unitRef="usd">1401000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-19686" unitRef="usd">2094000</ifrs-full:CashAndCashEquivalents>
    <xtlb:MarketableSecuritiesInterCureLtdTextBlock contextRef="c0" id="ixv-13775">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 6:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;MARKETABLE
                                            SECURITIES &#x2013; InterCure Ltd&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;All
                                            marketable securities held by the Company constitute Level 1 financial instruments, as defined
                                            in IFRS 13 - &#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt;&#x201d;. Level 1 inputs are quoted prices
                                            (unadjusted) in active markets for identical assets or liabilities that the entity can access
                                            at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company holds the following financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities - InterCure Ltd&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;605&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of December 31,
2023 and 2022 the Company holds approximately 1.04% of InterCure Ltd&#x2019;s shares (the shares are traded at the Tel-Aviv Stock Exchange
- &#x201c;TASE&#x201d; and at the Nasdaq Capital Market - &#x201c;Nasdaq&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: left; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value opening balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,158&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,411&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes
    in fair value during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,531&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;747&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value closing balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;605&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:MarketableSecuritiesInterCureLtdTextBlock>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-13803">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company holds the following financial instruments:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities - InterCure Ltd&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;605&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <xtlb:CurrentMarketableSecurities contextRef="c2" decimals="-3" id="ixv-19687" unitRef="usd">605000</xtlb:CurrentMarketableSecurities>
    <xtlb:CurrentMarketableSecurities contextRef="c3" decimals="-3" id="ixv-19688" unitRef="usd">1627000</xtlb:CurrentMarketableSecurities>
    <xtlb:PercentageOfHoldingShare contextRef="c0" decimals="4" id="ixv-19689" unitRef="pure">0.0104</xtlb:PercentageOfHoldingShare>
    <xtlb:DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock contextRef="c0" id="ixv-13888">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value opening balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,627&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,158&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,411&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes
    in fair value during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,531&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;747&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value closing balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;605&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,627&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:DisclosureOfDetailedInformationAboutMarketableSecuritiesExplanatoryTableTextBlock>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c3" decimals="-3" id="ixv-19690" unitRef="usd">1627000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c22" decimals="-3" id="ixv-19691" unitRef="usd">3158000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c31" decimals="-3" id="ixv-19692" unitRef="usd">2411000</ifrs-full:FinancialAssetsAvailableforsale>
    <xtlb:GainsLossesOnFairValueOnMarketableSecurities contextRef="c0" decimals="-3" id="ixv-19693" unitRef="usd">-1022000</xtlb:GainsLossesOnFairValueOnMarketableSecurities>
    <xtlb:GainsLossesOnFairValueOnMarketableSecurities contextRef="c4" decimals="-3" id="ixv-19694" unitRef="usd">-1531000</xtlb:GainsLossesOnFairValueOnMarketableSecurities>
    <xtlb:GainsLossesOnFairValueOnMarketableSecurities contextRef="c5" decimals="-3" id="ixv-19695" unitRef="usd">747000</xtlb:GainsLossesOnFairValueOnMarketableSecurities>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c2" decimals="-3" id="ixv-19696" unitRef="usd">605000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c3" decimals="-3" id="ixv-19697" unitRef="usd">1627000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c22" decimals="-3" id="ixv-19698" unitRef="usd">3158000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory contextRef="c0" id="ixv-14067">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 7:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;PREPAID
                                            EXPENSES AND OTHE CURRENT ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Composition:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government
    authorities (*)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The government authorities are monetary items, which are denominated or linked is NIS.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying amount of government authorities is a reasonable approximation of the fair value because the effect of discounting is immaterial.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="c0" id="ixv-14080">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Composition:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Government
    authorities (*)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The government authorities are monetary items, which are denominated or linked is NIS.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c2" decimals="-3" id="ixv-19699" unitRef="usd">29000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c3" decimals="-3" id="ixv-19700" unitRef="usd">71000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <xtlb:GovernmentAuthorities contextRef="c2" decimals="-3" id="ix_2_fact" unitRef="usd">11000</xtlb:GovernmentAuthorities>
    <xtlb:GovernmentAuthorities contextRef="c3" decimals="-3" id="ix_3_fact" unitRef="usd">14000</xtlb:GovernmentAuthorities>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" id="ixv-19703" unitRef="usd">40000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" id="ixv-19704" unitRef="usd">85000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c0" id="ixv-14261">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 8:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;INTANGIBLE
                                            ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
                                            January 7, 2014, the Company signed a licensing agreement with Yeda, as amended on September
                                            6, 2015, to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus
                                            (&#x201c;SLE&#x201d;). The license from Yeda also included all clinical data of the phase 1
                                            and phase 2A conducted in the hCDR1. The terms of the licensing agreement include, among
                                            other things, expense reimbursement for patent expenses payable in six installments, certain
                                            milestone payments to Yeda, low single-digit royalties based on net sales, and additional
                                            customary royalties to the Office of the Israel innovation authority.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Under
the license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical
trial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European
Union&#x2019;s Group of Five. In addition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20%
of whatever it receives from any sub-licensee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Under
the license agreement, the Company is also required to meet certain development milestones including the delivery of a trial protocol
to Yeda by January 1, 2016 (which it delivered), receipt of investment of at least $5 million by August 1, 2016 (of which $4 million
was received in April 2015) and commencement of a Phase II clinical trial by January 1, 2017. In subsequent amendments signed between
the Company and Yeda, the parties agreed to postpone the last two installments of the patent expense reimbursement until April 7, 2017,
receipt of the remainder of the required $5 million investment by May 1, 2017 and commencement of a Phase 2 clinical trial in respect
of hCDR1 by October 1, 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
term of the license agreement is the later of the date of expiry of the last of the licensed patents or the expiry of a continuous period
of 11 years after first commercial sale in any country during which there shall not have been a first commercial sale in the U.S., EU,
Japan, China or any OECD member. The license agreement may be terminated by the Company without cause upon 60 days prior written notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
license agreement may also be terminated by Yeda upon 45 days prior written notice if either the Company fails to meet certain development
milestones or commercial sale shall have commenced and there shall be a period of 6 months of no sales, subject to certain exceptions.
Yeda shall also be entitled to terminate the license agreement if the Company were to commence legal action against Yeda challenging
the validity of any of the licensed patents, and the Company was unsuccessful in such challenge, in which event the Company would be
required to pay to Yeda liquidated damages of $8 million. Either party may also terminate the license agreement in the case of a material
breach that remains uncured or certain bankruptcy events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023, all expense reimbursement for patent expenses to Yeda in the amount of $380 thousands were paid, except for a remaining
liability of $127 thousand, disclosed under accounts payable. The reason for the remaining liability is that the Company decided not
to conduct the phase 2 by itself and to look for a strategic partner. As a result, the second milestone (commencement of Phase 2) was
not met yet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accordingly,
the license agreement may be terminated by Yeda upon 45 days prior written notice. To this date the Company and Yeda have held discussions
regarding further amendment to the payment scheme under the license agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company exclusively licensed two families of patents relating to hCDR1:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One
expired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January
14, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company reviews the hCDR1 asset for impairment once a year on December 31 or more frequently if events or changes in circumstances indicate
that there is an impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;If
the carrying amount exceeds their recoverable amount, the assets are reduced to their recoverable amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;This
asset is not ready for usage (the development was paused before finishing) and therefore has not been amortized yet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
order to measure the recoverable amount of the hCDR1 asset,&#160;Company management deducted the fair value of its other assets and liabilities
from the amount representing its market value as of December 31, 2023. The resulting fair value attributable to the hCDR1 asset was higher
than the book value of the hCDR1 asset and therefore no impairment was recorded in the Company's financial statements as of December
31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Composition
                                            and movement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;changes or movements in 2023, 2022 and 2021 and the balance remained
$380 thousands.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <xtlb:LicenseAgreement contextRef="c0" id="ixv-14282">Under
the license agreement, the Company is required to make milestone payments of up to $2.2 million: $200,000 upon starting a Phase 3 clinical
trial, $1 million upon FDA approval to market in the U.S., and $250,000 for marketing approval in each of China and three of the European
Union&#x2019;s Group of Five. In addition, the Company is required to pay 2%-3% royalties of annual net sales and sublicense fees of 15%-20%
of whatever it receives from any sub-licensee.</xtlb:LicenseAgreement>
    <xtlb:PercentageOfRoyalties contextRef="c50" decimals="2" id="ixv-19705" unitRef="pure">0.02</xtlb:PercentageOfRoyalties>
    <xtlb:PercentageOfRoyalties contextRef="c51" decimals="2" id="ixv-19706" unitRef="pure">0.03</xtlb:PercentageOfRoyalties>
    <xtlb:PercentageOfSublicenseFees contextRef="c50" decimals="2" id="ixv-19707" unitRef="pure">0.15</xtlb:PercentageOfSublicenseFees>
    <xtlb:PercentageOfSublicenseFees contextRef="c51" decimals="2" id="ixv-19708" unitRef="pure">0.20</xtlb:PercentageOfSublicenseFees>
    <ifrs-full:InvestmentIncome contextRef="c52" decimals="-6" id="ixv-19709" unitRef="usd">5000000</ifrs-full:InvestmentIncome>
    <ifrs-full:LoansReceived contextRef="c53" decimals="-6" id="ixv-19710" unitRef="usd">4000000</ifrs-full:LoansReceived>
    <xtlb:ReceiptOfRequiredInvestment contextRef="c54" decimals="-6" id="ixv-19711" unitRef="usd">5000000</xtlb:ReceiptOfRequiredInvestment>
    <xtlb:ExpirTerm contextRef="c0" id="ixv-19712">P11Y</xtlb:ExpirTerm>
    <ifrs-full:ReceivablesFromContractsWithCustomers contextRef="c2" decimals="-6" id="ixv-19713" unitRef="usd">8000000</ifrs-full:ReceivablesFromContractsWithCustomers>
    <xtlb:RemainingLiability contextRef="c0" decimals="-3" id="ixv-19714" unitRef="usd">380000</xtlb:RemainingLiability>
    <xtlb:RemainingLiability contextRef="c55" decimals="-3" id="ixv-19715" unitRef="usd">127000</xtlb:RemainingLiability>
    <xtlb:IntangibleAssetOtherInformationMaturityDate contextRef="c0" id="ixv-14353">The
Company exclusively licensed two families of patents relating to hCDR1:One
expired on September 22, 2022 (in the US. For all other countries, it expired on February 26, 2022) and the other expired on January
14, 2024.</xtlb:IntangibleAssetOtherInformationMaturityDate>
    <xtlb:AssetsRemainedAmount contextRef="c0" decimals="-3" id="ixv-19716" unitRef="usd">380000</xtlb:AssetsRemainedAmount>
    <xtlb:AssetsRemainedAmount contextRef="c4" decimals="-3" id="ixv-19717" unitRef="usd">380000</xtlb:AssetsRemainedAmount>
    <xtlb:AssetsRemainedAmount contextRef="c5" decimals="-3" id="ixv-19718" unitRef="usd">380000</xtlb:AssetsRemainedAmount>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-14395">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
                            9:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;ACCOUNTS
                                            PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Composition:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;206&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying amount of accounts payable is a reasonable approximation of their fair value because the effect of discounting is immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The carrying amount of accounts payable is denominated in the following currencies:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;157&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;137&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NIS
    (not linked to the Israeli CPI)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;206&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock contextRef="c0" id="ixv-14414">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Composition:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;205&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;206&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:ScheduleOfCompositionOfAccountsPayableTextBlock>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-19719" unitRef="usd">1000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-19720" unitRef="usd">2000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c2" decimals="-3" id="ixv-19721" unitRef="usd">205000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c3" decimals="-3" id="ixv-19722" unitRef="usd">185000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-19723" unitRef="usd">206000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-19724" unitRef="usd">187000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <xtlb:ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock contextRef="c0" id="ixv-14602">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The carrying amount of accounts payable is denominated in the following currencies:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;157&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;137&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NIS
    (not linked to the Israeli CPI)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;206&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:ScheduleOfCarryingAmountOfOtherAccountsPayableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c56" decimals="-3" id="ixv-19725" unitRef="usd">157000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c57" decimals="-3" id="ixv-19726" unitRef="usd">137000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c58" decimals="-3" id="ixv-19727" unitRef="usd">49000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c59" decimals="-3" id="ixv-19728" unitRef="usd">50000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-19729" unitRef="usd">206000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-19730" unitRef="usd">187000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <xtlb:DisclosureOfWarrantsTextBlock contextRef="c0" id="ixv-14737">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 10:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;WARRANTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2017, the Company raised gross funds amounted to $5,300 thousand by issuance of 2,400,000 ADS's and 2,400,000
warrants to purchase the same amount of ADS's. The warrants shall be exercisable six months following the issuance date and will expire
five and one-half years from the issuance date. The number of warrants and their exercise price could be adjusted upon standard anti-dilution
protection clauses and subject to a cashless exercise mechanism.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IFRS
13 "Fair Value Measurement", ("IFRS 13"), defines fair value as the price that would be received from selling an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;When
determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal
or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the
asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IFRS
13 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level
of input that is significant to the fair value measurement. IFRS 13 establishes three levels of inputs that may be used to measure fair
value.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1 -&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;quoted prices in active markets for identical
    assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2 -&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;inputs other than Level 1 that are observable,
    either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical
    or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3 -&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;unobservable inputs that are supported by
    little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounted for the warrants issued to investors with a cashless exercise mechanism as a non-current liability according to provisions
of IAS 32. The Company measured the warrants at fair value by using a Black-Scholes model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
warrants were measured in each reporting period. Changes in the fair value were recognized in the Company`s statement of comprehensive
income (loss) as financial income or expense, as appropriate. The warrants were classified as level&#160;3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company used the following assumptions to estimate the Investors' warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
    interest rate (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    volatility (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;60.83-62.46&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual
    term life (in years) (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.63-0.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend
    yield (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; -sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
life - the expected life was based on the expiration date of the warrants.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
more information about the warrants exercised during 2021, see Note 18.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
2022, all warrants have expired and as such, as of December 31, 2023 and 2022 there are no outstanding warrants.&lt;/span&gt;&lt;/p&gt;</xtlb:DisclosureOfWarrantsTextBlock>
    <xtlb:GrossFundRaised contextRef="c60" decimals="-3" id="ixv-19731" unitRef="usd">5300000</xtlb:GrossFundRaised>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c61"
      decimals="0"
      id="ixv-19732"
      unitRef="shares">2400000</ifrs-full:NumberOfSharesIssued>
    <xtlb:WarrantsIssued
      contextRef="c62"
      decimals="0"
      id="ixv-19733"
      unitRef="shares">2400000</xtlb:WarrantsIssued>
    <xtlb:DescriptionOfWarrantsExercisable contextRef="c0" id="ixv-19734">The warrants shall be exercisable six months following the issuance date and will expire
five and one-half years from the issuance date.</xtlb:DescriptionOfWarrantsExercisable>
    <ifrs-full:InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted contextRef="c0" id="ixv-19735">the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal
or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the
asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.</ifrs-full:InformationAboutHowExpectedVolatilityWasDeterminedShareOptionsGranted>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="c0" id="ixv-14849">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company used the following assumptions to estimate the Investors' warrants:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
    interest rate (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
    volatility (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;60.83-62.46&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual
    term life (in years) (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.63-0.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend
    yield (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-44; -sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected
life - the expected life was based on the expiration date of the warrants.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c5" decimals="4" id="ix_4_fact" unitRef="pure">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c63" decimals="4" id="ix_5_fact" unitRef="pure">0.6083</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c64" decimals="4" id="ix_6_fact" unitRef="pure">0.6246</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c63" id="ix_7_fact">P0Y7M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c64" id="ix_8_fact">P0Y8M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c5" decimals="2" id="ix_9_fact" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <xtlb:ShareCapitalReservesAndRetainedEarnings contextRef="c0" id="ixv-15070">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
                            11:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;SHARE
                                            CAPITAL, RESERVES AND ACCUMULATED DEFICIT&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company&#x2019;s Ordinary shares of NIS&#160;0.1 par value are traded on the TASE. The Company&#x2019;s ADSs are listed for trading on the Nasdaq Capital Market in the U.S. Each ADS consist of 100 Company&#x2019;s Ordinary shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary
shares confer upon their holders voting rights and right to participate in the shareholders&#x2019; meeting, right to receive dividends
and the right to participate in the excess of assets upon liquidation of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company&#x2019;s authorized share capital is 1,450,000,000 Ordinary Shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xtlb:ShareCapitalReservesAndRetainedEarnings>
    <ifrs-full:ParValuePerShare
      contextRef="c65"
      decimals="1"
      id="ixv-19742"
      unitRef="ilsPershares">0.1</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c65"
      decimals="0"
      id="ixv-19743"
      unitRef="shares">1450000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-15137">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOTE
                            12:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;SHARE-BASED
                                            &lt;b&gt;PAYMENT&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 29, 2011, the Company&#x2019;s Board of Directors approved the adoption of an employee share option plan for the grant of options
exercisable into shares of the Company, in accordance with section 102 to the Israeli Tax Ordinance (the &#x201c;2011 Plan&#x201d;) which
ended after 10 years, and the holding of up to 10,000,000 shares in the framework of the 2011 Plan, for option allocation to Company
employees, directors and consultants. The terms of the options, which will be granted according to the 2011 Plan, including the option
period, exercise price, vesting period and exercise period shall be determined by the Company&#x2019;s Board of Directors on the date
of the actual allocation. On January 29, 2020, it was decided to increase the reserve by 10 million and on May 19, 2020 it was decided
to increase the reserve by another 10 million options. The total reserve after these increases is 30 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December&#160;31, 2023, the remaining number of options available for grant under the 2011 Plan is 17,450,000 options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 2, 2023, the Company&#x2019;s shareholders approved the grant of options exercisable into 150,000 of the Company&#x2019;s ordinary
shares to one of Company&#x2019;s directors for an exercise price of NIS 0.0495 per share (USD 0.014 per share, respectively, based on
the exchange rate reported by the Bank of Israel on the same day). The options were fully vested on the day of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 14, 2023, Company&#x2019;s Board of directors approved retroactively to extend the expire date of the 2011 plan by additional 5
years to August 29, 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regarding
options granted subsequent to balance sheet date and the extension of exercise period for certain directors, refer to Note 19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Movements
in the number of share options and their related weighted average exercise prices (in dollars) during the years ended December 31, 2023,
2022 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; exercise&lt;br/&gt; price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.07&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,433,331&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(366,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at end of
    year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at end of
    year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,733,330&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,399,998&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Below
is information about the exercise price (in dollars) and the remaining contractual life (in years) for options outstanding at end of
year:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;br/&gt;
    outstanding at&lt;br/&gt;
 end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range
    of&lt;br/&gt; exercise prices&lt;br/&gt; (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;br/&gt;
    outstanding at &lt;br/&gt; end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range
    of&lt;br/&gt; exercise prices&lt;br/&gt; (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; remaining&lt;br/&gt; contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.03 - 0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.03 - 0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    &lt;br/&gt; outstanding at&lt;br/&gt;
    end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range
    of&lt;br/&gt; exercise prices &lt;br/&gt; (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 31%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 31%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.03 - 0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 30%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.66&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share
based expenses recognized in the Company&#x2019;s statements of comprehensive income (loss) for the years ended December 31, 2023, 2022
and 2021 for grant of options to employees and service providers were $3, $14 and $37 thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below summarizes the outstanding options as of December 31, 2023 that have been granted to the Company&#x2019;s executives, directors
and consultants &#x2013;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    &lt;br/&gt; &#160;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Position&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;date
                                            (*)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;br/&gt;
    price in&lt;br/&gt;
    NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
                                            value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;USD
                                            in&lt;br/&gt;
                                            thousands&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vesting
    schedule&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 13%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Four Directors&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 30, 2014&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.4325-0.4915&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One Director&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Chairman of Board&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12 equal portions each quarter over a period of 3 years from the date of grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Chief Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 7, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12 equal portions each quarter over a period of 3 years from the grant date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Director&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.0495&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fully vested on date of grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Date of the Company's Board of Directors&#x2019; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value for options granted in 2023 is estimated at the date of grant using a Black-Scholes model with the following weighted average
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
have calculated the volatility based on the Company's historical volatility. The share price was set according to the Company's share
market value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;No
options were granted in 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <xtlb:SharebasedPaymentAwardRemainingContractualTerm contextRef="c66" id="ixv-19744">P10Y</xtlb:SharebasedPaymentAwardRemainingContractualTerm>
    <xtlb:NumberOfShareExercisableInSharebasedPaymentArrangement
      contextRef="c67"
      decimals="0"
      id="ixv-19745"
      unitRef="shares">10000000</xtlb:NumberOfShareExercisableInSharebasedPaymentArrangement>
    <xtlb:IncreaseOfReserve
      contextRef="c68"
      decimals="-6"
      id="ixv-19746"
      unitRef="shares">10000000</xtlb:IncreaseOfReserve>
    <xtlb:IncreaseOfReserve
      contextRef="c69"
      decimals="-6"
      id="ixv-19747"
      unitRef="shares">10000000</xtlb:IncreaseOfReserve>
    <xtlb:OptionsReserve
      contextRef="c70"
      decimals="-6"
      id="ixv-19748"
      unitRef="shares">30000000</xtlb:OptionsReserve>
    <xtlb:RemainingNumberOfOptionsAvailableForGrant
      contextRef="c2"
      decimals="0"
      id="ixv-19749"
      unitRef="shares">17450000</xtlb:RemainingNumberOfOptionsAvailableForGrant>
    <xtlb:OptionsExercisableIntoOrdinaryShares
      contextRef="c71"
      decimals="0"
      id="ixv-19750"
      unitRef="shares">150000</xtlb:OptionsExercisableIntoOrdinaryShares>
    <xtlb:OrdinarySharesExercisePrice
      contextRef="c71"
      decimals="4"
      id="ixv-19751"
      unitRef="ilsPershares">0.0495</xtlb:OrdinarySharesExercisePrice>
    <xtlb:OrdinarySharesExercisePrice
      contextRef="c71"
      decimals="3"
      id="ixv-19752"
      unitRef="usdPershares">0.014</xtlb:OrdinarySharesExercisePrice>
    <xtlb:ExtendedExpiryTerm contextRef="c72" id="ixv-19753">P5Y</xtlb:ExtendedExpiryTerm>
    <xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock contextRef="c0" id="ixv-15169">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Movements
in the number of share options and their related weighted average exercise prices (in dollars) during the years ended December 31, 2023,
2022 and 2021 are as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; exercise&lt;br/&gt; price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,200,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.07&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,433,331&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(366,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at end of
    year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at end of
    year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,733,330&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,399,998&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</xtlb:DisclosureOfDetailedInformationAboutNumberAndWeightedAverageExercisePricesOfShareOptionsTableTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c73" decimals="0" id="ixv-19754" unitRef="pure">12400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c73"
      decimals="2"
      id="ixv-19755"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c74" decimals="0" id="ixv-19756" unitRef="pure">12400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c74"
      decimals="2"
      id="ixv-19757"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c75" decimals="0" id="ixv-19758" unitRef="pure">16200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c75"
      decimals="2"
      id="ixv-19759"
      unitRef="usdPershares">0.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c76" decimals="0" id="ixv-19760" unitRef="pure">150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c76"
      decimals="2"
      id="ixv-19761"
      unitRef="usdPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c78" decimals="0" id="ixv-19762" unitRef="pure">3433331</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c78"
      decimals="2"
      id="ixv-19763"
      unitRef="usdPershares">0.16</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c78" decimals="0" id="ixv-19764" unitRef="pure">366669</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c78"
      decimals="2"
      id="ixv-19765"
      unitRef="usdPershares">0.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c79" decimals="0" id="ixv-19766" unitRef="pure">12550000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c79"
      decimals="2"
      id="ixv-19767"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c73" decimals="0" id="ixv-19768" unitRef="pure">12400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c73"
      decimals="2"
      id="ixv-19769"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c74" decimals="0" id="ixv-19770" unitRef="pure">12400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c74"
      decimals="2"
      id="ixv-19771"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c79" decimals="0" id="ixv-19772" unitRef="pure">12550000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c79"
      decimals="2"
      id="ixv-19773"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c73" decimals="0" id="ixv-19774" unitRef="pure">10733330</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c73"
      decimals="2"
      id="ixv-19775"
      unitRef="usdPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c74" decimals="0" id="ixv-19776" unitRef="pure">7399998</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c74"
      decimals="2"
      id="ixv-19777"
      unitRef="usdPershares">0.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <xtlb:DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock contextRef="c0" id="ixv-15802">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Below
is information about the exercise price (in dollars) and the remaining contractual life (in years) for options outstanding at end of
year:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;br/&gt;
    outstanding at&lt;br/&gt;
 end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range
    of&lt;br/&gt; exercise prices&lt;br/&gt; (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;br/&gt;
    outstanding at &lt;br/&gt; end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range
    of&lt;br/&gt; exercise prices&lt;br/&gt; (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    average&lt;br/&gt; remaining&lt;br/&gt; contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.03 - 0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.03 - 0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    &lt;br/&gt; outstanding at&lt;br/&gt;
    end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range
    of&lt;br/&gt; exercise prices &lt;br/&gt; (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 31%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 31%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.03 - 0.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 30%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.94&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.66&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,400,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:DisclosureOfDetailedInformationAboutExercisePriceAndContractualLifeForOptionsOutstandingTableTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c80" decimals="0" id="ixv-19778" unitRef="pure">10900000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c81"
      decimals="2"
      id="ixv-19779"
      unitRef="usdPershares">0.03</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c82"
      decimals="2"
      id="ixv-19780"
      unitRef="usdPershares">0.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c83" id="ixv-15928">P6Y25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c84" decimals="0" id="ixv-19781" unitRef="pure">10900000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c85"
      decimals="2"
      id="ixv-19782"
      unitRef="usdPershares">0.03</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c86"
      decimals="2"
      id="ixv-19783"
      unitRef="usdPershares">0.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c87" id="ixv-15953">P6Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c88" decimals="0" id="ixv-19784" unitRef="pure">1500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c88"
      decimals="2"
      id="ixv-19785"
      unitRef="usdPershares">0.17</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c89" id="ixv-15977">P1Y7M28D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c90" decimals="0" id="ixv-19786" unitRef="pure">1500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c90"
      decimals="2"
      id="ixv-19787"
      unitRef="usdPershares">0.17</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c91" id="ixv-16002">P2Y7M28D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c92" decimals="0" id="ixv-19788" unitRef="pure">150000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c92"
      decimals="2"
      id="ixv-19789"
      unitRef="usdPershares">0.01</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c93" id="ixv-16026">P9Y2M1D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c79" decimals="0" id="ixv-19790" unitRef="pure">12550000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c73" decimals="0" id="ixv-19791" unitRef="pure">12400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c96" decimals="0" id="ixv-19792" unitRef="pure">10900000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c97"
      decimals="2"
      id="ixv-19793"
      unitRef="usdPershares">0.03</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c98"
      decimals="2"
      id="ixv-19794"
      unitRef="usdPershares">0.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c99" id="ixv-16218">P7Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c100"
      decimals="0"
      id="ixv-19795"
      unitRef="pure">1500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c100"
      decimals="2"
      id="ixv-19796"
      unitRef="usdPershares">0.17</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c101" id="ixv-16242">P3Y7M28D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c74" decimals="0" id="ixv-19797" unitRef="pure">12400000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees contextRef="c0" decimals="-3" id="ixv-19798" unitRef="usd">3000</xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees>
    <xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees contextRef="c4" decimals="-3" id="ixv-19799" unitRef="usd">14000</xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees>
    <xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees contextRef="c5" decimals="-3" id="ixv-19800" unitRef="usd">37000</xtlb:ShareBasedPaymentTransactionsToEmployeesAndNonEmployees>
    <xtlb:DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock contextRef="c0" id="ixv-19801">The
table below summarizes the outstanding options as of December 31, 2023 that have been granted to the Company&#x2019;s executives, directors
and consultants &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    &lt;br/&gt; &#160;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Position&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;date
                                            (*)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;br/&gt;
    price in&lt;br/&gt;
    NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
                                            value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;USD
                                            in&lt;br/&gt;
                                            thousands&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vesting
    schedule&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 13%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Four Directors&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 30, 2014&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.4325-0.4915&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One Director&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Chairman of Board&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12 equal portions each quarter over a period of 3 years from the date of grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Chief Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July 7, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12 equal portions each quarter over a period of 3 years from the grant date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Director&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.0495&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fully vested on date of grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,550,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Date of the Company's Board of Directors&#x2019; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;</xtlb:DisclosureOfDetailedInformationAboutOutstandingOptionsTableTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c102"
      decimals="0"
      id="ixv-19802"
      unitRef="pure">750000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition contextRef="c103" id="ixv-16386">Four Directors</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c103" id="ix_10_fact">December 30, 2014</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice
      contextRef="c104"
      decimals="4"
      id="ixv-19803"
      unitRef="ilsPershares">0.4325</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice
      contextRef="c105"
      decimals="4"
      id="ixv-19804"
      unitRef="ilsPershares">0.4915</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="c102"
      decimals="-3"
      id="ixv-19805"
      unitRef="usd">46000</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement contextRef="c103" id="ixv-16412">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c106"
      decimals="0"
      id="ixv-19806"
      unitRef="pure">150000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition contextRef="c107" id="ixv-16424">One Director</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c107" id="ix_11_fact">March 25, 2015</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice
      contextRef="c106"
      decimals="2"
      id="ixv-19807"
      unitRef="ilsPershares">0.4</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="c106"
      decimals="-3"
      id="ixv-19808"
      unitRef="usd">24000</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement contextRef="c107" id="ixv-16450">33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c108"
      decimals="0"
      id="ixv-19809"
      unitRef="pure">1500000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition contextRef="c109" id="ixv-16462">Chairman of Board</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c109" id="ix_12_fact">March 31, 2016</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice
      contextRef="c108"
      decimals="1"
      id="ixv-19810"
      unitRef="ilsPershares">0.6</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="c108"
      decimals="-3"
      id="ixv-19811"
      unitRef="usd">63000</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement contextRef="c109" id="ixv-16488">12 equal portions each quarter over a period of 3 years from the date of grant</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c110"
      decimals="0"
      id="ixv-19812"
      unitRef="pure">10000000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition contextRef="c111" id="ixv-16500">Chief Executive Officer</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c111" id="ix_13_fact">July 7, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice
      contextRef="c110"
      decimals="2"
      id="ixv-19813"
      unitRef="ilsPershares">0.09</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="c110"
      decimals="-3"
      id="ixv-19814"
      unitRef="usd">103000</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement contextRef="c111" id="ixv-16526">12 equal portions each quarter over a period of 3 years from the grant date</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c112"
      decimals="0"
      id="ixv-19815"
      unitRef="pure">150000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition contextRef="c113" id="ixv-16538">Director</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPosition>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c113" id="ix_14_fact">March 2, 2023</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice
      contextRef="c112"
      decimals="4"
      id="ixv-19816"
      unitRef="ilsPershares">0.0495</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice>
    <xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="c112"
      decimals="-3"
      id="ixv-19817"
      unitRef="usd">1000</xtlb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement contextRef="c113" id="ixv-16564">Fully vested on date of grant</ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c2" decimals="0" id="ixv-19818" unitRef="pure">12550000</ifrs-full:NumberOfOutstandingShareOptions>
    <xtlb:ScheduleOfFairValueForOptionsGrantedTableTextBlock contextRef="c0" id="ixv-16694">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value for options granted in 2023 is estimated at the date of grant using a Black-Scholes model with the following weighted average
assumptions:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:ScheduleOfFairValueForOptionsGrantedTableTextBlock>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c114"
      decimals="2"
      id="ixv-19819"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c114"
      decimals="3"
      id="ixv-19820"
      unitRef="pure">0.675</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c114"
      decimals="4"
      id="ixv-19821"
      unitRef="pure">0.0408</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c114" id="ixv-16759">P10Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-16775">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 13:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RESEARCH
                                            AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 67%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fees
    related to service providers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock contextRef="c0" id="ixv-16787">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 67%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fees
    related to service providers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesTableTextBlock>
    <xtlb:FeesRelatedToServiceProviders contextRef="c0" decimals="-3" id="ixv-19822" unitRef="usd">31000</xtlb:FeesRelatedToServiceProviders>
    <xtlb:FeesRelatedToServiceProviders contextRef="c4" decimals="-3" id="ixv-19823" unitRef="usd">30000</xtlb:FeesRelatedToServiceProviders>
    <xtlb:FeesRelatedToServiceProviders contextRef="c5" decimals="-3" id="ixv-19824" unitRef="usd">30000</xtlb:FeesRelatedToServiceProviders>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c0" id="ixv-16887">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE&lt;/b&gt; 14:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt; GENERAL AND ADMINISTRATIVE EXPENSES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 67%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management fees and expenses relating
    to service providers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payment expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents and fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;137&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investor relations and travel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Rent and office maintenance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;330&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;381&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,001&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c0" id="ixv-16900">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 67%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management fees and expenses relating
    to service providers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payment expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents and fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;137&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Directors&#x2019; fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Investor relations and travel&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Rent and office maintenance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;202&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;330&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;381&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,001&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:WagesAndSalaries contextRef="c0" decimals="-3" id="ixv-19825" unitRef="usd">107000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c4" decimals="-3" id="ixv-19826" unitRef="usd">117000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c5" decimals="-3" id="ixv-19827" unitRef="usd">123000</ifrs-full:WagesAndSalaries>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c0" decimals="-3" id="ixv-19828" unitRef="usd">3000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c4" decimals="-3" id="ixv-19829" unitRef="usd">14000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c5" decimals="-3" id="ixv-19830" unitRef="usd">37000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <xtlb:PatentsAndFees contextRef="c0" decimals="-3" id="ixv-19831" unitRef="usd">94000</xtlb:PatentsAndFees>
    <xtlb:PatentsAndFees contextRef="c4" decimals="-3" id="ixv-19832" unitRef="usd">141000</xtlb:PatentsAndFees>
    <xtlb:PatentsAndFees contextRef="c5" decimals="-3" id="ixv-19833" unitRef="usd">137000</xtlb:PatentsAndFees>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c0" decimals="-3" id="ixv-19834" unitRef="usd">60000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c4" decimals="-3" id="ixv-19835" unitRef="usd">68000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense contextRef="c5" decimals="-3" id="ixv-19836" unitRef="usd">64000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:TravelExpense contextRef="c5" decimals="-3" id="ixv-19837" unitRef="usd">3000</ifrs-full:TravelExpense>
    <xtlb:RentAndOfficeMaintenance contextRef="c0" decimals="-3" id="ixv-19838" unitRef="usd">12000</xtlb:RentAndOfficeMaintenance>
    <xtlb:RentAndOfficeMaintenance contextRef="c4" decimals="-3" id="ixv-19839" unitRef="usd">6000</xtlb:RentAndOfficeMaintenance>
    <xtlb:RentAndOfficeMaintenance contextRef="c5" decimals="-3" id="ixv-19840" unitRef="usd">15000</xtlb:RentAndOfficeMaintenance>
    <ifrs-full:InsuranceExpense contextRef="c0" decimals="-3" id="ixv-19841" unitRef="usd">119000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c4" decimals="-3" id="ixv-19842" unitRef="usd">202000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c5" decimals="-3" id="ixv-19843" unitRef="usd">229000</ifrs-full:InsuranceExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c0" decimals="-3" id="ixv-19844" unitRef="usd">330000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c4" decimals="-3" id="ixv-19845" unitRef="usd">291000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c5" decimals="-3" id="ixv-19846" unitRef="usd">381000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:OtherExpenseByNature contextRef="c0" decimals="-3" id="ixv-19847" unitRef="usd">9000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c4" decimals="-3" id="ixv-19848" unitRef="usd">11000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c5" decimals="-3" id="ixv-19849" unitRef="usd">12000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-19850" unitRef="usd">734000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ixv-19851" unitRef="usd">850000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-19852" unitRef="usd">1001000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c0" id="ixv-17294">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 15:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;FINANCE
                                            INCOME (EXPENSES), NET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,531&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank account management fees and commissions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange rate differences&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total finance expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,058&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,558&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance income:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of warrants to purchase ADS's&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;719&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;747&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest income on bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange rate differences&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total finance income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,090&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,487&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance income (expenses), net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,017&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(468&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock contextRef="c0" id="ixv-17306">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,531&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank account management fees and commissions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange rate differences&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total finance expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,058&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,558&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance income:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of warrants to purchase ADS's&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;719&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;747&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest income on bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exchange rate differences&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total finance income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,090&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,487&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance income (expenses), net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,017&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(468&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:ScheduleOfDetailsInformationAboutFinanceIncomeExpenseExplanatoryTableTextBlock>
    <xtlb:FinanceExpensesRevaluationOfMarketableSecurities contextRef="c0" decimals="-3" id="ixv-19853" unitRef="usd">-1022000</xtlb:FinanceExpensesRevaluationOfMarketableSecurities>
    <xtlb:FinanceExpensesRevaluationOfMarketableSecurities contextRef="c4" decimals="-3" id="ixv-19854" unitRef="usd">-1531000</xtlb:FinanceExpensesRevaluationOfMarketableSecurities>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-19855" unitRef="usd">4000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense contextRef="c4" decimals="-3" id="ixv-19856" unitRef="usd">11000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:FeeAndCommissionExpense contextRef="c5" decimals="-3" id="ixv-19857" unitRef="usd">21000</ifrs-full:FeeAndCommissionExpense>
    <xtlb:ExchangeDifferences contextRef="c0" decimals="-3" id="ixv-19858" unitRef="usd">32000</xtlb:ExchangeDifferences>
    <xtlb:ExchangeDifferences contextRef="c4" decimals="-3" id="ixv-19859" unitRef="usd">16000</xtlb:ExchangeDifferences>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-19860" unitRef="usd">1058000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="-3" id="ixv-19861" unitRef="usd">1558000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c5" decimals="-3" id="ixv-19862" unitRef="usd">21000</ifrs-full:FinanceCosts>
    <xtlb:RevaluationOfWarrantsToPurchaseADSs contextRef="c4" decimals="-3" id="ixv-19863" unitRef="usd">1054000</xtlb:RevaluationOfWarrantsToPurchaseADSs>
    <xtlb:RevaluationOfWarrantsToPurchaseADSs contextRef="c5" decimals="-3" id="ixv-19864" unitRef="usd">719000</xtlb:RevaluationOfWarrantsToPurchaseADSs>
    <xtlb:RevaluationMarketableSecurities contextRef="c5" decimals="-3" id="ixv-19865" unitRef="usd">747000</xtlb:RevaluationMarketableSecurities>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c0" decimals="-3" id="ixv-19866" unitRef="usd">41000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c4" decimals="-3" id="ixv-19867" unitRef="usd">36000</ifrs-full:InterestIncomeOnDeposits>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c5" decimals="-3" id="ixv-19868" unitRef="usd">8000</ifrs-full:InterestIncomeOnDeposits>
    <xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax contextRef="c5" decimals="-3" id="ixv-19869" unitRef="usd">13000</xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-19870" unitRef="usd">41000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-19871" unitRef="usd">1090000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c5" decimals="-3" id="ixv-19872" unitRef="usd">1487000</ifrs-full:FinanceIncome>
    <xtlb:FinanceIncomeexpensesNet contextRef="c0" decimals="-3" id="ixv-19873" unitRef="usd">-1017000</xtlb:FinanceIncomeexpensesNet>
    <xtlb:FinanceIncomeexpensesNet contextRef="c4" decimals="-3" id="ixv-19874" unitRef="usd">-468000</xtlb:FinanceIncomeexpensesNet>
    <xtlb:FinanceIncomeexpensesNet contextRef="c5" decimals="-3" id="ixv-19875" unitRef="usd">1466000</xtlb:FinanceIncomeexpensesNet>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-17778">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 16:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;TAXES
                                            ON INCOME&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 128.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax
                                            rates applicable to the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since
the tax year 2018, the taxable income of the Company and its subsidiary is subject to a corporate tax rate of 23%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Group&#x2019;s carryforward tax losses as of December&#160;31, 2023, totaled approximately $39 million which may be carried forward and offset against taxable income in the future for an indefinite period and approximately $23 million capital loss carryforward which may be offset against future capital gain. The Company did not recognize deferred taxes for carryforward losses and temporary differences, as well as capital losses and real losses, because their utilization in the foreseeable future is not probable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The main reconciling items between the &#x201c;theoretical&#x201d; tax expense, assuming that all the income were taxed at the regular tax rate applicable to companies in Israel (23%) and the taxes recorded in the statements of comprehensive income (loss) in the reporting year are revaluation expenses (income) not recognized for tax purposes, changes in taxes resulting from exchange rate differences, changes in deferred tax for tax losses carryforwards, and taxable losses for which no deferred taxes were recognized.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 85.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax
                                            assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company and Xtepo filed self-assessments that are deemed final through the 2018 tax year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-right: 85.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrecognized
                                            deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023 and 2022, the Company&#x2019;s had a deferred tax liability of approximately $141 thousand and $86 thousand, respectively
due to an investment in marketable securities &#x2013; InterCure Ltd. The deferred tax liability was fully offset by a deferred tax asset
due to utilization of tax losses from prior years.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate
      contextRef="c115"
      decimals="2"
      id="ixv-19876"
      unitRef="pure">0.23</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxEffectOfImpairmentOfGoodwill contextRef="c0" decimals="-6" id="ixv-19877" unitRef="usd">39000000</ifrs-full:TaxEffectOfImpairmentOfGoodwill>
    <xtlb:DeferredTaxAssetsCapitalLossCarryforward contextRef="c2" decimals="-6" id="ixv-19878" unitRef="usd">23000000</xtlb:DeferredTaxAssetsCapitalLossCarryforward>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c0" decimals="2" id="ixv-19879" unitRef="pure">-0.23</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="c0" decimals="-3" id="ixv-19880" unitRef="usd">141000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="c4" decimals="-3" id="ixv-19881" unitRef="usd">86000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0" id="ixv-17894">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 17:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;TRANSACTIONS
                                            AND BALANCES WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s key management personnel who are included, along with other factors, in the definition of related party, as above in
IAS 24, includes directors, members of the executive committee and InterCure Ltd.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensation
to key management personnel:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
compensation to key management personnel for employee services provided to the Company is shown below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management fees, directors, and
    consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;262&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;263&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of persons&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company pays to an accounting firm of which the company's CFO is a Partner (&#x201c;accounting firm&#x201d;), a monthly fees of NIS 15
thousand (approximately $4 thousand) for controller and bookkeeping services. Total fees for controller and bookkeeping services for
the years ended 2023, 2022 and 2021 were approximately $49 thousand, $53 thousand and $66 thousands respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, as of December 31, 2023 and 2022, the Company&#x2019;s balances with key management personnel and the accounting firm, totaled
approximately $32 thousand and $34 thousands (all of which were linked to the NIS).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
further information regarding share-based payment to related parties, see also Note 12 above and Note 19.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;InterCure
Ltd:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023 and 2022, the Company's share in the shares of InterCure Ltd was 1.04%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company's investment in the shares of InterCure Ltd is presented as Marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023 and 2022, the Company&#x2019;s balances of InterCure Ltd's shares total approximately $605 thousand and $1,627 thousand,
respectively. See also Note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company subleases an office from Canndoc Ltd., which is a subsidiary of InterCure Ltd. During 2023, 2022 and 2021, the Company recorded
rent expenses of approximately $11 thousands, $5 thousands and $14 thousands to Canndoc Ltd. As of December 31, 2023, the balance due
from Canndoc Ltd was $3 thousands.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Regarding
investment agreement signed subsequent to balance sheet date with one of the Company&#x2019;s shareholders see Note 1d.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory contextRef="c0" id="ixv-17914">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
compensation to key management personnel for employee services provided to the Company is shown below:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Management fees, directors, and
    consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;262&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;263&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;276&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of persons&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c0" decimals="-3" id="ixv-19882" unitRef="usd">240000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c4" decimals="-3" id="ixv-19883" unitRef="usd">262000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c5" decimals="-3" id="ixv-19884" unitRef="usd">263000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-19885" unitRef="usd">3000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-19886" unitRef="usd">14000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-19887" unitRef="usd">37000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="-3" id="ixv-19888" unitRef="usd">243000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c4" decimals="-3" id="ixv-19889" unitRef="usd">276000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c5" decimals="-3" id="ixv-19890" unitRef="usd">300000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:NumberOfEmployees contextRef="c2" decimals="0" id="ixv-19891" unitRef="pure">8</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees contextRef="c3" decimals="0" id="ixv-19892" unitRef="pure">8</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees contextRef="c22" decimals="0" id="ixv-19893" unitRef="pure">8</ifrs-full:NumberOfEmployees>
    <ifrs-full:OtherFeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-19894" unitRef="ils">15000</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:OtherFeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-19895" unitRef="usd">4000</ifrs-full:OtherFeeAndCommissionExpense>
    <xtlb:AdministrativeFeeExpense contextRef="c0" decimals="-3" id="ixv-19896" unitRef="usd">49000</xtlb:AdministrativeFeeExpense>
    <xtlb:AdministrativeFeeExpense contextRef="c4" decimals="-3" id="ixv-19897" unitRef="usd">53000</xtlb:AdministrativeFeeExpense>
    <xtlb:AdministrativeFeeExpense contextRef="c5" decimals="-3" id="ixv-19898" unitRef="usd">66000</xtlb:AdministrativeFeeExpense>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c2" decimals="-3" id="ixv-19899" unitRef="usd">32000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c3" decimals="-3" id="ixv-19900" unitRef="usd">34000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <xtlb:PercentageOfShare contextRef="c0" decimals="4" id="ixv-19901" unitRef="pure">0.0104</xtlb:PercentageOfShare>
    <xtlb:PercentageOfShare contextRef="c4" decimals="4" id="ixv-19902" unitRef="pure">0.0104</xtlb:PercentageOfShare>
    <xtlb:CurrentMarketableSecuritie
      contextRef="c116"
      decimals="-3"
      id="ixv-19903"
      unitRef="usd">605000</xtlb:CurrentMarketableSecuritie>
    <xtlb:CurrentMarketableSecuritie
      contextRef="c117"
      decimals="-3"
      id="ixv-19904"
      unitRef="usd">1627000</xtlb:CurrentMarketableSecuritie>
    <xtlb:RentExpense contextRef="c0" decimals="-3" id="ixv-19905" unitRef="usd">11000</xtlb:RentExpense>
    <xtlb:RentExpense
      contextRef="c118"
      decimals="-3"
      id="ixv-19906"
      unitRef="usd">5000</xtlb:RentExpense>
    <xtlb:RentExpense contextRef="c5" decimals="-3" id="ixv-19907" unitRef="usd">14000</xtlb:RentExpense>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-19908" unitRef="usd">3000</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c0" id="ixv-18228">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 18:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;EARNINGS
                                            (LOSS) PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Basic
earnings (loss) per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
calculation of basic earnings per share (EPS) is based on the following profit (loss) attributable to shareholders and weighted-average
number of ordinary shares outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Profit
(loss) attributed to ordinary shareholders (basic)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total comprehensive
    income (loss) for the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,782&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average
number of ordinary shares (basic)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued ordinary shares at January
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;514,205,799&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued March 7,2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,634,406&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued May 4, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;639,508&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued July 6, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,145,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued August 30, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,179,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued September 1, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,384&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued October 11, 2021
    due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,713&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number
    of ordinary shares (basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;531,995,467&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Diluted
earnings (loss) per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
calculation of diluted EPS is based on the following profit (loss) attributable to shareholders and weighted-average number of ordinary
shares outstanding after adjustment for the effects of all dilutive potential ordinary shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Profit
(loss) attributed to ordinary shareholders (diluted)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. dollars
    in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total comprehensive income (loss)
    for the year (basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,782&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant revaluation
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(660&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,782&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(225&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average
number of ordinary shares (diluted)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number of ordinary
    shares (basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;531,995,467&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effect of warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,552,979&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number
    of ordinary shares (diluted)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;615,548,446&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
2023 and 2022 all options and warrants were excluded from the diluted weighted average number of shares calculation because their effect
would have been anti-dilutive. In 2021,&#160;12,400,000&#160;options and&#160;650,000&#160;warrants (each warrant is exercisable to&#160;100&#160;shares)
were excluded from the diluted weighted-average number of ordinary shares calculation because their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
average market value of the Company&#x2019;s shares for calculating the dilutive effect of share options and warrants was based on quoted
market prices for the year during which the options were outstanding.&lt;/span&gt;&lt;/p&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0" id="ixv-18250">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Profit
(loss) attributed to ordinary shareholders (basic)&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    dollars in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total comprehensive
    income (loss) for the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,782&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-19909" unitRef="usd">-1782000</ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-19910" unitRef="usd">-1348000</ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c5" decimals="-3" id="ixv-19911" unitRef="usd">435000</ifrs-full:OtherComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c0" id="ixv-18316">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average
number of ordinary shares (basic)&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued ordinary shares at January
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;514,205,799&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued March 7,2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,634,406&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued May 4, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;639,508&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued July 6, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,145,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued August 30, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,179,452&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued September 1, 2021 due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,384&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued October 11, 2021
    due to warrant exercise&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;776,713&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number
    of ordinary shares (basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;531,995,467&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <xtlb:IssuedOrdinarySharesAtJanuary1
      contextRef="c0"
      decimals="INF"
      id="ixv-19912"
      unitRef="shares">544906149</xtlb:IssuedOrdinarySharesAtJanuary1>
    <xtlb:IssuedOrdinarySharesAtJanuary1
      contextRef="c4"
      decimals="INF"
      id="ixv-19913"
      unitRef="shares">544906149</xtlb:IssuedOrdinarySharesAtJanuary1>
    <xtlb:IssuedOrdinarySharesAtJanuary1
      contextRef="c5"
      decimals="INF"
      id="ixv-19914"
      unitRef="shares">514205799</xtlb:IssuedOrdinarySharesAtJanuary1>
    <xtlb:Issued
      contextRef="c121"
      decimals="INF"
      id="ixv-19915"
      unitRef="shares">10634406</xtlb:Issued>
    <xtlb:Issued
      contextRef="c124"
      decimals="INF"
      id="ixv-19916"
      unitRef="shares">639508</xtlb:Issued>
    <xtlb:Issued
      contextRef="c127"
      decimals="INF"
      id="ixv-19917"
      unitRef="shares">4145205</xtlb:Issued>
    <xtlb:Issued
      contextRef="c130"
      decimals="INF"
      id="ixv-19918"
      unitRef="shares">1179452</xtlb:Issued>
    <xtlb:Issued
      contextRef="c133"
      decimals="INF"
      id="ixv-19919"
      unitRef="shares">414384</xtlb:Issued>
    <xtlb:Issued
      contextRef="c136"
      decimals="INF"
      id="ixv-19920"
      unitRef="shares">776713</xtlb:Issued>
    <xtlb:WeightedAverageNumberOfOrdinarySharesbasic
      contextRef="c0"
      decimals="INF"
      id="ixv-19921"
      unitRef="shares">544906149</xtlb:WeightedAverageNumberOfOrdinarySharesbasic>
    <xtlb:WeightedAverageNumberOfOrdinarySharesbasic
      contextRef="c4"
      decimals="INF"
      id="ixv-19922"
      unitRef="shares">544906149</xtlb:WeightedAverageNumberOfOrdinarySharesbasic>
    <xtlb:WeightedAverageNumberOfOrdinarySharesbasic
      contextRef="c5"
      decimals="INF"
      id="ixv-19923"
      unitRef="shares">531995467</xtlb:WeightedAverageNumberOfOrdinarySharesbasic>
    <xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock contextRef="c0" id="ixv-18653">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Profit
(loss) attributed to ordinary shareholders (diluted)&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. dollars
    in thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total comprehensive income (loss)
    for the year (basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,782&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant revaluation
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(660&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,782&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,348&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(225&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:ScheduleOfProfitlossAttributedToOrdinaryShareholdersdilutedTableTexBlock>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="c0" decimals="-3" id="ixv-19924" unitRef="usd">-1782000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="c4" decimals="-3" id="ixv-19925" unitRef="usd">-1348000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="c5" decimals="-3" id="ixv-19926" unitRef="usd">435000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <xtlb:WarrantRevaluationIncome contextRef="c5" decimals="-3" id="ixv-19927" unitRef="usd">-660000</xtlb:WarrantRevaluationIncome>
    <xtlb:comprehensiveIncome contextRef="c0" decimals="-3" id="ixv-19928" unitRef="usd">-1782000</xtlb:comprehensiveIncome>
    <xtlb:comprehensiveIncome contextRef="c4" decimals="-3" id="ixv-19929" unitRef="usd">-1348000</xtlb:comprehensiveIncome>
    <xtlb:comprehensiveIncome contextRef="c5" decimals="-3" id="ixv-19930" unitRef="usd">-225000</xtlb:comprehensiveIncome>
    <xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock contextRef="c0" id="ixv-18773">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average
number of ordinary shares (diluted)&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average number of ordinary
    shares (basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;531,995,467&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effect of warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,552,979&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number
    of ordinary shares (diluted)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;544,906,149&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;615,548,446&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</xtlb:ScheduleOfWeightedaverageNumberOfOrdinarySharesdilutedTableTexBlock>
    <xtlb:WeightedaverageNumberOfOrdinarySharesbasic
      contextRef="c137"
      decimals="INF"
      id="ixv-19931"
      unitRef="shares">544906149</xtlb:WeightedaverageNumberOfOrdinarySharesbasic>
    <xtlb:WeightedaverageNumberOfOrdinarySharesbasic
      contextRef="c138"
      decimals="INF"
      id="ixv-19932"
      unitRef="shares">544906149</xtlb:WeightedaverageNumberOfOrdinarySharesbasic>
    <xtlb:WeightedaverageNumberOfOrdinarySharesbasic
      contextRef="c139"
      decimals="INF"
      id="ixv-19933"
      unitRef="shares">531995467</xtlb:WeightedaverageNumberOfOrdinarySharesbasic>
    <xtlb:EffectOfWarrants
      contextRef="c139"
      decimals="INF"
      id="ixv-19934"
      unitRef="shares">83552979</xtlb:EffectOfWarrants>
    <xtlb:WeightedAverageNumberOfOrdinarySharesdiluted
      contextRef="c137"
      decimals="INF"
      id="ixv-19935"
      unitRef="shares">544906149</xtlb:WeightedAverageNumberOfOrdinarySharesdiluted>
    <xtlb:WeightedAverageNumberOfOrdinarySharesdiluted
      contextRef="c138"
      decimals="INF"
      id="ixv-19936"
      unitRef="shares">544906149</xtlb:WeightedAverageNumberOfOrdinarySharesdiluted>
    <xtlb:WeightedAverageNumberOfOrdinarySharesdiluted
      contextRef="c139"
      decimals="INF"
      id="ixv-19937"
      unitRef="shares">615548446</xtlb:WeightedAverageNumberOfOrdinarySharesdiluted>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="c5"
      decimals="0"
      id="ixv-19938"
      unitRef="shares">12400000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <xtlb:warrants
      contextRef="c5"
      decimals="0"
      id="ixv-19939"
      unitRef="shares">650000</xtlb:warrants>
    <xtlb:EachWarrantIsExercisableToShares
      contextRef="c5"
      decimals="0"
      id="ixv-19940"
      unitRef="shares">100</xtlb:EachWarrantIsExercisableToShares>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-18929">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 19:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;SUBSEQUENT
                                            EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 17, 2024 the Company&#x2019;s board of directors approved the grant of 148,500 options exercisable into 148,500 ADSs of the Company,
out of which 138,500 are subject to shareholders meeting to be held on April 30, 2024 (which was approved on April 30, 2024 by Company&#x2019;s shareholders
meeting) to certain officers and directors of the Company.
100,000 options will be fully vested on date of grant and 48,500 options will vest according to Company&#x2019;s 2011 share option plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 19, 2024, the Company signed a binding term sheet, subject to due diligence, with THE SOCIAL PROXY Ltd. (the &#x201c;Social Proxy&#x201d;)
to acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis. The acquisition included, among
other things, the grant to the Social Proxy current shareholders of the right to appoint of 2 new directors to the Company&#x2019;s board
of directors, against the resignation of 2 Company&#x2019;s current directors. Consequently, the Company approved to extend the resigning
directors options exercise period for an additional 9 months period and up to an aggregate 12 months period following such termination
date, which is subject to shareholders approval&lt;/span&gt; (which was approved on April 30, 2024 by Company&#x2019;s shareholders meeting).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
addition, the Company has secured a commitment of an investment of an amount of US$1,500 thousands through a private placement to be
consummated upon the closing of the Transaction, see also Note 1d.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On March 27, 2024 the Company entered into a loan agreement with the
Social Proxy. According to the loan agreement, on March 27, 2024, the Company provided the Social Proxy with a loan of US$150 thousand.
The loan bears an annual interest of 8%. The loan and accrued interest will be repaid at the earlier of (1) 120 days following March 27,
2024 or (2) the date upon which the parties decide to abandon attempts for Transaction. Upon repayment date, Social Proxy may repay the
outstanding loan and accrued interest in 18 equal monthly installments. Social Proxy provided a first priority floating charge over all
of it assets as a security to ensure repayment of the loan and accrued interest.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <xtlb:NumberOfShareOptionsExercisableSharebasedPaymentArrangement
      contextRef="c140"
      decimals="0"
      id="ixv-19941"
      unitRef="shares">148500</xtlb:NumberOfShareOptionsExercisableSharebasedPaymentArrangement>
    <xtlb:ADSIssued
      contextRef="c140"
      decimals="0"
      id="ixv-19942"
      unitRef="shares">148500</xtlb:ADSIssued>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c141"
      decimals="0"
      id="ixv-19943"
      unitRef="shares">138500</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <xtlb:NumberOfOptionsFullyVested
      contextRef="c140"
      decimals="0"
      id="ixv-19944"
      unitRef="shares">100000</xtlb:NumberOfOptionsFullyVested>
    <xtlb:NumberOfOptionsVest
      contextRef="c140"
      decimals="0"
      id="ixv-19945"
      unitRef="shares">48500</xtlb:NumberOfOptionsVest>
    <xtlb:ExercisedPeriod contextRef="c142" id="ixv-19946">P9M</xtlb:ExercisedPeriod>
    <xtlb:TerminationPeriod contextRef="c142" id="ixv-19947">P12M</xtlb:TerminationPeriod>
    <ifrs-full:InvestmentIncome
      contextRef="c142"
      decimals="-3"
      id="ixv-19948"
      unitRef="usd">1500000</ifrs-full:InvestmentIncome>
    <ifrs-full:GrossLoanCommitments
      contextRef="c143"
      decimals="-3"
      id="ixv-19949"
      unitRef="usd">150000</ifrs-full:GrossLoanCommitments>
    <xtlb:LoanInterestRate
      contextRef="c144"
      decimals="2"
      id="ixv-19950"
      unitRef="pure">0.08</xtlb:LoanInterestRate>
    <xtlb:RevaluationOfWarrantsToPurchaseAds
      contextRef="c0"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c10"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c11"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c13"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c10"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c11"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c13"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c23"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c24"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c26"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c23"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c24"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c26"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c32"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c33"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c35"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c34"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c35"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c32"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c33"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c35"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c4"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="c4"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationExpense
      contextRef="c0"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:RevaluationOfWarrantsToPurchase
      contextRef="c0"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c0"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c4"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c41"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:SettlementsFairValueMeasurementLiabilities
      contextRef="c42"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c43"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c0"
      id="hidden-fact-32"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c4"
      id="hidden-fact-33"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c63"
      id="hidden-fact-34"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c64"
      id="hidden-fact-35"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c4"
      id="hidden-fact-37"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c5"
      id="hidden-fact-38"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c0" id="hidden-fact-39" xsi:nil="true"/>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c4" id="hidden-fact-40" xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c4"
      id="hidden-fact-42"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c63"
      id="hidden-fact-43"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c64"
      id="hidden-fact-44"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c77"
      id="hidden-fact-45"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c77"
      id="hidden-fact-46"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c78"
      id="hidden-fact-47"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c78"
      id="hidden-fact-48"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c76"
      id="hidden-fact-49"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c76"
      id="hidden-fact-50"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c77"
      id="hidden-fact-51"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c77"
      id="hidden-fact-52"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c78"
      id="hidden-fact-53"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c78"
      id="hidden-fact-54"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c76"
      id="hidden-fact-55"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c76"
      id="hidden-fact-56"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c77"
      id="hidden-fact-57"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c77"
      id="hidden-fact-58"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c76"
      id="hidden-fact-59"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c76"
      id="hidden-fact-60"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c77"
      id="hidden-fact-61"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c77"
      id="hidden-fact-62"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c94"
      id="hidden-fact-63"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c94"
      id="hidden-fact-64"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c95" id="hidden-fact-65" xsi:nil="true"/>
    <ifrs-full:TravelExpense
      contextRef="c0"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TravelExpense
      contextRef="c4"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:FinanceExpensesRevaluationOfMarketableSecurities
      contextRef="c5"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:ExchangeDifferences
      contextRef="c5"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:RevaluationOfWarrantsToPurchaseADSs
      contextRef="c0"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:RevaluationMarketableSecurities
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:RevaluationMarketableSecurities
      contextRef="c4"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c0"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:GainOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c4"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c119"
      id="hidden-fact-75"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c120"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c122"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c123"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c125"
      id="hidden-fact-79"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c126"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c128"
      id="hidden-fact-81"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c129"
      id="hidden-fact-82"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c131"
      id="hidden-fact-83"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c132"
      id="hidden-fact-84"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c134"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:Issued
      contextRef="c135"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:WarrantRevaluationIncome
      contextRef="c0"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:WarrantRevaluationIncome
      contextRef="c4"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <xtlb:EffectOfWarrants
      contextRef="c137"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <xtlb:EffectOfWarrants
      contextRef="c138"
      id="hidden-fact-90"
      unitRef="shares"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-20044">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-20045">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-20046">0001023549</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Deposits with maturity of less than three months, which in 2023 bear an interest of 4.41%-5.1% per annum (in 2022: 4.5 %).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The government authorities are monetary items, which are denominated or linked is NIS.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-35"
          xlink:label="hidden-fact-35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-33"
          xlink:label="hidden-fact-33"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-32"
          xlink:label="hidden-fact-32"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-34"
          xlink:label="hidden-fact-34"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Risk-free
interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-35"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-33"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-32"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-34"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-38"
          xlink:label="hidden-fact-38"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-37"
          xlink:label="hidden-fact-37"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-36"
          xlink:label="hidden-fact-36"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Expected
volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual
term of the option.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-38"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-37"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-36"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-39"
          xlink:label="hidden-fact-39"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-40"
          xlink:label="hidden-fact-40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Expected
life - the expected life was based on the expiration date of the warrants.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-39"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-40"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-41"
          xlink:label="hidden-fact-41"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-42"
          xlink:label="hidden-fact-42"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-44"
          xlink:label="hidden-fact-44"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-43"
          xlink:label="hidden-fact-43"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Dividend
yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends
to its shareholders in the future.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-41"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-42"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-44"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-43"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Date of the Company's Board of Directors&#x2019; decision (or shareholders, if required).&#160;As of December 31, 2023, all options are vested and therefore there is no unrecognized compensation cost.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
